<SEC-DOCUMENT>0000950170-23-057738.txt : 20231102
<SEC-HEADER>0000950170-23-057738.hdr.sgml : 20231102
<ACCEPTANCE-DATETIME>20231102070046
ACCESSION NUMBER:		0000950170-23-057738
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		58
CONFORMED PERIOD OF REPORT:	20230930
FILED AS OF DATE:		20231102
DATE AS OF CHANGE:		20231102

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Pediatrix Medical Group, Inc.
		CENTRAL INDEX KEY:			0000893949
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-HOSPITALS [8060]
		IRS NUMBER:				263667538
		STATE OF INCORPORATION:			FL
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12111
		FILM NUMBER:		231369989

	BUSINESS ADDRESS:	
		STREET 1:		1301 CONCORD TERRACE
		CITY:			SUNRISE
		STATE:			FL
		ZIP:			33323
		BUSINESS PHONE:		9543840175

	MAIL ADDRESS:	
		STREET 1:		1301 CONCORD TERRACE
		CITY:			SUNRISE
		STATE:			FL
		ZIP:			33323

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MEDNAX, INC.
		DATE OF NAME CHANGE:	20090102

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PEDIATRIX MEDICAL GROUP INC
		DATE OF NAME CHANGE:	19950801
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>md-20230930.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?><!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2023-11-01T17:51:08.8022+00:00 --><!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:md="http://www.mednax.com/20230930" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:srt="http://fasb.org/srt/2023" xmlns:utr="http://www.xbrl.org/2009/utr">
 <head>
  <title>10-Q</title>
  <meta http-equiv="Content-Type" content="text/html" />
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_6f29d740-8345-4b23-aaea-9bf2993e594b" name="dei:DocumentFiscalPeriodFocus" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a">Q3</ix:nonNumeric><ix:nonNumeric id="F_fb628bf3-7b5c-4ca7-ba3a-53a7c8c17429" name="dei:EntityCentralIndexKey" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a">0000893949</ix:nonNumeric><ix:nonNumeric id="F_dca61a52-b8ec-461f-b1ae-6247e9b87d8e" name="dei:CurrentFiscalYearEndDate" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a">--12-31</ix:nonNumeric><ix:nonNumeric id="F_c598e0f1-6e9c-4db1-88d8-3ff80c15284f" name="dei:AmendmentFlag" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a">false</ix:nonNumeric><ix:nonFraction id="F_71b38540-0a46-456d-b52f-5551e74ee66d" name="us-gaap:CommitmentsAndContingencies" contextRef="C_5d513fe3-41de-49c7-8231-3b67764cba30" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_88126968-94b4-42e4-8930-40061df59b00" name="us-gaap:CommitmentsAndContingencies" contextRef="C_ad3c19c0-ada4-44fc-bdd3-c29b5398a40a" unitRef="U_USD" xsi:nil="true"></ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="md-20230930.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="C_03cd8a32-d1bc-4934-bd34-28363e85b18a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">md:NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f2e4e009-3726-45e0-a90a-5d336cda6f04"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AllOtherCorporateBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_92f598fa-4d7f-4e9b-b277-8567385e3d27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fd83bf41-3f3e-4283-8803-bc13fec411ef"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4ec257e6-7ad0-419f-b83a-531d36bb3987"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">md:SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bbb0586b-efa6-4d4e-b6e9-1b625c1dbc91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fdee2685-4fe9-4dac-b896-4bbc5d69816d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">md:SixPointTwentyFivePercentageSeniorUnsecuredNotesDue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_17d5429f-d92b-4cb2-97ef-26e7d7d1dbfb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-10-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_35888be5-90cc-40bd-b51a-b4a5ef520e02"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_350c5db7-f64b-4e63-97fa-733cc8e8f783"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0b560b9e-bc42-4716-8570-2af20d2cca64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">md:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c8155ad1-ff2e-4bfe-b9f9-a6805aed62f4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ad3c19c0-ada4-44fc-bdd3-c29b5398a40a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_340f9a3e-b672-4edc-82ab-7e12ef61b6da"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:GovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_874771f9-e875-4db9-94d5-bb53a324cb51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_134848fe-680a-4e25-830f-371c8b8fb100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:GovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fa51030c-8ae1-44ad-b260-2c8ee8428637"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_64e6ce54-7a3c-4a04-9100-a67300b48c30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_99c7da7a-966d-481a-9f87-07899a403107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:SelfPayMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_19a977fa-7760-40e4-8833-ab4c31af2173"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ece3d6f0-dcae-48a9-bc24-698ee8c17506"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_07cad879-2c61-450d-9518-d6bbda76d09e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">md:HospitalsContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_377d4d1b-904e-4983-aaf7-ccda1f31ece5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c5cbe39a-b446-4f38-9bc0-7315c1df92ff"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a66a0d65-33d2-4b8c-a2fa-57b2aec20870"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f8d7ba49-dc8b-448a-ba32-eed7f3fb3be4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_86f7c920-c7dd-49eb-b9e5-c81407859e32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6aabcea2-797e-41b7-aefa-4ccc2147de8f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0b8cfdec-f0c4-4429-b94a-75b07f7aae51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e4839b2a-c828-4c77-8f2c-55160784c52b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2e0a629f-a677-4b59-a478-5cbb505d9530"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_115e1478-c36e-4914-b961-b19a8a7591a9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ec45eaa6-d9c5-4fd0-84cf-6b2be759e02b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_899d2caa-e2bb-4aac-bb5e-119389b4c1f1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_85574474-f392-4916-ac36-f721aeb624d6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0a32aa8a-cbb8-411d-957d-680d318c2384"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">md:TwoZeroThreeZeroMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_33f86df0-142f-4408-9f5e-9de3e9f21458"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">md:ContractedManagedCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c77e289a-1111-40d7-9df0-645b35738672"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_24d8347f-a523-4cf1-8d04-a1595106e838"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">md:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7b75f74d-09a8-4e26-8d61-3a48b9fa176e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cf213a70-35ae-48c9-9339-37927b488110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_56cb679d-6a88-4a31-abf3-f1c779c4bcb9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_97d10031-02ee-416c-bb86-cd6e6928957a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f56f4f7a-19b8-4635-8355-ce0222c24e4b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_45911ccf-f5d4-4c4e-8dd0-c5ea09a1db36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_887ab47d-2465-4e8c-8649-d0d114c06f6c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d1b666e6-0f27-4c23-9240-3207e18d4a31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2ed09d19-c783-4eb4-860c-7e590254f539"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5d513fe3-41de-49c7-8231-3b67764cba30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6494afcc-dadf-426c-b613-8f9a7abfe318"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:GovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f0afc955-4abd-4ca2-99cf-97256b13481a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ee5ce32e-37b5-4efc-a6e1-d6be8df2025a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2f1c7dd7-f01c-4015-a37d-1caeb69540b9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">md:FivePointThreeSevenFivePercentUnsecuredSeniorNotesDueTwoThousandThirtyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d9967c70-bdd9-46f2-a73f-0af130ef6ca5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fd02f20b-c7c9-4b18-9720-432b8fd1f5bc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4c2decbf-697c-4da3-a4c5-727a578f77dc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f56c48df-9031-48bb-ae3d-40c5aabd6cc4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ec1dd730-3062-4268-8e06-714c3ed2af24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">md:FivePointThreeSevenFivePercentUnsecuredSeniorNotesDueTwoThousandThirtyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0c4b440a-242a-4875-a46f-4a05a1426d70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_db14decc-aca0-4ce7-bed7-40edd1c86538"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_07ab98db-f259-45b0-b05a-833bf8d33505"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_260cff1e-4c05-484b-8a25-8a1e82704661"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_86bee92f-7914-4dbf-a4cd-38a1fed2ab1c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c10c4eef-bb70-4725-bb7d-0a8da3fa54db"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f6042715-3400-472b-a63f-651373917338"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_89fa872a-ad9d-4262-8559-732e6a088cd4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_aca7d163-6a33-4b3d-9ea5-b99aa4fe9e34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ee0dda75-7533-43f8-ba6d-8b3ddadca454"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b7a3aab8-6e4f-488e-bd25-e4acf1837264"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2f54399b-eb59-443e-af5f-01b59be7c4b3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b3dc82b2-20f3-4300-82a6-75ad6389cab0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b42eab6a-90cf-43fc-9fc6-2ad25a6ef134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_22bf64d7-53dd-4c56-b931-fbaef641de7e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cd23234b-4b27-4574-a7f1-454baa006e0e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_af3a863a-e1d2-476d-ab71-08e497384468"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_61935c85-fd8d-48a0-b0e8-e2ace38d0aca"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_13a9d66b-1b0e-497a-b873-fe7ac09c44cf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">md:HospitalsContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c7f29732-6f5b-49e4-a848-639b94127316"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">md:HospitalsContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7bab9990-2405-4ad2-b988-70145110847c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a04c17b2-e635-4a34-a0cc-839bf6802112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">md:NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1a90cf11-7660-475d-b876-c49b675c3a0d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">md:ContractedManagedCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9a67fb14-6a35-4389-82c8-b724c79c3f38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_99787654-98fb-4075-b2d1-551ddbc6deed"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">md:UnnamedCorporateJointVentureTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_894b93ff-c06d-4c0f-a734-2f6884d5b7f7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">md:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_477d8b88-2dd5-4c27-a308-f22d4cb31970"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_56dd7543-31f8-4ae4-badc-c16562ed7f07"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_965dd392-85a0-4cd0-8ea9-4961c1f6dc80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_86ceec74-75ab-4b30-bf4d-aa99084da5fc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_73fe2b81-82a7-41de-a03c-5ba651cc8568"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3ed13396-e9c9-4ccc-91fd-b54c8527fe2e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ebc061e7-b2d9-4c21-8b03-fda66e7ff5fd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">md:FivePointThreeSevenFivePercentUnsecuredSeniorNotesDueTwoThousandThirtyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8d549597-a6a3-4f65-960a-276c382d6949"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6ea9b9a0-3cfd-421c-9583-235675ef66b6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">md:ContractedManagedCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1c0cfd23-24b4-45dc-8a0f-30d68714c292"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">md:FivePointThreeSevenFivePercentUnsecuredSeniorNotesDueTwoThousandThirtyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-11</xbrli:startDate><xbrli:endDate>2022-02-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_75ad9bd0-8190-4d2d-9f0a-71bf1ddf7588"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_eb46e330-b646-43c3-95f2-112f68583c49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">md:NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6a82b64e-6fb9-48f9-99fe-5081ff6fca6c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="md:ExtraordinaryItemsAxis">md:CovidNinenteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f4b8c51a-4dae-4dd3-9d9f-ef95a7c7a1b4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f2431026-3a3b-40cd-9fb3-55962d2dfba5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-11</xbrli:startDate><xbrli:endDate>2022-02-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_36d93c5d-b688-4948-8aa6-b10b1986e10f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ea09ed9a-1817-4610-877d-b7f92fa5faba"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_43c976d5-88bb-433a-adbb-5b5571f16c99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="md:ExtraordinaryItemsAxis">md:CovidNinenteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0c7585a4-747b-415b-a754-892864d85f80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">md:AmendedAndRestatedTwoThousandEightPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3f1eae59-7db7-4f63-b33e-689ca6ac6166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9b225ad0-d1c0-4862-9853-9d52295b37b4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_012cf148-5766-4e38-bab9-71a218133486"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e97fbd72-ea7b-4883-b296-14825e3e504f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_830bbec2-bf82-42ba-aab7-1b87e55627e6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0be151b0-34b3-4da7-b3ba-2f77da9f751e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">md:TwoThousandFifteenNonQualifiedStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_461e1df7-29c9-4340-9d09-2d305db85278"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ecfb99fe-0958-4180-b890-77afb1efe059"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AllOtherCorporateBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_071df110-5688-40d6-b07e-cf79e845dffc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b98e3dec-68cf-411f-84d8-48f4345c2f5e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_530a9bb3-d0af-4d65-93b6-103b6c414d75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">md:ContractedManagedCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4a7eedc9-2d63-42bd-9695-8d9ce87c5067"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:GovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8350a8fa-b313-4bbc-8d3d-a43cfa5262b4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c2300a5a-f622-49a9-b54c-dcabb14d6824"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">md:NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7ae55b15-375d-4829-8fee-0964b045a7cf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">md:UnnamedCorporateJointVentureOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_659d9bd3-6f8d-448a-9462-197a2c4b64c7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fc6992a8-5cd9-42e1-ba09-8be4221adf6f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9b7a1e9b-0052-493b-8b97-41fc5afb54f6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1ccfbb16-e844-487b-90c8-99c1b5604082"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ec5297e8-5a0c-4bde-9aa8-9737b4ffc31c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ead630e6-3bc1-4158-acab-0cd6d0a20d53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_308516ff-d843-45b5-8b06-0a3e134f255e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3fe9a616-cb85-448a-a3c7-88b42ca6650a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7b747bea-61e9-4a99-b3d9-c96dee793375"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_61e8dbc9-4c0e-40e5-bc06-8dbeefba5d20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7ad99fb3-5525-4459-a4cb-b1188d7c5224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_06c01cd0-0e05-46ab-a1e5-d6467d9be312"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">md:TwoZeroThreeZeroMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dba1d7c4-12e0-4e88-888d-efc09f476c71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8fa77ca8-719f-4df1-bf5f-88fe5ee7eebb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:SelfPayMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b3dba50b-b27a-4103-9cc0-9ccc2aeac984"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9340fe71-cf84-4fe9-b488-79ab1cff7146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">md:AmendedAndRestatedTwoThousandEightPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3f7aa872-26d0-45a9-b1bb-119611e8d6c8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">md:HospitalsContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3ecbf02e-8155-43fd-bfae-75d93b4d3bb0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4c16c34d-3859-4415-b98c-b075a026c528"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9d124535-a548-449d-8d4b-80ec4d95973a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0002ecca-b81e-4c48-8d05-eefbc915ed5a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a53e34bc-3154-419c-8471-2c496997bd8c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:SelfPayMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8b93e2e5-8344-474d-908a-5783596f5a9f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f61ab540-a2d0-4d45-8e9f-d043538b0a26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:SelfPayMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7cfd52bf-5193-4a6c-bf56-23a18e131b5e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e5943398-0732-4d17-9fe7-25777d223b65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_48f6c028-da90-4698-9d57-8fadb9aedae6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_846d24c8-9524-45a4-a1b6-aa7b223ba8ec"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_USDollarShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_6b743967-0814-4084-a3b5-92c63ce424bd" fromRefs="F_db831608-272d-4dea-9813-f388fa6a3dd7 F_30c66a9a-0756-4d02-9e4a-1f60b3066ad9 F_e8442405-4700-449c-a708-92b165088fb6"></ix:relationship></ix:resources></ix:header></div>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:2.25pt double;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:1pt;font-family:Times New Roman;min-width:fit-content;">t</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;min-width:fit-content;">UNITED STATES</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Washington, D.C. 20549</span></p>
  <p style="margin-left:26.667%;text-indent:0;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:26.667%;text-align:center;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;min-width:fit-content;">FORM </span><span style="font-size:16pt;font-family:Times New Roman;"><ix:nonNumeric id="F_18c2d184-1ed2-41a0-824e-adf2ef186adb" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;min-width:fit-content;">10-Q</span></ix:nonNumeric></span></p>
  <p style="margin-left:26.667%;text-indent:0;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:26.667%;text-align:center;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:-4.895%;padding-left:4.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:11pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4c1f07f4-07e2-4e7c-a9bd-a6954857e531" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">    QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the quarterly period ended </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b4917864-2eb2-4e7e-87b3-db41d988475d" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">September 30, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b97d51dd-ce3b-451a-bbbd-f92cc137e583" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="dei:DocumentFiscalYearFocus"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2023</span></ix:nonNumeric></span></ix:nonNumeric></span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">OR</span></p>
  <p style="text-indent:-4.895%;padding-left:4.667%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:11pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3faaaf3c-7981-49e1-a197-6c4964e2f58b" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">     TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the transition period from ______ to ______</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Commission File Number: </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3ea713e6-f581-447e-8504-f9d44845cef7" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">001-12111</span></ix:nonNumeric></span></p>
  <p style="margin-left:26.667%;text-indent:0;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:26.667%;text-align:center;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img259349275_0.jpg" alt="img259349275_0.jpg" style="width:134px;height:84px;" />&#160;</p>
  <p style="text-indent:0;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:14.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_382fd7e1-9c07-4dd7-9f3f-d1344d3634bd" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14.5pt;font-family:Times New Roman;min-width:fit-content;">Pediatrix Medical Group, Inc.</span></ix:nonNumeric></span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(Exact name of registrant as specified in its charter)</span></p>
  <p style="margin-left:26.667%;text-indent:0;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:26.667%;text-align:center;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:47.71%;"></td>
    <td style="width:3.821%;"></td>
    <td style="width:48.47%;"></td>
   </tr>
   <tr style="height:9pt;">
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_129ff8e6-0c3e-4561-94ef-13af465c28b6" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Florida</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0d091436-e490-4798-9408-350c2fe9cb83" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">26-3667538</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7pt;">
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-family:Times New Roman;min-width:fit-content;">(State or other jurisdiction of</span></p><p style="text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-family:Times New Roman;min-width:fit-content;">incorporation or organization)</span></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-family:Times New Roman;min-width:fit-content;">(I.R.S. Employer</span></p><p style="text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-family:Times New Roman;min-width:fit-content;">Identification No.)</span></p></td>
   </tr>
   <tr>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;text-indent:48.95pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="margin-left:48.95pt;text-indent:0;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_85cc452c-e4ad-4206-8c8b-cc0afc89af5e" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">1301 Concord Terrace</span></ix:nonNumeric></span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b1218875-159a-4d97-ac38-9de162803281" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Sunrise</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e8cf648e-551f-4a86-be8a-5b353a3a9c56" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Florida</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_78a1570b-d994-4e94-9c46-988c3b47248d" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">33323</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7pt;">
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-family:Times New Roman;min-width:fit-content;">(Address of principal executive offices)</span></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-family:Times New Roman;min-width:fit-content;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9d5a276f-bae6-4a26-bc81-f29564ba8122" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">954</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">) </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3f2726b5-3ac6-461f-ae70-bf5a9eb26d63" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">384-0175</span></ix:nonNumeric></span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(Registrant's telephone number, including area code)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Not Applicable</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(Former name, former address and former fiscal year, if changed since last report)</span></p>
  <p style="margin-left:26.667%;text-indent:0;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:26.667%;text-align:center;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:4pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:4pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:39.76%;"></td>
    <td style="width:1%;"></td>
    <td style="width:18.08%;"></td>
    <td style="width:1.06%;"></td>
    <td style="width:40.1%;"></td>
   </tr>
   <tr style="height:8pt;">
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.06in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.06in;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Title of each class</span></p></td>
    <td style="text-indent:31.5pt;word-break:break-word;white-space:pre-wrap;padding-left:0.06in;vertical-align:top;border-bottom:0.5pt solid #ffffff03;padding-right:0.06in;text-align:left;"><p style="text-indent:-31.5pt;padding-left:31.5pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:31.5pt;word-break:break-word;white-space:pre-wrap;padding-left:0.06in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.06in;text-align:left;"><p style="text-indent:-31.5pt;padding-left:31.5pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Trading Symbol</span></p></td>
    <td style="text-indent:31.5pt;word-break:break-word;white-space:pre-wrap;padding-left:0.06in;vertical-align:top;border-bottom:0.5pt solid #ffffff03;padding-right:0.06in;text-align:left;"><p style="text-indent:-31.5pt;padding-left:31.5pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.06in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.06in;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.06in;vertical-align:top;padding-right:0.06in;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ac588deb-dd1b-4271-bfb1-5b9fcbca3f9e" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Common Stock, par value $.01 per share</span></ix:nonNumeric></span></p></td>
    <td style="text-indent:4.5pt;word-break:break-word;white-space:pre-wrap;padding-left:0.06in;vertical-align:top;padding-right:0.06in;text-align:left;"><p style="margin-left:4.5pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:4.5pt;word-break:break-word;white-space:pre-wrap;padding-left:0.06in;vertical-align:top;padding-right:0.06in;text-align:left;"><p style="margin-left:4.5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_776a6f11-a31a-4be8-9a1c-5318b1855e4e" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">MD</span></ix:nonNumeric></span></p></td>
    <td style="text-indent:4.5pt;word-break:break-word;white-space:pre-wrap;padding-left:0.06in;vertical-align:top;padding-right:0.06in;text-align:left;"><p style="margin-left:4.5pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.06in;vertical-align:top;padding-right:0.06in;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9f59ce3e-2dbd-42ac-9123-ab88d03333cd" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">New York Stock Exchange</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1880982c-0b29-4688-a0af-21ba66e52f70" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="dei:EntityCurrentReportingStatus"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">   &#9745;  No   &#9744;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8351983b-08f2-4672-befe-5a0569aefa3f" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="dei:EntityInteractiveDataCurrent"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">   &#9745;  No   &#9744;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#x201c;large accelerated filer,&#x201d; &#x201c;accelerated filer,&#x201d; &#x201c;smaller reporting company,&#x201d; and &#x201c;emerging growth company&#x201d; in Rule 12b-2 of the Exchange Act.</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:18.455%;"></td>
    <td style="width:1.946%;"></td>
    <td style="width:55.527%;"></td>
    <td style="width:22.066%;"></td>
    <td style="width:2.006%;"></td>
   </tr>
   <tr style="height:9pt;">
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_33e3db1c-f081-48bf-808f-4c3f37b322ab" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Large accelerated filer</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#9745;</span></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Accelerated filer</span></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#9744;</span></p></td>
   </tr>
   <tr>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Non-accelerated filer</span></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#9744;</span></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Smaller reporting company</span></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_955f5112-fab3-4d2c-87f0-ad0fc450435b" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Emerging growth company</span></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fdb820a2-5815-416f-87fd-eef922985aae" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   &#9744;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes &#9744; No   </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4e8182c8-67df-476f-ae6d-9aafc93b338f" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="dei:EntityShellCompany" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#9745;</span></ix:nonNumeric></span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">On October 27, 2023, the registrant had outstanding </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_4866c0a6-c503-4f59-a7e5-38ad889736df" contextRef="C_17d5429f-d92b-4cb2-97ef-26e7d7d1dbfb" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">84,023,916</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> shares of Common Stock, par value $.01 per share.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:2.25pt double;text-align:left;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pediatrix Medical Group, Inc.</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">INDEX</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:10.74%;"></td>
    <td style="width:84%;"></td>
    <td style="width:5.26%;"></td>
   </tr>
   <tr style="height:10pt;">
    <td colspan="2" style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Page</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td colspan="2" style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PART I - FINANCIAL INFORMATION</span></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#financial_statements"><span style="color:#0000ff;white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 1.</span></a></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#financial_statements"><span style="color:#0000ff;white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial Statements</span></a></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3</span></p></td>
   </tr>
   <tr>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#balance_sheet"><span style="color:#0000ff;white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Consolidated Balance Sheets as of September 30, 2023 and December 31, 2022 (Unaudited)</span></a></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3</span></p></td>
   </tr>
   <tr>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#statements_income"><span style="color:#0000ff;white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Consolidated Statements of Income and Comprehensive Income for the Three and Nine Months</span><span style="color:#0000ff;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></a></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#statements_income"><span style="color:#0000ff;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">   </span><span style="color:#0000ff;white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Ended</span></a><span style="color:#000000;white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><a href="#statements_income"><span style="color:#0000ff;white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">September 30, 2023 and 2022 (Unaudited)</span></a></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4</span></p></td>
   </tr>
   <tr>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#statements_equity"><span style="color:#0000ff;white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Consolidated Statements of Equity for the Three and Nine Months Ended</span></a></p><p style="text-indent:7.2pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#statements_equity"><span style="color:#0000ff;white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">September 30, 2023 and 2022 (Unaudited)</span></a></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5</span></p></td>
   </tr>
   <tr>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#statements_cash_flows"><span style="color:#0000ff;white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Consolidated Statements of Cash Flows for the Nine Months Ended</span></a></p><p style="text-indent:7.2pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#statements_cash_flows"><span style="color:#0000ff;white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">September 30, 2023 and 2022 (Unaudited)</span></a></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6</span></p></td>
   </tr>
   <tr>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#notes_financial_statements"><span style="color:#0000ff;white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Notes to Consolidated Financial Statements (Unaudited)</span></a></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7</span></p></td>
   </tr>
   <tr>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#mda"><span style="color:#0000ff;white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 2.</span></a></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#mda"><span style="color:#0000ff;white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">13</span></p></td>
   </tr>
   <tr>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_3"><span style="color:#0000ff;white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 3.</span></a></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_3"><span style="color:#0000ff;white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">21</span></p></td>
   </tr>
   <tr>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_4"><span style="color:#0000ff;white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 4.</span></a></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_4"><span style="color:#0000ff;white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Controls and Procedures</span></a></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">21</span></p></td>
   </tr>
   <tr>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td colspan="2" style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_ii"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PART II - OTHER INFORMATION</span></a></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1"><span style="color:#0000ff;white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 1.</span></a></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1"><span style="color:#0000ff;white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Legal Proceedings</span></a></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">22</span></p></td>
   </tr>
   <tr>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1a"><span style="color:#0000ff;white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 1A.</span></a></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1a"><span style="color:#0000ff;white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risk Factors</span></a></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">22</span></p></td>
   </tr>
   <tr>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_2"><span style="color:#0000ff;white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 2.</span></a></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_2"><span style="color:#0000ff;white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Unregistered Sales of Equity Securities and Use of Proceeds</span></a></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">22</span></p></td>
   </tr>
   <tr>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_5"><span style="color:#0000ff;white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 5.</span></a><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_5"><span style="color:#0000ff;white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other Information</span></a></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">23</span></p></td>
   </tr>
   <tr>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#exhibit_index"><span style="color:#0000ff;white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 6.</span></a></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#exhibit_index"><span style="color:#0000ff;white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibits</span></a></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">24</span></p></td>
   </tr>
   <tr>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td colspan="2" style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#signatures"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SIGNATURES</span></a></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">25</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">2</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="financial_statements"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">P</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">e</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">diatrix Medical Group, Inc.</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="balance_sheet"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Consolidated</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Balance Sheets</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(in thousands)</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(Unaudited)</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:67.28%;"></td>
    <td style="width:1.46%;"></td>
    <td style="width:1%;"></td>
    <td style="width:12.9%;"></td>
    <td style="width:1%;"></td>
    <td style="width:1.46%;"></td>
    <td style="width:1%;"></td>
    <td style="width:12.9%;"></td>
    <td style="width:1%;"></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">September 30, 2023</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2022</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">ASSETS</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#ffffff;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Current assets:</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#cff0fc;text-indent:20pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Cash and cash equivalents</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_0e1a7495-4dff-4c40-87e8-822ff211d6ac" contextRef="C_5d513fe3-41de-49c7-8231-3b67764cba30" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,179</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_a9038791-b462-4cfb-bebe-c76e5498e8f6" contextRef="C_ad3c19c0-ada4-44fc-bdd3-c29b5398a40a" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,824</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#ffffff;text-indent:20pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Short-term investments</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_32d96254-d191-49bf-badc-b9d8d70f8e2f" contextRef="C_5d513fe3-41de-49c7-8231-3b67764cba30" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">103,541</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_70221fa5-d2d7-45d8-b9fa-a70bfeb6eaee" contextRef="C_ad3c19c0-ada4-44fc-bdd3-c29b5398a40a" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">93,239</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#cff0fc;text-indent:20pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Accounts receivable, net</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_1db442cd-773f-4e73-8679-7ba18a742158" contextRef="C_5d513fe3-41de-49c7-8231-3b67764cba30" name="us-gaap:AccountsReceivableNetCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">277,352</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_132b755b-0f59-4879-a947-0a8613136b32" contextRef="C_ad3c19c0-ada4-44fc-bdd3-c29b5398a40a" name="us-gaap:AccountsReceivableNetCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">296,787</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#ffffff;text-indent:20pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Prepaid expenses</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_c97679ba-775c-4ad0-9831-5c4914895982" contextRef="C_5d513fe3-41de-49c7-8231-3b67764cba30" name="us-gaap:PrepaidExpenseCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,586</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_a8d54fd7-b688-40da-a408-879a61781576" contextRef="C_ad3c19c0-ada4-44fc-bdd3-c29b5398a40a" name="us-gaap:PrepaidExpenseCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,878</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#cff0fc;text-indent:20pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Other current assets</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_5071e514-ecac-4995-b74c-287ca0cd5cf8" contextRef="C_5d513fe3-41de-49c7-8231-3b67764cba30" name="us-gaap:OtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,866</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_f59cd0a2-1709-41ee-ae37-d7b8f45480d0" contextRef="C_ad3c19c0-ada4-44fc-bdd3-c29b5398a40a" name="us-gaap:OtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,261</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#ffffff;text-indent:30pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:30pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Total current assets</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_17dca86e-43fc-493a-8379-6a62161cd736" contextRef="C_5d513fe3-41de-49c7-8231-3b67764cba30" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">420,524</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_88f32090-0659-4060-9618-2f66acab4d23" contextRef="C_ad3c19c0-ada4-44fc-bdd3-c29b5398a40a" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">427,989</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#cff0fc;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment, net</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_57e816dd-a2e6-4f7c-aad4-32dea2ed70eb" contextRef="C_5d513fe3-41de-49c7-8231-3b67764cba30" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">75,146</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_a456906d-13f3-452f-97b3-f21c05a3f9d1" contextRef="C_ad3c19c0-ada4-44fc-bdd3-c29b5398a40a" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">73,290</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#ffffff;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Goodwill</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_cf69e7ff-84dd-4791-bca8-46fb8ab96244" contextRef="C_5d513fe3-41de-49c7-8231-3b67764cba30" name="us-gaap:Goodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,532,092</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_6d302b7d-78cf-470c-8437-a8e310c75bee" contextRef="C_ad3c19c0-ada4-44fc-bdd3-c29b5398a40a" name="us-gaap:Goodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,532,092</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#cff0fc;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Intangible assets, net</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_4eca23c2-d601-422c-88cf-edbe98aeaabe" contextRef="C_5d513fe3-41de-49c7-8231-3b67764cba30" name="us-gaap:FiniteLivedIntangibleAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,486</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_0b869055-6240-4b06-bc41-ffc9cc2d3e6d" contextRef="C_ad3c19c0-ada4-44fc-bdd3-c29b5398a40a" name="us-gaap:FiniteLivedIntangibleAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,491</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#ffffff;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Operating and finance lease right-of-use assets</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_a7b4f3f8-4317-4863-a892-c6680e44214a" contextRef="C_5d513fe3-41de-49c7-8231-3b67764cba30" name="md:OperatingAndFinanceLeaseRightOfUseAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">72,443</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_7c7f2b45-8507-418a-bf27-4a05be2b29d9" contextRef="C_ad3c19c0-ada4-44fc-bdd3-c29b5398a40a" name="md:OperatingAndFinanceLeaseRightOfUseAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">66,924</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#cff0fc;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Deferred income tax assets</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_10214fcc-63d5-4012-accd-01c9b30f82a7" contextRef="C_5d513fe3-41de-49c7-8231-3b67764cba30" name="us-gaap:DeferredIncomeTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">102,638</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_8b83c189-2a2e-4e61-8438-1f6c6855c4b0" contextRef="C_ad3c19c0-ada4-44fc-bdd3-c29b5398a40a" name="us-gaap:DeferredIncomeTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">105,925</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#ffffff;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Other assets</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_7a64f3fc-b7ed-4364-b125-83184bcb688f" contextRef="C_5d513fe3-41de-49c7-8231-3b67764cba30" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">108,010</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_36b6a9b9-c06a-4cf3-ae22-252db23e6a3c" contextRef="C_ad3c19c0-ada4-44fc-bdd3-c29b5398a40a" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">123,176</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#cff0fc;text-indent:20pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Total assets</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_88f119fd-71b4-49ca-91b2-3a31edbfe55e" contextRef="C_5d513fe3-41de-49c7-8231-3b67764cba30" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,326,339</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_0005ac0b-d3ec-4bee-8944-cf2a9c426522" contextRef="C_ad3c19c0-ada4-44fc-bdd3-c29b5398a40a" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,347,887</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">LIABILITIES AND SHAREHOLDERS' EQUITY</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Current liabilities:</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#ffffff;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Accounts payable and accrued expenses</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_488e588f-31c3-4889-a45e-8b29577eb406" contextRef="C_5d513fe3-41de-49c7-8231-3b67764cba30" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">302,583</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_2600b71c-1cc8-434e-86f4-efc36e8263f0" contextRef="C_ad3c19c0-ada4-44fc-bdd3-c29b5398a40a" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">374,225</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#cff0fc;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Current portion of debt and finance lease liabilities, net</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_15583fe9-fa63-4a56-afe8-4a3def14aa8b" contextRef="C_5d513fe3-41de-49c7-8231-3b67764cba30" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,929</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_639b8a79-279b-41e1-bb07-62ee5d07c831" contextRef="C_ad3c19c0-ada4-44fc-bdd3-c29b5398a40a" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,898</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#ffffff;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Current portion of operating lease liabilities</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_6070a841-bb96-4d96-8d53-61c3ed255d1c" contextRef="C_5d513fe3-41de-49c7-8231-3b67764cba30" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,814</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_a543d000-1978-46bb-8be8-ddc287b05db0" contextRef="C_ad3c19c0-ada4-44fc-bdd3-c29b5398a40a" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,589</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#cff0fc;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Income taxes payable</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_7bbb4ae1-4de1-4ebd-968f-20494c57bef6" contextRef="C_5d513fe3-41de-49c7-8231-3b67764cba30" name="us-gaap:AccruedIncomeTaxesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,118</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_7bac66f0-bd27-42bf-84a5-ae2bdd3a35fa" contextRef="C_ad3c19c0-ada4-44fc-bdd3-c29b5398a40a" name="us-gaap:AccruedIncomeTaxesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,271</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#ffffff;text-indent:20pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Total current liabilities</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_23894717-0d90-4c77-a85f-0a26be500704" contextRef="C_5d513fe3-41de-49c7-8231-3b67764cba30" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">350,444</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_9703a4ae-cd59-45d7-8446-ca62c1dab2dd" contextRef="C_ad3c19c0-ada4-44fc-bdd3-c29b5398a40a" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">426,983</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#cff0fc;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Line of credit</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_e71f49b1-ad69-42c6-acba-d5313347ec48" contextRef="C_5d513fe3-41de-49c7-8231-3b67764cba30" name="us-gaap:LineOfCredit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_d75683e4-784c-453a-a153-e4f5b4701262" contextRef="C_ad3c19c0-ada4-44fc-bdd3-c29b5398a40a" name="us-gaap:LineOfCredit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,000</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#ffffff;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Long-term debt and finance lease liabilities, net</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_ef86586a-43f5-4348-96fa-662f458439c3" contextRef="C_5d513fe3-41de-49c7-8231-3b67764cba30" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">621,691</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_ab5d7a07-9d22-4d46-a921-b0f138621531" contextRef="C_ad3c19c0-ada4-44fc-bdd3-c29b5398a40a" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">632,381</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#cff0fc;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Long-term operating lease liabilities</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_e5f9ad40-c592-4bf9-a8c2-7fa70eb9fbad" contextRef="C_5d513fe3-41de-49c7-8231-3b67764cba30" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">48,489</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_df5fa4ef-62b6-4d33-9ffe-7be73b3de7f7" contextRef="C_ad3c19c0-ada4-44fc-bdd3-c29b5398a40a" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">44,213</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#ffffff;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Long-term professional liabilities</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_d2984d7b-9286-4aea-a64e-ceb3dc5b33e7" contextRef="C_5d513fe3-41de-49c7-8231-3b67764cba30" name="us-gaap:MalpracticeLossContingencyAccrualUndiscountedNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">265,523</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_d4fe6f28-b830-4afb-bbce-49f037f399ed" contextRef="C_ad3c19c0-ada4-44fc-bdd3-c29b5398a40a" name="us-gaap:MalpracticeLossContingencyAccrualUndiscountedNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">275,629</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#cff0fc;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Deferred income tax liabilities</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_54796c21-40f6-4314-ad38-3949d1f140e9" contextRef="C_5d513fe3-41de-49c7-8231-3b67764cba30" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">41,018</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_c756bbeb-4054-4fb0-a45c-f972eb8804e8" contextRef="C_ad3c19c0-ada4-44fc-bdd3-c29b5398a40a" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,638</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#ffffff;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Other liabilities</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_4b6cf6db-5bc1-43b1-b290-5454a7ebe10b" contextRef="C_5d513fe3-41de-49c7-8231-3b67764cba30" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">31,189</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_1b72b7ad-70f7-413b-91ad-136cc40f9892" contextRef="C_ad3c19c0-ada4-44fc-bdd3-c29b5398a40a" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">39,411</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#cff0fc;text-indent:20pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Total liabilities</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_eb3f6a75-ec0f-4bab-afc6-622217038006" contextRef="C_5d513fe3-41de-49c7-8231-3b67764cba30" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,358,354</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_d5107f29-0906-4619-987c-71157fc66c5a" contextRef="C_ad3c19c0-ada4-44fc-bdd3-c29b5398a40a" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,456,255</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_71b38540-0a46-456d-b52f-5551e74ee66d;"><span style="-sec-ix-hidden:F_88126968-94b4-42e4-8930-40061df59b00;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Commitments and contingencies</span></span></span></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#cff0fc;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Shareholders&#x2019; equity:</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#ffffff;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Preferred stock; $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_7661b2d5-bfeb-44c3-ad14-c38aa3f4862a" contextRef="C_5d513fe3-41de-49c7-8231-3b67764cba30" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_USDollarShare" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_8fa2d263-481b-4733-8b68-314c7a340185" contextRef="C_ad3c19c0-ada4-44fc-bdd3-c29b5398a40a" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_USDollarShare" decimals="INF" format="ixt:num-dot-decimal">.01</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;par value; </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_dbdb73c9-85fc-4c97-bce7-8eae366ac932" contextRef="C_5d513fe3-41de-49c7-8231-3b67764cba30" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" scale="3" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_7ae6c393-4466-4e5a-9bf8-37c167c4d36e" contextRef="C_ad3c19c0-ada4-44fc-bdd3-c29b5398a40a" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" scale="3" decimals="INF" format="ixt:num-dot-decimal">1,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;shares authorized; </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_3afeca6b-45b9-4b74-9b29-31661d29d7da" contextRef="C_5d513fe3-41de-49c7-8231-3b67764cba30" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" scale="3" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_d117537c-f69b-451d-8cc7-c753309b71b1" contextRef="C_ad3c19c0-ada4-44fc-bdd3-c29b5398a40a" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" scale="3" decimals="INF" format="ixt-sec:numwordsen">none</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;issued</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_15934e47-abae-4343-8023-eeee18b6dd89" contextRef="C_5d513fe3-41de-49c7-8231-3b67764cba30" name="us-gaap:PreferredStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_cbeee8df-2ddd-4fa2-aff5-dbc8f86cc3be" contextRef="C_ad3c19c0-ada4-44fc-bdd3-c29b5398a40a" name="us-gaap:PreferredStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#cff0fc;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Common stock; $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_be26397e-bf73-43f1-a355-bf5ffa15c045" contextRef="C_5d513fe3-41de-49c7-8231-3b67764cba30" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_USDollarShare" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_94df4832-6ea4-4f52-a220-a41129be4310" contextRef="C_ad3c19c0-ada4-44fc-bdd3-c29b5398a40a" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_USDollarShare" decimals="INF" format="ixt:num-dot-decimal">.01</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;par value; </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_b4c04065-9664-4ce9-80a9-5ce897994a5e" contextRef="C_5d513fe3-41de-49c7-8231-3b67764cba30" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" scale="3" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_aa822d09-a9cd-4564-a4ab-5173faf4ea46" contextRef="C_ad3c19c0-ada4-44fc-bdd3-c29b5398a40a" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" scale="3" decimals="INF" format="ixt:num-dot-decimal">200,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;shares authorized; </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_3b14118e-c923-4e8f-a37d-8bfd14f4c0c7" contextRef="C_5d513fe3-41de-49c7-8231-3b67764cba30" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" scale="3" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_ca50f794-4581-4814-8bf2-fe59b2165c9c" contextRef="C_5d513fe3-41de-49c7-8231-3b67764cba30" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" scale="3" decimals="INF" format="ixt:num-dot-decimal">83,929</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;and </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_45d5227a-9c23-4055-a43d-de54206ab840" contextRef="C_ad3c19c0-ada4-44fc-bdd3-c29b5398a40a" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" scale="3" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_9baf2b09-a127-42a5-b88f-744cd7801b7d" contextRef="C_ad3c19c0-ada4-44fc-bdd3-c29b5398a40a" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" scale="3" decimals="INF" format="ixt:num-dot-decimal">82,947</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;shares<br />&#160;&#160;&#160;issued and outstanding, respectively</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_7982167c-d8d2-4eca-8631-89339d337730" contextRef="C_5d513fe3-41de-49c7-8231-3b67764cba30" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">839</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_a5b5efc4-de6a-4602-8467-670db71d97f6" contextRef="C_ad3c19c0-ada4-44fc-bdd3-c29b5398a40a" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">829</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#ffffff;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Additional paid-in capital</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_be364441-03a0-497d-b75a-1fe4eae771cc" contextRef="C_5d513fe3-41de-49c7-8231-3b67764cba30" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">995,847</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_f0f6cc84-89a2-4141-8e35-33b96c064226" contextRef="C_ad3c19c0-ada4-44fc-bdd3-c29b5398a40a" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">983,601</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#cff0fc;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Accumulated other comprehensive loss</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_ade3154e-8f0c-40b8-98b4-1779ced2bd71" contextRef="C_5d513fe3-41de-49c7-8231-3b67764cba30" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">3,517</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_4a47e8b5-f9f3-4482-88b6-e29888d10ca5" contextRef="C_ad3c19c0-ada4-44fc-bdd3-c29b5398a40a" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">3,735</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#ffffff;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Retained deficit</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_03b8ef7e-43d0-4482-945c-1e4a2afb8132" contextRef="C_5d513fe3-41de-49c7-8231-3b67764cba30" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">25,184</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_5ddd502c-d689-4a30-8673-d935e647433a" contextRef="C_ad3c19c0-ada4-44fc-bdd3-c29b5398a40a" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">89,063</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#cff0fc;text-indent:20pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Total shareholders&#x2019; equity</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_0867c892-a35a-4b06-ab02-0ca320b17a40" contextRef="C_5d513fe3-41de-49c7-8231-3b67764cba30" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">967,985</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_a0399b2c-fd58-4af1-8ace-fc3691b4871b" contextRef="C_ad3c19c0-ada4-44fc-bdd3-c29b5398a40a" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">891,632</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#ffffff;text-indent:20pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Total liabilities and shareholders' equity</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_4cb8b9b7-1bab-44da-8c66-6c6ce4a626d6" contextRef="C_5d513fe3-41de-49c7-8231-3b67764cba30" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,326,339</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_98759eb4-56bb-46de-9b76-6e4912b209d2" contextRef="C_ad3c19c0-ada4-44fc-bdd3-c29b5398a40a" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,347,887</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The accompanying notes are an integral part of these Consolidated Financial Statements.</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">3</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pediatrix Medical Group, Inc.</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="statements_income"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Consolidated Sta</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">tements of Income and Comprehensive Income</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(in thousands, except per share data)</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(Unaudited)</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:56.86%;"></td>
    <td style="width:1%;"></td>
    <td style="width:1%;"></td>
    <td style="width:7%;"></td>
    <td style="width:1%;"></td>
    <td style="width:1.02%;"></td>
    <td style="width:1%;"></td>
    <td style="width:7.48%;"></td>
    <td style="width:1%;"></td>
    <td style="width:1.5%;"></td>
    <td style="width:1%;"></td>
    <td style="width:7.64%;"></td>
    <td style="width:1%;"></td>
    <td style="width:1.18%;"></td>
    <td style="width:1%;"></td>
    <td style="width:8.32%;"></td>
    <td style="width:1%;"></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Three Months Ended<br />September 30,</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Nine Months Ended<br />September 30,</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">2023</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">2023</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Net revenue</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_abdb39bd-f44c-43cb-959c-d20c5d1261a4" contextRef="C_e5943398-0732-4d17-9fe7-25777d223b65" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">506,612</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_798782dc-ea56-49e8-a8e6-5440188598c2" contextRef="C_350c5db7-f64b-4e63-97fa-733cc8e8f783" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">489,915</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_182028e1-2cc9-418b-9079-ff08f9a253eb" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,498,197</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_ee3d3c1a-0178-4672-a742-043d3d750ed5" contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,458,177</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Operating expenses:</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#cff0fc;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Practice salaries and benefits</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_acabae4c-6b27-47e9-8729-ce2f03625386" contextRef="C_e5943398-0732-4d17-9fe7-25777d223b65" name="md:PracticeSalariesAndBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">368,404</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_d929f50a-c3ad-4d72-b2be-f6c7274f743e" contextRef="C_350c5db7-f64b-4e63-97fa-733cc8e8f783" name="md:PracticeSalariesAndBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">342,850</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_2dd1cd02-f2cc-40d2-a4d3-42bd7048e876" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="md:PracticeSalariesAndBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,084,671</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_784ea84d-c7de-4457-bc95-e3f9fbc02cae" contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72" name="md:PracticeSalariesAndBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,016,762</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#ffffff;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Practice supplies and other operating expenses</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_e67a28ee-b598-48db-8e74-ee3deae35429" contextRef="C_e5943398-0732-4d17-9fe7-25777d223b65" name="md:PracticeSuppliesAndOtherOperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">31,319</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_5e2a3538-f169-4da9-a465-9c5e61cb7301" contextRef="C_350c5db7-f64b-4e63-97fa-733cc8e8f783" name="md:PracticeSuppliesAndOtherOperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">31,857</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_8269fa6f-6293-495e-8eab-887bb62fb9a5" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="md:PracticeSuppliesAndOtherOperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">93,128</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_4817dff5-70dc-4f52-8c80-4284e96db668" contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72" name="md:PracticeSuppliesAndOtherOperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">90,189</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#cff0fc;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">General and administrative expenses</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_8a82d992-e651-45c4-ac49-4425dcc2cd6f" contextRef="C_e5943398-0732-4d17-9fe7-25777d223b65" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">57,406</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_246afec6-2885-4204-b858-bb0e7e961a66" contextRef="C_350c5db7-f64b-4e63-97fa-733cc8e8f783" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">57,888</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_d435becd-abc5-44c3-9a5c-845d6f49a5c1" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">174,478</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_bf98c365-06d9-4762-b864-5829924a9c87" contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">180,340</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#ffffff;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Depreciation and amortization</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_750a2938-b0bd-40a7-9a3a-85dc6dbe6dc9" contextRef="C_e5943398-0732-4d17-9fe7-25777d223b65" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,211</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_3cfc43f1-ac71-4271-a70d-ed8ded869ec5" contextRef="C_350c5db7-f64b-4e63-97fa-733cc8e8f783" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,956</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_651d1f8d-792b-4798-bd5d-e6ed6f643779" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,109</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_7003876f-9d6f-4c02-b116-d25dc6319993" contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,500</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#cff0fc;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Transformational and restructuring related expenses</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_634abf69-f5f4-422e-a8a2-190ad69ab3d7" contextRef="C_e5943398-0732-4d17-9fe7-25777d223b65" name="us-gaap:RestructuringCharges" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_a00e6664-81d0-4982-9130-f28d426d0d22" contextRef="C_350c5db7-f64b-4e63-97fa-733cc8e8f783" name="us-gaap:RestructuringCharges" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">977</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_fcde0c0f-7f94-4358-8a3b-564564efce1f" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="us-gaap:RestructuringCharges" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_11e2914c-c6aa-4d93-bcc4-f5d7e037709e" contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72" name="us-gaap:RestructuringCharges" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,736</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#ffffff;text-indent:20pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_84190136-1a6f-4863-845e-105637bdc96f" contextRef="C_e5943398-0732-4d17-9fe7-25777d223b65" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">466,340</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_9ca552f6-3c5e-40f6-bc37-720c9e66d7b8" contextRef="C_350c5db7-f64b-4e63-97fa-733cc8e8f783" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">442,528</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_e2531228-acfd-4934-bcf4-9c8c9b08d190" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,379,386</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_293158b4-061b-4858-8af6-16828f525be1" contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,321,527</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#cff0fc;text-indent:20pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Income from operations</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_736bac3c-6da9-43a4-a719-c492eea1d738" contextRef="C_e5943398-0732-4d17-9fe7-25777d223b65" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">40,272</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_65ec6fc1-e2c4-4bae-b377-af462754b6f8" contextRef="C_350c5db7-f64b-4e63-97fa-733cc8e8f783" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">47,387</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_b10713e9-216d-43ed-9fbf-3856f33bd2f6" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">118,811</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_df90f895-659a-4527-bb87-d4cc1fbf2a6e" contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">136,650</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Investment and other income</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_608695bb-e781-4865-97dc-40d1e27d2ad4" contextRef="C_e5943398-0732-4d17-9fe7-25777d223b65" name="us-gaap:InvestmentIncomeNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">273</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_60e1c1a5-1ca9-4d88-8ec1-fb41f4ab2010" contextRef="C_350c5db7-f64b-4e63-97fa-733cc8e8f783" name="us-gaap:InvestmentIncomeNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">617</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_fdbcbac0-28df-4520-bd6a-e90365b6505a" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="us-gaap:InvestmentIncomeNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,096</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_00020cbd-c8ac-45d5-8eee-2e4db5b4b0ae" contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72" name="us-gaap:InvestmentIncomeNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,336</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Interest expense</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_c7c7e89a-3e4f-4ced-8813-7b70f5ffa124" contextRef="C_e5943398-0732-4d17-9fe7-25777d223b65" name="us-gaap:InterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,374</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_7416b800-1a41-4d6a-9401-cbc140bd3f60" contextRef="C_350c5db7-f64b-4e63-97fa-733cc8e8f783" name="us-gaap:InterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,516</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_0262e82e-83a2-44e9-9162-5fa6720b0e0f" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="us-gaap:InterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">31,994</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_e9b129b1-508b-460c-b30c-30443a01259d" contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72" name="us-gaap:InterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,743</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Loss on early extinguishment of debt</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_b3534908-86fa-4e08-b9af-b1d2fc128961" contextRef="C_e5943398-0732-4d17-9fe7-25777d223b65" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_5790c282-b2fd-49a0-a4a7-d794e63e8478" contextRef="C_350c5db7-f64b-4e63-97fa-733cc8e8f783" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_92571667-fb70-4e42-846e-bf949fee5ee6" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_e5b9aa6f-1c66-40cf-a6f5-f366d73bd4e9" contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">57,016</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Equity in earnings of unconsolidated affiliate</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_fe9c87bd-3739-4686-b039-9d4873453cd6" contextRef="C_e5943398-0732-4d17-9fe7-25777d223b65" name="us-gaap:IncomeLossFromEquityMethodInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">661</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_125cd9e3-b7d0-4a06-8f7a-1bc4bd5da61c" contextRef="C_350c5db7-f64b-4e63-97fa-733cc8e8f783" name="us-gaap:IncomeLossFromEquityMethodInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">371</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_55ab4882-a025-4176-8999-7b238c6b3010" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="us-gaap:IncomeLossFromEquityMethodInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,578</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_a691d898-3dad-4cf6-995d-8c169ca7199d" contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72" name="us-gaap:IncomeLossFromEquityMethodInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,319</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#ffffff;text-indent:20pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Total non-operating expenses</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_bf6e3776-b2a8-4471-ae66-4649840232bb" contextRef="C_e5943398-0732-4d17-9fe7-25777d223b65" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">9,440</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_9e34d732-aec9-4c56-9f61-827db090df7b" contextRef="C_350c5db7-f64b-4e63-97fa-733cc8e8f783" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">8,528</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_df2274f5-5b18-4af9-9b5c-e2b9d37440b0" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">28,320</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_836adb4d-173d-4512-b4ff-4fdcfe21c293" contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">83,104</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#cff0fc;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Income from continuing operations before income taxes</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_bc59bf71-259b-4310-9a69-ff0e50333008" contextRef="C_e5943398-0732-4d17-9fe7-25777d223b65" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">30,832</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_8e815fca-7afd-4762-8f0d-8c0a984706da" contextRef="C_350c5db7-f64b-4e63-97fa-733cc8e8f783" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">38,859</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_7591f214-9a15-4ef7-ad87-121b3b2c0d09" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">90,491</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_14a2225c-41d1-45a8-ab03-b0a2c44e0c9a" contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">53,546</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Income tax provision</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_3c226481-efac-4eda-a269-4f2c6717d449" contextRef="C_e5943398-0732-4d17-9fe7-25777d223b65" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,441</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_e0da988d-74e6-48b3-8dcc-5b35694cd5a6" contextRef="C_350c5db7-f64b-4e63-97fa-733cc8e8f783" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,051</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_b7ca2719-196c-47e5-baa8-bb31e9675d9b" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,612</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_34f10f40-b690-42c7-9636-7245cab1b3f8" contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,982</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#cff0fc;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Income from continuing operations</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_5fa2dc32-8046-47bf-8c49-5cfae6ec1f2c" contextRef="C_e5943398-0732-4d17-9fe7-25777d223b65" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,391</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_ac445e00-0391-4c59-a4b7-9e7750b58350" contextRef="C_350c5db7-f64b-4e63-97fa-733cc8e8f783" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,808</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_2363f8e5-7a6d-4413-86cf-6417f3ea8da1" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">63,879</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_18d34d2d-b9b2-4f0a-9f9b-0b780ee4ecb2" contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">38,564</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#ffffff;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Income (loss) from discontinued operations, net of tax</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_926a944e-8e48-42fe-9b76-4ec8075fa910" contextRef="C_e5943398-0732-4d17-9fe7-25777d223b65" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_112c7353-62d1-47b3-9b6f-be2af4b3a00b" contextRef="C_350c5db7-f64b-4e63-97fa-733cc8e8f783" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,920</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_e3a13458-b75d-4cc6-a4ce-59f4441e161c" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_74ca11be-380b-4e4a-9478-c210ee49789e" contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,892</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#cff0fc;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Net income</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_92c651aa-0e64-4a1f-8d2c-50eece64a984" contextRef="C_e5943398-0732-4d17-9fe7-25777d223b65" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,391</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_9d1977ed-35b6-4548-b3f2-1109c4a34482" contextRef="C_350c5db7-f64b-4e63-97fa-733cc8e8f783" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">30,728</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_7d91f236-aca0-4920-8ff6-1a95df622598" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">63,879</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_64c67a80-5a54-40ab-9ffe-316bcfbf724c" contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">36,672</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#ffffff;text-indent:20pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Net loss attributable to noncontrolling interest</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_f24b8e92-931a-4e85-982a-3ab88fbadcfc" contextRef="C_e5943398-0732-4d17-9fe7-25777d223b65" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_06378054-873c-4b50-8946-eede3c60f97f" contextRef="C_350c5db7-f64b-4e63-97fa-733cc8e8f783" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_eaa25679-be21-4dd5-bdc5-c5e5cb2c313f" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_804d15ac-be62-4e5b-8d02-1b36334aa9b1" contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">4</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#cff0fc;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Net income attributable to Pediatrix Medical Group, Inc.</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_11b79449-2f0c-444d-adec-77c1089a9771" contextRef="C_e5943398-0732-4d17-9fe7-25777d223b65" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,391</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_0ebf7a43-b5b3-4166-836f-f64cf825c794" contextRef="C_350c5db7-f64b-4e63-97fa-733cc8e8f783" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">30,728</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_9dac50f1-2561-43ad-890b-6be113ed0c7f" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">63,879</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_ea4c19e6-dc9b-4123-a229-c48ae14af870" contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">36,676</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Other comprehensive income (loss), net of tax</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Unrealized holding gain (loss) on investments, net of tax of $ </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_cc21f3c7-d677-4a05-b8b1-c9cbc18edb51" contextRef="C_e5943398-0732-4d17-9fe7-25777d223b65" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">, $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_af57d4e3-5955-440d-90a6-d3c16bc6158c" contextRef="C_350c5db7-f64b-4e63-97fa-733cc8e8f783" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">508</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">, $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_5cdbb24e-cbfa-4a6d-9187-547bbf8617dc" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">100</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;and $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_b96b4b29-59bc-4b4a-8c84-45aefec390d1" contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,816</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_9e96f77b-6240-441f-8d05-f7d30351a86f" contextRef="C_e5943398-0732-4d17-9fe7-25777d223b65" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_6a3e3631-711f-461f-a45b-803b94722f21" contextRef="C_350c5db7-f64b-4e63-97fa-733cc8e8f783" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,515</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_6c7275fa-50b8-495b-96cf-71b15ad1b25c" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">218</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_d58c2143-417d-4c4e-b413-4dbfbf8101ed" contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">5,417</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Total comprehensive income attributable to Pediatrix Medical <br />&#160;&#160;&#160;&#160;&#160;Group, Inc.</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_0ee3bb62-844e-40dc-8764-2534323198f4" contextRef="C_e5943398-0732-4d17-9fe7-25777d223b65" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,392</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_ddd00d0b-14ef-4787-9b60-b69946450365" contextRef="C_350c5db7-f64b-4e63-97fa-733cc8e8f783" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,213</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_baed36f0-6cad-464c-8129-c03915b4f212" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">64,097</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_822bdec5-995a-44c1-a459-0625d4823bed" contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">31,259</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Per common and common equivalent share data:</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Net income attributable to Pediatrix Medical Group, Inc.:</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#cff0fc;text-indent:20pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Basic</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_0c1450b8-19aa-4a72-929f-08fef30bb523" contextRef="C_e5943398-0732-4d17-9fe7-25777d223b65" name="us-gaap:EarningsPerShareBasic" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">0.26</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_0e4faaef-88b6-444c-af70-ef42e279ee4b" contextRef="C_350c5db7-f64b-4e63-97fa-733cc8e8f783" name="us-gaap:EarningsPerShareBasic" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">0.37</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_27feec94-ce44-48a8-9ed1-91b1fbd5ff83" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="us-gaap:EarningsPerShareBasic" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">0.78</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_a215652c-d6f4-4843-8973-af475acd9ad7" contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72" name="us-gaap:EarningsPerShareBasic" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">0.44</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#ffffff;text-indent:20pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Diluted</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_9f22e474-75cc-47cd-a166-9f47d1194cfb" contextRef="C_e5943398-0732-4d17-9fe7-25777d223b65" name="us-gaap:EarningsPerShareDiluted" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">0.26</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_53e83e0b-d9c9-4feb-b358-8e718340bb8e" contextRef="C_350c5db7-f64b-4e63-97fa-733cc8e8f783" name="us-gaap:EarningsPerShareDiluted" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">0.37</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_ae18b686-03d7-4875-ab76-f0a20386ae94" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="us-gaap:EarningsPerShareDiluted" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">0.77</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_5682410d-74f1-4b19-a838-3821a052e88c" contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72" name="us-gaap:EarningsPerShareDiluted" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">0.43</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Weighted average common shares:</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#ffffff;text-indent:20pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Basic</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_c4380448-49c9-4105-92f6-8f57d08b11ba" contextRef="C_e5943398-0732-4d17-9fe7-25777d223b65" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">82,543</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_8c15fe26-0121-4e25-9062-ed172def33cc" contextRef="C_350c5db7-f64b-4e63-97fa-733cc8e8f783" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">82,126</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_261c544e-d14d-457d-9055-cdcd5e4597b3" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">82,127</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_852d352b-76f0-4690-93a7-08f39aa9b617" contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">84,122</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#cff0fc;text-indent:20pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Diluted</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_55ef88f4-1548-4458-b211-098202db11f6" contextRef="C_e5943398-0732-4d17-9fe7-25777d223b65" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">82,950</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_cce60e41-11f7-4734-80e7-54a56180c0c6" contextRef="C_350c5db7-f64b-4e63-97fa-733cc8e8f783" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">82,776</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_92bba9c7-35f4-4531-8795-a4da613d70bd" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">82,492</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_dd022416-ec7a-43c8-9bed-33753d2aa3b9" contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">84,821</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The accompanying notes are an integral part of these Consolidated Financial Statements.</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">4</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pediatrix Medical Group, Inc.</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="statements_equity"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Consolidated Sta</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">tements of Shareholders' Equity</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(in thousands)</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(Unaudited)</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:37.728%;"></td>
    <td style="width:1%;"></td>
    <td style="width:1%;"></td>
    <td style="width:7.301%;"></td>
    <td style="width:1%;"></td>
    <td style="width:1%;"></td>
    <td style="width:1%;"></td>
    <td style="width:6.881%;"></td>
    <td style="width:1%;"></td>
    <td style="width:1%;"></td>
    <td style="width:1%;"></td>
    <td style="width:6.881%;"></td>
    <td style="width:1%;"></td>
    <td style="width:1%;"></td>
    <td style="width:1%;"></td>
    <td style="width:9.202%;"></td>
    <td style="width:1%;"></td>
    <td style="width:1%;"></td>
    <td style="width:1%;"></td>
    <td style="width:6.881%;"></td>
    <td style="width:1%;"></td>
    <td style="width:1%;"></td>
    <td style="width:1%;"></td>
    <td style="width:7.121%;"></td>
    <td style="width:1%;"></td>
   </tr>
   <tr style="height:8pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Common Stock</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Number of</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Additional<br />Paid-in</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Accumulated<br />Other<br />Comprehensive</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Retained</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Total</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Shares</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Amount</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Capital</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Loss</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Deficit</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Equity</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">2023</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Balance at January 1, 2023</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_ddf39837-e187-45cf-abe4-05170a11ffc9" contextRef="C_a66a0d65-33d2-4b8c-a2fa-57b2aec20870" name="us-gaap:SharesIssued" unitRef="U_shares" scale="3" decimals="INF" format="ixt:num-dot-decimal">82,947</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_124f0992-7509-489e-962a-5c1cc123cd0c" contextRef="C_a66a0d65-33d2-4b8c-a2fa-57b2aec20870" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">829</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_5a923b61-facd-4a30-8cf7-a64cf02a4060" contextRef="C_9b7a1e9b-0052-493b-8b97-41fc5afb54f6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">983,601</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_63011eab-bf6b-41c8-a54c-07e550b46fac" contextRef="C_61e8dbc9-4c0e-40e5-bc06-8dbeefba5d20" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">3,735</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_03bc9552-4d32-48a3-906c-2a513edfba52" contextRef="C_fa51030c-8ae1-44ad-b260-2c8ee8428637" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">89,063</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_03f88530-ab5d-47c3-86e3-519358464844" contextRef="C_ad3c19c0-ada4-44fc-bdd3-c29b5398a40a" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">891,632</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Net income</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_5efd5ab7-cbb3-4558-aedc-d046d3b66d59" contextRef="C_89fa872a-ad9d-4262-8559-732e6a088cd4" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,206</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_a5d7190f-4f17-4d79-8027-9226c8ccb72a" contextRef="C_ec5297e8-5a0c-4bde-9aa8-9737b4ffc31c" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,206</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Unrealized holding gain on investments, net of tax</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_8bfdd64b-9b19-4f48-a5ac-6efbb4e77757" contextRef="C_ead630e6-3bc1-4158-acab-0cd6d0a20d53" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">604</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_4aa27618-f44b-4dbf-8024-f6550a58c6f1" contextRef="C_ec5297e8-5a0c-4bde-9aa8-9737b4ffc31c" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">604</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Common stock issued under employee stock option,<br />&#160;&#160;&#160;employee stock purchase plan and stock purchase plan</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_a4d0279f-77c2-43b1-a17e-9aa3d7fe0c63" contextRef="C_0c4b440a-242a-4875-a46f-4a05a1426d70" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" scale="3" decimals="INF" format="ixt:num-dot-decimal">86</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_dd3b386a-5337-4288-aa12-6448cee2348b" contextRef="C_75ad9bd0-8190-4d2d-9f0a-71bf1ddf7588" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,095</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_bd3823c1-537a-4f93-8f45-076f7b339371" contextRef="C_ec5297e8-5a0c-4bde-9aa8-9737b4ffc31c" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,095</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Issuance of restricted stock</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_0df2e6e2-0add-4829-9b20-3f4b4cf8d79c" contextRef="C_0c4b440a-242a-4875-a46f-4a05a1426d70" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross" unitRef="U_shares" scale="3" decimals="INF" format="ixt:num-dot-decimal">871</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_2eeb267b-857f-4e23-a680-cae5c5b687d9" contextRef="C_0c4b440a-242a-4875-a46f-4a05a1426d70" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_3eddcda4-417a-4d06-b7d0-0dd906fb965e" contextRef="C_75ad9bd0-8190-4d2d-9f0a-71bf1ddf7588" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">9</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Forfeitures of restricted stock</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_b9b4c775-eaf8-4760-8347-16b58134e964" contextRef="C_0c4b440a-242a-4875-a46f-4a05a1426d70" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" unitRef="U_shares" scale="3" decimals="INF" sign="-" format="ixt:num-dot-decimal">221</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_237e6250-05b0-4917-816e-72b77d19a76e" contextRef="C_0c4b440a-242a-4875-a46f-4a05a1426d70" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_78287883-4558-4d9f-970c-fece0cdd13af" contextRef="C_75ad9bd0-8190-4d2d-9f0a-71bf1ddf7588" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Stock-based compensation expense</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_2c6e5a52-d038-4a30-9b78-15ba515b6d31" contextRef="C_75ad9bd0-8190-4d2d-9f0a-71bf1ddf7588" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,009</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_31178270-b8e3-4270-b216-3c838c0d9dd6" contextRef="C_ec5297e8-5a0c-4bde-9aa8-9737b4ffc31c" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,009</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Repurchased common stock</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_52b97121-f0b9-4171-a05f-a43fe2d2e549" contextRef="C_0c4b440a-242a-4875-a46f-4a05a1426d70" name="us-gaap:StockRepurchasedDuringPeriodShares" unitRef="U_shares" scale="3" decimals="INF" format="ixt:num-dot-decimal">49</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_01dc2850-797b-4d28-a958-082a89a92177" contextRef="C_75ad9bd0-8190-4d2d-9f0a-71bf1ddf7588" name="us-gaap:StockRepurchasedDuringPeriodValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">775</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_65784ced-6526-4198-96f7-2003ed43b1bd" contextRef="C_ec5297e8-5a0c-4bde-9aa8-9737b4ffc31c" name="us-gaap:StockRepurchasedDuringPeriodValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">775</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Balance at March 31, 2023</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_3e50d9b3-c60c-4a00-806f-35d5ea5649b8" contextRef="C_3fe9a616-cb85-448a-a3c7-88b42ca6650a" name="us-gaap:SharesIssued" unitRef="U_shares" scale="3" decimals="INF" format="ixt:num-dot-decimal">83,634</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_ff3549fd-f0f5-40f9-8fd8-7b7a964d5558" contextRef="C_3fe9a616-cb85-448a-a3c7-88b42ca6650a" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">836</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_d22dd1a8-2a78-4582-91e8-1a43e392698f" contextRef="C_2e0a629f-a677-4b59-a478-5cbb505d9530" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">986,923</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_b944ec4c-d08c-460c-88dd-854c0fd0a7ff" contextRef="C_9a67fb14-6a35-4389-82c8-b724c79c3f38" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">3,131</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_70a9afaa-6a3c-497e-88dd-8ccf8c9b8801" contextRef="C_d9967c70-bdd9-46f2-a73f-0af130ef6ca5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">74,857</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_609baaa7-7cde-43f7-a03f-abee079465fd" contextRef="C_308516ff-d843-45b5-8b06-0a3e134f255e" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">909,771</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Net income</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_8f8aea89-21dc-4af5-ac6d-480cd6bc9cee" contextRef="C_461e1df7-29c9-4340-9d09-2d305db85278" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,282</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_e0b61279-e36a-495a-b991-cdbc10ee9283" contextRef="C_874771f9-e875-4db9-94d5-bb53a324cb51" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,282</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Unrealized holding loss on investments, net of tax</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_e202fc9b-600c-4d7d-97c4-8db42edcd239" contextRef="C_fd83bf41-3f3e-4283-8803-bc13fec411ef" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">387</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_e10e7954-6300-4abe-8b4f-236f595ba34c" contextRef="C_874771f9-e875-4db9-94d5-bb53a324cb51" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">387</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Common stock issued under employee stock option,<br />&#160;&#160;&#160;employee stock purchase plan and stock purchase plan</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_b763ac14-9ae6-40ea-a573-1d45d35dfa31" contextRef="C_85574474-f392-4916-ac36-f721aeb624d6" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" scale="3" decimals="INF" format="ixt:num-dot-decimal">126</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_458fdcdd-b213-4b1e-8fe5-211ab146bff1" contextRef="C_85574474-f392-4916-ac36-f721aeb624d6" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_05bb350a-4704-43dc-8040-b0ebcdbe5b34" contextRef="C_86bee92f-7914-4dbf-a4cd-38a1fed2ab1c" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,593</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_cd576b35-ce53-4950-a5a0-cb7d42194c47" contextRef="C_874771f9-e875-4db9-94d5-bb53a324cb51" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,594</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Issuance of restricted stock</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_6906173f-346e-414c-978f-961db8a2865f" contextRef="C_85574474-f392-4916-ac36-f721aeb624d6" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross" unitRef="U_shares" scale="3" decimals="INF" format="ixt:num-dot-decimal">93</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_866aa9aa-0c83-44fc-a1b1-1547a3e0e5cc" contextRef="C_85574474-f392-4916-ac36-f721aeb624d6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_13655cb3-6cec-437b-800a-ff98c2ef2dd9" contextRef="C_86bee92f-7914-4dbf-a4cd-38a1fed2ab1c" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Forfeitures of restricted stock</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_b00f66e7-b3b6-4b3c-97d4-0c3c57646328" contextRef="C_85574474-f392-4916-ac36-f721aeb624d6" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" unitRef="U_shares" scale="3" decimals="INF" sign="-" format="ixt:num-dot-decimal">11</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Stock-based compensation expense</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_a9d86ff9-98c7-427c-abe8-a104f6c70c59" contextRef="C_86bee92f-7914-4dbf-a4cd-38a1fed2ab1c" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,126</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_dc31dc96-2c2a-406c-9649-33df18c2a0fc" contextRef="C_874771f9-e875-4db9-94d5-bb53a324cb51" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,126</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Repurchased common stock</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_4383a7cd-22e8-4fbd-94c5-5fbcdfc6e43c" contextRef="C_85574474-f392-4916-ac36-f721aeb624d6" name="us-gaap:StockRepurchasedDuringPeriodShares" unitRef="U_shares" scale="3" decimals="INF" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_21fc4828-aaec-43d2-8d40-65652cdc1f7c" contextRef="C_86bee92f-7914-4dbf-a4cd-38a1fed2ab1c" name="us-gaap:StockRepurchasedDuringPeriodValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_bf77b37b-f2d1-4b35-bebf-5b2e71fac933" contextRef="C_874771f9-e875-4db9-94d5-bb53a324cb51" name="us-gaap:StockRepurchasedDuringPeriodValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Balance at June 30, 2023</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_6c1b1039-772d-4b11-89cd-b272d351bcaa" contextRef="C_1ccfbb16-e844-487b-90c8-99c1b5604082" name="us-gaap:SharesIssued" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">83,841</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_a5712d0e-d85a-4c33-9e0d-8037dd249146" contextRef="C_1ccfbb16-e844-487b-90c8-99c1b5604082" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">838</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_1c1a7db7-2c2f-4463-b5d2-80d12e708412" contextRef="C_0b8cfdec-f0c4-4429-b94a-75b07f7aae51" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">991,630</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_d6418c86-5a11-4336-a47b-ac3f90d5c5ac" contextRef="C_846d24c8-9524-45a4-a1b6-aa7b223ba8ec" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">3,518</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_af667989-b6be-4210-b5c1-eb351ff62f69" contextRef="C_7b747bea-61e9-4a99-b3d9-c96dee793375" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">46,575</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_36d1ada0-a8df-45bc-9f72-930b3b9032f9" contextRef="C_c10c4eef-bb70-4725-bb7d-0a8da3fa54db" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">942,375</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Net income</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_af96e921-f0fe-4220-b689-29ab5fc4d18b" contextRef="C_fc6992a8-5cd9-42e1-ba09-8be4221adf6f" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,391</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_f97bfee8-355c-45f3-831e-ef18f60c0930" contextRef="C_e5943398-0732-4d17-9fe7-25777d223b65" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,391</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Unrealized holding gain on investments, net of tax</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_c3401d0b-aecc-4f25-af35-f3629e2ee93d" contextRef="C_0002ecca-b81e-4c48-8d05-eefbc915ed5a" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_cfddca4e-32e8-4ec5-a523-bbfc7c0eb475" contextRef="C_e5943398-0732-4d17-9fe7-25777d223b65" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Common stock issued under employee stock option,<br />&#160;&#160;&#160;employee stock purchase plan and stock purchase plan</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_2fcf2a38-98e8-4768-950e-d0df8f2e2a30" contextRef="C_ea09ed9a-1817-4610-877d-b7f92fa5faba" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">100</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_9c6c40ee-d32e-41bc-b88e-d4129a8efe6e" contextRef="C_ea09ed9a-1817-4610-877d-b7f92fa5faba" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_0cd5776d-79fd-4832-a325-564a0eee8797" contextRef="C_db14decc-aca0-4ce7-bed7-40edd1c86538" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,186</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_42fbdb8e-3329-4a09-bd40-566992e3a998" contextRef="C_e5943398-0732-4d17-9fe7-25777d223b65" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,187</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Issuance of restricted stock</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Forfeitures of restricted stock</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_49bf32a9-7179-413e-a23d-a84008c65a6d" contextRef="C_ea09ed9a-1817-4610-877d-b7f92fa5faba" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" unitRef="U_shares" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Stock-based compensation expense</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_ddceb111-f481-4be4-a247-ebdd5e4e8684" contextRef="C_db14decc-aca0-4ce7-bed7-40edd1c86538" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,164</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_edd3e902-ec77-41e1-a887-562f9302d88d" contextRef="C_e5943398-0732-4d17-9fe7-25777d223b65" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,164</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Repurchased common stock</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_f20ea5d1-21ee-4380-bbaf-1be1f001a9aa" contextRef="C_ea09ed9a-1817-4610-877d-b7f92fa5faba" name="us-gaap:StockRepurchasedDuringPeriodShares" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">11</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_b71d53a2-3754-405e-89f1-a60808751eb0" contextRef="C_db14decc-aca0-4ce7-bed7-40edd1c86538" name="us-gaap:StockRepurchasedDuringPeriodValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">133</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_3bf09661-b3a5-40e7-958c-58e7e5dbd141" contextRef="C_e5943398-0732-4d17-9fe7-25777d223b65" name="us-gaap:StockRepurchasedDuringPeriodValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">133</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Balance at September 30, 2023</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_52ab87b4-cc4e-4b85-9b50-859654091f45" contextRef="C_22bf64d7-53dd-4c56-b931-fbaef641de7e" name="us-gaap:SharesIssued" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">83,929</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_1894f102-19c1-4d7c-9a35-3bd843eba341" contextRef="C_22bf64d7-53dd-4c56-b931-fbaef641de7e" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">839</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_77130f77-c821-408d-98bf-51c4c3ada56c" contextRef="C_8350a8fa-b313-4bbc-8d3d-a43cfa5262b4" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">995,847</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_fba9e5ec-4115-4478-92ab-2c69f413dbe6" contextRef="C_92f598fa-4d7f-4e9b-b277-8567385e3d27" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">3,517</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_2f3f389c-fa1c-41d2-805c-785b61476a79" contextRef="C_fd02f20b-c7c9-4b18-9720-432b8fd1f5bc" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">25,184</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_469d4c72-eb7b-4786-9d24-a7619ce6c7be" contextRef="C_5d513fe3-41de-49c7-8231-3b67764cba30" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">967,985</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Balance at January 1, 2022</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_59e607ff-511a-4540-8516-d2ec90378553" contextRef="C_8d549597-a6a3-4f65-960a-276c382d6949" name="us-gaap:SharesIssued" unitRef="U_shares" scale="3" decimals="INF" format="ixt:num-dot-decimal">86,423</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_472bf551-73f3-4877-ac97-2e47b374cffb" contextRef="C_8d549597-a6a3-4f65-960a-276c382d6949" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">864</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_46b02eb1-ebdb-4225-bafc-e5006e5414b5" contextRef="C_35888be5-90cc-40bd-b51a-b4a5ef520e02" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,049,696</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_030237f0-b063-4ccb-a033-0693cc7dcc35" contextRef="C_b7a3aab8-6e4f-488e-bd25-e4acf1837264" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,317</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_55b46377-676e-44e5-b029-6d4c963104a6" contextRef="C_377d4d1b-904e-4983-aaf7-ccda1f31ece5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">155,185</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_59ed4992-846f-466f-84b4-bee9e78fb2da" contextRef="C_cf213a70-35ae-48c9-9339-37927b488110" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">896,692</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_0d4e0392-46f6-4675-a6f7-51a9e9bdbbb2" contextRef="C_bbb0586b-efa6-4d4e-b6e9-1b625c1dbc91" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">21,188</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_244bb3db-0618-44d6-a33c-5b322f7a58b2" contextRef="C_8b93e2e5-8344-474d-908a-5783596f5a9f" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">21,188</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Dissolution of and net loss attributable to noncontrolling interest </span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:normal;font-size:5.36pt;font-family:Times New Roman;position:relative;min-width:fit-content;">(1)</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_db831608-272d-4dea-9813-f388fa6a3dd7" contextRef="C_071df110-5688-40d6-b07e-cf79e845dffc" name="md:DissolutionOfAndNetIncomeLossAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_30c66a9a-0756-4d02-9e4a-1f60b3066ad9" contextRef="C_bbb0586b-efa6-4d4e-b6e9-1b625c1dbc91" name="md:DissolutionOfAndNetIncomeLossAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">213</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_e8442405-4700-449c-a708-92b165088fb6" contextRef="C_8b93e2e5-8344-474d-908a-5783596f5a9f" name="md:DissolutionOfAndNetIncomeLossAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">203</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Unrealized holding loss on investments, net of tax</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_d62be6cc-64f7-44e2-bf41-d0f4fc9471ef" contextRef="C_f0afc955-4abd-4ca2-99cf-97256b13481a" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,668</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_2bebe259-903e-4f00-9204-0f667933a569" contextRef="C_8b93e2e5-8344-474d-908a-5783596f5a9f" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,668</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Common stock issued under employee stock option,<br />&#160;&#160;&#160;employee stock purchase plan and stock purchase plan</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_c7a9b112-5718-4bd7-aa0c-38f3dffb67f7" contextRef="C_4c16c34d-3859-4415-b98c-b075a026c528" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" scale="3" decimals="INF" format="ixt:num-dot-decimal">50</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_02a789fd-c727-4abb-96fc-8f6b59290bc7" contextRef="C_071df110-5688-40d6-b07e-cf79e845dffc" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,174</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_4564caf0-031c-42c1-865c-58388cde0ca5" contextRef="C_8b93e2e5-8344-474d-908a-5783596f5a9f" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,174</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Issuance of restricted stock</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_ad4badba-e25d-43cb-aef9-ffffe728dd4d" contextRef="C_4c16c34d-3859-4415-b98c-b075a026c528" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross" unitRef="U_shares" scale="3" decimals="INF" format="ixt:num-dot-decimal">766</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_13d15678-e276-480e-ab82-747aa94ae12c" contextRef="C_4c16c34d-3859-4415-b98c-b075a026c528" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_acbb3dcc-efb3-4306-a1b2-18717c343109" contextRef="C_071df110-5688-40d6-b07e-cf79e845dffc" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">8</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Forfeitures of restricted stock</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_bdebf01f-4b21-49fd-8ccf-9e6c048a4e03" contextRef="C_4c16c34d-3859-4415-b98c-b075a026c528" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" unitRef="U_shares" scale="3" decimals="INF" sign="-" format="ixt:num-dot-decimal">5</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Stock-based compensation expense</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_8b5e1eca-d65f-431e-b14b-586cf30c7509" contextRef="C_071df110-5688-40d6-b07e-cf79e845dffc" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,435</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_e080009a-ad7c-4df2-b0ad-8fb8ece311f5" contextRef="C_8b93e2e5-8344-474d-908a-5783596f5a9f" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,435</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Repurchased common stock</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_5c45013a-3c03-4046-8721-15d8e0102b52" contextRef="C_4c16c34d-3859-4415-b98c-b075a026c528" name="us-gaap:StockRepurchasedDuringPeriodShares" unitRef="U_shares" scale="3" decimals="INF" format="ixt:num-dot-decimal">50</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_f5e599b7-2066-4253-88b2-ab9c037a0ba4" contextRef="C_071df110-5688-40d6-b07e-cf79e845dffc" name="us-gaap:StockRepurchasedDuringPeriodValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,166</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_7c5a4d02-4cc2-4873-8d15-799399461e26" contextRef="C_8b93e2e5-8344-474d-908a-5783596f5a9f" name="us-gaap:StockRepurchasedDuringPeriodValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,166</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Balance at March 31, 2022</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_5b2b4ba5-8bb8-4263-be7b-d1ba545db6e1" contextRef="C_e4839b2a-c828-4c77-8f2c-55160784c52b" name="us-gaap:SharesIssued" unitRef="U_shares" scale="3" decimals="INF" format="ixt:num-dot-decimal">87,184</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_2673f9ad-7ea6-49dd-8990-8633665a7cae" contextRef="C_e4839b2a-c828-4c77-8f2c-55160784c52b" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">872</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_bb8c3567-f747-4eb3-9fd2-259882be17c7" contextRef="C_115e1478-c36e-4914-b961-b19a8a7591a9" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,054,141</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_c976a2c7-590d-42c2-a6a7-a186671e5bf9" contextRef="C_cd23234b-4b27-4574-a7f1-454baa006e0e" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,351</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_37b4995a-6452-4db8-a745-6ac7305c1574" contextRef="C_aca7d163-6a33-4b3d-9ea5-b99aa4fe9e34" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">176,586</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_67ecd4f0-2b59-4a57-a978-d446129d6161" contextRef="C_f8d7ba49-dc8b-448a-ba32-eed7f3fb3be4" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">877,076</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Net income</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_b0d01d94-3dac-44c9-9fd3-c135fb36c641" contextRef="C_9b225ad0-d1c0-4862-9853-9d52295b37b4" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,136</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_7cff8f19-8924-443b-86c7-239923b0587a" contextRef="C_b3dba50b-b27a-4103-9cc0-9ccc2aeac984" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,136</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Unrealized holding loss on investments, net of tax</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_d7aa132d-7c41-4d53-b481-05d80236f245" contextRef="C_7cfd52bf-5193-4a6c-bf56-23a18e131b5e" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,234</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_53090571-5d61-4d31-bd06-ad8189365052" contextRef="C_b3dba50b-b27a-4103-9cc0-9ccc2aeac984" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,234</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Common stock issued under employee stock option,<br />&#160;&#160;&#160;employee stock purchase plan and stock purchase plan</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_11701037-d331-4da1-bf1d-5369c6ee89bf" contextRef="C_2f54399b-eb59-443e-af5f-01b59be7c4b3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" scale="3" decimals="INF" format="ixt:num-dot-decimal">82</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_09afb319-5b58-4970-9ed6-bc5273f11978" contextRef="C_2f54399b-eb59-443e-af5f-01b59be7c4b3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_5362b446-38c1-4829-bb58-1665d8c41ab1" contextRef="C_3ed13396-e9c9-4ccc-91fd-b54c8527fe2e" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,663</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_7548f1b8-1c51-44ff-9012-d674e934411a" contextRef="C_b3dba50b-b27a-4103-9cc0-9ccc2aeac984" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,664</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Issuance of restricted stock</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_2499b5d2-4180-41a1-9abd-f6c46fcca560" contextRef="C_2f54399b-eb59-443e-af5f-01b59be7c4b3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross" unitRef="U_shares" scale="3" decimals="INF" format="ixt:num-dot-decimal">74</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_2c303ac6-7268-4502-85e5-25bba8f45053" contextRef="C_2f54399b-eb59-443e-af5f-01b59be7c4b3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_ec2b69c4-c163-4edd-9688-ed3a6e3b6744" contextRef="C_3ed13396-e9c9-4ccc-91fd-b54c8527fe2e" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Forfeitures of restricted stock</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_b63235c0-62fa-471d-a0e8-87d9eec2d33d" contextRef="C_2f54399b-eb59-443e-af5f-01b59be7c4b3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" unitRef="U_shares" scale="3" decimals="INF" sign="-" format="ixt:num-dot-decimal">5</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Stock-based compensation expense</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_9a9b7c98-2049-4f17-8453-81640cb74461" contextRef="C_3ed13396-e9c9-4ccc-91fd-b54c8527fe2e" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,186</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_1319e240-7265-4b3a-b814-dd414e83a8c0" contextRef="C_b3dba50b-b27a-4103-9cc0-9ccc2aeac984" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,186</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Repurchased common stock</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_845251f3-bdf2-41ed-8066-bbc8b28bcdd2" contextRef="C_2f54399b-eb59-443e-af5f-01b59be7c4b3" name="us-gaap:StockRepurchasedDuringPeriodShares" unitRef="U_shares" scale="3" decimals="INF" format="ixt:num-dot-decimal">3,275</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_334ea6a2-790e-458a-a47a-4318f5a9824f" contextRef="C_2f54399b-eb59-443e-af5f-01b59be7c4b3" name="us-gaap:StockRepurchasedDuringPeriodValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_13dea7cd-af84-4737-b211-1e80cebc8409" contextRef="C_3ed13396-e9c9-4ccc-91fd-b54c8527fe2e" name="us-gaap:StockRepurchasedDuringPeriodValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">64,365</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_efa791de-5643-4ca9-be04-c1af890acd88" contextRef="C_b3dba50b-b27a-4103-9cc0-9ccc2aeac984" name="us-gaap:StockRepurchasedDuringPeriodValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">64,398</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Balance at June 30, 2022</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_095c7ddf-fa0c-4210-a8b8-91ea8ed2a864" contextRef="C_c77e289a-1111-40d7-9df0-645b35738672" name="us-gaap:SharesIssued" unitRef="U_shares" scale="3" decimals="INF" format="ixt:num-dot-decimal">84,060</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_da22d974-52ce-4fba-bdb3-e050823be07a" contextRef="C_c77e289a-1111-40d7-9df0-645b35738672" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">841</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_ee863410-21ba-47d4-9c5b-3bd66d995331" contextRef="C_c5cbe39a-b446-4f38-9bc0-7315c1df92ff" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">996,624</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_f587a6ab-a8b3-4760-8e38-2be4ca6de8b4" contextRef="C_887ab47d-2465-4e8c-8649-d0d114c06f6c" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,585</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_0bf25e73-e3bb-4ded-a937-d4dce0cecebf" contextRef="C_b3dc82b2-20f3-4300-82a6-75ad6389cab0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">149,450</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_8d290e54-a401-482c-a145-57ed2ff57bb5" contextRef="C_260cff1e-4c05-484b-8a25-8a1e82704661" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">845,430</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Net income</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_93edc715-cd38-4718-8722-89a7329826b8" contextRef="C_6aabcea2-797e-41b7-aefa-4ccc2147de8f" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">30,728</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_d9bcb0fa-bb89-470a-bfc2-4533a077a399" contextRef="C_350c5db7-f64b-4e63-97fa-733cc8e8f783" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">30,728</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Unrealized holding loss on investments, net of tax</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_49b6b171-0c3a-409c-ba19-a41b6a1a1f33" contextRef="C_73fe2b81-82a7-41de-a03c-5ba651cc8568" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,515</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_a00dc0cb-021e-429b-856b-75ce1cdac9e2" contextRef="C_350c5db7-f64b-4e63-97fa-733cc8e8f783" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,515</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Common stock issued under employee stock option,<br />&#160;&#160;&#160;employee stock purchase plan and stock purchase plan</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_68e2df0f-452e-4ef6-b8ca-c4094201f260" contextRef="C_7bab9990-2405-4ad2-b988-70145110847c" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" scale="3" decimals="INF" format="ixt:num-dot-decimal">74</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_62c467a9-55f8-430f-bc04-8adc130436bd" contextRef="C_7bab9990-2405-4ad2-b988-70145110847c" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_be1034ec-e38f-4af8-be84-fcc5de5b71ce" contextRef="C_899d2caa-e2bb-4aac-bb5e-119389b4c1f1" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,380</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_5b464d17-8843-430a-aed4-355c073f8188" contextRef="C_350c5db7-f64b-4e63-97fa-733cc8e8f783" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,381</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Issuance of restricted stock</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_08e01f85-9b41-4359-9e65-a3cdcfbf2bda" contextRef="C_7bab9990-2405-4ad2-b988-70145110847c" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross" unitRef="U_shares" scale="3" decimals="INF" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Forfeitures of restricted stock</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_a8fea8e9-b3b0-4a3c-ae64-175743225b20" contextRef="C_7bab9990-2405-4ad2-b988-70145110847c" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" unitRef="U_shares" scale="3" decimals="INF" sign="-" format="ixt:num-dot-decimal">8</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_4507c201-21af-4579-a0f3-6c9d67678e00" contextRef="C_7bab9990-2405-4ad2-b988-70145110847c" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_f6fcaea7-0f27-44de-9814-d6b59c4e002f" contextRef="C_899d2caa-e2bb-4aac-bb5e-119389b4c1f1" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Stock-based compensation expense</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_9b056984-8918-4a9e-9999-ec3b9c2b1e65" contextRef="C_899d2caa-e2bb-4aac-bb5e-119389b4c1f1" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,120</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_1c0a3555-55dc-4d04-bf56-1ce685c9b1c7" contextRef="C_350c5db7-f64b-4e63-97fa-733cc8e8f783" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,120</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Repurchased common stock</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_671bc632-a853-4ea6-ad2f-318711b6b36a" contextRef="C_7bab9990-2405-4ad2-b988-70145110847c" name="us-gaap:StockRepurchasedDuringPeriodShares" unitRef="U_shares" scale="3" decimals="INF" format="ixt:num-dot-decimal">1,121</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_fc1fbe35-157e-44b7-a50a-383554856f2b" contextRef="C_7bab9990-2405-4ad2-b988-70145110847c" name="us-gaap:StockRepurchasedDuringPeriodValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_957c7b45-0c68-472a-8e6f-5f0e21e91d3c" contextRef="C_899d2caa-e2bb-4aac-bb5e-119389b4c1f1" name="us-gaap:StockRepurchasedDuringPeriodValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,466</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_5e272111-3d16-4df5-b6d0-88dfae34a3fd" contextRef="C_350c5db7-f64b-4e63-97fa-733cc8e8f783" name="us-gaap:StockRepurchasedDuringPeriodValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,477</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Balance at September 30, 2022</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_df1776c8-3ad9-4df4-9f72-f855feb542dd" contextRef="C_56dd7543-31f8-4ae4-badc-c16562ed7f07" name="us-gaap:SharesIssued" unitRef="U_shares" scale="3" decimals="INF" format="ixt:num-dot-decimal">83,006</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_8d1e9588-721e-4f19-9802-68675bb58c77" contextRef="C_56dd7543-31f8-4ae4-badc-c16562ed7f07" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">830</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_c64a02d1-5dcd-421e-ac78-b915364aeb15" contextRef="C_f56c48df-9031-48bb-ae3d-40c5aabd6cc4" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">980,659</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_a24dfc69-1506-4179-9251-3678ce128b02" contextRef="C_3ecbf02e-8155-43fd-bfae-75d93b4d3bb0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">4,100</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_04372c30-0b85-4e45-b63d-db4ad668b075" contextRef="C_07ab98db-f259-45b0-b05a-833bf8d33505" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">118,722</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_cc035220-3d28-4ba6-a1fc-3d20e812782b" contextRef="C_659d9bd3-6f8d-448a-9462-197a2c4b64c7" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">858,667</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.13%;text-indent:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:7.5pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.1496818608532395%;">(1)</span><div style="width:100%;display:inline;"><ix:footnote id="FNT_6b743967-0814-4084-a3b5-92c63ce424bd" xml:lang="en-US"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">Net loss component is presented within retained deficit on the consolidated balance sheet as the balance is immaterial.</span></ix:footnote></div></div>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The accompanying notes are an integral part of these Consolidated Financial Statements.</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">5</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Pediatrix Medical Group, Inc.</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="statements_cash_flows"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Consolidated S</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">t</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">atements of Cash Flows</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(in thousands)</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(Unaudited)</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:67.28%;"></td>
    <td style="width:1.46%;"></td>
    <td style="width:1%;"></td>
    <td style="width:12.9%;"></td>
    <td style="width:1%;"></td>
    <td style="width:1.46%;"></td>
    <td style="width:1%;"></td>
    <td style="width:12.9%;"></td>
    <td style="width:1%;"></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Nine Months Ended September 30,</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">2023</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Cash flows from operating activities:</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#ffffff;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Net income</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_ac0edc1c-515a-4de2-8571-5361a9aebcdd" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">63,879</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_7405cc6c-d9d4-46b5-b273-26df99d4e8bc" contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">36,676</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#cff0fc;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Loss from discontinued operations</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_5ca437c3-3f93-4048-88cd-ffe68a909d68" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_03cd7656-2694-4f80-9fd9-b6a9535c63af" contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,892</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#ffffff;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Adjustments to reconcile net income to net cash from operating activities:</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#cff0fc;text-indent:20pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Depreciation and amortization</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_619548dc-1fc6-4a06-9280-dcc3d5e05023" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,109</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_20ca104c-dfd0-4736-873a-36a461910419" contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,500</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#ffffff;text-indent:20pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Amortization of premiums, discounts and issuance costs</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_879f6107-7399-47d9-8397-eb81ef716ea4" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,015</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_a2e01d72-0406-4ad4-b21a-13998dd60103" contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,346</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#cff0fc;text-indent:20pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Loss on early extinguishment of debt</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_a0031232-d564-4de9-af96-45951e4294aa" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:fixed-zero">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_9ab02542-5412-427e-9e3b-117e19be3191" contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">57,016</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#ffffff;text-indent:20pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Stock-based compensation expense</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_0cd9fe05-58cd-4e36-a911-ba5bd009c4e5" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,299</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_c4bbaa60-4870-44f2-b720-8925286037b7" contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,891</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#cff0fc;text-indent:20pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Deferred income taxes</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_ea75fbbe-2fca-4c00-956d-c53317034441" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="us-gaap:DeferredIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,589</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_e7d44dd1-96ed-4846-9e1e-fc53f8d22d3c" contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72" name="us-gaap:DeferredIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">8,702</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#ffffff;text-indent:20pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Other</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_c1bb5d2f-707e-4c41-aa1d-ebc9b8b29d6d" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="us-gaap:OtherNoncashIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,607</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_fd8acade-ab49-4794-894c-0c679d970208" contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72" name="us-gaap:OtherNoncashIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,379</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#cff0fc;text-indent:20pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Changes in assets and liabilities:</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#ffffff;text-indent:30pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Accounts receivable</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_65edefc8-e451-4760-9b23-1e15dd650542" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="us-gaap:IncreaseDecreaseInAccountsReceivable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">22,095</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_7f0e3600-b64d-429c-8012-f1d9b59daa2a" contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72" name="us-gaap:IncreaseDecreaseInAccountsReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">501</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#cff0fc;text-indent:30pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_b9381fd8-b222-49cc-9bf3-9f56d3e16ede" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">4,290</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_4c1c9eba-8ae2-4127-9361-e9ed7ef0d06c" contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">22,709</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#ffffff;text-indent:30pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Other long-term assets</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_0defdbb2-fd3e-4b52-b470-797d8d9bb7ac" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">13,343</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_e5376a6a-89bf-4e42-88ba-353dc699c6a5" contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">11,160</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#cff0fc;text-indent:30pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Accounts payable and accrued expenses</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_336121d3-b914-411b-bc03-ff78b7ac1a80" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">56,118</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_f0a1758b-c56c-45bd-b8ee-9a007e88c76e" contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">76,439</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#ffffff;text-indent:30pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Income taxes payable</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_954e7a1b-12af-46ad-98ae-121c409ed784" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">5,154</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_af2886c3-df77-4e8a-8be9-eb842fe7e81d" contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">799</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#cff0fc;text-indent:30pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Long-term professional liabilities</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_d43d5b85-bbaf-40c1-b8f8-a74275b3cd81" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="us-gaap:IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">838</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_d0be1ee7-637c-44f7-9534-795eefd662fd" contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72" name="us-gaap:IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,360</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#ffffff;text-indent:30pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Other liabilities</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_da806951-dab3-4ef7-88c8-1e13aba2159f" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">16,500</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_fb4ee22a-8e54-42f5-9212-aaf91ab58adb" contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">10,309</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#cff0fc;text-indent:20pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Net cash provided by operating activities &#x2013; continuing operations</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_45007861-5ca4-487f-9492-6eac22fa72a4" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">73,078</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_6edab1be-5bca-48f9-8d33-968929e59b1f" contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72" name="us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">80,019</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#ffffff;text-indent:20pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Net cash used in operating activities - discontinued operations</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_3b6a3f8c-1b94-4d56-87e2-890a37a0ebb6" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">5,003</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_2d76db6f-d09a-40c0-8b9b-66006de796aa" contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72" name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">11,764</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#cff0fc;text-indent:20pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Net cash provided by operating activities</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_84bc937a-ea35-4502-a7f6-1a514d330aef" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">68,075</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_a02d3967-273e-41c3-9bc0-8a64641faad8" contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">68,255</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Cash flows from investing activities:</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#cff0fc;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Acquisition payments, net of cash acquired</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_4536ae7d-8c64-4894-8983-12fae07a8bc6" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,667</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_b4e5efc6-2306-4bd3-9fcf-8660b15d1ead" contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,167</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#ffffff;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Purchases of investments</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_03964fa8-4c59-48e9-aa69-6540eeed1b63" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="us-gaap:PaymentsToAcquireInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,477</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_1c283040-98cc-4f14-baf2-0501067ddaaf" contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72" name="us-gaap:PaymentsToAcquireInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,938</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#cff0fc;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Proceeds from maturities or sales of investments</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_4ad4e9c6-848c-48d8-bf9c-8b5aa5b43b06" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,560</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_2e439120-d509-4c08-aa6e-0747d92634b5" contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,889</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#ffffff;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Purchases of property and equipment</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_9698161a-36d0-41b3-92a5-76128d690e4c" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="us-gaap:PaymentsToAcquireOtherPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,284</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_f573c9cf-a63d-40ed-ade3-223341cc19d0" contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72" name="us-gaap:PaymentsToAcquireOtherPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,650</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#cff0fc;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Other</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_c2f49ead-7449-49fe-b10a-cda145334d29" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="us-gaap:ProceedsFromSaleOfOtherProductiveAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">116</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_d9b7fc43-fd3e-4837-9d71-57418a1f4079" contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72" name="us-gaap:ProceedsFromSaleOfOtherProductiveAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,153</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#ffffff;text-indent:20pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Net cash used in investing activities</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_8ac28f01-492b-462a-83eb-ce50e55c84ec" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">35,752</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_0c264b0c-2bbe-4437-b527-8c9cba0da07f" contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">45,713</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Cash flows from financing activities:</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#ffffff;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Borrowings on credit agreement</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_f200a911-bd21-4271-a8a8-4e227bdd4468" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="us-gaap:ProceedsFromLinesOfCredit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">470,000</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_de6e0819-2c5f-4038-9144-db56733af019" contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72" name="us-gaap:ProceedsFromLinesOfCredit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">674,500</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#cff0fc;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Payments on credit agreement</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_92fc1953-15f1-42cf-b7d5-2af9fd5a9020" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="us-gaap:RepaymentsOfLinesOfCredit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">474,000</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_ecbb43de-a324-43e8-93e6-17d6586578a1" contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72" name="us-gaap:RepaymentsOfLinesOfCredit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">579,500</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#ffffff;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Payments on term loan</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_c573263e-7c8c-40fc-857c-efda9aa92d96" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="md:PaymentsToTermLoan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,375</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_e26fd345-e0e6-4fa4-98f1-7fb6552dfb47" contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72" name="md:PaymentsToTermLoan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,250</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#cff0fc;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Redemption of senior notes, including call premium</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_2c459bfb-cbf3-4ce2-985f-75b422882999" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="us-gaap:RepaymentsOfSeniorDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_2450777b-05b3-4d41-bfa6-81877fad776e" contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72" name="us-gaap:RepaymentsOfSeniorDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,046,880</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#ffffff;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Proceeds from senior notes and term loan</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_bee270e8-5fee-4da8-a099-e048fb8f8b29" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_a0348f3d-e81c-437d-8de8-cd8baca1c9ee" contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72" name="us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">650,000</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#cff0fc;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Payments for financing costs</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_6415a19f-c439-41d8-89a4-caf57e4add2f" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="us-gaap:PaymentsOfFinancingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_27391822-2991-41c6-af28-79a479fffea6" contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72" name="us-gaap:PaymentsOfFinancingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,621</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#ffffff;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Payments on finance lease obligations</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_07fba462-5381-4e4e-9d25-5d65e93290f6" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="md:RepaymentsOfLongTermCapitalLeaseObligation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,105</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_5ffed2b1-9258-4582-89c9-abd7eaa30121" contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72" name="md:RepaymentsOfLongTermCapitalLeaseObligation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,176</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#cff0fc;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Proceeds from issuance of common stock</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_73c37254-4b67-45a9-a39c-492fba9c28dc" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,876</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_59efc41c-297f-4cab-8dcb-7d7d63a71c19" contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,220</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#ffffff;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Repurchases of common stock</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_7198198a-1e2f-46c8-aadc-265d120aa6de" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="us-gaap:PaymentsForRepurchaseOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">919</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_c638d303-3ea2-4e12-b242-c89696a8a8b7" contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72" name="us-gaap:PaymentsForRepurchaseOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">87,041</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#cff0fc;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Other</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_184a5d30-a087-422b-a887-f2e7c23026a0" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">8,445</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_94583608-a074-416b-9766-17f4e2ed5513" contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">483</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#ffffff;text-indent:20pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Net cash used in financing activities</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_cd0812d9-a507-43bd-8c9a-7223736238bc" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">20,968</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_19b883e3-f04b-42bb-b94d-c38022632880" contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">401,265</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Net increase (decrease) in cash and cash equivalents</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_39800f79-c627-49ec-a33c-b4be2455bba6" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,355</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_b3ea1d36-d568-4998-8489-d39110e240d6" contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">378,723</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Cash and cash equivalents at beginning of period</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_eacd3bbc-960d-4558-94d4-0da48baa1cb8" contextRef="C_ad3c19c0-ada4-44fc-bdd3-c29b5398a40a" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,824</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_61cab7be-f2c5-4ff8-b70f-d60855b8e835" contextRef="C_cf213a70-35ae-48c9-9339-37927b488110" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">387,391</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Cash and cash equivalents at end of period</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_39d36e08-56d1-426c-8a4a-f37ebf28a716" contextRef="C_5d513fe3-41de-49c7-8231-3b67764cba30" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,179</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_1bb5e682-2954-4cb5-9a63-b1235a706e00" contextRef="C_659d9bd3-6f8d-448a-9462-197a2c4b64c7" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,668</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The accompanying notes are an integral part of these Consolidated Financial Statements.</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">6</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pediatrix Medical Group, Inc.</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="notes_financial_statements"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Notes to Consolidated </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial Statements</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">September 30, 2023</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(Unaudited)</span></p>
  <div style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_85b15263-cedb-4ae8-82a6-922b80944b0c" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" escape="true"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">1.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">            Basis of Presentation:</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">On July 1, 2022, effective after the close of the market, the Company changed its corporate name from &#34;Mednax, Inc.&#34; to &#x201c;Pediatrix Medical Group, Inc.&#34; signifying the Company's return to its core focus in caring for women, babies and children.  The Company&#x2019;s common stock continues to trade on the New York Stock Exchange under the ticker symbol &#x201c;MD.&#x201d;</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The accompanying unaudited Consolidated Financial Statements of the Company and the notes thereto presented in this Form 10-Q have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (&#34;SEC&#34;) applicable to interim financial statements, and do not include all disclosures required by accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;) for complete financial statements. In the opinion of management, these financial statements include all adjustments, consisting only of normal recurring adjustments, necessary for a fair statement of the results of interim periods. The financial statements include all the accounts of Pediatrix Medical Group, Inc. and its consolidated subsidiaries (collectively, &#x201c;PMG&#x201d;) together with the accounts of PMG&#x2019;s affiliated business corporations or professional associations, professional corporations, limited liability companies and partnerships (the &#x201c;affiliated professional contractors&#x201d;). Certain subsidiaries of PMG have contractual management arrangements with its affiliated professional contractors, which are separate legal entities that provide physician services in certain states. The Company ceased providing services in Puerto Rico effective December 31, 2022.  The terms &#x201c;Pediatrix&#x201d; and the &#x201c;Company&#x201d; refer collectively to Pediatrix Medical Group Inc., its subsidiaries and the affiliated professional contractors.</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The Compan</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">y is a party to a joint venture in which it owns a </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_9182de45-7c4e-421c-8d20-bbbe3b134cd1" contextRef="C_7ae55b15-375d-4829-8fee-0964b045a7cf" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">37.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">% economic interest.  The Company accounts for this joint venture under the equity method of accounting because the Company exercises significant influence over, but does not control, this entity.  The Company was also a party to another joint venture in which it owned a </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_8d64eca6-569c-4fa2-bc5c-f5e63775a2cf" contextRef="C_99787654-98fb-4075-b2d1-551ddbc6deed" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">51</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">% economic interest and for which it was deemed the primary beneficiary. This joint venture was dissolved in February 2022.  The operating results related to this joint venture prior to the dissolution and impacts from such dissolution were not material.</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The consolidated results of operations for the interim periods presented are not necessarily indicative of the results to be experienced for the entire fiscal year. In addition, the accompanying unaudited Consolidated Financial Statements and the notes thereto should be read in conjunction with the Consolidated Financial Statements and the notes thereto included in the Company&#x2019;s most recent Annual Report on Form 10-K (the &#x201c;Form 10-K&#x201d;).</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cb286af8-9507-4f56-8c4c-147459d064a1" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" escape="true"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">2.            Cash Equivalents and Investments:</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">As of September 30, 2023 and December 31, 2022, the Company's cash equivalents consisted entirely of money market funds totaling $</span><span style="font-size:9pt;font-family:Times New Roman;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_d64de107-ae35-4336-af98-d93907056dd3" contextRef="C_d1b666e6-0f27-4c23-9240-3207e18d4a31" name="us-gaap:MoneyMarketFundsAtCarryingValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:9pt;font-family:Times New Roman;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_8b3ec187-d9f8-4ce8-b827-3f6c75d25597" contextRef="C_ece3d6f0-dcae-48a9-bc24-698ee8c17506" name="us-gaap:MoneyMarketFundsAtCarryingValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><div style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d993e294-a7d5-4c97-b940-8ac0f3460f7d" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" escape="true"><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Investments held are all classified as current and at </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">September 30, 2023 and December 31, 2022 are summarized as follows (in thousands):</span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:74.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.52%;"></td>
        <td style="width:1.42%;"></td>
        <td style="width:1%;"></td>
        <td style="width:18.32%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.42%;"></td>
        <td style="width:1%;"></td>
        <td style="width:18.32%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">September 30, 2023</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Corporate securities</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_f6d1e09d-7e6e-4668-a3ce-1f1a22542ba8" contextRef="C_ecfb99fe-0958-4180-b890-77afb1efe059" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">58,830</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_e142e9cf-6b63-4eb0-8ac4-37f8588762d9" contextRef="C_f2e4e009-3726-45e0-a90a-5d336cda6f04" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">61,385</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Municipal debt securities</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_d643ec94-9b5b-43c2-ae66-621517ce96b1" contextRef="C_7ad99fb3-5525-4459-a4cb-b1188d7c5224" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,419</ix:nonFraction></span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_469e0776-9511-4f29-a14b-1c923845152c" contextRef="C_36d93c5d-b688-4948-8aa6-b10b1986e10f" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,377</ix:nonFraction></span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">U.S. Treasury securities</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_8bb6ddd3-27e2-4f57-9a9f-719d32035d82" contextRef="C_b98e3dec-68cf-411f-84d8-48f4345c2f5e" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,888</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_aca2620c-9fc8-4e89-8ca6-3cfd50657c7f" contextRef="C_64e6ce54-7a3c-4a04-9100-a67300b48c30" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,205</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Certificates of deposit</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_2030c7da-1a30-4855-b977-37b75d541122" contextRef="C_012cf148-5766-4e38-bab9-71a218133486" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,906</ix:nonFraction></span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_31f17d3d-ea03-44c8-b49a-55f8488b496c" contextRef="C_c8155ad1-ff2e-4bfe-b9f9-a6805aed62f4" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,710</ix:nonFraction></span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Federal home loan securities</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_4d387c5e-f673-4d1a-b97d-cda7efbc0de9" contextRef="C_b42eab6a-90cf-43fc-9fc6-2ad25a6ef134" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,498</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_d6f13c45-e6ee-4816-8e58-3f95aceea311" contextRef="C_ee5ce32e-37b5-4efc-a6e1-d6be8df2025a" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,562</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_8700d041-1a46-4820-a5d5-12738be096b8" contextRef="C_5d513fe3-41de-49c7-8231-3b67764cba30" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">103,541</ix:nonFraction></span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_27e79806-f0c0-4df2-9c61-38a19974207d" contextRef="C_ad3c19c0-ada4-44fc-bdd3-c29b5398a40a" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">93,239</ix:nonFraction></span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:12pt;font-family:Arial;"><ix:nonNumeric id="F_d9933e2c-0522-40b2-b28c-016aafe487f3" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="us-gaap:FairValueDisclosuresTextBlock" escape="true"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">3.            Fair Value Measurements:</span></p><p style="margin-left:6.667%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The accounting guidance establishes a fair value hierarchy that prioritizes valuation inputs into three levels based on the extent to which inputs used in measuring fair value are observable in the market. Each fair value measurement is reported in one of three levels:</span></p><p style="margin-left:6.667%;text-indent:0;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Level 1 &#x2013; inputs are based upon unadjusted quoted prices for identical instruments traded in active markets.</span></p><p style="margin-left:6.667%;text-indent:0;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Level 2 &#x2013; inputs are based upon quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></p><p style="margin-left:6.667%;text-indent:0;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Level 3 &#x2013; inputs are generally unobservable and typically reflect management&#x2019;s estimates of assumptions that market participants would use in pricing the asset or liability. The fair values are therefore determined using model-based techniques that include option pricing models, discounted cash flow models, and similar techniques.</span></p><ix:exclude><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">7</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</span></p></ix:exclude><div style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9ed74e82-7c54-4a75-9819-f3c854ceab6a" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" escape="true"><p style="text-indent:6.667%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The following table presents information about the Company&#x2019;s financial instruments that are accounted for at fair value on a recurring basis at </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">September 30, 2023 and December 31, 2022 (in thousands):</span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:95.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:47.464%;"></td>
        <td style="width:1.062%;"></td>
        <td style="width:12.668%;"></td>
        <td style="width:1.062%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.818999999999999%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.105%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.818999999999999%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Fair Value</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Fair Value<br />Category</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">September 30, 2023</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Assets:</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#ffffff;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Money market funds</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Level 1</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_80b7c1ea-eb40-4a5b-ab85-8bd359f2a1f6" contextRef="C_3f1eae59-7db7-4f63-b33e-689ca6ac6166" name="md:MoneyMarketFundsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,201</ix:nonFraction></span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_5baeb897-7266-4d0c-b6d0-744582525290" contextRef="C_af3a863a-e1d2-476d-ab71-08e497384468" name="md:MoneyMarketFundsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,415</ix:nonFraction></span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#cff0fc;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Short-term investments</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_327c0ec7-105c-4015-a8a8-75a6fb9bfd2a" contextRef="C_f56f4f7a-19b8-4635-8355-ce0222c24e4b" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">103,541</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_a4527b7a-1e53-4cc8-8bca-54768285f6c0" contextRef="C_2ed09d19-c783-4eb4-860c-7e590254f539" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">93,239</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#ffffff;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Mutual Funds</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Level 1</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_f819e413-e59f-455f-ac61-91d0da3ff34b" contextRef="C_3f1eae59-7db7-4f63-b33e-689ca6ac6166" name="md:MutualFundsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,851</ix:nonFraction></span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_348c3779-c95c-4203-8ae7-d641b6ec2cd5" contextRef="C_af3a863a-e1d2-476d-ab71-08e497384468" name="md:MutualFundsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,544</ix:nonFraction></span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_51d10d86-ef0b-4149-bf26-5b01424c15ba" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="md:FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock" escape="true"><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The following table presents information about the Company&#x2019;s financial instruments that are not carried at fair value at </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">September 30, 2023 and December 31, 2022 (in thousands):</span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.72%;"></td>
        <td style="width:1.08%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.24%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.08%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.84%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.32%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.72%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">September 30, 2023</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Carrying<br />Amount</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Fair<br />Value</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Carrying<br />Amount</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Fair<br />Value</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Liabilities:</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#ffffff;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">2030 Notes</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_0a2c5b3d-3e4f-4868-ba14-74a0c9053641" contextRef="C_06c01cd0-0e05-46ab-a1e5-d6467d9be312" name="us-gaap:NotesPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">400,000</ix:nonFraction></span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_a83d196b-674a-46fd-868a-8663a39ef6c9" contextRef="C_06c01cd0-0e05-46ab-a1e5-d6467d9be312" name="us-gaap:NotesPayableFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">352,680</ix:nonFraction></span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_5ec06143-d379-43c5-9412-489a2d8f31d0" contextRef="C_0a32aa8a-cbb8-411d-957d-680d318c2384" name="us-gaap:NotesPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">400,000</ix:nonFraction></span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_45cc327e-b0d1-4591-8629-1c348399e49c" contextRef="C_0a32aa8a-cbb8-411d-957d-680d318c2384" name="us-gaap:NotesPayableFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">344,000</ix:nonFraction></span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The carrying amounts of cash equivalents, accounts receivable and accounts payable and accrued expenses approximate fair value due to the short maturities of the respective instruments. The carrying value of the line of credit approximates fair value.  If the Company&#x2019;s line of credit was measured at fair value, it would be categorized as Level 2 in the fair value hierarchy.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">  </span></p></ix:nonNumeric></div>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:12pt;font-family:Arial;"><ix:nonNumeric id="F_6ee7e28a-0388-4873-8097-fbd1e664274c" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="md:AccountsReceivableAndNetRevenueDisclosureTextBlock" escape="true"><p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">4. </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Arial;min-width:fit-content;">            </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Accounts Receivable and Net Revenue:</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ecbd98fa-61dd-4859-a0ca-9c1d04f274b4" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" escape="true"><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Accounts receivable, net consists of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:96.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:64.696%;"></td>
        <td style="width:1.042%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.61%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.042%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.61%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">September 30, 2023</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Gross accounts receivable</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_ef95e3c6-0055-43bc-aa71-75df3a1e96b9" contextRef="C_5d513fe3-41de-49c7-8231-3b67764cba30" name="us-gaap:AccountsReceivableGrossCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,448,620</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_cb72d82d-b720-4d6f-9fbd-02fac7b7b0a3" contextRef="C_ad3c19c0-ada4-44fc-bdd3-c29b5398a40a" name="us-gaap:AccountsReceivableGrossCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,548,492</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Allowance for contractual adjustments and uncollectibles</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_48fb7516-0775-4000-8b21-c83e4c098247" contextRef="C_5d513fe3-41de-49c7-8231-3b67764cba30" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,171,268</ix:nonFraction></span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_6ae96a95-0c7b-4ffd-a72f-90e6d81bd572" contextRef="C_ad3c19c0-ada4-44fc-bdd3-c29b5398a40a" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,251,705</ix:nonFraction></span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_c528d194-b55a-4f76-bf26-1f5fb20232db" contextRef="C_5d513fe3-41de-49c7-8231-3b67764cba30" name="us-gaap:AccountsReceivableNetCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">277,352</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_514aa901-c4a0-4a52-ba6f-8a9a83af9537" contextRef="C_ad3c19c0-ada4-44fc-bdd3-c29b5398a40a" name="us-gaap:AccountsReceivableNetCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">296,787</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Patient service revenue is recognized at the time services are provided by the Company&#x2019;s affiliated physicians. The Company&#x2019;s performance obligations related to the delivery of services to patients are satisfied at the time of service. Accordingly, there are no performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period with respect to patient service revenue. Almost all of the Company&#x2019;s patient service revenue is reimbursed by government-sponsored healthcare programs (&#x201c;GHC Programs&#x201d;) and third-party insurance payors. Payments for services rendered to the Company&#x2019;s patients are generally less than billed charges. The Company monitors its revenue and receivables from these sources and records an estimated contractual allowance to properly account for the anticipated differences between billed and reimbursed amounts.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Accordingly, patient service revenue is presented net of an estimated provision for contractual adjustments and uncollectibles. The Company estimates allowances for contractual adjustments and uncollectibles on accounts receivable based upon historical experience and other factors, including days sales outstanding (&#x201c;DSO&#x201d;) for accounts receivable, evaluation of expected adjustments and delinquency rates, past adjustments and collection experience in relation to amounts billed, an aging of accounts receivable, current contract and reimbursement terms, changes in payor mix and other relevant information. Contractual adjustments result from the difference between the physician rates for services performed and the reimbursements by GHC Programs and third-party insurance payors for such services.</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Collection of patient service revenue the Company expects to receive is normally a function of providing complete and correct billing information to the GHC Programs and third-party insurance payors within the various filing deadlines and typically occurs within 30 to 60 days of billing.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Some of the Company&#x2019;s hospital agreements require hospitals to pay the Company administrative fees. Some agreements provide for fees if the hospital does not generate sufficient patient volume in order to guarantee that the Company receives a specified minimum revenue level. The Company also receives fees from hospitals for administrative services performed by its affiliated physicians providing medical director or other services at the hospital.</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><ix:exclude><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">8</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</span></p></ix:exclude><div style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8baf98d9-c6d5-449b-970b-9ff3b42f90a7" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="us-gaap:DisaggregationOfRevenueTableTextBlock" escape="true"><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes the Company&#x2019;s net revenue by category (in thousands):</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:30.731%;"></td>
        <td style="width:1.147%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.426%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.147%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.552999999999999%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.147%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.84%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.68%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.324%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Three Months Ended<br />September 30,</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Nine Months Ended<br />September 30,</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Net patient service revenue</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_38bd285e-ec0c-4bc2-9e36-ccbdc1c1dbba" contextRef="C_ee0dda75-7533-43f8-ba6d-8b3ddadca454" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">437,321</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_5b36f8d1-d29b-4924-b8f3-ef52a68dbf99" contextRef="C_ec45eaa6-d9c5-4fd0-84cf-6b2be759e02b" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">421,085</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_168d3e20-67ed-4a38-835e-3ea454b2e74a" contextRef="C_56cb679d-6a88-4a31-abf3-f1c779c4bcb9" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,290,888</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_27bbcaa5-d4ab-4d95-887e-91158c61d748" contextRef="C_f6042715-3400-472b-a63f-651373917338" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,245,627</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Hospital contract administrative fees</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_3a3923a6-6b1c-4790-a07a-bc03809e4110" contextRef="C_3f7aa872-26d0-45a9-b1bb-119611e8d6c8" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">68,712</ix:nonFraction></span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_fbe4de99-d056-42e4-93fb-9211340573ab" contextRef="C_07cad879-2c61-450d-9518-d6bbda76d09e" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">67,418</ix:nonFraction></span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_9549cf7e-a640-4974-87c8-9943c4dcb864" contextRef="C_13a9d66b-1b0e-497a-b873-fe7ac09c44cf" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">204,286</ix:nonFraction></span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_e4db46d9-8733-4cba-9e3d-d3f72eb78d2c" contextRef="C_c7f29732-6f5b-49e4-a848-639b94127316" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">196,425</ix:nonFraction></span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Other revenue</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_ba942851-31f0-45ad-bd3d-2cd0863da2bb" contextRef="C_9d124535-a548-449d-8d4b-80ec4d95973a" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">579</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_9a45574a-f71b-4b9e-a3a2-09bc6f335cd5" contextRef="C_97d10031-02ee-416c-bb86-cd6e6928957a" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,412</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_507601c0-d789-42ff-a1b4-62928afd4b40" contextRef="C_7b75f74d-09a8-4e26-8d61-3a48b9fa176e" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,023</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_696cc059-84e3-4301-8a4c-3367988748d7" contextRef="C_dba1d7c4-12e0-4e88-888d-efc09f476c71" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,125</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_34be22ff-66f0-4553-9b14-fd6bf0193b39" contextRef="C_e5943398-0732-4d17-9fe7-25777d223b65" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">506,612</ix:nonFraction></span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_a8864712-8ffe-447f-94c7-4218452b12dc" contextRef="C_350c5db7-f64b-4e63-97fa-733cc8e8f783" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">489,915</ix:nonFraction></span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_2e76be2b-622b-4c59-b4e0-a080aefd8201" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,498,197</ix:nonFraction></span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_1bc093e1-281f-4414-9d75-b1f3680bd879" contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,458,177</ix:nonFraction></span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_374b8d02-68d0-4bc7-80ef-565379d13594" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" escape="true"><p style="margin-left:4.533%;text-indent:6.983%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The approximate percentage of net patient service revenue by type of payor was as follows:</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:91.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:36.233%;"></td>
        <td style="width:1.3%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.597%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.82%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.798%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.078%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.177999999999999%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Three Months Ended<br />September 30,</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Nine Months Ended<br />September 30,</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Contracted managed care</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_897fe119-c40a-4380-9ffc-487b552ec1a0" contextRef="C_1a90cf11-7660-475d-b876-c49b675c3a0d" name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">67</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">%</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_2e2eae32-e31e-4634-8cdb-51887825659c" contextRef="C_33f86df0-142f-4408-9f5e-9de3e9f21458" name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">65</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">%</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_a4315de3-e6e5-4a20-8901-3222a9fc578b" contextRef="C_530a9bb3-d0af-4d65-93b6-103b6c414d75" name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">67</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">%</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_4b89f645-8956-4410-9b45-eac3815abfc5" contextRef="C_6ea9b9a0-3cfd-421c-9583-235675ef66b6" name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">67</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Government</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_0a4591aa-45af-41ac-b628-bc042a80706b" contextRef="C_134848fe-680a-4e25-830f-371c8b8fb100" name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">25</ix:nonFraction></span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_55db95f4-b93e-4f22-9157-1dbc7e1d95b0" contextRef="C_340f9a3e-b672-4edc-82ab-7e12ef61b6da" name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">28</ix:nonFraction></span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_343c6340-6e7f-477c-920f-b661e7caa767" contextRef="C_4a7eedc9-2d63-42bd-9695-8d9ce87c5067" name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">25</ix:nonFraction></span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_e42d64e5-2d62-49b0-a7d6-2053ef325b4d" contextRef="C_6494afcc-dadf-426c-b613-8f9a7abfe318" name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">26</ix:nonFraction></span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Other third-parties</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_b1201bdd-6579-40c7-a573-2807019ff47a" contextRef="C_45911ccf-f5d4-4c4e-8dd0-c5ea09a1db36" name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">5</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_3454cd16-dabd-4029-bba3-b01528179cc5" contextRef="C_477d8b88-2dd5-4c27-a308-f22d4cb31970" name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">5</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_d6052b92-7988-4e54-9f5f-d65a76f288af" contextRef="C_86ceec74-75ab-4b30-bf4d-aa99084da5fc" name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">6</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_1c57df55-3821-48a0-abdc-d44df2f5c9f1" contextRef="C_61935c85-fd8d-48a0-b0e8-e2ace38d0aca" name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">5</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Private-pay patients</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_1ae46cc2-e8c5-4e1a-8347-ad0aa2527449" contextRef="C_f61ab540-a2d0-4d45-8e9f-d043538b0a26" name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_9d0d640b-91db-4863-b434-d968c9779c24" contextRef="C_a53e34bc-3154-419c-8471-2c496997bd8c" name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_6d3d7e9d-9852-4eab-b9f7-8ef7ae38fa1b" contextRef="C_99c7da7a-966d-481a-9f87-07899a403107" name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_fd24f76b-e812-42af-8de3-938814012b3f" contextRef="C_8fa77ca8-719f-4df1-bf5f-88fe5ee7eebb" name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_6cc28bf6-0331-4cc4-bdaf-7243baaf4314" contextRef="C_e5943398-0732-4d17-9fe7-25777d223b65" name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">100</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">%</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_aecc3b0d-1630-4608-bc63-5922e5c096ef" contextRef="C_350c5db7-f64b-4e63-97fa-733cc8e8f783" name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">100</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">%</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_6df9bb3b-c4f9-43a7-9894-b07e5a36713c" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">100</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">%</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_c53e3bf1-5f62-4311-8ea7-ef72d5128943" contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72" name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">100</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8485ca08-a4a0-4ece-940a-a6c2a355c67f" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" escape="true"><p style="text-indent:0;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">5.            Accounts Payable and Accrued Expenses:	</span></p><div style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_46d81c01-e39a-41e1-b607-507dcdf4784b" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" escape="true"><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Accounts payable and accrued expenses consist of the following (in thousands):</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:54.314%;"></td>
        <td style="width:1.253%;"></td>
        <td style="width:1%;"></td>
        <td style="width:21.479%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.253%;"></td>
        <td style="width:1%;"></td>
        <td style="width:17.7%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">September 30, 2023</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Accounts payable</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_f49b9748-e887-4472-b408-4ff787baa2a7" contextRef="C_5d513fe3-41de-49c7-8231-3b67764cba30" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">31,696</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_6dd383ce-3695-4d4d-96bb-679f5efb45b2" contextRef="C_ad3c19c0-ada4-44fc-bdd3-c29b5398a40a" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">31,857</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Accrued salaries and incentive compensation</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_504fa1a4-757a-4c34-9a03-c63be7082262" contextRef="C_5d513fe3-41de-49c7-8231-3b67764cba30" name="us-gaap:AccruedSalariesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">150,014</ix:nonFraction></span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_b232405e-7779-46c6-8f6a-20c7adad3f17" contextRef="C_ad3c19c0-ada4-44fc-bdd3-c29b5398a40a" name="us-gaap:AccruedSalariesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">197,831</ix:nonFraction></span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Accrued payroll taxes and benefits</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_10db8282-116d-4b43-98da-bb98136dffec" contextRef="C_5d513fe3-41de-49c7-8231-3b67764cba30" name="md:AccruedPayrollTaxesAndBenefitsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">35,366</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_91dd8815-5544-4769-acdb-60c68bd0fc06" contextRef="C_ad3c19c0-ada4-44fc-bdd3-c29b5398a40a" name="md:AccruedPayrollTaxesAndBenefitsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">34,983</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Accrued professional liabilities</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_2d5440a1-28f2-40b0-809f-afa2b008f1d0" contextRef="C_5d513fe3-41de-49c7-8231-3b67764cba30" name="us-gaap:MalpracticeLossContingencyAccrualUndiscountedCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">30,169</ix:nonFraction></span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_6b87c6e8-48bb-412c-82f7-764dbb33e6a2" contextRef="C_ad3c19c0-ada4-44fc-bdd3-c29b5398a40a" name="us-gaap:MalpracticeLossContingencyAccrualUndiscountedCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">32,232</ix:nonFraction></span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Accrued interest</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_e2f3a222-82ff-4ecd-92ef-453ff6682dd3" contextRef="C_5d513fe3-41de-49c7-8231-3b67764cba30" name="us-gaap:InterestPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,204</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_79b9b388-c7b7-4ff5-94e7-c51a79c1eca0" contextRef="C_ad3c19c0-ada4-44fc-bdd3-c29b5398a40a" name="us-gaap:InterestPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,921</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Other accrued expenses</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_a1ec613f-df46-4bbf-99d5-5968fd0bb6ca" contextRef="C_5d513fe3-41de-49c7-8231-3b67764cba30" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">52,134</ix:nonFraction></span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_30a2541d-ddfd-4a49-b5d9-000776d65ddf" contextRef="C_ad3c19c0-ada4-44fc-bdd3-c29b5398a40a" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">68,401</ix:nonFraction></span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_d607ce6d-09ea-494a-8fd0-674eedcbf56a" contextRef="C_5d513fe3-41de-49c7-8231-3b67764cba30" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">302,583</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_273c0ba0-a554-44fa-b9ed-cad6d6bf4765" contextRef="C_ad3c19c0-ada4-44fc-bdd3-c29b5398a40a" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">374,225</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The net decrease in accrued salaries and incentive compensation of $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_556f52b4-69d5-4ed7-85d6-9a0778ea096e" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="md:IncreaseDecreaseInAccruedSalariesAndBonuses" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">47.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million, from December 31, 2022 to September 30, 2023, is primarily due to the payment of performance-based incentive compensation, principally to the Company&#x2019;s affiliated physicians, partially offset by performance-based incentive compensation accrued during the nine months ended September 30, 2023</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">. A majority of the Company&#x2019;s payments for performance-based incentive compensation is paid annually during the first quarter.</span></p></ix:nonNumeric></div>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:12pt;font-family:Arial;"><ix:nonNumeric id="F_af8eef81-8cb0-4865-8bcc-27c84be43945" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="md:LineOfCreditAndLongTermDebtTextBlock" escape="true"><p style="text-indent:0;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">6.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Arial;min-width:fit-content;">          </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Line of Credit and Long-Term Debt:</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">On February 11, 2022, the Company issued $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_9d23fbb1-ee72-4c5e-b372-731d896ebae3" contextRef="C_2f1c7dd7-f01c-4015-a37d-1caeb69540b9" name="us-gaap:SeniorNotes" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">400.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million of </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_8061c29d-724c-44e2-ae8b-a80e793dd8db" contextRef="C_2f1c7dd7-f01c-4015-a37d-1caeb69540b9" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" unitRef="U_pure" scale="-2" decimals="5" format="ixt:num-dot-decimal">5.375</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">% unsecured senior notes due 2030 (the &#x201c;2030 Notes&#x201d;).  The Company used the net proceeds from the issuance of the </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_53ffe27f-4e86-465d-92e9-b3e5993d9687" contextRef="C_1c0cfd23-24b4-45dc-8a0f-30d68714c292" name="md:DebtInstrumentMaturityYear"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">2030</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> Notes, together with $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_acbeac04-9b28-4c56-879d-009b7351018f" contextRef="C_f2431026-3a3b-40cd-9fb3-55962d2dfba5" name="us-gaap:ProceedsFromIssuanceOfUnsecuredDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">100.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million drawn under the Revolving Credit Line (as defined below), $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_fa98cf72-5151-466f-b90a-87f281203dbb" contextRef="C_48f6c028-da90-4698-9d57-8fadb9aedae6" name="us-gaap:UnsecuredLongTermDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">250.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million of Term A Loan (as defined below) and approximately $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_5c481440-9fc9-4c83-aa3f-d9cff586bd0c" contextRef="C_48f6c028-da90-4698-9d57-8fadb9aedae6" name="us-gaap:Cash" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">308.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million of cash on hand, to redeem (the &#x201c;Redemption&#x201d;) the </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_49550e3e-3af5-4c54-bcb2-442b7080974f" contextRef="C_fdee2685-4fe9-4dac-b896-4bbc5d69816d" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">6.25</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">% senior unsecured notes due 2027, which had an outstanding principal balance of $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_ec07acbd-d30d-4227-a376-0570df7c3d9d" contextRef="C_4ec257e6-7ad0-419f-b83a-531d36bb3987" name="us-gaap:LongTermDebt" unitRef="U_USD" scale="9" decimals="-8" format="ixt:num-dot-decimal">1.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> billion, and to pay costs, fees and expenses associated with the Redemption and the Credit Agreement Amendment (as defined below).</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Interest on the 2030 Notes accrues at the rate of </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_b430f25c-87bd-4fa1-881e-b57ba3d12ba1" contextRef="C_5d513fe3-41de-49c7-8231-3b67764cba30" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" unitRef="U_pure" scale="-2" decimals="5" format="ixt:num-dot-decimal">5.375</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">% per annum, or $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_8aaee20e-8b5c-472f-88ef-ad1f566114d7" contextRef="C_ebc061e7-b2d9-4c21-8b03-fda66e7ff5fd" name="us-gaap:DebtInstrumentPeriodicPaymentInterest" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">21.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million, and is </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a6b3266f-b030-4629-a4ae-2c6841843195" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="us-gaap:DebtInstrumentFrequencyOfPeriodicPayment"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">payable semi-annually in arrears on February 15 and August 15, beginning on August 15, 2022</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">. The Company's obligations under the 2030 </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9dcd5aca-95aa-473b-be9f-d53f9fb5f327" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="us-gaap:DebtInstrumentDescription"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Notes are guaranteed on an unsecured senior basis by the same subsidiaries and affiliated professional contractors that guarantee the Amended Credit Agreement (as defined below). The indenture under which the 2030 Notes are issued, among other things, limits the Company's ability to (1) incur liens and (2) enter into sale and lease-back transactions, and also limits the Company's ability to merge or dispose of all or substantially all of its assets, in all cases, subject to a number of customary exceptions</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">. Although the Company is not required to make mandatory redemption or sinking fund payments with respect to the 2030 Notes, upon the occurrence of a change in control, the Company may be required to repurchase the 2030 Notes at a purchase price equal to </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_60ee85ec-06ca-4c33-b2de-4ede79a7c497" contextRef="C_5d513fe3-41de-49c7-8231-3b67764cba30" name="md:PurchasePrice" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">101</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">% of the aggregate principal amount of the 2030 Notes repurchased plus accrued and unpaid interest.</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Also in connection with the Redemption, the Company amended its credit agreement (the &#x201c;Credit Agreement&#x201d;, and such amendment, the &#34;Credit Agreement Amendment&#34;), concurrently with the issuance of the 2030 Notes. The Credit Agreement Amendment, among other things, (i) refinanced the prior unsecured revolving credit facility with a $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_66217e07-bc79-4161-ab4b-28fdb0f7aa10" contextRef="C_894b93ff-c06d-4c0f-a734-2f6884d5b7f7" name="us-gaap:UnsecuredDebt" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">450</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million unsecured revolving credit facility, including a $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_77b91daa-16ff-4a9e-a0fc-20f30d856490" contextRef="C_f4b8c51a-4dae-4dd3-9d9f-ef95a7c7a1b4" name="us-gaap:ProceedsFromLinesOfCredit" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">37.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million sub-facility for the issuance of letters of credit (the &#x201c;Revolving Credit Line&#x201d;), and a $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_b1d62f75-5ba0-49c3-8711-cd61fc3973e8" contextRef="C_e97fbd72-ea7b-4883-b296-14825e3e504f" name="us-gaap:UnsecuredLongTermDebt" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">250</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">9</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="margin-left:4.533%;text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">term </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">A loan facility (&#x201c;Term A Loan&#x201d;) and (ii) removed JPMorgan Chase Bank, N.A., as the administrative agent under the Credit Agreement and appointed Bank of America, N.A. as the administrative agent for the lenders.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The Credit Agreement, as amended by the Credit Agreement Amendment (the &#x201c;Amended Credit Agreement&#x201d;) matures on February 11, 2027 and is guaranteed on an unsecured basis by substantially all of the Company's subsidiaries and affiliated professional contractors. At the Company's option, borrowings under the Amended Credit Agreement bear interest at </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_012bd1e1-13bd-42e3-a9ae-393af576cac6" contextRef="C_24d8347f-a523-4cf1-8d04-a1595106e838" name="us-gaap:DescriptionOfInterestRateRiskExposure"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(i) the Alternate Base Rate (defined as the highest of (a) the prime rate as announced by Bank of America, N.A., (b) the Federal Funds Rate plus 0.50% and (c) Term Secured Overnight Financing Rate (&#34;SOFR&#34;) for an interest period of one month plus 1.00% with a 1.00% floor) plus an applicable margin rate of 0.50% for the first two fiscal quarters after the date of the Credit Agreement Amendment, and thereafter at an applicable margin rate ranging from 0.125% to 0.750% based on the Company's consolidated net leverage ratio or (ii) Term SOFR rate (calculated as the Secured Overnight Financing Rate published on the applicable Reuters screen page plus a spread adjustment of 0.10%, 0.15% or 0.25% depending on if the Company selects a one-month, three-month or six-month interest period, respectively, for the applicable loan with a 0% floor), plus an applicable margin rate of 1.50% for the first two full fiscal quarters after the date of the Credit Agreement Amendment, and thereafter at an applicable margin rate ranging from 1.125% to 1.750% based on the Company's consolidated net leverage ratio. The Amended Credit Agreement also provides for other customary fees and charges, including an unused commitment fee with respect to the Revolving Credit Line ranging from 0.150% to 0.200% of the unused lending commitments under the Revolving Credit Line</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">, based on the Company's consolidated net leverage ratio.</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The Amended Credit Agreement contains customary covenants and restrictions, including covenants that require the Company to maintain a minimum interest coverage ratio, a maximum consolidated net leverage ratio and to comply with laws, and restrictions on the ability to pay dividends, incur indebtedness or liens and make certain other distributions subject to baskets and exceptions, in each case, as specified therein. Failure to comply with these covenants would constitute an event of default under the Amended Credit Agreement, notwithstanding the ability of the Company to meet its debt service obligations. The Amended Credit Agreement includes various customary remedies for the lenders following an event of default, including the acceleration of repayment of outstanding amounts under the Amended Credit Agreement. In addition, the Company may increase the principal amount of the Revolving Credit Line or incur additional term loans under the Amended Credit Agreement in an aggregate principal amount such that on a pro forma basis after giving effect to such increase or additional term loans, the Company would be in compliance with the financial covenants, subject to the satisfaction of specified conditions and additional caps in the event that the Amended Credit Agreement is secured.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">At September 30, 2023, the Company had an outstanding principal balance on the Amended Credit Agreement of $</span><span style="font-size:9pt;font-family:Times New Roman;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_3974d7a3-f4ec-4976-9fc3-acee00758dcd" contextRef="C_0b560b9e-bc42-4716-8570-2af20d2cca64" name="us-gaap:LongTermDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">231.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million, comprised solely of the Term A Loan. The Company had $</span><span style="font-size:9pt;font-family:Times New Roman;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_2d2dc8ab-7844-4a58-bb20-3f38963c8020" contextRef="C_0b560b9e-bc42-4716-8570-2af20d2cca64" name="us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">450.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million available on its Amended Credit Agreement at </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">September 30, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">At September 30, 2023</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">, the Company had an outstanding principal balance of $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_723ba245-1356-486e-b98b-68c14e1825e9" contextRef="C_ec1dd730-3062-4268-8e06-714c3ed2af24" name="us-gaap:LongTermDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">400.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million on the 2030 Notes.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2addddaa-c963-4954-a21d-d00d348de6c6" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="us-gaap:EarningsPerShareTextBlock" escape="true"><p style="text-indent:0;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">7.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Arial;min-width:fit-content;">            </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Common and Common Equivalent Shares:</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Basic net income per common share is calculated by dividing net income by the weighted average number of common shares outstanding during the period. Diluted net income per common share is calculated by dividing net income by the weighted average number of common and potential common shares outstanding during the period. Potential common shares consist of outstanding restricted stock and stock options and is calculated using the treasury stock method.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f21cf8ae-4855-417a-9b91-23c9ff6c689f" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" escape="true"><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The calculation of shares used in the basic and diluted net income per common share calculation for the </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">three and nine months ended September 30, 2023 and 2022 is as follows (in thousands):</span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.07%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.498%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.88%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.178%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.978%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.398%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Three Months Ended<br />September 30,</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Nine Months Ended<br />September 30,</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Weighted average number of common shares outstanding</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_67c1160e-c408-4dc0-850b-663f5f75af84" contextRef="C_e5943398-0732-4d17-9fe7-25777d223b65" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">82,543</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_bc293ef6-848f-46aa-b6ed-e375d468e477" contextRef="C_350c5db7-f64b-4e63-97fa-733cc8e8f783" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">82,126</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_c0a0e541-1ff4-454a-8ce1-ea90c445b9b6" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">82,127</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_dc452491-2f95-4ba8-a19e-b26f5c5ae2b1" contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">84,122</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Weighted average number of dilutive common share<br />&#160;&#160;&#160;equivalents</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_6cd3fada-f28e-4b41-9588-4b263e5d926e" contextRef="C_e5943398-0732-4d17-9fe7-25777d223b65" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">407</ix:nonFraction></span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_8ab90170-ca1a-4ebe-af9f-96b991349964" contextRef="C_350c5db7-f64b-4e63-97fa-733cc8e8f783" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">650</ix:nonFraction></span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_cd61e4ec-7575-45d7-98b3-9215a4dff5c6" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">365</ix:nonFraction></span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_475c21e4-b0f2-41c2-98cc-cdc6210ea3b0" contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">699</ix:nonFraction></span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Weighted average number of common and common<br />&#160;&#160;&#160;equivalent shares outstanding</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_006cbebe-6cfc-48de-bec7-f486c6d861e7" contextRef="C_e5943398-0732-4d17-9fe7-25777d223b65" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">82,950</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_23b5e724-0a6a-4712-9fbb-caf6e589b5cf" contextRef="C_350c5db7-f64b-4e63-97fa-733cc8e8f783" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">82,776</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_57d616fe-affa-4468-835c-5edae52c0070" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">82,492</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_82742aab-2891-483b-b886-9cb471337597" contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">84,821</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Antidilutive securities (restricted stock and stock options) not included in the diluted net income per common share calculation</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_433b9cb3-f0a2-4805-a157-56837c84bf56" contextRef="C_e5943398-0732-4d17-9fe7-25777d223b65" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="INF" format="ixt:num-dot-decimal">888</ix:nonFraction></span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_8277df68-1012-49ae-a68d-d2db0388c4dc" contextRef="C_350c5db7-f64b-4e63-97fa-733cc8e8f783" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="INF" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_217a14e3-26c5-4f18-b24b-ba2be32643c3" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="INF" format="ixt:num-dot-decimal">1,201</ix:nonFraction></span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_ef4e34e1-41a4-4256-af09-1798d37225a2" contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="INF" format="ixt:num-dot-decimal">273</ix:nonFraction></span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:4.533%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:5.36pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div>
  <p style="margin-left:6.667%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:12pt;font-family:Arial;"><ix:nonNumeric id="F_ec64bf19-3694-4ee7-a70f-60219a187d47" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" escape="true"><p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">8.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Arial;min-width:fit-content;">            </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Stock Incentive Plans and Stock Purchase Plans:</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The Company&#x2019;s Amended and Restated 2008 Incentive Compensation Plan (the &#x201c;Amended and Restated 2008 Incentive Plan&#x201d;) provides for grants of stock options, stock appreciation rights, restricted stock, deferred stock, and other stock-related awards and performance awards that may be settled in cash, stock or other property.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><ix:exclude><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">10</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Under the Amended and Restated 2008 Incentive Plan, options to purchase shares of common stock may be granted at a price not less than the fair market value of the shares on the date of grant. The options must be exercised within </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2e72ff87-2ad2-4039-b30d-4ba7497bd2e7" contextRef="C_86f7c920-c7dd-49eb-b9e5-c81407859e32" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">10 years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> from the date of grant and generally become exercisable on a pro rata basis over a </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f95d5c0d-7ab2-4db1-9fd6-075c46d6019c" contextRef="C_830bbec2-bf82-42ba-aab7-1b87e55627e6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">three-year</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> period from the date of grant. The Company issues new shares of its common stock upon exercise of its stock options. Restricted stock awards generally vest over periods of </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4bedc097-e7c4-43e2-989c-051ba75df91c" contextRef="C_19a977fa-7760-40e4-8833-ab4c31af2173" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">three years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> upon the fulfillment of specified service-based conditions and in certain instances performance-based conditions. Deferred stock awards generally vest upon the satisfaction of specified performance-based conditions and service-based conditions. The Company recognizes compensation expense related to its restricted stock and deferred stock awards ratably over the corresponding vesting periods. During the </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">nine months ended September 30, 2023, the Company granted </span><span style="font-size:9pt;font-family:Times New Roman;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_edc46cc0-7182-452b-ad1f-5af51d5a6244" contextRef="C_0c7585a4-747b-415b-a754-892864d85f80" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million shares of restricted stock to its employees and non-employee directors under the Amended and Restated 2008 Incentive Plan. At </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">September 30, 2023, the Company had </span><span style="font-size:9pt;font-family:Times New Roman;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_6c6b18fc-35a2-4b11-83ae-78eab08ae793" contextRef="C_9340fe71-cf84-4fe9-b488-79ab1cff7146" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" scale="6" decimals="-5" format="ixt:num-dot-decimal">8.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million shares available for future grants and awards under the Amended and Restated 2008 Incentive Plan.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">   </span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Under the Company&#x2019;s Amended and Restated 1996 Non-Qualified Employee Stock Purchase Plan, as amended (the &#x201c;ESPP&#x201d;), employees are permitted to purchase the Company's common stock at </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_e03143e7-ce7b-464d-9f3a-cc17574f903b" contextRef="C_a04c17b2-e635-4a34-a0cc-839bf6802112" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">85</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">% of market value on January 1st, April 1st, July 1st and October 1st of each year. Under the Company&#x2019;s 2015 Non-Qualified Stock Purchase Plan (the &#x201c;SPP&#x201d;), certain eligible non-employee service providers are permitted to purchase the Company&#x2019;s common stock at </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_2ea1923f-5c38-4a7e-acda-3baa2a11a80c" contextRef="C_0be151b0-34b3-4da7-b3ba-2f77da9f751e" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">90</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">% of market value on January 1st, April 1st, July 1st and October 1st of each year.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The Company recognizes stock-based compensation expense for the discount received by participating employees and non-employee service providers. During the nine months ended September 30, 2023, approximately </span><span style="font-size:9pt;font-family:Times New Roman;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_82dcd0ed-010c-42b6-8f83-54b7b71e471d" contextRef="C_a04c17b2-e635-4a34-a0cc-839bf6802112" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million shares were issued under the ESPP. At </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">September 30, 2023, the Company had approximately </span><span style="font-size:9pt;font-family:Times New Roman;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_ebc44efa-a76e-455f-b81d-c695d2b39df6" contextRef="C_03cd8a32-d1bc-4934-bd34-28363e85b18a" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million shares reserved for issuance under the ESPP. At </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">September 30, 2023, the Company had approximately </span><span style="font-size:9pt;font-family:Times New Roman;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_218bca35-7cb6-4781-92c7-dad2a70ca641" contextRef="C_eb46e330-b646-43c3-95f2-112f68583c49" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">61,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> shares in the aggregate reserved for issuance under the SPP.  </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_118079d5-8260-4326-a772-fb2e3857b439" contextRef="C_c2300a5a-f622-49a9-b54c-dcabb14d6824" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" scale="6" decimals="-6" format="ixt-sec:numwordsen">No</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> shares have been issued under the SPP since 2020.</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">During the three and nine months ended September 30, 2023 and 2022, the Company recognized stock-based compensation expense of $</span><span style="font-size:9pt;font-family:Times New Roman;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_bb810f6f-f5ac-4822-892a-0a5140bb546d" contextRef="C_e5943398-0732-4d17-9fe7-25777d223b65" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:9pt;font-family:Times New Roman;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_dfd3dba1-60ad-43ab-8451-11d8ad040d02" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">9.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:9pt;font-family:Times New Roman;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_da26af57-bfeb-4802-afd2-faa587c256ff" contextRef="C_350c5db7-f64b-4e63-97fa-733cc8e8f783" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:9pt;font-family:Times New Roman;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_69105bec-ac33-43a3-8837-aea9ced50872" contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">12.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">  </span></p></ix:nonNumeric></div>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_32a48e64-a6f1-42ab-9608-49bc6ab17459" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="md:CommonStockRepurchasesTextBlock" escape="true"><p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">9.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Arial;min-width:fit-content;">            </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Common Stock Repurchase Programs:</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">In July 2013, the Company&#x2019;s Board of Directors authorized the repurchase of shares of the Company&#x2019;s common stock up to an amount sufficient to offset the dilutive impact from the issuance of shares under the Company&#x2019;s equity compensation programs. The share repurchase program allows the Company to make open market purchases from time-to-time based on general economic and market conditions and trading restrictions. The repurchase program also allows for the repurchase of shares of the Company&#x2019;s common stock to offset the dilutive impact from the issuance of shares, if any, related to the Company&#x2019;s acquisition program. </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_d000cdf2-2ff7-4c01-9d62-6a2028e8f046" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="us-gaap:StockRepurchasedDuringPeriodShares" unitRef="U_shares" scale="3" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> shares were purchased under this program during the </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">nine months ended September 30, 2023.</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">In August 2018, the Company announced that its Board of Directors had authorized the repurchase of up to $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_94aa2aee-d90d-4a03-80a0-17075755876f" contextRef="C_4c2decbf-697c-4da3-a4c5-727a578f77dc" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">500.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million of the Company&#x2019;s common stock in addition to its existing share repurchase program, of which $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_5799655f-0fb2-45cd-8f27-0455393e448d" contextRef="C_4c2decbf-697c-4da3-a4c5-727a578f77dc" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million remained available for repurchase as of December 31, 2022. Under this share repurchase program, during the nine months ended September 30, 2023, the Company purchased a nominal number of shares of its common stock for $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_0885e3f9-7c14-4389-b748-0bfbd6041fa6" contextRef="C_965dd392-85a0-4cd0-8ea9-4961c1f6dc80" name="us-gaap:PaymentsForRepurchaseOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million representing shares withheld to satisfy minimum statutory withholding obligations in connection with the vesting of restricted stock, resulting in $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_be3956c1-3129-4907-a014-c8d7c9143253" contextRef="C_22bf64d7-53dd-4c56-b931-fbaef641de7e" name="us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" unitRef="U_shares" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million remaining available for repurchase under this authorization as of September 30, 2023.</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The Company intends to utilize various methods to effect any future share repurchases, including, among others, open market purchases and accelerated share repurchase programs. The amount and timing of repurchases will depend upon several factors, including general economic and market conditions and trading restrictions.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2a25024b-607e-484b-a36e-c25a0321ce89" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="md:CoronavirusPandemicCOVIDNineteenDisclosureTextBlock" escape="true"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">10.            Coronavirus Pandemic (&#x201c;COVID-19&#x201d;):</span></p><p style="margin-left:6.667%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">COVID-19 has had an impact on the demand for medical services provided by the Company's affiliated clinicians. </span><span style="color:#222222;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Beginning in mid-March 2020 and throughout the second quarter of 2020, </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">the Company's operating results were significantly impacted by COVID-19, but volumes began to normalize in mid-2020 and substantially recovered throughout 2020 with no material impacts from COVID-19 or its variants since that time. However, due to the continued uncertainties surrounding the timeline of and impacts from COVID-19 and with multiple variant strains still circulating, the Company is unable to predict the ultimate impact of COVID-19 on its business, financial condition, results of operations, cash flows and the trading price of its securities at this time.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">  </span><span style="color:#222222;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">CARES Act</span></p><p style="margin-left:6.667%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">In March 2020, the Coronavirus Aid, Relief, and Economic Security Act (&#34;CARES Act&#34;) was signed into law. The CARES Act is a relief package intended to assist many aspects of the American economy, including providing financial aid to the healthcare industry to reimburse healthcare providers for lost revenue and expenses attributable to COVID-19. The Department of Health and Human Services is administering this program and began disbursing funds in April 2020, of which the Company&#x2019;s affiliated physician practices within continuing operations recognized an aggregate of $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_a4a0a148-9225-4404-b241-39fbacc7dc2e" contextRef="C_6a82b64e-6fb9-48f9-99fe-5081ff6fca6c" name="md:ProceedsFromContributionInAidOfReimbursementOfLostRevenue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_8bc5bc6e-d23d-4533-9aed-e17ccf7afb0d" contextRef="C_43c976d5-88bb-433a-adbb-5b5571f16c99" name="md:ProceedsFromContributionInAidOfReimbursementOfLostRevenue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">11.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million during the three and nine months ended September 30, 2022</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:12pt;font-family:Arial;"><ix:nonNumeric id="F_f1d670d8-f539-4c51-93f9-ad01a2ac5384" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true"><p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">11.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Arial;min-width:fit-content;">            </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Commitments and Contingencies:	</span></p><ix:exclude><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">11</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The Company expects that audits, inquiries and investigations from government authorities and agencies will occur in the ordinary course of business. Such audits, inquiries and investigations and their ultimate resolutions, individually or in the aggregate, could have a material adverse effect on the Company's business, financial condition, results of operations, cash flows and the trading price of its securities. The Company has not included an accrual for these matters as of September 30, 2023 in its Consolidated Financial Statements, as the variables affecting any potential eventual liability depend on the currently unknown facts and circumstances that arise out of, and are specific to, any particular future audit, inquiry and investigation and cannot be reasonably estimated at this time.</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">In the ordinary course of business, the Company becomes involved in pending and threatened legal actions and proceedings, most of which involve claims of medical malpractice related to medical services provided by the Company's affiliated physicians. The Company's contracts with hospitals generally require the Company to indemnify them and their affiliates for losses resulting from the negligence of the Company's affiliated physicians. The Company may also become subject to other lawsuits which could involve large claims and significant costs. The Company believes, based upon a review of pending actions and proceedings, that the outcome of such legal actions and proceedings will not have a material adverse effect on its business, financial condition, results of operations, cash flows and the trading price of its securities. The outcome of such actions and proceedings, however, cannot be predicted with certainty and an unfavorable resolution of one or more of them could have a material adverse effect on the Company's business, financial condition, results of operations, cash flows and the trading price of its securities.</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Although the Company currently maintains liability insurance coverage intended to cover professional liability and certain other claims, the Company cannot assure that its insurance coverage will be adequate to cover liabilities arising out of claims asserted against it in the future where the outcomes of such claims are unfavorable. With respect to professional liability risk, the Company generally self-insures a portion of this risk through its wholly owned captive insurance subsidiary. Liabilities in excess of the Company's insurance coverage, including coverage for professional liability and certain other claims, could have a material adverse effect on the Company's business, financial condition, results of operations, cash flows and the trading price of its securities.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">12</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="mda"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Item 2. Management&#x2019;s Discussion and Analysis</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> of Financial Condition and Results</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">of Operations</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The following discussion highlights the principal factors that have affected our financial condition and results of operations, as well as our liquidity and capital resources, for the periods described. This discussion should be read in conjunction with the unaudited Consolidated Financial Statements and the notes thereto included in this Quarterly Report. In addition, reference is made to our audited consolidated financial statements and notes thereto and related Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022, filed with the Securities and Exchange Commission on February 17, 2023 (the &#x201c;2022 Form 10-K&#x201d;). As used in this Quarterly Report, the terms &#x201c;Pediatrix&#x201d;, the &#x201c;Company&#x201d;, &#x201c;we&#x201d;, &#x201c;us&#x201d; and &#x201c;our&#x201d; refer to the parent company, Pediatrix Medical Group, Inc., a Florida corporation, and the consolidated subsidiaries through which its businesses are actually conducted (collectively, &#x201c;PMG&#x201d;), together with PMG&#x2019;s affiliated business corporations or professional associations, professional corporations, limited liability companies and partnerships (&#x201c;affiliated professional contractors&#x201d;). Certain subsidiaries of PMG have contracts with our affiliated professional contractors, which are separate legal entities that provide physician services in certain states. We ceased providing services in Puerto Rico on December 31, 2022. The following discussion contains forward-looking statements. Please see the Company&#x2019;s 2022 Form 10-K, including Item 1A, Risk Factors, for a discussion of the uncertainties, risks and assumptions associated with these forward-looking statements. In addition, please see &#x201c;Caution Concerning Forward-Looking Statements&#x201d; below.</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Overview</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Pediatrix (formerly known as Mednax, Inc.) is a leading provider of physician services including newborn, maternal-fetal, pediatric cardiology and other pediatric subspecialty care. Our national network is comprised of affiliated physicians who provide clinical care in 37 states. We ceased providing services in Puerto Rico on December 31, 2022. Our affiliated physicians provide neonatal clinical care, primarily within hospital-based neonatal intensive care units (&#x201c;NICUs&#x201d;), to babies born prematurely or with medical complications; and maternal-fetal and obstetrical medical care to expectant mothers experiencing complicated pregnancies, primarily in areas where our affiliated neonatal physicians practice. Our network also includes other pediatric subspecialists, including those who provide pediatric intensive care, pediatric cardiology care, hospital-based pediatric care, pediatric surgical care, pediatric ear, nose and throat, pediatric ophthalmology, pediatric urology services and pediatric primary and urgent care.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">General Economic Conditions and Other Factors</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Our operations and performance depend significantly on economic conditions. During the three months ended September 30, 2023, the percentage of our patient service revenue being reimbursed under government-sponsored healthcare programs (&#x201c;GHC Programs&#x201d;) decreased as compared to the three months ended September 30, 2022. However, we could experience shifts toward GHC Programs if changes occur in economic behaviors or population demographics within geographic locations in which we provide services, including an increase in unemployment and underemployment as well as losses of commercial health insurance or if there are additional impacts from COVID-19 or its variants. Payments received from GHC Programs are substantially less for equivalent services than payments received from commercial insurance payors. In addition, costs of managed care premiums and patient responsibility amounts continue to rise, and accordingly, we may experience lower net revenue resulting from increased bad debt due to patients&#x2019; inability to pay for certain services.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#x201c;Surprise&#x201d; Billing Legislation</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">	</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">In late 2020, Congress enacted legislation intended to protect patients from &#x201c;surprise&#x201d; medical bills when services are furnished by providers who are not in network with the patient&#x2019;s insurer (the &#x201c;No Surprises Act&#34; or the &#34;NSA&#34;). Effective January 1, 2022, if the patient&#x2019;s insurance plan is subject to the NSA, providers are not permitted to send patients an unexpected or &#x201c;surprise&#x201d; medical bill that arises from out-of-network emergency care provided at certain out-of-network facilities or at certain in-network facilities by out-of-network emergency providers, as well as out-of-network nonemergency care provided at certain in-network facilities without the patient&#x2019;s informed consent. Many states have legislation on this topic and will continue to modify and review their laws pertaining to surprise billing.</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Under the NSA, patients are required to pay no more than the in-network cost-sharing amount. Insurers are required to calculate the patient&#x2019;s total cost-sharing amount pursuant to rules set forth in the NSA and its implementing regulations which, in some cases, can be calculated by reference to the applicable qualifying payment amount (&#x201c;QPA&#x201d;) for the items or services received. Patient cost-sharing amounts for items and services subject to the NSA count toward the patient&#x2019;s health plan deductible and out-of-pocket cost-sharing limits. For claims subject to the NSA, providers are generally not permitted to balance bill patients beyond this cost-sharing amount. An out-of-network provider is only permitted to bill a patient more than the cost-sharing amount allowed under the NSA for certain types of services if the provider satisfies all aspects of an informed consent process set forth in the NSA&#x2019;s implementing regulations. Providers that violate these surprise billing prohibitions may be subject to state enforcement action or federal civil monetary penalties.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">For claims subject to the NSA, including many emergency care services, out of network providers will be paid an amount determined by the patient&#x2019;s insurer; if a provider is not satisfied with the amount paid for the services, the provider can pursue recourse through an independent dispute resolution (&#x201c;IDR&#x201d;) process. The outcome of each IDR dispute is generally binding on both the provider and payor with respect to the particular claims at issue in that dispute but may not affect an insurer&#x2019;s future offers of payment. In July 2021 and October 2021, the United States Department of Health and Human Services, Department of Labor and Department of Treasury (the &#x201c;Departments&#x201d;) issued interim final rules implementing the NSA. Certain provisions of the October 2021 rule were vacated by a federal district court in the Eastern District of Texas in February 2022. In August 2022, the Departments issued a final rule and corresponding guidance replacing the vacated provisions of the October 2021 interim final rule. Provisions of this final rule were vacated by the federal court in the Eastern District of Texas in February 2023. The Departments are currently appealing that decision. In August 2023, the federal court in the Eastern District of Texas vacated provisions of the July 2021 interim final rule relating to the methodology for calculating QPAs. The Departments are currently appealing that decision. The outcome of the Departments&#x2019; pending legal appeals and the content of the additional rules and guidance that the</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">13</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Departments plan to issue in the coming months and years, including the Departments' proposed IDR procedure rule issued on October 27, 2023, may affect our future likelihood of success in IDR and the amount of reimbursement we receive through IDR. Accordingly, we cannot predict how these IDR results will compare to the rates that our affiliated physicians customarily receive for their services.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">These measures could limit the amount we can charge and recover for services we furnish where we have not contracted with the patient&#x2019;s insurer, and therefore could have a material adverse effect on our business, financial condition, results of operations, cash flows and the trading price of our securities. Moreover, these measures could affect our ability to contract with certain payors and under historically similar terms and may cause, and the prospect of these changes may have caused, payors to terminate their contracts with us and our affiliated practices, further affecting our business, financial condition, results of operations, cash flows and the trading price of our securities.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Healthcare Reform</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act (collectively the &#x201c;ACA&#x201d;) have altered how health care is delivered and reimbursed in the U.S. and contain various provisions, including the establishment of health insurance exchanges to facilitate the purchase of qualified health plans, expanded Medicaid eligibility, subsidized insurance premiums and additional requirements and incentives for businesses to provide healthcare benefits. Other provisions have expanded the scope and reach of the Frederal Civil False Claims Act and other healthcare fraud and abuse laws. Moreover, we could be affected by potential changes to various aspects of the ACA, including changes to subsidies, healthcare insurance marketplaces and Medicaid expansion.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The status of the ACA may be subject to change as a result of political, legislative, regulatory, and administrative developments, as well as judicial proceedings.  While there have been multiple attempts to repeal or amend the ACA through legislative action and legal challenges, legislative attempts to completely repeal the ACA have been unsuccessful to date, and on June 17, 2021, the United States Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Another potentially existential challenge to the ACA is advancing in federal courts. Specifically, in </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Braidwood Management v. Becerra</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">, the plaintiffs argue that the ACA&#x2019;s requirement that insurance cover certain preventive services without cost sharing is unconstitutional. In September 2022, a federal district court in Texas ruled partly in favor of the plaintiffs and partly in favor of the Department of Health and Human Services, which is defending the ACA, finding, among other things, that the requirement that self-funded plans and insurers cover certain preventive services violates the plaintiffs' rights under the Religious Freedom Restoration Act. The federal government appealed this decision to the Fifth Circuit Court of Appeals and the case may ultimately be resolved by the United States Supreme Court. If the case succeeds, millions of Americans could lose access to preventive care guaranteed by the ACA or be forced to pay out of pocket for these services. We cannot say for certain whether there will be additional future challenges to the ACA or what impact, if any, such challenges may have on our business. Changes resulting from these proceedings, and any legislative or administrative change to the current healthcare financing system, could have a material adverse effect  on our business, financial condition, results of operations, cash flows and the trading price of our securities.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">In addition to the ACA, there could be changes to other GHC Programs, such as a change to the Medicaid program design or Medicaid coverage and reimbursement rates set forth under federal or state law. Historically, Congress and the Administration have sought to convert Medicaid into a block grant or to institute per capita spending caps, among other things. These changes, if implemented, could eliminate the guarantee that everyone who is eligible and applies for Medicaid benefits would receive them and could potentially give states new authority to restrict eligibility, cut benefits and/or make it more difficult for people to enroll. Additionally, several states are considering and pursuing changes to their Medicaid programs, such as requiring recipients to engage in employment or education activities as a condition of eligibility for most adults, disenrolling recipients for failure to pay a premium, or adjusting premium amounts based on income. Many states have transitioned a substantial portion of their Medicaid program beneficiaries into Managed Medicaid Plans, which are administered by commercial insurance companies. Managed Medicaid Plans have some flexibility to set rates for providers, but many states require minimum provider rates in their contracts with such plans. In July of each year, CMS releases the annual Medicaid Managed Care Rate Development Guide which provides federal baseline rules for setting reimbursement rates in managed care plans. We could be affected by lower reimbursement rates in some or all of the Managed Medicaid Plans with which we participate. We could also be materially impacted if we are dropped from the provider network in one or more of the Managed Medicaid Plans with which we currently participate.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">We cannot predict with any assurance the ultimate effect of these laws and resulting changes to payments under GHC Programs, nor can we provide any assurance that they will not have a material adverse effect on our business, financial condition, results of operations, cash flows and the trading price of our securities. Further, any fiscal tightening impacting GHC Programs or changes to the structure of any GHC Programs could have a material adverse effect on our financial condition, results of operations, cash flows and the trading price of our securities.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Finally, the expiration of the federal government's national emergency and public health emergency declarations in May 2023 may impact the coverage for and access to certain services for Medicaid patients. Expiration of the national emergency and public health emergency declarations will also end waivers for the provision of certain services, and returning our services to a pre-pandemic regulatory state similarly may increase our exposure to legal, regulatory, compliance and clinical risks.</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Medicaid Expansion</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The ACA also allows states to expand their Medicaid programs through federal payments that fund most of the cost of increasing the Medicaid eligibility income limit from a state&#x2019;s historic eligibility levels to 133% of the federal poverty level. To date, 39 states and the District of Columbia have expanded Medicaid eligibility to cover this additional low-income patient population, and other states are considering</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">14</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">expansion.  All of the states in which we operate, however, already cover children in the first year of life and pregnant women if their household income is at or below 133% of the federal poverty level.  Recently, Democrats in Congress have sought to expand Medicaid or Medicaid-like coverage in states that have not yet expanded Medicaid. They also have sought to reduce payments to certain hospitals in some of these states. Additionally, as noted above, Congress is currently considering altering the terms and state remuneration for Medicaid expansion pursuant to the ACA.  Should any of these changes take effect, we cannot predict with any assurance the ultimate effect to reimbursements for our services.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Coronavirus Pandemic (&#34;COVID-19&#34;)</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">COVID-19 has had an impact on the demand for medical services provided by our affiliated clinicians. Beginning in mid-March 2020 and continuing throughout the second quarter of 2020, our operating results were significantly impacted by COVID-19, but volumes began to normalize in mid-2020 and substantially recovered throughout 2020 with no material impacts from COVID-19 or its variants since that time.  However, due to the continued uncertainties surrounding the timeline of and impacts from COVID-19 and with multiple variant strains still circulating, we are unable to predict the ultimate impact on our business, financial condition, results of operations, cash flows and the trading price of our securities at this time.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">CARES Act</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (&#34;CARES Act&#34;) was signed into law. The CARES Act is a relief package intended to assist many aspects of the American economy, including providing financial aid to the healthcare industry to reimburse healthcare providers for lost revenue and expenses attributable to COVID-19.  The Department of Health and Human Services is administering this program, and our affiliated physician practices within continuing operations recognized an aggregate of $0.3 million and $11.4 million of CARES Act relief within miscellaneous revenue during the three and nine months ended September 30, 2022, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Non-GAAP Measures</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">In our analysis of our results of operations, we use certain non-GAAP financial measures. We report adjusted earnings before interest, taxes and depreciation and amortization (&#34;Adjusted EBITDA&#34;) from continuing operations, which is defined as income (loss) from continuing operations before interest, income taxes, depreciation and amortization, and transformational and restructuring related expenses. We also report adjusted earnings per share (&#x201c;Adjusted EPS&#x201d;) from continuing operations which consists of diluted income (loss) from continuing operations per common and common equivalent share adjusted for amortization expense, stock-based compensation expense, transformational and restructuring related expenses and any impacts from discrete tax events. For the nine months ended September 30, 2022, both Adjusted EBITDA and Adjusted EPS are being further adjusted to exclude the impacts from the loss on the early extinguishment of debt.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">We believe these measures, in addition to income from continuing operations, net income and diluted net income from continuing operations per common and common equivalent share, provide investors with useful supplemental information to compare and understand our underlying business trends and performance across reporting periods on a consistent basis.  These measures should be considered a supplement to, and not a substitute for, financial performance measures determined in accordance with GAAP.  In addition, since these non-GAAP measures are not determined in accordance with GAAP, they are susceptible to varying calculations and may not be comparable to other similarly titled measures of other companies.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">For a reconciliation of each of Adjusted EBITDA from continuing operations and Adjusted EPS from continuing operations to the most directly comparable GAAP measures for the three and nine months ended September 30, 2023 and 2022, refer to the tables below (in thousands, except per share data).</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:58.218%;"></td>
    <td style="width:1.003%;"></td>
    <td style="width:1%;"></td>
    <td style="width:8.856%;"></td>
    <td style="width:1%;"></td>
    <td style="width:1.244%;"></td>
    <td style="width:1%;"></td>
    <td style="width:6.808999999999999%;"></td>
    <td style="width:1%;"></td>
    <td style="width:1.003%;"></td>
    <td style="width:1%;"></td>
    <td style="width:7.029999999999999%;"></td>
    <td style="width:1%;"></td>
    <td style="width:1.003%;"></td>
    <td style="width:1%;"></td>
    <td style="width:6.829000000000001%;"></td>
    <td style="width:1%;"></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Three Months Ended<br />September 30,</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Nine Months Ended<br />September 30,</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">2023</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">2023</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Income from continuing operations attributable to Pediatrix Medical Group, Inc.</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">21,391</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">28,808</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">63,879</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">38,568</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#ffffff;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Interest expense</span></p></td>
    <td style="background-color:#ffffff;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">10,374</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">9,516</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">31,994</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">29,743</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#cff0fc;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Loss on early extinguishment of debt</span></p></td>
    <td style="background-color:#cff0fc;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">57,016</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#ffffff;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Income tax provision</span></p></td>
    <td style="background-color:#ffffff;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">9,441</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">10,051</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">26,612</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">14,982</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#cff0fc;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Depreciation and amortization expense</span></p></td>
    <td style="background-color:#cff0fc;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">9,211</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">8,956</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">27,109</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">26,500</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#ffffff;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Transformational and restructuring related expenses</span></p></td>
    <td style="background-color:#ffffff;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">977</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">7,736</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Adjusted EBITDA from continuing operations attributable to Pediatrix Medical Group, Inc.</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">50,417</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">58,308</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">149,594</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">174,545</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">15</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:56.957%;"></td>
    <td style="width:1.444%;"></td>
    <td style="width:1%;"></td>
    <td style="width:8.171%;"></td>
    <td style="width:1%;"></td>
    <td style="width:1.017%;"></td>
    <td style="width:1%;"></td>
    <td style="width:7.1129999999999995%;"></td>
    <td style="width:1%;"></td>
    <td style="width:1.017%;"></td>
    <td style="width:1%;"></td>
    <td style="width:8.129999999999999%;"></td>
    <td style="width:1%;"></td>
    <td style="width:1.017%;"></td>
    <td style="width:1%;"></td>
    <td style="width:7.132999999999999%;"></td>
    <td style="width:1%;"></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="14" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Three Months Ended<br />September 30,</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">2023</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Weighted average diluted shares outstanding</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">82,950</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">82,776</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Income from continuing operations and diluted income from<br />&#160;&#160;&#160;continuing operations per share attributable to Pediatrix Medical Group, Inc.</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">21,391</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">0.26</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">28,808</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">0.35</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Adjustments </span><span style="color:#000000;top:-4.221pt;white-space:pre-wrap;font-weight:normal;font-size:6.03pt;font-family:Times New Roman;position:relative;min-width:fit-content;">(1)</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">:</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#ffffff;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Amortization (net of tax of $498 and $554)</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">1,493</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">0.02</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">1,662</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">0.02</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#cff0fc;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Stock-based compensation (net of tax of $791 and $1,030)</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">2,373</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">0.03</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">3,090</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">0.03</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#ffffff;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Transformational and restructuring expenses (net of tax of $244)</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">733</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">0.01</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#cff0fc;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Net impact from discrete tax events</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">1,114</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">0.01</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(1,083</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(0.01</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Adjusted income and diluted EPS from continuing operations<br />&#160;&#160;&#160;attributable to Pediatrix Medical Group, Inc.</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">26,371</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">0.32</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">33,210</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">0.40</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="text-indent:0;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:8pt;font-family:Times New Roman;transform-origin:top left;min-width:fit-content;text-indent:0;display:inline-flex;font-size:8pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">A blended tax rate of 25% was used to calculate the tax effects of the adjustments for the three months ended September 30, 2023 and 2022. </span></div></div>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:57.808%;"></td>
    <td style="width:1.017%;"></td>
    <td style="width:1%;"></td>
    <td style="width:8.166999999999998%;"></td>
    <td style="width:1%;"></td>
    <td style="width:1.017%;"></td>
    <td style="width:1%;"></td>
    <td style="width:7.151%;"></td>
    <td style="width:1%;"></td>
    <td style="width:1.017%;"></td>
    <td style="width:1%;"></td>
    <td style="width:8.614999999999998%;"></td>
    <td style="width:1%;"></td>
    <td style="width:1.017%;"></td>
    <td style="width:1%;"></td>
    <td style="width:6.194999999999999%;"></td>
    <td style="width:1%;"></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="14" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Nine Months Ended<br />September 30,</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">2023</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Weighted average diluted shares outstanding</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">82,492</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">84,821</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Income from continuing operations and diluted income from<br />&#160;&#160;&#160;continuing operations per share attributable to Pediatrix Medical Group, Inc.</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">63,879</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">0.77</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">38,568</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">0.45</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Adjustments </span><span style="color:#000000;top:-4.221pt;white-space:pre-wrap;font-weight:normal;font-size:6.03pt;font-family:Times New Roman;position:relative;min-width:fit-content;">(1)</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">:</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#ffffff;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Amortization (net of tax of $1,508 and $1,635)</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">4,522</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">0.06</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">4,907</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">0.06</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#cff0fc;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Stock-based compensation (net of tax of $2,325 and $3,223)</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">6,974</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">0.09</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">9,668</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">0.12</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#ffffff;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Transformational and restructuring expenses (net of tax of $1,934)</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">5,802</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">0.07</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#cff0fc;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Loss on early extinguishment of debt (net of tax of $14,254)</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">42,762</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">0.50</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#ffffff;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Net impact from discrete tax events</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">1,984</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">0.02</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(297</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Adjusted income and diluted EPS from continuing operations<br />&#160;&#160;&#160;attributable to Pediatrix Medical Group, Inc.</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">77,359</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">0.94</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">101,410</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">1.20</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="text-indent:0;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:8pt;font-family:Times New Roman;transform-origin:top left;min-width:fit-content;text-indent:0;display:inline-flex;font-size:8pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">A blended tax rate of 25% was used to calculate the tax effects of the adjustments for the nine months ended September 30, 2023 and 2022. </span></div></div>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Results of Operations</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Three Months Ended September 30, 2023 as Compared to Three Months Ended September 30, 2022</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Our net revenue attributable to continuing operations was $506.6 million for the three months ended September 30, 2023, as compared to $489.9 million for the same period in 2022. The increase in net revenue of $16.7 million, or 3.4%, was primarily attributable to an increase in same-unit revenue, partially offset by a decrease in revenue from net non-same unit activity. Same units are those units at which we provided services for the entire current period and the entire comparable period. Same-unit net revenue increased by $19.8 million, or 4.1%. The increase in same-unit net revenue was comprised of an increase of $25.1 million, or 5.3%, from net reimbursement-related factors, partially offset by a decrease of $5.3 million, or 1.2%, related to patient service volumes. The net increase in revenue related to net reimbursement-related factors was primarily due to an increase in revenue resulting from improved cash collection rates in the current period as compared to those rates in the prior year period, which prior year rates were significantly impacted by unfavorable revenue cycle management performance and a decrease in the percentage of our patients being enrolled in GHC Programs. The decrease in revenue from patient service volumes was related to decreases in hospital-based women&#x2019;s and children&#x2019;s services and primary and urgent care, partially offset by a modest increase in maternal-fetal medicine.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Practice salaries and benefits attributable to continuing operations increased $25.5 million, or 7.4%, to $368.4 million for the three months ended September 30, 2023, as compared to $342.9 million for the same period in 2022. Of the $25.5 million increase, $13.5 million was related to salaries, driven by increases in clinical compensation expense at our existing units, and $12.0 million was related to benefits and incentive compensation, primarily due to increases in incentive compensation related to practice results as well as increases in malpractice expense and group health insurance costs.  We anticipate that we will continue to experience a higher rate of growth in clinician compensation expense at our existing units over historic averages, which could adversely affect our business, financial condition, results of operations, cash flows and the trading price of our securities.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Practice supplies and other operating expenses attributable to continuing operations decreased $0.5 million, or 1.7%, to $31.3 million for the three months ended September 30, 2023, as compared to $31.9 million for the same period in 2022. The decrease was primarily attributable to decreases in practice supply, rent and other costs related to our non-same unit practices. Costs at our existing units were essentially flat with decreases in operating taxes and medical supply costs, almost entirely offset by increases in professional fees, and workers' compensation expenses, as compared to the prior year period.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">General and administrative expenses attributable to continuing operations primarily include all billing and collection functions and all other salaries, benefits, supplies and operating expenses not specifically related to the day-to-day operations of our affiliated physician practices and services. General and administrative expenses were $57.4 million for the three months ended September 30, 2023, as compared</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">16</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">to $57.9 million for the same period in 2022.  The net decrease of $0.5 million was primarily related to decreases in expenses across several categories, including information technology professional service fees, insurance expense and net staffing cost reductions, partially offset by an increase in bonus expense as compared to the prior year. General and administrative expenses as a percentage of net revenue was 11.3% for the three months ended September 30, 2023, as compared to 11.8% for the same period in 2022.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Transformational and restructuring related expenses attributable to continuing operations were $1.0 million for three months ended September 30, 2022 and primarily related to consulting fees and contract terminations.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Depreciation and amortization expense attributable to continuing operations was $9.2 million for the three months ended September 30, 2023, as compared to $9.0 million for the same period in 2022. The net increase of $0.2 million was primarily related to an increase in depreciation expense for information technology and other equipment, partially offset by lower amortization expenses related to intangible assets, both at our existing units.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Income from operations attributable to continuing operations decreased $7.1 million, or 15.0%, to $40.3 million for the three months ended September 30, 2023, as compared to $47.4 million for the same period in 2022. Our operating margin was 7.9% for the three months ended September 30, 2023, as compared to 9.7% for the same period in 2022.  The decrease in our operating margin was primarily due to unfavorable impacts in our same-unit results driven by higher operating expenses, partially offset by same-unit revenue increases and lower general and administrative expenses. Excluding transformation and restructuring related expenses for the three months ended September 30, 2022, our income from operations attributable to continuing operations was $48.4 million and our operating margin was 9.9% for such period.  We believe excluding the impacts from the transformational and restructuring related activity provides a more comparable view of our operating income and operating margin from continuing operations.</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Total non-operating expenses attributable to continuing operations were $9.4 million for the three months ended September 30, 2023, as compared to $8.5 million for the same period in 2022. The net increase in non-operating expenses was primarily related to an increase of $0.9 million in interest expense from higher interest rates on lower average borrowings.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Our effective income tax rate attributable to continuing operations (&#x201c;tax rate&#x201d;) was 30.6% for the three months ended September 30, 2023 as compared to 25.9% for the three months ended September 30, 2022. The third quarter 2023 tax rate includes net discrete tax expense of $1.1 million, and the third quarter 2022 tax rate includes net discrete tax benefits of $1.1 million. After excluding discrete tax impacts during the three months ended September 30, 2023 and 2022, our effective income tax rate was 27.0% and 28.7%, respectively. We believe excluding discrete tax impacts provides a more comparable view of our tax rate.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Income from continuing operations was $21.4 million for the three months ended September 30, 2023, as compared to $28.8 million for the three months ended September 30, 2022. Net income attributable to Pediatrix Medical Group, Inc. was $21.4 million for the three months ended September 30, 2023, as compared to $30.7 million for the same period in 2022. Adjusted EBITDA from continuing operations attributable to Pediatrix Medical Group, Inc. was $50.4 million for the three months ended September 30, 2023, as compared to $58.3 million for the same period in 2022.  The decrease in our Adjusted EBITDA was primarily due to net unfavorable impacts in our same-unit results, primarily from higher operating expenses.</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Diluted net income per common and common equivalent share attributable to Pediatrix Medical Group, Inc. was $0.26 on weighted average shares outstanding of 83.0 million for the three months ended September 30, 2023, as compared to $0.37 per common and common equivalent share on weighted average shares outstanding of 82.8 million for the same period in 2022. Adjusted EPS from continuing operations was $0.32 for the three months ended September 30, 2023, as compared to $0.40 for the same period in 2022.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Nine Months Ended September 30, 2023 as Compared to Nine Months Ended September 30, 2022</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Our net revenue attributable to continuing operations was $1.50 billion for the nine months ended September 30, 2023, as compared to $1.46 billion for the same period in 2022. The increase in net revenue of $40.0 million, or 2.7%, was primarily attributable to increases in same-unit revenue and slight increases in revenue from non-same unit activity. Same units are those units at which we provided services for the entire current period and the entire comparable period. Same-unit net revenue increased by $39.2 million, or 2.8%. The increase in same-unit net revenue was due to an increase of $39.5 million, or 2.8%, from net reimbursement-related factors, partially offset by a decrease of $0.3 million, related to patient service volumes. The net increase in revenue related to net reimbursement-related factors was primarily due to an increase in revenue resulting from improved cash collection rates in the current period as compared to those rates in the prior year period, which prior year rates were significantly impacted by unfavorable revenue cycle management performance, partially offset by decreases in revenue from CARES Act relief and from an increase in the percentage of our patients being enrolled in GHC Programs. The decrease in revenue from patient service volumes was primarily related to decreases in our hospital-based women&#x2019;s and children&#x2019;s services and primary and urgent care, partially offset by a modest increase in maternal-fetal medicine and other pediatric services.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Practice salaries and benefits attributable to continuing operations increased $67.9 million, or 6.7%, to $1.08 billion for the nine months ended September 30, 2023, as compared to $1.02 billion for the same period in 2022. Of the $67.9 million increase, $43.8 million was related to salaries, driven by increases in clinical compensation expense at our existing units, and $24.1 million was related to benefits and incentive compensation, primarily due to increases in incentive compensation related to practice results as well as increases in malpractice expense and group health insurance costs.  We anticipate that we will continue to experience a higher rate of growth in clinician compensation expense at our existing units over historic averages, which could adversely affect our business, financial condition, results of operations, cash flows and the trading price of our securities.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">17</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Practice supplies and other operating expenses attributable to continuing operations increased $2.9 million, or 3.2%, to $93.1 million for the nine months ended September 30, 2023, as compared to $90.2 million for the same period in 2022. The increase was primarily attributable to increases in practice supply, rent and other costs at our existing units, including increases in workers' compensation insurance and professional services expense, partially offset by a decrease in operating taxes. The increases in our same-unit activity were partially offset by modest decreases in practice supply, rent and other costs related to non-same unit activity.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">General and administrative expenses attributable to continuing operations primarily include all billing and collection functions and all other salaries, benefits, supplies and operating expenses not specifically identifiable to the day-to-day operations of our affiliated physician practices and services. General and administrative expenses were $174.5 million for the nine months ended September 30, 2023, as compared to $180.3 million for the same period in 2022. The net decrease of $5.8 million is primarily related to lower professional services fees, primarily related to information technology, lower insurance expense and decreases in expenses from net staffing reductions. General and administrative expenses as a percentage of net revenue was 11.6% for the nine months ended September 30, 2023, as compared to 12.4% for the same period in 2022.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Transformational and restructuring related expenses attributable to continuing operations were $7.7 million for the nine months ended September 30, 2022 and primarily related to position eliminations.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Depreciation and amortization expense attributable to continuing operations was $27.1 million for the nine months ended September 30, 2023, as compared to $26.5 million for the same period in 2022. The increase of $0.6 million was primarily related to an increase in depreciation expense related to information technology equipment, partially offset by lower amortization expenses related to intangible assets, both at our existing units.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Income from operations attributable to continuing operations decreased $17.9 million, or 13.1%, to $118.8 million for the nine months ended September 30, 2023, as compared to $136.7 million for the same period in 2022. Our operating margin was 7.9% for the nine months ended September 30, 2023, as compared to 9.4% for the same period in 2022. The decrease in our operating margin was primarily due to net increases in overall operating expenses and a decrease in CARES Act relief, partially offset by higher same-unit revenue and favorable general and administrative expenses. Excluding transformation and restructuring related expenses for the nine months ended September 30, 2022, our income from operations attributable to continuing operations was $144.4 million and our operating margin was 9.9% for such period. We believe excluding the impacts from the transformational and restructuring related activity provides a more comparable view of our operating income and operating margin from continuing operations.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Total non-operating expenses attributable to continuing operations were $28.3 million for the nine months ended September 30, 2023, as compared to $83.1 million for the same period in 2022. The net decrease in non-operating expenses was primarily related to a decrease of $57.0 million in loss on early extinguishment of debt from the redemption of our 6.25% senior unsecured notes due 2027 (the &#x201c;2027 Notes&#x201d;) in February 2022, partially offset by an increase in interest expense from higher interest rates on lower average borrowings.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Our tax rate was 29.4% for the nine months ended September 30, 2023 compared to 28.0% for the nine months ended September 30, 2022. The tax rate for the nine months ended September 30, 2023 includes net discrete tax expense of $2.0 million. Discrete tax impacts during the nine months ended September 30, 2022 were nominal. After excluding discrete tax impacts, during the nine months ended September 30, 2023 and 2022, our tax rate was 27.2% and 28.5%, respectively. We believe excluding discrete tax impacts on our tax rate provides a more comparable view of our effective income tax rate.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Income from continuing operations was $63.9 million for the nine months ended September 30, 2023, as compared to $38.6 million for the nine months ended September 30, 2022. Net income attributable to Pediatrix Medical Group, Inc. was $63.9 million for the nine months ended September 30, 2023, as compared to $36.7 million for the same period in 2022. Adjusted EBITDA from continuing operations attributable to Pediatrix Medical Group, Inc. was $149.6 million for the nine months ended September 30, 2023, as compared to $174.5 million for the same period in 2022.  The decrease in our Adjusted EBITDA was primarily due to net unfavorable impacts in our same-unit results, primarily from higher operating expenses as well as a decrease in CARES Act relief.</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Diluted net income per common and common equivalent share attributable to Pediatrix Medical Group, Inc. was $0.77 on weighted average shares outstanding of 82.5 million for the nine months ended September 30, 2023, as compared to $0.43 per common and common equivalent share on weighted average shares outstanding of 84.8 million for the same period in 2022. Adjusted EPS from continuing operations was $0.94 for the three months ended September 30, 2023, as compared to $1.20 for the same period in 2022.  The decrease in weighted average shares outstanding resulted from the share repurchases completed during 2022.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Liquidity and Capital Resources</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">As of September 30, 2023, we had $21.2 million of cash and cash equivalents attributable to continuing operations as compared to $9.8 million at December 31, 2022. Additionally, we had working capital attributable to continuing operations of $70.1 million at September 30, 2023, an increase of $69.1 million from working capital of $1.0 million at December 31, 2022.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash Flows from Continuing Operations</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:6.667%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Cash (used in) provided from operating, investing and financing activities from continuing operations is summarized as follows (in thousands):</span></p>
  <p style="margin-left:6.667%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">18</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:67.28%;"></td>
    <td style="width:1.46%;"></td>
    <td style="width:1%;"></td>
    <td style="width:12.9%;"></td>
    <td style="width:1%;"></td>
    <td style="width:1.46%;"></td>
    <td style="width:1%;"></td>
    <td style="width:12.9%;"></td>
    <td style="width:1%;"></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Nine Months Ended<br />September 30,</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">2023</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Operating activities</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">73,078</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">80,019</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Investing activities</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(35,752</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(45,713</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Financing activities</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(20,968</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(401,265</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="margin-left:6.667%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Operating Activities from Continuing Operations</span></p>
  <p style="text-indent:2.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">During the nine months ended September 30, 2023, our net cash provided by operating activities for continuing operations was $73.1 million, compared to $80.0 million for the same period in 2022. The net decrease in cash provided of $6.9 million was primarily due to decreases in cash flow from prepaid expenses and other current assets, income taxes and other liabilities, partially offset by increases in cash flow from accounts receivable and accounts payable and accrued expenses.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">During the nine months ended September 30, 2023, cash flow from accounts receivable for continuing operations increased by $22.1 million, as compared to a decrease of $0.5 million for the same period in 2022. The increase in cash flow from accounts receivable for the nine months ended September 30, 2023 as compared to the prior year period was primarily due to improved cash collections at existing units.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Days sales outstanding (&#x201c;DSO&#x201d;) is one of the key factors that we use to evaluate the condition of our accounts receivable and the related allowances for contractual adjustments and uncollectibles. DSO reflects the timeliness of cash collections on billed revenue and the level of reserves on outstanding accounts receivable. Our DSO for continuing operations was 50.4 days at September 30, 2023 as compared to 53.1 days at December 31, 2022 and 55.3 days at September 30, 2022.  The improvement in our DSO was primarily related to improved cash collections at our existing units.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Investing Activities from Continuing Operations</span></p>
  <p style="text-indent:2.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">During the nine months ended September 30, 2023, our net cash used in investing activities for continuing operations of $35.8 million consisted primarily of capital expenditures of $24.3 million and net purchases of investments of $9.9 million.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Financing Activities from Continuing Operations</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">During the nine months ended September 30, 2023, our net cash used in financing activities for continuing operations of $21.0 million primarily consisted of net payments on our Revolving Credit Line (as defined below) of $4.0 million and payments on our Term A Loan (as defined below) of $9.4 million.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">    </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Liquidity</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">On February 11, 2022, we issued $400.0 million of 5.375% unsecured senior notes due 2030 (the &#x201c;2030 Notes&#x201d;).  We used the net proceeds from the issuance of the 2030 Notes, together with $100.0 million drawn under our Revolving Credit Line (as defined below), $250.0 million of Term A Loan and approximately $308.0 million of cash on hand, to redeem (the &#x201c;Redemption&#x201d;) the 2027 Notes, which had an outstanding principal balance of $1.0 billion, and to pay costs, fees and expenses associated with the Redemption and the Credit Agreement Amendment (as defined below).</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Also in connection with the Redemption, we amended and restated the Credit Agreement (the &#34;Credit Agreement&#34;), and such amendment and restatement (the &#x201c;Credit Agreement Amendment&#x201d;), concurrently with the issuance of the 2030 Notes. The Credit Agreement, as amended by the Credit Agreement Amendment (the &#x201c;Amended Credit Agreement&#x201d;), among other things, (i) refinanced the prior unsecured revolving credit facility with a $450.0 million unsecured revolving credit facility, including a $37.5 million sub-facility for the issuance of letters of credit (the &#x201c;Revolving Credit Line&#x201d;), and a new $250.0 million term A loan facility (&#x201c;Term A Loan&#x201d;) and  (ii) removed JPMorgan Chase Bank, N.A., as the administrative agent under the Credit Agreement and appointed Bank of America, N.A. as the administrative agent for the lenders under the Amended Credit Agreement.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The Amended Credit Agreement matures on February 11, 2027 and is guaranteed on an unsecured basis by substantially all of our subsidiaries and affiliated professional contractors. At our option, borrowings under the Amended Credit Agreement bear interest at (i) the Alternate Base Rate (defined as the highest of (a) the prime rate as announced by Bank of America, N.A., (b) the Federal Funds Rate plus 0.50% and (c) Term Secured Overnight Financing Rate (&#34;SOFR&#34;) for an interest period of one month plus 1.00% with a 1.00% floor) plus an applicable margin rate of 0.50% for the first two fiscal quarters after the date of the Credit Agreement Amendment, and thereafter at an applicable margin rate ranging from 0.125% to 0.750% based on our consolidated net leverage ratio or (ii) Term SOFR rate (calculated as the Secured Overnight Financing Rate published on the applicable Reuters screen page plus a spread adjustment of 0.10%, 0.15% or 0.25% depending on if we select a one-month, three-month or six-month interest period, respectively, for the applicable loan with a 0% floor), plus an applicable margin rate of 1.50% for the first two full fiscal quarters after the date of the Credit Agreement Amendment, and thereafter at an applicable margin rate ranging from 1.125% to 1.750% based on our consolidated net leverage ratio. The Amended Credit Agreement also provides for other customary fees and charges, including an unused commitment fee with respect to the Revolving Credit Line ranging from 0.150% to 0.200% of the unused lending commitments under the Revolving Credit Line, based on our consolidated net leverage ratio.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The Amended Credit Agreement contains customary covenants and restrictions, including covenants that require us to maintain a minimum interest coverage ratio, a maximum consolidated net leverage ratio and to comply with laws, and restrictions on the ability to pay dividends, incur indebtedness or liens and make certain other distributions subject to baskets and exceptions, in each case, as specified therein.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">19</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Failure to comply with these covenants would constitute an event of default under the Amended Credit Agreement, notwithstanding the ability of the company to meet its debt service obligations. The Amended Credit Agreement includes various customary remedies for the lenders following an event of default, including the acceleration of repayment of outstanding amounts under the Amended Credit Agreement. In addition, we may increase the principal amount of the Revolving Credit Line or incur additional term loans under the Amended Credit Agreement in an aggregate principal amount such that on a pro forma basis after giving effect to such increase or additional term loans, we are in compliance with the financial covenants, subject to the satisfaction of specified conditions and additional caps in the event that the Amended Credit Agreement is secured.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">At September 30, 2023, we had an outstanding principal balance on the Amended Credit Agreement of $231.3 million, comprised solely of the Term A Loan. At September 30, 2023, the Company had no outstanding balance under the Revolving Credit Line. We had $450.0 million available on the Amended Credit Agreement at September 30, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">At September 30, 2023, we had an outstanding principal balance of $400.0 million on the 2030 Notes. Our obligations under the 2030 Notes are guaranteed on an unsecured senior basis by the same subsidiaries and affiliated professional contractors that guarantee our Amended Credit Agreement. Interest on the 2030 Notes accrues at the rate of 5.375% per annum, or $21.5 million, and is payable semi-annually in arrears on February 15 and August 15, beginning on August 15, 2022.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The indenture under which the 2030 Notes are issued, among other things, limits our ability to (1) incur liens and (2) enter into sale and lease-back transactions, and also limits our ability to merge or dispose of all or substantially all of our assets, in all cases, subject to a number of customary exceptions.  Although we are not required to make mandatory redemption or sinking fund payments with respect to the 2030 Notes, upon the occurrence of a change in control, we may be required to repurchase the 2030 Notes at a purchase price equal to 101% of the aggregate principal amount of the 2030 Notes repurchased plus accrued and unpaid interest.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">At September 30, 2023, we believe we were in compliance, in all material respects, with the financial covenants and other restrictions applicable to us under the Amended Credit Agreement and the 2030 Notes. We believe we will be in compliance with these covenants throughout 2023.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">We maintain professional liability insurance policies with third-party insurers, subject to self-insured retention, exclusions and other restrictions. We self-insure our liabilities to pay self-insured retention amounts under our professional liability insurance coverage through a wholly owned captive insurance subsidiary. We record liabilities for self-insured amounts and claims incurred but not reported based on an actuarial valuation using historical loss information, claim emergence patterns and various actuarial assumptions. Our total liability related to professional liability risks at September 30, 2023 was $295.7 million, of which $30.2 million is classified as a current liability within accounts payable and accrued expenses in the Consolidated Balance Sheet. In addition, there is a corresponding insurance receivable of $40.6 million recorded as a component of other assets for certain professional liability claims that are covered by insurance policies.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">We anticipate that funds generated from operations, together with our current cash on hand and funds available under our Amended Credit Agreement, will be sufficient to finance our working capital requirements, fund anticipated acquisitions and capital expenditures, fund expenses, if any, related to our transformational and restructuring activities, fund our share repurchase programs and meet our contractual obligations for at least the next 12 months from the date of issuance of this Quarterly Report on Form 10-Q.</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Caution Concerning Forward-Looking Statements</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Certain information included or incorporated by reference in this Quarterly Report may be deemed to be &#x201c;forward-looking statements&#x201d; within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the &#x201c;Exchange Act&#x201d;). Forward-looking statements may include, but are not limited to, statements relating to our objectives, plans and strategies, and all statements, other than statements of historical facts, that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future are forward-looking statements. These statements are often characterized by terminology such as &#x201c;believe,&#x201d; &#x201c;hope,&#x201d; &#x201c;may,&#x201d; &#x201c;anticipate,&#x201d; &#x201c;should,&#x201d; &#x201c;intend,&#x201d; &#x201c;plan,&#x201d; &#x201c;will,&#x201d; &#x201c;expect,&#x201d; &#x201c;estimate,&#x201d; &#x201c;project,&#x201d; &#x201c;positioned,&#x201d; &#x201c;strategy&#x201d; and similar expressions, and are based on assumptions and assessments made by our management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. Any forward-looking statements in this Quarterly Report are made as of the date hereof, and we undertake no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in the 2022 Form 10-K and this Quarterly Report, including the section entitled &#x201c;Risk Factors.&#x201d;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">20</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_3"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Item 3. Quantitative and Qual</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">itative Disclosures about Market Risk</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">We are subject to market risk primarily from exposure to changes in interest rates based on our financing, investing and cash management activities.  We intend to manage interest rate risk through the use of a combination of fixed rate and variable rate debt.  We borrow under our Amended Credit Agreement at various interest rate options based on the Alternate Base Rate or SOFR rate depending on certain financial ratios. At September 30, 2023, the outstanding principal balance on our Amended Credit Agreement was $231.3 million, comprised solely of the Term A Loan. Considering the outstanding balance, a 1% change in interest rates would result in an impact to income before taxes of approximately $2.3 million per year.</span></p>
  <p style="text-indent:2.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_4"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Item 4. Controls a</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">nd Procedures</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Evaluation of Disclosure Controls and Procedures</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">We maintain disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) that are designed to provide reasonable assurance that information required to be disclosed by the Company in reports it files or submits under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in SEC rules and forms and (ii) accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">We carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our disclosure controls and procedures. Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of September 30, 2023.</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Changes in Internal Controls Over Financial Reporting</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">No changes in our internal control over financial reporting occurred during the three months ended September 30, 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">21</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_ii"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">PART II - OTH</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">ER INFORMATION</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Item 1.	Legal Pro</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">ceedings	</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">We expect that audits, inquiries and investigations from government authorities and agencies will occur in the ordinary course of business. Such audits, inquiries and investigations and their ultimate resolutions, individually or in the aggregate, could have a material adverse effect on our business, financial condition, results of operations, cash flows and the trading price of our securities.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">In the ordinary course of our business, we become involved in pending and threatened legal actions and proceedings, most of which involve claims of medical malpractice related to medical services provided by our affiliated physicians. Our contracts with hospitals generally require us to indemnify them and their affiliates for losses resulting from the negligence of our affiliated physicians and other clinicians. We may also become subject to other lawsuits, including with payors or other counterparties that could involve large claims and significant defense costs. We believe, based upon a review of pending actions and proceedings, that the outcome of such legal actions and proceedings will not have a material adverse effect on our business, financial condition, results of operations, cash flows or the trading price of our securities. The outcome of such actions and proceedings, however, cannot be predicted with certainty and an unfavorable resolution of one or more of them could have a material adverse effect on our business, financial condition, results of operations, cash flows and the trading price of our securities.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">	Although we currently maintain liability insurance coverage intended to cover professional liability and certain other claims, we cannot assure that our insurance coverage will be adequate to cover liabilities arising out of claims asserted against us in the future where the outcomes of such claims are unfavorable to us. With respect to professional liability risk, we self-insure a significant portion of this risk through our wholly owned captive insurance subsidiary. Liabilities in excess of our insurance coverage, including coverage for professional liability and certain other claims, could have a material adverse effect on our business, financial condition, results of operations, cash flows and the trading price of our securities.</span></p>
  <p style="text-indent:0.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1a"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Item 1A. Risk</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> Factors</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Item 1A. Risk Factors in our most recent Annual Report on Form 10-K includes a discussion of our risk factors. The information presented below updates, and should be read in conjunction with, the risk factors disclosed in our most recent Annual Report on Form 10-K. Except as presented below, there have been no material changes to the risk factors disclosed in our most recent Annual Report on Form 10-K.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">We have begun to undertake a transformation of our revenue cycle management function from an outsourced provider to a hybrid function that utilizes both our corporate personnel as well as one or more third-party service providers. This transition will involve significant time and resources, and our failure to execute this transition efficiently and effectively may have a material impact on our business, financial condition, results of operations, cash flows and the trading price of our securities.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">On October 30, 2023, we provided notice to R1 RCM Holdco Inc. (f/k/a R1 RCM Inc.) (&#x201c;R1RCM&#x201d;) that we were terminating that certain Services Agreement, dated May 12, 2021, as amended, by and between our wholly-owned subsidiary PMG Services, Inc. and R1RCM (the &#x201c;Services Agreement&#x201d;), effective as of December 15, 2023. Pursuant to the Services Agreement, R1RCM is the primary provider of our enterprise revenue cycle management services. Our termination of the Services Agreement was in connection with R1RCM&#x2019;s performance, specifically R1RCM's failure to meet certain service levels set forth in the Services Agreement.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Following the termination of the Services Agreement, we are undertaking a transformation of our revenue cycle management function from R1RCM, as an outsourced provider, to a hybrid function that utilizes both our corporate personnel as well as one or more third-party service providers that we intend to engage to support these activities.  The success of this plan depends, in part, on our ability to scale our internal operations to handle certain revenue cycle management functions internally, to engage one or more third-party service providers to handle other revenue cycle management functions, and to integrate those service providers with our systems in a timely and efficient manner.  If we are not able to successfully achieve these objectives, the anticipated benefits of this transformation may not be realized fully or at all or may take longer to realize than expected. These activities may be complex and time consuming and involve delays or additional and unforeseen expenses. The process of transitioning to these third-party service providers, the integration process and other disruptions may also disrupt our ongoing businesses or cause inconsistencies in standards, controls, procedures and policies that could adversely affect our relationships with payors, patients, hospitals and others. The transformation may entail significant management and staff personnel time and a complicated phase-in process, where difficulties in training personnel in new technology can frequently occur. In connection with the transformation of our revenue cycle management function, we could experience a further reduction in revenue due to delays in collection efforts or the inability to collect from patients or third-party payors, claim denials, recoupments, or governmental and third-party audits, all of which may impact our profitability and cash flow.  Further, the costs associated with the transformation of our revenue cycle management function, as well as the additional costs and risks associated with any operational problems, delays in collections from payors, and errors and control issues during the termination and transition process, may impact our ability to realize the intended benefits from transforming our revenue cycle management function and may have a material adverse effect on our business, financial condition, results of operations, cash flows and the trading price of our securities.</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_2"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Item 2. Unregiste</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">red Sales of Equity Securities and Use of Proceeds</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:7pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">During the three months ended September 30, 2023, we withheld 10,667 shares of our common stock to satisfy minimum statutory withholding obligations in connection with the vesting of restricted stock.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">22</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:40.092%;"></td>
    <td style="width:1%;"></td>
    <td style="width:1%;"></td>
    <td style="width:11.018%;"></td>
    <td style="width:1%;"></td>
    <td style="width:1.1%;"></td>
    <td style="width:1%;"></td>
    <td style="width:10.278%;"></td>
    <td style="width:1%;"></td>
    <td style="width:1%;"></td>
    <td style="width:1%;"></td>
    <td style="width:13.417%;"></td>
    <td style="width:1%;"></td>
    <td style="width:1.26%;"></td>
    <td style="width:14.837%;"></td>
   </tr>
   <tr style="height:8pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Period</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Total Number<br />of Shares<br />Repurchased </span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;font-family:Times New Roman;position:relative;min-width:fit-content;">(a)</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Average Price<br />Paid per Share</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Total Number of<br />Shares Purchased<br />as part of<br />the Repurchase<br />Program</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Approximate Dollar<br />Value of Shares<br />that May Yet<br />Be Purchased<br />Under the<br />Repurchase<br />Programs </span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;font-family:Times New Roman;position:relative;min-width:fit-content;">(a)</span></p></td>
   </tr>
   <tr style="height:8pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">July 1 &#x2013;  July 31, 2023</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(a)</span></p></td>
   </tr>
   <tr style="height:8pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">August 1 &#x2013; August 31, 2023</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(a)</span></p></td>
   </tr>
   <tr style="height:8pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">September 1 &#x2013; September 30, 2023</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">10,667 (b)</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">12.46</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(a)</span></p></td>
   </tr>
   <tr style="height:8pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Total</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">10,667</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">12.46</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(a)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:8pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(a)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">We have two active repurchase programs. Our July 2013 program allows us to repurchase shares of our common stock up to an amount sufficient to offset the dilutive impact from the issuance of shares under our equity compensation programs, which is estimated to be approximately 1.1 million shares for 2023. </span><span style="color:#231f20;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Our August 2018 repurchase program allows us to repurchase up to an additional $500.0 million of shares of our common stock, of which we repurchased $495.4</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#231f20;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">million as of September 30, 2023.  </span></div></div>
  <div style="margin-left:4.528%;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:8pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(b)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Shares withheld to satisfy nominal minimum statutory withholding obligations in connection with the vesting of restricted stock.</span></div></div>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The amount and timing of any future repurchases will depend upon several factors, including general economic and market conditions and trading restrictions.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;" id="item_5"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Item 5. Other Information</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Rule 10b5-1 Trading Plans</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">During the three months ended September 30, 2023, none of the Company&#x2019;s directors or officers </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_db7bad9e-2b2d-4060-91f4-b43e068d75a2" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_f86f2217-3287-481e-a206-a4830f08c620" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">adopted</span></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> or </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_25ee6790-1cb0-4b0b-a508-44ed22c0bc21" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_2f7b80dc-eedb-4fc8-bc3a-ad4f2dbaad21" contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">terminated</span></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> any Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement (as such terms are defined in Item 408 of Regulation S-K).</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">R1 Services Agreement</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">On October 30, 2023, PMG Services, Inc. (f/k/a Mednax Services, Inc.), a wholly-owned subsidiary of the Company (&#x201c;PMG&#x201d;), provided notice to R1 RCM Holdco Inc. (f/k/a R1 RCM Inc.) (&#x201c;R1RCM&#x201d;) that PMG was terminating that certain Services Agreement, dated May 12, 2021, as amended, by and between PMG and R1RCM (the &#x201c;Services Agreement&#x201d;), effective as of December 15, 2023. Pursuant to the Services Agreement, R1RCM is the primary provider of enterprise revenue cycle management services for the Company (the &#x201c;Services&#x201d;). The Company&#x2019;s termination of the Services Agreement was a result of the occurrence of certain Service Level Termination Events (as defined in the Services Agreement) related to performance, which permitted PMG to terminate the Services Agreement. PMG anticipates incurring certain immaterial early termination fees in connection with the termination of the Services Agreement. Pursuant to the terms of the Services Agreement, R1RCM is obligated to provide PMG with certain termination assistance following the termination of the Services Agreement to allow the Services to continue without interruption or adverse effect and to facilitate the orderly transfer of the Services to the Company or any successor vendor.</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">23</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="exhibit_index"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Item 6. 	Exh</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">ibits</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;padding-bottom:1pt;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Exhibit No.		    	Description								</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:10%;"></td>
    <td style="width:90%;"></td>
   </tr>
   <tr>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">3.1</span></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/893949/000095017023037565/md-ex3_1.htm"><span style="color:#0000ff;white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Second Amended and Restated Bylaws of Pediatrix Medical Group, Inc. (incorporated by reference to Exhibit 3.1 to the Company&#x2019;s Quarterly Report on Form 10-Q for the period ended June 30, 2023, filed on August 3, 2023).</span></a></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">31.1+</span></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="md-ex31_1.htm"><span style="color:#0000ff;white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Certification of Chief Executive Officer pursuant to Securities Exchange Act Rule 13a-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">31.2+</span></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="md-ex31_2.htm"><span style="color:#0000ff;white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Certification of Chief Financial Officer pursuant to Securities Exchange Act Rule 13a-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">32.1++</span></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:9pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="md-ex32_1.htm"><span style="color:#0000ff;white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p><p style="text-indent:-54pt;padding-left:54pt;font-size:9pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">101.1+</span></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:9pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Interactive Data File</span></p><p style="text-indent:0;font-size:9pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">101.INS+</span></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">XBRL Instance Document &#x2013; the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></p><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">101.SCH+</span></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:9pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">XBRL Schema Document.</span></p><p style="text-indent:0;font-size:9pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">101.CAL+</span></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:9pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">XBRL Calculation Linkbase Document.</span></p><p style="text-indent:0;font-size:9pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">101.DEF+</span></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:9pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">XBRL Definition Linkbase Document.</span></p><p style="text-indent:0;font-size:9pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">101.LAB+</span></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:9pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">XBRL Label Linkbase Document.</span></p><p style="text-indent:0;font-size:9pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">101.PRE+</span></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:9pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">XBRL Presentation Linkbase Document.</span></p><p style="text-indent:0;font-size:9pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">104+</span></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:9pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</span></p><p style="text-indent:0;font-size:9pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:-11.111%;padding-left:10%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">+  Filed herewith.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">++  Furnished herewith.</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">24</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:center;" id="signatures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">SIGNAT</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">URES</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">	</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:57.8%;"></td>
    <td style="width:42.2%;"></td>
   </tr>
   <tr style="height:10pt;">
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Pediatrix Medical Group, Inc</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Date:  November 2, 2023</span></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">By:</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;/s/ James D. Swift, M.D.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">             </span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;&#160;&#160;James D. Swift, M.D.</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;&#160;&#160;Chief Executive Officer</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;&#160;&#160;(Principal Executive Officer)</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Date:  November 2, 2023</span></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">By:</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;/s/ C. Marc Richards</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">        </span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;&#160;&#160;C. Marc Richards</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;&#160;&#160;Chief Financial Officer</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;&#160;&#160;(Principal Financial Officer and</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;&#160;&#160;&#160;Principal Accounting Officer)</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:-74.419%;padding-left:42.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:-74.419%;padding-left:42.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:-74.419%;padding-left:42.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">25</span></p>
  <hr style="page-break-after:always;" />
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>md-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html>
 <head>
  <title>EX-31.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 31.1</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">I, James D. Swift, M.D., certify that:</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">I have reviewed this quarterly report on Form 10-Q of Pediatrix Medical Group, Inc.;</font></div></div>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The registrant&#x2019;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:6.667%;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:6.667%;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:6.667%;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:6.667%;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font></div></div>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The registrant&#x2019;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></div></div>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:6.667%;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font></div></div>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:6.667%;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></div></div>
  <p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Date: November 2, 2023</font></p>
  <p style="margin-left:43.333%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">By:	</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">/s/</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">James D. Swift, M.D</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">	</font></p>
  <p style="margin-left:43.333%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">	           James D. Swift, M.D.</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:43.333%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">	           Chief Executive Officer</font></p>
  <p style="margin-left:43.333%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">	           (Principal Executive Officer)</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>md-ex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html>
 <head>
  <title>EX-31.2</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:43.333%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 31.2</font></p>
  <p style="margin-left:43.333%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">I, C. Marc Richards, certify that:</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">I have reviewed this quarterly report on Form 10-Q of Pediatrix Medical Group, Inc.;</font></div></div>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The registrant&#x2019;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:6.667%;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:6.667%;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:6.667%;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:6.667%;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font></div></div>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The registrant&#x2019;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></div></div>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:6.667%;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font></div></div>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:6.667%;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></div></div>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Date: November 2, 2023</font></p>
  <p style="margin-left:43.333%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">By:	</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">/s/</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">C. Marc Richards	</font></p>
  <p style="margin-left:43.333%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">	           C. Marc Richards</font></p>
  <p style="margin-left:43.333%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">	           Chief Financial Officer</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:43.333%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">	          (Principal Financial Officer and</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:43.333%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">                Principal Accounting Officer)</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>md-ex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html>
 <head>
  <title>EX-32.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 32.1</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Certification Pursuant to 18 U.S.C Section 1350</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(Adopted by Section 906 of the Sarbanes-Oxley Act of 2002)</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:2.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">In connection with the Quarterly Report of Pediatrix Medical Group, Inc. on Form 10-Q for the quarter ended September 30, 2023 (the &#x201c;Report&#x201d;), each of the undersigned hereby certifies, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that (i) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and (ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Pediatrix Medical Group, Inc.</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:2.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">A signed original of this written statement required by Section 906 has been provided to Pediatrix Medical Group, Inc. and will be retained by Pediatrix Medical Group, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">November 2, 2023</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">By: </font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">/s/ James D. Swift, M.D. 	</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">	James D. Swift, M.D.</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">	Chief Executive Officer</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">	(Principal Executive Officer)</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">By: </font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">s/</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">C. Marc Richards	</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">	C. Marc Richards</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">	Chief Financial Officer</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">	(Principal Financial Officer and</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">         Principal Accounting Officer)</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>img259349275_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img259349275_0.jpg
M_]C_X1FB17AI9@  34T *@    @ !P$2  ,    !  $   $:  4    !
M8@$;  4    !    :@$H  ,    !  (   $Q  (    A    <@$R  (    4
M    DX=I  0    !    J    -0 +<;    G$  MQL   "<0061O8F4@4&AO
M=&]S:&]P(#(S+C0@*$UA8VEN=&]S:"D ,C R,CHP-SHR-R Q-3HS.#HS-
M  .@ 0 #     0 !  "@ @ $     0  !D"@ P $     0   ^D
M!@$#  ,    !  8   $:  4    !   !(@$;  4    !   !*@$H  ,    !
M  (   (!  0    !   !,@("  0    !   8:         !(     0   $@
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MR@)R@ 8R&27'*7%_C<*?NQ.,QD8B5\0,(\(C6SQ.9_C-P[.F6-HQ;J\^RLM
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M<')I;G1E<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,
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M      !%;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0
M     %)'0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6)
M;^            !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M             $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X
M;$!RP           "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !0
M9U!S     %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N
M=$8C4FQT                4V-L(%5N=$8C4')C0%D            08W)O
M<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P
M   ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M        "V-R;W!296-T5&]P;&]N9P      .$))30/M       0 2P    !
M  $!+     $  3A"24T$)@      #@             _@   .$))300-
M   $    6CA"24T$&0      !    !XX0DE- _,       D           $
M.$))32<0       *  $          3A"24T#]0      2  O9F8  0!L9F8
M!@       0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U
M     0 M    !@       3A"24T#^       <   ____________________
M_________P/H     /____________________________\#Z     #_____
M________________________ ^@     ____________________________
M_P/H   X0DE-!         (  3A"24T$ @      !      X0DE-!#
M  (! 3A"24T$+0      !@ !     CA"24T$"       $     $   )    "
M0      X0DE-!$0      !     "   "0    D      .$))300>       $
M     #A"24T$&@     #20    8              ^D   9     "@!5 &X
M= !I '0 ; !E &0 +0 Q     0                         !
M      9    #Z0                     !
M !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $       !2
M8W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T
M;VUL;VYG   #Z0    !29VAT;&]N9P  !D     &<VQI8V5S5FQ,<P    %/
M8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '
M9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN
M    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90
M  !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P
M(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   ^D
M4F=H=&QO;F<   9      W5R;%1%6%0    !        ;G5L;%1%6%0    !
M        37-G951%6%0    !       &86QT5&%G5$585     $       YC
M96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH
M;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT
M"79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0
M   +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO
M;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M    #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P
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MW7/%=5;2^Q[C#6M:-SGN<?HM:U)34ZSUC$Z/A.R\DDB=M=;?I/<?S&K%H?\
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MO_0JHW#RLKHMF6ZJW)ZGC]4JS.MX): YYHVL?C8M+?T5]'H-IOQ/?9]J_?\
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M]).CUWV/R_R^5!Z;;]7ZJ27RJDFI?JI)?*J22G__V3A"24T$(0      5P
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M   ,2$QI;F\"$   ;6YT<E)'0B!865H@!\X  @ )  8 ,0  86-S<$U31E0
M    245#('-21T(               $  /;6  $     TRU(4" @
M                                                       18W!R
M=    5     S9&5S8P   80   !L=W1P=    ?     48FMP=    @0    4
M<EA96@   A@    49UA96@   BP    48EA96@   D     49&UN9    E0
M  !P9&UD9    L0   "(=G5E9    TP   "&=FEE=P   ]0    D;'5M:0
M _@    4;65A<P  ! P    D=&5C:   !#     ,<E120P  !#P   @,9U12
M0P  !#P   @,8E120P  !#P   @,=&5X=     !#;W!Y<FEG:'0@*&,I(#$Y
M.3@@2&5W;&5T="U086-K87)D($-O;7!A;GD  &1E<V,         $G-21T(@
M245#-C$Y-C8M,BXQ               2<U)'0B!)14,V,3DV-BTR+C$
M
M %A96B        #S40 !     1;,6%E:(                     !865H@
M        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(
M "2@   /A   ML]D97-C         !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M             !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M                                            9&5S8P         N
M245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M               N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@
M<W!A8V4@+2!S4D="                             &1E<V,
M+%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M             "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#
M-C$Y-C8M,BXQ                                  !V:65W       3
MI/X %%\N !#/%  #[<P !!,+  -<G@    %865H@      !,"58 4    %<?
MYVUE87,          0                        */     G-I9R
M0U)4(&-U<G8        $      4 "@ / !0 &0 > ", *  M #( -P [ $
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M0R0T5%8)XF/"@Z/41(2D)97#Q$;PX62%)K4G_]H # ,!  (1 Q$ /P"_P
M
M
M
M
M
M                              __T+_
M
M
M
M
M
M        #__1O\
M
M                                                  ##VV.06CM%
M5Y66X=L8%KEAQE3\5C*LEK*RTL6T=>[ZD4KKGODQ7@?S(K#BO _#P,9"PRG,
M\TGP9?0G6?3PQ;2\;W+S6C>-&<L^87,2Y]ZZ&R6\S22>$G;T*E2G!_\ <JI=
ME27AJ3BO"17[9]=_AYA"Y<+753LK<UBT:TQIE)0-XABKZT>'1VVS-R-8(29_
M2J;IW",NI^SIUWFPY7:AN<)7DJ=LNE.7'+SH8Q_MHF)HO_CHYY:@C"XU16L<
MAI2PXHU:SN;A)]5.U52BWUJ5S!]'7A';L/XA'>=JMYO5NB=7X5'6:DMNYI<Y
M/L*>V@_ G&UU*\=8)?REWL+27L,E#;K3E-EE/;?752J_I%&FOH]H_HHE#IC_
M (RN7EFHRUAJ+,,PDMZM:5O90;ZFJBO9X>*<7X4:=Y;ZR_J#90X[[IN*JPZ(
M]U(X&):YU_';01^PFI]W73IJ>GR&F5U_5&PV_+K2=!>5;NHUTSJ5/04HQ^@=
MRR7N(]V;*(1[?(JE]./J[F^O9-^.%*O1I/S:9@2X]1/G+>*6J;RGW,P:S,U?
M4?,9^.I+K_F)Q\XI)_[$D0RM/2.F*7I;&B_'!2]EB='L>Z_W><N25OH[*Y8?
M;;:%?S^V[3'S3X]SFSS+<5W*Y:<ER/IT_8]Z[/:3X?Z+5H1?Y>@]"TUIU?\
MP%O]XI_6F=CR Y$Q6"T5D7FY18/T;=GM:[GGS7JW"=C<KN0+JB,CZ6.U\SMV
M_#Z+5M+?0?\ E2/G/2VFYK"5A0\RE!>@D>*Z[N/(*\CP5=&9,E])EUK2?GTZ
M<']$R[C7JO\ J"XJ:/<.2.26#:3+N:R7&L!RPG$_*A;N2U,ITNOT4N$KZ!D8
M\%;0FDZ_I[.*^IE./L9)&DYMW,N[/G*?OG2M"DWTT*]Y;8>%*A<4X^>FNM&U
M."^O5S(QQ;#67XYIO8D-)I*4[98K<X[<O)+V^1-QBRCQ&U'\IJKUE]!)#!77
M*S3M;%V\ZU%]&$E)>=*+?]I''=1?\</(K-8RGDEUF>5U'Z50N*5>DO'"O0G4
MDO%6B_";Z:N^(3U5:.1XNX]!9QAAJ[&G;;7^24N>Q#6?@<ERKO&Z)YELC\5(
M;>D+(O9WGX#5K[E-?03EEUW"IX*D7!^+&/&F_,1'#5__ !DZQLXRK:%U):7^
M]JG>4*MG+#UJJ4I7<92ZFXTXM[^%;24'3'J0\*M[G$B83OK#J^^F&VVWBV=O
MOZ]R%<MSV08</,40T37O'V5[L@C\>BCZ'TTG,=':DRO&5S:S<5ZJ'MD<.MN&
M."^J2(B:\[JW/SERIUL_TW<U;:&+=Q9I7M%17JY2M75=*/AK1IOK2Q1O"E25
MI2I*B4E1$I*DF1I4DRZDI)E[2/Y#&LD?&G%X/8T?Z!_
M
M
M                  #_TK_
M
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MY#6@
M
M                                   /_]._P
M
M
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MF^=PP;S"[A&4X3Z[6CY5*U2>/#*'%7P;C*O-$;HW E4
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M[6O.VN82IU*<G&<))QE&47A*,HO!QDFFFFDTU@SR1_#Y
M
M
M            !__4O\
M
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MG"KJ>%62Z*-GF%9/Q3IVLH?VMO0??M>B=Z@3B#6O7&',*))*)IW9^$FLS/\
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M!1JTY=:PE!XPJ1A4C*"SL,6<Z
M
M                                                    _]6_P
M
M
M                     #T>39-CV&8]=99EMW68WC..ULNXO;ZZFL5U545<
M!DY$R?/FR5);::;0DU*4I1$/K1HUKFM&A;Q<YS:48I8MM[DDM[,AE.4YGGV9
MT,ER6WJ75W=3C2HT:47.I4J3>$80A%-RE)O!)(I\^I;ZL.4\FYMWIG1-A:8C
MQZCNNP+>U04BKR7;YM+-#DBW(^UZ'1J,O]VJS[5OI_99Q=5(BQI!:,T)0R6,
M<QS1*I=O:EOC2\70Y]<MRW1]<[Q.ZAW,<GY2V]OKOF+2IWNIY)3ITWA4H9;B
ML5&GOC5NUZNX6,:;\BW>"=:K"D.D$^P     1&9D1$9F9]"(O$S,_81$!_-V
MUDE7&OTGN8O))NONX>")U7@D[RW49MME4S%H\J(OHLI%+C7DNW$U+C?SH[S<
M%,9SP_WE)'W%IN<Z[T]D[=.57MZJ]12PE@_#+%07A7%Q+J(I<UN^=R,Y53JY
M?7S'\L9C3Q3M,NX;B49+9PU:_%&VI.+V3@ZSK1V^U-K G.T7Z"G&;!VX=CNW
M+\TW==MDA4JJC2'-=8,I?TRFBKZ!YRW7VG\TG/JT@E$74VD]>A<QS/FGG5RW
M#+:<+:/0W[9/SY+@_L/QE>/,3_D?YLZAE4M= 6-KI^W>/#4DE>W>'7QUHQME
MCOX?>LFGL4WABY8M5\8>.VD&HZ-3:4UK@DB.A*$VU#B5.QD+Q)\$JFY,ZTNP
MD*+_ #Y$I:OU1HE]G>;YFV[^YJ54^B4WP^9''A7F(ACK'FYS0Y@SE+6F?WV8
MQF\>SK7-5T%]104E1@O!"G%> SJ,6<Z       ^:RK#,/SJJ=HLWQ3&LQI'R
M43U/E5%5Y#5/$HNU1.U]NT\RKJ7@?5 ^U"YN+6?:VU25.2Z8R<7YZ:9E<GS[
M/-.WBS'3][7L;B.ZK;UJE&HO%.G*,EYC(XMT^CUP7W"B7)B:QD:COY)+--[J
M"U<Q5IE9]303>)2D2Z%*"5XF3=6A1EX$LO#IN&6\P=3Y>U&5?WQ!>IJKB_M+
M"?\ :)3Z"[\?>'T-*%*MFZSNVAA[3F=-7#?7C<Q=.[;P]=<22>WA>W&%OD/Z
M"F_<$1.O./\ FN/;LI&?,>;QBW3'P+8"&OITL14V#[E1--"2,E.'815K/IY<
M?J?:71\HYIY5=-4LUIRMI/U2\NGYN"XX_P!66'2R>O+#_D>Y;:CE3R_F7E];
M3]Q+!.XI\5Y9M[L9<$(W-+%[H]C6C%8\57!8N$K/];[ U3DLW#=EX7D^!957
MG_O=!EE+845HVV:C0W(1%L6VU+9<[3-I]ON;<+YR%*29&.E6EY:7U%7%E4C5
MIO=*+4EYZZ>M;T3_ --:JTUK+*:>>Z3O[?,K.KZ6M;585J;?3'B@VE)8^5!X
M2B]DDGL/BQZ#/@    &Q'&7E)N'B7LF#LS3^1+J[!'DQL@H)OFRL6S.D0[YK
MM#E-0E:$R&%=5&VXE2'F%GYL=UITB66(SK),OSZS=EF$.);XR6R4'ZZ+Z']!
M[FFCE_-KE!H?G3I2II/7%JJU)XRHUHX1N+6JU@JUO4P;A-;.)-.G4BN"K"<&
MXEW3A-SBU/S;UNG*\(?*BS:B9B,;$UI8RVGK[#[20DR2\TLB1[Y625)6<&Q;
M;2EQ)&AQ#,A#K#<:]2Z9O]-7G87*XJ4L>SJ)>3-?R27JH]&]8IIO_/WS_P"[
MWK/N_P"JOR-J"/OC+[AR=E?PBU1N:<>AK;V5Q!-=M0DVXMJ4)3I2A4ENF-;.
M"
M
M                          '_UK_
M
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MWW-_G1.KE]W=O*<GGBEE]E*5.G*#Z+FMBJMTVL.)3:HN2XH4(,D<&GD60
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MK8TRRJTN[6_M:=[8U85J-:,9TZE.2G"<)+&,X2BW&49)IQDFTT\4\#PA^CT
M  !F/0N^MG<:]G8]MK4N0O8_EF/O=#(^]ZIO:EY:3L<<R.N)24RZ^6E))?84
M9&1DEQM3;S;3J,?FN566<V4["_AQTY^?%]$HOHDNA^8\4VGHO,?EQI'FOI&Z
MT5K6U5S97*\"J4:B3X*]">#=.M3;;A-)K!N$U*G*<)7I.$G-#6_-?4<3/\/6
MU3Y93E$K-E:^D2D/VN%9&ZR:^SN,DJD5TOL<=K)Y()+S:5(42)#+[+48M2Z<
MO--W[M;CRJ<L73J8;)Q_DDMTH]#ZTTW_ )W^\!R&U5R!UM/36>)U[*OQ5+&]
M46J=U03PQZ5"O3QC&O1Q;IR:DG*E.G.>Y UTX4
M
M
M '__U[_
M
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MH]C>V,W%X8N%6#VTZU*32XZ56#4Z<L$\'A)1DI167ACS2
M
M
M       /_]"_P
M
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M[7BI12[>4E=7(R41*29&DR(R,CZD9'XD9&0C>4&M-/!G^@?P
M
M
M        _]&_P
M
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M61\G^7N6Z R!)T[*FNTJ\*C*XN)^57N)[_*JU&Y)-O@APTXOAA%+ 0RITH
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MCG) X
M
M                         __2O\
M
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M6,E*C%2N;D1$1$1$1$70B+P(B+V$1".A0]OVL_T
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MH^9XP
M
M                       __]._P
M
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M:-6A/LZT7"2Z))I^<S)TZM.K'CI24EUIIKST>8/F?L
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MU/7.6T^"QU/3=:6"PC&^H<$+I>#M(RHW#;>,JE6K@L(DU8YN0&
M
M
M        #__4O\
M
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M(;K0[N^9:_LO>V:YDK"UISBZBI4^VJ5&EQ=GQ2G"-/AQC-OAJ)MQP6QE&?\
MR$?\I&0:PR&SY5\K\FNU;5IJZNZM[4IT)58TFU;T^QH2N$Z3K*=5J5:,W*E1
MDXPPP>8]L_$(^HUL9<EO%<NUOI2O?[VTQ=:ZYJ9THHZNI$A=MLM60R$N=OTS
MT=3)]?%!(\"+HN0=TCD[DZ3O[>XS.:Z;FXG%8_4VRMXX>"2EX<2F#.>\GS.S
M-M6=:A81?10HQ;P^JK]L\?#'A\&!'GG_ #VYL[16\>=\K^0%[&?-1N51[4S&
MMH>J_IC1CM/+CP$=?9\R.7AX>P=<RGE5RTR-+\EY#84I+=+WK1E4^^3C*;\V
M1S7,N8FO,W;_ "AG%Y43]3[XJ1A_4C)07F1-7+6ZN+Z6N?>6UG<SG.IN3;6?
M*L9:S,^IFN3,6M9]3\?$QO-"VM[6GV5K3C3BNB,5%><DD:C6KU[B?:7$Y3D^
MF3<GY[Q9ZT?8^0 'M:>^O,>EIGT%S:T<Y'3LFT]C,K):>T^J>V3"6A9=#\2Z
M*'PN+6UNZ?97=.-6#]3.*DO.::/M0N+BVGVEM.5.77&3B_/33-IM?\_N;VKE
ML'@W+'D!31HW3R:EW:677./H[3\.N-WLJ5 5]#YT8_#P]@T7-N4_++/$_P J
M9!85)2WS5K2A4^^0C&I_:-NRWF/K[*&OR?G-Y!+='WQ4E#^I.4H?V20_4OQ#
M'J+:Z7&:R_)=9[MKV>QMQC8VNZRKG*C)\#2U:ZR7C[GFDGP2](2\?7YRR<\>
MO(L_[HW)_.%*67T;G+)OIM[B4HX^&-RJZP\$>'J6!TO)N\KS-RQI7M6A?Q71
M6HQB\/JJ#HO'PRXO#B2U:*^)QTS?KAUG(KCYG.N9*_+8?R?65[6;%H3=/Z>;
M+HKM%+.AL%X]6X[L]POD[NO0N ZH[D^H[12K:/S>A>);53N82MYX>M4X.M"<
MO#)4EXCLNGN];D=RXTM39;5M7N=2A.-:'C<)=E.*\"=1^,G(XZ\^N'?*U$9K
M16_L"S&\DM$Z6%R;!W%]@-D2>YTU8'EC<&V4AL^J5O-Q%-=?8X9&1G&'6'*C
MF)H-REJG*:]O2B\.V455H>#V^DYTL7T)S4NM'?\ 3/,;1.L$EI[,:->H_P"Z
M;=.M]YJ*%3!=:BUX3< <]-U   #Y#-]@8)K2BD9/L3,\6P7'8O4G[S+KZKQZ
MK;7VFHFO?K5UILUF1'VMDHU*/P(C,>>YN[6RI.O>5(TH+U4Y**\]M&&SW4>G
M]+Y?+-=27U"PMH;ZMQ5A1IKP<5245B^A)XOH1%CN;UK>'^MURZ[!7<QW9=L=
M[2#PZF.EQ<I*/:W)R;+#B*4W\A/P(4M!^U)F7B-%S'F5IZS;A:\=S)>L6$<?
MJI8>?%21$O6_?FY,:8E.VR!W.>UXXI>]J?94.)=$J]QV;:^FI4JT7T8HC"VA
MZ\?(C(U28VJ]8ZVUG7N]Q,R[I=OL')(Q?K%-3GEUE?U^B3E4LOH?JZ1?<U,W
MK8QL*%.@NN6-22\WR8_V615U7_R"<R<S<J6DLJLLKIO=*JZEY7CXIMT*/GV\
MC0S.O4CYQ[#4\=YR0V%6-/&K]@PB5 URTVV?@339X%'K5]I%X=5+-1_KC,^I
MC5;K66I[S'M;RI''UC5/W-1(^Y_WG.?6I'+W_J>\I*71:RA9)+J7O2%%X>-M
MOI;-5LFV7L?-5N.9EL#-LM<>,S=7DV57M\MTS]IN*M7W35U_5&"KWMY<O&YK
M3J8^NE*7HMG),TU1J;/).6=YC=7CEO=>XJU6_'VDY8GQ(\Q@@ /](S(R,C,C
M(R,C(^AD9>)&1D 3:>*,HXIO#=6"*:7A&WMH8<IDR-D\7S[*Z#RS+V=GU*EM
M=![J&9YE:_Y:XJT\/6U)1]!HVS*->ZYT^U+(<YOK)QW=A=W%'#[W4B;<8#ZJ
M/.W7RF41-\7.406C3YE?GU-CF:)E)1[$/6MY$<L2(_E-J:@S^4QL%IKK5-IA
MPW3FNJHHSQ\V2<O.:.Q:=[VO/_3CC&CJ"K=TUOA=TZ-SQ>!U*M.59?T:L7X3
M+F]_57RKE9Q_R[1'(/3."V3ETB#8XOGV!S[G&K##\NI'RE4N2G07:K9N4?\
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M72QW\/O2=:;6YSIP;W)J\2(SG^>\
M
M                                              /_U;_
M
M
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M#I*YT'KK.-%7;;GE5Y<6O$_5JC5E",_%4BE-/I4DS*0\)IX
M
M
M   '_]:_P
M
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M?TLN'@?U1SGFQG;R+0&8W,&E4K0["&W!XUVJ<G%[^*-.4YKZD^O'92O<
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M)3A-*491:<91:Q336QIK:FMC6U'[C^GT
M
M                                               /_]>_P
M
M
M      _PS))&I1DE*2,S,S(B(B+J9F9AOV(;MK*P'JC^O=1ZK>R+0?".TJ,M
MV/&5*J,PWPE$.[PS!Y2>K$JMUVPZ3D6ZM&U=2<L74N5\<R[6T37%+.--WD=W
M5+K/8T=5\S*<[>S>$Z5CMA6K+>I7#6$J-)]%-85I[VZ:2XXF\V^\3;Y1*KIS
M04XUKI8QJ7>R5*D]SC16V-6HNF;QIQW)5'CPT]+K-\PS'-+38N8W=UG68S[&
M7F&17N36DNYN\@FUZ%7%A,MK6Q6X\\XM#*NY;BS/H73V$1"?U[9Y?DNF:N7Y
M;3A:V]*C*E2A3BH0I\2X(*$8I**XI+#!(B=I%7NH]?9=*_G*YJW%Y1G5E4DY
M2FE4C.HY2EBV^!2;Q-<AR@L9   #(N+,+9H9LIR*RINQMV(\2<9D;[*Z6&MR
MPB)3TZDAPI\99GU\307AX#<-%T8SOZ]QB\:=-1PZ&JDL<?&NRP\TC1WDLSE3
MRK+,G6ZM5JUGUIT8*$?/[>7]4]N.D$2#[W7VJMG[:N4XYJO7.=[*R!9MDFDP
M'$K_ #"V_93[6S.OQ^/(=(C,CZ&:.G@8Q6;Y[DF06WOS/;RA94O7UZM.E#9]
M-4E%?1,CEN3YMG-?WKE%K5NJGK:-.=27G039)7J_T/?4MV@AB4WQ\?P"J?))
ME9[0S##\-6T:O$DOX])FN7*3Z>)]:WH7L,^O@.+YYWG.2^1MTWFZNZB]3;4:
MU;'Q5%!47]\.IY3R"YJ9LE-9:[:#]57J4Z7GP<G5_L&[F(?#*\PK-EI[--U\
M>,3\WM-46IL-A99.CH/Z8GTJHZYCO+_-;D+3_I_0YGF'?6Y>4)..6Y;F%QAT
MSC;THOQ>WU)8>.*?@-]LNZGK:K%2OK^SHX]$76J->/VJ"Q\4FO"9M@?"Y9VX
ME!V?,;$H:S(O,3 TQ<6*4'^N)"Y&1Q35T^0S2GK^H-:J]^+*TWV&G:LET<5Y
M"/H6\OY3/T^Z5F#7MN>4X^*UE+T:T3^++X7//FFU'4<Q,/G/$:NQNRTW=53:
MDE](:G8N0S#(S^4B0?3Z)C^T>_%E,I?XC3M6*^EO(2?G.WAZ)_*O=*S%+VG.
MZ<G]-;2CZ%:7H&"LR^&:YFU#;S^&;?X[9DVT1FB).N<_Q6UDET\$L,O4,R*2
MC_\ M)J"_5&T9=WU.7%PU#,LOS"V;Z8PH58KQM5X2\Z#\1KU]W5=<T4Y6-[9
M5TNARK4Y/Q)T91\^2-&-I^BGZE>J6Y4R?QKO,VJHQ*4FRU9D.)[$<E$CQ5[K
MCF.37;DS^@2JQ)G\A&?7IU#(N\IR8SZ4:=+.H6U1^INJ=6W2\=2I!4?.J,Y_
MF_(CFGDZ<ZF53KP7JK>=.MCXH0DZO]@C;S;7V>ZUNWL:V-A&7X!D<<C-^@S;
M&KG%;M@B5VF;U5>LL/IZ'X?.;+Q'9<LS?*LZME>Y/=4KNB]U2C4A5@_%*#E%
M^><NO\MS'*J[M<SMZEM56^%6$J<EXXS2?T#T,&![R2Y$AXH=>QU]YFK1W]#)
M/<F-$9ZI-Z0OP)MI*B+Q[G%-M)6ZC0N:'-G27*?)/RKJ.KQ5JF*M[6FTZ]Q-
M;U"+]+".*[2K+"$$TL7.4(3]^1:?O\_N>QM5PPCZ>H_2P7\LGZF*VO>\(J4E
M_4BRZQ_<8+1PH)I_9T$OODSU^83OF6,DB3YA)4E/E-$E+;?:1I1YAN..5.<U
MN<^L>;>:.YSRKV-E3EC0LJ;?845M2DUL[6M@WQ5IKB?%)05.FU37=LDR#+\A
MM^RLXXS:\NH_3SZ=KZ(XI806Q8)O&6,GZL<D,T   'M*>ZM<?L&+2FG/U\^.
MHE-OL*+YR>XE*9?:61H=:7TZ.-.)4A9?-4DR,R'QN+>A=T96]S!5(36#C)8I
MKPIGDO["RS2SJ9?F5&%>A57#.G4BIPDM^$HR33VI-=32:VHW UWMBMR]+57:
M$S59)W$VVP2C*#;$KZ1=:MTS-+O7YJHRU&H_FJ;4YW+2UQ756@ZN7*689.G4
MH+%RI[YTUUKIG!?UHK:^)8R4(^;'=_NM/0JZBT5&=Q8QQE4M]LZUO'>Y0;QE
M6HQZ<<:M..$I=I%5*D<P)2I:DH0E2UK424I21J4I2CZ)2E)>)F9^PAS4C$DY
M/ACM;-K-:<&>7NWD1W\#X];,L8$M*51+FWH',0Q^4A?BE<;(LR57P7$^/BI$
M@R+Y1GK+2^H<PP=K9U&GN;CP1?BE/AC]$ZYI?D'SFUE&-33^F[ZK3GZ6I4I.
MVHRQZ8UKET:37A4V;M8=Z'O-/)$-.W[VH]?)4E*G6,FSB99S6B/Z9!(PFNMF
M%++Z'O!)_P!(;-;\L=2UEC5=*C]5-M_V(R7T3NN2]P[GCF<5/,99?EV.]5[J
M4Y+P86M&XBW_ $\/"9_I_0!VD^E!Y!R(P"L6?3S$T^&Y%>)0?R]BYLFN-7^5
M*1EJ?*>^:]NO*<?%"4O1<3HME_QVZLJ)?E'4MI2?3V=M6J^<Y3HX^<CZ5?P^
M^1$V1M\I:53WCU;7J*<VV7^;T=3D:C\?E^9X?JC[?NEK8;+Z./W)_A#)R_XZ
M,RX<8ZLI.74\NFEY_OQ^@?&W?H"[DCDO^3>_=96JBZ]A7>.Y3CY*\/#O5 *S
MZ?Y",>:KRHS%?8;NG+ZJ,H^AQ&$O_P#COUM33_)FHK&MU=K1KT?/X.WP^B:Y
M9IZ*/.+%6WW:6DUML8F>XTMX9L"'$>>2GY6D9ZQ2>/3Q[3,C^0NIC#W/+74]
M!-TXTZWU%1+V:@<TSSN,<^LIC*5C0LLSX>BVNXQ;\2NX6OG&C&S^)G)C3#;\
MG9VC-EXE6QN\WKV;BMG*QI'E^*^F45B'ZX^A>)]LD_#Q]@U>^R#.LM3=[:U*
M<5ZIQ;C_ %EC'Z)P/57)_FEHB,JNJL@O;.E'?5E0G*ALW^WP4J/G3W;37D8@
MYN?-YE3.9#B634;,=F5*MJ&V@P6I'^J^J,B"MNN=,^A]#;?-MQ)D7@:2,9W3
M%T[/4%I77VR,7XI^0_.4F=I[NFI:NDN>>ELYIX)?E"A;S;>"5*\;LZTOZ-*O
M-^81)B3!_HB   #=_B?:27Z',:51(]SJ[>JM&E=?V0Y-["=B/D:?\TDUS?0^
MOM,<GYH6[<+.[2V)U(-^/A<5]"16#_R09%.5KI74U."X83O;6I+IQFK>K1CX
ML*=PR?/@IZGVV>(\VMPO*%V.S-#+D);E83-F$NZP]AYSK(L->6<Q71@TF9NJ
MJWE^Z/'W=ONSKJI):SI;6^8:?E&VKXU[7I@WMAX:;>[KX7Y+^E;XB+W('O5Z
MPY.5Z61YJYYKI]O"5K*6-6V3>V=G.3\C#TSH2?8S>.'93DZI;RTIO#6'(77]
M1LS4N50<KQ6W3V>?&4;4^IL6VTKETE_6.]'H4UCN3YL9])*(C2M/<VM"U2#R
MW,['-[2-[E]15*<NK>GTQDMZDNE/Q[FF7*Z&UYI7F1IVCJG1UW"[M*VS&.R=
M.:2<J56#\JG5ABN*$DG@U)8QE&3RP/>;@
M
M                                              '_T+_
M
M
M   \2?/@U4&;:6DV)6UM;$DS[&QGR68<&!!ALG(ES9LN0:6VFFFTJ6XXM1)2
MDC4HR(C,?2E2JUZL:%"+G.;48QBFY2DW@DDMK;>Q);6]B/Q4J4Z-.56K)1A%
M-RDVDDDL6VWL22VMO8D4J/5\];6XWI(R?C+Q%R*;1Z1;5,HMB[8JW7H%WM\B
M,X\^AQ:2GM=AXRKYS;[R>UZS3U2?EP34W+LH[OG=HM]+PH:UY@T55S-X3M[6
M24H6G3&I56U3N>F*VQH/;MJX.G!+G5SYK:@E5TIHNJZ=@L85KB.*E<]#A3>^
M-#H;V2JK9LIXJ=:430(KG\NS)%="M)C#9N=M58PWO$B)N/<Q543CA]?H>]%_
MEZ#6]6<+R.K"3P<I4\/"XU(SP\Z+.J\E*#K<RLN>&*@J\GX,+>JD_P"LXF)1
MRLGR !^K##TEYF-&9=D2)#K;$>.PVMUY]YU9-M,LM-D:E*4HR2E*2,S,^A#^
M2E&$7.;P2VMO8DETL_L8RG)0@FVW@DMK;>Y)=9.=Z>GHK\G^;&&U.<HO\5U%
MIA=Y:QYV6Y:XJXR$K5AQJ);PL=P"H6F2_(:9;B+=*RE5[74S0EXW&UH+GN>]
MY'0O+2WKV"IU,RS*4L52HX1I\'"N!U+B2<8QXG-+LXU9=+BDTSFW.7NX<SL[
MUM8V^H[>>1VT;*E42O*<X5\*M6L^.%JU&IY<%3E%U>Q4XX2C)IINT=QJ] G@
M3HAJ#9YUBUWR.S..33KMQMJ<2L5:E)_UI5NNJ'W:M5'7T_U-O]45%X_LO0Q%
M;6G>NYJZIE*AE=>&36SQ2A:Q]M:Z.*XGQ5.)>NI=BOI3,:6[NG+K3RC5S"C/
M-*Z]5</VO'Z6C#AAAX*G:OPDR&'X3AFO:*'BV XCC&#XQ7I[(&.8?056-44%
M'0D]L.HI6F([1="(NB&R]@CKF.9YEF]U*^S:XJW5>?IJE:I*I.7CG-RD_-9V
M^RL+'+;>-IEU&G;TH[H4X1A!>*,4DO,1]./">L        (UO4JY3\<] :E=
MQ[<& 8%O#,\PA2_Y#:7S2BI,HJ[-1D<5>291 N&9"(E2PLC2M[RR=D+2;$?Y
MQ.N,8C,^8EYR]PS#)KNK;7TE[5V%6=*>SU4I4Y1DH)^'RGL72U&[O(<[=#<I
M=+=CG]M1S7,[R,O>F7U(PFI]';5U)2[.W@]CEAQ5))TZ>U3E"C-L#7>&Y];6
MMR=#7X?)L;"PL(\#"&$T6.TY35+=:J:C'#\V)'@LK41I:9;0XHB^>\:C4L^5
MYESMUWJ/-I9SK*ZEFU:>"<ZTGVBA'TM.$UBHPCCL3C+>WO;953IOO)ZOR:XF
MLRM+6[M:E2=3LJ=-6KIJ;;[.C*DG",(M[.TI59\*4>/I-:LGTAE=(;C]-VY1
M!(_F_4]E;-PE/5MM)NTRC6I:EK69(1$=?5VI-:R07LVW)];9'F[5)3["J_45
M,(XO9Z66/#+%O!+%2?K23NC.=V@]92A:4KCWE=SP2H7.%-RD^%84ZF+I5'*3
MPA%3566&/9(PTI*D*4A:5)6E1I4E1&E25)/HI*DGXD9'[2&WG7C^0  'LHM7
M)DMIDK-J% 4X;9V$Y:F8G5MUIN03/0E./K:\YM;C,9MQTD'W=G3Q&ZZ+Y=ZU
MYA7SL-'Y=5O91:4YQ2C1IXIM=K6FXTJ>*3X5.:<L,(IO8>',,SR_*J7;9A6C
M2B]V+VO:D^&*QE+#%8\*>"VO8>2AVG@J;6W'>N7VS:6HYBWH%9W$E:)#!1H2
MTRG4]W8ME\I,=7AT6S\@FOH7N1V\8QO.8V:.<M[MK'R8K<UQW-6#<MF*E&%"
M&#VQJLYSF?,E)\&3T,?IZOFXX0@\>IJ3GXX%D3T2_4UT9J?+*[17)O!=:XY:
M9':(BZ]Y1.XO10\EK[*<Z3<7$MIY4XU[P4%QPR3#NE/))AQ1E/-32U2V,1SI
M[G6G<BLIZNY/Y>J4Z,7*XLUQ5:DXI8RK6\ZCG5E/>YT>)\>^DE+R)[SW?M;:
M!TWG4['/\JL;6ZNZCE#,H6U&G552;Q=.O44$XTW)^1.+C&#?EK!N<;KR5)6E
M*DJ)25$2DJ29&E23+J2DF7M(_D,09::>#+!T\=J/]         !I]NO@/Q'W
M^B:_L+2>(_5Z:3BG,OQ2(>%9=[ROQ3,D7N+G%=EK0?BE,_SV_D4A1=2&O9EI
M33^;8N[MH<;]7%<$_'Q1P;_I8KP'%]<]WKDYS$4ZFH\BM_?$\<;BWC[VN.+U
MSJT.SE4:Z%5[2/7%K80J<A_0>R>H1,O^,.S6\H9:\Q]G =G'%J,@[4?.0S59
MK5-(@27E'T2A$R%"0DBZJD&9CF^:\KKFA+WQD-?C<7BH5,%+9M6$TN%OQQBO
M"0@Y@=P7.\GK?EOE#F_OB=&2J4[:]X:5>,H/BCV5U3BJ4YXI<*J4J$5ABZC*
M1^S=;Y1JO,LBP_*:B=5RZ*_NJ(ERD(6Q)>IIQPY/N\V.:F'5(/M)TFG%=BC[
M5=%$9#K]W8WMA-4KZE*E*24DI)K%/<UT23Z&FT^AEOF>:8U-I6O2L]4Y?7R^
MO6I0K0A7IRAQTZBQC4IMKAJTI>IJ4W*G+?&31C\>4P@ &TW%*=*3EV35;9E[
MG)QDK.2DS,C\ZLMH\.*HO^PIKA'_ -HY]S)I.>0PFO45HM^)PFO1:()_\A&7
M5+ODE97E-8^],VMIR?5"=M>4OHSG3-ZAPLI@-IN)O+W;?#[8K&<ZULSD54Y<
M6/FN"63[QXOF].PX:O<K2.WU\J2T2EG"L&D^='6I7;WM+>9=SN0:AS#3UXKJ
MREC%X<<'Z6:ZFNAKHDMJ\3:?6>4'.76/)?4L<^TO5XJ-1Q5U:3;["ZII^EFE
MZ6<<7V5:*XZ;;PQA*<)W5.+/*?5G+C6$#9>LK(_FFU!RO%+!QE.1X3D'E>8]
M2WD5HS]OBN+)1U:D-_/;/J2THDGD6>V.H+%7ME+P2@_30EZV2]![FMJ+R>4W
M-K27./2E/5&E:N["%Q;S:[:UK88NE5BO/A->14CY47O2V2&9.G@
M
M
M  ?_T;_
M
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M*G00
M
M             #__TK_
M
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MR6O&YM+NG"K1JP>,9TYQ4HR7C3W/!I[&DTT?1C[&3
M
M                                                 #__T[_
M
M
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MEVO(Q?!;K3^JWD.Q).#8W.V52*LLOSV*X1*^J\NM4][C6*Z%7M+\Z01SS2U
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M<RQE.UQ>Q0N-LZ2V)7'%%*4KC9:''<"UL
M
M                                         /_4O\
M
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M_IN   "T1\/%GZ9&*<E-6O.DE=3D."9_6L&KYSZ<AK9N.W;J$_0:.LKR4?\
M]HD<2YMVF%>SOEZJ,Z;_ *+C*/G\4O.*A/\ D\TTZ><Z4UA3CBJU&\LZCZNQ
MG2KTD_JNWK-?4LLCCCI56      !$EZO/+]SCKH$]<8=9'$VIO./:8W6OQ7N
MR;C6#--)8S')$*;/O:>>;>16P5_-42WG7VE=\4R&@<P=0O)\I]YVTL*]UC%8
M;XP]7+P-X\,?"VUZ4AWWR^<TN6G+S]F<EJ\&;Y^JE&#B\)4+5)*YKK#;&4E)
M4:3V/BG.I!XT6BG (ZE*0   9PXZ: S_ ).;<Q73^N(1/WF1237.LI"'3JL8
MQ^(I*[G*+QYHC\N)#:/N5^N<6;;#1*>=;0K)Y/E-WG>84\NLUC*;VOHC%;Y2
M\"7GO!+:T;YRUY=ZBYJ:QM-%Z9I\5>YEC*;3[.A1CAVM>JUNITX[7TRDXTX)
MSG&+O/<:..&NN*^I<>U)K: 35=5-^]W=Y(::3<YADTEI";;*+YYOZ>1(4A))
M1U-#+26V&B2TTA)2@R7)K/(LOAE]DO)CME)[YR>^4O"_H+!+8D7Y<KN66FN4
MNCK;1VF*>%*BN*K5DEVMQ7DEVE>JUOG-I8+=""C3AA"$4L_#+'0P   _E24K
M2I"TI6A:32M"B)25)47125)/P,C+P,C']3:>*V-!I-8,HW>N5Z5C/&'+9/*G
M0>/>[<?MA7A-YUBE3&,H.G<]N)!FTN'&9+I'QZX>490DD1-0Y9G#(VVGH+0L
M\[L//66M\OCH35=;'-K2&-"K-^5=T(+;BWZ:XHKT_JJE/VS;*-61 'G_ ,H8
MZ3O7J_3E+#+;F?MM.*V6U:3Z$O2T:K]+T0GY&Q2IQ*ZPE^1E   ";?T,^>+O
M$CE-!UGFMN<;1_(V=2X3E'O;_978GGBY!Q, SDO-,D,ME(?.LLW34A!19/O#
MIJ]S:(HS]Y_E9'7^AI9UEE/BS/)XSK4L%Y56AAC7H;-K?#'M*:VOCAP1P[21
MWKN_\PY:,U='*K^>&7YHXTJF+\FG5QPHU>I+B?9S>Q<$N*6/ CH"BILL>
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M&O**S*V_PU_!8+"YIQ6-11Z(5X.-:."X8N4J:;=-F[XV8[N
M
M                                                     !__U;_
M
M
M      @?]?SF:YQQXCGIG$+;W+9_)]RUPALXSQHG4^JX##:ME6Z3;/J@YK<B
M+1H)9%WMS9"VS[XY])3=T_EPM8\P/VCS"GQ6.2<-;:O)G=2;][0\/ XRK/#<
MZ<$UA,CUWC=<O2^C/R'93X;O-N*EL>V-NDNWEX.).-)=:J2:VQ*$8M6*[
M DQ]*K@/;\^>35/AMFQ-BZ7U\4#,]WY!&4['4UB[<LT5^'UTUOIY=A?/MKAQ
MS2HEM,)E2T$OW4T*XKSVYK6_*G153,:#4LRN^*C94W@\:N'E59+IIT(M3ET2
MDZ=-X=IBNJ\H.75;F+JN%C535C;85;J:V>UX^33B^B=9KACTJ*G-8\&#Z.6.
MX]18C04F*XO45^/XUC5374./T51%9@U5-2U$1$"KJZV%')+;+$=AM#33:")*
M4I(B+H0IVO+RZS"[JW]]4E5K5IRG4G-N4ISFW*4I2>URDVVV]K;+/+:VM[*V
MIV=I"-.E2C&$(1248QBDHQBEL22222W(\RRKX=M7SZJP93)@6<*57SHZ_I'X
M<UA4:2RO]12%*2?_ &CX0G*G-5(/!Q::\:W'NM;FO975.\MI<%2C*,X26]2B
MU*+7B:3.;ILW"9VM-D; US:$LK+ ,VRK"[#S4]CGON+7K]')-:?#H9K849B8
MEE<QO;.E>0W581FO%**DO1/]4^DM06VK-*Y9JFSP[+,K2WNH8;5PW%&%6.'F
M31\0/2;" !+SZ(^VV];<XL?QF=+]VJMR85E>N7?-7VQBMVV6LSQ]:R/_ .M<
MD5/N3!].O=([?8LQH',JP=YIF=:*QE;SC4\.&V$O,PEB_$0C_P"0#14M5]WN
MYS:WAQULBNK>^6"\KLVY6M9+Z50N.UGT84L?4HNK"-Y08     >-,F1*^)*G
MSY+$*#!C/S)LR4ZAB-$B1FC>D29#[IDE#;:$FI:U&1$1&9GT'\E*,(N<W@EM
M;>Y)=)\JU:C;49W%Q)0ITXN4I2:48QBL92;>Q))-MO8D4.>='):?RLY*9_M$
MY,AS%&YJL5UO">[T)KM?8](<CT/:PYXM.334]9RFSZ]LB2Z1'VD72*^J,ZGG
MV=5;['VO'AIKJIQQX?%CMD_#)G^?CG[S0N.;O-#,=6<3=FI=A91>*X+.BY*E
ML?I75QE7FNBI5FMV!J$-?.-  ?VVVX\XAII"W775I;;;;2I;CCBU=J$(0GJ9
MF9F1$1%U,P2;>"/[&,IR4()MMX)+:VWN27672_2ZX21N)NE&,BS"K;;WAM6%
M NLZ>?;(YF*U"D>\T6OHZU%U;]T2OSK(D?3S%+2:G&X\=29):'TRL@RQ5KB/
M^*KI2GUQ6^-/S-\NN6.])%XO=0Y%4N4&A8YEG5)+/LWC"K=-KRK>GAQ4K-/H
M[-/BK8>FKMIN4:=-J3X;N2K       ^*V1KK"]N8%E^L=BX_!RG!L[H++&,I
MQ^Q0:XMG3VL94:4R:DF2VW"(^]E]I27&G$I<;4EQ"5%DLFSC,M/YK;YWD]:5
M"ZM:D:E*I'?&<7BGU-=#B\5)-QDFFT>#-,LL<ZRZME.9TU6M[B$J=2$MTHR6
M#76GTIK!IX---)G-9]0SA7EW!#DSF.E+Q4RSQ-Q7\J=4Y?):)!9AKBWDNIH[
M!U;:4H]]BJ;=KK-"$DE,MATT%Y*FE*N<Y1<R<OYIZ*MM2VN$+A>U75)/[#<0
M2XXKIX)8JI3;Q;ISCCY2DE5KS+T)>\O-5U\AN,9T7[9;U&OLE"3? ^KBC@X5
M$MTXO#R6F]'ATXT   1F1]2\#+Q(R]I& .C-Z.7,MWF5PNPF\R>V^J>V]3K1
MJ?:RY#WF6-E;X]";5CN7R^\^]9W-4N+)D2#225S4S$(_U1]*>>\3RYCRYYD7
M-K8T^#+[_P#Q5K@O)C"I)]I170NQJJ48QWJFZ;?IBSGDCKAZXT+0N+N?'>V?
M^'N,7Y4I02X*CZ7VM-QDWN=3C2W$JPX2=?     (@/6[VVWKK@_?8C'E^1<;
MFS3$\"B-MKZ2OJ57S?Y;Y!(2GV^2;-4B&\KV=)*4_KR,= Y:6#O-30N&L8VT
M)3?5BUP1\W&6*^I)O_\ 'YHJ>J>\';9W4AQ4,AM;F\DVO)[2</>E&/U7%<.K
M!?\ :;]24KQ(\OP   "X[Z#>N5XGPUN<WDL&B3M3;.4W4.0:>WSJ#%X43#(;
M:3_7$W/A6A]>O3JHR^0^L>>:5YV^HHVT7LH4HI_52;F_[+B46_\ (WJE9USV
MH:?I2QADV76]*4>JM<3J74GX,:-6WV=23Z2;(<V(!$"_K/\ "!K8F%.\K=;U
M"/Y=:\JT,[5@06.C^5:_@H)+.3K0T7[),HD_Z]:B[EU_<:E]L)I!\KYD:85Y
M;?EZSC[;17MJ7JJ:]5XX=/TGU*17SWW^0\=2Y&^;NF*/_P!PRVFE?P@MM>SB
MME=X;ZEJO3-[7;XXRPH0BZK8X45*   !*;Z1_*-?'GE%38K?6/NFN-YJK]?Y
M.E]WLAU^1NR5%@.1N=QDE)L3GE077%J)#<>8^XKKV)Z;SR_SQY1GD:%66%&Z
MPIRZE+'VN7F2?"WT*3?02S[G/->7+?FO0RC,*O!EF?\ !9U\7A&%9R?O2L^A
M<-63I2DVE&G7J2?I47/Q) N^
M
M                               __]:_P
M
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M':X1KI=$:L3<0;$=I
M
M                      /_U[_
M
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M;GU,M5RV'3^E:9D0FRZ%T(<!YH9*[3-89O27M=RL)>"I!8?VHX-=;4F4D?\
M(OREGI?F1:\T,MI866H::IUVELA?VT%!XX;(]O;JG./3.=*O)[<2> <N*YP
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MURJ4ITI/Z6W;+.X[:6I@
M
M                        '__0O\
M
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MB7VQ*L_T)
M
M              '_T;_
M
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M(+M;^JT!#$]OK\YV0W/</V"0/+'/??V52RBM+VVU]+UNE)[/ZDL8^!.*+O\
M_CQYQQUARWK<L,VJ\68:<>-!2?E5,OK2;IX8[7[VK.=&71"E*VCTD%PZ<6(
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MKS\%2I1A*HGX8U.*+\*,SC)&[@
M
M                            !__2O\
M
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MLM+S"^7NFZ>6G.0&GJ#CA.ZHU+N;]=[ZK5*T&_%2E3BO!%$@@VTD8
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M.;XIV4[NVD_J+JK."\RE4IKS"3,;J2E
M
M                                  #_T[_
M
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M3\,:5O7V?UIQ?F(D_P!U6R5;7-]>R6/8V4DO!*I6H[?ZL9+S67@A603Y
M    "M9ZY'!=RRCIYG:QIS<F5\>OI-ZU5='[G9%<PE%=CFR/*:+JHXR":K;1
M1=>C)1'NU*&9+@[)RRU.H/\ 9R]EL>,J#?7OE3\W;*/AXEO:1:W_ ,>O>(C:
M57R'U;7PA5E.KE%2<MD9O&=>QQ>Q*H^*O;K9[8ZU/%RJ4HE8,=K+=    R]H
MG>>R>.&T,8V[JF]=HLMQB63K1GWNUES6O&2;/'K^"E22E0)C9&U)849'TZ+;
M4AU#;B,?FF66><64\OOX<=.:\U/HE%]$EO3\QXIM&C\Q>7FE>:>D+O1.LK97
M-E=QP>Y5*4U]CK49X-TZU*7E0FD^F,E*$I1E*_ZE'.K >;>HN*>0X<P_09'0
MN[5+:6"RW%/R,3REZ-C;->W'F=J$RH$E"9;U?,2DO,;[D+0V^T\TBO\ Y_Z?
MO=-W]E85O+I2[:4*B6R2? HX]4EA+&/FK%8,_P 57_,SR-U;R!UEI;1V;XW.
M7UORC<6E[&+5*XI2=I"DI;U2N(*%55:+;::<H.=)QG*(41W*3    Z&6@\;1
MANBM+XBVV33>+:GUUCJ&TEVDA-+B$.M))%^IY8EUE5%6V5VUNO[NE3C_ %8)
M?R'^D'EYED<DT!D>306"M,OLZ*75V5O3A_X3+0]YN               !0+^
M(=Q%O&_4CRFY0T3:L_U+JG+G5D70WW(50]@A.J/Y3)%(E'7Z"2+Y!:]W1,P=
MYR:H6S>/O2ZNJ2\&,U7P\^LWYI7-WEK)6O-&M72P]\V]O4?APBZ/_P"EAYA!
MN)/'   -FN%>71\ YA<6,YFR4PZW$.0^F\DN);AFEF-1TVPJ^PO'Y*R^E91$
M;>4\HS(DH)1F9$74:-S.M(W_ "XS^Q>^ME]Y!?52MZBAAX>)K#K>"-YY8T;V
MXYCY#0RZG*M7GF%FH0@L93;N*:X4O"MGBVO83F^J!ZF%SS!R5S6&KY-E0\<\
M3M#=A,N$_!L=I74)PTL99D<17:MJ"T9&JIK72[D=?>9*2D*;:BUF:)T93T]1
M]^WJ4[RHMO2J2?J8OID_527U*V8N7^U'NB]TVPY'92M7:NA"YU3>T\)M83AE
M]*:VVU"6U2JR6RYKQV2^Q4GV2E.M$*-_)N@  !N)P9XCY3S,W[C6K:<IE?B<
M12,AV;E;#7<WBV#0)""LGVW5I4CWV8I285<VHC[GW$K4GR6WE(U[4^?T-.Y5
M.^J8.H_)IQ]=-[O,6^7@76T<,[PW.S)^1'+:[UA?<-6]GC1L+=O;<7<XO@32
M:?94TG5KR6&%.#BGQR@I7YL-P_&M?8EC6"X;41*#$\0I*S',=I8*#1$K*:HB
M(@U\-DC,S,D-H21J49J4?52C-1F9Q7N+BM=UYW5Q)SJ5).4F][;>+9_FYSW/
M,VU-G5WJ+/:\KF]OJM2O7JS>,JE6K)SG)]&V3>Q8)+8DDDCZ4?$Q(      $
M?GJG8VWE' CD-#6CN<KJ#&\D841=5M.8QG57?+6@_DZMQW$*/_-4H:EKJBJ^
ME+R+]3&,OZLXR_D(Z=[/+(YKW>]24)+%TJ-&LO Z%U0JM_U8-/P-E'81C*&0
M   MI^@Y>*G<3MB4CJS6NAWSD*V$F?@W!ML&Q^0V@B_^[HDJ_P H[[RLJ\60
M5J3]17EYSA3_ )<2X3_C[OW<<H,RL)/%V^;5FO!&I:V;2_K*;\TFY'3"=H
M
M
M ?_4O\
M
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M<9O25(0[)<247]6:DKZES-W+QC1IXQI0ZH];^FEOEYD<6HH_SI]Y?G[F_/\
MYA5,_J<=#*;/BHY=;2?V*AQ8NK42;C[XN&E4K-8X)0I*4H4H,WJ&KD=@
M    U/YW1$S>&'*-E:242-&;(ED1].G= QB1.0KQ^@ILC(8#5,>+3=\G]HJ/
MSHMG(.\!15?DAJR$MN&57LOZE"<E]&)0C$53_/:   %I/T!9*EZ;W[#-1&AC
M9N.R4H^5*I>+$TM1_P#:3*2+_L'<N5$O_MUW'JJ1?GQ__D6Q?\=]5O1.HJ..
MR-]1EA]50P^CPKSB?D=7+#P
M
M                          __U;_
M
M                                  #X':T,['5VR:]*36J?@.80R02>
M\UG*QZ2P223X=>O=TZ=1E<AJ=CGEE6>S@KT7YU2+,=G$.URFZI[^*C47GPDC
ME B^<IX   "T[\+Q8M-;4Y;U)K(GINOM7V+;?0NJFJO([6,\LC]OS3F(+_*(
M+]^"C*61:?N,-D:]S'S94Z37L'YQ+KNEU4LWSFCTRHT)?U9U$_9(N/BNLF\
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MBK*GI>PJ8N:QB\RKP>RO-/!JVIO_ "U*2QD_;ZBXW3A1F7'.B"0
M!J7SSFHK^%W*%]Q78ES2&PH1&?0NJ[/'GJUM/CU^F4Z2?\HP&JI*&F[YO[34
M7GQ:_E./=X.O&VY'ZKJ2>&.5WD?-G1E!>>Y8%"<15/\ />   %IGT!XIHTGO
MB;VGVR-ITL4E>/0SB8DTZI)>'R>>77Q^7Y/E[GRHC_\ ;+J7752\Z"_G+9?^
M/"DUH74%?UU_2C_5MXO_ ,1/F.K%A@
M
M                                 ?_6O\
M
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MNWTR4(K^E4BG]#$C;WNLTCE/=YU%4Q\JM"WH176ZUW0IR\Z#D_$BD&(RE$
M  6X/0CHEUW$/-K=ULTKR+?&528[AET)V!787CU8UT^CVR&Y)=1W_E;2X-/U
M:C]77EYRA37HXEQ?_'_E[MN35_>S6#N<VKM/KA"VLX+SIJ9-8.E$Y@
M
M                                                         __7
MO\
M
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MH
M
M    /__0O\
M
M               H-_$1ZE=U]ZAUMF[<?LK]WZKU[GK;Z$=K"K.@@.:PLXI&
M7AYJ44,:0Z1?(^E1^*A:SW0L_CFW**GEC>,\LNKBAAT\-22N8OQ8UY17U+70
M5U]YC)GEO,N=^EY-_;T:V/1Q03H27CPHQ;^J3Z2"<2C(]@ ?5X'F5UKG.<,V
M%C;Q1\BP3*\=S*A?/N(F+K&+AF[JWC-!D?1+[#:O R/P\#'@S7+K;.,KN<HO
M%C1NJ52C-=<*L'"2\V,F>S+KZOEF84,RM7A5MZD*L'U2IR4XOSTCJKZOV#1;
M9UKKW:>+N^=C6R<(Q7/*!WO2X:Z;+J-B_K34M'@:O)D([NGR]11-GF4W609U
M=Y%?+"M95JM"HOIZ4Y4Y?1BRWS*<RM\YRJVS>T>-*ZI4ZT/J:D%./T&C[H8L
MR              >/+B19\63!G1H\V%-CO1)D.6RW(BRXLALV9$:3'>(T.-N
M(,TK0HC)1&9&1D8_L92A)2B\&MJ:WI]:/K1K5K:M"XMYRIU*<E*,HMQE&47C
M&49+!J2:333Q3VHK4>JKZ*NM,HU!N/=/&>2SK.WH\1O,URK5*6758)=1L9;_
M )4S96)E&2X]4.H.*;RH#33L5Q*2;CM1#(N_:,UUW=5]*7.69XG6C"*G&MOJ
M0[.2F^)>K\A26/I]K],R3FLN^EJ/,.[UG?+_ )PTY9M;VM&E=6^9I.=[;*RJ
MTZ]1UX+%WB][TZL.T2]]82DW[YG))48LEQ3(L/L#J\EJ9=3,[>]M,A*5,R6B
M/M-Z%,9-3+[?<1I-QEQ2>XC3UZD9%SFTO+6_H*YLZD:E.6Z47BO%X&NE/!K<
MT17TMJS36MLEI:BTE?4<PLJR\BK1FIQQZ8RPVPJ1QPG3FHU(2\F<8R31\^/2
M;" !M_QPN4/T%_0J)I+U;;,VC2U/]7Y$>WBE&6TU'/V-QUP^Y:B/Z9\NI>/C
MW+DYF7^<R>;];6@O[%1^YEK7_&EKA8ZDY;7%1X^TYG;PPV=%K>3QZ'ML4ET[
M=V&W8X=Q+6P             \"ULV:6KLKF2T3\>HKYMH]'-Y+!R6Z^,J6N*
MAU1ET6Z2/+1\O<9$7B/?E=E+,<QH6,?[V<8]>";VOS%B_,.3<]^8$.5O)S4F
MONT5*KEUA7G0DUBO?=2/8V<6NJ=U4HPV[/*VD9+KKCSCCSSBW7G5K====6IQ
MQUQQ7<MQQ:NIJ4HS,S,SZF8E*DHI1BL$C_)^VV\7M;/S']!_24J6I*$)4I:E
M$E*4D:E*4H^B4I27B9F?L(-VU@G+]%[TU[SFQM79<C(LPD:^P'6='C3&>.UT
M)JPRB4UEML])K:"N:DI.-#F2%4TG]DE&M48F5J=B.=S:'.$]X'5E71^G+"+H
M<52^J3E1XGPIJC!<4\/3."[6&W!*?$N&6]KN_=-[PN0<HN9&;ZMR:TIYUF=C
ME]2VMXN;5M:W5W5II5:U2&VIPT*-S3="E)2?&XSJ47@R^QQ_XW:9XP8+&U[I
M;":W$:-'E/6<MI)RK_)K)MORU7&4WTCK)G2E=3Z+>6:6TGY;*&FDI;3 3-LY
MS'.[IW>9574ET+=&*ZHQW17BW[WB]IEN9?-77G-W44]3Z]S"I>W#Q5.+\FC0
M@WCV5O1CA"E36S9%8S?EU)3FW)YS&,.>               %2SUU=MHS#DWA
M>JX4@GH.GM?1UV#1+ZG%RO83Z+^R:-!>!=:MBD7U]I]3Z^!$.!<T<P]\9W3L
M(O9;T]O@E4\I_P!E0*>^_P":QCG7-.QTE0EC3R6S7&O6W%XU6FO-H1M7U[>K
M A&',R"0 '[,,/2GV8T9IQ^1)=;8CL-(4XZ\\\LFVFFFT]34I2C(DD7B9C^I
M.345M;/W3ISJU(TJ2<I2:22VMMO!)+I;>Q'0UT?K]&J-,ZGUB@D==?:XPK#7
M5-]II>DXYCD:IER#4GP4IUUI;BE?*:C/Y1+K++3WAEMO8_::<(>;&*3\]H_T
MA:#T['2&B,GTK'#_ .W65M;/#IE1HPIR?A<I1;;Z6\3*(]QM@
M
M                                                    ?__1O\
M
M
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MN9QEU*IV2I>.:6]E[L2E/] (
M
M                            !__2O\
M
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MV<A-:K1^O:%.ZGPVF8I6U7%[(RDUV-1]"X:F$6WLC"<V=#D5$EE@
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M**\$$U&/4DD6YZ=R:WT[D-GD-I]CLZ-.DGNQX(J+D_#)IR?6VV99& ,R
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ML>E)6T4UT2G''>G90'9BSX
M
M                           __]._P
M
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M4P]*R1_=HT<\]UK+45S'&WRJ'&L5L=Q43C27]&/:5-GI91AUE[@5:EA(
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M;45*Y:P?%=5FZMP\?5)59RA!O^[C!;DD;/#-G50
M
M                                           #_]2_P
M
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MFEKOF:M89E3XLNT[P5]J\FI>2Q]ZP6._LW&5Q)KTLJ5-26%1%PL2'+H@
M
M
M  /_U;_
M
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ML>3O+BQTA;\,KE+MKRK'^^NZJ3JRQV8QAA&C2Q2?94X8^5B;9#/G7P
M
M
M/__6O\
M
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M-NU+1^E<LT5IVVTYE2]JMXX.37E5)O;.I/Z:<L6^A+"*\E)+8D:@;,
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M-)27.G5-'#T]/*Z<UUXPJWN#Z,.*C;M[\:M3#[%,LCCLI9R
M
M                                                       '_]>_
MP
M
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M*7"N;7/#-^8$YY1E*E9Y2G]CQPJ5\'LE7:>'#TQI1;BGMDYR47&$L27.#
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MC1H4(1ITZ<(J,(4X1480A%8*,8Q244MB221[(?L]0
M
M                                                 ?_0O\
M
M
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MT_"GK35E+"^FL;:A-?Y>+7V2HGNKR7I8O[%%[?;'A3LS"%9*H
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MZD'A;0:WTZ$G/>I5Y0DX$,)F:C-2C-2E&9F9F9F9F?4S,S'-R$#;;Q9_@
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ML%QU:DL93DTL6\$E%**RJ/>;<
M
M                                   ?_]&_P
M
M                                                    /\4E*TJ2
MI)*2HC2I*B(TJ29=#2HC]I'\I FT\4&L=C*B'J_>AU)AOY1RDX38DJ37O'+O
MMI\?,=AFJ1 =,SDV67:DJHJ>KC"OG.S,>93WM'W+KTJ;,HC-@G=[[SL*D:&A
MN9=QA-80M;^H]DENC2NI/=+<H7#V2V*LU+VR4+N=7(&<)5=6Z#HXQ>,[BS@M
MJZ95+>*WKIE16U;Z2:\B-3125(4I"TJ0M"C2I*B-*DJ2?125)/Q(R/P,C$^$
MTUBB'+33P9_@'\     ).>(OJ\<W>'3=;0X7LQ>PM:5R66&M5;=1-S3$H<)K
MHA$/'9CC[-K3MH3W>6Q5V+$?N/N<8</P'$^8'=]Y9<Q'.ZS*R]Z7L\6[JTX:
M-5M]-1<+I5F^F56G*>&Q21U?1?.C7NB%"WL;KWS:QP7O>YQJTTET0>*J4TNA
M4YQCCM<662N-?Q)/%38C5=3\C,%S;C[DCI-M3,@K6']G:U\PNC:Y!S:%AN]C
M>8KYY,?41]+:>I*DK[>Y4--9]S77>42G<:/NJ.;T5M5.35M<^+AJ2="6&[B[
M:#;W06."E'I;O1:0S-1H:GMZN6U7OG%.O0\>,$JL<=^'922Z9/>YP-,\I../
M(>$B=H_>&L-H$IKSG8&(9C26MY!1V]_2VQQITK"&LB^<;<N,VHB\3+H(R:CT
M-K'2%3LM3Y9<V.W!2JT9QA+ZBHUV<UX8R:.^9'J[2^IJ?:9!F%"[Z6J=6,IK
MZJ&/'%^"44S/(U4V(        (M/4JN/3VS'5]C@W+3>^KM8Y-1-R[#"[D\A
MJ[':^&7#C)$N;1X/4*D7,^*[VMHGUR(:FY""1U-MY##S6:M^2FK^:MJK3),G
MN;K'['7A2<:=.3Z77GPT4GTQE42DET-)J._>#TIR@Y@Z5GD',2_H65Q1XIVM
M=2C*[MJK7IJ=*.-6I3E@E5H\/#4BEZ6<:<X4;]@;?PC%K.RB8?/>V34,V4R)
M2Y76PK'&Z"]@QWG&6YZ&LB8;LHKJB2V\<*77-N$A9&:B2I*E<FU3W;=<<NLZ
M64<PZ?O*4EQT^SPJ1K0]=3K)NEBL4I*+J.#\F23*PM)]VF&:W%2YS7.:52SI
MU91C[TA/M*L(RDE*3N(4_>\II*<5*E6\E[4F:Q91M/,<J;=BRIZ:ZM>1V.U=
M.AR%$>0IM+;J)3BEK?>0LTDM33SRVR5U-*$^P9/*--Y/DD4[&BE/IJ2\J;Z_
M*>['I4>&/@)/Z0Y;:-T/37Y LH0K882KS]LKRQ24O;98N"EAC*%/@IM[>!&.
M1G3>@   \Z%8S*]2SBO=J'3:-^.ZVU)A2B9<\UE,R#)2MEY*5$2DI=;41'T/
MIU(9?(]09YIG,89MIZ[K65S#TM6C4E3FD]\<8M-QENE%XQDMDDT?*O;T+JDZ
M%S"-2$M\9)2B\-V*::V='4]J/8Q45]L_'AIKI\:PD.M1XZ:-IRT][=..3+$=
MJGEN$ZI^0_T-2VY?:74TMQ_80E_H;OJZMR:$;77UG2S2C%;;BDXVUPECBY3B
MHNWJ81V*,86_7*>\Y_FW+[**L)7%C5=IPIMJ3XZ:27TS4H[=LI.<DECA$LQ^
MB=QGX+X)ET#>')O=^M9_("DM"=UGJK,'9>.8;KZ6POI"RV7D.7QXE5=7ZE^-
M:U$DNLP3)+Z/.F*8<B:KSG[ZV0\QK*6D.7]Q/+[&K'AN:EQPT:]?'?1@XSG3
MC1Z)N%24JWI=E/%5,MW?L]Y"TL[G?ZCU'93S6VJRA0HUI3H6\'%X*M"O<PI4
M;BI)K&CP3DH[)Q4IN#A<PK[&OMH4:RJYT.RKIC27XD^ODLS(4IE?TKT:5'4I
M"TG\BDJ,A&"$X5(J=-J2>YIXI^)EBMO<V]Y0C<VE2-6G-8QG"2E&2ZXRBVFO
M"F>8/T?8      #U%[D%#B]9)NLFNZC'::&GOEVU[90JBLBHZ=>^3/L%MM(+
MH1^*ED/G5K4J$'4KR4(K>Y-)+S7L/'?YCE^56LK[-*].VH0VRJ59QIPBOIIS
M:BO-9'9NKU:.%&FVY4>/LH]L9!'[THH-0PTY:AU9?-2?\JEN1Z,D=W@KMLU+
M(NIDVKP(]/S+7VFLN32K>^)KU-)<?]K%0_M>81KUSWP>1FB8SIT\T_+%S''"
MEET??";^$.4+7#'?A7<L-JBR%CD1ZX?('8K<^AT;C=+H_'9!.,)OG%M9CL-Y
M@_V,W&K.P9;KH/F(ZF:6*]QYHS(VY?5)*/FV<<SLVO$Z65P5K!^J]/4\]KAC
MCX(MKHD0;YD]_+F+J6-3+]!6M+(;:6*[5M7-XUNQ4YQ5&EQ+HC1E.#]+6Q6)
M#/EF899GE_895F^37V7Y-;.^?9Y!DUO/O+F>[TZ$N7963CCSAD7@GN6?0O N
MA#G-Q<7%U5=>ZG*I.6^4FY-^-O%D)<XSK-]09C4S?/KJK>W59XSK5ZDZM6;Z
MY3FY2?@Q>Q;$?.#XF,     -WN$_!7:_-'."K<9CO8UK6CF,(SS9]A#<<IJ)
M@R2\Y55#9F@I]LZT9&Q!:67:2DN2%LM&2SV;36EK_4EUP4%P48ORZK6R/@7K
MIM;HKQMI;3N_(OD#J[GAGWO7*XNURNWDO?=].+=.DMC=.FMG:W$HO&-*+6&*
ME4E"#XG=%T#Q_P!8<:-:4FJ]44+=+CM0DWI4IXVW[O([AY"4S\BR6R2E"I4V
M0:2[W#224))#+*&V&VVD21RG*;');*-A80X81WOU4GTRD^F3_P#Y)))(O"Y=
M\NM*\KM+T-):0MU0MJ.V4G@ZM:HTN.M7G@G4JSP6+P2BDH0C&G&,8YI&2-X
M
M
M           __]*_P
M
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ME)MO[8>DSH
M
M                       ?_]._P
M
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MED7F>7QQ?:4HOM:<?^[16,L$M\Z?'#!<4N#' A-]@DL<&
M     /T9>=CNM/L.N,OLN(>9>96IMUIUM1+;=:<09&E23(C2HCZD?B0^=:C1
MN:,[>XA&I3J1<91DE*,HR6$HRB\4XM-IIK!K8S]0G.G-5*;<91:::>#36U--
M;4T]S/;%(@67:B>E-?,Z--ILXS'^ZN]I*;[K2 P74C\6S7(C)[NB%*4P^ZX:
MRA)S=[GN49Y*KGW+&<,ONI8RE93;5K4>]]A))NVD]N$&I4,7&,50@FSIF0<P
M:M%1M<\3J16"56*\M='EKU:W8R6$\$VU4DSQG*BQ0[%;;C.2_?WD1Z]R"1S&
MI\AQ+:TQHCD?N[WB)YHEL%^R(4HD+0E?S17KJC26I=%9I/)=5V56QN88^35C
M@I)-KCIS6,*M-M/"I3E*$L-DF=5M+VTOZ"NK*I&K3?JHO%;D\'TQ:36,9)27
M2D9OPS15C8>5/R]UVGA*3WHJ8YMG<ODII*V_>EK)3<1/S_G(4E;Q&A;:VVC,
MEEQ[/]?Y9EBE;Y=A<U_ _:XOPR7IO%#PIRBSA','O!:6TK&>7Z><<TOUBO(E
M_AJ<L-CJ5H_9&L5[71<L<)0G4I21M!55-71PFZVF@1JV RI2VXL5!I1YBTI;
M4\ZXLU+=<4E"$J>=6IQ1)3W*/H0XOFN<9AG-R[G,*CF^A;HQ75&.Y+=X7O;;
MVD(]6ZTU'K?,GF>HKF5:2QX(>EI4HO#R:5->3!8)8O;*>"E4E.6,G[ 8PU8
M                   V$X^<6=Z<H<G3C&F<"M<E-EYIJYR)U'U.P_&FW.BC
M?R+)Y9)BQ^B#-Q#'>I]TB,F&75?-/+Y1D6:9Y7[#+:3GAOENA'ZJ3V+Q;WT)
MG1^7'*;7W-?-?R5HC+ZEUPM*I6:X+>@GTUJ\L*<-FU0Q=2:3[.$WL+0/"[T@
M--\>7*K/-Q.5NZ]MQ#9F1$S8!GKC#Y[9DXAS'Z">GNL)+*_]7862/ R0XS%C
M.I[C[?IOE[EV4.-UF.%S<+:L5[7!_2Q?IFO72\#48LM8Y']S'1/+>5'4&M7#
M/<XAA*/%#_!6TUM3HT9K&M.+W5JZWJ,H4:4UB3#CH9-(
M
M
M#__4O\
M
M                          BEYF^C?POYENVF47&&.ZCVU8>?(<VGJ9NO
MQ^SM;!SYY2LRQQ;2ZNX-:^TWY$B,B:M)=B)K9>)=WY<=XKF1RYC"QMKG\H9?
M#!>];IRJ1C%=%&IBJM'!>EC&3I)[73D<?USR0T+KB4[NO0]Y7LL7[XM\(2D^
MNK#!TZN+WMQ51K8IHJU<J_0 YNZ!=M+S5M76<G=?Q#=>8LM:MK@["9@HZ]BK
M75UHXJ6X^KV$Q1R;,_$C,R\2*<NA.]CRRU9&%MGE2627<L$XW/E6[E]+<Q7
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M
M
M                  ?_U;_
M
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M6HW3MJC\2ACX#57)N"_,C$%N)NN,>Z^QGKYLFGU]D.306R+VJ588TS+8)/\
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M$1%["(;,=T226"/] _H
M
M                                        '__6O\
M
M
M
M
M
M                   /_]>_P
M
M
M
M
M                                                          __
MT+_
M
M
M
M
M                                    #__1O\
M
M
M
M
M
M               /_]*_P
M
M
M
M
M                                                      __T[_
M
M
M
M
M
M                                #__4O\
M
M
M
M
M
M           /_]6_P
M
M
M
M
M                                                  __UK_
M
M
M
M
M
M                            #__7O\
M
M
M
M
M
M       /_]"_P
M
M
M
M
M                                              __T;_
M
M
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M:POLNK0KT*BQA4IRC.$EUQE%M->)GTP\1Z@
M
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M7-K.-2G42E&<&I1E%[4XR3::?0T\&>T'P/L
M                                        ?__2O\
M
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MB-:Y+K[(*>?Y++R9>34IRPXZ-1).5.:72L4T]THM26QFU(T4V\
M
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MJ=I;UUBNB4)+9*G..WAG![)+S4W%IO.0U@V
M                                       /_]._P
M
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M*HM[6'10%0)9D
M                                                           !
M0F]?3FY9\C.5]GH7%KE;FGN,MA-Q)J%$D&<#(-MD@H^PLBFMH,DN.5SQ'012
M<)7E>[2G&C(ICA':KW4N6='1^@X:JOJ>&8YW&-5MKRJ=KOMZ:ZE47M\L,.+C
M@I8]G$KN[Q>O:NI]8ST[:5,;+*FZ>">R=QNK3?6X/VF./I>&;7IV0."4Y'@
M       )Y_0-YRV7'#E-7: RVX6C37)BU@8NJ)+D**#C.W74>Y8%DD)M9FEM
M5F[V4,TD$GS?/B.NJ-,)!"*_>LY84=8Z&GJS+Z?_ -QR6,JN*7E5+1;:].77
MV:QKPQQX>&I&*QJ,D1W=>8%72^KHZ<O)_P"!S62IX-[(7.ZC-=7:/"C+##'B
M@V_(1?5%598@
M               '_]2_P
M
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MG.:SXJE6WIJI)[Y5*:[*I+S9PD_--S!S@WD
M
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M-=,V
M     !__U;_
M
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M&SXO'[RM_P"3 LM[O+F^4F5\6Y2NL/%[[K_RXDP CT=K
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ME=5XWE6FIRC"+4(TJ$E'"$8K8YR>[';O)G1' [F
M                 $??JL3),#TYN8;\0UDZO2F30U^6HTJ]VL?*KYI&9?K?
M)=<[B^4NI'[1UKD13A5YPZ=C4W*\IOS8XR7T4CF_."<Z?+'.Y0W^]:B\R6"?
MT&SFCBZ(JO            Z6_I2N2G?3EX>JF=3>+2N-MHZ]?W*RIUJ#[?\
M[!+?04N\^%"/.'42I[O?E3SW@Y?VL2T_D^YOECDCGO\ >L/.VX?0P)!1R4Z2
M
M !__UK_
M
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MM9<=*M"-2$ENE&<5*+7C33*?+FWK6=S4M+B/#4I2E"2?1*+<9+S&FCTX]!\
M         #I>^E?K"7I_T\>)6$SXYQ)YZDJ<SGQ%-FT[$G;/FR-FS(LEI7BE
MYMRX4AY)^)+)77Q%+?/3.Z>H>;N?YG2?%#WU.C%[TXVT8VR:?4U237@P+4>4
M64SR3EIDUA47#+WO&JUU.NY5VGX4ZF#\.)O^.3G1P
M                              ",GUE/T9?+7[!L?_"%3#M?=S^>O(/N
M]3\7K'*>>'S4YS]RA[M3.;R+D2KT        +UGPU7X@>=?G0["_!SAXJZ[Y
M_P Z]K^K+?\ &+LL%[K/S<W'P^M[A;%A 1())@
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M+<M&93/(M(Y9DU183M;6A3E]7"E%3\^2;-A1J)LH
M                                         '__U[_
M
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MLPA"G!4Z:48Q222V));$DNA(\@?@_0
M                   !&3ZRGZ,OEK]@V/\ X0J8=K[N?SUY!]WJ?B]8Y3SP
M^:G.?N4/=J9S>1<B5>@       !>L^&J_$#SK\Z'87X.</%77?/^=>U_5EO^
M,798+W6?FYN/A];W"V+" B023
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MMM3AAAOX..2]*SHWBG8L[
M                        #__0O\
M
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M-O;V<,7B]CJ3;D\$H1C*R.$'8
M                 (R?64_1E\M?L&Q_\(5,.U]W/YZ\@^[U/Q>L<IYX?-3G
M/W*'NU,YO(N1*O0        O6?#5?B!YU^=#L+\'.'BKKOG_ #KVOZLM_P 8
MNRP7NL_-S<?#ZWN%L6$!$@DF
M    :#>HKP(UYZ@FA)VL,G>8QW.\>=E9#J+8I1?>)>%9><;R31+0WT<?JK%"
M41K6&2OV1!-O(Z2(\=:.K<G^:V;\I=51SRQ3K6M9*G=V^."K4L<=G1&K3>,J
M4^AXQ?D3FGSKF;RZRSF1IV64W;5*XI-SMJV&+I5,,-O2Z<]D:D>E827E1BUS
ML^1_&G<W$_:=]I[>6&S\/S"D=4MDWD+?I<DJ%/*:@Y-B=RE),V%;*[#-F2R?
M@9*:=2V^VZTBWW1VM-.:]R*EJ+2]S&XMZJVX;)TYX)RIU8;Z=2..V+\$HMQ<
M9.LW5&EL\T=F]3)-04'0KT]V.V,XX[*E.6Z<)=$EX4TI)I8(&TFO     &:.
M/_'K;W*':..Z>TCAEGFN<9&^268<)LT0*BN0XEN=D&1VBR\B!6Q26E4F9)4E
MM!&2>IK4A"M;U9J[3VA\CK:BU-<QMK6BMKEZ:<L'PTZ<=]2I+#",(IM[7N3:
MSNF]-9UJW-J629!0E7N*KV);HQZ9SENA"/JI2P2\;2?1/]-[@%@?I\Z"AZVH
MY$7)-C90]$R/<.PVXRF7,MRQ,8V685<3Q$ZU45:%KC5<=?0R2IV0M*7Y3_6H
M'G)S7S7FWJN6<W2=&SH)T[2WQQ[*ECBW+#8ZM5I2JR72HP3<(1+,N5_+G+N6
MVG(Y7;M5;JLU.YK88=I4PP2CCM5.FFXTXOPR:4IR)!1R4Z2
M                                                  '_T;_
M
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MJ*>TW.'.#>0
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M6PVB&CFV@
M             '__TK_
M
M              *VWQ.'XGFBOSE:S\%V2B9?<G^</-/U=+\9MR+O>M^1.7_#
MH^X5RD8+,2!(        =4GB_P#BT\>/N&:D^T&O%%>M_EIF_P -NO=ZA;QI
M/Y*Y9\$M_<8&<QJYL
M                           !&3ZRGZ,OEK]@V/\ X0J8=K[N?SUY!]WJ
M?B]8Y3SP^:G.?N4/=J9S>1<B5>@       !>L^&J_$#SK\Z'87X.</%77?/^
M=>U_5EO^,798+W6?FYN/A];W"V+" B023
M
M                               #_]._P
M
M                               "MM\3A^)YHK\Y6L_!=DHF7W)_G#S3
M]72_&;<B[WK?D3E_PZ/N%<I&"S$@2        '5)XO\ XM/'C[AFI/M!KQ17
MK?Y:9O\ #;KW>H6\:3^2N6?!+?W&!G,:N;
M                                             1D^LI^C+Y:_8-C_
M .$*F':^[G\]>0?=ZGXO6.4\\/FISG[E#W:F<WD7(E7H        7K/AJOQ
M\Z_.AV%^#G#Q5UWS_G7M?U9;_C%V6"]UGYN;CX?6]PMBP@(D$DP
M
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M=I'M=OW5N-#?OPJMKJ(9-P?$_P"?S')430?%_$,?80;B(=[MW,+G+GY*3/\
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M-:%.SPFDU_B5N:Q7J"/]3O+<LJ525*4[G&+:?M'2GAZ\\7_$4>G)_P 6W/\
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M:IG WWE>5J6/;W#_ /EYGC?XA_TWO^\NW/O56G^W'[_A#YR?:+3XU'ZT_/\
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MW^FMOC5,?Q*<K?M]?XO,?XA;TU_^^VT/O3Y&'\(W.;_36WQJF/XE.5OV^O\
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MY(VG1_.30NN,W_(>15ZCN."511J4I4U)0PXE%O8Y)/BX=_"I/<F25#C!U,
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M<@             __]6_P *-/Q,_X^&IOS1\#_#'GHL^[E7S67_ZUK_BEB0
M[U?SAV?ZNH_C-V5V1+XC,      !/]\.%M3^17/>VU_)D]L+<NELVQR+$-?:
ME_(L2EPM@P)*4_KEM5];;)(O\UQ1_((G]\;(ORGRIIYM"/E9;>4:C?53JJ="
M2\3J5*3\:1([NP9O[PYBSRV3\F^M:L$NN=-QK)^-0A4\]E[>5*C08TB;-D,0
MX<-AZ5+ERGFX\:+&CMFZ_(D/NF2$-H01J6M1D1$1F9D1"K:$)U9JE23E*322
M2Q;;V))+:VWL26\L(G.%.#J5&HQBFVV\$DMK;;W)=+*\G.KXA+0&A'[G7W%V
MMKN1VSX1OPI&7)G/1M)XU/09HZ_5V I,G(UMJ(C4U4+:B+2?S;,EI4V4NN5W
M=(U9JN-/-]<3EDUC+!JEPIWM2/U$O)MT^NJI5$]]'!ID:>8/>3TYIV4\MTE"
M.:7<<4ZF+5K!_5KRJS753:@^BKBFBI?RG]0#EKS*M)$K>^X,COL>7**5 UU3
M/GC6LZ8VU]\4H&$TYMPW'&2(DHF3$ORS(NJY"SZF<^="\IM <N:"AI;+J=*M
MAA*XFNTN9]?%6GC-)],(.-/J@D0XU=S'UEKBLYZAO9U*6.*HQ?!0CU84HX1;
M71*7%/KDS34=&-&          /Z0M;:T.-K4VXVI*VW$*-"T+0?<E:%)\2,C
M\2,A_&E)8/:F?U-IXK8T3/<)O7'YA<3GZC%\UOI'(W3D,V(SN$[,MY<C*Z6N
M;,DFWA>RG4R+"*:$$EMF-8)G0VT)[&HS1GWE'#F7W8>7FO8U+[+:2R?,98M5
MK:"5*<O^];)QIRQ>+<J?95&WC*<MQW/0?/\ UMHZ4+2_J/-+&."[*O)NI&/_
M &J[XIQP6Q1GVD$MBBMY<ZX4^H9QGYXXBN]TIE_E974PV9.8ZJRE,:HV-ARG
M#2VIVPI4N.(E0N]24-V=<Z_%4HR;-U#Q*:37#S*Y1:UY69@K74MOC0J-JC=4
ML9V];#HC/!.,\%BZ=10J);>%QPDYRZ$YE:5YAV3N,AKX5H).K;U,(UJ7U4<6
MI1QV*<'*#W8J6*6\0YB;^               >CR;)\;PO'[C+,POZ7%<7QZ!
M(M;[(\BLX5+14M9$1YLJPM;:Q6VQ'9;21J6ZZXE)%[3'JLK*\S*[IV&74IUZ
M]:2C"G3C*<YR>Q1C"*<I2?0DFV>>ZN[6QMIWE[4C1HTDY3G.2C",5OE*4FDD
MNEMX%8?G9\1OA>%OW6N>$&-P=C7\<WX$K>&;PYT? :^0GJT\[A.(*./-MU(,
MS\J=/7%BDM)*1'G1U$HYM<K>YWF690IYQS-K2LZ3PDK*BXNO);TJU7RH4L>F
M$%.>#P<Z4U@HH<P>\[8V,JF6:!I*ZJ+%.ZJIJBGN?94]DJF'1.;A#%8J-2+*
MJ6_^47(/E+E:\SW_ +9S#9MWYCKD)%_9&5'1I?/JY&QG%H!,UE6P9^)L5\1E
MLSZF:3,S,YW:3T/I+0U@LMTG84;*E@N+LX^7/#<ZE66-2K+Z:I.3\)$#4>K=
M2:NO/?VH[RI=U.CCEY$,>BG36$*:\$(Q7@,"#:C70             $9D9&1
MF1D9&1D?0R,O89& )<^&WK4\U>(S]50R<T>WMJ:#Y,=W6NW+"==N0:YOH@H^
M(9RX;EM5&VV79&9\Z1";+_\ 45]"$?\ F-W;.6O,"-2ZA;+*[^6+5S:1C#BD
M^FK0V4JN+VR>$*LOMJ.SZ'Y[:[T9*%M*N\PLXX+L+EN6$>JG5VU*>"V16,J:
M^ULN&\$_5FXI\[HT.@Q#('-<[G.)YUCI;8$F'!R5YQEKS)CV%VJ#*)?QD=KB
MR.$HI2&D^;)AQDF1"O#FER#UWRMG*[S"BKS+<<(WE!.5-8O8JT?3T)/8O+Q@
MY/AA4FR;/+WG'H_F%&-M95/>M]AC*UK-*;PWNE+TM:*VOR?+26,X0)/!Q(ZP
M               >FR+(\?Q"BM\IRR\J,9QF@KY-M>Y#D%E#IZ2FJX31O3+&
MUM+!;;$=AI!&IQUU:4I(NIF1#TV=G=YA=4[&PI3KUJLE&%.G%SG.3>"C&,4Y
M2DWL22;9\+JZMK*WG=WE2-*E33E.<Y*,8Q6URE)M))+>V\$5:N>_Q&=%C,BZ
MUIP4I(.76K!R*^=OW-:V0>+0Y"3-EQ[7>%3";=LE(/Q:L;8FXW>GYL*8PM+I
MSDY4]SRZO84LZYHU96]-X2C8T9+M6MZ5Q66*IX]-.EC/![:M.2<2)',7O.6]
MI*IE7+ZFJTUC%WE6+[-/=C1I/!SPZ)U,(XK93G%IE5#=?(#=?(W,9.?;SV=F
M&S\KDF[V6>5V[\YNN8=7YBH%%6%VQ*Z(1D1HAP&&6$_K6R$[M-:3TUH[+HY5
MI>RHV-!8>32@H\37JIRVSJ2ZYSE*3Z61 S[4>?:GOGF.H+NI=UGZJI)OA3Z(
M1]+"/TL%&*Z$8@&PF$          /H\2S'+L!R&LR[!<IR+"\KI9!2Z?)L3N
MK+'<@JI22Z)D5MQ4.LR&%D7AW-.)/]4>/,,NR_-;2>7YI0IW-"JL)TZL(U*<
MEU2A-.,EX&F>JROKW+KF%[E]:="M3>,:E.4H3B^N,HM23\3+"?"SXBCD/I]Z
MIP[E=3?VB-=M&U%<S. BOH=ST<0C)!/'-3Y-9?$T@O!JP;CRG5'W.V1].AQ'
MYD]T#2&H8U,QT'4_)%X\7V,N*=G-]7#Y52AB^FFYPBMD:))/0G>9U-DDH6.L
M*?Y3MEL[580NH+KQV0K8+HFHS;VNJ6[N+W,'COS'P5&?\?MCT^:US"(R;^C)
M2J[,<.FR4&I%;E^*3>R9!=,TN);<<;-E_L4N,Z\T1+.OS7'+S5_+K-'E.K;.
M=M-X]G/TU&M%>JI58XPFMJQ2?%'%*<8RV$T=):VTSK?+_P I:;NHUXK#CAZ6
MK3;]34IORH/?@VN&6#<926TA.^)P_$\T5^<K6?@NR426[D_SAYI^KI?C-N<'
M[UOR)R_X='W"N4C!9B0)        #JD\7_Q:>/'W#-2?:#7BBO6_RTS?X;=>
M[U"WC2?R5RSX);^XP,YC5S8     #DR9?_.S*/LBN_KDZ+\,O_R%#[G#V**<
M;W_.5OJY>R9\\/8>4      "TQ\+S_6WRS^YUK3[9K(09[\'Y@R#X1<^YTR7
M/=,_/.<_<:'LYER05TDWP         "+WGWZLG&/@1 DT.3V:]E[O?@E*I=*
M85.BJO&O/:\R%-SFZ43L>@A.=R%)7)0Y*<;5YD:'(02C3V_E1R$UMS6JQN[*
M'O++%+"=Y6B^!X/RE0ALE7FMNR+5.+6$ZD&UCR;F-SCTIRZINWNY^^K]K&-K
M2:X]JV.K+;&C%[-LDYM/&$)+'"F%S0]7+F3S4DVM+E6>/ZVU+-6ZU'T[J^3-
MQS%GZ]?5"(V6V33GU0O5*223>3925Q?,+S&(D?KVE8_RW[O_ "ZY;0IW-A:J
M]S".#=W<J-2JI==*+79T-N.#IQ4\-DJD]Y!C77.?7&NY3H7EP[6SENMJ#<*;
M754ECQU?#QR<,=L81W$80[<<G            DSX?^K?S6X:O5=1AFRY6P=8
MP/)95J/:[D[,,.:@-]$E$QR0^\BRI"2GN-M%3-88[S[G6'B+M/BO,+D!RUYC
M1G<9E9*TO9XOWW:J-&LY/IJ))TZV/2ZL)2PV1E'>=6T5SFUWH>4*-C=.YM(X
M+WM<8U*6'5!MJ=+P*G*,<=LHRW%OW@9ZUG%;FF[3X+=3/Z!M[6!L1&=:YY:Q
M%T^4V3O1/N^NLZ[(\6R6M1I2U!E,Q)RU&9-17D(-PZ]N:G=KUURVC4S2VC^5
M<KABW<T(OCI173<4,92II+:YQ=2DEZ:I%OA)J<O.>^D-=RAE]>7Y.S"6"5"M
M)<-2751J[(S;Z(24*C>Z$DL28P1V.W'-B]73;O\ 33ZC'*?*&97O-;0;%>UC
M4=B^^,W"U-6Q]</*AJ+J1M/2JR1*)23Z*4ZI9>"A<SW?M/\ [-\GLBL91X9U
M;=7,^O&ZE*X6/A4:D8^!12Z"K?G/G7Y=YG9O=Q>,:=9T(]6%O%4-G@<H2EX6
MV^DC@'8SEX      %NGX6G]P\X?WWQP_:<[%?O?E^RZ8\68>C8DS^Z/]CS_Q
MV7H79;3$!29( %<WXFK\1[3GYUF(_@BS43#[E/SFYC^JZOXW9D8^]9\@+']8
M4_Q:Z*.HLY(!@                 !F?CA^,/H;[L^KOMX@C6]8_)#-?@=S
M[C,SNF/E+EWPFA[K ZJHHG+>P    #P[#]P3OWG)_:5#Z4?LT/&O1/Q4^QR\
M3] Y)XOX*:@        ZI'%YTG^,_'9XEFX3VB]2.DX9F9K)S *]9+,U>/CU
MZ^(HKUQ'AUIG$6L,+VZ7_KU"WC23XM*Y9+?C:6_N,#.@U<V    ,"\@.4/'[
MBSB2LVY ;7Q'6-"M+QP"O[ U75Z['22GHF,8Q7I?L[1])&1J8KXCSA%\XTDG
MJ8VK2>A]6ZZS#\F:3L*M[5V<79Q\B">YU*LN&G2B_75)Q71CB:[J/5NF](V?
MO_4EY3M*>W#C?E3PWJG3CC4J/P0C)^ K8\J?B9:N$]98WPZTN=T:/-CL;1W8
MJ1"KEK(S:.53:VQR0B2ZV?\ K([\^WCK+H1.PO:D3,T+W*Z]6,+WF)F79XX-
MVUGA*77A.XJ1<4^B484IKUM7I(MZO[U5&FYVNB+'M.A5[K%1\<:$'Q-=*<ZD
M7UT^@KW\@_4HYP\GG)C6V^1>P9U!,-U+F%8M9)P'!3CN&9(C2,2PE,"%+)M)
M]B')S3[O3KW.*-2C.6^DN3/+'1$8RR#)[>-6.'MU6/;U\>M5:SG...]J#C'J
M2P1&W4G-+7^K')9SF=:5.7]U3EV-+#J=.EP1EAN3FI/K;VFC8Z><_,H:0_KI
MU#]U# /MKB#!ZF^3>8?!J_N4S+9!^?;+[O1]TB=6P4/EP0 &(^0']0V[?N1[
M(^TV:-@TG\J<L^%V_NT##:C^3U_\'K^Y2.4^+W"H         +A?PN7\P^8W
MV7:8^LV1BO+OQ?G33OW*\]G;DV>Z5^;\\^Z6OL:Y:Q$$"7X      &E/J%\2
MJGFOQ,VIHJ2W$;R>RJOY2:RMI?8E%%L[&$KL,1FG(61^2S(=[ZV<XDN[W.5(
M27BH=*Y1Z^K\M=?6&J8-NA"79W,%ZNVJ81JQPZ7%85(+=VD(/H-$YE:-HZ\T
M;>:>DDJLX\="3]17I^53>/0I/&$WZR<CF67=+;8U=6^.W]=+J+V@M)]+=5,]
ME<>=5VU5+7!LJZ;'<Z*;=8>;6TXA1=4J29'[!=7:W-O>VU.\M)JI2JQC.$XO
M&,H22E&2?2I)II]*951<4*UK7G:W,7"I3DXRBU@XRB\)1:Z&FFFNL]8/N?$
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ME<Y.95;F+J>56VDUEUIQ4[6#Q6*Q\JM)>OJM)X/;&"A%[4VXKQW0Y"
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M09%EFF<FM\BR>FJ5M;04(1Z>MRD^F<Y-RG+?*3;>\RL,"9@
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MX(LU$P^Y3\YN8_JNK^-V9&/O6?("Q_6%/\6NBCJ+.2 8
M  9GXX?C#Z&^[/J[[>((UO6/R0S7X'<^XS,[ICY2Y=\)H>ZP.JJ*)RWL
M \.P_<$[]YR?VE0^E'[-#QKT3\5/L<O$_0.2>+^"FH        .IOQ'=\_BE
MQC>[>WSN/6EW>WKU[?,UO6K[>OR].HHQY@1X=>9W'JO[Q?\ U%0MST9+BT?E
M,NNSM7_Z$#84:B;*?%;$V1@.H\-O=A[/S''<"P?&H:IU[E.56L2FIJZ.1]J/
M.F3%)2;CBS2VRRCJXZXI+;:5+4E)Y/)\FS;4&8TLHR2WJ7=U6?#"E2BYSD_
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M#B=G'*'EK:\N--1M:BC/,+GAG=5%MQGAY-*+^UTDVEZZ3G/9Q8*3D<3.K@
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MTL=W:32V.K-;9/:HK"$6TL91ICM!RL
M #JD\7_Q:>/'W#-2?:#7BBO6_P M,W^&W7N]0MXTG\E<L^"6_N,#.8U<V
M   Y,F7_ ,[,H^R*[^N3HOPR_P#R%#[G#V**<;W_ #E;ZN7LF?/#V'E
M  M,?"\_UM\L_N=:T^V:R$&>_!^8,@^$7/N=,ESW3/SSG/W&A[.9<D%=)-\
M     "LQZY_JR2]&UMMPXXX9*J'N#(JI#>Y,_II1HFZOQBYA$\QA^/S&#[F;
M^TC.I=D2D*)<"&M!M=)4EMV)-7NO\A*>IZU/F+K*CQ9=1EC9T)KR;FK!X.M4
M3]-0I2348O95J)\7M<'&I%3O \XYZ?I3T1I>KPWM6/\ B:T7MH4Y+%4X-;JU
M2+Q<M].#6'ER3A2J,S,^I^)GXF9^TS%DY!(
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MBS[N5?-9?_K6O^*6) #O5_.'9_JZC^,W979$OB,P
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M2S?-7H/**G^%LY)W+B]E6X6ZF\-\:'2NFMCBL:<65FQ-0BJ
M                    '5)XO_BT\>/N&:D^T&O%%>M_EIF_PVZ]WJ%O&D_D
MKEGP2W]Q@9S&KFP     ')DR_P#G9E'V17?UR=%^&7_Y"A]SA[%%.-[_ )RM
M]7+V3/GA[#R@      6F/A>?ZV^6?W.M:?;-9"#/?@_,&0?"+GW.F2Y[IGYY
MSG[C0]G,N2"NDF^     1U^I]SHI>!/%W)=FLJA3MI94MW"-+8Y+\MY%EG5E
M"<=;N["&9]RZZF82NQF^!)<-#44UH<E-J'8.2/*^YYJZXHY++BC8T,*UY46S
MAH1:7!%]%2M+"G#I6,JF#5.2.9<V.8-#EWI*KFL<)7E;&E:P>WBJR3\MKIA2
M6,Y]#P4,4YHYNN593D><9-D&9Y?=6.1Y7E=U9Y%DF06\ER9:75Y<S%V%I:6$
MITS4X\^\XMQQ9GXJ,Q<E8V-GEEE1R[+Z<:-"A"-.G3@L(PA!*,8Q2W**2274
M5>WEW=9A=U;Z]J2JUJTI3G.3QE*<FW*4GTMMML]"/4>8
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M6VWM;;VMO:V620A"E!4Z:48Q2226"26Q));$DMB2/)'X/T
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ML(QBEL22222V);"K"K5JUZLJ]>3G.;<I2;Q<I-XMMO:VWM;>]GA#ZGS
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M[3GYUF(_@BS43#[E/SFYC^JZOXW9D8^]9\@+']84_P 6NBCJ+.2 8
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MS#YC?9=ICZS9&*\N_%^=-._<KSV=N39[I7YOSS[I:^QKEK$00)?@
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MU&I"+PVX8$<M1Z4U'I*\]X:CLZEI4VX<<?)FEO=.:QA47AA*2\)@H;2:\
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M%K%2C)8IIK:FG@UN.!5:56A5E0KQ<)P;4HR34HM;&FGM33V-/:CP1]3Y@
M        =4GB_P#BT\>/N&:D^T&O%%>M_EIF_P -NO=ZA;QI/Y*Y9\$M_<8&
M<QJYL     !R9,O_ )V91]D5W]<G1?AE_P#D*'W.'L44XWO^<K?5R]DSYX>P
M\H      %ICX7G^MOEG]SK6GVS60@SWX/S!D'PBY]SIDN>Z9^><Y^XT/9S+D
M@KI)O@  !'-ZKO*)WB1P7W5LFGL%5V=9#4(U=K-]E[R)K.<["0Y31+6N<ZET
M?JH7OUTV7CU]S,NA^P=AY#:'CK_FAEN37$..UHS]\W*:Q3HV^$W&7TM6?!1?
MW0YCSAU:]&<O[_-*$N&XJQ["@T\&JM;&*E'PTX\=5?4'-<]HN;*M0
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M:OQ'M.?G68C^"+-1,/N4_.;F/ZKJ_C=F1C[UGR L?UA3_%KHHZBSD@&
M             &9^.'XP^AONSZN^WB"-;UC\D,U^!W/N,S.Z8^4N7?":'NL#
MJJBB<M[     /#L/W!._><G]I4/I1^S0\:]$_%3['+Q/T#DGB_@IJ
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MLY3J3D^F4Y-R;\;)NV5C99;:0L<NI0H4*2X84Z<5"$4NB,8I)+Q(^E'B/4
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MR:N^75VLURIRKY37EA&;VSH3>U4JK6]/^[J8+BP<9)22<H5Q),X2
M  6Z?A:?W#SA_??'#]ISL5^]^7[+ICQ9AZ-B3/[H_P!CS_QV7H79;3$!29(
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M*49)IIIK%--;&FMJ:V-%6%2G.E4E2JIQE%M--8--;&FGM33V-'C#]GX
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M&Y69\F>6-MR[TW&5U!/,[R,9W,]C<>F-"+]93Q\K#T]3BEBUP*,L8X(=B
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MX:F_-'P/\,>>BS[N5?-9?_K6O^*6) #O5_.'9_JZC^,W979$OB,P
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M6RZ&TK:Z+TI9:;MDO\/32G)>KJR\JK/K\JHY-8[HX1W)&T T@VP
M  "J5\3=QNC3L0T+RPI:Y!6>/W,W2.>366B4_*I+QB3EV /RE)+JEJ%+CW3'
M>KJ1KG-HZD?:1SP[E&LITLQS705S/R*T%>T$WL4X.-*NEX9QE1EAU4I/K(?=
MZW2\*EEEVL:$?+IR=K6:WN,U*I1;\$91JK'KJ)%/@6&$*         MT_"T_
MN'G#^^^.'[3G8K][\OV73'BS#T;$F?W1_L>?^.R]"[+:8@*3)       C)]9
M3]&7RU^P;'_PA4P[7W<_GKR#[O4_%ZQRGGA\U.<_<H>[4SF\BY$J]
M "_C\/!^C>QK[KFU?KHP*HN]Y\\E?X):^QD6,]VCYKZ7PBX]DB<L1@._@
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M?(#^H;=OW(]D?:;-&P:3^5.6?"[?W:!AM1_)Z_\ @]?W*1RGQ>X5
M !<+^%R_F'S&^R[3'UFR,5Y=^+\Z:=^Y7GL[<FSW2OS?GGW2U]C7+6(@@2_
M            "/3U0N'47FYP\V3JB##8>V+1QRV'IZ6X2$N1MDXG$>>JZY#[
MG@VBWC.2Z5]:NI(1+-WH:FT].N<D.8E3EGS$LL^JR:LZK][W:Z[>JTI2PZ72
MDH5HKI=/AW-G->;6B(:]T3=9/3BG=4UVUL^JO33<8X]"J1<J3?0IX[TCFJRH
MLF#)D0IL=^',AOO19<24RY'DQ9,=PVGX\AATB6AQ"R-*T*(C(R,C(C(7/0G"
MK!5*;4HR2::>*:>U--;&FMJ:WE6<X3IS=.HG&46TTU@TUO370UTH_ ?H_(
M              &7M":,V-R4V]@FD-3TB[[.]A7D>EIXO[(B'#;-)R+*[N)3
M:5^[P*^*AZ;.DFDR:8:<7T/IT/7M5:HR?1FGKK4V?U>RM;2#G-]+Z(P@MG%.
MI)J$(^JE)(S>G=/YIJG.K?(,FI]I<7,U&*Z%TRG)]$(13E.71%-G2HX1\/\
M7/![CUAVB==M-RU537U7S?+G(J(UGGV?63#99%EMFE)J-/FJ;0Q#84XOW>(U
M'C$M9-=QTQ\S.86<<SM77&J<W?#VCX*-+'&-"A%OLZ4?$FY3E@N.I*<\%Q8*
MTO06BLKT#IJAI[+%Q<'E5:F&$JU:27'4EX\$HK%\,%&.+PQ-MAH!N0
M                 ?_6O\ "C3\3/^/AJ;\T? _PQYZ+/NY5\UE_^M:_XI8D
M .]7\X=G^KJ/XS=E=D2^(S        !U2^,NLF-+\<]$:DCQ2AEK?4.N\,?9
M(NBCG8]BD6MLGWO NKKLAMUUU1EU4M2E'XF**M:YW+4FL,US^<N+WY=W%9/Z
M6I5E**7@46DET))%O.E,JCD6F,OR:*X?>MM1I->&%.,9-^%R3;\+,XC6#/@
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MD4Y5JLZ]:5>H\93;DWUMO%_1/ 'U/F
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MEFLPUAE.7R6*KWEK3?\ 3KPC_*8+5-R[+3.8WD=CHVMQ/^K2G+^0Y5HO7*A
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M_F'S&^R[3'UFR,5Y=^+\Z:=^Y7GL[<FSW2OS?GGW2U]C7+6(@@2_
M       *"WKY\,/[-?+V5MW$JCW+5?)TK3/8!Q6>R!3[.BOMELZB+L+H@Y,A
M]B\;ZF1'[\ZVV7;'/I:UW4N8_P"V?+V.G[^IQ7V2<-"6+\J=LT_>T_#PQC*B
M_N47+;-%=/>*T-^RVM7G5G#AL\VXJRP6R-=-=O#^E)JJONC2V1(+!*(CZ
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M\SMYU4O,57!>#!%;?>-LHVG-6]JQ6'OBE;U/-[&--^?V?GD+PD@<+
M\RNE*@V$&:A:FUPYD:4AQ'TZ%1WDNI6G]4C+J0^=:"JTI4GM4DUYZP/I2FZ=
M2-1;.%I^<SK8"@<N4,%\H;)RFXT<B+AI78[5:+VW9-+ZF7:Y!P"PE(5U3U/P
M-)'X$-HT/15SK3)[>6ZI>VD?ZU>FOY37]6U70TKF==;X6EQ+SJ,V<K<7J%0X
M                                    %A+X:S'G[7GKG-RE"BBXOQKS
MN:Z[X]A2++.\8IHT<S+]<M+[RR(_D0KY2(1([YUW&ARJM;9^FKYC0BEX(T+F
M;?F.*7FHDGW6K:5;F)<5UNHV-5M^&56A%+S<6_,+U0JZ+!2G+\43*4O9_$6"
M:C[(^![5E)3W%VDJ9D-.RI1)^0S)@NI_+T+Z L3[C\$LDU!5Z77M5YU.L_\
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M)]93]&7RU^P;'_PA4P[7W<_GKR#[O4_%ZQRGGA\U.<_<H>[4SF\BY$J]
M    "_C\/!^C>QK[KFU?KHP*HN]Y\\E?X):^QD6,]VCYKZ7PBX]DB<L1@._@
M         #V@#DAB_P *9P        F5]";C%5<D.>^&V64US5EA6A*&PW==
M0I31.0K&\QVQB5.!U[_>1I,T7,Z)9>4HC)QN&Z@R[3,1S[TFMZ^C>55S1L9N
M%SFLXV4&GA*,*D93KR73MHPG3Q6V+J1:VG<>[YI.CJCF+0JWD>.AET'=23W2
MG"48T8O_ ,V<9X=*@UN.A.*CRR<               Q'R _J&W;]R/9'VFS1
ML&D_E3EGPNW]V@8;4?R>O_@]?W*1RGQ>X5         !<+^%R_F'S&^R[3'U
MFR,5Y=^+\Z:=^Y7GL[<FSW2OS?GGW2U]C7+6(@@2_               (Y_5
M0X;L\V^'.QM8U<%J3LO&&BV3IV0I*"?3L+%(CSD2E:=7T[4W,-R93+-1]J#E
M)>41FTGIV'D7S%ERSYBV>=UY.-E7?O>[71[WJM)S:Z71FH5ETO@<5Z9G,>;N
MB(Z]T1=951CC=4O;[9]/;4T\(_\ FQ<J3Z%QJ70<V!]A^*^]&DLNQY,=UQB1
M'?;6R^P^RLVW67FG")25I41I4E1$9&70_$7,QE&<5.#3BUBFMJ:>YI]*95O*
M,H2<)K!K8T]C370S\A^C\@            !95] STS?Z;LYA\S=U8_YVHM8W
MJDZ@Q^UB]8FQ-F4LCJK)W6'RZ/5..OI(T&1=C]DE+?<I,*4RN&'>MYU?LSE<
MN7&FJN&87L/\74B]MO;37V--;JMQ'?TPHMO!.K"2E-W=>57Y>S".N<^IXV5I
M/_#0DME:O%_9,'OIT7NZ)5<%CA3G%W9Q6D3R
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M/Q,_X^&IOS1\#_#'GHL^[E7S67_ZUK_BEB0 [U?SAV?ZNH_C-V5V1+XC,
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MV>6>82>"H5Z-1OZBI&7\ACLXM7>Y3=645BZU&I#^O"4?Y3E "^<IX
M #Z:APK,LI:D/XQB639&Q$<2S*>H:&UMVHSJT]Z&I#E>TX2%&7B25&1F7B/%
M=9GEUC)0OKBG1<MJ4YQ@VNM<36)Z[>POKN+E:4:E5+8W"$I)/PX)X'OOZ(-L
M_P#2_8G_ "3DO\&'D_:'(/\ 76_WZG]<>C\BYS_I*WWJ?UH_H@VS_P!+]B?\
MDY+_  8/VAR#_76_WZG]</R+G/\ I*WWJ?UH_H@VS_TOV)_R3DO\&#]H<@_U
MUO\ ?J?UP_(N<_Z2M]ZG]:/Z(-L_]+]B?\DY+_!@_:'(/]=;_?J?UP_(N<_Z
M2M]ZG]:/Z(-L_P#2_8G_ "3DO\&#]H<@_P!=;_?J?UP_(N<_Z2M]ZG]:/Z(-
ML_\ 2_8G_).2_P &#]H<@_UUO]^I_7#\BYS_ *2M]ZG]:/Z(-L_]+]B?\DY+
M_!@_:'(/]=;_ 'ZG]</R+G/^DK?>I_6C^B#;/_2_8G_).2_P8/VAR#_76_WZ
MG]</R+G/^DK?>I_6C^B#;/\ TOV)_P DY+_!@_:'(/\ 76_WZG]</R+G/^DK
M?>I_6C^B#;/_ $OV)_R3DO\ !@_:'(/]=;_?J?UP_(N<_P"DK?>I_6C^B#;/
M_2_8G_).2_P8/VAR#_76_P!^I_7#\BYS_I*WWJ?UH_H@VS_TOV)_R3DO\&#]
MH<@_UUO]^I_7#\BYS_I*WWJ?UH_H@VS_ -+]B?\ ).2_P8/VAR#_ %UO]^I_
M7#\BYS_I*WWJ?UH_H@VS_P!+]B?\DY+_  8/VAR#_76_WZG]</R+G/\ I*WW
MJ?UH_H@VS_TOV)_R3DO\&#]H<@_UUO\ ?J?UP_(N<_Z2M]ZG]:/Z(-L_]+]B
M?\DY+_!@_:'(/]=;_?J?UP_(N<_Z2M]ZG]:=!ST5^-L[C3Z?>HJ;(:IZFS;:
M3EKNW-(,J.N)-CS\]\D\:C3HSQ$XU(8QZ+3,2&72);;J'$*2DR,BJ3[R>LJ6
MM.;687-I452VL>&RHR3Q3C0Q[1Q:V.,KB5:46MCBTTV62<B=+5-*\M[*A<P<
M*]WQ755-8-.MAP)I[4U1C24D]JDFG@2N#@YV$JC_ !1N+.R<-X<9LA!^329-
MNC%I+A)\#=RBJQNVA(6K]0JB0:2_54)X]QV^C#,=198WMJT[.JO%2E<0E[K'
MZ!#[O:VCG8Y'?K=3J75-_P#F1H27N;*?8L+(4        !TH_2/SZ/LCTWN(
MM]'>2\55JB#@+W11&IJ1J^UE:W=967M(TG5>!'^MZ&7@9&*9.?\ E,\FYR:@
MM9K#M+J5=>%7,8W"?_J^>6E<F<QCFG*_);B+QX+=47XZ$I4,/_3)&1QXZ<
M           %$[XD;:+&9<[<8U_!E>;'T_H_$*2TBDHE>ZY1EUO8YQ-49$?S
M3<JYM,?0RZ^!'[#(6C]S;(YY=RMKYM5C@\QO:LXOKI4H4Z*\ZK"L5\]Z+-HW
MW,*EEM-XJRM:<)+JJ5)3JOSZ<J17T$M2-H        =4GB_^+3QX^X9J3[0:
M\45ZW^6F;_#;KW>H6\:3^2N6?!+?W&!G,:N;      <F3+_YV91]D5W]<G1?
MAE_^0H?<X>Q13C>_YRM]7+V3/GA[#R@      6F/A>?ZV^6?W.M:?;-9"#/?
M@_,&0?"+GW.F2Y[IGYYSG[C0]G,N2"NDF^ !BK>V*N9UH_<F$LH-Q[,=5;#Q
M5ILD]QN.9#B,RH0@D_+U-XBZ#/:6OEE>I\NS.6Q6]U;U7_Y=6$_Y##ZALWF&
M07UA':Z]O6I_UZ<H_P IRF!>\4_@       !9!^&9SZ/1\P-R:^E/I93GVA)
MMG 2I73WJWPG-JIYJ(VGY5^YV$Y[]1+2A#?OJ95.ZY>Y=FU-8^]+Z,9>"%:C
M56/BXZ<(^.2)0]U7,8V^M;[+9O#WS:.2\,J56F\/'PSF_$F7>Q663W
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M\+E_,/F-]EVF/K-D8KR[\7YTT[]RO/9VY-GNE?F_//NEK[&N6L1! E^
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MPG<3PG<U4MM6LUMPQV]G#TM-;,(KB:XI2;WT'*SH@
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M8P&;,2      !)KZ..MU[0]2GBK3G&-^+CF=3=D37#0:FH:-8XS.SN#)>/\
M6D<V!%:0?_M%H+Y1Q3O%9RLCY,9[<<6$JU"-O'K?OFI"A)+^A.3?@3.K<D<K
M>;<TLGH88JE5==^#L*<ZR;_I0BEX6CI#BFXM"  Y6?)O7R]3<C]^ZO6PJ.6O
M-S[.PMII23011L:S2;41%MD?M0MII"VU%X*29&74C(7JZ)S99_HW*<\3Q]^6
M=M6;\-2C";\U-M/J94/JO+7DVJ,QREK#WM=5Z6'@A5E%>8TDUX#!XV<U\
M   "Q!\.3RDC:DY8Y7Q^R.P*)C/)3&&(U"<AXD1FMGZ\;E7>.,]73)#?OU8_
M<12Z&2GI'NC1$I1H(HA]\30T]0:"M]6V<.*ODM5N>"VNVN.&%1[-KX*D:,NJ
M,.TEL6))?NQ:MADVL:VF[J7#2S6FE#%[%7H\4X+J7'!U8]<I<"V["\X*ORP$
M                            (#?B.-;KS+T^HN8QXQK>U'N_7V72Y2$=
MRH]/D$.QUS(:<5^M;<F7, S^BM*"$K.YUG*R[FU++IRP6865Q22ZYTW3N$_&
MH4:GF-D=>\]E;ON6ZOHK;975&HWU1FIT7YCE5AYJ10U%J!7B        %TGX
M9WD5$RC1&Y.,EM/0>0:KS9O9&*Q7G")Y_!MA1D0K6/!9^5NON(+K\A?R*LFB
M^4NE;G?3T?4L=4Y=K:A#VJ_H^]ZK6Y5[=N47)]=2C-1BNJC(G5W5=30N]/7V
ME*TO;+.KV]-/>Z59)2275"I!N7AJHLYB$Q*X           #U]M:UM#56=Y<
MSHU93TU?,M;6RFNH8AU];71E3)TZ6^YT2AIII"W'%J/H22,S'UMZ%:ZKPM;:
M+G4J248Q2Q<I2:48I=+;:276?.M6I6]&=Q7DH0@G*4F\%&,5BVWT))8MG+HY
MC[[E\H.4N]]]R%OJC;*V-?W5 U*2I,F%AT:1]2,&JWR7X]\2FC08JO O%OV%
M["O#Y=:5IZ(T-E6E()<5E;TX5&MTJS7'7DO!.M*<O-*E=;ZBGJS5V8:BECA=
M5YRACO5)/AI1?AC2C"/F&M0W0U4        .J3Q?_%IX\?<,U)]H->**];_+
M3-_AMU[O4+>-)_)7+/@EO[C SF-7-@     .3)E_\[,H^R*[^N3HOPR__(4/
MN</8HIQO?\Y6^KE[)GSP]AY0      +3'PO/];?+/[G6M/MFLA!GOP?F#(/A
M%S[G3)<]TS\\YS]QH>SF7)!723?   #E9\FM;KT[R-WUJA<8XB=<;BV3A4=@
MT=B2A8WF$RJ@.,E\K;C#3;C2B\%(4DR,R,C%ZNBLY6HM'95GREQ>_+2WK-_3
M5*4)23\*DVGU--%0VJ\K>2:GS')VN'WK<UZ27@A4E%8>!I)KP&#QLY@
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M%1<6 D,         MT_"T_N'G#^^^.'[3G8K][\OV73'BS#T;$F?W1_L>?\
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MQ/-WWQ.KR]TW5\B+PO:L7Z:2_P#AHM>IB_LS6^7M6Y5%*J")YD/
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M$S_CX:F_-'P/\,>>BS[N5?-9?_K6O^*6) #O5_.'9_JZC^,W979$OB,P
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MI/\ H3[2FO,H5:2\PK6[PV2/)N:-[52PA>PI7,/Z<.";\VK3J/S2'$2*.(
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MBG8GI7SU1,ILI:4&9MJOUH71Q4+3T=CG8J2I*V$]9;=TSE;5U9K%:WS.G_\
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M^7:T4][MZLL9)?<ZS;;Z%5@EN++XA:2I
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M\39QW=O]6Z&Y/TL#S).O,DMM49O)8;[WOY.9NT5YB,V8OI\V/"L8,R,D^O\
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MJJ^EJ1*K>;&EY:1Y@9EE$8\-%U76H]78UO;()>"'$Z;\,&:##JQSD
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ME@E6;J74>;:LSNOG^=U.TN+B6,GNC%;HP@MO#"$<(Q70EM;>+>%QLA@@
M     #JD\7_Q:>/'W#-2?:#7BBO6_P M,W^&W7N]0MXTG\E<L^"6_N,#.8U<
MV      Y,F7_ ,[,H^R*[^N3HOPR_P#R%#[G#V**<;W_ #E;ZN7LF?/#V'E
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MO*S[5NP<+2R1=3=5E.)2Z,FR+_2\_H,YI?,EDVI<NSAO#WI<T*V/5V56$_\
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M'.<XS'4&:5\YS>JZUS<S<YS?2WT);E%+",8K!1BE%)))&.QES&
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M!))8))+8DMB6XCE4J5*U25:M)SG-MRDVVVV\6VWM;;VMO:V>(/H?@
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M;[+M,?6;(Q 'OQ?G33OW*\]G;DS>Z5^;\\^Z6OL:Y:Q$$"7X   <D,7^%,X
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MUK_BEB0 [U?SAV?ZNH_C-V5V1+XC,
M  %X[X>K@B_HG15IRKV)2JA;-Y$5D1G"(LYCRYV-Z28D(L:I\B61*;7DDI#5
MHM/B2H;%:LC2I3B16)WN.:4-4ZIAH3)ZO%991)NLXOR:EZTXR7A5O%NDNJI*
MLGBDF3][M?+V6GM/3UAF=/AN\SBE236V%JFI1?@=>251]<(TGO;18N$/B38
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MU/=:<S!-NC+VN>&"JTI;:=1='E1PQ2QX9*4'MBS5X;P:D
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MGYS&^Q'3/UYR(01[\7YJT[]UO/86Y+_NE?G'._N=M[*L7#!7B39
M      ,1\@/ZAMV_<CV1]ILT;!I/Y4Y9\+M_=H&&U'\GK_X/7]RD<I\7N%0
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M=G->MS#SOWCELG'*;.35&.U=M/:G<37A6*I)[80>Y2G-$-8D8<.
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M?_K6O^*6) #O5_.'9_JZC^,W979$OB,P
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M9)E6&MM'YKH74=?3N;1\ND\832PC5I-O@JP^EDEM6+X9*4'Y46:Q#=C4P
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M3'UFR,5Y=^+\Z:=^Y7GL[<FSW2OS?GGW2U]C7+6(@@2_   #DAB_PIG
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MXI8D .]7\X=G^KJ/XS=E=D2^(S                              &\7
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M*3LYTMIC*-'Y'0T_DE/LZ%!8?33D_35)O9Q3F]LGYB2BDEG4:N;
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M316AG.39GI_,ZV39Q1E0N;>3C.$MZ?6GN<6L'&2;C*+4HMIIF.AF#&
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M3K'U7I3.M%YW5R'/J3IUJ3V/:X5(/'AJ4Y8+BA+#8]Z>,9)2C**U_&V&M@
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M^?G,;[$=,_7G(A!'OQ?FK3OW6\]A;DO^Z5^<<[^YVWLJQ<,%>)-D
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M/.6V;.A>)UK*JW[WN4O)FM_#/UE6*]-!O;@Y0<H[2.<=A.8@
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M+<91:VIIM-;B$-Q;W%I7G:W=.5*K3;C*$XN,HR3P<91:333V--8H]2/0?$
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M=I#/-$9W4R+/J79U8;8R6+A5ACY-2G+!<4)8;]C3QC)1DG%:YC<#6
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M3J)V3\DN5U/E[I[WUF,$\TO5&5>6Q]E'?&WB^J.^HULE4QVRC"#4Q CN=M
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MS@^.4N(89CU+B>*8Y7QZF@QO'*R'345+5Q$>7%KZNJKT-L,,MI+HEMM!)+Z
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MO.36MM!3G7O+=W5E'=<T$YTTNNI'#CHO=CQI0QV1G+>1BCMAR<
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M:?W#SA_??'#]ISL5^]^7[+ICQ9AZ-B3/[H_V//\ QV7H79;3$!29(
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M56*F)W;^5/;U(<Q,_I^1!OWE3DO326QW+3Z(O&-'Z;BJ+#AIR=OL5[DU
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M/9'IJS67Y!:4K2BO4TH*.+ZY-;9R^FDW)]+,LC &9
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MPS' _P#ZL\N/^?-.?^ @_C5YI_Z#*OO%W_[X?PJ<O/\ 69C]^MO_ &@_PS'
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M\I-.<LZUU7R&O<UG=QIQG[XG2DDJ;DX\/9T:6#?&\<>+HPPZ9)1QHZB
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MS^"7'N,S-:<^4-A\(H>ZQ.K"*(RWX
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M \)ZP
M
M
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M<8U+2MC.VKX;*E/'TLFMBJT\5&I'9MPDEPSB1[CK9S4
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MI3[K>M_MQA#7]6?);,_@EQ[C,S6G/E#8?"*'NL3JPBB,M^
M
M
M
M
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M[<80U_5GR6S/X)<>XS,UISY0V'PBA[K$ZL(HC+?@
M
M
M
M
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M*(RWX
M
M
M
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M'N,S-:<^4-A\(H>ZQ.K"*(RWX
M
M
M
M
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M!_7OI3[K>M_MQA#7]6?);,_@EQ[C,S6G/E#8?"*'NL3JPBB,M^
M
M
M
M
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M9\ELS^"7'N,S-:<^4-A\(H>ZQ.K"*(RWX
M
M
M
M
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MEQ[C,S6G/E#8?"*'NL3JPBB,M^
M
M
M
M
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MOX0A7HRE)VE=))5(MMMT\$DMK;V)'2K%,1:8
M
M
M
M
M                                                      '_U;_
M
M
M
M
M
M                                #__6O\
M
M
M
M
M
M           /_]>_P
M
M
M
M
M                                                  __T+_
M
M
M
M
M
M                            #__1O\
M
M
M
M
M
M       /_]*_P ,$[GY/\=^.KN.L[WW3KC4CN6MVCN,-Y]E57C:[YND5'1;K
MJTV3B/.*,<N,3QHZ]OFHZ_3$-ITWHC5^L(UI:6RVXS!6_"JG84I5.#CXN#BX
M4\.+AEACOX7U&O9[JS3.F'2CJ&_H63K<79]M4C#CX,.+AXFL>'BCCANQ7680
M_O-/3V_++XZ_?1QC_;C9OW*<V_\ ;F8?%JOUI@/WK<M?TY9??Z?\Y]+AOJ!<
M(=AY508-@W*S1&59AE5G%I<;QNEV/C<VWO+B:ORH575PFG^]Z0\LR0TT@C4M
M1DE)&HR(_%F/*;F;E%A5S3-,AOJ%O0BYU*D[>I&$(1VN4FXX**6UM[$MKV'K
ML>9&@<SO*>7Y?G%I6KUI*,(1KP<IR>Z,5CM;>Q);6]B-P!STW4
MU"S;G_PDUQEE]@F><JM%8GF6+6+U1DF-7FQ\;@W%':QNA2:VSA.ODME]HS[7
M6ED2D*ZI41*(R'0<LY3\S,YL*6:95D5]<6U>*G3J0MZDH3B]THR4<'%]#6QK
M:MAI5_S'T%E=Y4R_,<XM*->C)QG"=:"E"2WQDL<4UTI[5N9\O_>:>GM^67QU
M^^CC'^W'N_<IS;_VYF'Q:K]:>3]ZW+7].67W^G_.9MTSRBXZ<BG\@C:)W5K?
M;<C%&JU_)6<"RJJR1RB9N%OMU3MFFM<6;*9"HT@FC7T[C;7T^E,:UJ/0^L-'
MPHSU3EMQEZKN2INO2E3XW##B4>)+'AXHXX;L5UF?R+5NF-32J0T]?T+UT>%S
M5&I&? I8\/%PMX8\+PZ\&9X&JFP@ 8RVSNC4VA\53G.Y]B8CK##E6D.D3DN:
MW<*@ICM[!MQV#6E/GJ0WYSJ675-HZ]3)"NGL,9O(--Y_JF__ "7INSJWUQPN
M?9T82J3X(X*4N&*;P3:Q?A1BLYSW)M/6?Y0SVYIVE#B4>.K)0CQ/'".+P6+P
M>"\!K/\ WFGI[?EE\=?OHXQ_MQNG[E.;?^W,P^+5?K35/WK<M?TY9??Z?\X_
MO-/3V_++XZ_?1QC_ &X?N4YM_P"W,P^+5?K1^];EK^G++[_3_G']YIZ>WY9?
M'7[Z.,?[</W*<V_]N9A\6J_6C]ZW+7].67W^G_./[S3T]ORR^.OWT<8_VX?N
M4YM_[<S#XM5^M'[UN6OZ<LOO]/\ G']YIZ>WY9?'7[Z.,?[</W*<V_\ ;F8?
M%JOUH_>MRU_3EE]_I_SC^\T]/;\LOCK]]'&/]N'[E.;?^W,P^+5?K1^];EK^
MG++[_3_G']YIZ>WY9?'7[Z.,?[</W*<V_P#;F8?%JOUH_>MRU_3EE]_I_P X
M_O-/3V_++XZ_?1QC_;A^Y3FW_MS,/BU7ZT?O6Y:_IRR^_P!/^<^YUMSGX<[C
MS6EUQJKDQIC8.>Y']4?J#B&)YY0W606_U(J7[ZT]PK(3JG7?=X461*=[4GVM
MMK6?@DQB\YY7\Q=.Y;4SG/<EO+2TH\/'5JT)PIPXYQA'BDTDN*<HQ6.^32Z3
M(97S T1GE_3RO)\UM;FXJ\7!3IUH2G+ABYRPBGB\(QE)]239M8-$-P  UQW!
MR_XN<?<C@8AN_?NJM593:TC&25M!G694^.VLZ@E3Y%7'N(T.Q<0M<=<B)*92
MZ1=IK:6GKU28W'3W+W7&K;.>8:9RFZOZ%.;IRJ4*,ZD8U%&,G!N*:4E&<6UO
MPDGTFL9WK726F[J-EG^8V]G6G%3C"K5C"3@W**DDVGPN49+'K3ZC%']YIZ>W
MY9?'7[Z.,?[<9[]RG-O_ &YF'Q:K]:8;]ZW+7].67W^G_./[S3T]ORR^.OWT
M<8_VX?N4YM_[<S#XM5^M'[UN6OZ<LOO]/^<?WFGI[?EE\=?OHXQ_MP_<IS;_
M -N9A\6J_6C]ZW+7].67W^G_ #C^\T]/;\LOCK]]'&/]N'[E.;?^W,P^+5?K
M1^];EK^G++[_ $_YSZ*C]0K@?D;R(U1S)XQR)+ADEJ*_N_75?*>4?L0Q&L;!
MI:U?Z*$F8\=URCYIV<>.XTYF2BM[5E<22\;C3:7FGJM^97+RZEPT<\L6WN3N
MJ,6_$I339L_B^98AG%<FXPO*\;R^I4:23:8O>5=_7*-1=R23-J77FCZEXE\X
M:3?9=F&65O>^94*EO4];5A*G+^K-)_0-LM+ZROZ7;V%:%>'KJ<XSCY\6T?2#
MQ'J          -0\VY^\)M;99?8)G_*?1V'YGBU@[4Y'C&0["Q^LNZ2S8(C>
M@V5?)>2XTZGJ7<A9$9=1T'+.5',O.;"EFN4Y%>W%M7BITZM.WJ2A.+W2C)+!
MI]:-+O\ F/H/*[RIEV8YO:T*]&7#.G.M",HR6]23>*?@/EO[S3T]ORR^.OWT
M<8_VX]W[E.;?^W,P^+5?K3Q_O6Y:_IRR^_T_YS9C4VZ-3;XQ56<Z8V)B.S\.
M3:3*162X5=PK^F*WKVVW9U:<^ I;?G-)>:4XCKU(EIZ^TAI>?Z;S_2U_^2]2
M6=6QN.%3[.M"5.?!+%1EPR2>#:>#\#-KR;/<FU#9_E#(KFG=T.)QXZ4E./$L
M,8XK%8K%8KPF31A#*@       !K-N_F9Q2XW>:UO'D#JS7-DTT3W\G+S+*U>
M8/,FCO)Z)A=<I^V>3T,C[F82B\2^B77==,\N->:RPEIC*;J\@WAVD*4NQ3ZG
M6DHTHOQS1JN?ZYT?I?%:@S*WM9K;P3J1[1KK5*.-1^9%D:^:_$+>FUBLAYBE
MS+:6QTM*4DI&%:JOHD=XT_*R>P%T2S(_81J07_H\1V;+>Z-SEOX*5S;6UGCT
M5KJ#:\?8*NOHG++_ +RG*ZSDXT*]Q=8=-*WFD_%VW9&+FOB5N CCQM+P/E%'
M1U27O+NO=;J9,C]JB2QF*W.A?+^Q]?H$8SDNYAS74>)766-]2N+C'Z-HE]$Q
M*[TW+ERP=O?KP]C0P^A<M_0,UX-\0!Z:.8/LQ[7:&<:Z<?42$'G.J\R-A*U'
MT2EZ5A<>Y:;(_P#/<6E!>U2B(:UFG=.YT9=%SH6-&\2^T75''S%6E1;\23?4
MC.Y?WCN5=[)1K7=6U;^VV]7#S7255+QMX=;)*],<J.-O(F-[QH[>>KMHN(9.
M1(K</S*DM;^ R1=35:XVT]]4(G0C(^DJ,V?3QZ=!QC4FA=9:0GP:GRNYL5C@
MI5J,XTY/Z6HUV<_Z,F=3R+5^EM31XM/YA0NWABXTZL)32^FACQQ_I11GP:H;
M&           !C/<6XM:Z UIE>X-P97#PG6^$0H]AD^3SHME.8K8TNP9JH9)
M@4S$F6^Z])D,1V6(T=QUQQ:4(0I1D0S6G=.YUJS.J&GM/4'<WEU)QI4XN,7)
MJ+D_*FXPBE&,I.4I**2;;2,5G>=Y5IS*JV=YW65O:VZ3J5&I-13:BMD5*3;D
MTDHIMMI)$<_]^5Z67Y5$3[T&_O\ PH.P_P ,///]!/XW8?\ NCF/[_\ E%^E
MU\6O/_;GTF&^LYZ:&?Y=B^"XKR>K)V3YGD--BN.P9>M-TTD6;>Y!8MU53$D7
M%[C<:%%0X^ZVA4B7(:9;(^YQQ""-1>/,>[CSIRG+Z^:7^22C0MJ<ZM22N;.;
M4*<7*;4(7$IR:BF^&$92>Y)O8>JQYY<J\QO:.7V>;1E5KSC3@G0NH)SG)1BG
M*=",8XMI8RDHK>VD2@#B!UD          UCVMS2XEZ+RQS ]Q\BM0ZSS-JOA
M6SF,9IF])0W:*RQ)1P)RJ^>ZAPFGB0KRU].A]#Z>P;MD/+?7VJ+!9KIW)[N]
MMG)Q[6C1G4AQ1]-'BBFL5BL5T&J9QKK1NG[S\G9YF=M:5U%2[.K5C"7#+<\&
M\<'AL,;?WFGI[?EE\=?OHXQ_MQF?W*<V_P#;F8?%JOUIBOWK<M?TY9??Z?\
M.9XTSR3T#R*8R"3HG<.O=MQ\4=K6,E>P')ZS)&Z)ZX0^Y5-6:JU:R95(3&D&
MT2^G<3:^GTIC5M1Z,U9H^5&&J<NN,O=PI.FJ].5/C4.'B<>)+'AXHXX;L5UF
MQ9%JG3FIHU9Z>O:-ZJ/"INC4C/@<L>'BX6\,>%X=>#,VC63/
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MVX?N4YM_[<S#XM5^M'[UN6OZ<LOO]/\ G']YIZ>WY9?'7[Z.,?[</W*<V_\
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MW<2ZS8,BU9IK4[JK3U]1O>PX>T[&I&?!Q\7#Q<+>'%PRPQWX/J,ZC5S8
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MWSYWLH_^:_$KDZ)HJ"+,@ *.GQ-7X\6G?S4L0_"]FPLZ[E/S8YC^M*OXI9D
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M.;%\[X<7]'C+^[_LOZS48JN[XOSO1^ 6WLZQ8?W8?FT?PRO[&D3W"*A(D
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M_K;E8KU[\?\ G]-_<[WV5J36[I/^3SWZNT]C<%KP0-)A
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M8YG_ (X?*_\ .5WK^%&U%Y/+CYO,A_5UE^+4BI'7/RVSCX==^[U#6H;F:J
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M---/!II[4T]C3VIDL83A5@JE-J49)--/%-/:FFMC36U-'DC\'Z
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M?5 _)0R/_G[4'_B$/XE.2'Z>I_>+O_VX_<1S9_0\_OUM^&']RCZH'Y*&1_\
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M"CZ=4MM/3,*:9-7R'WNI21^PS+Q&HT^^ERKG4X)66:1CZYT+7#QM*\;\Y-^
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M<4JLDOIHPDY1\U(U'.-+ZDT^\,]L+BSQV)UJ-2FGXG.*3\QLPN-D,$ !:9]
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M?I&^'OW9\>_:GAR3GS\SNHO@=3T4=)Y/?.=DGPJ'\ITM12\6G@
M  !1T^)J_'BT[^:EB'X7LV%G7<I^;',?UI5_%+,@'WJ_E_8_J^G^,W17.$PB
M,9:D^%V_K+Y>?8+J?Z_W0@KWX?S+I[[O=>YT27G=+_.N=?<K?V=4N,"NTFX
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MJPC6I-]-.HEQ1V[7%XPDUY<9+84,?4L]+_;?IXY[&.Q?D9]HK,;"0QK?;42
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M$1C+:7PM/[OYP?O/CC^W9T("]^7[#ICQYAZ%D3)[H_V3/_%9>C=ENH5^DSP
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M1?I&^'OW9\>_:GAR3GS\SNHO@=3T4=)Y/?.=DGPJ'\ITM12\6G@
M   !1T^)J_'BT[^:EB'X7LV%G7<I^;',?UI5_%+,@'WJ_E_8_J^G^,W17.$P
MB,9:D^%V_K+Y>?8+J?Z_W0@KWX?S+I[[O=>YT27G=+_.N=?<K?V=4N,"NTFX
M      !3&^()]-BFU3=-\W=)X\S585G>0M5.]\9J8J6:W',]NW3^I&PX46.7
M8Q%O'NZ-9D24H38FR[U6Y8+)%CO=+YS7.?6SY9ZEK.I<VM-SL:DWC*I0@O+M
MVWME*@O*I[VZ*E'8J*Q@UWD.5M#)ZZU[D-)0H7$U&[IQ6$85I>EK)+8HU7Y-
M3<E5X7M=1X5?!-\B89JXY;TS#C/O35N^<#?6UD^L,PJ\FB1R?7'9MX$=PX][
MC<YULC446T@.2:Z61%U-E]PB\3&M:QTOEVM=+WVE<U6-"^HRIMX8N$FL85(K
MUU*HHU(?311GM,:@O=*Z@M-19<\*MI4C42QP4DMDX/Z6I!RA+Z63.H[K;8&-
M;8UW@FT,,F?5#$=C8?C><8S-,DI5*H<JIV;RJ><0DS)*S8?1WHZGVJZD?B0H
MZSG*;W(<WNLCS*/!<6=:I1J1ZITIN$EXN*+P?2MI;7E>96N<99;YM8RXJ-U3
MA5IOKA4BIQ?G-8GVHQI[P .:5ZKOZ1OF%]V?(?VID70\AOF=T[\#I^BRK#G#
M\YV=_"I_R$? ZV<V+YWPXOZ/&7]W_9?UFHQ5=WQ?G>C\ MO9UBP_NP_-H_AE
M?V-(GN$5"1( %5/XF/E1*HL/TWP^QJR7'=SAQ>X]H,,/&VX_C%#/=H]=T\I"
M3,G(TNT:LISB%D7:]715EU^2=O<LT+3NLQS'F'>PQ5JO>ELVMU6<5.XFNJ4:
M3IP36^-::(@]ZK5\[>RL=$VL\'<?XFND]].#<*,7UQE44YM>NI093O%AY"4S
M5QST1FW)S>.L="Z[CD_ENSLJ@XY ><;6Y%J8:R5,O<CL4-F2O=*N U*L9AH^
M<3+#AI(U="/6M8:IRS1.F+W56</"WLJ4JDDMCF]T*<>CCJS<:<,=G%)8[#/:
M8T]?ZKS^TT[EBQK7=103Z(K?.<OI:<%*<OI8LZ;'&/CEK;B=I# M#ZIK$P,4
MP:G:AJF.-,HM,EO'B\^^R[('F2(G9]E*-R5)7]*DU$VTE#+;:$TI:VUCG.O=
M3W>JL^GQU[J;>&+X:<%LA2II[H4XX1BM[PXI8R;;M8TIIC*]'9!;:>R>'#1M
MXX8[.*<WMG4FUOG.6,I/<L<%A%)+/0U4V(      #T-_BV,96S6Q\IQRBR1B
MFO*G)Z=F^J(%PU59)02BG4605K=@VX3$Z$^DGHDMHDNM+(E-J2KQ'JM+Z]L)
M3G8UIT74A.G-PG*#E3J+AG3EPM<4)QV2B\8R6QIH\]S:6EY&$;NE"JJ<XU(J
M<5+AG!XPG'%/"<7MC);8O:FCWP\IZ       'L '-Q]6WEM_;$YO;3SJFL_J
MCKC!I1:FU0IIWS83V%X1+?C.7D%1'T4U<6;EA<-*-)*\J2VA7^K(7*<@= ?N
M[Y96.5W,."\NE[ZNL5@U6K*+X)>&C35.DUNXH-K>5=\YM9_MMKZ\S"A/BM;=
M^][?;BG2I-KC7@J5'.HNG":3W$:([0<K+^/H"\3/[//">MVAD-9[GL+D]/B;
M,LEOL^7-BZ\B1W(&K*E:NGSFG8;DF\9/V]+,TG]+T*J+O7Z^_:[F7/([2?%:
M9)%VT<'L=PVI74O&IJ-%_<,>DL9[N>C?V:T'#-KF'#<YLU7EBMJHI-6\?$XN
M55?=<.@KI>OIQ*_LZ\V;;9>/5GN>N^3L*7M"I6PSY<*)L!B0B%M2H0KH7<ZN
M<Y'NW>G@16:4E]*9%,'NI:__ &PY:4\EO)\5YDDE;3Q>,G0:;M9^)04J*^X-
M])&3O%Z-_9G7D\UMH<-MFR=>."V*LFE<1\;FU5?W5+H(.Q)PX"6^_AHN6_O]
M'MCAAE5GUDT+C^Y=2MRGNJE4]@^Q4;(QR'YAD1)CRUU]HQ';ZJ4<J>Z9$EM1
MBO?OHZ [*ZL.9%A#R:N%G=8+U<5*=O4>'KH*I2E)[%P4H[VB:G=7UGVEO>:%
MO)[:>-S;XOU+:C7@O%)PJ)+:^.I+H+8(@63$       H,_$3_I&[;[C&K?VF
M<+6>Z!\SM/X9<^C KJ[S/SGS^#6_H2(*1*,CX7 /A;_YI\S_ +(M%_6W*Q7K
MWX_\_IO[G>^RM2:W=)_R>>_5VGL;@M>"!I,(                    H8?$
M*<JY6[N9ZM)TMDM_ .,E*C$6HS+QKA3-E9-'CWNP+7M(R+S(Z?J?2K2HNJ'(
M+W:?1P^MJ/='T)3TSRW_ &EN887>=S[5MKRE;4W*%"'BE[9636]58X[BO#O*
M:PGG^N?R#0GC;93'L\$]CKS2G6EXUY%)]3IRPWD"0E61V))/2MX,R^>7*S&=
M<W#4YC4N&1_Y?[GMX:G&'&\,JI;;+.-0IJ33Y<R[EK9KF5)7YC32Y$I"5^ZJ
M2.-<]>9]/E7H.OG%NXO,+E]A9P>#]NDFW4:Z848)U'BL)24*;:XTSJ7*'E_/
MF'K"EEE=-65!=M=26SVJ+24$^B5634%TI.4TGP,Z0&/8]18E0TN+8Q45V/XW
MC=37T5!15$1B!54U-4Q$0:RKK8,8DMLL1V6T---(224I21$1$0IPN[NZO[JK
M?7U256M6E*=2<VY2G.;<I2E)[7*3;;;VMLL_MK:WL[>G:6D(TZ5**A"$4E&,
M8K",8I;$DDDDMR/<#SGW               .6QS/_'#Y7_G*[U_"C:B\GEQ\
MWF0_JZR_%J14CKGY;9Q\.N_=ZAK4-S-5.B#Z#_Z++C5^_-U_A]R@5#=Z;Y\\
MZ\5G^(VQ9?W>OFBRKQW7XY7)>Q'P[2     :C<^\!I]G<(^5^%WD=F1#L] ;
M2F1O/2E;<6[Q_$961XU9]JO#NAV,2+*1_I-EXE[1T#E1FMQDG,S(<RM6U*%_
M;)X=,*E6-.I'^G3G*+\#-,YC9=0S;06<6%PDXSL[AK'HG"G*<)?T9QC)>%'+
M\%WA4T !U+^'EI+O.(_%J[L%K<GW''+2%I-<<Z^8N78:SK)<E:^ORFM:C,4:
M<PZ%.UY@9[;4MD*>87L8^*-S42^@BW'1-:=QHS*+BIME.RM9/QRH4V_HLV-&
MG&SD'OK[\K9?';A#9Z^QBR7 SSDO<.ZK@.1W3:FP\";A?5/9]DR9=.K;L(V*
M1XO:2;,E)Z&GJ4G.ZCH.GJ_F;#-KV'':Y+!74L5C%U\>&VB_"I\59>&C@]YP
M+O&:PGIG0,\MM)\-QFLO>ZPWJCAQ5Y+P..%)_=<2@*+8"N0]M04-SE-[2XQC
ME;+N<AR.VKJ&BIZ]E4B?;7-O,17U=;"81XK>??<0TV@O$U*(B]H\]W=6UC:U
M;V\FJ=&C"4YSD\(QA!.4I2?0HQ3;?0D?:VMZ]W<4[2U@ZE6K*,(12Q<I2:48
MI=+;:276=)_TT^"N)<">-.,:UAQ*^5M#)8T#*MVYA'0V[)R//94,CD5C$XB[
MEUE,2U5]4V7:CRTKDFA+\J0I=,W.CFCF'-76E?.JDI1L:+E2LZ+V*G03V2<>
MBI6P52J]KQ:ABXP@E:3RKY?67+O2M+*H13NZJ52ZJ+?.LUMBG]KI8\%-;%@G
M+#BG+&0<<D.D@      87Y"Z"UKR>T[G.CMMT;=[A&>TSU7/:[6DSZJ8DR?J
M<CHI3J5^[V%=)2U,A2"2?8ZVDS)2>Y*MDTCJO.M$:BM=3Z?JNE=6LU*+V\,E
MNG3FDUQ4ZD6X3CTQ;W/!K!:ETYE6K,DN,@SFGVEO<1<7UQ>^,X/;PSA+"47T
M-+>L4<S+E?QOS;B1R#V?Q]S])N7FO,B>KXENB.N-#R?&YC:;+%LLKFEFKM8L
MJ]Z/+0CO4;9K-I9^8VLBNIT'K++-?Z2L=6Y3LI7E-2<,<72J+R:M*3]=3J*4
M&\$I8*2V-%56L-+W^C-27>F\QVU+:;2EA@JD'Y5.I'P3@XR2QV8X/:F:\#;S
M62U1\,]RIE5&=;@X>Y'9+.FRZJ7N/6D>0ZKRHF4T!1Z3/:F$E1GU785RH$XD
M$1)2FN?7],X?6"G?3T+3N,KR[F'9P]LMY>]+EI;72J<4Z$GX*=13ACO;K16Y
M$O>ZMJ^=',+W1-U+VNM'WS03Z*D,(UHKPSAP3PW+LI/>RXH*[B;8 %*+XG;\
M:;CS]P!_\(ML+*NY+\ALW^'K\7I$$.]?\KLL^!OW:H5H!-(BL6=OA@OQA^3'
MW&,<^WAH0E[[GR0R7X94]Q9*_NG?*;-?@L/=471A6Z3I       B$]>#]%ER
M5_?FE/P^XN)!]UGY\\E\5Y^(W)Q;O"_-%FOCM?QR@<[X6\E:!LKPP_'#XH?G
M*Z*_"C5#3.8_S>9]^KKW\6JFU:&^6V3_  ZT]WIG4G%&Q;< !HUZFGZ/;F7^
M;KM'[6'QT_DI\[>G/UA;>ZQ.?\UOFUSSX%7]S9S*!=:53@ =;"O_ '!!_><;
M]I2*!ZWV:?C?HERM/[''Q+T#S!\S]@  !XTR'$L8<NOL(L>; G1GX<V'+9;D
M19<24T;$F+)8=(TK;<0I2%H41D9&9&70Q^Z=2I1J1K4I.,XM.+3P::>*::VI
MI[4S\3A"K!TZB4HR333VII[&FNE-;SE>\G-;0M-\D>0.HZPE?4S5^Z]IZ^JS
M6M3BE5F'9Q.QZO6;BO%7<S'0KN/Q/KU,7I:)SFKJ+1N4Z@K^GOK.UN)?55J$
M*DOHR945JO*Z>1ZHS+):7I+2ZN*,?J:56<(_0BC!PV<U\Z 7P]V3RK_TU<"J
MY#IN-85LO;.,04F9GY,65E*LQ4UX_P#VULZOP_SA4YWM[*G:<Y[JO!8.YMK6
MI+PM4E1Q\ZDEYA8[W;+N=SRLMZ,GBJ%>XIKP)U.U]&HR;H1F.]@
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M@?,[3^&7/HP*ZN\S\Y\_@UOZ$B"D2C(^%P#X6_\ FGS/^R+1?UMRL5Z]^/\
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M6=OA@OQA^3'W&,<^WAH0E[[GR0R7X94]Q9*_NG?*;-?@L/=471A6Z3I
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MKM:TUA[XK7%1>)5'2_\ TWZ)-@(U'>              I1?$[?C3<>?N /\
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M5;BHWXWQKS$BPGNNVL*'+BK72VU[VM)OZFG1@EXEPOS6RP((F$CP
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M8+H2)I<CM4Y[K#0=/.M1U_?%S*M6@Y\%.GY,&E%<-*$(;.OAQ?2V2LCA!V
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M"(QEM+X6G]W\X/WGQQ_;LZ$!>_+]ATQX\P]"R)D]T?[)G_BLO1NRW4*_29X
M',!]06\D9'SMYDVTA:EJ>Y/[TC,FL^JDP:W95E65S1]?\R.RTC_(+NN4MK"S
MY6Z<MX;,,MLF_JI6U.4GYLFV5.<R+B5US"SRM+IO[M+Q1KSC'SDDC4$="-*+
MMWPQV-18O$/?&8(;(IM[R/FXW(=Z%U<B8IK+'K.&CK[>B5W,@RZ^'SCZ?**S
M^^Q>SJ<P<JRYOR:67*HEX:MS<1?GJC'SB>G=1M80T7F-ZEY52]<'XJ="C)?1
MJLLG"&9*0                     #_T;_  J%?%)__ ![A/_\ *.0/_OF&
MBP;N-_Y74OU=AZ%X0M[V_P#F,A^IO/1MBIP)[$.2Q[\,E^.ENO\ ->R'\*^)
M"'/?7^;;+?UG3_%;LD_W4_EW?_ )_C%L7?Q623Y(3?6T].M/-'CZK9&MZ1,K
MD5HFML[K#VX3!'8[ PDB.?E&MEFT7>\^HDJGTB#)1E,2N.V2"GO+*2W=HYP/
MEOJW\C9S5X<GS2485G)^30K>EI7&W8H[>"L]GM;4WCV44<&Y\\LEKK3?Y4RN
MGCF>7QE*E@O*K4M]2AUM^KI+;Y:<5AVDF<_925(4I"TJ0M"C2I*B-*DJ2?12
M5)/Q(R/P,C%LR::Q17"TT\&?X!_#R84*993(E=71)5A86$IB% @0F'94R;,E
M.DQ%B1(K!*6XZXM24-MH2:E*,B(C,Q^*M6G1IRK5I*$()RE*3244EBVV]B26
MUM[$C]TZ<ZLXTJ47*4FDDEBVWL226UMO8DMYT2/1^]/2%P0XWQ',OK8W]H/<
M#%7E>W[ R:=D8^E+"G<;UG#DM]2\BE:?<][4A2DNSW93B5K9*.2*A.\+S<J<
MT]9267S?Y(RYRI6D=J53;A4N6O75G%<&*3C2C!-*7'C9AR4Y:T^7NEXN]BOR
ME>J-2YELQAL\B@GU4DWQ88IU'-IN/#A+6. G92B]\2[^/MK;\U/ /PJ9L+0N
MY=\U5Y^M*_XK9E?O>H^<2U_5]'\8NBO()=$:2UW\+?\ SMYG?8YHSZYY4(&]
M^/\ -^F_NE[[&U)A]TG_ #F>_46GLK@N BO4FJ ! C\1U^CQB?=_UI]9KP2K
M[G7SO2^ 7/LZ)';O/?-HOAE#V-4H8BU$KP/?8MBF49SD-1B.%8W?YAE=_,;K
MJ'&,6I['(,AN[!TC-J#44M2V])DO*Z'VM,M*4?3P(>2^O['*[2IF&95J=O0I
M+BG4JSC3IPBM\ISFU&*76VD>FTL[O,+F%E84IUZU1\,*=.,ISDWT1C%.4GX$
MFS8W^PCSA_(UY6?^7C;O\3C3_P!Z7++_ ''E?Q^T_"FS_N]U_P#H/,/B5S^#
M']A'G#^1KRL_\O&W?XG#]Z7++_<>5_'[3\*/W>Z__0>8?$KG\&/["/.'\C7E
M9_Y>-N_Q.'[TN67^X\K^/VGX4?N]U_\ H/,/B5S^#']A'G#^1KRL_P#+QMW^
M)P_>ERR_W'E?Q^T_"C]WNO\ ]!YA\2N?P8_L(\X?R->5G_EXV[_$X?O2Y9?[
MCROX_:?A1^[W7_Z#S#XE<_@S[/77!KFQ"V#@DR9P]Y2Q(D3,L8DRI4GC[MEB
M-&C,7;#K\B0^[4$E"$)(U+6HR(B(S,^@QV<<S^6M3*+JG3U#EDI2HU4DK^U;
M;<))))5<6V]R/=EG+_7E/,K><\DOXQC5IMMV=PDDIK%M]GL2.F\*3RUH   *
M.GQ-7X\6G?S4L0_"]FPLZ[E/S8YC^M*OXI9D ^]7\O[']7T_QFZ*YPF$1C+4
MGPNW]9?+S[!=3_7^Z$%>_#^9=/?=[KW.B2\[I?YUSK[E;^SJEQ@5VDW
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MD;MON,:M_:9PM9[H'S.T_AESZ,"NKO,_.?/X-;^A(@I$HR/A< ^%O_FGS/\
MLBT7];<K%>O?C_S^F_N=[[*U)K=TG_)Y[]7:>QN"UX(&DP@
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ML7-?N[\H+BPJ0U_J:DX5'%^\Z,UA**DL'<3B]J;BVJ*>W!NIAMILM;B!Q,$
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M*+G57]&O4JQ?A197W>LBGDG*^RG5CPU+V52ZDO!4?#3?]*C3IR\TF)$=SMH
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M"%:$(+PUB5?=7U/3L-27NEKB6"OZ<:E+'IJT.)RBO#*E.4GX*1=7%:Y.T
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MS\1/^D;MON,:M_:9PM9[H'S.T_AESZ,"NKO,_.?/X-;^A(@I$HR/A< ^%O\
MYI\S_LBT7];<K%>O?C_S^F_N=[[*U)K=TG_)Y[]7:>QN"UX(&DP@
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M'@_1O8U]US:OUT8%47>\^>2O\$M?8R+&>[1\U]+X1<>R1.6(P'?P .6QS/\
MQP^5_P"<KO7\*-J+R>7'S>9#^KK+\6I%2.N?EMG'PZ[]WJ&M0W,U4V[U;P&Y
MF[MP:EV9J7C;M78& 9$JR11Y;C.-/V%+:*I[5^BM$PY:#(E>1,C2([GT%MJ+
MY!S[/>:W+C3.:5,ES_.;6TNZ/#QTJE11G'CC&<<5T<4)1DO T;IE'+K7.?9?
M3S7)LKN+FVJ\7!4A!N,N&3A+!^"47%^%,R#_ '6'J*_D=;S_ .3I7_K#$_OT
MY/\ ^XK+[\C)?NBYF_H2[^],_ASTM/43:;6ZOAUO7L;0IQ79A4UQ?:A/<KM;
M;,U*/I[$I(S/V$74?V///E!)J*U%9;?^\E]%G\?*/F8EB\DN]G_:9H4\R]&>
M=CR&G8\B.ZXR^P\VMIYEYI9H=:=:61*2I*B,E),B,C+H8ZI&49Q4X---8IK:
MFGN:?2F<\E&4).,E@UL:>]/J9^8_1^2T7Z'7I_>G=RYU[:[#VBQE^S=Z:UO_
M '7.].97DC-7K^I@2Y3DC#<MJJ3&FHDZS@S6FU-/IL)[K!267V'8IM>6X_![
MO.\V>;_+_-Z>49&Z5EE=[#&A=TJ;E7G))*M2E.HYPIS@VG'LZ<9<$HSC/BXE
M"6O('EORSUGEL\SS95+O,+6>%6VJ34:,4VW2J1A!1G4A)+!\<W'CC*+AA@Y7
M#\3Q#%,"QRHP_!L9Q_#<2H(;=?18QBU/7X_C]-!:,S;AU=/5-M1X[1&9F2&F
MTEU,SZ>(KPO\PO\ -;RIF.:5ZES<57Q3J59RJ5)R?3*<FY2?A;9-JSLK/+K6
M%EE]*%"C36$*=.,80BNJ,8I12\"1]$/&>D   *-_Q*FGI.'<RM<[=CQ5-TNY
M].UL9V8:#),G,-:V[U%=LI7TZ'Y57*H#]O4N_P 2Z=.MGG<QU%#,>7-YI^<L
M:F6W<FEU4KF"G!^;5C7\[QD N]+DDK'7%KG45A3OK:*;ZZE"3A->93E1\\KI
MB8!&0F%]##DC"X[>H+KB/?SVZ[$-YU5IHK()4A?;'C3LPE1;'!GU$KH@E+R&
M!5PS=49>6U(=5U[>XCCQWH-&U-7\I;R=I!SN,KE&^II;W&BI1KKKV6]2K/#I
ME"*WX';.[]JBGIGF1:QN9<-#,(RM)M[DZCC*D_-K0IQQZ%)G0W%1198
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MGG',KZ&$HPX<+:E);G&,MM62>Z=1**V-4U)*18,$2B2(
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M7R"XEPT\THX1\-:AQ3@NK;3E62ZY.*6UEZ 5?%@0
M '__T[_  J%?%)__ ![A/_\ *.0/_OF&BP;N-_Y74OU=AZ%X0M[V_P#F,A^I
MO/1MBIP)[$.2Q[\,E^.ENO\ ->R'\*^)"'/?7^;;+?UG3_%;LD_W4_EW?_ )
M_C%L7?Q623Y  Q#OO1^O>26GM@:.VG4)NL&V-C\JAN8Y>6F7#6X92*R[J7W4
MK)F=7RVV)T%_M/RGVFU]#[>A[!I74^;Z,U%::GR*IV=U9U%4@^A]$H32PQA4
MBY0G''RH2:Z3"ZBR#+=4Y)<Y!F\.TM[J#A)=*Z8SB]N$X22G!]$DF4"<)]([
M?-]ZBLO@?=L384?&[<\ERS:,2N<33-:&;DH?9VE5D]WMF=A&<:AP8REJ)-HZ
M4%Y:5-/J;M?S/O :5M>3\>:=LU)UH=G2MG+RW?--.VEA@_:Y)SG+!8T(]K%-
M2BG7+8<F=17',V7+RNG%4I<=2NH^3[TQQ5Q'>O+BU&$<7A5?9R::DUT%]7:R
MPC3&NL+U1K>BBXS@NO\ ':S%\7I(9?L<*JJHY1V?-=5\]Y]PR-Z3(=,W'G5K
M=<4IQ:E'4KGF=YGJ3.+G/LYJNO=7=256K-[Y2D\7@MRBMT8K!1BE&*2219'E
M&56&1990R?*Z:I6]M"-.G!=$8K!>-O?*3VRDVVVVV?>C%&1  HO?$N_C[:V_
M-3P#\*F;"T+N7?-5>?K2O^*V97[WJ/G$M?U?1_&+HKR"71&DM=_"W_SMYG?8
MYHSZYY4(&]^/\WZ;^Z7OL;4F'W2?\YGOU%I[*X+@(KU)J@ 0(_$=?H\8GW?]
M:?6:\$J^YU\[TO@%S[.B1V[SWS:+X90]C5*&(M1*\"0?THOTC?#W[L^/?M3P
MY)SY^9W47P.IZ*.D\GOG.R3X5#^4Z6HI>+3P             HZ?$U?CQ:=_
M-2Q#\+V;"SKN4_-CF/ZTJ_BEF0#[U?R_L?U?3_&;HKG"81&,M2?"[?UE\O/L
M%U/]?[H05[\/YET]]WNO<Z)+SNE_G7.ON5O[.J7&!7:3<       I,^OIZF=
M+OS*(W#W1F0LV^J=:Y%]5=L9=422=J\]V14FN+!QJIEL'VR:JA4IU3SI*4U)
MGF2D$:(+#[UEO=2Y*W.E+&7,/5%%T[^]I\-K2FL)4+>>#E4DGZ6K7V8+9*%+
M8WC5E&,#>\7S5H:BNUHG3]53L[6?%<5(OR:U>.*4(M>FIT=N+W3J;5LIQE*M
M2)GD639/B#QNRKEQR1U-Q^Q)$E$O8.50X-U:QV?.+&L/A=;/,LI?)1&GMKZQ
MF5)2E?0G%I0T75;B2/3.86LK'E_HV_U;?M.-I2<H1;P[2M+R:-)=/ME1QCLW
M)N6Y,VG16E[S6>J+/3=GCC<U$I22])37E5:C^HIJ4O"TEO:.H1B.*T."XIC&
M$8K7,U&,8=CU+BN.5,<C*/64./5K513US!'X]C$=EMM/7Y$D*0<PO[K-+^OF
M=]-U*]S4G5J2>^4ZDG.<GX7)MOQELUE9V^7V=*PLXJ%*A"-.$5NC"$5&,5X%
M%)'T(\AZ0 .:5ZKOZ1OF%]V?(?VID70\AOF=T[\#I^BRK#G#\YV=_"I_R$?
MZV<V+YWPXOZ/&7]W_9?UFHQ5=WQ?G>C\ MO9UBP_NP_-H_AE?V-(GN$5"1(
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M-*4I0X9'=WWFG^Q^=?LQG53#+;^:X92?DV]P\(QGB]BIU-D*G0GP3;2C/&^
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M_K-1BJ[OB_.]'X!;>SK%A_=A^;1_#*_L:1/<(J$B0   CA]2GTY];>H9IO\
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M:=@7=YYI_M5E'[(YW4QS"Q@NSE)[:]O'!)XO?4I;(SZ90X9^4^-JPT(BDE@
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MW-G,H%UI5. !UL*_]P0?WG&_:4B@>M]FGXWZ)<K3^QQ\2] \P?,_8
M 4@/B;?QTM*?FO8]^%?+19MW*/FVS+]9U/Q6T(#=ZSY=V'P"'XQ<E<(3&(P$
MR'H'?I0=$_8[N7\#]V(Z=ZSYD,T^Z6?XW1.X=W7YV<O^HN?Q:J="P5'%E
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ME^.ENO\ ->R'\*^)"'/?7^;;+?UG3_%;LD_W4_EW?_ )_C%L7?Q623Y
M     *+WQ+OX^VMOS4\ _"IFPM"[EWS57GZTK_BMF5^]ZCYQ+7]7T?QBZ*\@
MET1I+7?PM_\ .WF=]CFC/KGE0@;WX_S?IO[I>^QM28?=)_SF>_46GLK@N BO
M4FJ ! C\1U^CQB?=_P!:?6:\$J^YU\[TO@%S[.B1V[SWS:+X90]C5*&(M1*\
M            -\/2^_2'<-_N_P"O?KR@<LYW_-#J/X!<>P9T/E-\Y>1_#*/L
MD=,P4K%JH %'3XFK\>+3OYJ6(?A>S86==RGYL<Q_6E7\4LR ?>K^7]C^KZ?X
MS=%<X3"(Q@      9EU;QTW]N^6S"T[I7:FSWWG2:)6"X'DV316C-7:I<N=4
MQG6&&T^U;KSB4)+Q4HB+J-<SS6&D],4W5U%F5K8I+'V^O3IM^*,Y*4GU))M]
M",YE&F-1Y_-4\DL+B[;^U4:E1>:XQ:2ZVVDNDF@XR_#J<S=MR:^UWK8XEQJP
MUU3;LIFYFPL^V._%7T6E5?B&*2506C4GJ2DV-S&=:,R[F%'U24;]:]\#EQD$
M)T-+PJYU<K%)P3H6Z?TU6K'C?@[.C.,NB2WG=-*=V77.<SC6U!*GE5![U)JM
M7:\%.G+@7].K!KUKW%J'A/Z6_$K@I$8LM786YDVT%Q%1;/<NP50[_/Y"7VC;
MF1J20AEJ)317"4I"H]5&8-QOM3)<D*22Q!;F7SQU_P T:CHYY<]A8XXQLZ&-
M.@L'L<UBY5I+>I592X7BX*">!+O0?*31O+Z"JY10[6[PPE<UL)UGCO47@HTH
MO=A3C'%8*;EAB2+#CYTT      #FE>J[^D;YA?=GR']J9%T/(;YG=._ Z?HL
MJPYP_.=G?PJ?\A'P.MG-B^=\.+^CQE_=_P!E_6:C%5W?%^=Z/P"V]G6+#^[#
M\VC^&5_8TB>X14)$@    &IW+KA-QWYNZ^/7V^\(8O$0DR7,5S&J6W4Y[@EA
M*027+'$<F0VMQ@U&EM3\1Y#L21V(*3'>2A)%OO+_ )EZOY99O^5M*7+I<6"J
MT9>70KQ6Z-6GBE+#%\,DXU(8O@G%MFG:TT'IG7N6_DW45NJG#CV=6/DUJ3?J
MJ<\&UT8Q:<)8+CC+!%.#F9\/YRWX_3+;)M#1E<GM6M+?DQBQ*&F#MJFA$9K1
M'N->+<6NQ6DC2VEVA=E./&1N*B1DGV%8KRX[V6@-6TZ=EJJ7Y$OG@GVKXK6;
MZX7&"5-/>U75-1V)5)O:0AUSW<-9Z;G.[TZORM:+%KLUA<175*CCC-]&-%S<
MM[A!;""O(,=R#$[B?CN545SC.053ZHMI19!63::XK9*/%4>?66*&WV7"^5#B
M"/\ 4$HK2\M+^WA>6%6%>C46,9TY1G"2ZXRBW%KPID?;FVN;.O*VO*<J52#P
ME"<7&47U.,DFGX&CTX]!\    RKJ/1FY=]Y,SAVE=7YUM')75-$NJPC&K7('
M8;;R^Q,NT>@-K:AQR\37)E+;:01&I:TI(S+!:@U1IS2ED\QU+?4+&BL?*K5(
MTT\.B*DTYRZHQ3D]R39F,FT_GFHKI6.16E6[JOU-*$IX8],FDU&/7*3272RS
M#P6^'!R:SFTVP>=F0L8]2,KCSF]"Z_NVIV0V?:9.>XY[L"J4J+!:,R['HM$[
M(=<0KJBPBN)Z"%G-'OC65"G4RGE;1=:J\8^_J\'&G'Z:A0DE*;Z5*NH136VE
M43)4\ON[!=U:D,RYA552IK!^]*,L9R\%:M'R8+KC2<FT]E2#+:6N]<X'J3"\
M?UUK+$:#!<&Q6 W6X_BV,UL:JIZN(@S6I+$2,DB-;BS4Z\\OJXZXI3CBEN*4
MHX"YOG&:Y_F5;.,[N*EU=5Y<52K4DY3D_"WT);$ELBDDDDDB9.699EV36-/+
M,JHPM[>BN&%.G%1C%>!+I;VM[VVVVVVS[08T]Q"MZ[_+?^S1P@R3"\>L_<MD
M\DY$O4>-)8>\N;#Q"5#*1M*^;21I4;:*I95)N(42FWK*.X77M,23[K.@/VTY
MFT<RNX<5EDR5W4Q7DNJGA;4_&ZJ[7!['&C-=)PGO"ZS_ &5T#5L;:?#=9HW;
M0P>U4VL;B?B5-]GBMJE5BSGV"VDK=-E.'O'2^Y9<F=-\?<?]Y:=V/F=?6W5C
M%03CM%AT$E7&;Y$E*B-)G7U$>;+2E7@M3:4>U1#3.8>L+30.BLQU;=X-6=&4
MH1>Z=:6$*-/_ ,RK*$'AN3;Z#:=$Z8N-8ZJL=-VV*=U54926^%->55G_ $*<
M92\+6'2=0K%<8H<(Q?&\,Q6MCTN,8C0T^,8Y3PTFB)4T-!7MU516Q4'UZ-L1
MVFVD%U]B2%(-_?769WU;,KZ;J5[B<ZE2;WRG4DY3D_#*3;?C+9[.TM["TI6-
MG!4Z5&$:<(K=&$(J,8KP)))'OAY#T        !"-Z]W%#^T7P>OM@4%;[YL+
MC-.D;7I5LL^9,DX.45,':=0A?0S2R5:ENZ=(BZJ56-)(_$^LF>ZIKW]C^9U+
M*;N?#:9U%6L\7L5;'BM9^/M,:*ZE7DS@G>)T=^T^@:F96T.*YRINXC@MKI88
M7$?%P857UNDD<_P6QE<1F/CUNO*^..\-6;UPATT9+J[-*3+H+!O+89M&*Z61
MVM!-<;(U>[6,-3\"41%U-EY9?*-=U=IJPUCIB^TOF:]IOJ,Z4GABXN2\FI'Z
M:G/AG'Z:*9G--9]>:7S^SU!8/VVTJPJ);E)1?E0?TLXXPE]+)G4:U3LO%-S:
MRP#;6"SBLL.V3B&/YKC<SYA..5&1UC=I#1);0:O+?;2Z3<AHS[FW$J0KHI)D
M*.\^R6_TYG5WD&:0X+BRJU*-1=''3DXO#KBVL8O<TTUL9;5D^:V>>95;9SE\
MN.A=4X58/Z6<5)8]36.#70TT]J/OQB3)%!GXB?\ 2-VWW&-6_M,X6L]T#YG:
M?PRY]&!75WF?G/G\&M_0D04B49'P          S]Q0_&EXU_=^TY^$2N&J:\
M^0V=? ;O\7J&QZ/^5V5?#+;W:!U/A1<6Z@            !$QZ@GH^<:.>*)
MV92&%Z?WV<4FXNW\-K(KRKYQAHF8D?9&+FMAF[:0DDH1(\Z/.0A+;:)GD(\D
M^^<I>\-K3E8XY=!_E'*L=MI6DUP8O%NWJX2E1;>+<<)TFVVZ?$^(XWS(Y*:5
MYAJ5])>\LQPV7-**?'@L$J]/%*JDMBEC&HDDE/A7"4]>6'HY\Z.)TNSL+G55
MAMC74)3SC&S=,QY^;T10&S[O>[VCALE<5)(0:?/<L*]N.E1FEN0\1=QV':"[
MQ/*_7M.%&VOXV%Y+#&VO'&C/BZH3;[&KB_2JG4<VMKA'<0GUCR1Y@Z.G.I7L
MW>6T<<*]LG5AAUS@EVE/!;W."CCL4I;R+9:%MK6VXA3;C:E(<;6DTK0M)]JD
M+2KQ(R/P,C'<4U)8K:F<D::>#WG\C^G\   #,6G>/>\^0E\G&=(:DV!M.Y\U
MIJ1'PG%[:]CUOFG\QZZL8;2HT%GQZJ?F/--I+Q4LB&NZBU=I?2-K[]U/F%"Q
MIX-IUJL(.6'1"+?%-_2P4I/H1G,DTUJ#4MQ[UR"RK7D^E4J<IJ./3*27#!>&
M32766(N'7PVFU<NDU66\SL[B:KQKN9E/ZJUQ85F3[%GMD9*7 N\P04BDJ>OR
MJ@_512D]4_L"NBBB%S$[Y>0Y?"IE_+BU=]6VI75Q&5*WC]-"EY-:KXI]@D]O
ME+827T1W7,XO90O=<W"LZ6QNWH.-2L_!*IMI4_Z':M[O)>TM@<>.,FB>*> Q
M=::"UOC^N\59-IZ:W5,./6^06#37D_5C*LAG*=G6<PT_-]YG2'%I3T0@TMI2
M@H%ZOUMJG7F;2SK5=Y4O*[Q2XGA"G%O'@I4XX0IP^EA&*;VO%MLF)IK2FGM'
MY<LJTY:PMJ*VOA6,IO=Q5)O&=27TTVWAL6"P1G@:L;"   '+8YG_ (X?*_\
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M3DMO"VMJ2PC3@L$NMOIE)[Y2DW*3VR;;Q,C##F3  YG_ *I_Z17F+]W/,?\
MWI(NEY%_,_IWX%1] JMYN_.;G?PNKZ)H&.KG.2V]\+-__'5__K'_ /O"$ >_
M-_\ NO\ _P!R_P#V F9W1O\ ]X/_ )'_ /;"V\( DS#_U[_  QQGVG-1;675
MN;1U7KC9+E&F8BE7GV#XQF*Z=%B;2K!%6K(HLDXY/FPR;Q-=O?Y:.[KVIZ9G
M*=1:@R%5%D=_<62JX<?85JE'CX<>'B[.4>+AXGACCAB\-[,7F.1Y+G#@\WLZ
M%TZ>/#VU*G5X>+#'AXXRPQP6.&&."QW&//[('$O\EWCK]Y/6G\6#+_O#U_\
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MO3N:5_?69V%M<U<$N.K0I5)8+<N*<6\%T+'8?)_V0.)?Y+O'7[R>M/XL'O\
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M"#]BM&_HBR^*T/P9L21$DB2DB2E)$24D1$1$1="(B+Y!I[;;Q9L^[8C_ $
M       &*\ZT5I':-I%N]F:<U7L6Z@P$54*WSK7N(Y=:0ZMN0Y+;K8L_((<A
MUN.EUYYU+*%D@EK6HBZJ49YW*]4:FR.A*VR3,;JSIREQ2A0N*M*+E@EQ.-.<
M4Y8)+%K'!);DC$9AI[(,WK*XS6QM[JI%<*E5HTZDE'%OA3G%M+%MX)X8MOI.
M>YZS$W4[GJ);YH=+XYB&+X3@SN'X(JLP6DI\>QQ&48SAL&'FC<:JHVF8[;L>
MU.7"E=K9&;S+AJZF?4[;N[E2SY<H,JNM25JM>YNE6K\5><ZE3LJE:;HXRFW)
MJ5+@G';LC)8%;//&ID[YF9C;Y%2IT;>W[.EPTH1A#M(4H*KA&"2353BC+9Z:
M+-L_AQ-<3LMY^V&;)C+.KU3I3.[^3--!FRU9Y-+@816P>\O8Z\S8374$?M0R
MY] :%WQ<YI9?RGAECEY=_>4*:CTN--3K2EXDZ<$_#)&X]V#*ZE[S&E?I>19V
MM6;?1Q3<*45XVIR:\$67Q!5B6&          &+L[T?I7:4^%:[-U!J[8UI6P
MSKZZRSO7^)Y?/@0#>5).#"F9!$D.-,^8M;GE(42>Y1JZ=3,QG,JU/J7(J4J&
M29A<V<)OBE&A7JTHREAAQ-4YQ3>"2Q>W!8&(S'(,BS>I&MFUE;W4XKAC*M1I
MU&ECC@G.,FEB\<%LQ/AO[('$O\EWCK]Y/6G\6#*?O#U_^G,P^.W/X0Q_[%:-
M_1%E\5H?@S[O ]):8U9-G66L=1:PUS8VD5$&SGX'@.*8A-L83;I/MQ)TK'XD
M=;S25D2TMN*-)*\2+J,5FNIM29[3C1SO,+F\A!\48UZ]6JHMK#&*J3DD\-F*
MVX&1R[(<BRB<JN4V5"UE-82=&C3IN2WX-PC%M8[<&9/&$,L !ZB^H*'*J:SQ
MS**2HR3'KJ&]7W-#?5L.XIK:!(3V2(-G5V"'&'V7"\%M.MJ2HO R,>BTN[JP
MN87EC5G1K4FI0G3DX3A);I1E%J46NAIIH^-Q;6]Y0G:W=.-6E43C*$XJ49)[
MU*,DTT^E-8&#/[('$O\ )=XZ_>3UI_%@VC]X>O\ ].9A\=N?PAKW[%:-_1%E
M\5H?@S]6.(_%**^S*B\8^/4:3&=;?CR&-+ZW9?8?963C+S+S=:2DK2HB4E23
M(R,NI>(_,^8&O*D'">=W\HR333O+AII[TUVFU/I1^HZ,T?"2G#*;--;4U:T$
MTUN:? ;"C4390        ^1S77^![*I?Y-[&PG$<_P >*8Q8%0YKC=-E5*4^
M*E2(T[ZEWK+['G-DM9-N^7W))2NAEU,9#+<VS7);GWYD]S5M*V#CVE&I.E/A
M>&,>*#C+!X+%8X/!'BO\MR[-:'O7,[>G<TL4^"K"-2.*W/AFFL5B\'ABL3$?
M]D#B7^2[QU^\GK3^+!L'[P]?_IS,/CMS^$,+^Q6C?T19?%:'X,R)@.GM1ZI.
MU5J[5NN=;*O2A%>*P'",9PX[DJPW3K2M3QV+&]X*/[P_Y'G=WE^8YV].]77#
MYMJ+4&?*FL\OKB][+BX.WK5*W!Q8<7#VDI</%PQXL,,<%CN1D\NR3)<GXWE%
MI0M>TPX^QI4Z7%PX\/%P1CQ88O#''#%X;V9&&',H        &+-HZ,TMN^K3
M2[DU+K?:E4TA:(\+8.%8[E[,0E^)K@_5V.^;"R,^Y+C)I4D_G$9'XC.Y'JC4
MFF:_OG3F87%A4>^5O6J4F_JN"4>)>!XI[F8C-]/Y%G]+L,\LZ%Y!;E6I0J)>
M+CB\'X5@R.S-?0[],7-I#TU[C7%QJ<^I2E2,*V'M#&(Z.[Y&:6!<E7(+Y2)$
M,O\ T> Z_EO><YVY9!4XYTZT5T5K>VJ/S9RH]H_-F<SO^0/*B_DZDLK5*3Z:
M5:O37F157@7]4QFQ\/IZ:#+Q.N:VV'*02TJ.,_MS-4LF1)Z&V:HLAMSH?M/H
MYUZ^PR+P&:GWM>=,H\*O;>+ZU:4<?HQ:^@8J/=NY5QEB[6L_ [FKA]!I_1,[
M8%Z,_IG:ZD,RZ;BEAES+9,E&[GM]G>R([RR/KW/56>6MC",OHH*,2?\ 1\3&
MK9KWC>=6<0=.YSZM3B^BA"A;M>*5"E3GYO%CX38,NY'<JLLDIT,GI5&OMTZM
M=/QQK5)Q_LX$AF$:]P'6=&SC.M\'P_7^-QS[H^/81C5+BE&PHDDCJS4T+$=A
M)]"(OFMEX> Y%F>;YMG5T[W.;JK=UGOJ5JDZLWXYSE*3\\Z789;EV56ZM,KM
MZ=M26Z%*$:<%XHP27T#[ 8\]H    !@V_P",'&K++JSR3*>/.C<ER*ZENS[B
M_O\ 4N W-U;3GCZO3;.TL:]Q]]U9^*G'7%*/Y3&T6FM]:6%M"RL<WO:-&FE&
M%.G=5X0A%;E&,:BC%+H221K]SI/2MY7G=7F66E6K4>,ISMZ,I2;WN4I0;;\+
M>)Z?^R!Q+_)=XZ_>3UI_%@]'[P]?_IS,/CMS^$/A^Q6C?T19?%:'X,R+@&G]
M2ZH^JW]%NKM=:U^KWN'U=_D!A.-8=]6OJ7YWU,^JW\G8L;WGW;WF1Y'G=WE^
M:YV=.]77#YMJ'/\ /NS_ "Y?7%[V7%P=O6J5N#BPXN#M)2X>+ACQ888\*QW(
MRF79)DV3\?Y(M*-KVF''V-*%+BX<>'BX(QXN'BEACCAB\-[,BC#F3/_0O\
M
M
M
M
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M%QH/2T[O-X<&89BXU*L7OI4XI]E2?TRXI3FNB4^!^DQ<TXC:=V
M
M/__1O\
M
M
M
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M!5HW]I2E=WL=UQ<82E!]=*"2A3\$DG42V<;39*L.$G7P
M                                                       /_]*_
MP
M
M
M
M
M                                  __T[_
M
M
M
M
M
M            #__4O\
M
M
M
M
I                                                   /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>md-20230930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-11-01T17:51:08.4112+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.mednax.com/20230930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited" xlink:href="md-20230930.xsd#ConsolidatedBalanceSheetsUnaudited" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited" xlink:href="md-20230930.xsd#StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="md-20230930.xsd#StatementConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.mednax.com/20230930/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail" xlink:href="md-20230930.xsd#AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.mednax.com/20230930/taxonomy/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail" xlink:href="md-20230930.xsd#AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.mednax.com/20230930/taxonomy/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail" xlink:href="md-20230930.xsd#CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail" xlink:type="simple"/>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.mednax.com/20230930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LineOfCredit" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Goodwill" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LongTermDebtAndCapitalLeaseObligations" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedIncomeTaxesCurrent" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="md_OperatingAndFinanceLeaseRightOfUseAssets" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet" order="5" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet" order="5" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="6" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="6" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_OperatingAndFinanceLeaseRightOfUseAssets" xlink:label="md_OperatingAndFinanceLeaseRightOfUseAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent" xlink:label="us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="md_PracticeSalariesAndBenefits" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InvestmentIncomeNet" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" order="0" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_NonoperatingIncomeExpense" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="md_PracticeSuppliesAndOtherOperatingExpenses" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InterestExpense" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_ProfitLoss" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_RestructuringCharges" order="4" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_PracticeSalariesAndBenefits" xlink:label="md_PracticeSalariesAndBenefits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeNet" xlink:label="us-gaap_InvestmentIncomeNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_PracticeSuppliesAndOtherOperatingExpenses" xlink:label="md_PracticeSuppliesAndOtherOperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_NetIncomeLoss" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" order="0" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromLinesOfCredit" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireInvestments" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfLinesOfCredit" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="2" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleOfOtherProductiveAssets" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="md_PaymentsToTermLoan" order="2" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_ShareBasedCompensation" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment" order="3" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfSeniorDebt" order="3" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="4" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="5" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" order="5" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfFinancingCosts" order="5" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="6" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" order="6" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="md_RepaymentsOfLongTermCapitalLeaseObligation" order="6" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="7" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="7" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="8" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock" order="8" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" order="9" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" order="9" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve" order="10" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" order="11" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" order="12" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts" order="13" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="15" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="us-gaap_ProceedsFromLinesOfCredit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:label="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="us-gaap_PaymentsToAcquireInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="us-gaap_RepaymentsOfLinesOfCredit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfOtherProductiveAssets" xlink:label="us-gaap_ProceedsFromSaleOfOtherProductiveAssets"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_PaymentsToTermLoan" xlink:label="md_PaymentsToTermLoan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfSeniorDebt" xlink:label="us-gaap_RepaymentsOfSeniorDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:label="us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_RepaymentsOfLongTermCapitalLeaseObligation" xlink:label="md_RepaymentsOfLongTermCapitalLeaseObligation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve" xlink:label="us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.mednax.com/20230930/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableGrossCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" order="1" weight="-1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableGrossCurrent" xlink:label="us-gaap_AccountsReceivableGrossCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.mednax.com/20230930/taxonomy/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedSalariesCurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="md_AccruedPayrollTaxesAndBenefitsCurrent" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_InterestPayableCurrent" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="7" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_AccruedPayrollTaxesAndBenefitsCurrent" xlink:label="md_AccruedPayrollTaxesAndBenefitsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent" xlink:label="us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.mednax.com/20230930/taxonomy/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" order="1" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>md-20230930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-11-01T17:51:08.2196+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfEquityUnaudited" xlink:href="md-20230930.xsd#StatementConsolidatedStatementsOfEquityUnaudited" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.mednax.com/20230930/taxonomy/role/DisclosureBasisOfPresentationAdditionalInformationDetail" xlink:href="md-20230930.xsd#DisclosureBasisOfPresentationAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.mednax.com/20230930/taxonomy/role/CashEquivalentsAndInvestmentsAdditionalInformationDetail" xlink:href="md-20230930.xsd#CashEquivalentsAndInvestmentsAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.mednax.com/20230930/taxonomy/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail" xlink:href="md-20230930.xsd#CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.mednax.com/20230930/taxonomy/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails" xlink:href="md-20230930.xsd#FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.mednax.com/20230930/taxonomy/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails" xlink:href="md-20230930.xsd#FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.mednax.com/20230930/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail" xlink:href="md-20230930.xsd#FairValueMeasurementsAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.mednax.com/20230930/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail" xlink:href="md-20230930.xsd#AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.mednax.com/20230930/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail" xlink:href="md-20230930.xsd#AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.mednax.com/20230930/taxonomy/role/BusinessCombinationsAndDiscontinuedOperationsAdditionalInformationDetail" xlink:href="md-20230930.xsd#BusinessCombinationsAndDiscontinuedOperationsAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.mednax.com/20230930/taxonomy/role/AccountsPayableAndAccruedExpensesAdditionalInformationDetail" xlink:href="md-20230930.xsd#AccountsPayableAndAccruedExpensesAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.mednax.com/20230930/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails" xlink:href="md-20230930.xsd#DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.mednax.com/20230930/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail" xlink:href="md-20230930.xsd#StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.mednax.com/20230930/taxonomy/role/CommonStockRepurchaseProgramsAdditionalInformationDetail" xlink:href="md-20230930.xsd#CommonStockRepurchaseProgramsAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.mednax.com/20230930/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail" xlink:href="md-20230930.xsd#DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail" xlink:type="simple"/>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfEquityUnaudited">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember" xlink:label="md_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_DissolutionOfAndNetIncomeLossAttributableToNoncontrollingInterest" xlink:label="md_DissolutionOfAndNetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="md_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="md_DissolutionOfAndNetIncomeLossAttributableToNoncontrollingInterest" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/20230930/taxonomy/role/DisclosureBasisOfPresentationAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_BasisOfPresentationLineItems" xlink:label="md_BasisOfPresentationLineItems"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_BasisOfPresentationAndNewAccountingPronouncementsTable" xlink:label="md_BasisOfPresentationAndNewAccountingPronouncementsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateJointVentureMember" xlink:label="us-gaap_CorporateJointVentureMember"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_UnnamedCorporateJointVentureOneMember" xlink:label="md_UnnamedCorporateJointVentureOneMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_UnnamedCorporateJointVentureTwoMember" xlink:label="md_UnnamedCorporateJointVentureTwoMember"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_PrimaryBeneficiaryMember" xlink:label="md_PrimaryBeneficiaryMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="md_BasisOfPresentationLineItems" xlink:to="md_BasisOfPresentationAndNewAccountingPronouncementsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="md_BasisOfPresentationAndNewAccountingPronouncementsTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_CorporateJointVentureMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="md_UnnamedCorporateJointVentureOneMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="md_BasisOfPresentationLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="md_BasisOfPresentationAndNewAccountingPronouncementsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="md_UnnamedCorporateJointVentureTwoMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="md_PrimaryBeneficiaryMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/20230930/taxonomy/role/CashEquivalentsAndInvestmentsAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_CashEquivalentsAndInvestmentsLineItems" xlink:label="md_CashEquivalentsAndInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_CashEquivalentsAndInvestmentsTable" xlink:label="md_CashEquivalentsAndInvestmentsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsMember" xlink:label="us-gaap_CashEquivalentsMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="md_CashEquivalentsAndInvestmentsLineItems" xlink:to="md_CashEquivalentsAndInvestmentsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="md_CashEquivalentsAndInvestmentsTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="md_CashEquivalentsAndInvestmentsLineItems" xlink:to="us-gaap_MoneyMarketFundsAtCarryingValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CashEquivalentsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="md_CashEquivalentsAndInvestmentsTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/20230930/taxonomy/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllOtherCorporateBondsMember" xlink:label="us-gaap_AllOtherCorporateBondsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:label="us-gaap_USStatesAndPoliticalSubdivisionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_InvestmentTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_AllOtherCorporateBondsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USStatesAndPoliticalSubdivisionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CertificatesOfDepositMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/20230930/taxonomy/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_MoneyMarketFundsFairValueDisclosure" xlink:label="md_MoneyMarketFundsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_MutualFundsFairValueDisclosure" xlink:label="md_MutualFundsFairValueDisclosure"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="md_MoneyMarketFundsFairValueDisclosure" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_InvestmentsFairValueDisclosure" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="md_MutualFundsFairValueDisclosure" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/20230930/taxonomy/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="us-gaap_NotesPayableFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAbstract" xlink:label="us-gaap_LiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayable" xlink:label="us-gaap_NotesPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_TwoThousandTwentyThreeMember" xlink:label="md_TwoThousandTwentyThreeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_TwoThousandTwentySevenMember" xlink:label="md_TwoThousandTwentySevenMember"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_TwoZeroThreeZeroMember" xlink:label="md_TwoZeroThreeZeroMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_NotesPayableFairValueDisclosure" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_NotesPayable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="md_TwoThousandTwentyThreeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="md_TwoThousandTwentySevenMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="md_TwoZeroThreeZeroMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/20230930/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_FairValueDisclosuresLineItems" xlink:label="md_FairValueDisclosuresLineItems"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_FairValueDisclosuresTable" xlink:label="md_FairValueDisclosuresTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_GaapSeniorNotesMember" xlink:label="md_GaapSeniorNotesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_FivePointTwoFivePercentageSeniorNotesDueTwoThousandTwentyThreeMember" xlink:label="md_FivePointTwoFivePercentageSeniorNotesDueTwoThousandTwentyThreeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_SixPointTwoFivePercentageSeniorNotesDueTwoThousandTwentySevenMember" xlink:label="md_SixPointTwoFivePercentageSeniorNotesDueTwoThousandTwentySevenMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="md_FairValueDisclosuresLineItems" xlink:to="md_FairValueDisclosuresTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="md_FairValueDisclosuresTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="md_GaapSeniorNotesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="md_FivePointTwoFivePercentageSeniorNotesDueTwoThousandTwentyThreeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="md_FairValueDisclosuresLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="md_FairValueDisclosuresTable" xlink:to="us-gaap_LongtermDebtTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="md_SixPointTwoFivePercentageSeniorNotesDueTwoThousandTwentySevenMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/20230930/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail">
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_ScheduleOfFinancingReceivablesLineItems" xlink:label="md_ScheduleOfFinancingReceivablesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueAbstract" xlink:label="us-gaap_DisaggregationOfRevenueAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HealthCarePatientServiceMember" xlink:label="us-gaap_HealthCarePatientServiceMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_HospitalsContractsMember" xlink:label="md_HospitalsContractsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductAndServiceOtherMember" xlink:label="us-gaap_ProductAndServiceOtherMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="md_ScheduleOfFinancingReceivablesLineItems" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="md_ScheduleOfFinancingReceivablesLineItems" xlink:to="us-gaap_DisaggregationOfRevenueAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_HealthCarePatientServiceMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="md_HospitalsContractsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductAndServiceOtherMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/20230930/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems" xlink:label="us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable" xlink:label="us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:label="us-gaap_HealthCareOrganizationRevenueSourcesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:label="us-gaap_HealthCareOrganizationRevenueSourcesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:label="us-gaap_HealthCareOrganizationRevenueSourcesDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_PercentageOfNetPatientServiceRevenueByTypeOfPayor" xlink:label="md_PercentageOfNetPatientServiceRevenueByTypeOfPayor"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_ContractedManagedCareMember" xlink:label="md_ContractedManagedCareMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GovernmentMember" xlink:label="us-gaap_GovernmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ThirdPartyPayorMember" xlink:label="us-gaap_ThirdPartyPayorMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SelfPayMember" xlink:label="us-gaap_SelfPayMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems" xlink:to="us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable" xlink:to="us-gaap_HealthCareOrganizationRevenueSourcesAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:to="us-gaap_HealthCareOrganizationRevenueSourcesDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:to="us-gaap_HealthCareOrganizationRevenueSourcesDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems" xlink:to="md_PercentageOfNetPatientServiceRevenueByTypeOfPayor" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:to="md_ContractedManagedCareMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:to="us-gaap_GovernmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:to="us-gaap_ThirdPartyPayorMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:to="us-gaap_SelfPayMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/20230930/taxonomy/role/BusinessCombinationsAndDiscontinuedOperationsAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_DeferredTaxAssetsAxis" xlink:label="md_DeferredTaxAssetsAxis"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_DeferredTaxAssetsDomain" xlink:label="md_DeferredTaxAssetsDomain"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_DeferredTaxAssetsDomain" xlink:label="md_DeferredTaxAssetsDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_NumberOfPediatricOrThopedicPracticesAcquired" xlink:label="md_NumberOfPediatricOrThopedicPracticesAcquired"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_PediatricGastroenterologyAndGynecologyPracticeAndMultiLocationPediatricUrgentCarePracticeMember" xlink:label="md_PediatricGastroenterologyAndGynecologyPracticeAndMultiLocationPediatricUrgentCarePracticeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="us-gaap_DisposalGroupClassificationDomain"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_NorthAmericanPartnersInAnesthesiaMember" xlink:label="md_NorthAmericanPartnersInAnesthesiaMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="us-gaap_DisposalGroupClassificationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="us-gaap_DisposalGroupClassificationDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_NumberOfMultiLocationPediatricUrgentCarePracticeAcquired" xlink:label="md_NumberOfMultiLocationPediatricUrgentCarePracticeAcquired"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_PediatricSubspecialtyPracticeMember" xlink:label="md_PediatricSubspecialtyPracticeMember"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_AnesthesiologyServicesMedicalGroupMember" xlink:label="md_AnesthesiologyServicesMedicalGroupMember"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_NumberOfPediatricGastroenterologyPracticeAcquired" xlink:label="md_NumberOfPediatricGastroenterologyPracticeAcquired"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_RadiologyServicesMedicalGroupMember" xlink:label="md_RadiologyServicesMedicalGroupMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized" xlink:label="us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:label="us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions" xlink:label="us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_IncreaseInDeferredTaxAssets" xlink:label="md_IncreaseInDeferredTaxAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="md_DeferredTaxAssetsAxis" xlink:to="md_DeferredTaxAssetsDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="md_DeferredTaxAssetsAxis" xlink:to="md_DeferredTaxAssetsDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="md_DeferredTaxAssetsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="md_NumberOfPediatricOrThopedicPracticesAcquired" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="md_PediatricGastroenterologyAndGynecologyPracticeAndMultiLocationPediatricUrgentCarePracticeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisposalGroupClassificationDomain" xlink:to="md_NorthAmericanPartnersInAnesthesiaMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DisposalGroupClassificationAxis" xlink:to="us-gaap_DisposalGroupClassificationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DisposalGroupClassificationAxis" xlink:to="us-gaap_DisposalGroupClassificationDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DisposalGroupClassificationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="md_NumberOfMultiLocationPediatricUrgentCarePracticeAcquired" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="md_PediatricSubspecialtyPracticeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisposalGroupClassificationDomain" xlink:to="md_AnesthesiologyServicesMedicalGroupMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="md_NumberOfPediatricGastroenterologyPracticeAcquired" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisposalGroupClassificationDomain" xlink:to="md_RadiologyServicesMedicalGroupMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TaxPeriodAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="md_IncreaseInDeferredTaxAssets" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherAssetsNoncurrent" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/20230930/taxonomy/role/AccountsPayableAndAccruedExpensesAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_IncreaseDecreaseInAccruedSalariesAndBonuses" xlink:label="md_IncreaseDecreaseInAccruedSalariesAndBonuses"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="md_IncreaseDecreaseInAccruedSalariesAndBonuses" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/20230930/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ExtinguishmentOfDebtTypeDomain" xlink:label="us-gaap_ExtinguishmentOfDebtTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMember" xlink:label="us-gaap_LongTermDebtMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_CreditAgreementMember" xlink:label="md_CreditAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ExtinguishmentOfDebtAxis" xlink:label="us-gaap_ExtinguishmentOfDebtAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ExtinguishmentOfDebtTypeDomain" xlink:label="us-gaap_ExtinguishmentOfDebtTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="us-gaap_RevolvingCreditFacilityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeniorNotes" xlink:label="us-gaap_SeniorNotes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_FivePointThreeSevenFivePercentUnsecuredSeniorNotesDueTwoThousandThirtyMember" xlink:label="md_FivePointThreeSevenFivePercentUnsecuredSeniorNotesDueTwoThousandThirtyMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnsecuredDebt" xlink:label="us-gaap_UnsecuredDebt"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_SixPointTwentyFivePercentageSeniorUnsecuredNotesDue2027Member" xlink:label="md_SixPointTwentyFivePercentageSeniorUnsecuredNotesDue2027Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember" xlink:label="md_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_DebtInstrumentMaturityYear" xlink:label="md_DebtInstrumentMaturityYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:label="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDateDescription" xlink:label="us-gaap_DebtInstrumentMaturityDateDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnsecuredLongTermDebt" xlink:label="us-gaap_UnsecuredLongTermDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfUnsecuredDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfUnsecuredDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentDescription" xlink:label="us-gaap_DebtInstrumentDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionDescription" xlink:label="us-gaap_DebtConversionDescription"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_PurchasePrice" xlink:label="md_PurchasePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="us-gaap_ProceedsFromLinesOfCredit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DescriptionOfInterestRateRiskExposure" xlink:label="us-gaap_DescriptionOfInterestRateRiskExposure"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ExtinguishmentOfDebtTypeDomain" xlink:to="us-gaap_LongTermDebtMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_CreditFacilityAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="md_CreditAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ExtinguishmentOfDebtAxis" xlink:to="us-gaap_ExtinguishmentOfDebtTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ExtinguishmentOfDebtAxis" xlink:to="us-gaap_ExtinguishmentOfDebtTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_RevolvingCreditFacilityMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_SeniorNotes" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="md_FivePointThreeSevenFivePercentUnsecuredSeniorNotesDueTwoThousandThirtyMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_UnsecuredDebt" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_ExtinguishmentOfDebtAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="md_SixPointTwentyFivePercentageSeniorUnsecuredNotesDue2027Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="md_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="md_DebtInstrumentMaturityYear" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDateDescription" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_UnsecuredLongTermDebt" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfUnsecuredDebt" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_Cash" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentInterest" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebt" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentDescription" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtConversionDescription" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="md_PurchasePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromLinesOfCredit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCredit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DescriptionOfInterestRateRiskExposure" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/20230930/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember" xlink:label="md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember" xlink:label="md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_AmendedAndRestatedTwoThousandEightPlanMember" xlink:label="md_AmendedAndRestatedTwoThousandEightPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember" xlink:label="md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="md_AmendedAndRestatedTwoThousandEightPlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/20230930/taxonomy/role/CommonStockRepurchaseProgramsAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_CommonStockLineItems" xlink:label="md_CommonStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_CommonStockTable" xlink:label="md_CommonStockTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:label="us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:label="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:label="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="md_CommonStockLineItems" xlink:to="md_CommonStockTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="md_CommonStockTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="md_CommonStockLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="md_CommonStockLineItems" xlink:to="us-gaap_StockRepurchaseProgramAuthorizedAmount1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="md_CommonStockLineItems" xlink:to="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="md_CommonStockLineItems" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="md_CommonStockLineItems" xlink:to="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/20230930/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ExecutiveOfficerMember" xlink:label="srt_ExecutiveOfficerMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_ExtraordinaryItemsDomain" xlink:label="md_ExtraordinaryItemsDomain"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_CovidNinenteenMember" xlink:label="md_CovidNinenteenMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_PercentageIncreaseDecreaseInSalaryAndWage" xlink:label="md_PercentageIncreaseDecreaseInSalaryAndWage"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_TwoThousandTwentyTaxYearMember" xlink:label="md_TwoThousandTwentyTaxYearMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeographicDistributionDomain" xlink:label="us-gaap_GeographicDistributionDomain"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_RuralAreaMember" xlink:label="md_RuralAreaMember"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_ExtraordinaryItemsAxis" xlink:label="md_ExtraordinaryItemsAxis"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_ExtraordinaryItemsDomain" xlink:label="md_ExtraordinaryItemsDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeographicDistributionAxis" xlink:label="us-gaap_GeographicDistributionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeographicDistributionDomain" xlink:label="us-gaap_GeographicDistributionDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_ContributionsInAidOfReimbursementOfLostRevenue" xlink:label="md_ContributionsInAidOfReimbursementOfLostRevenue"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue" xlink:label="md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_PercentageOfRefundOfIncomeTaxAtThePriorPeriodCorporateTaxRate" xlink:label="md_PercentageOfRefundOfIncomeTaxAtThePriorPeriodCorporateTaxRate"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ExecutiveOfficerMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="md_ExtraordinaryItemsDomain" xlink:to="md_CovidNinenteenMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="md_PercentageIncreaseDecreaseInSalaryAndWage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="md_TwoThousandTwentyTaxYearMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GeographicDistributionDomain" xlink:to="md_RuralAreaMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="md_ExtraordinaryItemsAxis" xlink:to="md_ExtraordinaryItemsDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="md_ExtraordinaryItemsAxis" xlink:to="md_ExtraordinaryItemsDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_GeographicDistributionAxis" xlink:to="us-gaap_GeographicDistributionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_GeographicDistributionAxis" xlink:to="us-gaap_GeographicDistributionDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="md_ExtraordinaryItemsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="md_ContributionsInAidOfReimbursementOfLostRevenue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementScenarioAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="md_PercentageOfRefundOfIncomeTaxAtThePriorPeriodCorporateTaxRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CreditFacilityAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_GeographicDistributionAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TaxPeriodAxis" priority="2" use="optional"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>8
<FILENAME>md-20230930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-11-01T17:51:08.2160+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.mednax.com/20230930/taxonomy/role/CoverPage" xlink:href="md-20230930.xsd#CoverPage" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.mednax.com/20230930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited" xlink:href="md-20230930.xsd#ConsolidatedBalanceSheetsUnaudited" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.mednax.com/20230930/taxonomy/role/ConsolidatedBalanceSheetsUnauditedParenthetical" xlink:href="md-20230930.xsd#ConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited" xlink:href="md-20230930.xsd#StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnauditedParenthetical" xlink:href="md-20230930.xsd#StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnauditedParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfEquityUnaudited" xlink:href="md-20230930.xsd#StatementConsolidatedStatementsOfEquityUnaudited" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="md-20230930.xsd#StatementConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.mednax.com/20230930/taxonomy/role/DisclosureBasisOfPresentation" xlink:href="md-20230930.xsd#DisclosureBasisOfPresentation" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.mednax.com/20230930/taxonomy/role/CashEquivalentsAndInvestments" xlink:href="md-20230930.xsd#CashEquivalentsAndInvestments" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.mednax.com/20230930/taxonomy/role/FairValueMeasurements" xlink:href="md-20230930.xsd#FairValueMeasurements" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.mednax.com/20230930/taxonomy/role/AccountsReceivableAndNetRevenue" xlink:href="md-20230930.xsd#AccountsReceivableAndNetRevenue" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.mednax.com/20230930/taxonomy/role/BusinessCombinationsAndDiscontinuedOperations" xlink:href="md-20230930.xsd#BusinessCombinationsAndDiscontinuedOperations" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.mednax.com/20230930/taxonomy/role/AccountsPayableAndAccruedExpenses" xlink:href="md-20230930.xsd#AccountsPayableAndAccruedExpenses" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.mednax.com/20230930/taxonomy/role/DisclosureLineOfCreditAndLongTermDebt" xlink:href="md-20230930.xsd#DisclosureLineOfCreditAndLongTermDebt" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.mednax.com/20230930/taxonomy/role/CommonAndCommonEquivalentShares" xlink:href="md-20230930.xsd#CommonAndCommonEquivalentShares" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.mednax.com/20230930/taxonomy/role/StockIncentivePlansAndStockPurchasePlans" xlink:href="md-20230930.xsd#StockIncentivePlansAndStockPurchasePlans" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.mednax.com/20230930/taxonomy/role/CommonStockRepurchasePrograms" xlink:href="md-20230930.xsd#CommonStockRepurchasePrograms" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.mednax.com/20230930/taxonomy/role/DisclosureCoronavirusPandemicCovid191" xlink:href="md-20230930.xsd#DisclosureCoronavirusPandemicCovid191" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.mednax.com/20230930/taxonomy/role/CommitmentsAndContingencies" xlink:href="md-20230930.xsd#CommitmentsAndContingencies" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.mednax.com/20230930/taxonomy/role/DisclosureBasisOfPresentationPolicies" xlink:href="md-20230930.xsd#DisclosureBasisOfPresentationPolicies" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.mednax.com/20230930/taxonomy/role/CashEquivalentsAndInvestmentsTables" xlink:href="md-20230930.xsd#CashEquivalentsAndInvestmentsTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.mednax.com/20230930/taxonomy/role/FairValueMeasurementsTables" xlink:href="md-20230930.xsd#FairValueMeasurementsTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.mednax.com/20230930/taxonomy/role/AccountsReceivableAndNetRevenueTables" xlink:href="md-20230930.xsd#AccountsReceivableAndNetRevenueTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.mednax.com/20230930/taxonomy/role/AccountsPayableAndAccruedExpensesTables" xlink:href="md-20230930.xsd#AccountsPayableAndAccruedExpensesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.mednax.com/20230930/taxonomy/role/CommonAndCommonEquivalentSharesTables" xlink:href="md-20230930.xsd#CommonAndCommonEquivalentSharesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.mednax.com/20230930/taxonomy/role/DisclosureBasisOfPresentationAdditionalInformationDetail" xlink:href="md-20230930.xsd#DisclosureBasisOfPresentationAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.mednax.com/20230930/taxonomy/role/CashEquivalentsAndInvestmentsAdditionalInformationDetail" xlink:href="md-20230930.xsd#CashEquivalentsAndInvestmentsAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.mednax.com/20230930/taxonomy/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail" xlink:href="md-20230930.xsd#CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.mednax.com/20230930/taxonomy/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails" xlink:href="md-20230930.xsd#FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.mednax.com/20230930/taxonomy/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails" xlink:href="md-20230930.xsd#FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.mednax.com/20230930/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail" xlink:href="md-20230930.xsd#FairValueMeasurementsAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.mednax.com/20230930/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail" xlink:href="md-20230930.xsd#AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.mednax.com/20230930/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail" xlink:href="md-20230930.xsd#AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.mednax.com/20230930/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail" xlink:href="md-20230930.xsd#AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.mednax.com/20230930/taxonomy/role/BusinessCombinationsAndDiscontinuedOperationsAdditionalInformationDetail" xlink:href="md-20230930.xsd#BusinessCombinationsAndDiscontinuedOperationsAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.mednax.com/20230930/taxonomy/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail" xlink:href="md-20230930.xsd#AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.mednax.com/20230930/taxonomy/role/AccountsPayableAndAccruedExpensesAdditionalInformationDetail" xlink:href="md-20230930.xsd#AccountsPayableAndAccruedExpensesAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.mednax.com/20230930/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails" xlink:href="md-20230930.xsd#DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.mednax.com/20230930/taxonomy/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail" xlink:href="md-20230930.xsd#CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.mednax.com/20230930/taxonomy/role/DisclosureCommonAndCommonEquivalentSharesAdditionalInformationDetails" xlink:href="md-20230930.xsd#DisclosureCommonAndCommonEquivalentSharesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.mednax.com/20230930/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail" xlink:href="md-20230930.xsd#StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.mednax.com/20230930/taxonomy/role/CommonStockRepurchaseProgramsAdditionalInformationDetail" xlink:href="md-20230930.xsd#CommonStockRepurchaseProgramsAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.mednax.com/20230930/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail" xlink:href="md-20230930.xsd#DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.mednax.com/20230930/taxonomy/role/CoverPage" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentQuarterlyReport" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="71.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="72.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="73.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="74.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="75.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="76.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="77.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.mednax.com/20230930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_OperatingAndFinanceLeaseRightOfUseAssets" xlink:label="md_OperatingAndFinanceLeaseRightOfUseAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent" xlink:label="us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LineOfCredit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Goodwill" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LongTermDebtAndCapitalLeaseObligations" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedIncomeTaxesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="md_OperatingAndFinanceLeaseRightOfUseAssets" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.mednax.com/20230930/taxonomy/role/ConsolidatedBalanceSheetsUnauditedParenthetical" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:label="us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_PracticeSalariesAndBenefits" xlink:label="md_PracticeSalariesAndBenefits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationNetOfTaxPerBasicAndDilutedShareAbstract" xlink:label="md_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationNetOfTaxPerBasicAndDilutedShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_IncomelossFromContinuingOperationsPerBasicAndDilutedShareAbstract" xlink:label="md_IncomelossFromContinuingOperationsPerBasicAndDilutedShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_PracticeSuppliesAndOtherOperatingExpenses" xlink:label="md_PracticeSuppliesAndOtherOperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeNet" xlink:label="us-gaap_InvestmentIncomeNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="md_PracticeSalariesAndBenefits" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="md_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationNetOfTaxPerBasicAndDilutedShareAbstract" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="md_IncomelossFromContinuingOperationsPerBasicAndDilutedShareAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="md_PracticeSuppliesAndOtherOperatingExpenses" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="md_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationNetOfTaxPerBasicAndDilutedShareAbstract" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="md_IncomelossFromContinuingOperationsPerBasicAndDilutedShareAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_InvestmentIncomeNet" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_RestructuringCharges" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_InterestExpense" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ProfitLoss" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="md_IncomelossFromContinuingOperationsPerBasicAndDilutedShareAbstract" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="md_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationNetOfTaxPerBasicAndDilutedShareAbstract" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareAbstract" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnauditedParenthetical" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfEquityUnaudited" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember" xlink:label="md_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_DissolutionOfAndNetIncomeLossAttributableToNoncontrollingInterest" xlink:label="md_DissolutionOfAndNetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_14"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued_15"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssued" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="md_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="md_DissolutionOfAndNetIncomeLossAttributableToNoncontrollingInterest" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodValue" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_14" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssued_15" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="us-gaap_ProceedsFromLinesOfCredit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="us-gaap_RepaymentsOfLinesOfCredit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="us-gaap_PaymentsToAcquireInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_PaymentsToTermLoan" xlink:label="md_PaymentsToTermLoan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfSeniorDebt" xlink:label="us-gaap_RepaymentsOfSeniorDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfOtherProductiveAssets" xlink:label="us-gaap_ProceedsFromSaleOfOtherProductiveAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve" xlink:label="us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_5"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:label="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_RepaymentsOfLongTermCapitalLeaseObligation" xlink:label="md_RepaymentsOfLongTermCapitalLeaseObligation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:label="us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromLinesOfCredit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfLinesOfCredit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireInvestments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="md_PaymentsToTermLoan" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfSeniorDebt" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfOtherProductiveAssets" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfFinancingCosts" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="md_RepaymentsOfLongTermCapitalLeaseObligation" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.mednax.com/20230930/taxonomy/role/DisclosureBasisOfPresentation" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.mednax.com/20230930/taxonomy/role/CashEquivalentsAndInvestments" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.mednax.com/20230930/taxonomy/role/FairValueMeasurements" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.mednax.com/20230930/taxonomy/role/AccountsReceivableAndNetRevenue" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TextBlockAbstract" xlink:label="us-gaap_TextBlockAbstract"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_AccountsReceivableAndNetRevenueDisclosureTextBlock" xlink:label="md_AccountsReceivableAndNetRevenueDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TextBlockAbstract" xlink:to="md_AccountsReceivableAndNetRevenueDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.mednax.com/20230930/taxonomy/role/BusinessCombinationsAndDiscontinuedOperations" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_BusinessCombinationAndDiscontinuedOperationsAbstract" xlink:label="md_BusinessCombinationAndDiscontinuedOperationsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_BusinessCombinationAndDiscontinuedOperationsTextBlock" xlink:label="md_BusinessCombinationAndDiscontinuedOperationsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="md_BusinessCombinationAndDiscontinuedOperationsAbstract" xlink:to="md_BusinessCombinationAndDiscontinuedOperationsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.mednax.com/20230930/taxonomy/role/AccountsPayableAndAccruedExpenses" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.mednax.com/20230930/taxonomy/role/DisclosureLineOfCreditAndLongTermDebt" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_LineOfCreditLongTermDebtAndFinanceLeaseObligationsDisclosureTextBlock" xlink:label="md_LineOfCreditLongTermDebtAndFinanceLeaseObligationsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_LineOfCreditAndLongTermDebtTextBlock" xlink:label="md_LineOfCreditAndLongTermDebtTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="md_LineOfCreditLongTermDebtAndFinanceLeaseObligationsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="md_LineOfCreditAndLongTermDebtTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.mednax.com/20230930/taxonomy/role/CommonAndCommonEquivalentShares" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.mednax.com/20230930/taxonomy/role/StockIncentivePlansAndStockPurchasePlans" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.mednax.com/20230930/taxonomy/role/CommonStockRepurchasePrograms" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_CommonStockRepurchasesTextBlock" xlink:label="md_CommonStockRepurchasesTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="md_CommonStockRepurchasesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.mednax.com/20230930/taxonomy/role/DisclosureCoronavirusPandemicCovid191" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_ExtraordinaryItemsAbstract" xlink:label="md_ExtraordinaryItemsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_CoronavirusPandemicCOVIDNineteenDisclosureTextBlock" xlink:label="md_CoronavirusPandemicCOVIDNineteenDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="md_ExtraordinaryItemsAbstract" xlink:to="md_CoronavirusPandemicCOVIDNineteenDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.mednax.com/20230930/taxonomy/role/CommitmentsAndContingencies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.mednax.com/20230930/taxonomy/role/DisclosureBasisOfPresentationPolicies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.mednax.com/20230930/taxonomy/role/CashEquivalentsAndInvestmentsTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.mednax.com/20230930/taxonomy/role/FairValueMeasurementsTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock" xlink:label="md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.mednax.com/20230930/taxonomy/role/AccountsReceivableAndNetRevenueTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TextBlockAbstract" xlink:label="us-gaap_TextBlockAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TextBlockAbstract" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TextBlockAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TextBlockAbstract" xlink:to="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.mednax.com/20230930/taxonomy/role/AccountsPayableAndAccruedExpensesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.mednax.com/20230930/taxonomy/role/CommonAndCommonEquivalentSharesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:label="us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.mednax.com/20230930/taxonomy/role/DisclosureBasisOfPresentationAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_BasisOfPresentationAndNewAccountingPronouncementsTable" xlink:label="md_BasisOfPresentationAndNewAccountingPronouncementsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateJointVentureMember" xlink:label="us-gaap_CorporateJointVentureMember"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_UnnamedCorporateJointVentureOneMember" xlink:label="md_UnnamedCorporateJointVentureOneMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_BasisOfPresentationLineItems" xlink:label="md_BasisOfPresentationLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_UnnamedCorporateJointVentureTwoMember" xlink:label="md_UnnamedCorporateJointVentureTwoMember"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_PrimaryBeneficiaryMember" xlink:label="md_PrimaryBeneficiaryMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="md_BasisOfPresentationAndNewAccountingPronouncementsTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_CorporateJointVentureMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="md_UnnamedCorporateJointVentureOneMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="md_BasisOfPresentationAndNewAccountingPronouncementsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="md_BasisOfPresentationLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="md_BasisOfPresentationAndNewAccountingPronouncementsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="md_UnnamedCorporateJointVentureTwoMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="md_BasisOfPresentationAndNewAccountingPronouncementsTable" xlink:to="md_BasisOfPresentationLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="md_PrimaryBeneficiaryMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.mednax.com/20230930/taxonomy/role/CashEquivalentsAndInvestmentsAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_CashEquivalentsAndInvestmentsTable" xlink:label="md_CashEquivalentsAndInvestmentsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_CashEquivalentsAndInvestmentsLineItems" xlink:label="md_CashEquivalentsAndInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsMember" xlink:label="us-gaap_CashEquivalentsMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="md_CashEquivalentsAndInvestmentsTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="md_CashEquivalentsAndInvestmentsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="md_CashEquivalentsAndInvestmentsLineItems" xlink:to="us-gaap_MoneyMarketFundsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CashEquivalentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="md_CashEquivalentsAndInvestmentsTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="md_CashEquivalentsAndInvestmentsTable" xlink:to="md_CashEquivalentsAndInvestmentsLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.mednax.com/20230930/taxonomy/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllOtherCorporateBondsMember" xlink:label="us-gaap_AllOtherCorporateBondsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:label="us-gaap_USStatesAndPoliticalSubdivisionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_InvestmentTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_AllOtherCorporateBondsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USStatesAndPoliticalSubdivisionsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CertificatesOfDepositMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.mednax.com/20230930/taxonomy/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_MoneyMarketFundsFairValueDisclosure" xlink:label="md_MoneyMarketFundsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_MutualFundsFairValueDisclosure" xlink:label="md_MutualFundsFairValueDisclosure"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="md_MoneyMarketFundsFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_InvestmentsFairValueDisclosure" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="md_MutualFundsFairValueDisclosure" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.mednax.com/20230930/taxonomy/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="us-gaap_NotesPayableFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAbstract" xlink:label="us-gaap_LiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayable" xlink:label="us-gaap_NotesPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_TwoThousandTwentyThreeMember" xlink:label="md_TwoThousandTwentyThreeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_TwoThousandTwentySevenMember" xlink:label="md_TwoThousandTwentySevenMember"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_TwoZeroThreeZeroMember" xlink:label="md_TwoZeroThreeZeroMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_NotesPayableFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_NotesPayable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="md_TwoThousandTwentyThreeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="md_TwoThousandTwentySevenMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="md_TwoZeroThreeZeroMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.mednax.com/20230930/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_FairValueDisclosuresTable" xlink:label="md_FairValueDisclosuresTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_GaapSeniorNotesMember" xlink:label="md_GaapSeniorNotesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_FivePointTwoFivePercentageSeniorNotesDueTwoThousandTwentyThreeMember" xlink:label="md_FivePointTwoFivePercentageSeniorNotesDueTwoThousandTwentyThreeMember"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_FairValueDisclosuresLineItems" xlink:label="md_FairValueDisclosuresLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_SixPointTwoFivePercentageSeniorNotesDueTwoThousandTwentySevenMember" xlink:label="md_SixPointTwoFivePercentageSeniorNotesDueTwoThousandTwentySevenMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="md_FairValueDisclosuresTable" xlink:to="us-gaap_DebtInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="md_GaapSeniorNotesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="md_FivePointTwoFivePercentageSeniorNotesDueTwoThousandTwentyThreeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="md_FairValueDisclosuresLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="md_FairValueDisclosuresTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="md_FairValueDisclosuresTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="md_SixPointTwoFivePercentageSeniorNotesDueTwoThousandTwentySevenMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="md_FairValueDisclosuresTable" xlink:to="md_FairValueDisclosuresLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.mednax.com/20230930/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesAbstract" xlink:label="us-gaap_ReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableGrossCurrent" xlink:label="us-gaap_AccountsReceivableGrossCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_AccountsReceivableGrossCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.mednax.com/20230930/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_ScheduleOfFinancingReceivablesLineItems" xlink:label="md_ScheduleOfFinancingReceivablesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueAbstract" xlink:label="us-gaap_DisaggregationOfRevenueAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HealthCarePatientServiceMember" xlink:label="us-gaap_HealthCarePatientServiceMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableGrossAllowanceAndNetAbstract" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableGrossAllowanceAndNetAbstract"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_HospitalsContractsMember" xlink:label="md_HospitalsContractsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductAndServiceOtherMember" xlink:label="us-gaap_ProductAndServiceOtherMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="srt_ProductOrServiceAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="md_ScheduleOfFinancingReceivablesLineItems" xlink:to="us-gaap_DisaggregationOfRevenueAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_HealthCarePatientServiceMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableGrossAllowanceAndNetAbstract" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="md_ScheduleOfFinancingReceivablesLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="md_HospitalsContractsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductAndServiceOtherMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.mednax.com/20230930/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable" xlink:label="us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:label="us-gaap_HealthCareOrganizationRevenueSourcesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:label="us-gaap_HealthCareOrganizationRevenueSourcesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HealthCareOrganizationRevenueAndExpenseAbstract" xlink:label="us-gaap_HealthCareOrganizationRevenueAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems" xlink:label="us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_PercentageOfNetPatientServiceRevenueByTypeOfPayor" xlink:label="md_PercentageOfNetPatientServiceRevenueByTypeOfPayor"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_ContractedManagedCareMember" xlink:label="md_ContractedManagedCareMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GovernmentMember" xlink:label="us-gaap_GovernmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ThirdPartyPayorMember" xlink:label="us-gaap_ThirdPartyPayorMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SelfPayMember" xlink:label="us-gaap_SelfPayMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable" xlink:to="us-gaap_HealthCareOrganizationRevenueSourcesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:to="us-gaap_HealthCareOrganizationRevenueSourcesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HealthCareOrganizationRevenueAndExpenseAbstract" xlink:to="us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems" xlink:to="md_PercentageOfNetPatientServiceRevenueByTypeOfPayor" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:to="md_ContractedManagedCareMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable" xlink:to="us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:to="us-gaap_GovernmentMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:to="us-gaap_ThirdPartyPayorMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:to="us-gaap_SelfPayMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.mednax.com/20230930/taxonomy/role/BusinessCombinationsAndDiscontinuedOperationsAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_BusinessCombinationAndDiscontinuedOperationsAbstract" xlink:label="md_BusinessCombinationAndDiscontinuedOperationsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_DeferredTaxAssetsAxis" xlink:label="md_DeferredTaxAssetsAxis"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_DeferredTaxAssetsDomain" xlink:label="md_DeferredTaxAssetsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_NumberOfPediatricOrThopedicPracticesAcquired" xlink:label="md_NumberOfPediatricOrThopedicPracticesAcquired"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_PediatricGastroenterologyAndGynecologyPracticeAndMultiLocationPediatricUrgentCarePracticeMember" xlink:label="md_PediatricGastroenterologyAndGynecologyPracticeAndMultiLocationPediatricUrgentCarePracticeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="us-gaap_DisposalGroupClassificationDomain"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_NorthAmericanPartnersInAnesthesiaMember" xlink:label="md_NorthAmericanPartnersInAnesthesiaMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="us-gaap_DisposalGroupClassificationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_NumberOfMultiLocationPediatricUrgentCarePracticeAcquired" xlink:label="md_NumberOfMultiLocationPediatricUrgentCarePracticeAcquired"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_PediatricSubspecialtyPracticeMember" xlink:label="md_PediatricSubspecialtyPracticeMember"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_AnesthesiologyServicesMedicalGroupMember" xlink:label="md_AnesthesiologyServicesMedicalGroupMember"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_NumberOfPediatricGastroenterologyPracticeAcquired" xlink:label="md_NumberOfPediatricGastroenterologyPracticeAcquired"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_RadiologyServicesMedicalGroupMember" xlink:label="md_RadiologyServicesMedicalGroupMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized" xlink:label="us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:label="us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions" xlink:label="us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_IncreaseInDeferredTaxAssets" xlink:label="md_IncreaseInDeferredTaxAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="md_BusinessCombinationAndDiscontinuedOperationsAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="md_DeferredTaxAssetsAxis" xlink:to="md_DeferredTaxAssetsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="md_DeferredTaxAssetsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="md_NumberOfPediatricOrThopedicPracticesAcquired" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="md_PediatricGastroenterologyAndGynecologyPracticeAndMultiLocationPediatricUrgentCarePracticeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupClassificationDomain" xlink:to="md_NorthAmericanPartnersInAnesthesiaMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupClassificationAxis" xlink:to="us-gaap_DisposalGroupClassificationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DisposalGroupClassificationAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="md_NumberOfMultiLocationPediatricUrgentCarePracticeAcquired" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="md_PediatricSubspecialtyPracticeMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupClassificationDomain" xlink:to="md_AnesthesiologyServicesMedicalGroupMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="md_NumberOfPediatricGastroenterologyPracticeAcquired" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupClassificationDomain" xlink:to="md_RadiologyServicesMedicalGroupMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TaxPeriodAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="md_IncreaseInDeferredTaxAssets" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherAssetsNoncurrent" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.mednax.com/20230930/taxonomy/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_AccruedPayrollTaxesAndBenefitsCurrent" xlink:label="md_AccruedPayrollTaxesAndBenefitsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent" xlink:label="us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedSalariesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="md_AccruedPayrollTaxesAndBenefitsCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_InterestPayableCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.mednax.com/20230930/taxonomy/role/AccountsPayableAndAccruedExpensesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_IncreaseDecreaseInAccruedSalariesAndBonuses" xlink:label="md_IncreaseDecreaseInAccruedSalariesAndBonuses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="md_IncreaseDecreaseInAccruedSalariesAndBonuses" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.mednax.com/20230930/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ExtinguishmentOfDebtTypeDomain" xlink:label="us-gaap_ExtinguishmentOfDebtTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMember" xlink:label="us-gaap_LongTermDebtMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_CreditAgreementMember" xlink:label="md_CreditAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ExtinguishmentOfDebtAxis" xlink:label="us-gaap_ExtinguishmentOfDebtAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="us-gaap_RevolvingCreditFacilityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeniorNotes" xlink:label="us-gaap_SeniorNotes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_FivePointThreeSevenFivePercentUnsecuredSeniorNotesDueTwoThousandThirtyMember" xlink:label="md_FivePointThreeSevenFivePercentUnsecuredSeniorNotesDueTwoThousandThirtyMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnsecuredDebt" xlink:label="us-gaap_UnsecuredDebt"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_SixPointTwentyFivePercentageSeniorUnsecuredNotesDue2027Member" xlink:label="md_SixPointTwentyFivePercentageSeniorUnsecuredNotesDue2027Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember" xlink:label="md_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_DebtInstrumentMaturityYear" xlink:label="md_DebtInstrumentMaturityYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:label="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDateDescription" xlink:label="us-gaap_DebtInstrumentMaturityDateDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnsecuredLongTermDebt" xlink:label="us-gaap_UnsecuredLongTermDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfUnsecuredDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfUnsecuredDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentDescription" xlink:label="us-gaap_DebtInstrumentDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionDescription" xlink:label="us-gaap_DebtConversionDescription"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_PurchasePrice" xlink:label="md_PurchasePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="us-gaap_ProceedsFromLinesOfCredit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DescriptionOfInterestRateRiskExposure" xlink:label="us-gaap_DescriptionOfInterestRateRiskExposure"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ExtinguishmentOfDebtTypeDomain" xlink:to="us-gaap_LongTermDebtMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_CreditFacilityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="md_CreditAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ExtinguishmentOfDebtAxis" xlink:to="us-gaap_ExtinguishmentOfDebtTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_RevolvingCreditFacilityMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_SeniorNotes" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="md_FivePointThreeSevenFivePercentUnsecuredSeniorNotesDueTwoThousandThirtyMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_UnsecuredDebt" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_ExtinguishmentOfDebtAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="md_SixPointTwentyFivePercentageSeniorUnsecuredNotesDue2027Member" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="md_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="md_DebtInstrumentMaturityYear" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDateDescription" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_UnsecuredLongTermDebt" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfUnsecuredDebt" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_Cash" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentInterest" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebt" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentDescription" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtConversionDescription" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="md_PurchasePrice" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromLinesOfCredit" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCredit" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DescriptionOfInterestRateRiskExposure" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.mednax.com/20230930/taxonomy/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.mednax.com/20230930/taxonomy/role/DisclosureCommonAndCommonEquivalentSharesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_IncrementalSharesInContinuingOperation" xlink:label="md_IncrementalSharesInContinuingOperation"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="md_IncrementalSharesInContinuingOperation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.mednax.com/20230930/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember" xlink:label="md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember" xlink:label="md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_AmendedAndRestatedTwoThousandEightPlanMember" xlink:label="md_AmendedAndRestatedTwoThousandEightPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember" xlink:label="md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="md_AmendedAndRestatedTwoThousandEightPlanMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="5.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.mednax.com/20230930/taxonomy/role/CommonStockRepurchaseProgramsAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_CommonStockTable" xlink:label="md_CommonStockTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_CommonStockLineItems" xlink:label="md_CommonStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:label="us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:label="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:label="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="md_CommonStockTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="md_CommonStockLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="md_CommonStockTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="md_CommonStockTable" xlink:to="md_CommonStockLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="md_CommonStockLineItems" xlink:to="us-gaap_StockRepurchaseProgramAuthorizedAmount1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="md_CommonStockLineItems" xlink:to="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="md_CommonStockLineItems" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="md_CommonStockLineItems" xlink:to="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.mednax.com/20230930/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ExecutiveOfficerMember" xlink:label="srt_ExecutiveOfficerMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_ExtraordinaryItemsDomain" xlink:label="md_ExtraordinaryItemsDomain"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_CovidNinenteenMember" xlink:label="md_CovidNinenteenMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_PercentageIncreaseDecreaseInSalaryAndWage" xlink:label="md_PercentageIncreaseDecreaseInSalaryAndWage"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_ExtraordinaryItemsAbstract" xlink:label="md_ExtraordinaryItemsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_TwoThousandTwentyTaxYearMember" xlink:label="md_TwoThousandTwentyTaxYearMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeographicDistributionDomain" xlink:label="us-gaap_GeographicDistributionDomain"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_RuralAreaMember" xlink:label="md_RuralAreaMember"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_ExtraordinaryItemsAxis" xlink:label="md_ExtraordinaryItemsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeographicDistributionAxis" xlink:label="us-gaap_GeographicDistributionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_ContributionsInAidOfReimbursementOfLostRevenue" xlink:label="md_ContributionsInAidOfReimbursementOfLostRevenue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue" xlink:label="md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_PercentageOfRefundOfIncomeTaxAtThePriorPeriodCorporateTaxRate" xlink:label="md_PercentageOfRefundOfIncomeTaxAtThePriorPeriodCorporateTaxRate"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ExecutiveOfficerMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="md_ExtraordinaryItemsDomain" xlink:to="md_CovidNinenteenMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="md_PercentageIncreaseDecreaseInSalaryAndWage" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="md_ExtraordinaryItemsAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="md_TwoThousandTwentyTaxYearMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GeographicDistributionDomain" xlink:to="md_RuralAreaMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="md_ExtraordinaryItemsAxis" xlink:to="md_ExtraordinaryItemsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GeographicDistributionAxis" xlink:to="us-gaap_GeographicDistributionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="md_ExtraordinaryItemsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="md_ContributionsInAidOfReimbursementOfLostRevenue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementScenarioAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="md_PercentageOfRefundOfIncomeTaxAtThePriorPeriodCorporateTaxRate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CreditFacilityAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_GeographicDistributionAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TaxPeriodAxis" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>md-20230930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-11-01T17:51:11.7485+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_PaymentsToTermLoan" xlink:label="md_PaymentsToTermLoan"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_IncreaseDecreaseInAccruedSalariesAndBonuses" xlink:label="md_IncreaseDecreaseInAccruedSalariesAndBonuses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableGrossCurrent" xlink:label="us-gaap_AccountsReceivableGrossCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllOtherCorporateBondsMember" xlink:label="us-gaap_AllOtherCorporateBondsMember"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_BasisOfPresentationAndNewAccountingPronouncementsTable" xlink:label="md_BasisOfPresentationAndNewAccountingPronouncementsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_RepaymentsOfLongTermCapitalLeaseObligation" xlink:label="md_RepaymentsOfLongTermCapitalLeaseObligation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_BusinessCombinationAndDiscontinuedOperationsAbstract" xlink:label="md_BusinessCombinationAndDiscontinuedOperationsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_CashEquivalentsAndInvestmentsTable" xlink:label="md_CashEquivalentsAndInvestmentsTable"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_CovidNinenteenMember" xlink:label="md_CovidNinenteenMember"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_PediatricGastroenterologyAndGynecologyPracticeAndMultiLocationPediatricUrgentCarePracticeMember" xlink:label="md_PediatricGastroenterologyAndGynecologyPracticeAndMultiLocationPediatricUrgentCarePracticeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeniorNotes" xlink:label="us-gaap_SeniorNotes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMember" xlink:label="us-gaap_LongTermDebtMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_RadiologyServicesMedicalGroupMember" xlink:label="md_RadiologyServicesMedicalGroupMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDateDescription" xlink:label="us-gaap_DebtInstrumentMaturityDateDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ExtinguishmentOfDebtTypeDomain" xlink:label="us-gaap_ExtinguishmentOfDebtTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnsecuredLongTermDebt" xlink:label="us-gaap_UnsecuredLongTermDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent" xlink:label="us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_FivePointTwoFivePercentageSeniorNotesDueTwoThousandTwentyThreeMember" xlink:label="md_FivePointTwoFivePercentageSeniorNotesDueTwoThousandTwentyThreeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable" xlink:label="us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember" xlink:label="md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_TwoThousandTwentyThreeMember" xlink:label="md_TwoThousandTwentyThreeMember"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_CommonStockTable" xlink:label="md_CommonStockTable"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_UnnamedCorporateJointVentureTwoMember" xlink:label="md_UnnamedCorporateJointVentureTwoMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_ScheduleOfFinancingReceivablesLineItems" xlink:label="md_ScheduleOfFinancingReceivablesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnsecuredDebt" xlink:label="us-gaap_UnsecuredDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_FairValueDisclosuresTable" xlink:label="md_FairValueDisclosuresTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_IncreaseInDeferredTaxAssets" xlink:label="md_IncreaseInDeferredTaxAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:label="us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SelfPayMember" xlink:label="us-gaap_SelfPayMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfOtherProductiveAssets" xlink:label="us-gaap_ProceedsFromSaleOfOtherProductiveAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_NumberOfMultiLocationPediatricUrgentCarePracticeAcquired" xlink:label="md_NumberOfMultiLocationPediatricUrgentCarePracticeAcquired"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeNet" xlink:label="us-gaap_InvestmentIncomeNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ExecutiveOfficerMember" xlink:label="srt_ExecutiveOfficerMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_TwoThousandTwentySevenMember" xlink:label="md_TwoThousandTwentySevenMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ThirdPartyPayorMember" xlink:label="us-gaap_ThirdPartyPayorMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueAbstract" xlink:label="us-gaap_DisaggregationOfRevenueAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_LineOfCreditLongTermDebtAndFinanceLeaseObligationsDisclosureTextBlock" xlink:label="md_LineOfCreditLongTermDebtAndFinanceLeaseObligationsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesAbstract" xlink:label="us-gaap_ReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="us-gaap_RepaymentsOfLinesOfCredit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_AnesthesiologyServicesMedicalGroupMember" xlink:label="md_AnesthesiologyServicesMedicalGroupMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:label="us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:label="us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_DeferredTaxAssetsAxis" xlink:label="md_DeferredTaxAssetsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:label="us-gaap_HealthCareOrganizationRevenueSourcesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HealthCarePatientServiceMember" xlink:label="us-gaap_HealthCarePatientServiceMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_RuralAreaMember" xlink:label="md_RuralAreaMember"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_CommonStockRepurchasesTextBlock" xlink:label="md_CommonStockRepurchasesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_ContributionsInAidOfReimbursementOfLostRevenue" xlink:label="md_ContributionsInAidOfReimbursementOfLostRevenue"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_ExtraordinaryItemsDomain" xlink:label="md_ExtraordinaryItemsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock" xlink:label="md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_NumberOfPediatricOrThopedicPracticesAcquired" xlink:label="md_NumberOfPediatricOrThopedicPracticesAcquired"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember" xlink:label="md_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_BusinessCombinationAndDiscontinuedOperationsTextBlock" xlink:label="md_BusinessCombinationAndDiscontinuedOperationsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_SixPointTwoFivePercentageSeniorNotesDueTwoThousandTwentySevenMember" xlink:label="md_SixPointTwoFivePercentageSeniorNotesDueTwoThousandTwentySevenMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionDescription" xlink:label="us-gaap_DebtConversionDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_PediatricSubspecialtyPracticeMember" xlink:label="md_PediatricSubspecialtyPracticeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAbstract" xlink:label="us-gaap_LiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ExtinguishmentOfDebtAxis" xlink:label="us-gaap_ExtinguishmentOfDebtAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_PercentageOfNetPatientServiceRevenueByTypeOfPayor" xlink:label="md_PercentageOfNetPatientServiceRevenueByTypeOfPayor"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_CommonStockLineItems" xlink:label="md_CommonStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="us-gaap_RevolvingCreditFacilityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfSeniorDebt" xlink:label="us-gaap_RepaymentsOfSeniorDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_PercentageIncreaseDecreaseInSalaryAndWage" xlink:label="md_PercentageIncreaseDecreaseInSalaryAndWage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GovernmentMember" xlink:label="us-gaap_GovernmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_SixPointTwentyFivePercentageSeniorUnsecuredNotesDue2027Member" xlink:label="md_SixPointTwentyFivePercentageSeniorUnsecuredNotesDue2027Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_MoneyMarketFundsFairValueDisclosure" xlink:label="md_MoneyMarketFundsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentDescription" xlink:label="us-gaap_DebtInstrumentDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:label="us-gaap_USStatesAndPoliticalSubdivisionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TextBlockAbstract" xlink:label="us-gaap_TextBlockAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HealthCareOrganizationRevenueAndExpenseAbstract" xlink:label="us-gaap_HealthCareOrganizationRevenueAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_MutualFundsFairValueDisclosure" xlink:label="md_MutualFundsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationNetOfTaxPerBasicAndDilutedShareAbstract" xlink:label="md_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationNetOfTaxPerBasicAndDilutedShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized" xlink:label="us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_AccruedPayrollTaxesAndBenefitsCurrent" xlink:label="md_AccruedPayrollTaxesAndBenefitsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_PracticeSalariesAndBenefits" xlink:label="md_PracticeSalariesAndBenefits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions" xlink:label="us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DescriptionOfInterestRateRiskExposure" xlink:label="us-gaap_DescriptionOfInterestRateRiskExposure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:label="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve" xlink:label="us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems" xlink:label="us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_CoronavirusPandemicCOVIDNineteenDisclosureTextBlock" xlink:label="md_CoronavirusPandemicCOVIDNineteenDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_TwoZeroThreeZeroMember" xlink:label="md_TwoZeroThreeZeroMember"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_PracticeSuppliesAndOtherOperatingExpenses" xlink:label="md_PracticeSuppliesAndOtherOperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_AmendedAndRestatedTwoThousandEightPlanMember" xlink:label="md_AmendedAndRestatedTwoThousandEightPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfUnsecuredDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfUnsecuredDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_FairValueDisclosuresLineItems" xlink:label="md_FairValueDisclosuresLineItems"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_AccountsReceivableAndNetRevenueDisclosureTextBlock" xlink:label="md_AccountsReceivableAndNetRevenueDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_UnnamedCorporateJointVentureOneMember" xlink:label="md_UnnamedCorporateJointVentureOneMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember" xlink:label="md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent" xlink:label="us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:label="us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_NumberOfPediatricGastroenterologyPracticeAcquired" xlink:label="md_NumberOfPediatricGastroenterologyPracticeAcquired"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_GaapSeniorNotesMember" xlink:label="md_GaapSeniorNotesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_IncrementalSharesInContinuingOperation" xlink:label="md_IncrementalSharesInContinuingOperation"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_ExtraordinaryItemsAbstract" xlink:label="md_ExtraordinaryItemsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_PrimaryBeneficiaryMember" xlink:label="md_PrimaryBeneficiaryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="us-gaap_NotesPayableFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductAndServiceOtherMember" xlink:label="us-gaap_ProductAndServiceOtherMember"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_LineOfCreditAndLongTermDebtTextBlock" xlink:label="md_LineOfCreditAndLongTermDebtTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_FivePointThreeSevenFivePercentUnsecuredSeniorNotesDueTwoThousandThirtyMember" xlink:label="md_FivePointThreeSevenFivePercentUnsecuredSeniorNotesDueTwoThousandThirtyMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateJointVentureMember" xlink:label="us-gaap_CorporateJointVentureMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_CashEquivalentsAndInvestmentsLineItems" xlink:label="md_CashEquivalentsAndInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayable" xlink:label="us-gaap_NotesPayable"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_DissolutionOfAndNetIncomeLossAttributableToNoncontrollingInterest" xlink:label="md_DissolutionOfAndNetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:label="us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_PurchasePrice" xlink:label="md_PurchasePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_BasisOfPresentationLineItems" xlink:label="md_BasisOfPresentationLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="us-gaap_ProceedsFromLinesOfCredit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:label="us-gaap_HealthCareOrganizationRevenueSourcesDomain"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue" xlink:label="md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsMember" xlink:label="us-gaap_CashEquivalentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="us-gaap_DisposalGroupClassificationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_OperatingAndFinanceLeaseRightOfUseAssets" xlink:label="md_OperatingAndFinanceLeaseRightOfUseAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember" xlink:label="md_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="us-gaap_PaymentsToAcquireInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_NorthAmericanPartnersInAnesthesiaMember" xlink:label="md_NorthAmericanPartnersInAnesthesiaMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_PercentageOfRefundOfIncomeTaxAtThePriorPeriodCorporateTaxRate" xlink:label="md_PercentageOfRefundOfIncomeTaxAtThePriorPeriodCorporateTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeographicDistributionDomain" xlink:label="us-gaap_GeographicDistributionDomain"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_TwoThousandTwentyTaxYearMember" xlink:label="md_TwoThousandTwentyTaxYearMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:label="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableGrossAllowanceAndNetAbstract" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableGrossAllowanceAndNetAbstract"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_ExtraordinaryItemsAxis" xlink:label="md_ExtraordinaryItemsAxis"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_DebtInstrumentMaturityYear" xlink:label="md_DebtInstrumentMaturityYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember" xlink:label="md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_DeferredTaxAssetsDomain" xlink:label="md_DeferredTaxAssetsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_HospitalsContractsMember" xlink:label="md_HospitalsContractsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:label="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:label="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="us-gaap_DisposalGroupClassificationAxis"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_CreditAgreementMember" xlink:label="md_CreditAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_IncomelossFromContinuingOperationsPerBasicAndDilutedShareAbstract" xlink:label="md_IncomelossFromContinuingOperationsPerBasicAndDilutedShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="md-20230930.xsd#md_ContractedManagedCareMember" xlink:label="md_ContractedManagedCareMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeographicDistributionAxis" xlink:label="us-gaap_GeographicDistributionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PaymentsToTermLoan_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payments on term loan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PaymentsToTermLoan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Term Loan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PaymentsToTermLoan_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash outflow to term loan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_IncreaseDecreaseInAccruedSalariesAndBonuses_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net decrease in accrued salaries and bonuses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_IncreaseDecreaseInAccruedSalariesAndBonuses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accrued Salaries and Bonuses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_IncreaseDecreaseInAccruedSalariesAndBonuses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase (decrease) in accrued salaries and bonuses.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableGrossCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross accounts receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableGrossCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable, before Allowance for Credit Loss, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllOtherCorporateBondsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Corporate Bonds [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllOtherCorporateBondsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_BasisOfPresentationAndNewAccountingPronouncementsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis of Presentation and New Accounting Pronouncements [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by operating activities - continuing operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities, Continuing Operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_RepaymentsOfLongTermCapitalLeaseObligation_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payment on finance lease obligation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_RepaymentsOfLongTermCapitalLeaseObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Repayments Of Long Term Capital Lease Obligation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_RepaymentsOfLongTermCapitalLeaseObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Repayments Of Long Term Capital Lease Obligation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award vesting period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-sale, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Available-for-sale Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">(Loss) income from continuing operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income from continuing operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Liabilities, Noncurrent, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Prepaid Expense and Other Assets, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Income taxes payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income taxes receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Income Taxes Receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_BusinessCombinationAndDiscontinuedOperationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination And Discontinued Operations [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_BusinessCombinationAndDiscontinuedOperationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Business combination and discontinued operations [Abstract].</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_CashEquivalentsAndInvestmentsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Equivalents and Investments [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_CovidNinenteenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">COVID-19 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_CovidNinenteenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Covid Ninenteen [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_CovidNinenteenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Covid Ninenteen [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PediatricGastroenterologyAndGynecologyPracticeAndMultiLocationPediatricUrgentCarePracticeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pediatric Gastroenterology And Gynecology practice And Multi Location Pediatric Urgent Care Practice [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PediatricGastroenterologyAndGynecologyPracticeAndMultiLocationPediatricUrgentCarePracticeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Pediatric Gastroenterology And Gynecology practice And Multi Location Pediatric Urgent Care Practice [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeniorNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Senior Notes, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeniorNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Senior Notes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeniorNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Senior notes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase decrease in valuation allowance deferred tax assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Net Revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Acquisition payments, net of cash acquired</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Businesses, Net of Cash Acquired, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Long-Term Debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term A loan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Basis of Presentation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of Individual [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Repurchased common stock, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Repurchased During Period, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock repurchased during period, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_RadiologyServicesMedicalGroupMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Radiology Services Medical Group [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_RadiologyServicesMedicalGroupMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Radiology Services Medical Group [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments, Fair Value Disclosure</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Investments, Fair Value Disclosure, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Net loss attributable to noncontrolling interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss) Attributable to Noncontrolling Interest, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss attributable to noncontrolling interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Net loss attributable to noncontrolling interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Dissolution of and net loss attributable to noncontrolling interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentMaturityDateDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Maturity Date, Description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentMaturityDateDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument maturity date description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ExtinguishmentOfDebtTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Extinguishment of Debt, Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnsecuredLongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unsecured Long-Term Debt, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnsecuredLongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of unsecured debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and shareholders' equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term professional liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Malpractice Loss Contingency, Accrual, Undiscounted, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred income tax assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Assets, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Income Tax Assets, Net, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_FivePointTwoFivePercentageSeniorNotesDueTwoThousandTwentyThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Five Point Two Five Percentage Senior Notes Due Two Thousand Twenty Three [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_FivePointTwoFivePercentageSeniorNotesDueTwoThousandTwentyThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Five Point Two Five Percentage Senior Notes Due Two Thousand Twenty Three [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_FivePointTwoFivePercentageSeniorNotesDueTwoThousandTwentyThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Five Point Two Five Percentage Senior Notes Due Two Thousand Twenty Three [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Revenue Sources, Health Care Organization [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Revenue Sources, Health Care Organization [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total comprehensive income (loss) attributable to Pediatrix Medical Group, Inc.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total comprehensive income attributable to Pediatrix Medical Group, Inc.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2015 Non-Qualified Stock Purchase Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Fifteen Non Qualified Stock Purchase Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two Thousand Fifteen Non Qualified Stock Purchase Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Shares, Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Available-for-sale [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_TwoThousandTwentyThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023 Notes [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_TwoThousandTwentyThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Three [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_CommonStockTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_CommonStockTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_CommonStockTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common Stock [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_UnnamedCorporateJointVentureTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unnamed Corporate Joint Venture Two [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_UnnamedCorporateJointVentureTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Unnamed Corporate Joint Venture Two [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit Facility, Remaining Borrowing Capacity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Line of Credit facility, available balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_ScheduleOfFinancingReceivablesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Financing Receivables [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_ScheduleOfFinancingReceivablesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Financing Receivables [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_ScheduleOfFinancingReceivablesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of financing receivables.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, reserved for issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Loss [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">AOCI Attributable to Parent [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnsecuredDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Unsecured Debt, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnsecuredDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unsecured Debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnsecuredDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unsecured note issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_FairValueDisclosuresTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_FairValueDisclosuresTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value disclosures.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income taxes payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Income Taxes Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_IncreaseInDeferredTaxAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in deferred tax assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_IncreaseInDeferredTaxAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase In Deferred Tax assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_IncreaseInDeferredTaxAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase in deferred tax Assets.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-in Capital [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid-in Capital [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Allowance for contractual adjustments and uncollectibles</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current portion of operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer, Including Assessed Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average common shares:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic, Other Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Maturity Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument Maturity Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Long-term Debt, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long term debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, Plant and Equipment, Net, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Net, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Net, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Transformational and restructuring related expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Charges</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Restructuring Charges, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scenario [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SelfPayMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Private-Pay Patients [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SelfPayMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Self-Pay [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfOtherProductiveAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfOtherProductiveAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Sale of Other Productive Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">(Loss) income from continuing operations before income taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income from continuing operations before income taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in assets and liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instruments [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment, Name [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock issued under employee stock option, employee stock purchase plan and stock purchase plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net cash used in investing activities - continuing operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities, Continuing Operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in investing activities - continuing operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_NumberOfMultiLocationPediatricUrgentCarePracticeAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of other multi location pediatric urgent care practice acquired</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_NumberOfMultiLocationPediatricUrgentCarePracticeAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Multi Location Pediatric Urgent Care Practice Acquired</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_NumberOfMultiLocationPediatricUrgentCarePracticeAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of multi location pediatric urgent care practice acquired.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeNet_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Investment and other income (expense)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Investment Income, Net, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment and other income</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ExecutiveOfficerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Executive Officer [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ExecutiveOfficerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Executive Officer [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party, Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Retained deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings (Accumulated Deficit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Retained Earnings (Accumulated Deficit), Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Retained Earnings (Accumulated Deficit), Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_TwoThousandTwentySevenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027 Notes [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_TwoThousandTwentySevenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Seven [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred income tax liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Liabilities, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Income Tax Liabilities, Net, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate number Shares issued under Stock Purchase Plans</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock issued under employee stock option, employee stock purchase plan and stock purchase plan, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Minimum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ThirdPartyPayorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Third-Parties [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ThirdPartyPayorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Third-Party Payor [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Income Taxes, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income taxes payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disaggregation of Revenue [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation of Revenue [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_LineOfCreditLongTermDebtAndFinanceLeaseObligationsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Line of Credit and Long Term Debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_LineOfCreditLongTermDebtAndFinanceLeaseObligationsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line Of Credit Long Term Debt And Finance Lease Obligations Disclosure Text Block</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_LineOfCreditLongTermDebtAndFinanceLeaseObligationsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Line of credit long term debt and finance lease obligations disclosure text block.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReceivablesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Receivables [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of premiums, discounts and issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Amortization of Debt Issuance Costs and Discounts, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfLinesOfCredit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payments on credit agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfLinesOfCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Repayments of Lines of Credit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net income to net cash from operating activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_AnesthesiologyServicesMedicalGroupMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Anesthesiology Services Medical Group [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_AnesthesiologyServicesMedicalGroupMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Anesthesiology services medical group.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock, shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, aggregate shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition, Goodwill, Expected Tax Deductible Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchaseProgramAuthorizedAmount1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock authorized for repurchase</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchaseProgramAuthorizedAmount1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Repurchase Program, Authorized Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASSETS</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares available for future grants and awards under Stock Incentive Plans</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_DeferredTaxAssetsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock; $.01 par value; 200,000 shares authorized; 83,929 and 82,947 shares issued and outstanding, respectively</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Value, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Value, Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Value, Issued, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Value, Issued, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations, Per Diluted Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Noncash Income (Expense)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Noncash Income (Expense), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_HealthCareOrganizationRevenueSourcesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Health Care Organization, Revenue Sources [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_HealthCareOrganizationRevenueSourcesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Health Care Organization, Revenue Sources [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_HealthCarePatientServiceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net patient service revenue [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_HealthCarePatientServiceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Health Care, Patient Service [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Payment Arrangement, Noncash Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income from operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income from operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income (Loss)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Consideration Transferred</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Business Combination, Consideration Transferred, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business acquisition total consideration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxPeriodAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Period [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred income taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Expense (Benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Income Tax Expense (Benefit), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense (Benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income Tax Expense (Benefit), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Income tax benefit (provision)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Income tax provision</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_RuralAreaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rural Area [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_RuralAreaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Rural Area [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_RuralAreaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Rural Area [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_CommonStockRepurchasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock Repurchase Programs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_CommonStockRepurchasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Repurchases [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_CommonStockRepurchasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Entire disclosure of common stock repurchases.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_ContributionsInAidOfReimbursementOfLostRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reimbursement of Lost Revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_ContributionsInAidOfReimbursementOfLostRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contributions In Aid Of Reimbursement of Lost Revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_ContributionsInAidOfReimbursementOfLostRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contributions In Aid Of Reimbursement of Lost Revenue.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_ExtraordinaryItemsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Extraordinary Items [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_ExtraordinaryItemsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Extraordinary Items [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Cash_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Cash_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Cash_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Cash_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash on hand</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts Payable and Accrued Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Finite-Lived Intangible Assets, Net, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Finite-Lived Intangible Assets, Net, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Finite-Lived Intangible Assets, Net, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Financial Instruments Measured At Carrying Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instruments Measured At Carrying Amount Table Text Block</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tabular disclosure of financial instruments measured at carrying amount.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_NumberOfPediatricOrThopedicPracticesAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of other pediatric orthopedic practice acquired</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_NumberOfPediatricOrThopedicPracticesAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Pediatric Or thopedic Practices Acquired</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_NumberOfPediatricOrThopedicPracticesAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of pediatric or thopedic practices acquired.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Retained Deficit [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings And Accumulated Other Comprehensive Income [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Retained earnings and accumulated other comprehensive income [Member].</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive (loss) income, net of tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_BusinessCombinationAndDiscontinuedOperationsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Business Combination and Discontinued Operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_BusinessCombinationAndDiscontinuedOperationsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination And Discontinued Operations [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_BusinessCombinationAndDiscontinuedOperationsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Business combination and discontinued operations [Text Block].</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_SixPointTwoFivePercentageSeniorNotesDueTwoThousandTwentySevenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Six Point Two Five Percentage Senior Notes Due Two Thousand Twenty Seven [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_SixPointTwoFivePercentageSeniorNotesDueTwoThousandTwentySevenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Six Point Two Five Percentage Senior Notes Due Two Thousand Twenty Seven [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_SixPointTwoFivePercentageSeniorNotesDueTwoThousandTwentySevenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Six Point Two Five Percentage Senior Notes Due Two Thousand Twenty Seven [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Schedule of Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtConversionDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Conversion, Description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtConversionDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Conversion Description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Federal Home Loan Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Government-sponsored Enterprises Debt Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Other non-current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Assets, Noncurrent, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PediatricSubspecialtyPracticeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Pediatric Subspecialty Practice [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PediatricSubspecialtyPracticeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pediatric Subspecialty Practice [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PediatricSubspecialtyPracticeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pediatric Subspecialty Practice [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other accrued expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedSalariesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued salaries and incentive compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedSalariesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Salaries, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ExtinguishmentOfDebtAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Extinguishment of Debt [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shareholders' equity:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of property and equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Other Property, Plant, and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net income attributable to Pediatrix Medical Group, Inc.:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PercentageOfNetPatientServiceRevenueByTypeOfPayor_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of net patient service revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PercentageOfNetPatientServiceRevenueByTypeOfPayor_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Net Patient Service Revenue By Type Of Payor</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PercentageOfNetPatientServiceRevenueByTypeOfPayor_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of net patient service revenue by type payor.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_EquityMethodInvesteeNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment, Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementScenarioAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scenario [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_CommonStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_CommonStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_CommonStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common Stock [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument, interest rate, effective percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevolvingCreditFacilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revolving Credit Facility [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Short-term investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-sale, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfSeniorDebt_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Redemption of senior notes, including call premium</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfSeniorDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Repayments of Senior Debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfSeniorDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Repayments of Senior Debt, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party, Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable and accrued expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accounts Payable and Accrued Liabilities, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PercentageIncreaseDecreaseInSalaryAndWage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Decrease In Salary | %</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PercentageIncreaseDecreaseInSalaryAndWage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Increase Decrease In Salary And Wage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PercentageIncreaseDecreaseInSalaryAndWage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage Increase Decrease In Salary And Wage.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Range [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by operating activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GovernmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Government [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GovernmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Government [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Range [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Diluted, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_SixPointTwentyFivePercentageSeniorUnsecuredNotesDue2027Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">6.25% senior unsecured notes due 2027</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_SixPointTwentyFivePercentageSeniorUnsecuredNotesDue2027Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Six Point Twenty Five Percentage senior unsecured notes due 2027 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_SixPointTwentyFivePercentageSeniorUnsecuredNotesDue2027Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Six Point Twenty Five Percentage senior unsecured notes due 2027 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_MoneyMarketFundsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value of money market funds.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_MoneyMarketFundsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds Fair Value Disclosure</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_MoneyMarketFundsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money market funds</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument, Description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid in Capital, Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Additional Paid in Capital, Common Stock, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Additional Paid in Capital, Common Stock, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Treasury securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Treasury Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Payments for repurchase of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amount withheld to satisfy minimum statutory tax withholding obligations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Repurchases of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments for Repurchase of Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">LIABILITIES AND EQUITY</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Restricted Stock Award, Forfeitures</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Forfeitures of restricted stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CreditFacilityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Credit Facility [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USStatesAndPoliticalSubdivisionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Municipal Debt Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USStatesAndPoliticalSubdivisionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US States and Political Subdivisions Debt Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TextBlockAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Text Block [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_HealthCareOrganizationRevenueAndExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Health Care Organization Revenue and Expense [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_MutualFundsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Mutual funds fair value disclosure.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_MutualFundsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Mutual Funds Fair Value Disclosure</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_MutualFundsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Mutual funds</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Components [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accounts receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationNetOfTaxPerBasicAndDilutedShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income from discontinued operations:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationNetOfTaxPerBasicAndDilutedShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operation, Net of Tax, Per Basic and Diluted Share [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationNetOfTaxPerBasicAndDilutedShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operation, Net of Tax, Per Basic and Diluted Share [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Other Operating Liabilities, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Businesses, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business acquisition consideration paid in cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from maturities or sales of investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Sale, Maturity and Collection of Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds from Sale, Maturity and Collection of Investments, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Goodwill, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Goodwill, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Goodwill, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Cash Flows [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Liabilities Arising from Contingencies, Amount Recognized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business combination consideration identifiable as current and long term liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_AccruedPayrollTaxesAndBenefitsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued payroll taxes and benefits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_AccruedPayrollTaxesAndBenefitsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Payroll Taxes And Benefits Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_AccruedPayrollTaxesAndBenefitsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued payroll taxes and benefits current.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PracticeSalariesAndBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Practice salaries and benefits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PracticeSalariesAndBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Practice Salaries and Benefits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PracticeSalariesAndBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Practice salaries and benefits.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Accumulated other comprehensive loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Other Comprehensive Income (Loss), Net of Tax, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Par or Stated Value Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument interest rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax adjustments, sttlements and unusual provisions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Adjustments, Settlements, and Unusual Provisions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DescriptionOfInterestRateRiskExposure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Description of Interest Rate Risk Exposure</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DescriptionOfInterestRateRiskExposure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest Rate, description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Other intangible assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net cash used in operating activities - discontinued operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Provided by (Used in) Operating Activities, Discontinued Operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net cash provided by operating activities - discontinued operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash Provided by (Used in) Operating Activities, Discontinued Operations, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Long-Term Debt and Lease Obligation, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt and Lease Obligation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term debt and finance lease liabilities, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payables and Accruals [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term professional liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Liability for Claims and Claims Adjustment Expense Reserve</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Health Care Organization, Receivable and Revenue Disclosures [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Health Care Organization, Receivable and Revenue Disclosures [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_CoronavirusPandemicCOVIDNineteenDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Coronavirus Pandemic COVID Nineteen Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_CoronavirusPandemicCOVIDNineteenDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Coronavirus Pandemic COVID Nineteen Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_CoronavirusPandemicCOVIDNineteenDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Coronavirus Pandemic (COVID-19)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average number of dilutive common share equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Incremental Common Shares Attributable to Share-based Payment Arrangements, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Forfeitures of restricted stock, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Restricted Stock Award, Forfeited</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Forfeitures of restricted stock, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from operating activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Cash Equivalents and Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_TwoZeroThreeZeroMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two Zero Three Zero [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_TwoZeroThreeZeroMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Zero Three Zero [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_TwoZeroThreeZeroMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2030 Notes [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PracticeSuppliesAndOtherOperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Practice supplies and other operating expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PracticeSuppliesAndOtherOperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Practice Supplies And Other Operating Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PracticeSuppliesAndOtherOperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The aggregate amount of supplies and other operating expenses directly attributable to the physician practices.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_AmendedAndRestatedTwoThousandEightPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amended and Restated 2008 Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_AmendedAndRestatedTwoThousandEightPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amended and Restated Two Thousand Eight Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_AmendedAndRestatedTwoThousandEightPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amended and restated two thousand eight plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">General and Administrative Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfUnsecuredDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Unsecured Debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfUnsecuredDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of unsecured debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted average number of common shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Basic, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from financing activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Loss on early extinguishment of debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss on early extinguishment of debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Gain (Loss) on Extinguishment of Debt, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_FairValueDisclosuresLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_FairValueDisclosuresLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value disclosures.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_AccountsReceivableAndNetRevenueDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts Receivable and Net Revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_AccountsReceivableAndNetRevenueDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable And Net Revenue Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_AccountsReceivableAndNetRevenueDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accounts receivable and net revenue disclosure.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_UnnamedCorporateJointVentureOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unnamed Corporate Joint Venture One [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_UnnamedCorporateJointVentureOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unnamed Corporate Joint Venture [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity in earnings of unconsolidated affiliate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Equity Method Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income (Loss) from Equity Method Investments, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">1996 Non-Qualified Employee Stock Purchase Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nineteen Ninety Six Non Qualified Employee Stock Purchase Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">1996 non-qualified employee stock purchase plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued professional liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Malpractice Loss Contingency, Accrual, Undiscounted, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net cash used in investing activities - discontinued operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Provided by (Used in) Investing Activities, Discontinued Operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net cash provided by investing activities - discontinued operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfFinancingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments of Financing Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfFinancingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments of Financing Costs, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfFinancingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payments for financing costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfFinancingCosts_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payments for financing costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_NumberOfPediatricGastroenterologyPracticeAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Pediatric Gastroenterology Practice Acquired</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_NumberOfPediatricGastroenterologyPracticeAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Pediatric Gastroenterology Practice Acquired</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_NumberOfPediatricGastroenterologyPracticeAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of Pediatric Gastroenterology Practice Acquired</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_GaapSeniorNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">GAAP Senior Notes [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_GaapSeniorNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">GAAP Senior Notes [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_GaapSeniorNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">GAAP Senior Notes [Member].</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Antidilutive securities (restricted stock and stock options) not included in the diluted net income per common share calculation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts receivable, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts receivable, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_IncrementalSharesInContinuingOperation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Incremental Shares In Continuing operation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_IncrementalSharesInContinuingOperation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Incremental Shares In Continuing operation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_ExtraordinaryItemsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Extraordinary Items [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_ExtraordinaryItemsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Extraordinary Items [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and cash equivalents at beginning of period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and cash equivalents at end of period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and Cash Equivalents, at Carrying Value, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Repurchased common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Repurchased common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Repurchased During Period, Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Prepaid Expense, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Incremental loss on sale, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PrimaryBeneficiaryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Primary beneficiary [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PrimaryBeneficiaryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Primary beneficiary [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fixed assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Senior Long-Term Debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from senior notes and term loan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NotesPayableFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Notes Payable Fair Value Disclosure</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NotesPayableFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Notes Payable, Fair Value Disclosure</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProductAndServiceOtherMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Other revenue [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProductAndServiceOtherMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service, Other [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_LineOfCreditAndLongTermDebtTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Line Of Credit And Long Term Debt [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_LineOfCreditAndLongTermDebtTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line Of Credit And Long Term Debt [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_LineOfCreditAndLongTermDebtTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Line of Credit and Long Term Debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Payable, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_FivePointThreeSevenFivePercentUnsecuredSeniorNotesDueTwoThousandThirtyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Five point three seven five percent unsecured senior notes due two thousand thirty member.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_FivePointThreeSevenFivePercentUnsecuredSeniorNotesDueTwoThousandThirtyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Five Point Three Seven Five Percent Unsecured Senior Notes Due Two Thousand Thirty Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_FivePointThreeSevenFivePercentUnsecuredSeniorNotesDueTwoThousandThirtyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">5.375% Unsecured Senior Notes Due 2030 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateJointVentureMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Corporate Joint Venture [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of restricted stock and conversion of restricted stock units to common stock, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of restricted stock, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued, Shares, Share-Based Payment Arrangement, before Forfeiture</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting period of options, maximum years</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">New Accounting Pronouncements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Preferred Stock, Shares Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_CashEquivalentsAndInvestmentsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Equivalents And Investments [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NotesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Notes Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NotesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Notes Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NotesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Notes Payable, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_DissolutionOfAndNetIncomeLossAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Dissolution Of And Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_DissolutionOfAndNetIncomeLossAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Dissolution Of And Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_DissolutionOfAndNetIncomeLossAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dissolution of and net loss attributable to noncontrolling interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instrument [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Comprehensive Income (Loss), Available-for-Sale Securities, Tax, Portion Attributable to Parent, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Available-for-Sale Securities, Tax, Portion Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Other Comprehensive Income (Loss), Available-for-Sale Securities, Tax, Portion Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Comprehensive Income (Loss), Available-for-Sale Securities, Tax, Portion Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Calculation of Shares Used in Basic and Diluted Net Income Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Weighted Average Number of Shares [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PurchasePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Purchase price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PurchasePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Purchase price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PurchasePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity method ownership percentage in joint venture</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investment, Ownership Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_BasisOfPresentationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis Of Presentation [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromLinesOfCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds from Lines of Credit, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromLinesOfCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Borrowings on credit agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromLinesOfCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Lines of Credit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromLinesOfCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Borrowings on revolving credit line</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_HealthCareOrganizationRevenueSourcesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Health Care Organization, Revenue Sources [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_HealthCareOrganizationRevenueSourcesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Health Care Organization, Revenue Sources [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds From Contribution In Aid Of Reimbursement of Lost Revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Contribution In Aid Of Reimbursement of Lost Revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds From Contribution In Aid Of Reimbursement of Lost Revenue.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxPeriodDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Period [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Securities Act File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized holding gain (loss) on investments, net of tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Equivalents [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income (loss) from discontinued operations, net of tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Loss (income) from discontinued operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Loss from discontinued operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisposalGroupClassificationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disposal Group Classification [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_OperatingAndFinanceLeaseRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating and finance lease right-of-use assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_OperatingAndFinanceLeaseRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating And Finance Lease Right Of Use Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_OperatingAndFinanceLeaseRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating and finance lease right-of-use assets.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Percentage of Net Revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">2027 Notes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">6.25% Senior Unsecured Notes Due 2027 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Six Point Two Five Percent Senior Unsecured Notes Due Two Thousand Twenty Seven [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Six point two five percent senior unsecured notes due two thousand twenty seven.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock; $.01 par value; 1,000 shares authorized; none issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Value, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Preferred Stock, Value, Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Value, Issued, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Value, Issued, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of Individual [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Investments, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CertificatesOfDepositMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Certificates of Deposit [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CertificatesOfDepositMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Certificates of Deposit [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_NorthAmericanPartnersInAnesthesiaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">North American Partners In Anesthesia [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_NorthAmericanPartnersInAnesthesiaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">North American Partners In Anesthesia [member].</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common and Common Equivalent Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PercentageOfRefundOfIncomeTaxAtThePriorPeriodCorporateTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Percentage of refund of income tax at the prior period corporate tax rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PercentageOfRefundOfIncomeTaxAtThePriorPeriodCorporateTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Refund Of Income Tax At The Prior Period Corporate Tax Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PercentageOfRefundOfIncomeTaxAtThePriorPeriodCorporateTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of refund of income tax at the prior period corporate tax rate.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeographicDistributionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographic Distribution [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_TwoThousandTwentyTaxYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">2020 Tax Year [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_TwoThousandTwentyTaxYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Tax Year [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_TwoThousandTwentyTaxYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty tax year.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net income</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Debt Instrument, Frequency of Periodic Payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Frequency of Periodic Payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument maturity date description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableGrossAllowanceAndNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts, Notes, Loans and Financing Receivable, Gross, Allowance, and Net [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_ExtraordinaryItemsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Extraordinary Items [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_ExtraordinaryItemsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Extraordinary Items [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_DebtInstrumentMaturityYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument, maturity year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_DebtInstrumentMaturityYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Maturity Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_DebtInstrumentMaturityYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument maturity year.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Depreciation and amortization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation, Depletion and Amortization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Depletion and Amortization, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">1996 Non-Qualified Employee Stock Purchase Plan and 2015 Non-Qualified Stock Purchase Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nineteen Ninety Six Non Qualified Employee Stock Purchase Plan And Two Thousand Fifteen Non Qualified Stock Purchase Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Nineteen Ninety Six Non Qualified Employee Stock Purchase Plan And Two Thousand Fifteen Non Qualified Stock Purchase Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Cash equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds, at Carrying Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_DeferredTaxAssetsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_HospitalsContractsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Hospital contract administrative fees [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_HospitalsContractsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Hospitals Contracts [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_HospitalsContractsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Hospitals Contracts [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from investing activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts payable and accrued expenses, total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable and Accrued Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable and accrued expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Long-term Line of Credit, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Line of Credit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Line of credit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current portion of debt and finance lease liabilities, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt and Lease Obligation, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Long-Term Debt and Lease Obligation, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Company's Common stock repurchased</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Repurchase Program, Remaining Authorized Repurchase Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Shares, Outstanding, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Shares, Outstanding, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Repurchase Program, Number of Shares Authorized to be Repurchased</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Incentive Plans and Stock Purchase Plans</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Accounts Receivable, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in investing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentQuarterlyReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Quarterly Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisposalGroupClassificationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disposal Group Classification [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_CreditAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Credit Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_CreditAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Credit Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_CreditAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Credit Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_CreditAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amended Credit Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_IncomelossFromContinuingOperationsPerBasicAndDilutedShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">(Loss) income from continuing operations:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_IncomelossFromContinuingOperationsPerBasicAndDilutedShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Loss from Continuing Operations Per Basic and Diluted Share [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_IncomelossFromContinuingOperationsPerBasicAndDilutedShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">It represents Income (Loss) from continuing operations, per basic and diluted share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in financing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Periodic Payment, Interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest accrued periodically</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other long-term assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total non-operating expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income (Expense)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_ContractedManagedCareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contracted Managed Care [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_ContractedManagedCareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contracted Managed Care [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_ContractedManagedCareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contracted Managed Care [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of restricted stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued, Value, Share-Based Payment Arrangement, before Forfeiture</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total shareholders' equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Stockholders' Equity Attributable to Parent, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Stockholders' Equity Attributable to Parent, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net income</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net income attributable to Pediatrix Medical Group, Inc.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Interest expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Interest Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeographicDistributionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographic Distribution [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business combination consideration identifiable as current and long term liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted average number of common and common equivalent shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CreditFacilityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Credit Facility [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations, Per Basic Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income (Loss) from Continuing Operations, Per Outstanding Share, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Accounts Payable and Accrued Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of market value of common stock at which employees are permitted to purchase</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and cash equivalents at end of period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and cash equivalents at beginning of period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_PaymentsToTermLoan" xlink:to="md_PaymentsToTermLoan_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_IncreaseDecreaseInAccruedSalariesAndBonuses" xlink:to="md_IncreaseDecreaseInAccruedSalariesAndBonuses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableGrossCurrent" xlink:to="us-gaap_AccountsReceivableGrossCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllOtherCorporateBondsMember" xlink:to="us-gaap_AllOtherCorporateBondsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_BasisOfPresentationAndNewAccountingPronouncementsTable" xlink:to="md_BasisOfPresentationAndNewAccountingPronouncementsTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_RepaymentsOfLongTermCapitalLeaseObligation" xlink:to="md_RepaymentsOfLongTermCapitalLeaseObligation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:to="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_BusinessCombinationAndDiscontinuedOperationsAbstract" xlink:to="md_BusinessCombinationAndDiscontinuedOperationsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_CashEquivalentsAndInvestmentsTable" xlink:to="md_CashEquivalentsAndInvestmentsTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_CovidNinenteenMember" xlink:to="md_CovidNinenteenMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_PediatricGastroenterologyAndGynecologyPracticeAndMultiLocationPediatricUrgentCarePracticeMember" xlink:to="md_PediatricGastroenterologyAndGynecologyPracticeAndMultiLocationPediatricUrgentCarePracticeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeniorNotes" xlink:to="us-gaap_SeniorNotes_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMember" xlink:to="us-gaap_LongTermDebtMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_RadiologyServicesMedicalGroupMember" xlink:to="md_RadiologyServicesMedicalGroupMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsFairValueDisclosure" xlink:to="us-gaap_InvestmentsFairValueDisclosure_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDateDescription" xlink:to="us-gaap_DebtInstrumentMaturityDateDescription_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExtinguishmentOfDebtTypeDomain" xlink:to="us-gaap_ExtinguishmentOfDebtTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnsecuredLongTermDebt" xlink:to="us-gaap_UnsecuredLongTermDebt_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent" xlink:to="us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_FivePointTwoFivePercentageSeniorNotesDueTwoThousandTwentyThreeMember" xlink:to="md_FivePointTwoFivePercentageSeniorNotesDueTwoThousandTwentyThreeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable" xlink:to="us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember" xlink:to="md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_TwoThousandTwentyThreeMember" xlink:to="md_TwoThousandTwentyThreeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_CommonStockTable" xlink:to="md_CommonStockTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_UnnamedCorporateJointVentureTwoMember" xlink:to="md_UnnamedCorporateJointVentureTwoMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_ScheduleOfFinancingReceivablesLineItems" xlink:to="md_ScheduleOfFinancingReceivablesLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnsecuredDebt" xlink:to="us-gaap_UnsecuredDebt_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_FairValueDisclosuresTable" xlink:to="md_FairValueDisclosuresTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:to="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_IncreaseInDeferredTaxAssets" xlink:to="md_IncreaseInDeferredTaxAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:to="us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCharges" xlink:to="us-gaap_RestructuringCharges_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SelfPayMember" xlink:to="us-gaap_SelfPayMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfOtherProductiveAssets" xlink:to="us-gaap_ProceedsFromSaleOfOtherProductiveAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_NumberOfMultiLocationPediatricUrgentCarePracticeAcquired" xlink:to="md_NumberOfMultiLocationPediatricUrgentCarePracticeAcquired_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeNet" xlink:to="us-gaap_InvestmentIncomeNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ExecutiveOfficerMember" xlink:to="srt_ExecutiveOfficerMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_TwoThousandTwentySevenMember" xlink:to="md_TwoThousandTwentySevenMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ThirdPartyPayorMember" xlink:to="us-gaap_ThirdPartyPayorMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedIncomeTaxesCurrent" xlink:to="us-gaap_AccruedIncomeTaxesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueAbstract" xlink:to="us-gaap_DisaggregationOfRevenueAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_LineOfCreditLongTermDebtAndFinanceLeaseObligationsDisclosureTextBlock" xlink:to="md_LineOfCreditLongTermDebtAndFinanceLeaseObligationsDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_ReceivablesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLinesOfCredit" xlink:to="us-gaap_RepaymentsOfLinesOfCredit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_AnesthesiologyServicesMedicalGroupMember" xlink:to="md_AnesthesiologyServicesMedicalGroupMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:to="us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="us-gaap_StockRepurchaseProgramAuthorizedAmount1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_DeferredTaxAssetsAxis" xlink:to="md_DeferredTaxAssetsAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashIncomeExpense" xlink:to="us-gaap_OtherNoncashIncomeExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:to="us-gaap_HealthCareOrganizationRevenueSourcesAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HealthCarePatientServiceMember" xlink:to="us-gaap_HealthCarePatientServiceMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_RuralAreaMember" xlink:to="md_RuralAreaMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_CommonStockRepurchasesTextBlock" xlink:to="md_CommonStockRepurchasesTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_ContributionsInAidOfReimbursementOfLostRevenue" xlink:to="md_ContributionsInAidOfReimbursementOfLostRevenue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_ExtraordinaryItemsDomain" xlink:to="md_ExtraordinaryItemsDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock" xlink:to="md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_NumberOfPediatricOrThopedicPracticesAcquired" xlink:to="md_NumberOfPediatricOrThopedicPracticesAcquired_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember" xlink:to="md_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_LongtermDebtTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_BusinessCombinationAndDiscontinuedOperationsTextBlock" xlink:to="md_BusinessCombinationAndDiscontinuedOperationsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_SixPointTwoFivePercentageSeniorNotesDueTwoThousandTwentySevenMember" xlink:to="md_SixPointTwoFivePercentageSeniorNotesDueTwoThousandTwentySevenMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionDescription" xlink:to="us-gaap_DebtConversionDescription_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_PediatricSubspecialtyPracticeMember" xlink:to="md_PediatricSubspecialtyPracticeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedSalariesCurrent" xlink:to="us-gaap_AccruedSalariesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExtinguishmentOfDebtAxis" xlink:to="us-gaap_ExtinguishmentOfDebtAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_PercentageOfNetPatientServiceRevenueByTypeOfPayor" xlink:to="md_PercentageOfNetPatientServiceRevenueByTypeOfPayor_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="srt_EquityMethodInvesteeNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_CommonStockLineItems" xlink:to="md_CommonStockLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevolvingCreditFacilityMember" xlink:to="us-gaap_RevolvingCreditFacilityMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfSeniorDebt" xlink:to="us-gaap_RepaymentsOfSeniorDebt_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_PercentageIncreaseDecreaseInSalaryAndWage" xlink:to="md_PercentageIncreaseDecreaseInSalaryAndWage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GovernmentMember" xlink:to="us-gaap_GovernmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_SixPointTwentyFivePercentageSeniorUnsecuredNotesDue2027Member" xlink:to="md_SixPointTwentyFivePercentageSeniorUnsecuredNotesDue2027Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_MoneyMarketFundsFairValueDisclosure" xlink:to="md_MoneyMarketFundsFairValueDisclosure_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentDescription" xlink:to="us-gaap_DebtInstrumentDescription_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasurySecuritiesMember" xlink:to="us-gaap_USTreasurySecuritiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_CreditFacilityDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:to="us-gaap_USStatesAndPoliticalSubdivisionsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TextBlockAbstract" xlink:to="us-gaap_TextBlockAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HealthCareOrganizationRevenueAndExpenseAbstract" xlink:to="us-gaap_HealthCareOrganizationRevenueAndExpenseAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_MutualFundsFairValueDisclosure" xlink:to="md_MutualFundsFairValueDisclosure_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationNetOfTaxPerBasicAndDilutedShareAbstract" xlink:to="md_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationNetOfTaxPerBasicAndDilutedShareAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:to="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized" xlink:to="us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_AccruedPayrollTaxesAndBenefitsCurrent" xlink:to="md_AccruedPayrollTaxesAndBenefitsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_PracticeSalariesAndBenefits" xlink:to="md_PracticeSalariesAndBenefits_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions" xlink:to="us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DescriptionOfInterestRateRiskExposure" xlink:to="us-gaap_DescriptionOfInterestRateRiskExposure_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:to="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:to="us-gaap_LongTermDebtAndCapitalLeaseObligations_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve" xlink:to="us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems" xlink:to="us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_CoronavirusPandemicCOVIDNineteenDisclosureTextBlock" xlink:to="md_CoronavirusPandemicCOVIDNineteenDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_TwoZeroThreeZeroMember" xlink:to="md_TwoZeroThreeZeroMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_PracticeSuppliesAndOtherOperatingExpenses" xlink:to="md_PracticeSuppliesAndOtherOperatingExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_AmendedAndRestatedTwoThousandEightPlanMember" xlink:to="md_AmendedAndRestatedTwoThousandEightPlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfUnsecuredDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfUnsecuredDebt_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_FairValueDisclosuresLineItems" xlink:to="md_FairValueDisclosuresLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_AccountsReceivableAndNetRevenueDisclosureTextBlock" xlink:to="md_AccountsReceivableAndNetRevenueDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_UnnamedCorporateJointVentureOneMember" xlink:to="md_UnnamedCorporateJointVentureOneMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember" xlink:to="md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent" xlink:to="us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:to="us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfFinancingCosts" xlink:to="us-gaap_PaymentsOfFinancingCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_NumberOfPediatricGastroenterologyPracticeAcquired" xlink:to="md_NumberOfPediatricGastroenterologyPracticeAcquired_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_GaapSeniorNotesMember" xlink:to="md_GaapSeniorNotesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_IncrementalSharesInContinuingOperation" xlink:to="md_IncrementalSharesInContinuingOperation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_ExtraordinaryItemsAbstract" xlink:to="md_ExtraordinaryItemsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="us-gaap_StockRepurchasedDuringPeriodValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_PrimaryBeneficiaryMember" xlink:to="md_PrimaryBeneficiaryMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableFairValueDisclosure" xlink:to="us-gaap_NotesPayableFairValueDisclosure_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductAndServiceOtherMember" xlink:to="us-gaap_ProductAndServiceOtherMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_LineOfCreditAndLongTermDebtTextBlock" xlink:to="md_LineOfCreditAndLongTermDebtTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrent" xlink:to="us-gaap_InterestPayableCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_FivePointThreeSevenFivePercentUnsecuredSeniorNotesDueTwoThousandThirtyMember" xlink:to="md_FivePointThreeSevenFivePercentUnsecuredSeniorNotesDueTwoThousandThirtyMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateJointVentureMember" xlink:to="us-gaap_CorporateJointVentureMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_CashEquivalentsAndInvestmentsLineItems" xlink:to="md_CashEquivalentsAndInvestmentsLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayable" xlink:to="us-gaap_NotesPayable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_DissolutionOfAndNetIncomeLossAttributableToNoncontrollingInterest" xlink:to="md_DissolutionOfAndNetIncomeLossAttributableToNoncontrollingInterest_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:to="us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_PurchasePrice" xlink:to="md_PurchasePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_BasisOfPresentationLineItems" xlink:to="md_BasisOfPresentationLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLinesOfCredit" xlink:to="us-gaap_ProceedsFromLinesOfCredit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:to="us-gaap_HealthCareOrganizationRevenueSourcesDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue" xlink:to="md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_TaxPeriodDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsMember" xlink:to="us-gaap_CashEquivalentsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupClassificationDomain" xlink:to="us-gaap_DisposalGroupClassificationDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_OperatingAndFinanceLeaseRightOfUseAssets" xlink:to="md_OperatingAndFinanceLeaseRightOfUseAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember" xlink:to="md_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireInvestments" xlink:to="us-gaap_PaymentsToAcquireInvestments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CertificatesOfDepositMember" xlink:to="us-gaap_CertificatesOfDepositMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_NorthAmericanPartnersInAnesthesiaMember" xlink:to="md_NorthAmericanPartnersInAnesthesiaMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_PercentageOfRefundOfIncomeTaxAtThePriorPeriodCorporateTaxRate" xlink:to="md_PercentageOfRefundOfIncomeTaxAtThePriorPeriodCorporateTaxRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeographicDistributionDomain" xlink:to="us-gaap_GeographicDistributionDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_TwoThousandTwentyTaxYearMember" xlink:to="md_TwoThousandTwentyTaxYearMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:to="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableGrossAllowanceAndNetAbstract" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivableGrossAllowanceAndNetAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_ExtraordinaryItemsAxis" xlink:to="md_ExtraordinaryItemsAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_DebtInstrumentMaturityYear" xlink:to="md_DebtInstrumentMaturityYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember" xlink:to="md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsAtCarryingValue" xlink:to="us-gaap_MoneyMarketFundsAtCarryingValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_DeferredTaxAssetsDomain" xlink:to="md_DeferredTaxAssetsDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InvestmentTypeCategorizationMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_HospitalsContractsMember" xlink:to="md_HospitalsContractsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCredit" xlink:to="us-gaap_LineOfCredit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:to="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:to="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:to="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupClassificationAxis" xlink:to="us-gaap_DisposalGroupClassificationAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_CreditAgreementMember" xlink:to="md_CreditAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_IncomelossFromContinuingOperationsPerBasicAndDilutedShareAbstract" xlink:to="md_IncomelossFromContinuingOperationsPerBasicAndDilutedShareAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentInterest_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_ContractedManagedCareMember" xlink:to="md_ContractedManagedCareMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeographicDistributionAxis" xlink:to="us-gaap_GeographicDistributionAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>md-20230930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-11-01T17:51:08.3083+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.mednax.com/20230930" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2023" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2023" xmlns:md="http://www.mednax.com/20230930" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" namespace="http://xbrl.sec.gov/dei/2023"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-sub-2023.xsd" namespace="http://xbrl.sec.gov/ecd-sub/2023"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" namespace="http://www.xbrl.org/dtr/type/2022-03-31"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" namespace="http://fasb.org/us-gaap/2023"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" namespace="http://fasb.org/srt/2023"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="md-20230930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Labels link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="md-20230930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="md-20230930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="md-20230930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:title="Calculation link" xlink:type="simple"/>
      <link:roleType roleURI="http://www.mednax.com/20230930/taxonomy/role/CoverPage" id="CoverPage">
        <link:definition>100000 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20230930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited" id="ConsolidatedBalanceSheetsUnaudited">
        <link:definition>100010 - Statement - Consolidated Balance Sheets (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20230930/taxonomy/role/ConsolidatedBalanceSheetsUnauditedParenthetical" id="ConsolidatedBalanceSheetsUnauditedParenthetical">
        <link:definition>100020 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited" id="StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited">
        <link:definition>100030 - Statement - Consolidated Statements of Income and Comprehensive Income (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnauditedParenthetical" id="StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnauditedParenthetical">
        <link:definition>100040 - Statement - Consolidated Statements of Income and Comprehensive Income (Unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfEquityUnaudited" id="StatementConsolidatedStatementsOfEquityUnaudited">
        <link:definition>100050 - Statement - Consolidated Statements of Equity (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited" id="StatementConsolidatedStatementsOfCashFlowsUnaudited">
        <link:definition>100060 - Statement - Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20230930/taxonomy/role/DisclosureBasisOfPresentation" id="DisclosureBasisOfPresentation">
        <link:definition>995455 - Disclosure - Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20230930/taxonomy/role/CashEquivalentsAndInvestments" id="CashEquivalentsAndInvestments">
        <link:definition>995465 - Disclosure - Cash Equivalents and Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20230930/taxonomy/role/FairValueMeasurements" id="FairValueMeasurements">
        <link:definition>995475 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20230930/taxonomy/role/AccountsReceivableAndNetRevenue" id="AccountsReceivableAndNetRevenue">
        <link:definition>995485 - Disclosure - Accounts Receivable and Net Revenue</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20230930/taxonomy/role/BusinessCombinationsAndDiscontinuedOperations" id="BusinessCombinationsAndDiscontinuedOperations">
        <link:definition>995495 - Disclosure - Business Combinations and Discontinued Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20230930/taxonomy/role/AccountsPayableAndAccruedExpenses" id="AccountsPayableAndAccruedExpenses">
        <link:definition>995505 - Disclosure - Accounts Payable and Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20230930/taxonomy/role/DisclosureLineOfCreditAndLongTermDebt" id="DisclosureLineOfCreditAndLongTermDebt">
        <link:definition>995515 - Disclosure - Line of Credit and Long Term Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20230930/taxonomy/role/CommonAndCommonEquivalentShares" id="CommonAndCommonEquivalentShares">
        <link:definition>995525 - Disclosure - Common and Common Equivalent Shares</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20230930/taxonomy/role/StockIncentivePlansAndStockPurchasePlans" id="StockIncentivePlansAndStockPurchasePlans">
        <link:definition>995535 - Disclosure - Stock Incentive Plans and Stock Purchase Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20230930/taxonomy/role/CommonStockRepurchasePrograms" id="CommonStockRepurchasePrograms">
        <link:definition>995545 - Disclosure - Common Stock Repurchase Programs</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20230930/taxonomy/role/DisclosureCoronavirusPandemicCovid191" id="DisclosureCoronavirusPandemicCovid191">
        <link:definition>995555 - Disclosure - Coronavirus Pandemic (COVID-19)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20230930/taxonomy/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
        <link:definition>995565 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20230930/taxonomy/role/DisclosureBasisOfPresentationPolicies" id="DisclosureBasisOfPresentationPolicies">
        <link:definition>995575 - Disclosure - Basis of Presentation (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20230930/taxonomy/role/CashEquivalentsAndInvestmentsTables" id="CashEquivalentsAndInvestmentsTables">
        <link:definition>995585 - Disclosure - Cash Equivalents and Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20230930/taxonomy/role/FairValueMeasurementsTables" id="FairValueMeasurementsTables">
        <link:definition>995595 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20230930/taxonomy/role/AccountsReceivableAndNetRevenueTables" id="AccountsReceivableAndNetRevenueTables">
        <link:definition>995605 - Disclosure - Accounts Receivable and Net Revenue (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20230930/taxonomy/role/AccountsPayableAndAccruedExpensesTables" id="AccountsPayableAndAccruedExpensesTables">
        <link:definition>995615 - Disclosure - Accounts Payable and Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20230930/taxonomy/role/CommonAndCommonEquivalentSharesTables" id="CommonAndCommonEquivalentSharesTables">
        <link:definition>995625 - Disclosure - Common and Common Equivalent Shares (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20230930/taxonomy/role/DisclosureBasisOfPresentationAdditionalInformationDetail" id="DisclosureBasisOfPresentationAdditionalInformationDetail">
        <link:definition>995635 - Disclosure - Basis of Presentation - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20230930/taxonomy/role/CashEquivalentsAndInvestmentsAdditionalInformationDetail" id="CashEquivalentsAndInvestmentsAdditionalInformationDetail">
        <link:definition>995645 - Disclosure - Cash Equivalents and Investments - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20230930/taxonomy/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail" id="CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail">
        <link:definition>995655 - Disclosure - Cash Equivalents and Investments - Schedule of Investments (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20230930/taxonomy/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails" id="FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails">
        <link:definition>995665 - Disclosure - Fair Value Measurements - Schedule of fair value on a recurring basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20230930/taxonomy/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails" id="FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails">
        <link:definition>995675 - Disclosure - Fair Value Measurements - Schedule of financial instruments that are not carried at fair value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20230930/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail" id="FairValueMeasurementsAdditionalInformationDetail">
        <link:definition>995685 - Disclosure - Fair Value Measurements - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20230930/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail" id="AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail">
        <link:definition>995695 - Disclosure - Accounts Receivable and Net Revenue - Schedule of Accounts Receivable, Net (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20230930/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail" id="AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail">
        <link:definition>995705 - Disclosure - Accounts Receivable and Net Revenue - Schedule of Net Revenue (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20230930/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail" id="AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail">
        <link:definition>995715 - Disclosure - Accounts Receivable and Net Revenue - Schedule of Net Patient Service Revenue by Type of Payor (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20230930/taxonomy/role/BusinessCombinationsAndDiscontinuedOperationsAdditionalInformationDetail" id="BusinessCombinationsAndDiscontinuedOperationsAdditionalInformationDetail">
        <link:definition>995725 - Disclosure - Business Combinations and Discontinued Operations -  Additional information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20230930/taxonomy/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail" id="AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail">
        <link:definition>995735 - Disclosure - Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20230930/taxonomy/role/AccountsPayableAndAccruedExpensesAdditionalInformationDetail" id="AccountsPayableAndAccruedExpensesAdditionalInformationDetail">
        <link:definition>995745 - Disclosure - Accounts Payable and Accrued Expenses - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20230930/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails" id="DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails">
        <link:definition>995755 - Disclosure - Line of Credit and Long Term Debt (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20230930/taxonomy/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail" id="CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail">
        <link:definition>995765 - Disclosure - Common and Common Equivalent Shares - Schedule of Calculation of Shares Used in Basic and Diluted Net Income Per Share (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20230930/taxonomy/role/DisclosureCommonAndCommonEquivalentSharesAdditionalInformationDetails" id="DisclosureCommonAndCommonEquivalentSharesAdditionalInformationDetails">
        <link:definition>995775 - Disclosure - Common and Common Equivalent Shares (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20230930/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail" id="StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail">
        <link:definition>995785 - Disclosure - Stock Incentive Plans and Stock Purchase Plans - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20230930/taxonomy/role/CommonStockRepurchaseProgramsAdditionalInformationDetail" id="CommonStockRepurchaseProgramsAdditionalInformationDetail">
        <link:definition>995795 - Disclosure - Common Stock Repurchase Programs - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20230930/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail" id="DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail">
        <link:definition>995805 - Disclosure - Coronavirus Pandemic (COVID-19) - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="md_IncreaseInDeferredTaxAssets" name="IncreaseInDeferredTaxAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="md_PercentageIncreaseDecreaseInSalaryAndWage" name="PercentageIncreaseDecreaseInSalaryAndWage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="md_MutualFundsFairValueDisclosure" name="MutualFundsFairValueDisclosure" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="md_IncomelossFromContinuingOperationsPerBasicAndDilutedShareAbstract" name="IncomelossFromContinuingOperationsPerBasicAndDilutedShareAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_MoneyMarketFundsFairValueDisclosure" name="MoneyMarketFundsFairValueDisclosure" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="md_FairValueDisclosuresTable" name="FairValueDisclosuresTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_AccountsReceivableAndNetRevenueDisclosureTextBlock" name="AccountsReceivableAndNetRevenueDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock" name="FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="md_TwoZeroThreeZeroMember" name="TwoZeroThreeZeroMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_IncrementalSharesInContinuingOperation" name="IncrementalSharesInContinuingOperation" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="md_ContributionsInAidOfReimbursementOfLostRevenue" name="ContributionsInAidOfReimbursementOfLostRevenue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="md_CashEquivalentsAndInvestmentsTable" name="CashEquivalentsAndInvestmentsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_NumberOfPediatricGastroenterologyPracticeAcquired" name="NumberOfPediatricGastroenterologyPracticeAcquired" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="md_NumberOfMultiLocationPediatricUrgentCarePracticeAcquired" name="NumberOfMultiLocationPediatricUrgentCarePracticeAcquired" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="md_BusinessCombinationAndDiscontinuedOperationsTextBlock" name="BusinessCombinationAndDiscontinuedOperationsTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="md_RepaymentsOfLongTermCapitalLeaseObligation" name="RepaymentsOfLongTermCapitalLeaseObligation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember" name="NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_FivePointTwoFivePercentageSeniorNotesDueTwoThousandTwentyThreeMember" name="FivePointTwoFivePercentageSeniorNotesDueTwoThousandTwentyThreeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember" name="TwoThousandFifteenNonQualifiedStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_TwoThousandTwentyThreeMember" name="TwoThousandTwentyThreeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_HospitalsContractsMember" name="HospitalsContractsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_FivePointThreeSevenFivePercentUnsecuredSeniorNotesDueTwoThousandThirtyMember" name="FivePointThreeSevenFivePercentUnsecuredSeniorNotesDueTwoThousandThirtyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_ExtraordinaryItemsDomain" name="ExtraordinaryItemsDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_NorthAmericanPartnersInAnesthesiaMember" name="NorthAmericanPartnersInAnesthesiaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_OperatingAndFinanceLeaseRightOfUseAssets" name="OperatingAndFinanceLeaseRightOfUseAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="md_PercentageOfRefundOfIncomeTaxAtThePriorPeriodCorporateTaxRate" name="PercentageOfRefundOfIncomeTaxAtThePriorPeriodCorporateTaxRate" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="md_NumberOfPediatricOrThopedicPracticesAcquired" name="NumberOfPediatricOrThopedicPracticesAcquired" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="md_TwoThousandTwentyTaxYearMember" name="TwoThousandTwentyTaxYearMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_PurchasePrice" name="PurchasePrice" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="md_CashEquivalentsAndInvestmentsLineItems" name="CashEquivalentsAndInvestmentsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_SixPointTwentyFivePercentageSeniorUnsecuredNotesDue2027Member" name="SixPointTwentyFivePercentageSeniorUnsecuredNotesDue2027Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_DeferredTaxAssetsDomain" name="DeferredTaxAssetsDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_CovidNinenteenMember" name="CovidNinenteenMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember" name="NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_LineOfCreditAndLongTermDebtTextBlock" name="LineOfCreditAndLongTermDebtTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="md_AnesthesiologyServicesMedicalGroupMember" name="AnesthesiologyServicesMedicalGroupMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_RadiologyServicesMedicalGroupMember" name="RadiologyServicesMedicalGroupMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_UnnamedCorporateJointVentureTwoMember" name="UnnamedCorporateJointVentureTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_DebtInstrumentMaturityYear" name="DebtInstrumentMaturityYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="md_BusinessCombinationAndDiscontinuedOperationsAbstract" name="BusinessCombinationAndDiscontinuedOperationsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_SixPointTwoFivePercentageSeniorNotesDueTwoThousandTwentySevenMember" name="SixPointTwoFivePercentageSeniorNotesDueTwoThousandTwentySevenMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_PediatricSubspecialtyPracticeMember" name="PediatricSubspecialtyPracticeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_ContractedManagedCareMember" name="ContractedManagedCareMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_BasisOfPresentationAndNewAccountingPronouncementsTable" name="BasisOfPresentationAndNewAccountingPronouncementsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_PracticeSuppliesAndOtherOperatingExpenses" name="PracticeSuppliesAndOtherOperatingExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="md_CreditAgreementMember" name="CreditAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_GaapSeniorNotesMember" name="GaapSeniorNotesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_TwoThousandTwentySevenMember" name="TwoThousandTwentySevenMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_PrimaryBeneficiaryMember" name="PrimaryBeneficiaryMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_DeferredTaxAssetsAxis" name="DeferredTaxAssetsAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember" name="RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_AccruedPayrollTaxesAndBenefitsCurrent" name="AccruedPayrollTaxesAndBenefitsCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="md_ExtraordinaryItemsAbstract" name="ExtraordinaryItemsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_DissolutionOfAndNetIncomeLossAttributableToNoncontrollingInterest" name="DissolutionOfAndNetIncomeLossAttributableToNoncontrollingInterest" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="md_CoronavirusPandemicCOVIDNineteenDisclosureTextBlock" name="CoronavirusPandemicCOVIDNineteenDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="md_RuralAreaMember" name="RuralAreaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_LineOfCreditLongTermDebtAndFinanceLeaseObligationsDisclosureTextBlock" name="LineOfCreditLongTermDebtAndFinanceLeaseObligationsDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="md_PracticeSalariesAndBenefits" name="PracticeSalariesAndBenefits" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue" name="ProceedsFromContributionInAidOfReimbursementOfLostRevenue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="md_BasisOfPresentationLineItems" name="BasisOfPresentationLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_PaymentsToTermLoan" name="PaymentsToTermLoan" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="md_AmendedAndRestatedTwoThousandEightPlanMember" name="AmendedAndRestatedTwoThousandEightPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_IncreaseDecreaseInAccruedSalariesAndBonuses" name="IncreaseDecreaseInAccruedSalariesAndBonuses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="md_PediatricGastroenterologyAndGynecologyPracticeAndMultiLocationPediatricUrgentCarePracticeMember" name="PediatricGastroenterologyAndGynecologyPracticeAndMultiLocationPediatricUrgentCarePracticeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_FairValueDisclosuresLineItems" name="FairValueDisclosuresLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationNetOfTaxPerBasicAndDilutedShareAbstract" name="IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationNetOfTaxPerBasicAndDilutedShareAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember" name="SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_CommonStockLineItems" name="CommonStockLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_UnnamedCorporateJointVentureOneMember" name="UnnamedCorporateJointVentureOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_PercentageOfNetPatientServiceRevenueByTypeOfPayor" name="PercentageOfNetPatientServiceRevenueByTypeOfPayor" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="md_ScheduleOfFinancingReceivablesLineItems" name="ScheduleOfFinancingReceivablesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_ExtraordinaryItemsAxis" name="ExtraordinaryItemsAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_CommonStockTable" name="CommonStockTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_CommonStockRepurchasesTextBlock" name="CommonStockRepurchasesTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139893750377056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Oct. 27, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Pediatrix Medical Group, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000893949<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $.01 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Securities Act File Number</a></td>
<td class="text">001-12111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">FL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">26-3667538<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1301 Concord Terrace<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Sunrise<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">FL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">33323<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">954<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">384-0175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,023,916<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139893749466656">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 21,179<span></span>
</td>
<td class="nump">$ 9,824<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">103,541<span></span>
</td>
<td class="nump">93,239<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">277,352<span></span>
</td>
<td class="nump">296,787<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">10,586<span></span>
</td>
<td class="nump">14,878<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">7,866<span></span>
</td>
<td class="nump">13,261<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">420,524<span></span>
</td>
<td class="nump">427,989<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">75,146<span></span>
</td>
<td class="nump">73,290<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">1,532,092<span></span>
</td>
<td class="nump">1,532,092<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">15,486<span></span>
</td>
<td class="nump">18,491<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_OperatingAndFinanceLeaseRightOfUseAssets', window );">Operating and finance lease right-of-use assets</a></td>
<td class="nump">72,443<span></span>
</td>
<td class="nump">66,924<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred income tax assets</a></td>
<td class="nump">102,638<span></span>
</td>
<td class="nump">105,925<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">108,010<span></span>
</td>
<td class="nump">123,176<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">2,326,339<span></span>
</td>
<td class="nump">2,347,887<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">302,583<span></span>
</td>
<td class="nump">374,225<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent', window );">Current portion of debt and finance lease liabilities, net</a></td>
<td class="nump">14,929<span></span>
</td>
<td class="nump">14,898<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liabilities</a></td>
<td class="nump">21,814<span></span>
</td>
<td class="nump">21,589<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Income taxes payable</a></td>
<td class="nump">11,118<span></span>
</td>
<td class="nump">16,271<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">350,444<span></span>
</td>
<td class="nump">426,983<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Line of credit</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligations', window );">Long-term debt and finance lease liabilities, net</a></td>
<td class="nump">621,691<span></span>
</td>
<td class="nump">632,381<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="nump">48,489<span></span>
</td>
<td class="nump">44,213<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent', window );">Long-term professional liabilities</a></td>
<td class="nump">265,523<span></span>
</td>
<td class="nump">275,629<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred income tax liabilities</a></td>
<td class="nump">41,018<span></span>
</td>
<td class="nump">33,638<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">31,189<span></span>
</td>
<td class="nump">39,411<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">1,358,354<span></span>
</td>
<td class="nump">1,456,255<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock; $.01 par value; 1,000 shares authorized; none issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock; $.01 par value; 200,000 shares authorized; 83,929 and 82,947 shares issued and outstanding, respectively</a></td>
<td class="nump">839<span></span>
</td>
<td class="nump">829<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">995,847<span></span>
</td>
<td class="nump">983,601<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(3,517)<span></span>
</td>
<td class="num">(3,735)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained deficit</a></td>
<td class="num">(25,184)<span></span>
</td>
<td class="num">(89,063)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders' equity</a></td>
<td class="nump">967,985<span></span>
</td>
<td class="nump">891,632<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders' equity</a></td>
<td class="nump">$ 2,326,339<span></span>
</td>
<td class="nump">$ 2,347,887<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_OperatingAndFinanceLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating and finance lease right-of-use assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_OperatingAndFinanceLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the noncurrent portion of the accrued liability on an undiscounted basis for malpractice claims (including general and professional liability).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139893750260912">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">83,929,000<span></span>
</td>
<td class="nump">82,947,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">83,929,000<span></span>
</td>
<td class="nump">82,947,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139893749306688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Income and Comprehensive Income (Unaudited) - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">$ 506,612<span></span>
</td>
<td class="nump">$ 489,915<span></span>
</td>
<td class="nump">$ 1,498,197<span></span>
</td>
<td class="nump">$ 1,458,177<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_PracticeSalariesAndBenefits', window );">Practice salaries and benefits</a></td>
<td class="nump">368,404<span></span>
</td>
<td class="nump">342,850<span></span>
</td>
<td class="nump">1,084,671<span></span>
</td>
<td class="nump">1,016,762<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_PracticeSuppliesAndOtherOperatingExpenses', window );">Practice supplies and other operating expenses</a></td>
<td class="nump">31,319<span></span>
</td>
<td class="nump">31,857<span></span>
</td>
<td class="nump">93,128<span></span>
</td>
<td class="nump">90,189<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">57,406<span></span>
</td>
<td class="nump">57,888<span></span>
</td>
<td class="nump">174,478<span></span>
</td>
<td class="nump">180,340<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">9,211<span></span>
</td>
<td class="nump">8,956<span></span>
</td>
<td class="nump">27,109<span></span>
</td>
<td class="nump">26,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Transformational and restructuring related expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">977<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,736<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">466,340<span></span>
</td>
<td class="nump">442,528<span></span>
</td>
<td class="nump">1,379,386<span></span>
</td>
<td class="nump">1,321,527<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income from operations</a></td>
<td class="nump">40,272<span></span>
</td>
<td class="nump">47,387<span></span>
</td>
<td class="nump">118,811<span></span>
</td>
<td class="nump">136,650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNet', window );">Investment and other income</a></td>
<td class="nump">273<span></span>
</td>
<td class="nump">617<span></span>
</td>
<td class="nump">2,096<span></span>
</td>
<td class="nump">2,336<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(10,374)<span></span>
</td>
<td class="num">(9,516)<span></span>
</td>
<td class="num">(31,994)<span></span>
</td>
<td class="num">(29,743)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on early extinguishment of debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(57,016)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in earnings of unconsolidated affiliate</a></td>
<td class="nump">661<span></span>
</td>
<td class="nump">371<span></span>
</td>
<td class="nump">1,578<span></span>
</td>
<td class="nump">1,319<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total non-operating expenses</a></td>
<td class="num">(9,440)<span></span>
</td>
<td class="num">(8,528)<span></span>
</td>
<td class="num">(28,320)<span></span>
</td>
<td class="num">(83,104)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income from continuing operations before income taxes</a></td>
<td class="nump">30,832<span></span>
</td>
<td class="nump">38,859<span></span>
</td>
<td class="nump">90,491<span></span>
</td>
<td class="nump">53,546<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax provision</a></td>
<td class="num">(9,441)<span></span>
</td>
<td class="num">(10,051)<span></span>
</td>
<td class="num">(26,612)<span></span>
</td>
<td class="num">(14,982)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Income from continuing operations</a></td>
<td class="nump">21,391<span></span>
</td>
<td class="nump">28,808<span></span>
</td>
<td class="nump">63,879<span></span>
</td>
<td class="nump">38,564<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Income (loss) from discontinued operations, net of tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,920<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,892)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">21,391<span></span>
</td>
<td class="nump">30,728<span></span>
</td>
<td class="nump">63,879<span></span>
</td>
<td class="nump">36,672<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to noncontrolling interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Pediatrix Medical Group, Inc.</a></td>
<td class="nump">21,391<span></span>
</td>
<td class="nump">30,728<span></span>
</td>
<td class="nump">63,879<span></span>
</td>
<td class="nump">36,676<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Other comprehensive (loss) income, net of tax</a></td>
<td class="nump">1<span></span>
</td>
<td class="num">(1,515)<span></span>
</td>
<td class="nump">218<span></span>
</td>
<td class="num">(5,417)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive income attributable to Pediatrix Medical Group, Inc.</a></td>
<td class="nump">$ 21,392<span></span>
</td>
<td class="nump">$ 29,213<span></span>
</td>
<td class="nump">$ 64,097<span></span>
</td>
<td class="nump">$ 31,259<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net income attributable to Pediatrix Medical Group, Inc.:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic</a></td>
<td class="nump">$ 0.26<span></span>
</td>
<td class="nump">$ 0.37<span></span>
</td>
<td class="nump">$ 0.78<span></span>
</td>
<td class="nump">$ 0.44<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted</a></td>
<td class="nump">$ 0.26<span></span>
</td>
<td class="nump">$ 0.37<span></span>
</td>
<td class="nump">$ 0.77<span></span>
</td>
<td class="nump">$ 0.43<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract', window );"><strong>Weighted average common shares:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic</a></td>
<td class="nump">82,543<span></span>
</td>
<td class="nump">82,126<span></span>
</td>
<td class="nump">82,127<span></span>
</td>
<td class="nump">84,122<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted</a></td>
<td class="nump">82,950<span></span>
</td>
<td class="nump">82,776<span></span>
</td>
<td class="nump">82,492<span></span>
</td>
<td class="nump">84,821<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_PracticeSalariesAndBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Practice salaries and benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_PracticeSalariesAndBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_PracticeSuppliesAndOtherOperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of supplies and other operating expenses directly attributable to the physician practices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_PracticeSuppliesAndOtherOperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482551/740-270-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3A<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-4<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481664/323-10-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a),(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482047/420-10-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139893854016592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Income and Comprehensive Income (Unaudited) (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent', window );">Other Comprehensive Income (Loss), Available-for-Sale Securities, Tax, Portion Attributable to Parent</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 508<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 1,816<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after reclassification adjustment, of tax expense (benefit) for gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139893746768672">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Equity (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss [Member]</div></th>
<th class="th"><div>Retained Deficit [Member]</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 896,692<span></span>
</td>
<td class="nump">$ 864<span></span>
</td>
<td class="nump">$ 1,049,696<span></span>
</td>
<td class="nump">$ 1,317<span></span>
</td>
<td class="num">$ (155,185)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, Shares at Dec. 31, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,423,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(21,188)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,188)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_DissolutionOfAndNetIncomeLossAttributableToNoncontrollingInterest', window );">Dissolution of and net loss attributable to noncontrolling interest</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(203)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(213)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized holding gain (loss) on investments, net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,668)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,668)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Common stock issued under employee stock option, employee stock purchase plan and stock purchase plan</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Common stock issued under employee stock option, employee stock purchase plan and stock purchase plan, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross', window );">Issuance of restricted stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross', window );">Issuance of restricted stock, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">766,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited', window );">Forfeitures of restricted stock, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchased common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,166)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,166)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchased common stock, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(50,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Mar. 31, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">877,076<span></span>
</td>
<td class="nump">$ 872<span></span>
</td>
<td class="nump">1,054,141<span></span>
</td>
<td class="num">(1,351)<span></span>
</td>
<td class="num">(176,586)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, Shares at Mar. 31, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,184,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">896,692<span></span>
</td>
<td class="nump">$ 864<span></span>
</td>
<td class="nump">1,049,696<span></span>
</td>
<td class="nump">1,317<span></span>
</td>
<td class="num">(155,185)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, Shares at Dec. 31, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,423,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">36,676<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Sep. 30, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">858,667<span></span>
</td>
<td class="nump">$ 830<span></span>
</td>
<td class="nump">980,659<span></span>
</td>
<td class="num">(4,100)<span></span>
</td>
<td class="num">(118,722)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, Shares at Sep. 30, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,006,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Mar. 31, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">877,076<span></span>
</td>
<td class="nump">$ 872<span></span>
</td>
<td class="nump">1,054,141<span></span>
</td>
<td class="num">(1,351)<span></span>
</td>
<td class="num">(176,586)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, Shares at Mar. 31, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,184,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">27,136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,136<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized holding gain (loss) on investments, net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,234)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,234)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Common stock issued under employee stock option, employee stock purchase plan and stock purchase plan</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,664<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">1,663<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Common stock issued under employee stock option, employee stock purchase plan and stock purchase plan, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross', window );">Issuance of restricted stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross', window );">Issuance of restricted stock, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited', window );">Forfeitures of restricted stock, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchased common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(64,398)<span></span>
</td>
<td class="num">$ (33)<span></span>
</td>
<td class="num">(64,365)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchased common stock, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,275,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Jun. 30, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">845,430<span></span>
</td>
<td class="nump">$ 841<span></span>
</td>
<td class="nump">996,624<span></span>
</td>
<td class="num">(2,585)<span></span>
</td>
<td class="num">(149,450)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, Shares at Jun. 30, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,060,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">30,728<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,728<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized holding gain (loss) on investments, net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,515)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,515)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Common stock issued under employee stock option, employee stock purchase plan and stock purchase plan</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,381<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">1,380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Common stock issued under employee stock option, employee stock purchase plan and stock purchase plan, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross', window );">Issuance of restricted stock, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures', window );">Forfeitures of restricted stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1)<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited', window );">Forfeitures of restricted stock, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchased common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(21,477)<span></span>
</td>
<td class="num">$ (11)<span></span>
</td>
<td class="num">(21,466)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchased common stock, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,121,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Sep. 30, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">858,667<span></span>
</td>
<td class="nump">$ 830<span></span>
</td>
<td class="nump">980,659<span></span>
</td>
<td class="num">(4,100)<span></span>
</td>
<td class="num">(118,722)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, Shares at Sep. 30, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,006,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">891,632<span></span>
</td>
<td class="nump">$ 829<span></span>
</td>
<td class="nump">983,601<span></span>
</td>
<td class="num">(3,735)<span></span>
</td>
<td class="num">(89,063)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, Shares at Dec. 31, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82,947,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">14,206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,206<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized holding gain (loss) on investments, net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">604<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">604<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Common stock issued under employee stock option, employee stock purchase plan and stock purchase plan</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Common stock issued under employee stock option, employee stock purchase plan and stock purchase plan, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross', window );">Issuance of restricted stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross', window );">Issuance of restricted stock, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">871,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures', window );">Forfeitures of restricted stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2)<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited', window );">Forfeitures of restricted stock, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(221,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,009<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,009<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchased common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(775)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(775)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchased common stock, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(49,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Mar. 31, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">909,771<span></span>
</td>
<td class="nump">$ 836<span></span>
</td>
<td class="nump">986,923<span></span>
</td>
<td class="num">(3,131)<span></span>
</td>
<td class="num">(74,857)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, Shares at Mar. 31, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,634,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">891,632<span></span>
</td>
<td class="nump">$ 829<span></span>
</td>
<td class="nump">983,601<span></span>
</td>
<td class="num">(3,735)<span></span>
</td>
<td class="num">(89,063)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, Shares at Dec. 31, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82,947,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 63,879<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchased common stock, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Sep. 30, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 967,985<span></span>
</td>
<td class="nump">$ 839<span></span>
</td>
<td class="nump">995,847<span></span>
</td>
<td class="num">(3,517)<span></span>
</td>
<td class="num">(25,184)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, Shares at Sep. 30, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,929,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Mar. 31, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">909,771<span></span>
</td>
<td class="nump">$ 836<span></span>
</td>
<td class="nump">986,923<span></span>
</td>
<td class="num">(3,131)<span></span>
</td>
<td class="num">(74,857)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, Shares at Mar. 31, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,634,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">28,282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,282<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized holding gain (loss) on investments, net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(387)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(387)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Common stock issued under employee stock option, employee stock purchase plan and stock purchase plan</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,594<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">1,593<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Common stock issued under employee stock option, employee stock purchase plan and stock purchase plan, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross', window );">Issuance of restricted stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross', window );">Issuance of restricted stock, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited', window );">Forfeitures of restricted stock, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchased common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(11)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchased common stock, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Jun. 30, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">942,375<span></span>
</td>
<td class="nump">$ 838<span></span>
</td>
<td class="nump">991,630<span></span>
</td>
<td class="num">(3,518)<span></span>
</td>
<td class="num">(46,575)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, Shares at Jun. 30, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,841,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">21,391<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,391<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized holding gain (loss) on investments, net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Common stock issued under employee stock option, employee stock purchase plan and stock purchase plan</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,187<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">1,186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Common stock issued under employee stock option, employee stock purchase plan and stock purchase plan, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited', window );">Forfeitures of restricted stock, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,164<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,164<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchased common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(133)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(133)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchased common stock, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Sep. 30, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 967,985<span></span>
</td>
<td class="nump">$ 839<span></span>
</td>
<td class="nump">$ 995,847<span></span>
</td>
<td class="num">$ (3,517)<span></span>
</td>
<td class="num">$ (25,184)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, Shares at Sep. 30, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,929,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">Net loss component is presented within retained deficit on the consolidated balance sheet as the balance is immaterial.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_DissolutionOfAndNetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Dissolution Of And Net Income (Loss) Attributable to Noncontrolling Interest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_DissolutionOfAndNetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares related to Restricted Stock Award forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-3<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 38: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 40: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 41: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-15<br><br>Reference 42: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-16<br><br>Reference 43: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139893750456144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 63,879<span></span>
</td>
<td class="nump">$ 36,676<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Loss from discontinued operations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,892<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">27,109<span></span>
</td>
<td class="nump">26,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of premiums, discounts and issuance costs</a></td>
<td class="nump">1,015<span></span>
</td>
<td class="nump">1,346<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on early extinguishment of debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">57,016<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">9,299<span></span>
</td>
<td class="nump">12,891<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="nump">10,589<span></span>
</td>
<td class="num">(8,702)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="num">(1,607)<span></span>
</td>
<td class="num">(2,379)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">22,095<span></span>
</td>
<td class="num">(501)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">4,290<span></span>
</td>
<td class="nump">22,709<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other long-term assets</a></td>
<td class="nump">13,343<span></span>
</td>
<td class="nump">11,160<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="num">(56,118)<span></span>
</td>
<td class="num">(76,439)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable', window );">Income taxes payable</a></td>
<td class="num">(5,154)<span></span>
</td>
<td class="nump">799<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve', window );">Long-term professional liabilities</a></td>
<td class="nump">838<span></span>
</td>
<td class="nump">7,360<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other liabilities</a></td>
<td class="num">(16,500)<span></span>
</td>
<td class="num">(10,309)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash provided by operating activities - continuing operations</a></td>
<td class="nump">73,078<span></span>
</td>
<td class="nump">80,019<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations', window );">Net cash used in operating activities - discontinued operations</a></td>
<td class="num">(5,003)<span></span>
</td>
<td class="num">(11,764)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">68,075<span></span>
</td>
<td class="nump">68,255<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisition payments, net of cash acquired</a></td>
<td class="num">(1,667)<span></span>
</td>
<td class="num">(28,167)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchases of investments</a></td>
<td class="num">(26,477)<span></span>
</td>
<td class="num">(14,938)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments', window );">Proceeds from maturities or sales of investments</a></td>
<td class="nump">16,560<span></span>
</td>
<td class="nump">15,889<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(24,284)<span></span>
</td>
<td class="num">(20,650)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfOtherProductiveAssets', window );">Other</a></td>
<td class="nump">116<span></span>
</td>
<td class="nump">2,153<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(35,752)<span></span>
</td>
<td class="num">(45,713)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Borrowings on credit agreement</a></td>
<td class="nump">470,000<span></span>
</td>
<td class="nump">674,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLinesOfCredit', window );">Payments on credit agreement</a></td>
<td class="num">(474,000)<span></span>
</td>
<td class="num">(579,500)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_PaymentsToTermLoan', window );">Payments on term loan</a></td>
<td class="num">(9,375)<span></span>
</td>
<td class="num">(6,250)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfSeniorDebt', window );">Redemption of senior notes, including call premium</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,046,880)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt', window );">Proceeds from senior notes and term loan</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">650,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Payments for financing costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(8,621)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_RepaymentsOfLongTermCapitalLeaseObligation', window );">Payment on finance lease obligation</a></td>
<td class="num">(2,105)<span></span>
</td>
<td class="num">(2,176)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">3,876<span></span>
</td>
<td class="nump">4,220<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchases of common stock</a></td>
<td class="num">(919)<span></span>
</td>
<td class="num">(87,041)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other</a></td>
<td class="num">(8,445)<span></span>
</td>
<td class="nump">483<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="num">(20,968)<span></span>
</td>
<td class="num">(401,265)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">11,355<span></span>
</td>
<td class="num">(378,723)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">9,824<span></span>
</td>
<td class="nump">387,391<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">$ 21,179<span></span>
</td>
<td class="nump">$ 8,668<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_PaymentsToTermLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash outflow to term loan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_PaymentsToTermLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_RepaymentsOfLongTermCapitalLeaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Repayments Of Long Term Capital Lease Obligation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_RepaymentsOfLongTermCapitalLeaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482551/740-270-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3A<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-4<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in liability to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from the acquisition of or improvements to long-lived, physical assets used to produce goods and services and not intended for resale, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing with the highest claim on the assets of the entity in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfOtherProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from the sale of tangible or intangible assets used to produce goods or deliver services, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfOtherProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfSeniorDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a long-term debt where the holder has highest claim on the entity's asset in case of bankruptcy or liquidation during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfSeniorDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139893753954928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="nump">$ 21,391<span></span>
</td>
<td class="nump">$ 28,282<span></span>
</td>
<td class="nump">$ 14,206<span></span>
</td>
<td class="nump">$ 30,728<span></span>
</td>
<td class="nump">$ 27,136<span></span>
</td>
<td class="num">$ (21,188)<span></span>
</td>
<td class="nump">$ 63,879<span></span>
</td>
<td class="nump">$ 36,676<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139893752734048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139893853989120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">1.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">            Basis of Presentation:</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">On July 1, 2022, effective after the close of the market, the Company changed its corporate name from "Mednax, Inc." to &#8220;Pediatrix Medical Group, Inc." signifying the Company's return to its core focus in caring for women, babies and children.  The Company&#8217;s common stock continues to trade on the New York Stock Exchange under the ticker symbol &#8220;MD.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The accompanying unaudited Consolidated Financial Statements of the Company and the notes thereto presented in this Form 10-Q have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission ("SEC") applicable to interim financial statements, and do not include all disclosures required by accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) for complete financial statements. In the opinion of management, these financial statements include all adjustments, consisting only of normal recurring adjustments, necessary for a fair statement of the results of interim periods. The financial statements include all the accounts of Pediatrix Medical Group, Inc. and its consolidated subsidiaries (collectively, &#8220;PMG&#8221;) together with the accounts of PMG&#8217;s affiliated business corporations or professional associations, professional corporations, limited liability companies and partnerships (the &#8220;affiliated professional contractors&#8221;). Certain subsidiaries of PMG have contractual management arrangements with its affiliated professional contractors, which are separate legal entities that provide physician services in certain states. The Company ceased providing services in Puerto Rico effective December 31, 2022.  The terms &#8220;Pediatrix&#8221; and the &#8220;Company&#8221; refer collectively to Pediatrix Medical Group Inc., its subsidiaries and the affiliated professional contractors.</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The Compan</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">y is a party to a joint venture in which it owns a </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">37.5</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">% economic interest.  The Company accounts for this joint venture under the equity method of accounting because the Company exercises significant influence over, but does not control, this entity.  The Company was also a party to another joint venture in which it owned a </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">51</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">% economic interest and for which it was deemed the primary beneficiary. This joint venture was dissolved in February 2022.  The operating results related to this joint venture prior to the dissolution and impacts from such dissolution were not material.</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The consolidated results of operations for the interim periods presented are not necessarily indicative of the results to be experienced for the entire fiscal year. In addition, the accompanying unaudited Consolidated Financial Statements and the notes thereto should be read in conjunction with the Consolidated Financial Statements and the notes thereto included in the Company&#8217;s most recent Annual Report on Form 10-K (the &#8220;Form 10-K&#8221;).</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 250<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//250/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139893755883920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash Equivalents and Investments<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Cash Equivalents and Investments</a></td>
<td class="text"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">2.            Cash Equivalents and Investments:</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">As of September 30, 2023 and December 31, 2022, the Company's cash equivalents consisted entirely of money market funds totaling $</span><span style="font-size:9pt;font-family:Times New Roman;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">1.2</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:9pt;font-family:Times New Roman;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">1.4</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><div style="font-size:9pt;font-family:Times New Roman;"><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Investments held are all classified as current and at </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">September 30, 2023 and December 31, 2022 are summarized as follows (in thousands):</span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:74.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.52%;"></td>
        <td style="width:1.42%;"></td>
        <td style="width:1%;"></td>
        <td style="width:18.32%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.42%;"></td>
        <td style="width:1%;"></td>
        <td style="width:18.32%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">September 30, 2023</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Corporate securities</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">58,830</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">61,385</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Municipal debt securities</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">13,419</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">14,377</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">U.S. Treasury securities</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">21,888</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">10,205</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Certificates of deposit</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">3,906</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">3,710</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Federal home loan securities</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">5,498</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">3,562</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">103,541</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">93,239</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//320/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-6B<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-6B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br> -Publisher SEC<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//946-320/tableOfContent<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 940<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//940-320/tableOfContent<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//942-320/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139893756988352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">3.            Fair Value Measurements:</span></p><p style="margin-left:6.667%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The accounting guidance establishes a fair value hierarchy that prioritizes valuation inputs into three levels based on the extent to which inputs used in measuring fair value are observable in the market. Each fair value measurement is reported in one of three levels:</span></p><p style="margin-left:6.667%;text-indent:0;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Level 1 &#8211; inputs are based upon unadjusted quoted prices for identical instruments traded in active markets.</span></p><p style="margin-left:6.667%;text-indent:0;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Level 2 &#8211; inputs are based upon quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></p><p style="margin-left:6.667%;text-indent:0;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Level 3 &#8211; inputs are generally unobservable and typically reflect management&#8217;s estimates of assumptions that market participants would use in pricing the asset or liability. The fair values are therefore determined using model-based techniques that include option pricing models, discounted cash flow models, and similar techniques.</span></p><div style="font-size:9pt;font-family:Times New Roman;"><p style="text-indent:6.667%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The following table presents information about the Company&#8217;s financial instruments that are accounted for at fair value on a recurring basis at </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">September 30, 2023 and December 31, 2022 (in thousands):</span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:95.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:47.464%;"></td>
        <td style="width:1.062%;"></td>
        <td style="width:12.668%;"></td>
        <td style="width:1.062%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.818999999999999%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.105%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.818999999999999%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Fair Value</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Fair Value<br/>Category</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">September 30, 2023</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Assets:</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#ffffff;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Money market funds</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Level 1</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">1,201</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">1,415</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#cff0fc;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Short-term investments</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">103,541</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">93,239</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#ffffff;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Mutual Funds</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Level 1</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">15,851</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">14,544</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:9pt;font-family:Times New Roman;"><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The following table presents information about the Company&#8217;s financial instruments that are not carried at fair value at </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">September 30, 2023 and December 31, 2022 (in thousands):</span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.72%;"></td>
        <td style="width:1.08%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.24%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.08%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.84%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.32%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.72%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">September 30, 2023</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Carrying<br/>Amount</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Fair<br/>Value</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Carrying<br/>Amount</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Fair<br/>Value</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Liabilities:</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#ffffff;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">2030 Notes</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">400,000</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">352,680</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">400,000</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">344,000</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The carrying amounts of cash equivalents, accounts receivable and accounts payable and accrued expenses approximate fair value due to the short maturities of the respective instruments. The carrying value of the line of credit approximates fair value.  If the Company&#8217;s line of credit was measured at fair value, it would be categorized as Level 2 in the fair value hierarchy.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139893757723312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Receivable and Net Revenue<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_AccountsReceivableAndNetRevenueDisclosureTextBlock', window );">Accounts Receivable and Net Revenue</a></td>
<td class="text"><p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">4. </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Arial;min-width:fit-content;">            </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Accounts Receivable and Net Revenue:</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:9pt;font-family:Times New Roman;"><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Accounts receivable, net consists of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:96.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:64.696%;"></td>
        <td style="width:1.042%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.61%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.042%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.61%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">September 30, 2023</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Gross accounts receivable</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">1,448,620</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">1,548,492</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Allowance for contractual adjustments and uncollectibles</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">1,171,268</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">1,251,705</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">277,352</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">296,787</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Patient service revenue is recognized at the time services are provided by the Company&#8217;s affiliated physicians. The Company&#8217;s performance obligations related to the delivery of services to patients are satisfied at the time of service. Accordingly, there are no performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period with respect to patient service revenue. Almost all of the Company&#8217;s patient service revenue is reimbursed by government-sponsored healthcare programs (&#8220;GHC Programs&#8221;) and third-party insurance payors. Payments for services rendered to the Company&#8217;s patients are generally less than billed charges. The Company monitors its revenue and receivables from these sources and records an estimated contractual allowance to properly account for the anticipated differences between billed and reimbursed amounts.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Accordingly, patient service revenue is presented net of an estimated provision for contractual adjustments and uncollectibles. The Company estimates allowances for contractual adjustments and uncollectibles on accounts receivable based upon historical experience and other factors, including days sales outstanding (&#8220;DSO&#8221;) for accounts receivable, evaluation of expected adjustments and delinquency rates, past adjustments and collection experience in relation to amounts billed, an aging of accounts receivable, current contract and reimbursement terms, changes in payor mix and other relevant information. Contractual adjustments result from the difference between the physician rates for services performed and the reimbursements by GHC Programs and third-party insurance payors for such services.</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Collection of patient service revenue the Company expects to receive is normally a function of providing complete and correct billing information to the GHC Programs and third-party insurance payors within the various filing deadlines and typically occurs within 30 to 60 days of billing.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Some of the Company&#8217;s hospital agreements require hospitals to pay the Company administrative fees. Some agreements provide for fees if the hospital does not generate sufficient patient volume in order to guarantee that the Company receives a specified minimum revenue level. The Company also receives fees from hospitals for administrative services performed by its affiliated physicians providing medical director or other services at the hospital.</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:9pt;font-family:Times New Roman;"><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes the Company&#8217;s net revenue by category (in thousands):</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:30.731%;"></td>
        <td style="width:1.147%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.426%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.147%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.552999999999999%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.147%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.84%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.68%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.324%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Three Months Ended<br/>September 30,</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Nine Months Ended<br/>September 30,</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Net patient service revenue</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">437,321</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">421,085</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">1,290,888</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">1,245,627</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Hospital contract administrative fees</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">68,712</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">67,418</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">204,286</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">196,425</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Other revenue</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">579</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">1,412</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">3,023</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">16,125</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">506,612</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">489,915</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">1,498,197</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">1,458,177</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:9pt;font-family:Times New Roman;"><p style="margin-left:4.533%;text-indent:6.983%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The approximate percentage of net patient service revenue by type of payor was as follows:</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:91.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:36.233%;"></td>
        <td style="width:1.3%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.597%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.82%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.798%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.078%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.177999999999999%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Three Months Ended<br/>September 30,</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Nine Months Ended<br/>September 30,</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Contracted managed care</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">67</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">%</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">65</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">%</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">67</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">%</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">67</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Government</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">25</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">28</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">25</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">26</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Other third-parties</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">5</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">5</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">6</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">5</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Private-pay patients</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">3</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">2</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">2</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">2</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">100</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">%</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">100</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">%</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">100</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">%</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">100</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_AccountsReceivableAndNetRevenueDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts receivable and net revenue disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_AccountsReceivableAndNetRevenueDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139893757804272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accounts Payable and Accrued Expenses</a></td>
<td class="text"><p style="text-indent:0;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">5.            Accounts Payable and Accrued Expenses:	</span></p><div style="font-size:9pt;font-family:Times New Roman;"><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Accounts payable and accrued expenses consist of the following (in thousands):</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:54.314%;"></td>
        <td style="width:1.253%;"></td>
        <td style="width:1%;"></td>
        <td style="width:21.479%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.253%;"></td>
        <td style="width:1%;"></td>
        <td style="width:17.7%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">September 30, 2023</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Accounts payable</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">31,696</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">31,857</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Accrued salaries and incentive compensation</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">150,014</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">197,831</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Accrued payroll taxes and benefits</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">35,366</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">34,983</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Accrued professional liabilities</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">30,169</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">32,232</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Accrued interest</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">3,204</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">8,921</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Other accrued expenses</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">52,134</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">68,401</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">302,583</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">374,225</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The net decrease in accrued salaries and incentive compensation of $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">47.8</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million, from December 31, 2022 to September 30, 2023, is primarily due to the payment of performance-based incentive compensation, principally to the Company&#8217;s affiliated physicians, partially offset by performance-based incentive compensation accrued during the nine months ended September 30, 2023</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">. A majority of the Company&#8217;s payments for performance-based incentive compensation is paid annually during the first quarter.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139893752448512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Line of Credit and Long Term Debt<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_LineOfCreditAndLongTermDebtTextBlock', window );">Line of Credit and Long Term Debt</a></td>
<td class="text"><p style="text-indent:0;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">6.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Arial;min-width:fit-content;">          </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Line of Credit and Long-Term Debt:</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">On February 11, 2022, the Company issued $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">400.0</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million of </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">5.375</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">% unsecured senior notes due 2030 (the &#8220;2030 Notes&#8221;).  The Company used the net proceeds from the issuance of the </span><span style="font-size:9pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">2030</span></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> Notes, together with $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">100.0</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million drawn under the Revolving Credit Line (as defined below), $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">250.0</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million of Term A Loan (as defined below) and approximately $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">308.0</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million of cash on hand, to redeem (the &#8220;Redemption&#8221;) the </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">6.25</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">% senior unsecured notes due 2027, which had an outstanding principal balance of $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">1.0</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> billion, and to pay costs, fees and expenses associated with the Redemption and the Credit Agreement Amendment (as defined below).</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Interest on the 2030 Notes accrues at the rate of </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">5.375</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">% per annum, or $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">21.5</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million, and is </span><span style="font-size:9pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">payable semi-annually in arrears on February 15 and August 15, beginning on August 15, 2022</span></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">. The Company's obligations under the 2030 </span><span style="font-size:9pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Notes are guaranteed on an unsecured senior basis by the same subsidiaries and affiliated professional contractors that guarantee the Amended Credit Agreement (as defined below). The indenture under which the 2030 Notes are issued, among other things, limits the Company's ability to (1) incur liens and (2) enter into sale and lease-back transactions, and also limits the Company's ability to merge or dispose of all or substantially all of its assets, in all cases, subject to a number of customary exceptions</span></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">. Although the Company is not required to make mandatory redemption or sinking fund payments with respect to the 2030 Notes, upon the occurrence of a change in control, the Company may be required to repurchase the 2030 Notes at a purchase price equal to </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">101</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">% of the aggregate principal amount of the 2030 Notes repurchased plus accrued and unpaid interest.</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Also in connection with the Redemption, the Company amended its credit agreement (the &#8220;Credit Agreement&#8221;, and such amendment, the "Credit Agreement Amendment"), concurrently with the issuance of the 2030 Notes. The Credit Agreement Amendment, among other things, (i) refinanced the prior unsecured revolving credit facility with a $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">450</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million unsecured revolving credit facility, including a $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">37.5</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million sub-facility for the issuance of letters of credit (the &#8220;Revolving Credit Line&#8221;), and a $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">250</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">term </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">A loan facility (&#8220;Term A Loan&#8221;) and (ii) removed JPMorgan Chase Bank, N.A., as the administrative agent under the Credit Agreement and appointed Bank of America, N.A. as the administrative agent for the lenders.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The Credit Agreement, as amended by the Credit Agreement Amendment (the &#8220;Amended Credit Agreement&#8221;) matures on February 11, 2027 and is guaranteed on an unsecured basis by substantially all of the Company's subsidiaries and affiliated professional contractors. At the Company's option, borrowings under the Amended Credit Agreement bear interest at </span><span style="font-size:9pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(i) the Alternate Base Rate (defined as the highest of (a) the prime rate as announced by Bank of America, N.A., (b) the Federal Funds Rate plus 0.50% and (c) Term Secured Overnight Financing Rate ("SOFR") for an interest period of one month plus 1.00% with a 1.00% floor) plus an applicable margin rate of 0.50% for the first two fiscal quarters after the date of the Credit Agreement Amendment, and thereafter at an applicable margin rate ranging from 0.125% to 0.750% based on the Company's consolidated net leverage ratio or (ii) Term SOFR rate (calculated as the Secured Overnight Financing Rate published on the applicable Reuters screen page plus a spread adjustment of 0.10%, 0.15% or 0.25% depending on if the Company selects a one-month, three-month or six-month interest period, respectively, for the applicable loan with a 0% floor), plus an applicable margin rate of 1.50% for the first two full fiscal quarters after the date of the Credit Agreement Amendment, and thereafter at an applicable margin rate ranging from 1.125% to 1.750% based on the Company's consolidated net leverage ratio. The Amended Credit Agreement also provides for other customary fees and charges, including an unused commitment fee with respect to the Revolving Credit Line ranging from 0.150% to 0.200% of the unused lending commitments under the Revolving Credit Line</span></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">, based on the Company's consolidated net leverage ratio.</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The Amended Credit Agreement contains customary covenants and restrictions, including covenants that require the Company to maintain a minimum interest coverage ratio, a maximum consolidated net leverage ratio and to comply with laws, and restrictions on the ability to pay dividends, incur indebtedness or liens and make certain other distributions subject to baskets and exceptions, in each case, as specified therein. Failure to comply with these covenants would constitute an event of default under the Amended Credit Agreement, notwithstanding the ability of the Company to meet its debt service obligations. The Amended Credit Agreement includes various customary remedies for the lenders following an event of default, including the acceleration of repayment of outstanding amounts under the Amended Credit Agreement. In addition, the Company may increase the principal amount of the Revolving Credit Line or incur additional term loans under the Amended Credit Agreement in an aggregate principal amount such that on a pro forma basis after giving effect to such increase or additional term loans, the Company would be in compliance with the financial covenants, subject to the satisfaction of specified conditions and additional caps in the event that the Amended Credit Agreement is secured.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">At September 30, 2023, the Company had an outstanding principal balance on the Amended Credit Agreement of $</span><span style="font-size:9pt;font-family:Times New Roman;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">231.3</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million, comprised solely of the Term A Loan. The Company had $</span><span style="font-size:9pt;font-family:Times New Roman;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">450.0</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million available on its Amended Credit Agreement at </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">September 30, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">At September 30, 2023</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">, the Company had an outstanding principal balance of $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">400.0</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million on the 2030 Notes.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_LineOfCreditAndLongTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line Of Credit And Long Term Debt [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_LineOfCreditAndLongTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139893752363168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common and Common Equivalent Shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Common and Common Equivalent Shares</a></td>
<td class="text"><p style="text-indent:0;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">7.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Arial;min-width:fit-content;">            </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Common and Common Equivalent Shares:</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Basic net income per common share is calculated by dividing net income by the weighted average number of common shares outstanding during the period. Diluted net income per common share is calculated by dividing net income by the weighted average number of common and potential common shares outstanding during the period. Potential common shares consist of outstanding restricted stock and stock options and is calculated using the treasury stock method.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:9pt;font-family:Times New Roman;"><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The calculation of shares used in the basic and diluted net income per common share calculation for the </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">three and nine months ended September 30, 2023 and 2022 is as follows (in thousands):</span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.07%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.498%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.88%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.178%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.978%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.398%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Three Months Ended<br/>September 30,</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Nine Months Ended<br/>September 30,</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Weighted average number of common shares outstanding</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">82,543</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">82,126</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">82,127</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">84,122</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Weighted average number of dilutive common share<br/>&#160;&#160;&#160;equivalents</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">407</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">650</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">365</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">699</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Weighted average number of common and common<br/>&#160;&#160;&#160;equivalent shares outstanding</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">82,950</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">82,776</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">82,492</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">84,821</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Antidilutive securities (restricted stock and stock options) not included in the diluted net income per common share calculation</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">888</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">1</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">1,201</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">273</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:4.533%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:5.36pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139893752363168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive Plans and Stock Purchase Plans<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock Incentive Plans and Stock Purchase Plans</a></td>
<td class="text"><p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">8.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Arial;min-width:fit-content;">            </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Stock Incentive Plans and Stock Purchase Plans:</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s Amended and Restated 2008 Incentive Compensation Plan (the &#8220;Amended and Restated 2008 Incentive Plan&#8221;) provides for grants of stock options, stock appreciation rights, restricted stock, deferred stock, and other stock-related awards and performance awards that may be settled in cash, stock or other property.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Under the Amended and Restated 2008 Incentive Plan, options to purchase shares of common stock may be granted at a price not less than the fair market value of the shares on the date of grant. The options must be exercised within </span><span style="font-size:9pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">10 years</span></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> from the date of grant and generally become exercisable on a pro rata basis over a </span><span style="font-size:9pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">three-year</span></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> period from the date of grant. The Company issues new shares of its common stock upon exercise of its stock options. Restricted stock awards generally vest over periods of </span><span style="font-size:9pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">three years</span></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> upon the fulfillment of specified service-based conditions and in certain instances performance-based conditions. Deferred stock awards generally vest upon the satisfaction of specified performance-based conditions and service-based conditions. The Company recognizes compensation expense related to its restricted stock and deferred stock awards ratably over the corresponding vesting periods. During the </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">nine months ended September 30, 2023, the Company granted </span><span style="font-size:9pt;font-family:Times New Roman;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">0.8</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million shares of restricted stock to its employees and non-employee directors under the Amended and Restated 2008 Incentive Plan. At </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">September 30, 2023, the Company had </span><span style="font-size:9pt;font-family:Times New Roman;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">8.1</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million shares available for future grants and awards under the Amended and Restated 2008 Incentive Plan.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">   </span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Under the Company&#8217;s Amended and Restated 1996 Non-Qualified Employee Stock Purchase Plan, as amended (the &#8220;ESPP&#8221;), employees are permitted to purchase the Company's common stock at </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">85</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">% of market value on January 1st, April 1st, July 1st and October 1st of each year. Under the Company&#8217;s 2015 Non-Qualified Stock Purchase Plan (the &#8220;SPP&#8221;), certain eligible non-employee service providers are permitted to purchase the Company&#8217;s common stock at </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">90</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">% of market value on January 1st, April 1st, July 1st and October 1st of each year.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The Company recognizes stock-based compensation expense for the discount received by participating employees and non-employee service providers. During the nine months ended September 30, 2023, approximately </span><span style="font-size:9pt;font-family:Times New Roman;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million shares were issued under the ESPP. At </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">September 30, 2023, the Company had approximately </span><span style="font-size:9pt;font-family:Times New Roman;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">2.2</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million shares reserved for issuance under the ESPP. At </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">September 30, 2023, the Company had approximately </span><span style="font-size:9pt;font-family:Times New Roman;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">61,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> shares in the aggregate reserved for issuance under the SPP.  </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> shares have been issued under the SPP since 2020.</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">During the three and nine months ended September 30, 2023 and 2022, the Company recognized stock-based compensation expense of $</span><span style="font-size:9pt;font-family:Times New Roman;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">3.2</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:9pt;font-family:Times New Roman;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">9.3</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:9pt;font-family:Times New Roman;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">4.1</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:9pt;font-family:Times New Roman;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">12.9</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139893751580512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock Repurchase Programs<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_CommonStockRepurchasesTextBlock', window );">Common Stock Repurchase Programs</a></td>
<td class="text"><p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">9.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Arial;min-width:fit-content;">            </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Common Stock Repurchase Programs:</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">In July 2013, the Company&#8217;s Board of Directors authorized the repurchase of shares of the Company&#8217;s common stock up to an amount sufficient to offset the dilutive impact from the issuance of shares under the Company&#8217;s equity compensation programs. The share repurchase program allows the Company to make open market purchases from time-to-time based on general economic and market conditions and trading restrictions. The repurchase program also allows for the repurchase of shares of the Company&#8217;s common stock to offset the dilutive impact from the issuance of shares, if any, related to the Company&#8217;s acquisition program. </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> shares were purchased under this program during the </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">nine months ended September 30, 2023.</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">In August 2018, the Company announced that its Board of Directors had authorized the repurchase of up to $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">500.0</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million of the Company&#8217;s common stock in addition to its existing share repurchase program, of which $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">5.5</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million remained available for repurchase as of December 31, 2022. Under this share repurchase program, during the nine months ended September 30, 2023, the Company purchased a nominal number of shares of its common stock for $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">0.9</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million representing shares withheld to satisfy minimum statutory withholding obligations in connection with the vesting of restricted stock, resulting in $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">4.6</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million remaining available for repurchase under this authorization as of September 30, 2023.</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The Company intends to utilize various methods to effect any future share repurchases, including, among others, open market purchases and accelerated share repurchase programs. The amount and timing of repurchases will depend upon several factors, including general economic and market conditions and trading restrictions.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_CommonStockRepurchasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entire disclosure of common stock repurchases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_CommonStockRepurchasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139893751571696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Coronavirus Pandemic (COVID-19)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_ExtraordinaryItemsAbstract', window );"><strong>Extraordinary Items [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_CoronavirusPandemicCOVIDNineteenDisclosureTextBlock', window );">Coronavirus Pandemic (COVID-19)</a></td>
<td class="text"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">10.            Coronavirus Pandemic (&#8220;COVID-19&#8221;):</span></p><p style="margin-left:6.667%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">COVID-19 has had an impact on the demand for medical services provided by the Company's affiliated clinicians. </span><span style="color:#222222;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Beginning in mid-March 2020 and throughout the second quarter of 2020, </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">the Company's operating results were significantly impacted by COVID-19, but volumes began to normalize in mid-2020 and substantially recovered throughout 2020 with no material impacts from COVID-19 or its variants since that time. However, due to the continued uncertainties surrounding the timeline of and impacts from COVID-19 and with multiple variant strains still circulating, the Company is unable to predict the ultimate impact of COVID-19 on its business, financial condition, results of operations, cash flows and the trading price of its securities at this time.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">  </span><span style="color:#222222;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">CARES Act</span></p><p style="margin-left:6.667%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">In March 2020, the Coronavirus Aid, Relief, and Economic Security Act ("CARES Act") was signed into law. The CARES Act is a relief package intended to assist many aspects of the American economy, including providing financial aid to the healthcare industry to reimburse healthcare providers for lost revenue and expenses attributable to COVID-19. The Department of Health and Human Services is administering this program and began disbursing funds in April 2020, of which the Company&#8217;s affiliated physician practices within continuing operations recognized an aggregate of $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">11.4</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million during the three and nine months ended September 30, 2022</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_CoronavirusPandemicCOVIDNineteenDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Coronavirus Pandemic COVID Nineteen Disclosure [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_CoronavirusPandemicCOVIDNineteenDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_ExtraordinaryItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Extraordinary Items [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_ExtraordinaryItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139893751580512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">11.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Arial;min-width:fit-content;">            </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Commitments and Contingencies:	</span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The Company expects that audits, inquiries and investigations from government authorities and agencies will occur in the ordinary course of business. Such audits, inquiries and investigations and their ultimate resolutions, individually or in the aggregate, could have a material adverse effect on the Company's business, financial condition, results of operations, cash flows and the trading price of its securities. The Company has not included an accrual for these matters as of September 30, 2023 in its Consolidated Financial Statements, as the variables affecting any potential eventual liability depend on the currently unknown facts and circumstances that arise out of, and are specific to, any particular future audit, inquiry and investigation and cannot be reasonably estimated at this time.</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">In the ordinary course of business, the Company becomes involved in pending and threatened legal actions and proceedings, most of which involve claims of medical malpractice related to medical services provided by the Company's affiliated physicians. The Company's contracts with hospitals generally require the Company to indemnify them and their affiliates for losses resulting from the negligence of the Company's affiliated physicians. The Company may also become subject to other lawsuits which could involve large claims and significant costs. The Company believes, based upon a review of pending actions and proceedings, that the outcome of such legal actions and proceedings will not have a material adverse effect on its business, financial condition, results of operations, cash flows and the trading price of its securities. The outcome of such actions and proceedings, however, cannot be predicted with certainty and an unfavorable resolution of one or more of them could have a material adverse effect on the Company's business, financial condition, results of operations, cash flows and the trading price of its securities.</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Although the Company currently maintains liability insurance coverage intended to cover professional liability and certain other claims, the Company cannot assure that its insurance coverage will be adequate to cover liabilities arising out of claims asserted against it in the future where the outcomes of such claims are unfavorable. With respect to professional liability risk, the Company generally self-insures a portion of this risk through its wholly owned captive insurance subsidiary. Liabilities in excess of the Company's insurance coverage, including coverage for professional liability and certain other claims, could have a material adverse effect on the Company's business, financial condition, results of operations, cash flows and the trading price of its securities.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139893750269184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash Equivalents and Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Schedule of Investments</a></td>
<td class="text"><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Investments held are all classified as current and at </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">September 30, 2023 and December 31, 2022 are summarized as follows (in thousands):</span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:74.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.52%;"></td>
        <td style="width:1.42%;"></td>
        <td style="width:1%;"></td>
        <td style="width:18.32%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.42%;"></td>
        <td style="width:1%;"></td>
        <td style="width:18.32%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">September 30, 2023</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Corporate securities</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">58,830</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">61,385</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Municipal debt securities</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">13,419</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">14,377</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">U.S. Treasury securities</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">21,888</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">10,205</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Certificates of deposit</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">3,906</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">3,710</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Federal home loan securities</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">5,498</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">3,562</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">103,541</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">93,239</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139893751641280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</a></td>
<td class="text"><p style="text-indent:6.667%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The following table presents information about the Company&#8217;s financial instruments that are accounted for at fair value on a recurring basis at </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">September 30, 2023 and December 31, 2022 (in thousands):</span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:95.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:47.464%;"></td>
        <td style="width:1.062%;"></td>
        <td style="width:12.668%;"></td>
        <td style="width:1.062%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.818999999999999%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.105%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.818999999999999%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Fair Value</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Fair Value<br/>Category</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">September 30, 2023</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Assets:</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#ffffff;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Money market funds</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Level 1</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">1,201</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">1,415</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#cff0fc;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Short-term investments</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">103,541</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">93,239</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#ffffff;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Mutual Funds</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Level 1</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">15,851</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">14,544</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock', window );">Financial Instruments Measured At Carrying Amount</a></td>
<td class="text"><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The following table presents information about the Company&#8217;s financial instruments that are not carried at fair value at </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">September 30, 2023 and December 31, 2022 (in thousands):</span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.72%;"></td>
        <td style="width:1.08%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.24%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.08%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.84%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.32%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.72%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">September 30, 2023</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Carrying<br/>Amount</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Fair<br/>Value</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Carrying<br/>Amount</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Fair<br/>Value</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Liabilities:</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#ffffff;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">2030 Notes</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">400,000</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">352,680</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">400,000</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">344,000</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at carrying amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139893750239632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Receivable and Net Revenue (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock', window );">Schedule of Accounts Receivable, Net</a></td>
<td class="text"><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Accounts receivable, net consists of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:96.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:64.696%;"></td>
        <td style="width:1.042%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.61%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.042%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.61%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">September 30, 2023</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Gross accounts receivable</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">1,448,620</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">1,548,492</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Allowance for contractual adjustments and uncollectibles</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">1,171,268</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">1,251,705</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">277,352</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">296,787</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Net Revenue</a></td>
<td class="text"><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes the Company&#8217;s net revenue by category (in thousands):</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:30.731%;"></td>
        <td style="width:1.147%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.426%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.147%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.552999999999999%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.147%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.84%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.68%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.324%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Three Months Ended<br/>September 30,</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Nine Months Ended<br/>September 30,</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Net patient service revenue</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">437,321</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">421,085</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">1,290,888</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">1,245,627</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Hospital contract administrative fees</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">68,712</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">67,418</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">204,286</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">196,425</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Other revenue</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">579</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">1,412</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">3,023</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">16,125</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">506,612</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">489,915</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">1,498,197</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">1,458,177</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Schedule of Percentage of Net Revenue</a></td>
<td class="text"><p style="margin-left:4.533%;text-indent:6.983%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The approximate percentage of net patient service revenue by type of payor was as follows:</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:91.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:36.233%;"></td>
        <td style="width:1.3%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.597%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.82%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.798%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.078%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.177999999999999%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Three Months Ended<br/>September 30,</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Nine Months Ended<br/>September 30,</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Contracted managed care</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">67</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">%</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">65</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">%</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">67</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">%</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">67</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Government</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">25</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">28</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">25</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">26</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Other third-parties</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">5</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">5</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">6</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">5</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Private-pay patients</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">3</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">2</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">2</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">2</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">100</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">%</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">100</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">%</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">100</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">%</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">100</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3,4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-16<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139893752376416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accounts Payable and Accrued Expenses</a></td>
<td class="text"><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Accounts payable and accrued expenses consist of the following (in thousands):</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:54.314%;"></td>
        <td style="width:1.253%;"></td>
        <td style="width:1%;"></td>
        <td style="width:21.479%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.253%;"></td>
        <td style="width:1%;"></td>
        <td style="width:17.7%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">September 30, 2023</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Accounts payable</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">31,696</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">31,857</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Accrued salaries and incentive compensation</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">150,014</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">197,831</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Accrued payroll taxes and benefits</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">35,366</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">34,983</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Accrued professional liabilities</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">30,169</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">32,232</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Accrued interest</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">3,204</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">8,921</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Other accrued expenses</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">52,134</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">68,401</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">302,583</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">374,225</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139893851611824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common and Common Equivalent Shares (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock', window );">Schedule of Calculation of Shares Used in Basic and Diluted Net Income Per Share</a></td>
<td class="text"><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The calculation of shares used in the basic and diluted net income per common share calculation for the </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">three and nine months ended September 30, 2023 and 2022 is as follows (in thousands):</span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.07%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.498%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.88%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.178%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.978%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.398%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Three Months Ended<br/>September 30,</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Nine Months Ended<br/>September 30,</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Weighted average number of common shares outstanding</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">82,543</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">82,126</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">82,127</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">84,122</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Weighted average number of dilutive common share<br/>&#160;&#160;&#160;equivalents</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">407</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">650</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">365</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">699</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Weighted average number of common and common<br/>&#160;&#160;&#160;equivalent shares outstanding</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">82,950</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">82,776</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">82,492</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">84,821</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Antidilutive securities (restricted stock and stock options) not included in the diluted net income per common share calculation</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">888</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">1</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">1,201</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">273</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139893749502288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Basis of Presentation - Additional Information (Detail)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=md_UnnamedCorporateJointVentureOneMember', window );">Unnamed Corporate Joint Venture One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_BasisOfPresentationLineItems', window );"><strong>Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method ownership percentage in joint venture</a></td>
<td class="nump">37.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=md_UnnamedCorporateJointVentureTwoMember', window );">Unnamed Corporate Joint Venture Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_BasisOfPresentationLineItems', window );"><strong>Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method ownership percentage in joint venture</a></td>
<td class="nump">51.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_BasisOfPresentationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_BasisOfPresentationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=md_UnnamedCorporateJointVentureOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=md_UnnamedCorporateJointVentureOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=md_UnnamedCorporateJointVentureTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=md_UnnamedCorporateJointVentureTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139893749291856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash Equivalents and Investments - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashEquivalentsMember', window );">Cash Equivalents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_CashEquivalentsAndInvestmentsLineItems', window );"><strong>Cash Equivalents And Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MoneyMarketFundsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="nump">$ 1.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_CashEquivalentsAndInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_CashEquivalentsAndInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MoneyMarketFundsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MoneyMarketFundsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139893749487248">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash Equivalents and Investments - Schedule of Investments (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale Securities</a></td>
<td class="nump">$ 103,541<span></span>
</td>
<td class="nump">$ 93,239<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AllOtherCorporateBondsMember', window );">Corporate securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale Securities</a></td>
<td class="nump">58,830<span></span>
</td>
<td class="nump">61,385<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember', window );">Municipal Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale Securities</a></td>
<td class="nump">13,419<span></span>
</td>
<td class="nump">14,377<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale Securities</a></td>
<td class="nump">21,888<span></span>
</td>
<td class="nump">10,205<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of Deposit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale Securities</a></td>
<td class="nump">3,906<span></span>
</td>
<td class="nump">3,710<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">Federal Home Loan Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale Securities</a></td>
<td class="nump">$ 5,498<span></span>
</td>
<td class="nump">$ 3,562<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AllOtherCorporateBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AllOtherCorporateBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139893753214992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of fair value on a recurring basis (Details) - Fair Value, Recurring [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_MoneyMarketFundsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">$ 1,201<span></span>
</td>
<td class="nump">$ 1,415<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_MutualFundsFairValueDisclosure', window );">Mutual funds</a></td>
<td class="nump">15,851<span></span>
</td>
<td class="nump">14,544<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Short-term investments</a></td>
<td class="nump">$ 103,541<span></span>
</td>
<td class="nump">$ 93,239<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_MoneyMarketFundsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of money market funds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_MoneyMarketFundsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_MutualFundsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Mutual funds fair value disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_MutualFundsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139893753202848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of financial instruments that are not carried at fair value (Details) - 2030 Notes [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes Payable</a></td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes Payable Fair Value Disclosure</a></td>
<td class="nump">$ 352,680<span></span>
</td>
<td class="nump">$ 344,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of notes payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20,22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=md_TwoZeroThreeZeroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=md_TwoZeroThreeZeroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139893752714976">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounts Receivable and Net Revenue - Schedule of Accounts Receivable, Net (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableGrossCurrent', window );">Gross accounts receivable</a></td>
<td class="nump">$ 1,448,620<span></span>
</td>
<td class="nump">$ 1,548,492<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowance for contractual adjustments and uncollectibles</a></td>
<td class="num">(1,171,268)<span></span>
</td>
<td class="num">(1,251,705)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">$ 277,352<span></span>
</td>
<td class="nump">$ 296,787<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableGrossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableGrossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479344/326-20-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139893749551264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Receivable and Net Revenue - Schedule of Net Revenue (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueAbstract', window );"><strong>Disaggregation of Revenue [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">$ 506,612<span></span>
</td>
<td class="nump">$ 489,915<span></span>
</td>
<td class="nump">$ 1,498,197<span></span>
</td>
<td class="nump">$ 1,458,177<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_HealthCarePatientServiceMember', window );">Net patient service revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueAbstract', window );"><strong>Disaggregation of Revenue [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">437,321<span></span>
</td>
<td class="nump">421,085<span></span>
</td>
<td class="nump">1,290,888<span></span>
</td>
<td class="nump">1,245,627<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=md_HospitalsContractsMember', window );">Hospital contract administrative fees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueAbstract', window );"><strong>Disaggregation of Revenue [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">68,712<span></span>
</td>
<td class="nump">67,418<span></span>
</td>
<td class="nump">204,286<span></span>
</td>
<td class="nump">196,425<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueAbstract', window );"><strong>Disaggregation of Revenue [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">$ 579<span></span>
</td>
<td class="nump">$ 1,412<span></span>
</td>
<td class="nump">$ 3,023<span></span>
</td>
<td class="nump">$ 16,125<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_HealthCarePatientServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_HealthCarePatientServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=md_HospitalsContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=md_HospitalsContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139893753260032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Receivable and Net Revenue - Schedule of Net Patient Service Revenue by Type of Payor (Detail)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems', window );"><strong>Health Care Organization, Receivable and Revenue Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_PercentageOfNetPatientServiceRevenueByTypeOfPayor', window );">Percentage of net patient service revenue</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=md_ContractedManagedCareMember', window );">Contracted Managed Care [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems', window );"><strong>Health Care Organization, Receivable and Revenue Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_PercentageOfNetPatientServiceRevenueByTypeOfPayor', window );">Percentage of net patient service revenue</a></td>
<td class="nump">67.00%<span></span>
</td>
<td class="nump">65.00%<span></span>
</td>
<td class="nump">67.00%<span></span>
</td>
<td class="nump">67.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_GovernmentMember', window );">Government [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems', window );"><strong>Health Care Organization, Receivable and Revenue Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_PercentageOfNetPatientServiceRevenueByTypeOfPayor', window );">Percentage of net patient service revenue</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">28.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">26.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_ThirdPartyPayorMember', window );">Other Third-Parties [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems', window );"><strong>Health Care Organization, Receivable and Revenue Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_PercentageOfNetPatientServiceRevenueByTypeOfPayor', window );">Percentage of net patient service revenue</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_SelfPayMember', window );">Private-Pay Patients [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems', window );"><strong>Health Care Organization, Receivable and Revenue Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_PercentageOfNetPatientServiceRevenueByTypeOfPayor', window );">Percentage of net patient service revenue</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_PercentageOfNetPatientServiceRevenueByTypeOfPayor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of net patient service revenue by type payor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_PercentageOfNetPatientServiceRevenueByTypeOfPayor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=md_ContractedManagedCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueSourcesAxis=md_ContractedManagedCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_GovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_GovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_ThirdPartyPayorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_ThirdPartyPayorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_SelfPayMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_SelfPayMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139893756970080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Business Combinations and Discontinued Operations -  Additional information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">$ 108,010<span></span>
</td>
<td class="nump">$ 123,176<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139893753970176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">$ 31,696<span></span>
</td>
<td class="nump">$ 31,857<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Accrued salaries and incentive compensation</a></td>
<td class="nump">150,014<span></span>
</td>
<td class="nump">197,831<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_AccruedPayrollTaxesAndBenefitsCurrent', window );">Accrued payroll taxes and benefits</a></td>
<td class="nump">35,366<span></span>
</td>
<td class="nump">34,983<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent', window );">Accrued professional liabilities</a></td>
<td class="nump">30,169<span></span>
</td>
<td class="nump">32,232<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest</a></td>
<td class="nump">3,204<span></span>
</td>
<td class="nump">8,921<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued expenses</a></td>
<td class="nump">52,134<span></span>
</td>
<td class="nump">68,401<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses, total</a></td>
<td class="nump">$ 302,583<span></span>
</td>
<td class="nump">$ 374,225<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_AccruedPayrollTaxesAndBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued payroll taxes and benefits current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_AccruedPayrollTaxesAndBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the current portion of the accrued liability on an undiscounted basis for malpractice claims (including general and professional liability).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139893752357376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Accrued Expenses - Additional Information (Detail)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_IncreaseDecreaseInAccruedSalariesAndBonuses', window );">Net decrease in accrued salaries and bonuses</a></td>
<td class="nump">$ 47.8<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_IncreaseDecreaseInAccruedSalariesAndBonuses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in accrued salaries and bonuses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_IncreaseDecreaseInAccruedSalariesAndBonuses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139893743670304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Line of Credit and Long Term Debt (Additional Information) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 11, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment', window );">Debt Instrument, Frequency of Periodic Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">payable semi-annually in arrears on February 15 and August 15, beginning on August 15, 2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescription', window );">Debt Instrument, Description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Notes are guaranteed on an unsecured senior basis by the same subsidiaries and affiliated professional contractors that guarantee the Amended Credit Agreement (as defined below). The indenture under which the 2030 Notes are issued, among other things, limits the Company's ability to (1) incur liens and (2) enter into sale and lease-back transactions, and also limits the Company's ability to merge or dispose of all or substantially all of its assets, in all cases, subject to a number of customary exceptions<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_PurchasePrice', window );">Purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Borrowings on revolving credit line</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 470,000<span></span>
</td>
<td class="nump">$ 674,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtAxis=us-gaap_LongTermDebtMember', window );">Long-Term Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnsecuredLongTermDebt', window );">Proceeds from issuance of unsecured debt</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash on hand</a></td>
<td class="nump">308,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=md_CreditAgreementMember', window );">Credit Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Line of Credit facility, available balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">231,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfUnsecuredDebt', window );">Proceeds from issuance of unsecured debt</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Borrowings on revolving credit line</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility [Member] | Long-Term Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnsecuredLongTermDebt', window );">Proceeds from issuance of unsecured debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility [Member] | Credit Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnsecuredDebt', window );">Unsecured note issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DescriptionOfInterestRateRiskExposure', window );">Interest Rate, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">(i) the Alternate Base Rate (defined as the highest of (a) the prime rate as announced by Bank of America, N.A., (b) the Federal Funds Rate plus 0.50% and (c) Term Secured Overnight Financing Rate ("SOFR") for an interest period of one month plus 1.00% with a 1.00% floor) plus an applicable margin rate of 0.50% for the first two fiscal quarters after the date of the Credit Agreement Amendment, and thereafter at an applicable margin rate ranging from 0.125% to 0.750% based on the Company's consolidated net leverage ratio or (ii) Term SOFR rate (calculated as the Secured Overnight Financing Rate published on the applicable Reuters screen page plus a spread adjustment of 0.10%, 0.15% or 0.25% depending on if the Company selects a one-month, three-month or six-month interest period, respectively, for the applicable loan with a 0% floor), plus an applicable margin rate of 1.50% for the first two full fiscal quarters after the date of the Credit Agreement Amendment, and thereafter at an applicable margin rate ranging from 1.125% to 1.750% based on the Company's consolidated net leverage ratio. The Amended Credit Agreement also provides for other customary fees and charges, including an unused commitment fee with respect to the Revolving Credit Line ranging from 0.150% to 0.200% of the unused lending commitments under the Revolving Credit Line<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=md_FivePointThreeSevenFivePercentUnsecuredSeniorNotesDueTwoThousandThirtyMember', window );">5.375% Unsecured Senior Notes Due 2030 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeniorNotes', window );">Senior notes</a></td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate</a></td>
<td class="nump">5.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_DebtInstrumentMaturityYear', window );">Debt instrument, maturity year</a></td>
<td class="text">2030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentInterest', window );">Interest accrued periodically</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=md_SixPointTwentyFivePercentageSeniorUnsecuredNotesDue2027Member', window );">6.25% senior unsecured notes due 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Debt instrument, interest rate, effective percentage</a></td>
<td class="nump">6.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=md_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember', window );">2027 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long term debt</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_DebtInstrumentMaturityYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument maturity year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_DebtInstrumentMaturityYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_PurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_PurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480555/946-210-45-21<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480555/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480848/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the frequency of periodic payments (monthly, quarterly, annual).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480848/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFrequencyOfPeriodicPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPaymentInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments applied to interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPaymentInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DescriptionOfInterestRateRiskExposure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the sources of interest rate risk exposure faced by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 815<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1A<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1B<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DescriptionOfInterestRateRiskExposure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfUnsecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of long-term debt that is not secured by collateral. Excludes proceeds from tax exempt unsecured debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfUnsecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeniorNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer). Senior note holders are paid off in full before any payments are made to junior note holders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.16)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeniorNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnsecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of uncollateralized debt obligations (with maturities initially due after one year or beyond the operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnsecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnsecuredLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of uncollateralized debt obligation (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnsecuredLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtinguishmentOfDebtAxis=us-gaap_LongTermDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtinguishmentOfDebtAxis=us-gaap_LongTermDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=md_CreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=md_CreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=md_FivePointThreeSevenFivePercentUnsecuredSeniorNotesDueTwoThousandThirtyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=md_FivePointThreeSevenFivePercentUnsecuredSeniorNotesDueTwoThousandThirtyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=md_SixPointTwentyFivePercentageSeniorUnsecuredNotesDue2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=md_SixPointTwentyFivePercentageSeniorUnsecuredNotesDue2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=md_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=md_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139893749506832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common and Common Equivalent Shares - Schedule of Calculation of Shares Used in Basic and Diluted Net Income Per Share (Detail) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of common shares outstanding</a></td>
<td class="nump">82,543,000<span></span>
</td>
<td class="nump">82,126,000<span></span>
</td>
<td class="nump">82,127,000<span></span>
</td>
<td class="nump">84,122,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Weighted average number of dilutive common share equivalents</a></td>
<td class="nump">407,000<span></span>
</td>
<td class="nump">650,000<span></span>
</td>
<td class="nump">365,000<span></span>
</td>
<td class="nump">699,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of common and common equivalent shares outstanding</a></td>
<td class="nump">82,950,000<span></span>
</td>
<td class="nump">82,776,000<span></span>
</td>
<td class="nump">82,492,000<span></span>
</td>
<td class="nump">84,821,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (restricted stock and stock options) not included in the diluted net income per common share calculation</a></td>
<td class="nump">888,000<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">1,201,000<span></span>
</td>
<td class="nump">273,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480454/718-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-22<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-28A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139893743776240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive Plans and Stock Purchase Plans - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 3.2<span></span>
</td>
<td class="nump">$ 4.1<span></span>
</td>
<td class="nump">$ 9.3<span></span>
</td>
<td class="nump">$ 12.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Vesting period of options, maximum years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember', window );">1996 Non-Qualified Employee Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Aggregate number Shares issued under Stock Purchase Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember', window );">2015 Non-Qualified Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Percentage of market value of common stock at which employees are permitted to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=md_AmendedAndRestatedTwoThousandEightPlanMember', window );">Amended and Restated 2008 Plan [Member] | Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future grants and awards under Stock Incentive Plans</a></td>
<td class="nump">8,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=md_AmendedAndRestatedTwoThousandEightPlanMember', window );">Amended and Restated 2008 Plan [Member] | Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember', window );">1996 Non-Qualified Employee Stock Purchase Plan and 2015 Non-Qualified Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Percentage of market value of common stock at which employees are permitted to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Aggregate number Shares issued under Stock Purchase Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, reserved for issuance</a></td>
<td class="nump">2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember', window );">1996 Non-Qualified Employee Stock Purchase Plan and 2015 Non-Qualified Stock Purchase Plan [Member] | Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, reserved for issuance</a></td>
<td class="nump">61,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=md_AmendedAndRestatedTwoThousandEightPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=md_AmendedAndRestatedTwoThousandEightPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139893753353920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock Repurchase Programs - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Aug. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_CommonStockLineItems', window );"><strong>Common Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchased common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Common stock authorized for repurchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1', window );">Company's Common stock repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for repurchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 919<span></span>
</td>
<td class="nump">$ 87,041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_CommonStockLineItems', window );"><strong>Common Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchased common stock, shares</a></td>
<td class="num">(11,000)<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
<td class="num">(49,000)<span></span>
</td>
<td class="num">(1,121,000)<span></span>
</td>
<td class="num">(3,275,000)<span></span>
</td>
<td class="num">(50,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for repurchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased', window );">Stock Repurchase Program, Number of Shares Authorized to be Repurchased</a></td>
<td class="nump">4,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_CommonStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_CommonStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares authorized to be repurchased by an entity's Board of Directors under a stock repurchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount remaining of a stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139893750374320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Coronavirus Pandemic (COVID-19) - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_ExtraordinaryItemsAxis=md_CovidNinenteenMember', window );">COVID-19 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue', window );">Proceeds From Contribution In Aid Of Reimbursement of Lost Revenue</a></td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="nump">$ 11.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Contribution In Aid Of Reimbursement of Lost Revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_ExtraordinaryItemsAxis=md_CovidNinenteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_ExtraordinaryItemsAxis=md_CovidNinenteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>md-20230930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:md="http://www.mednax.com/20230930"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="md-20230930.xsd" xlink:type="simple"/>
    <context id="C_03cd8a32-d1bc-4934-bd34-28363e85b18a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">md:NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="C_f2e4e009-3726-45e0-a90a-5d336cda6f04">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AllOtherCorporateBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_92f598fa-4d7f-4e9b-b277-8567385e3d27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="C_fd83bf41-3f3e-4283-8803-bc13fec411ef">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_4ec257e6-7ad0-419f-b83a-531d36bb3987">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">md:SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-11</instant>
        </period>
    </context>
    <context id="C_bbb0586b-efa6-4d4e-b6e9-1b625c1dbc91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_fdee2685-4fe9-4dac-b896-4bbc5d69816d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">md:SixPointTwentyFivePercentageSeniorUnsecuredNotesDue2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-11</instant>
        </period>
    </context>
    <context id="C_17d5429f-d92b-4cb2-97ef-26e7d7d1dbfb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <instant>2023-10-27</instant>
        </period>
    </context>
    <context id="C_35888be5-90cc-40bd-b51a-b4a5ef520e02">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_350c5db7-f64b-4e63-97fa-733cc8e8f783">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_0b560b9e-bc42-4716-8570-2af20d2cca64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">md:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="C_c8155ad1-ff2e-4bfe-b9f9-a6805aed62f4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_ad3c19c0-ada4-44fc-bdd3-c29b5398a40a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_340f9a3e-b672-4edc-82ab-7e12ef61b6da">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:GovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_874771f9-e875-4db9-94d5-bb53a324cb51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_134848fe-680a-4e25-830f-371c8b8fb100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:GovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_fa51030c-8ae1-44ad-b260-2c8ee8428637">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_64e6ce54-7a3c-4a04-9100-a67300b48c30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_99c7da7a-966d-481a-9f87-07899a403107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:SelfPayMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_19a977fa-7760-40e4-8833-ab4c31af2173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_ece3d6f0-dcae-48a9-bc24-698ee8c17506">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_07cad879-2c61-450d-9518-d6bbda76d09e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">md:HospitalsContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_377d4d1b-904e-4983-aaf7-ccda1f31ece5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_c5cbe39a-b446-4f38-9bc0-7315c1df92ff">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="C_a66a0d65-33d2-4b8c-a2fa-57b2aec20870">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_f8d7ba49-dc8b-448a-ba32-eed7f3fb3be4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_86f7c920-c7dd-49eb-b9e5-c81407859e32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_6aabcea2-797e-41b7-aefa-4ccc2147de8f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_0b8cfdec-f0c4-4429-b94a-75b07f7aae51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="C_e4839b2a-c828-4c77-8f2c-55160784c52b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_2e0a629f-a677-4b59-a478-5cbb505d9530">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_115e1478-c36e-4914-b961-b19a8a7591a9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_ec45eaa6-d9c5-4fd0-84cf-6b2be759e02b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_899d2caa-e2bb-4aac-bb5e-119389b4c1f1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_85574474-f392-4916-ac36-f721aeb624d6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_0a32aa8a-cbb8-411d-957d-680d318c2384">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">md:TwoZeroThreeZeroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_33f86df0-142f-4408-9f5e-9de3e9f21458">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">md:ContractedManagedCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_c77e289a-1111-40d7-9df0-645b35738672">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="C_24d8347f-a523-4cf1-8d04-a1595106e838">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">md:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_7b75f74d-09a8-4e26-8d61-3a48b9fa176e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_cf213a70-35ae-48c9-9339-37927b488110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_56cb679d-6a88-4a31-abf3-f1c779c4bcb9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_97d10031-02ee-416c-bb86-cd6e6928957a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_f56f4f7a-19b8-4635-8355-ce0222c24e4b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="C_45911ccf-f5d4-4c4e-8dd0-c5ea09a1db36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_887ab47d-2465-4e8c-8649-d0d114c06f6c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="C_d1b666e6-0f27-4c23-9240-3207e18d4a31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="C_2ed09d19-c783-4eb4-860c-7e590254f539">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_5d513fe3-41de-49c7-8231-3b67764cba30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="C_6494afcc-dadf-426c-b613-8f9a7abfe318">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:GovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_f0afc955-4abd-4ca2-99cf-97256b13481a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_ee5ce32e-37b5-4efc-a6e1-d6be8df2025a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_2f1c7dd7-f01c-4015-a37d-1caeb69540b9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">md:FivePointThreeSevenFivePercentUnsecuredSeniorNotesDueTwoThousandThirtyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-11</instant>
        </period>
    </context>
    <context id="C_d9967c70-bdd9-46f2-a73f-0af130ef6ca5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_fd02f20b-c7c9-4b18-9720-432b8fd1f5bc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="C_4c2decbf-697c-4da3-a4c5-727a578f77dc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <instant>2018-08-31</instant>
        </period>
    </context>
    <context id="C_f56c48df-9031-48bb-ae3d-40c5aabd6cc4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="C_ec1dd730-3062-4268-8e06-714c3ed2af24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">md:FivePointThreeSevenFivePercentUnsecuredSeniorNotesDueTwoThousandThirtyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="C_0c4b440a-242a-4875-a46f-4a05a1426d70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_db14decc-aca0-4ce7-bed7-40edd1c86538">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_07ab98db-f259-45b0-b05a-833bf8d33505">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="C_260cff1e-4c05-484b-8a25-8a1e82704661">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="C_86bee92f-7914-4dbf-a4cd-38a1fed2ab1c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_c10c4eef-bb70-4725-bb7d-0a8da3fa54db">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="C_f6042715-3400-472b-a63f-651373917338">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_89fa872a-ad9d-4262-8559-732e6a088cd4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_aca7d163-6a33-4b3d-9ea5-b99aa4fe9e34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_ee0dda75-7533-43f8-ba6d-8b3ddadca454">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_b7a3aab8-6e4f-488e-bd25-e4acf1837264">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_2f54399b-eb59-443e-af5f-01b59be7c4b3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="C_b3dc82b2-20f3-4300-82a6-75ad6389cab0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="C_b42eab6a-90cf-43fc-9fc6-2ad25a6ef134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="C_22bf64d7-53dd-4c56-b931-fbaef641de7e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="C_cd23234b-4b27-4574-a7f1-454baa006e0e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_af3a863a-e1d2-476d-ab71-08e497384468">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_61935c85-fd8d-48a0-b0e8-e2ace38d0aca">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_13a9d66b-1b0e-497a-b873-fe7ac09c44cf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">md:HospitalsContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_c7f29732-6f5b-49e4-a848-639b94127316">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">md:HospitalsContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_7bab9990-2405-4ad2-b988-70145110847c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_a04c17b2-e635-4a34-a0cc-839bf6802112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">md:NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_1a90cf11-7660-475d-b876-c49b675c3a0d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">md:ContractedManagedCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_9a67fb14-6a35-4389-82c8-b724c79c3f38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_99787654-98fb-4075-b2d1-551ddbc6deed">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">md:UnnamedCorporateJointVentureTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="C_894b93ff-c06d-4c0f-a734-2f6884d5b7f7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">md:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="C_477d8b88-2dd5-4c27-a308-f22d4cb31970">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_56dd7543-31f8-4ae4-badc-c16562ed7f07">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="C_965dd392-85a0-4cd0-8ea9-4961c1f6dc80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_86ceec74-75ab-4b30-bf4d-aa99084da5fc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_73fe2b81-82a7-41de-a03c-5ba651cc8568">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_3ed13396-e9c9-4ccc-91fd-b54c8527fe2e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="C_ebc061e7-b2d9-4c21-8b03-fda66e7ff5fd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">md:FivePointThreeSevenFivePercentUnsecuredSeniorNotesDueTwoThousandThirtyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_8d549597-a6a3-4f65-960a-276c382d6949">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_6ea9b9a0-3cfd-421c-9583-235675ef66b6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">md:ContractedManagedCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_1c0cfd23-24b4-45dc-8a0f-30d68714c292">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">md:FivePointThreeSevenFivePercentUnsecuredSeniorNotesDueTwoThousandThirtyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-11</startDate>
            <endDate>2022-02-11</endDate>
        </period>
    </context>
    <context id="C_75ad9bd0-8190-4d2d-9f0a-71bf1ddf7588">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_eb46e330-b646-43c3-95f2-112f68583c49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">md:NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="C_6a82b64e-6fb9-48f9-99fe-5081ff6fca6c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="md:ExtraordinaryItemsAxis">md:CovidNinenteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="C_f4b8c51a-4dae-4dd3-9d9f-ef95a7c7a1b4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_f2431026-3a3b-40cd-9fb3-55962d2dfba5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-11</startDate>
            <endDate>2022-02-11</endDate>
        </period>
    </context>
    <context id="C_36d93c5d-b688-4948-8aa6-b10b1986e10f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_ea09ed9a-1817-4610-877d-b7f92fa5faba">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_43c976d5-88bb-433a-adbb-5b5571f16c99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="md:ExtraordinaryItemsAxis">md:CovidNinenteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="C_0c7585a4-747b-415b-a754-892864d85f80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">md:AmendedAndRestatedTwoThousandEightPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_3f1eae59-7db7-4f63-b33e-689ca6ac6166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="C_9b225ad0-d1c0-4862-9853-9d52295b37b4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="C_012cf148-5766-4e38-bab9-71a218133486">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="C_e97fbd72-ea7b-4883-b296-14825e3e504f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="C_830bbec2-bf82-42ba-aab7-1b87e55627e6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_0be151b0-34b3-4da7-b3ba-2f77da9f751e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">md:TwoThousandFifteenNonQualifiedStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_461e1df7-29c9-4340-9d09-2d305db85278">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_ecfb99fe-0958-4180-b890-77afb1efe059">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AllOtherCorporateBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="C_071df110-5688-40d6-b07e-cf79e845dffc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_b98e3dec-68cf-411f-84d8-48f4345c2f5e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="C_530a9bb3-d0af-4d65-93b6-103b6c414d75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">md:ContractedManagedCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_4a7eedc9-2d63-42bd-9695-8d9ce87c5067">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:GovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_8350a8fa-b313-4bbc-8d3d-a43cfa5262b4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="C_c2300a5a-f622-49a9-b54c-dcabb14d6824">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">md:NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_7ae55b15-375d-4829-8fee-0964b045a7cf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">md:UnnamedCorporateJointVentureOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="C_659d9bd3-6f8d-448a-9462-197a2c4b64c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="C_fc6992a8-5cd9-42e1-ba09-8be4221adf6f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_9b7a1e9b-0052-493b-8b97-41fc5afb54f6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_1ccfbb16-e844-487b-90c8-99c1b5604082">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="C_ec5297e8-5a0c-4bde-9aa8-9737b4ffc31c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_ead630e6-3bc1-4158-acab-0cd6d0a20d53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_308516ff-d843-45b5-8b06-0a3e134f255e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_3fe9a616-cb85-448a-a3c7-88b42ca6650a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_7b747bea-61e9-4a99-b3d9-c96dee793375">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="C_61e8dbc9-4c0e-40e5-bc06-8dbeefba5d20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_7ad99fb3-5525-4459-a4cb-b1188d7c5224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="C_06c01cd0-0e05-46ab-a1e5-d6467d9be312">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">md:TwoZeroThreeZeroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="C_dba1d7c4-12e0-4e88-888d-efc09f476c71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_8fa77ca8-719f-4df1-bf5f-88fe5ee7eebb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:SelfPayMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_b3dba50b-b27a-4103-9cc0-9ccc2aeac984">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="C_9340fe71-cf84-4fe9-b488-79ab1cff7146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">md:AmendedAndRestatedTwoThousandEightPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="C_3f7aa872-26d0-45a9-b1bb-119611e8d6c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">md:HospitalsContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_3ecbf02e-8155-43fd-bfae-75d93b4d3bb0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="C_4c16c34d-3859-4415-b98c-b075a026c528">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_9d124535-a548-449d-8d4b-80ec4d95973a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_0002ecca-b81e-4c48-8d05-eefbc915ed5a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_a53e34bc-3154-419c-8471-2c496997bd8c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:SelfPayMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_8b93e2e5-8344-474d-908a-5783596f5a9f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_f61ab540-a2d0-4d45-8e9f-d043538b0a26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:SelfPayMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_7cfd52bf-5193-4a6c-bf56-23a18e131b5e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="C_e5943398-0732-4d17-9fe7-25777d223b65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_48f6c028-da90-4698-9d57-8fadb9aedae6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-11</instant>
        </period>
    </context>
    <context id="C_846d24c8-9524-45a4-a1b6-aa7b223ba8ec">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_USDollarShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      id="F_6f29d740-8345-4b23-aaea-9bf2993e594b">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      id="F_fb628bf3-7b5c-4ca7-ba3a-53a7c8c17429">0000893949</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      id="F_dca61a52-b8ec-461f-b1ae-6247e9b87d8e">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:AmendmentFlag
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      id="F_c598e0f1-6e9c-4db1-88d8-3ff80c15284f">false</dei:AmendmentFlag>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_5d513fe3-41de-49c7-8231-3b67764cba30"
      id="F_71b38540-0a46-456d-b52f-5551e74ee66d"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_ad3c19c0-ada4-44fc-bdd3-c29b5398a40a"
      id="F_88126968-94b4-42e4-8930-40061df59b00"
      unitRef="U_USD"
      xsi:nil="true"/>
    <dei:DocumentType
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      id="F_18c2d184-1ed2-41a0-824e-adf2ef186adb">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      id="F_4c1f07f4-07e2-4e7c-a9bd-a6954857e531">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      id="F_b4917864-2eb2-4e7e-87b3-db41d988475d">2023-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      id="F_b97d51dd-ce3b-451a-bbbd-f92cc137e583">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      id="F_3faaaf3c-7981-49e1-a197-6c4964e2f58b">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      id="F_3ea713e6-f581-447e-8504-f9d44845cef7">001-12111</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      id="F_382fd7e1-9c07-4dd7-9f3f-d1344d3634bd">Pediatrix Medical Group, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      id="F_129ff8e6-0c3e-4561-94ef-13af465c28b6">FL</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      id="F_0d091436-e490-4798-9408-350c2fe9cb83">26-3667538</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      id="F_85cc452c-e4ad-4206-8c8b-cc0afc89af5e">1301 Concord Terrace</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      id="F_b1218875-159a-4d97-ac38-9de162803281">Sunrise</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      id="F_e8cf648e-551f-4a86-be8a-5b353a3a9c56">FL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      id="F_78a1570b-d994-4e94-9c46-988c3b47248d">33323</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      id="F_9d5a276f-bae6-4a26-bc81-f29564ba8122">954</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      id="F_3f2726b5-3ac6-461f-ae70-bf5a9eb26d63">384-0175</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      id="F_ac588deb-dd1b-4271-bfb1-5b9fcbca3f9e">Common Stock, par value $.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      id="F_776a6f11-a31a-4be8-9a1c-5318b1855e4e">MD</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      id="F_9f59ce3e-2dbd-42ac-9123-ab88d03333cd">NYSE</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      id="F_1880982c-0b29-4688-a0af-21ba66e52f70">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      id="F_8351983b-08f2-4672-befe-5a0569aefa3f">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      id="F_33e3db1c-f081-48bf-808f-4c3f37b322ab">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      id="F_955f5112-fab3-4d2c-87f0-ad0fc450435b">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      id="F_fdb820a2-5815-416f-87fd-eef922985aae">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      id="F_4e8182c8-67df-476f-ae6d-9aafc93b338f">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_17d5429f-d92b-4cb2-97ef-26e7d7d1dbfb"
      decimals="INF"
      id="F_4866c0a6-c503-4f59-a7e5-38ad889736df"
      unitRef="U_shares">84023916</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_5d513fe3-41de-49c7-8231-3b67764cba30"
      decimals="-3"
      id="F_0e1a7495-4dff-4c40-87e8-822ff211d6ac"
      unitRef="U_USD">21179000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_ad3c19c0-ada4-44fc-bdd3-c29b5398a40a"
      decimals="-3"
      id="F_a9038791-b462-4cfb-bebe-c76e5498e8f6"
      unitRef="U_USD">9824000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_5d513fe3-41de-49c7-8231-3b67764cba30"
      decimals="-3"
      id="F_32d96254-d191-49bf-badc-b9d8d70f8e2f"
      unitRef="U_USD">103541000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_ad3c19c0-ada4-44fc-bdd3-c29b5398a40a"
      decimals="-3"
      id="F_70221fa5-d2d7-45d8-b9fa-a70bfeb6eaee"
      unitRef="U_USD">93239000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_5d513fe3-41de-49c7-8231-3b67764cba30"
      decimals="-3"
      id="F_1db442cd-773f-4e73-8679-7ba18a742158"
      unitRef="U_USD">277352000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_ad3c19c0-ada4-44fc-bdd3-c29b5398a40a"
      decimals="-3"
      id="F_132b755b-0f59-4879-a947-0a8613136b32"
      unitRef="U_USD">296787000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="C_5d513fe3-41de-49c7-8231-3b67764cba30"
      decimals="-3"
      id="F_c97679ba-775c-4ad0-9831-5c4914895982"
      unitRef="U_USD">10586000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="C_ad3c19c0-ada4-44fc-bdd3-c29b5398a40a"
      decimals="-3"
      id="F_a8d54fd7-b688-40da-a408-879a61781576"
      unitRef="U_USD">14878000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="C_5d513fe3-41de-49c7-8231-3b67764cba30"
      decimals="-3"
      id="F_5071e514-ecac-4995-b74c-287ca0cd5cf8"
      unitRef="U_USD">7866000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="C_ad3c19c0-ada4-44fc-bdd3-c29b5398a40a"
      decimals="-3"
      id="F_f59cd0a2-1709-41ee-ae37-d7b8f45480d0"
      unitRef="U_USD">13261000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_5d513fe3-41de-49c7-8231-3b67764cba30"
      decimals="-3"
      id="F_17dca86e-43fc-493a-8379-6a62161cd736"
      unitRef="U_USD">420524000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_ad3c19c0-ada4-44fc-bdd3-c29b5398a40a"
      decimals="-3"
      id="F_88f32090-0659-4060-9618-2f66acab4d23"
      unitRef="U_USD">427989000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_5d513fe3-41de-49c7-8231-3b67764cba30"
      decimals="-3"
      id="F_57e816dd-a2e6-4f7c-aad4-32dea2ed70eb"
      unitRef="U_USD">75146000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_ad3c19c0-ada4-44fc-bdd3-c29b5398a40a"
      decimals="-3"
      id="F_a456906d-13f3-452f-97b3-f21c05a3f9d1"
      unitRef="U_USD">73290000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Goodwill
      contextRef="C_5d513fe3-41de-49c7-8231-3b67764cba30"
      decimals="-3"
      id="F_cf69e7ff-84dd-4791-bca8-46fb8ab96244"
      unitRef="U_USD">1532092000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="C_ad3c19c0-ada4-44fc-bdd3-c29b5398a40a"
      decimals="-3"
      id="F_6d302b7d-78cf-470c-8437-a8e310c75bee"
      unitRef="U_USD">1532092000</us-gaap:Goodwill>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_5d513fe3-41de-49c7-8231-3b67764cba30"
      decimals="-3"
      id="F_4eca23c2-d601-422c-88cf-edbe98aeaabe"
      unitRef="U_USD">15486000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_ad3c19c0-ada4-44fc-bdd3-c29b5398a40a"
      decimals="-3"
      id="F_0b869055-6240-4b06-bc41-ffc9cc2d3e6d"
      unitRef="U_USD">18491000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <md:OperatingAndFinanceLeaseRightOfUseAssets
      contextRef="C_5d513fe3-41de-49c7-8231-3b67764cba30"
      decimals="-3"
      id="F_a7b4f3f8-4317-4863-a892-c6680e44214a"
      unitRef="U_USD">72443000</md:OperatingAndFinanceLeaseRightOfUseAssets>
    <md:OperatingAndFinanceLeaseRightOfUseAssets
      contextRef="C_ad3c19c0-ada4-44fc-bdd3-c29b5398a40a"
      decimals="-3"
      id="F_7c7f2b45-8507-418a-bf27-4a05be2b29d9"
      unitRef="U_USD">66924000</md:OperatingAndFinanceLeaseRightOfUseAssets>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="C_5d513fe3-41de-49c7-8231-3b67764cba30"
      decimals="-3"
      id="F_10214fcc-63d5-4012-accd-01c9b30f82a7"
      unitRef="U_USD">102638000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="C_ad3c19c0-ada4-44fc-bdd3-c29b5398a40a"
      decimals="-3"
      id="F_8b83c189-2a2e-4e61-8438-1f6c6855c4b0"
      unitRef="U_USD">105925000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_5d513fe3-41de-49c7-8231-3b67764cba30"
      decimals="-3"
      id="F_7a64f3fc-b7ed-4364-b125-83184bcb688f"
      unitRef="U_USD">108010000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_ad3c19c0-ada4-44fc-bdd3-c29b5398a40a"
      decimals="-3"
      id="F_36b6a9b9-c06a-4cf3-ae22-252db23e6a3c"
      unitRef="U_USD">123176000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_5d513fe3-41de-49c7-8231-3b67764cba30"
      decimals="-3"
      id="F_88f119fd-71b4-49ca-91b2-3a31edbfe55e"
      unitRef="U_USD">2326339000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_ad3c19c0-ada4-44fc-bdd3-c29b5398a40a"
      decimals="-3"
      id="F_0005ac0b-d3ec-4bee-8944-cf2a9c426522"
      unitRef="U_USD">2347887000</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="C_5d513fe3-41de-49c7-8231-3b67764cba30"
      decimals="-3"
      id="F_488e588f-31c3-4889-a45e-8b29577eb406"
      unitRef="U_USD">302583000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="C_ad3c19c0-ada4-44fc-bdd3-c29b5398a40a"
      decimals="-3"
      id="F_2600b71c-1cc8-434e-86f4-efc36e8263f0"
      unitRef="U_USD">374225000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
      contextRef="C_5d513fe3-41de-49c7-8231-3b67764cba30"
      decimals="-3"
      id="F_15583fe9-fa63-4a56-afe8-4a3def14aa8b"
      unitRef="U_USD">14929000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
      contextRef="C_ad3c19c0-ada4-44fc-bdd3-c29b5398a40a"
      decimals="-3"
      id="F_639b8a79-279b-41e1-bb07-62ee5d07c831"
      unitRef="U_USD">14898000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_5d513fe3-41de-49c7-8231-3b67764cba30"
      decimals="-3"
      id="F_6070a841-bb96-4d96-8d53-61c3ed255d1c"
      unitRef="U_USD">21814000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_ad3c19c0-ada4-44fc-bdd3-c29b5398a40a"
      decimals="-3"
      id="F_a543d000-1978-46bb-8be8-ddc287b05db0"
      unitRef="U_USD">21589000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="C_5d513fe3-41de-49c7-8231-3b67764cba30"
      decimals="-3"
      id="F_7bbb4ae1-4de1-4ebd-968f-20494c57bef6"
      unitRef="U_USD">11118000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="C_ad3c19c0-ada4-44fc-bdd3-c29b5398a40a"
      decimals="-3"
      id="F_7bac66f0-bd27-42bf-84a5-ae2bdd3a35fa"
      unitRef="U_USD">16271000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_5d513fe3-41de-49c7-8231-3b67764cba30"
      decimals="-3"
      id="F_23894717-0d90-4c77-a85f-0a26be500704"
      unitRef="U_USD">350444000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_ad3c19c0-ada4-44fc-bdd3-c29b5398a40a"
      decimals="-3"
      id="F_9703a4ae-cd59-45d7-8446-ca62c1dab2dd"
      unitRef="U_USD">426983000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LineOfCredit
      contextRef="C_5d513fe3-41de-49c7-8231-3b67764cba30"
      decimals="-3"
      id="F_e71f49b1-ad69-42c6-acba-d5313347ec48"
      unitRef="U_USD">0</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit
      contextRef="C_ad3c19c0-ada4-44fc-bdd3-c29b5398a40a"
      decimals="-3"
      id="F_d75683e4-784c-453a-a153-e4f5b4701262"
      unitRef="U_USD">4000000</us-gaap:LineOfCredit>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="C_5d513fe3-41de-49c7-8231-3b67764cba30"
      decimals="-3"
      id="F_ef86586a-43f5-4348-96fa-662f458439c3"
      unitRef="U_USD">621691000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="C_ad3c19c0-ada4-44fc-bdd3-c29b5398a40a"
      decimals="-3"
      id="F_ab5d7a07-9d22-4d46-a921-b0f138621531"
      unitRef="U_USD">632381000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_5d513fe3-41de-49c7-8231-3b67764cba30"
      decimals="-3"
      id="F_e5f9ad40-c592-4bf9-a8c2-7fa70eb9fbad"
      unitRef="U_USD">48489000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_ad3c19c0-ada4-44fc-bdd3-c29b5398a40a"
      decimals="-3"
      id="F_df5fa4ef-62b6-4d33-9ffe-7be73b3de7f7"
      unitRef="U_USD">44213000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:MalpracticeLossContingencyAccrualUndiscountedNoncurrent
      contextRef="C_5d513fe3-41de-49c7-8231-3b67764cba30"
      decimals="-3"
      id="F_d2984d7b-9286-4aea-a64e-ceb3dc5b33e7"
      unitRef="U_USD">265523000</us-gaap:MalpracticeLossContingencyAccrualUndiscountedNoncurrent>
    <us-gaap:MalpracticeLossContingencyAccrualUndiscountedNoncurrent
      contextRef="C_ad3c19c0-ada4-44fc-bdd3-c29b5398a40a"
      decimals="-3"
      id="F_d4fe6f28-b830-4afb-bbce-49f037f399ed"
      unitRef="U_USD">275629000</us-gaap:MalpracticeLossContingencyAccrualUndiscountedNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="C_5d513fe3-41de-49c7-8231-3b67764cba30"
      decimals="-3"
      id="F_54796c21-40f6-4314-ad38-3949d1f140e9"
      unitRef="U_USD">41018000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="C_ad3c19c0-ada4-44fc-bdd3-c29b5398a40a"
      decimals="-3"
      id="F_c756bbeb-4054-4fb0-a45c-f972eb8804e8"
      unitRef="U_USD">33638000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_5d513fe3-41de-49c7-8231-3b67764cba30"
      decimals="-3"
      id="F_4b6cf6db-5bc1-43b1-b290-5454a7ebe10b"
      unitRef="U_USD">31189000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_ad3c19c0-ada4-44fc-bdd3-c29b5398a40a"
      decimals="-3"
      id="F_1b72b7ad-70f7-413b-91ad-136cc40f9892"
      unitRef="U_USD">39411000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_5d513fe3-41de-49c7-8231-3b67764cba30"
      decimals="-3"
      id="F_eb3f6a75-ec0f-4bab-afc6-622217038006"
      unitRef="U_USD">1358354000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_ad3c19c0-ada4-44fc-bdd3-c29b5398a40a"
      decimals="-3"
      id="F_d5107f29-0906-4619-987c-71157fc66c5a"
      unitRef="U_USD">1456255000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_5d513fe3-41de-49c7-8231-3b67764cba30"
      decimals="INF"
      id="F_7661b2d5-bfeb-44c3-ad14-c38aa3f4862a"
      unitRef="U_USDollarShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_ad3c19c0-ada4-44fc-bdd3-c29b5398a40a"
      decimals="INF"
      id="F_8fa2d263-481b-4733-8b68-314c7a340185"
      unitRef="U_USDollarShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_5d513fe3-41de-49c7-8231-3b67764cba30"
      decimals="INF"
      id="F_dbdb73c9-85fc-4c97-bce7-8eae366ac932"
      unitRef="U_shares">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_ad3c19c0-ada4-44fc-bdd3-c29b5398a40a"
      decimals="INF"
      id="F_7ae6c393-4466-4e5a-9bf8-37c167c4d36e"
      unitRef="U_shares">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_5d513fe3-41de-49c7-8231-3b67764cba30"
      decimals="INF"
      id="F_3afeca6b-45b9-4b74-9b29-31661d29d7da"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_ad3c19c0-ada4-44fc-bdd3-c29b5398a40a"
      decimals="INF"
      id="F_d117537c-f69b-451d-8cc7-c753309b71b1"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="C_5d513fe3-41de-49c7-8231-3b67764cba30"
      decimals="-3"
      id="F_15934e47-abae-4343-8023-eeee18b6dd89"
      unitRef="U_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="C_ad3c19c0-ada4-44fc-bdd3-c29b5398a40a"
      decimals="-3"
      id="F_cbeee8df-2ddd-4fa2-aff5-dbc8f86cc3be"
      unitRef="U_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_5d513fe3-41de-49c7-8231-3b67764cba30"
      decimals="INF"
      id="F_be26397e-bf73-43f1-a355-bf5ffa15c045"
      unitRef="U_USDollarShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_ad3c19c0-ada4-44fc-bdd3-c29b5398a40a"
      decimals="INF"
      id="F_94df4832-6ea4-4f52-a220-a41129be4310"
      unitRef="U_USDollarShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_5d513fe3-41de-49c7-8231-3b67764cba30"
      decimals="INF"
      id="F_b4c04065-9664-4ce9-80a9-5ce897994a5e"
      unitRef="U_shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_ad3c19c0-ada4-44fc-bdd3-c29b5398a40a"
      decimals="INF"
      id="F_aa822d09-a9cd-4564-a4ab-5173faf4ea46"
      unitRef="U_shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_5d513fe3-41de-49c7-8231-3b67764cba30"
      decimals="INF"
      id="F_3b14118e-c923-4e8f-a37d-8bfd14f4c0c7"
      unitRef="U_shares">83929000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_5d513fe3-41de-49c7-8231-3b67764cba30"
      decimals="INF"
      id="F_ca50f794-4581-4814-8bf2-fe59b2165c9c"
      unitRef="U_shares">83929000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_ad3c19c0-ada4-44fc-bdd3-c29b5398a40a"
      decimals="INF"
      id="F_45d5227a-9c23-4055-a43d-de54206ab840"
      unitRef="U_shares">82947000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_ad3c19c0-ada4-44fc-bdd3-c29b5398a40a"
      decimals="INF"
      id="F_9baf2b09-a127-42a5-b88f-744cd7801b7d"
      unitRef="U_shares">82947000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_5d513fe3-41de-49c7-8231-3b67764cba30"
      decimals="-3"
      id="F_7982167c-d8d2-4eca-8631-89339d337730"
      unitRef="U_USD">839000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_ad3c19c0-ada4-44fc-bdd3-c29b5398a40a"
      decimals="-3"
      id="F_a5b5efc4-de6a-4602-8467-670db71d97f6"
      unitRef="U_USD">829000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_5d513fe3-41de-49c7-8231-3b67764cba30"
      decimals="-3"
      id="F_be364441-03a0-497d-b75a-1fe4eae771cc"
      unitRef="U_USD">995847000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_ad3c19c0-ada4-44fc-bdd3-c29b5398a40a"
      decimals="-3"
      id="F_f0f6cc84-89a2-4141-8e35-33b96c064226"
      unitRef="U_USD">983601000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_5d513fe3-41de-49c7-8231-3b67764cba30"
      decimals="-3"
      id="F_ade3154e-8f0c-40b8-98b4-1779ced2bd71"
      unitRef="U_USD">-3517000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_ad3c19c0-ada4-44fc-bdd3-c29b5398a40a"
      decimals="-3"
      id="F_4a47e8b5-f9f3-4482-88b6-e29888d10ca5"
      unitRef="U_USD">-3735000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_5d513fe3-41de-49c7-8231-3b67764cba30"
      decimals="-3"
      id="F_03b8ef7e-43d0-4482-945c-1e4a2afb8132"
      unitRef="U_USD">-25184000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_ad3c19c0-ada4-44fc-bdd3-c29b5398a40a"
      decimals="-3"
      id="F_5ddd502c-d689-4a30-8673-d935e647433a"
      unitRef="U_USD">-89063000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_5d513fe3-41de-49c7-8231-3b67764cba30"
      decimals="-3"
      id="F_0867c892-a35a-4b06-ab02-0ca320b17a40"
      unitRef="U_USD">967985000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_ad3c19c0-ada4-44fc-bdd3-c29b5398a40a"
      decimals="-3"
      id="F_a0399b2c-fd58-4af1-8ace-fc3691b4871b"
      unitRef="U_USD">891632000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_5d513fe3-41de-49c7-8231-3b67764cba30"
      decimals="-3"
      id="F_4cb8b9b7-1bab-44da-8c66-6c6ce4a626d6"
      unitRef="U_USD">2326339000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_ad3c19c0-ada4-44fc-bdd3-c29b5398a40a"
      decimals="-3"
      id="F_98759eb4-56bb-46de-9b76-6e4912b209d2"
      unitRef="U_USD">2347887000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_e5943398-0732-4d17-9fe7-25777d223b65"
      decimals="-3"
      id="F_abdb39bd-f44c-43cb-959c-d20c5d1261a4"
      unitRef="U_USD">506612000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_350c5db7-f64b-4e63-97fa-733cc8e8f783"
      decimals="-3"
      id="F_798782dc-ea56-49e8-a8e6-5440188598c2"
      unitRef="U_USD">489915000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      decimals="-3"
      id="F_182028e1-2cc9-418b-9079-ff08f9a253eb"
      unitRef="U_USD">1498197000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72"
      decimals="-3"
      id="F_ee3d3c1a-0178-4672-a742-043d3d750ed5"
      unitRef="U_USD">1458177000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <md:PracticeSalariesAndBenefits
      contextRef="C_e5943398-0732-4d17-9fe7-25777d223b65"
      decimals="-3"
      id="F_acabae4c-6b27-47e9-8729-ce2f03625386"
      unitRef="U_USD">368404000</md:PracticeSalariesAndBenefits>
    <md:PracticeSalariesAndBenefits
      contextRef="C_350c5db7-f64b-4e63-97fa-733cc8e8f783"
      decimals="-3"
      id="F_d929f50a-c3ad-4d72-b2be-f6c7274f743e"
      unitRef="U_USD">342850000</md:PracticeSalariesAndBenefits>
    <md:PracticeSalariesAndBenefits
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      decimals="-3"
      id="F_2dd1cd02-f2cc-40d2-a4d3-42bd7048e876"
      unitRef="U_USD">1084671000</md:PracticeSalariesAndBenefits>
    <md:PracticeSalariesAndBenefits
      contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72"
      decimals="-3"
      id="F_784ea84d-c7de-4457-bc95-e3f9fbc02cae"
      unitRef="U_USD">1016762000</md:PracticeSalariesAndBenefits>
    <md:PracticeSuppliesAndOtherOperatingExpenses
      contextRef="C_e5943398-0732-4d17-9fe7-25777d223b65"
      decimals="-3"
      id="F_e67a28ee-b598-48db-8e74-ee3deae35429"
      unitRef="U_USD">31319000</md:PracticeSuppliesAndOtherOperatingExpenses>
    <md:PracticeSuppliesAndOtherOperatingExpenses
      contextRef="C_350c5db7-f64b-4e63-97fa-733cc8e8f783"
      decimals="-3"
      id="F_5e2a3538-f169-4da9-a465-9c5e61cb7301"
      unitRef="U_USD">31857000</md:PracticeSuppliesAndOtherOperatingExpenses>
    <md:PracticeSuppliesAndOtherOperatingExpenses
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      decimals="-3"
      id="F_8269fa6f-6293-495e-8eab-887bb62fb9a5"
      unitRef="U_USD">93128000</md:PracticeSuppliesAndOtherOperatingExpenses>
    <md:PracticeSuppliesAndOtherOperatingExpenses
      contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72"
      decimals="-3"
      id="F_4817dff5-70dc-4f52-8c80-4284e96db668"
      unitRef="U_USD">90189000</md:PracticeSuppliesAndOtherOperatingExpenses>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_e5943398-0732-4d17-9fe7-25777d223b65"
      decimals="-3"
      id="F_8a82d992-e651-45c4-ac49-4425dcc2cd6f"
      unitRef="U_USD">57406000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_350c5db7-f64b-4e63-97fa-733cc8e8f783"
      decimals="-3"
      id="F_246afec6-2885-4204-b858-bb0e7e961a66"
      unitRef="U_USD">57888000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      decimals="-3"
      id="F_d435becd-abc5-44c3-9a5c-845d6f49a5c1"
      unitRef="U_USD">174478000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72"
      decimals="-3"
      id="F_bf98c365-06d9-4762-b864-5829924a9c87"
      unitRef="U_USD">180340000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_e5943398-0732-4d17-9fe7-25777d223b65"
      decimals="-3"
      id="F_750a2938-b0bd-40a7-9a3a-85dc6dbe6dc9"
      unitRef="U_USD">9211000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_350c5db7-f64b-4e63-97fa-733cc8e8f783"
      decimals="-3"
      id="F_3cfc43f1-ac71-4271-a70d-ed8ded869ec5"
      unitRef="U_USD">8956000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      decimals="-3"
      id="F_651d1f8d-792b-4798-bd5d-e6ed6f643779"
      unitRef="U_USD">27109000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72"
      decimals="-3"
      id="F_7003876f-9d6f-4c02-b116-d25dc6319993"
      unitRef="U_USD">26500000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:RestructuringCharges
      contextRef="C_e5943398-0732-4d17-9fe7-25777d223b65"
      decimals="-3"
      id="F_634abf69-f5f4-422e-a8a2-190ad69ab3d7"
      unitRef="U_USD">0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="C_350c5db7-f64b-4e63-97fa-733cc8e8f783"
      decimals="-3"
      id="F_a00e6664-81d0-4982-9130-f28d426d0d22"
      unitRef="U_USD">977000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      decimals="-3"
      id="F_fcde0c0f-7f94-4358-8a3b-564564efce1f"
      unitRef="U_USD">0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72"
      decimals="-3"
      id="F_11e2914c-c6aa-4d93-bcc4-f5d7e037709e"
      unitRef="U_USD">7736000</us-gaap:RestructuringCharges>
    <us-gaap:OperatingExpenses
      contextRef="C_e5943398-0732-4d17-9fe7-25777d223b65"
      decimals="-3"
      id="F_84190136-1a6f-4863-845e-105637bdc96f"
      unitRef="U_USD">466340000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_350c5db7-f64b-4e63-97fa-733cc8e8f783"
      decimals="-3"
      id="F_9ca552f6-3c5e-40f6-bc37-720c9e66d7b8"
      unitRef="U_USD">442528000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      decimals="-3"
      id="F_e2531228-acfd-4934-bcf4-9c8c9b08d190"
      unitRef="U_USD">1379386000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72"
      decimals="-3"
      id="F_293158b4-061b-4858-8af6-16828f525be1"
      unitRef="U_USD">1321527000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_e5943398-0732-4d17-9fe7-25777d223b65"
      decimals="-3"
      id="F_736bac3c-6da9-43a4-a719-c492eea1d738"
      unitRef="U_USD">40272000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_350c5db7-f64b-4e63-97fa-733cc8e8f783"
      decimals="-3"
      id="F_65ec6fc1-e2c4-4bae-b377-af462754b6f8"
      unitRef="U_USD">47387000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      decimals="-3"
      id="F_b10713e9-216d-43ed-9fbf-3856f33bd2f6"
      unitRef="U_USD">118811000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72"
      decimals="-3"
      id="F_df90f895-659a-4527-bb87-d4cc1fbf2a6e"
      unitRef="U_USD">136650000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeNet
      contextRef="C_e5943398-0732-4d17-9fe7-25777d223b65"
      decimals="-3"
      id="F_608695bb-e781-4865-97dc-40d1e27d2ad4"
      unitRef="U_USD">273000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="C_350c5db7-f64b-4e63-97fa-733cc8e8f783"
      decimals="-3"
      id="F_60e1c1a5-1ca9-4d88-8ec1-fb41f4ab2010"
      unitRef="U_USD">617000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      decimals="-3"
      id="F_fdbcbac0-28df-4520-bd6a-e90365b6505a"
      unitRef="U_USD">2096000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72"
      decimals="-3"
      id="F_00020cbd-c8ac-45d5-8eee-2e4db5b4b0ae"
      unitRef="U_USD">2336000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InterestExpense
      contextRef="C_e5943398-0732-4d17-9fe7-25777d223b65"
      decimals="-3"
      id="F_c7c7e89a-3e4f-4ced-8813-7b70f5ffa124"
      unitRef="U_USD">10374000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="C_350c5db7-f64b-4e63-97fa-733cc8e8f783"
      decimals="-3"
      id="F_7416b800-1a41-4d6a-9401-cbc140bd3f60"
      unitRef="U_USD">9516000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      decimals="-3"
      id="F_0262e82e-83a2-44e9-9162-5fa6720b0e0f"
      unitRef="U_USD">31994000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72"
      decimals="-3"
      id="F_e9b129b1-508b-460c-b30c-30443a01259d"
      unitRef="U_USD">29743000</us-gaap:InterestExpense>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="C_e5943398-0732-4d17-9fe7-25777d223b65"
      decimals="-3"
      id="F_b3534908-86fa-4e08-b9af-b1d2fc128961"
      unitRef="U_USD">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="C_350c5db7-f64b-4e63-97fa-733cc8e8f783"
      decimals="-3"
      id="F_5790c282-b2fd-49a0-a4a7-d794e63e8478"
      unitRef="U_USD">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      decimals="-3"
      id="F_92571667-fb70-4e42-846e-bf949fee5ee6"
      unitRef="U_USD">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72"
      decimals="-3"
      id="F_e5b9aa6f-1c66-40cf-a6f5-f366d73bd4e9"
      unitRef="U_USD">-57016000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="C_e5943398-0732-4d17-9fe7-25777d223b65"
      decimals="-3"
      id="F_fe9c87bd-3739-4686-b039-9d4873453cd6"
      unitRef="U_USD">661000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="C_350c5db7-f64b-4e63-97fa-733cc8e8f783"
      decimals="-3"
      id="F_125cd9e3-b7d0-4a06-8f7a-1bc4bd5da61c"
      unitRef="U_USD">371000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      decimals="-3"
      id="F_55ab4882-a025-4176-8999-7b238c6b3010"
      unitRef="U_USD">1578000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72"
      decimals="-3"
      id="F_a691d898-3dad-4cf6-995d-8c169ca7199d"
      unitRef="U_USD">1319000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_e5943398-0732-4d17-9fe7-25777d223b65"
      decimals="-3"
      id="F_bf6e3776-b2a8-4471-ae66-4649840232bb"
      unitRef="U_USD">-9440000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_350c5db7-f64b-4e63-97fa-733cc8e8f783"
      decimals="-3"
      id="F_9e34d732-aec9-4c56-9f61-827db090df7b"
      unitRef="U_USD">-8528000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      decimals="-3"
      id="F_df2274f5-5b18-4af9-9b5c-e2b9d37440b0"
      unitRef="U_USD">-28320000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72"
      decimals="-3"
      id="F_836adb4d-173d-4512-b4ff-4fdcfe21c293"
      unitRef="U_USD">-83104000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_e5943398-0732-4d17-9fe7-25777d223b65"
      decimals="-3"
      id="F_bc59bf71-259b-4310-9a69-ff0e50333008"
      unitRef="U_USD">30832000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_350c5db7-f64b-4e63-97fa-733cc8e8f783"
      decimals="-3"
      id="F_8e815fca-7afd-4762-8f0d-8c0a984706da"
      unitRef="U_USD">38859000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      decimals="-3"
      id="F_7591f214-9a15-4ef7-ad87-121b3b2c0d09"
      unitRef="U_USD">90491000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72"
      decimals="-3"
      id="F_14a2225c-41d1-45a8-ab03-b0a2c44e0c9a"
      unitRef="U_USD">53546000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_e5943398-0732-4d17-9fe7-25777d223b65"
      decimals="-3"
      id="F_3c226481-efac-4eda-a269-4f2c6717d449"
      unitRef="U_USD">9441000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_350c5db7-f64b-4e63-97fa-733cc8e8f783"
      decimals="-3"
      id="F_e0da988d-74e6-48b3-8dcc-5b35694cd5a6"
      unitRef="U_USD">10051000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      decimals="-3"
      id="F_b7ca2719-196c-47e5-baa8-bb31e9675d9b"
      unitRef="U_USD">26612000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72"
      decimals="-3"
      id="F_34f10f40-b690-42c7-9636-7245cab1b3f8"
      unitRef="U_USD">14982000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_e5943398-0732-4d17-9fe7-25777d223b65"
      decimals="-3"
      id="F_5fa2dc32-8046-47bf-8c49-5cfae6ec1f2c"
      unitRef="U_USD">21391000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_350c5db7-f64b-4e63-97fa-733cc8e8f783"
      decimals="-3"
      id="F_ac445e00-0391-4c59-a4b7-9e7750b58350"
      unitRef="U_USD">28808000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      decimals="-3"
      id="F_2363f8e5-7a6d-4413-86cf-6417f3ea8da1"
      unitRef="U_USD">63879000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72"
      decimals="-3"
      id="F_18d34d2d-b9b2-4f0a-9f9b-0b780ee4ecb2"
      unitRef="U_USD">38564000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="C_e5943398-0732-4d17-9fe7-25777d223b65"
      decimals="-3"
      id="F_926a944e-8e48-42fe-9b76-4ec8075fa910"
      unitRef="U_USD">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="C_350c5db7-f64b-4e63-97fa-733cc8e8f783"
      decimals="-3"
      id="F_112c7353-62d1-47b3-9b6f-be2af4b3a00b"
      unitRef="U_USD">1920000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      decimals="-3"
      id="F_e3a13458-b75d-4cc6-a4ce-59f4441e161c"
      unitRef="U_USD">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72"
      decimals="-3"
      id="F_74ca11be-380b-4e4a-9478-c210ee49789e"
      unitRef="U_USD">-1892000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="C_e5943398-0732-4d17-9fe7-25777d223b65"
      decimals="-3"
      id="F_92c651aa-0e64-4a1f-8d2c-50eece64a984"
      unitRef="U_USD">21391000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_350c5db7-f64b-4e63-97fa-733cc8e8f783"
      decimals="-3"
      id="F_9d1977ed-35b6-4548-b3f2-1109c4a34482"
      unitRef="U_USD">30728000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      decimals="-3"
      id="F_7d91f236-aca0-4920-8ff6-1a95df622598"
      unitRef="U_USD">63879000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72"
      decimals="-3"
      id="F_64c67a80-5a54-40ab-9ffe-316bcfbf724c"
      unitRef="U_USD">36672000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="C_e5943398-0732-4d17-9fe7-25777d223b65"
      decimals="-3"
      id="F_f24b8e92-931a-4e85-982a-3ab88fbadcfc"
      unitRef="U_USD">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="C_350c5db7-f64b-4e63-97fa-733cc8e8f783"
      decimals="-3"
      id="F_06378054-873c-4b50-8946-eede3c60f97f"
      unitRef="U_USD">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      decimals="-3"
      id="F_eaa25679-be21-4dd5-bdc5-c5e5cb2c313f"
      unitRef="U_USD">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72"
      decimals="-3"
      id="F_804d15ac-be62-4e5b-8d02-1b36334aa9b1"
      unitRef="U_USD">-4000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="C_e5943398-0732-4d17-9fe7-25777d223b65"
      decimals="-3"
      id="F_11b79449-2f0c-444d-adec-77c1089a9771"
      unitRef="U_USD">21391000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_350c5db7-f64b-4e63-97fa-733cc8e8f783"
      decimals="-3"
      id="F_0ebf7a43-b5b3-4166-836f-f64cf825c794"
      unitRef="U_USD">30728000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      decimals="-3"
      id="F_9dac50f1-2561-43ad-890b-6be113ed0c7f"
      unitRef="U_USD">63879000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72"
      decimals="-3"
      id="F_ea4c19e6-dc9b-4123-a229-c48ae14af870"
      unitRef="U_USD">36676000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent
      contextRef="C_e5943398-0732-4d17-9fe7-25777d223b65"
      decimals="-3"
      id="F_cc21f3c7-d677-4a05-b8b1-c9cbc18edb51"
      unitRef="U_USD">0</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent
      contextRef="C_350c5db7-f64b-4e63-97fa-733cc8e8f783"
      decimals="-3"
      id="F_af57d4e3-5955-440d-90a6-d3c16bc6158c"
      unitRef="U_USD">508000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      decimals="-3"
      id="F_5cdbb24e-cbfa-4a6d-9187-547bbf8617dc"
      unitRef="U_USD">100000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent
      contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72"
      decimals="-3"
      id="F_b96b4b29-59bc-4b4a-8c84-45aefec390d1"
      unitRef="U_USD">1816000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="C_e5943398-0732-4d17-9fe7-25777d223b65"
      decimals="-3"
      id="F_9e96f77b-6240-441f-8d05-f7d30351a86f"
      unitRef="U_USD">1000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="C_350c5db7-f64b-4e63-97fa-733cc8e8f783"
      decimals="-3"
      id="F_6a3e3631-711f-461f-a45b-803b94722f21"
      unitRef="U_USD">-1515000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      decimals="-3"
      id="F_6c7275fa-50b8-495b-96cf-71b15ad1b25c"
      unitRef="U_USD">218000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72"
      decimals="-3"
      id="F_d58c2143-417d-4c4e-b413-4dbfbf8101ed"
      unitRef="U_USD">-5417000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_e5943398-0732-4d17-9fe7-25777d223b65"
      decimals="-3"
      id="F_0ee3bb62-844e-40dc-8764-2534323198f4"
      unitRef="U_USD">21392000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_350c5db7-f64b-4e63-97fa-733cc8e8f783"
      decimals="-3"
      id="F_ddd00d0b-14ef-4787-9b60-b69946450365"
      unitRef="U_USD">29213000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      decimals="-3"
      id="F_baed36f0-6cad-464c-8129-c03915b4f212"
      unitRef="U_USD">64097000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72"
      decimals="-3"
      id="F_822bdec5-995a-44c1-a459-0625d4823bed"
      unitRef="U_USD">31259000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_e5943398-0732-4d17-9fe7-25777d223b65"
      decimals="2"
      id="F_0c1450b8-19aa-4a72-929f-08fef30bb523"
      unitRef="U_USDollarShare">0.26</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_350c5db7-f64b-4e63-97fa-733cc8e8f783"
      decimals="2"
      id="F_0e4faaef-88b6-444c-af70-ef42e279ee4b"
      unitRef="U_USDollarShare">0.37</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      decimals="2"
      id="F_27feec94-ce44-48a8-9ed1-91b1fbd5ff83"
      unitRef="U_USDollarShare">0.78</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72"
      decimals="2"
      id="F_a215652c-d6f4-4843-8973-af475acd9ad7"
      unitRef="U_USDollarShare">0.44</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_e5943398-0732-4d17-9fe7-25777d223b65"
      decimals="2"
      id="F_9f22e474-75cc-47cd-a166-9f47d1194cfb"
      unitRef="U_USDollarShare">0.26</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_350c5db7-f64b-4e63-97fa-733cc8e8f783"
      decimals="2"
      id="F_53e83e0b-d9c9-4feb-b358-8e718340bb8e"
      unitRef="U_USDollarShare">0.37</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      decimals="2"
      id="F_ae18b686-03d7-4875-ab76-f0a20386ae94"
      unitRef="U_USDollarShare">0.77</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72"
      decimals="2"
      id="F_5682410d-74f1-4b19-a838-3821a052e88c"
      unitRef="U_USDollarShare">0.43</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_e5943398-0732-4d17-9fe7-25777d223b65"
      decimals="-3"
      id="F_c4380448-49c9-4105-92f6-8f57d08b11ba"
      unitRef="U_shares">82543000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_350c5db7-f64b-4e63-97fa-733cc8e8f783"
      decimals="-3"
      id="F_8c15fe26-0121-4e25-9062-ed172def33cc"
      unitRef="U_shares">82126000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      decimals="-3"
      id="F_261c544e-d14d-457d-9055-cdcd5e4597b3"
      unitRef="U_shares">82127000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72"
      decimals="-3"
      id="F_852d352b-76f0-4690-93a7-08f39aa9b617"
      unitRef="U_shares">84122000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_e5943398-0732-4d17-9fe7-25777d223b65"
      decimals="-3"
      id="F_55ef88f4-1548-4458-b211-098202db11f6"
      unitRef="U_shares">82950000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_350c5db7-f64b-4e63-97fa-733cc8e8f783"
      decimals="-3"
      id="F_cce60e41-11f7-4734-80e7-54a56180c0c6"
      unitRef="U_shares">82776000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      decimals="-3"
      id="F_92bba9c7-35f4-4531-8795-a4da613d70bd"
      unitRef="U_shares">82492000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72"
      decimals="-3"
      id="F_dd022416-ec7a-43c8-9bed-33753d2aa3b9"
      unitRef="U_shares">84821000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesIssued
      contextRef="C_a66a0d65-33d2-4b8c-a2fa-57b2aec20870"
      decimals="INF"
      id="F_ddf39837-e187-45cf-abe4-05170a11ffc9"
      unitRef="U_shares">82947000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_a66a0d65-33d2-4b8c-a2fa-57b2aec20870"
      decimals="-3"
      id="F_124f0992-7509-489e-962a-5c1cc123cd0c"
      unitRef="U_USD">829000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_9b7a1e9b-0052-493b-8b97-41fc5afb54f6"
      decimals="-3"
      id="F_5a923b61-facd-4a30-8cf7-a64cf02a4060"
      unitRef="U_USD">983601000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_61e8dbc9-4c0e-40e5-bc06-8dbeefba5d20"
      decimals="-3"
      id="F_63011eab-bf6b-41c8-a54c-07e550b46fac"
      unitRef="U_USD">-3735000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_fa51030c-8ae1-44ad-b260-2c8ee8428637"
      decimals="-3"
      id="F_03bc9552-4d32-48a3-906c-2a513edfba52"
      unitRef="U_USD">-89063000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_ad3c19c0-ada4-44fc-bdd3-c29b5398a40a"
      decimals="-3"
      id="F_03f88530-ab5d-47c3-86e3-519358464844"
      unitRef="U_USD">891632000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="C_89fa872a-ad9d-4262-8559-732e6a088cd4"
      decimals="-3"
      id="F_5efd5ab7-cbb3-4558-aedc-d046d3b66d59"
      unitRef="U_USD">14206000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_ec5297e8-5a0c-4bde-9aa8-9737b4ffc31c"
      decimals="-3"
      id="F_a5d7190f-4f17-4d79-8027-9226c8ccb72a"
      unitRef="U_USD">14206000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_ead630e6-3bc1-4158-acab-0cd6d0a20d53"
      decimals="-3"
      id="F_8bfdd64b-9b19-4f48-a5ac-6efbb4e77757"
      unitRef="U_USD">604000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_ec5297e8-5a0c-4bde-9aa8-9737b4ffc31c"
      decimals="-3"
      id="F_4aa27618-f44b-4dbf-8024-f6550a58c6f1"
      unitRef="U_USD">604000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_0c4b440a-242a-4875-a46f-4a05a1426d70"
      decimals="INF"
      id="F_a4d0279f-77c2-43b1-a17e-9aa3d7fe0c63"
      unitRef="U_shares">86000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_75ad9bd0-8190-4d2d-9f0a-71bf1ddf7588"
      decimals="-3"
      id="F_dd3b386a-5337-4288-aa12-6448cee2348b"
      unitRef="U_USD">1095000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_ec5297e8-5a0c-4bde-9aa8-9737b4ffc31c"
      decimals="-3"
      id="F_bd3823c1-537a-4f93-8f45-076f7b339371"
      unitRef="U_USD">1095000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross
      contextRef="C_0c4b440a-242a-4875-a46f-4a05a1426d70"
      decimals="INF"
      id="F_0df2e6e2-0add-4829-9b20-3f4b4cf8d79c"
      unitRef="U_shares">871000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="C_0c4b440a-242a-4875-a46f-4a05a1426d70"
      decimals="-3"
      id="F_2eeb267b-857f-4e23-a680-cae5c5b687d9"
      unitRef="U_USD">9000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="C_75ad9bd0-8190-4d2d-9f0a-71bf1ddf7588"
      decimals="-3"
      id="F_3eddcda4-417a-4d06-b7d0-0dd906fb965e"
      unitRef="U_USD">-9000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="C_0c4b440a-242a-4875-a46f-4a05a1426d70"
      decimals="INF"
      id="F_b9b4c775-eaf8-4760-8347-16b58134e964"
      unitRef="U_shares">-221000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
      contextRef="C_0c4b440a-242a-4875-a46f-4a05a1426d70"
      decimals="-3"
      id="F_237e6250-05b0-4917-816e-72b77d19a76e"
      unitRef="U_USD">-2000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
      contextRef="C_75ad9bd0-8190-4d2d-9f0a-71bf1ddf7588"
      decimals="-3"
      id="F_78287883-4558-4d9f-970c-fece0cdd13af"
      unitRef="U_USD">2000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_75ad9bd0-8190-4d2d-9f0a-71bf1ddf7588"
      decimals="-3"
      id="F_2c6e5a52-d038-4a30-9b78-15ba515b6d31"
      unitRef="U_USD">3009000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_ec5297e8-5a0c-4bde-9aa8-9737b4ffc31c"
      decimals="-3"
      id="F_31178270-b8e3-4270-b216-3c838c0d9dd6"
      unitRef="U_USD">3009000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="C_0c4b440a-242a-4875-a46f-4a05a1426d70"
      decimals="INF"
      id="F_52b97121-f0b9-4171-a05f-a43fe2d2e549"
      unitRef="U_shares">49000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="C_75ad9bd0-8190-4d2d-9f0a-71bf1ddf7588"
      decimals="-3"
      id="F_01dc2850-797b-4d28-a958-082a89a92177"
      unitRef="U_USD">775000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="C_ec5297e8-5a0c-4bde-9aa8-9737b4ffc31c"
      decimals="-3"
      id="F_65784ced-6526-4198-96f7-2003ed43b1bd"
      unitRef="U_USD">775000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:SharesIssued
      contextRef="C_3fe9a616-cb85-448a-a3c7-88b42ca6650a"
      decimals="INF"
      id="F_3e50d9b3-c60c-4a00-806f-35d5ea5649b8"
      unitRef="U_shares">83634000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_3fe9a616-cb85-448a-a3c7-88b42ca6650a"
      decimals="-3"
      id="F_ff3549fd-f0f5-40f9-8fd8-7b7a964d5558"
      unitRef="U_USD">836000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_2e0a629f-a677-4b59-a478-5cbb505d9530"
      decimals="-3"
      id="F_d22dd1a8-2a78-4582-91e8-1a43e392698f"
      unitRef="U_USD">986923000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_9a67fb14-6a35-4389-82c8-b724c79c3f38"
      decimals="-3"
      id="F_b944ec4c-d08c-460c-88dd-854c0fd0a7ff"
      unitRef="U_USD">-3131000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_d9967c70-bdd9-46f2-a73f-0af130ef6ca5"
      decimals="-3"
      id="F_70a9afaa-6a3c-497e-88dd-8ccf8c9b8801"
      unitRef="U_USD">-74857000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_308516ff-d843-45b5-8b06-0a3e134f255e"
      decimals="-3"
      id="F_609baaa7-7cde-43f7-a03f-abee079465fd"
      unitRef="U_USD">909771000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="C_461e1df7-29c9-4340-9d09-2d305db85278"
      decimals="-3"
      id="F_8f8aea89-21dc-4af5-ac6d-480cd6bc9cee"
      unitRef="U_USD">28282000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_874771f9-e875-4db9-94d5-bb53a324cb51"
      decimals="-3"
      id="F_e0b61279-e36a-495a-b991-cdbc10ee9283"
      unitRef="U_USD">28282000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_fd83bf41-3f3e-4283-8803-bc13fec411ef"
      decimals="-3"
      id="F_e202fc9b-600c-4d7d-97c4-8db42edcd239"
      unitRef="U_USD">-387000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_874771f9-e875-4db9-94d5-bb53a324cb51"
      decimals="-3"
      id="F_e10e7954-6300-4abe-8b4f-236f595ba34c"
      unitRef="U_USD">-387000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_85574474-f392-4916-ac36-f721aeb624d6"
      decimals="INF"
      id="F_b763ac14-9ae6-40ea-a573-1d45d35dfa31"
      unitRef="U_shares">126000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_85574474-f392-4916-ac36-f721aeb624d6"
      decimals="-3"
      id="F_458fdcdd-b213-4b1e-8fe5-211ab146bff1"
      unitRef="U_USD">1000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_86bee92f-7914-4dbf-a4cd-38a1fed2ab1c"
      decimals="-3"
      id="F_05bb350a-4704-43dc-8040-b0ebcdbe5b34"
      unitRef="U_USD">1593000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_874771f9-e875-4db9-94d5-bb53a324cb51"
      decimals="-3"
      id="F_cd576b35-ce53-4950-a5a0-cb7d42194c47"
      unitRef="U_USD">1594000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross
      contextRef="C_85574474-f392-4916-ac36-f721aeb624d6"
      decimals="INF"
      id="F_6906173f-346e-414c-978f-961db8a2865f"
      unitRef="U_shares">93000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="C_85574474-f392-4916-ac36-f721aeb624d6"
      decimals="-3"
      id="F_866aa9aa-0c83-44fc-a1b1-1547a3e0e5cc"
      unitRef="U_USD">1000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="C_86bee92f-7914-4dbf-a4cd-38a1fed2ab1c"
      decimals="-3"
      id="F_13655cb3-6cec-437b-800a-ff98c2ef2dd9"
      unitRef="U_USD">-1000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="C_85574474-f392-4916-ac36-f721aeb624d6"
      decimals="INF"
      id="F_b00f66e7-b3b6-4b3c-97d4-0c3c57646328"
      unitRef="U_shares">-11000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_86bee92f-7914-4dbf-a4cd-38a1fed2ab1c"
      decimals="-3"
      id="F_a9d86ff9-98c7-427c-abe8-a104f6c70c59"
      unitRef="U_USD">3126000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_874771f9-e875-4db9-94d5-bb53a324cb51"
      decimals="-3"
      id="F_dc31dc96-2c2a-406c-9649-33df18c2a0fc"
      unitRef="U_USD">3126000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="C_85574474-f392-4916-ac36-f721aeb624d6"
      decimals="INF"
      id="F_4383a7cd-22e8-4fbd-94c5-5fbcdfc6e43c"
      unitRef="U_shares">1000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="C_86bee92f-7914-4dbf-a4cd-38a1fed2ab1c"
      decimals="-3"
      id="F_21fc4828-aaec-43d2-8d40-65652cdc1f7c"
      unitRef="U_USD">11000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="C_874771f9-e875-4db9-94d5-bb53a324cb51"
      decimals="-3"
      id="F_bf77b37b-f2d1-4b35-bebf-5b2e71fac933"
      unitRef="U_USD">11000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:SharesIssued
      contextRef="C_1ccfbb16-e844-487b-90c8-99c1b5604082"
      decimals="-3"
      id="F_6c1b1039-772d-4b11-89cd-b272d351bcaa"
      unitRef="U_shares">83841000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_1ccfbb16-e844-487b-90c8-99c1b5604082"
      decimals="-3"
      id="F_a5712d0e-d85a-4c33-9e0d-8037dd249146"
      unitRef="U_USD">838000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0b8cfdec-f0c4-4429-b94a-75b07f7aae51"
      decimals="-3"
      id="F_1c1a7db7-2c2f-4463-b5d2-80d12e708412"
      unitRef="U_USD">991630000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_846d24c8-9524-45a4-a1b6-aa7b223ba8ec"
      decimals="-3"
      id="F_d6418c86-5a11-4336-a47b-ac3f90d5c5ac"
      unitRef="U_USD">-3518000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_7b747bea-61e9-4a99-b3d9-c96dee793375"
      decimals="-3"
      id="F_af667989-b6be-4210-b5c1-eb351ff62f69"
      unitRef="U_USD">-46575000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_c10c4eef-bb70-4725-bb7d-0a8da3fa54db"
      decimals="-3"
      id="F_36d1ada0-a8df-45bc-9f72-930b3b9032f9"
      unitRef="U_USD">942375000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="C_fc6992a8-5cd9-42e1-ba09-8be4221adf6f"
      decimals="-3"
      id="F_af96e921-f0fe-4220-b689-29ab5fc4d18b"
      unitRef="U_USD">21391000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_e5943398-0732-4d17-9fe7-25777d223b65"
      decimals="-3"
      id="F_f97bfee8-355c-45f3-831e-ef18f60c0930"
      unitRef="U_USD">21391000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_0002ecca-b81e-4c48-8d05-eefbc915ed5a"
      decimals="-3"
      id="F_c3401d0b-aecc-4f25-af35-f3629e2ee93d"
      unitRef="U_USD">1000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_e5943398-0732-4d17-9fe7-25777d223b65"
      decimals="-3"
      id="F_cfddca4e-32e8-4ec5-a523-bbfc7c0eb475"
      unitRef="U_USD">1000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_ea09ed9a-1817-4610-877d-b7f92fa5faba"
      decimals="-3"
      id="F_2fcf2a38-98e8-4768-950e-d0df8f2e2a30"
      unitRef="U_shares">100000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_ea09ed9a-1817-4610-877d-b7f92fa5faba"
      decimals="-3"
      id="F_9c6c40ee-d32e-41bc-b88e-d4129a8efe6e"
      unitRef="U_USD">1000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_db14decc-aca0-4ce7-bed7-40edd1c86538"
      decimals="-3"
      id="F_0cd5776d-79fd-4832-a325-564a0eee8797"
      unitRef="U_USD">1186000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_e5943398-0732-4d17-9fe7-25777d223b65"
      decimals="-3"
      id="F_42fbdb8e-3329-4a09-bd40-566992e3a998"
      unitRef="U_USD">1187000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="C_ea09ed9a-1817-4610-877d-b7f92fa5faba"
      decimals="-3"
      id="F_49bf32a9-7179-413e-a23d-a84008c65a6d"
      unitRef="U_shares">-1000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_db14decc-aca0-4ce7-bed7-40edd1c86538"
      decimals="-3"
      id="F_ddceb111-f481-4be4-a247-ebdd5e4e8684"
      unitRef="U_USD">3164000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_e5943398-0732-4d17-9fe7-25777d223b65"
      decimals="-3"
      id="F_edd3e902-ec77-41e1-a887-562f9302d88d"
      unitRef="U_USD">3164000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="C_ea09ed9a-1817-4610-877d-b7f92fa5faba"
      decimals="-3"
      id="F_f20ea5d1-21ee-4380-bbaf-1be1f001a9aa"
      unitRef="U_shares">11000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="C_db14decc-aca0-4ce7-bed7-40edd1c86538"
      decimals="-3"
      id="F_b71d53a2-3754-405e-89f1-a60808751eb0"
      unitRef="U_USD">133000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="C_e5943398-0732-4d17-9fe7-25777d223b65"
      decimals="-3"
      id="F_3bf09661-b3a5-40e7-958c-58e7e5dbd141"
      unitRef="U_USD">133000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:SharesIssued
      contextRef="C_22bf64d7-53dd-4c56-b931-fbaef641de7e"
      decimals="-3"
      id="F_52ab87b4-cc4e-4b85-9b50-859654091f45"
      unitRef="U_shares">83929000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_22bf64d7-53dd-4c56-b931-fbaef641de7e"
      decimals="-3"
      id="F_1894f102-19c1-4d7c-9a35-3bd843eba341"
      unitRef="U_USD">839000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_8350a8fa-b313-4bbc-8d3d-a43cfa5262b4"
      decimals="-3"
      id="F_77130f77-c821-408d-98bf-51c4c3ada56c"
      unitRef="U_USD">995847000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_92f598fa-4d7f-4e9b-b277-8567385e3d27"
      decimals="-3"
      id="F_fba9e5ec-4115-4478-92ab-2c69f413dbe6"
      unitRef="U_USD">-3517000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_fd02f20b-c7c9-4b18-9720-432b8fd1f5bc"
      decimals="-3"
      id="F_2f3f389c-fa1c-41d2-805c-785b61476a79"
      unitRef="U_USD">-25184000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_5d513fe3-41de-49c7-8231-3b67764cba30"
      decimals="-3"
      id="F_469d4c72-eb7b-4786-9d24-a7619ce6c7be"
      unitRef="U_USD">967985000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="C_8d549597-a6a3-4f65-960a-276c382d6949"
      decimals="INF"
      id="F_59e607ff-511a-4540-8516-d2ec90378553"
      unitRef="U_shares">86423000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_8d549597-a6a3-4f65-960a-276c382d6949"
      decimals="-3"
      id="F_472bf551-73f3-4877-ac97-2e47b374cffb"
      unitRef="U_USD">864000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_35888be5-90cc-40bd-b51a-b4a5ef520e02"
      decimals="-3"
      id="F_46b02eb1-ebdb-4225-bafc-e5006e5414b5"
      unitRef="U_USD">1049696000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_b7a3aab8-6e4f-488e-bd25-e4acf1837264"
      decimals="-3"
      id="F_030237f0-b063-4ccb-a033-0693cc7dcc35"
      unitRef="U_USD">1317000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_377d4d1b-904e-4983-aaf7-ccda1f31ece5"
      decimals="-3"
      id="F_55b46377-676e-44e5-b029-6d4c963104a6"
      unitRef="U_USD">-155185000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_cf213a70-35ae-48c9-9339-37927b488110"
      decimals="-3"
      id="F_59ed4992-846f-466f-84b4-bee9e78fb2da"
      unitRef="U_USD">896692000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="C_bbb0586b-efa6-4d4e-b6e9-1b625c1dbc91"
      decimals="-3"
      id="F_0d4e0392-46f6-4675-a6f7-51a9e9bdbbb2"
      unitRef="U_USD">-21188000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_8b93e2e5-8344-474d-908a-5783596f5a9f"
      decimals="-3"
      id="F_244bb3db-0618-44d6-a33c-5b322f7a58b2"
      unitRef="U_USD">-21188000</us-gaap:NetIncomeLoss>
    <md:DissolutionOfAndNetIncomeLossAttributableToNoncontrollingInterest
      contextRef="C_071df110-5688-40d6-b07e-cf79e845dffc"
      decimals="-3"
      id="F_db831608-272d-4dea-9813-f388fa6a3dd7"
      unitRef="U_USD">10000</md:DissolutionOfAndNetIncomeLossAttributableToNoncontrollingInterest>
    <md:DissolutionOfAndNetIncomeLossAttributableToNoncontrollingInterest
      contextRef="C_bbb0586b-efa6-4d4e-b6e9-1b625c1dbc91"
      decimals="-3"
      id="F_30c66a9a-0756-4d02-9e4a-1f60b3066ad9"
      unitRef="U_USD">-213000</md:DissolutionOfAndNetIncomeLossAttributableToNoncontrollingInterest>
    <md:DissolutionOfAndNetIncomeLossAttributableToNoncontrollingInterest
      contextRef="C_8b93e2e5-8344-474d-908a-5783596f5a9f"
      decimals="-3"
      id="F_e8442405-4700-449c-a708-92b165088fb6"
      unitRef="U_USD">-203000</md:DissolutionOfAndNetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_f0afc955-4abd-4ca2-99cf-97256b13481a"
      decimals="-3"
      id="F_d62be6cc-64f7-44e2-bf41-d0f4fc9471ef"
      unitRef="U_USD">-2668000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_8b93e2e5-8344-474d-908a-5783596f5a9f"
      decimals="-3"
      id="F_2bebe259-903e-4f00-9204-0f667933a569"
      unitRef="U_USD">-2668000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_4c16c34d-3859-4415-b98c-b075a026c528"
      decimals="INF"
      id="F_c7a9b112-5718-4bd7-aa0c-38f3dffb67f7"
      unitRef="U_shares">50000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_071df110-5688-40d6-b07e-cf79e845dffc"
      decimals="-3"
      id="F_02a789fd-c727-4abb-96fc-8f6b59290bc7"
      unitRef="U_USD">1174000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_8b93e2e5-8344-474d-908a-5783596f5a9f"
      decimals="-3"
      id="F_4564caf0-031c-42c1-865c-58388cde0ca5"
      unitRef="U_USD">1174000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross
      contextRef="C_4c16c34d-3859-4415-b98c-b075a026c528"
      decimals="INF"
      id="F_ad4badba-e25d-43cb-aef9-ffffe728dd4d"
      unitRef="U_shares">766000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="C_4c16c34d-3859-4415-b98c-b075a026c528"
      decimals="-3"
      id="F_13d15678-e276-480e-ab82-747aa94ae12c"
      unitRef="U_USD">8000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="C_071df110-5688-40d6-b07e-cf79e845dffc"
      decimals="-3"
      id="F_acbb3dcc-efb3-4306-a1b2-18717c343109"
      unitRef="U_USD">-8000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="C_4c16c34d-3859-4415-b98c-b075a026c528"
      decimals="INF"
      id="F_bdebf01f-4b21-49fd-8ccf-9e6c048a4e03"
      unitRef="U_shares">-5000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_071df110-5688-40d6-b07e-cf79e845dffc"
      decimals="-3"
      id="F_8b5e1eca-d65f-431e-b14b-586cf30c7509"
      unitRef="U_USD">4435000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_8b93e2e5-8344-474d-908a-5783596f5a9f"
      decimals="-3"
      id="F_e080009a-ad7c-4df2-b0ad-8fb8ece311f5"
      unitRef="U_USD">4435000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="C_4c16c34d-3859-4415-b98c-b075a026c528"
      decimals="INF"
      id="F_5c45013a-3c03-4046-8721-15d8e0102b52"
      unitRef="U_shares">50000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="C_071df110-5688-40d6-b07e-cf79e845dffc"
      decimals="-3"
      id="F_f5e599b7-2066-4253-88b2-ab9c037a0ba4"
      unitRef="U_USD">1166000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="C_8b93e2e5-8344-474d-908a-5783596f5a9f"
      decimals="-3"
      id="F_7c5a4d02-4cc2-4873-8d15-799399461e26"
      unitRef="U_USD">1166000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:SharesIssued
      contextRef="C_e4839b2a-c828-4c77-8f2c-55160784c52b"
      decimals="INF"
      id="F_5b2b4ba5-8bb8-4263-be7b-d1ba545db6e1"
      unitRef="U_shares">87184000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_e4839b2a-c828-4c77-8f2c-55160784c52b"
      decimals="-3"
      id="F_2673f9ad-7ea6-49dd-8990-8633665a7cae"
      unitRef="U_USD">872000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_115e1478-c36e-4914-b961-b19a8a7591a9"
      decimals="-3"
      id="F_bb8c3567-f747-4eb3-9fd2-259882be17c7"
      unitRef="U_USD">1054141000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_cd23234b-4b27-4574-a7f1-454baa006e0e"
      decimals="-3"
      id="F_c976a2c7-590d-42c2-a6a7-a186671e5bf9"
      unitRef="U_USD">-1351000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_aca7d163-6a33-4b3d-9ea5-b99aa4fe9e34"
      decimals="-3"
      id="F_37b4995a-6452-4db8-a745-6ac7305c1574"
      unitRef="U_USD">-176586000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_f8d7ba49-dc8b-448a-ba32-eed7f3fb3be4"
      decimals="-3"
      id="F_67ecd4f0-2b59-4a57-a978-d446129d6161"
      unitRef="U_USD">877076000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="C_9b225ad0-d1c0-4862-9853-9d52295b37b4"
      decimals="-3"
      id="F_b0d01d94-3dac-44c9-9fd3-c135fb36c641"
      unitRef="U_USD">27136000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_b3dba50b-b27a-4103-9cc0-9ccc2aeac984"
      decimals="-3"
      id="F_7cff8f19-8924-443b-86c7-239923b0587a"
      unitRef="U_USD">27136000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_7cfd52bf-5193-4a6c-bf56-23a18e131b5e"
      decimals="-3"
      id="F_d7aa132d-7c41-4d53-b481-05d80236f245"
      unitRef="U_USD">-1234000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_b3dba50b-b27a-4103-9cc0-9ccc2aeac984"
      decimals="-3"
      id="F_53090571-5d61-4d31-bd06-ad8189365052"
      unitRef="U_USD">-1234000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_2f54399b-eb59-443e-af5f-01b59be7c4b3"
      decimals="INF"
      id="F_11701037-d331-4da1-bf1d-5369c6ee89bf"
      unitRef="U_shares">82000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_2f54399b-eb59-443e-af5f-01b59be7c4b3"
      decimals="-3"
      id="F_09afb319-5b58-4970-9ed6-bc5273f11978"
      unitRef="U_USD">1000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_3ed13396-e9c9-4ccc-91fd-b54c8527fe2e"
      decimals="-3"
      id="F_5362b446-38c1-4829-bb58-1665d8c41ab1"
      unitRef="U_USD">1663000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_b3dba50b-b27a-4103-9cc0-9ccc2aeac984"
      decimals="-3"
      id="F_7548f1b8-1c51-44ff-9012-d674e934411a"
      unitRef="U_USD">1664000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross
      contextRef="C_2f54399b-eb59-443e-af5f-01b59be7c4b3"
      decimals="INF"
      id="F_2499b5d2-4180-41a1-9abd-f6c46fcca560"
      unitRef="U_shares">74000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="C_2f54399b-eb59-443e-af5f-01b59be7c4b3"
      decimals="-3"
      id="F_2c303ac6-7268-4502-85e5-25bba8f45053"
      unitRef="U_USD">1000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="C_3ed13396-e9c9-4ccc-91fd-b54c8527fe2e"
      decimals="-3"
      id="F_ec2b69c4-c163-4edd-9688-ed3a6e3b6744"
      unitRef="U_USD">-1000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="C_2f54399b-eb59-443e-af5f-01b59be7c4b3"
      decimals="INF"
      id="F_b63235c0-62fa-471d-a0e8-87d9eec2d33d"
      unitRef="U_shares">-5000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_3ed13396-e9c9-4ccc-91fd-b54c8527fe2e"
      decimals="-3"
      id="F_9a9b7c98-2049-4f17-8453-81640cb74461"
      unitRef="U_USD">5186000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_b3dba50b-b27a-4103-9cc0-9ccc2aeac984"
      decimals="-3"
      id="F_1319e240-7265-4b3a-b814-dd414e83a8c0"
      unitRef="U_USD">5186000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="C_2f54399b-eb59-443e-af5f-01b59be7c4b3"
      decimals="INF"
      id="F_845251f3-bdf2-41ed-8066-bbc8b28bcdd2"
      unitRef="U_shares">3275000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="C_2f54399b-eb59-443e-af5f-01b59be7c4b3"
      decimals="-3"
      id="F_334ea6a2-790e-458a-a47a-4318f5a9824f"
      unitRef="U_USD">33000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="C_3ed13396-e9c9-4ccc-91fd-b54c8527fe2e"
      decimals="-3"
      id="F_13dea7cd-af84-4737-b211-1e80cebc8409"
      unitRef="U_USD">64365000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="C_b3dba50b-b27a-4103-9cc0-9ccc2aeac984"
      decimals="-3"
      id="F_efa791de-5643-4ca9-be04-c1af890acd88"
      unitRef="U_USD">64398000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:SharesIssued
      contextRef="C_c77e289a-1111-40d7-9df0-645b35738672"
      decimals="INF"
      id="F_095c7ddf-fa0c-4210-a8b8-91ea8ed2a864"
      unitRef="U_shares">84060000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_c77e289a-1111-40d7-9df0-645b35738672"
      decimals="-3"
      id="F_da22d974-52ce-4fba-bdb3-e050823be07a"
      unitRef="U_USD">841000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_c5cbe39a-b446-4f38-9bc0-7315c1df92ff"
      decimals="-3"
      id="F_ee863410-21ba-47d4-9c5b-3bd66d995331"
      unitRef="U_USD">996624000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_887ab47d-2465-4e8c-8649-d0d114c06f6c"
      decimals="-3"
      id="F_f587a6ab-a8b3-4760-8e38-2be4ca6de8b4"
      unitRef="U_USD">-2585000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_b3dc82b2-20f3-4300-82a6-75ad6389cab0"
      decimals="-3"
      id="F_0bf25e73-e3bb-4ded-a937-d4dce0cecebf"
      unitRef="U_USD">-149450000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_260cff1e-4c05-484b-8a25-8a1e82704661"
      decimals="-3"
      id="F_8d290e54-a401-482c-a145-57ed2ff57bb5"
      unitRef="U_USD">845430000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="C_6aabcea2-797e-41b7-aefa-4ccc2147de8f"
      decimals="-3"
      id="F_93edc715-cd38-4718-8722-89a7329826b8"
      unitRef="U_USD">30728000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_350c5db7-f64b-4e63-97fa-733cc8e8f783"
      decimals="-3"
      id="F_d9bcb0fa-bb89-470a-bfc2-4533a077a399"
      unitRef="U_USD">30728000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_73fe2b81-82a7-41de-a03c-5ba651cc8568"
      decimals="-3"
      id="F_49b6b171-0c3a-409c-ba19-a41b6a1a1f33"
      unitRef="U_USD">-1515000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_350c5db7-f64b-4e63-97fa-733cc8e8f783"
      decimals="-3"
      id="F_a00dc0cb-021e-429b-856b-75ce1cdac9e2"
      unitRef="U_USD">-1515000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_7bab9990-2405-4ad2-b988-70145110847c"
      decimals="INF"
      id="F_68e2df0f-452e-4ef6-b8ca-c4094201f260"
      unitRef="U_shares">74000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_7bab9990-2405-4ad2-b988-70145110847c"
      decimals="-3"
      id="F_62c467a9-55f8-430f-bc04-8adc130436bd"
      unitRef="U_USD">1000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_899d2caa-e2bb-4aac-bb5e-119389b4c1f1"
      decimals="-3"
      id="F_be1034ec-e38f-4af8-be84-fcc5de5b71ce"
      unitRef="U_USD">1380000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_350c5db7-f64b-4e63-97fa-733cc8e8f783"
      decimals="-3"
      id="F_5b464d17-8843-430a-aed4-355c073f8188"
      unitRef="U_USD">1381000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross
      contextRef="C_7bab9990-2405-4ad2-b988-70145110847c"
      decimals="INF"
      id="F_08e01f85-9b41-4359-9e65-a3cdcfbf2bda"
      unitRef="U_shares">1000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="C_7bab9990-2405-4ad2-b988-70145110847c"
      decimals="INF"
      id="F_a8fea8e9-b3b0-4a3c-ae64-175743225b20"
      unitRef="U_shares">-8000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
      contextRef="C_7bab9990-2405-4ad2-b988-70145110847c"
      decimals="-3"
      id="F_4507c201-21af-4579-a0f3-6c9d67678e00"
      unitRef="U_USD">-1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
      contextRef="C_899d2caa-e2bb-4aac-bb5e-119389b4c1f1"
      decimals="-3"
      id="F_f6fcaea7-0f27-44de-9814-d6b59c4e002f"
      unitRef="U_USD">1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_899d2caa-e2bb-4aac-bb5e-119389b4c1f1"
      decimals="-3"
      id="F_9b056984-8918-4a9e-9999-ec3b9c2b1e65"
      unitRef="U_USD">4120000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_350c5db7-f64b-4e63-97fa-733cc8e8f783"
      decimals="-3"
      id="F_1c0a3555-55dc-4d04-bf56-1ce685c9b1c7"
      unitRef="U_USD">4120000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="C_7bab9990-2405-4ad2-b988-70145110847c"
      decimals="INF"
      id="F_671bc632-a853-4ea6-ad2f-318711b6b36a"
      unitRef="U_shares">1121000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="C_7bab9990-2405-4ad2-b988-70145110847c"
      decimals="-3"
      id="F_fc1fbe35-157e-44b7-a50a-383554856f2b"
      unitRef="U_USD">11000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="C_899d2caa-e2bb-4aac-bb5e-119389b4c1f1"
      decimals="-3"
      id="F_957c7b45-0c68-472a-8e6f-5f0e21e91d3c"
      unitRef="U_USD">21466000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="C_350c5db7-f64b-4e63-97fa-733cc8e8f783"
      decimals="-3"
      id="F_5e272111-3d16-4df5-b6d0-88dfae34a3fd"
      unitRef="U_USD">21477000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:SharesIssued
      contextRef="C_56dd7543-31f8-4ae4-badc-c16562ed7f07"
      decimals="INF"
      id="F_df1776c8-3ad9-4df4-9f72-f855feb542dd"
      unitRef="U_shares">83006000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_56dd7543-31f8-4ae4-badc-c16562ed7f07"
      decimals="-3"
      id="F_8d1e9588-721e-4f19-9802-68675bb58c77"
      unitRef="U_USD">830000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_f56c48df-9031-48bb-ae3d-40c5aabd6cc4"
      decimals="-3"
      id="F_c64a02d1-5dcd-421e-ac78-b915364aeb15"
      unitRef="U_USD">980659000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_3ecbf02e-8155-43fd-bfae-75d93b4d3bb0"
      decimals="-3"
      id="F_a24dfc69-1506-4179-9251-3678ce128b02"
      unitRef="U_USD">-4100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_07ab98db-f259-45b0-b05a-833bf8d33505"
      decimals="-3"
      id="F_04372c30-0b85-4e45-b63d-db4ad668b075"
      unitRef="U_USD">-118722000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_659d9bd3-6f8d-448a-9462-197a2c4b64c7"
      decimals="-3"
      id="F_cc035220-3d28-4ba6-a1fc-3d20e812782b"
      unitRef="U_USD">858667000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      decimals="-3"
      id="F_ac0edc1c-515a-4de2-8571-5361a9aebcdd"
      unitRef="U_USD">63879000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72"
      decimals="-3"
      id="F_7405cc6c-d9d4-46b5-b273-26df99d4e8bc"
      unitRef="U_USD">36676000</us-gaap:NetIncomeLoss>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      decimals="-3"
      id="F_5ca437c3-3f93-4048-88cd-ffe68a909d68"
      unitRef="U_USD">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72"
      decimals="-3"
      id="F_03cd7656-2694-4f80-9fd9-b6a9535c63af"
      unitRef="U_USD">-1892000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      decimals="-3"
      id="F_619548dc-1fc6-4a06-9280-dcc3d5e05023"
      unitRef="U_USD">27109000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72"
      decimals="-3"
      id="F_20ca104c-dfd0-4736-873a-36a461910419"
      unitRef="U_USD">26500000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      decimals="-3"
      id="F_879f6107-7399-47d9-8397-eb81ef716ea4"
      unitRef="U_USD">1015000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72"
      decimals="-3"
      id="F_a2e01d72-0406-4ad4-b21a-13998dd60103"
      unitRef="U_USD">1346000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      decimals="-3"
      id="F_a0031232-d564-4de9-af96-45951e4294aa"
      unitRef="U_USD">-0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72"
      decimals="-3"
      id="F_9ab02542-5412-427e-9e3b-117e19be3191"
      unitRef="U_USD">-57016000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:ShareBasedCompensation
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      decimals="-3"
      id="F_0cd9fe05-58cd-4e36-a911-ba5bd009c4e5"
      unitRef="U_USD">9299000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72"
      decimals="-3"
      id="F_c4bbaa60-4870-44f2-b720-8925286037b7"
      unitRef="U_USD">12891000</us-gaap:ShareBasedCompensation>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      decimals="-3"
      id="F_ea75fbbe-2fca-4c00-956d-c53317034441"
      unitRef="U_USD">10589000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72"
      decimals="-3"
      id="F_e7d44dd1-96ed-4846-9e1e-fc53f8d22d3c"
      unitRef="U_USD">-8702000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      decimals="-3"
      id="F_c1bb5d2f-707e-4c41-aa1d-ebc9b8b29d6d"
      unitRef="U_USD">1607000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72"
      decimals="-3"
      id="F_fd8acade-ab49-4794-894c-0c679d970208"
      unitRef="U_USD">2379000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      decimals="-3"
      id="F_65edefc8-e451-4760-9b23-1e15dd650542"
      unitRef="U_USD">-22095000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72"
      decimals="-3"
      id="F_7f0e3600-b64d-429c-8012-f1d9b59daa2a"
      unitRef="U_USD">501000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      decimals="-3"
      id="F_b9381fd8-b222-49cc-9bf3-9f56d3e16ede"
      unitRef="U_USD">-4290000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72"
      decimals="-3"
      id="F_4c1c9eba-8ae2-4127-9361-e9ed7ef0d06c"
      unitRef="U_USD">-22709000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      decimals="-3"
      id="F_0defdbb2-fd3e-4b52-b470-797d8d9bb7ac"
      unitRef="U_USD">-13343000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72"
      decimals="-3"
      id="F_e5376a6a-89bf-4e42-88ba-353dc699c6a5"
      unitRef="U_USD">-11160000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      decimals="-3"
      id="F_336121d3-b914-411b-bc03-ff78b7ac1a80"
      unitRef="U_USD">-56118000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72"
      decimals="-3"
      id="F_f0a1758b-c56c-45bd-b8ee-9a007e88c76e"
      unitRef="U_USD">-76439000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      decimals="-3"
      id="F_954e7a1b-12af-46ad-98ae-121c409ed784"
      unitRef="U_USD">-5154000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72"
      decimals="-3"
      id="F_af2886c3-df77-4e8a-8be9-eb842fe7e81d"
      unitRef="U_USD">799000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      decimals="-3"
      id="F_d43d5b85-bbaf-40c1-b8f8-a74275b3cd81"
      unitRef="U_USD">838000</us-gaap:IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve>
    <us-gaap:IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve
      contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72"
      decimals="-3"
      id="F_d0be1ee7-637c-44f7-9534-795eefd662fd"
      unitRef="U_USD">7360000</us-gaap:IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      decimals="-3"
      id="F_da806951-dab3-4ef7-88c8-1e13aba2159f"
      unitRef="U_USD">-16500000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72"
      decimals="-3"
      id="F_fb4ee22a-8e54-42f5-9212-aaf91ab58adb"
      unitRef="U_USD">-10309000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      decimals="-3"
      id="F_45007861-5ca4-487f-9492-6eac22fa72a4"
      unitRef="U_USD">73078000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
      contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72"
      decimals="-3"
      id="F_6edab1be-5bca-48f9-8d33-968929e59b1f"
      unitRef="U_USD">80019000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      decimals="-3"
      id="F_3b6a3f8c-1b94-4d56-87e2-890a37a0ebb6"
      unitRef="U_USD">-5003000</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
      contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72"
      decimals="-3"
      id="F_2d76db6f-d09a-40c0-8b9b-66006de796aa"
      unitRef="U_USD">-11764000</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      decimals="-3"
      id="F_84bc937a-ea35-4502-a7f6-1a514d330aef"
      unitRef="U_USD">68075000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72"
      decimals="-3"
      id="F_a02d3967-273e-41c3-9bc0-8a64641faad8"
      unitRef="U_USD">68255000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      decimals="-3"
      id="F_4536ae7d-8c64-4894-8983-12fae07a8bc6"
      unitRef="U_USD">1667000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72"
      decimals="-3"
      id="F_b4e5efc6-2306-4bd3-9fcf-8660b15d1ead"
      unitRef="U_USD">28167000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      decimals="-3"
      id="F_03964fa8-4c59-48e9-aa69-6540eeed1b63"
      unitRef="U_USD">26477000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72"
      decimals="-3"
      id="F_1c283040-98cc-4f14-baf2-0501067ddaaf"
      unitRef="U_USD">14938000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      decimals="-3"
      id="F_4ad4e9c6-848c-48d8-bf9c-8b5aa5b43b06"
      unitRef="U_USD">16560000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72"
      decimals="-3"
      id="F_2e439120-d509-4c08-aa6e-0747d92634b5"
      unitRef="U_USD">15889000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:PaymentsToAcquireOtherPropertyPlantAndEquipment
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      decimals="-3"
      id="F_9698161a-36d0-41b3-92a5-76128d690e4c"
      unitRef="U_USD">24284000</us-gaap:PaymentsToAcquireOtherPropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireOtherPropertyPlantAndEquipment
      contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72"
      decimals="-3"
      id="F_f573c9cf-a63d-40ed-ade3-223341cc19d0"
      unitRef="U_USD">20650000</us-gaap:PaymentsToAcquireOtherPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfOtherProductiveAssets
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      decimals="-3"
      id="F_c2f49ead-7449-49fe-b10a-cda145334d29"
      unitRef="U_USD">116000</us-gaap:ProceedsFromSaleOfOtherProductiveAssets>
    <us-gaap:ProceedsFromSaleOfOtherProductiveAssets
      contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72"
      decimals="-3"
      id="F_d9b7fc43-fd3e-4837-9d71-57418a1f4079"
      unitRef="U_USD">2153000</us-gaap:ProceedsFromSaleOfOtherProductiveAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      decimals="-3"
      id="F_8ac28f01-492b-462a-83eb-ce50e55c84ec"
      unitRef="U_USD">-35752000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72"
      decimals="-3"
      id="F_0c264b0c-2bbe-4437-b527-8c9cba0da07f"
      unitRef="U_USD">-45713000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      decimals="-3"
      id="F_f200a911-bd21-4271-a8a8-4e227bdd4468"
      unitRef="U_USD">470000000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72"
      decimals="-3"
      id="F_de6e0819-2c5f-4038-9144-db56733af019"
      unitRef="U_USD">674500000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:RepaymentsOfLinesOfCredit
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      decimals="-3"
      id="F_92fc1953-15f1-42cf-b7d5-2af9fd5a9020"
      unitRef="U_USD">474000000</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:RepaymentsOfLinesOfCredit
      contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72"
      decimals="-3"
      id="F_ecbb43de-a324-43e8-93e6-17d6586578a1"
      unitRef="U_USD">579500000</us-gaap:RepaymentsOfLinesOfCredit>
    <md:PaymentsToTermLoan
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      decimals="-3"
      id="F_c573263e-7c8c-40fc-857c-efda9aa92d96"
      unitRef="U_USD">9375000</md:PaymentsToTermLoan>
    <md:PaymentsToTermLoan
      contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72"
      decimals="-3"
      id="F_e26fd345-e0e6-4fa4-98f1-7fb6552dfb47"
      unitRef="U_USD">6250000</md:PaymentsToTermLoan>
    <us-gaap:RepaymentsOfSeniorDebt
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      decimals="-3"
      id="F_2c459bfb-cbf3-4ce2-985f-75b422882999"
      unitRef="U_USD">0</us-gaap:RepaymentsOfSeniorDebt>
    <us-gaap:RepaymentsOfSeniorDebt
      contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72"
      decimals="-3"
      id="F_2450777b-05b3-4d41-bfa6-81877fad776e"
      unitRef="U_USD">1046880000</us-gaap:RepaymentsOfSeniorDebt>
    <us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      decimals="-3"
      id="F_bee270e8-5fee-4da8-a099-e048fb8f8b29"
      unitRef="U_USD">0</us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt
      contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72"
      decimals="-3"
      id="F_a0348f3d-e81c-437d-8de8-cd8baca1c9ee"
      unitRef="U_USD">650000000</us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      decimals="-3"
      id="F_6415a19f-c439-41d8-89a4-caf57e4add2f"
      unitRef="U_USD">0</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72"
      decimals="-3"
      id="F_27391822-2991-41c6-af28-79a479fffea6"
      unitRef="U_USD">8621000</us-gaap:PaymentsOfFinancingCosts>
    <md:RepaymentsOfLongTermCapitalLeaseObligation
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      decimals="-3"
      id="F_07fba462-5381-4e4e-9d25-5d65e93290f6"
      unitRef="U_USD">2105000</md:RepaymentsOfLongTermCapitalLeaseObligation>
    <md:RepaymentsOfLongTermCapitalLeaseObligation
      contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72"
      decimals="-3"
      id="F_5ffed2b1-9258-4582-89c9-abd7eaa30121"
      unitRef="U_USD">2176000</md:RepaymentsOfLongTermCapitalLeaseObligation>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      decimals="-3"
      id="F_73c37254-4b67-45a9-a39c-492fba9c28dc"
      unitRef="U_USD">3876000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72"
      decimals="-3"
      id="F_59efc41c-297f-4cab-8dcb-7d7d63a71c19"
      unitRef="U_USD">4220000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      decimals="-3"
      id="F_7198198a-1e2f-46c8-aadc-265d120aa6de"
      unitRef="U_USD">919000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72"
      decimals="-3"
      id="F_c638d303-3ea2-4e12-b242-c89696a8a8b7"
      unitRef="U_USD">87041000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      decimals="-3"
      id="F_184a5d30-a087-422b-a887-f2e7c23026a0"
      unitRef="U_USD">-8445000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72"
      decimals="-3"
      id="F_94583608-a074-416b-9766-17f4e2ed5513"
      unitRef="U_USD">483000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      decimals="-3"
      id="F_cd0812d9-a507-43bd-8c9a-7223736238bc"
      unitRef="U_USD">-20968000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72"
      decimals="-3"
      id="F_19b883e3-f04b-42bb-b94d-c38022632880"
      unitRef="U_USD">-401265000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      decimals="-3"
      id="F_39800f79-c627-49ec-a33c-b4be2455bba6"
      unitRef="U_USD">11355000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72"
      decimals="-3"
      id="F_b3ea1d36-d568-4998-8489-d39110e240d6"
      unitRef="U_USD">-378723000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_ad3c19c0-ada4-44fc-bdd3-c29b5398a40a"
      decimals="-3"
      id="F_eacd3bbc-960d-4558-94d4-0da48baa1cb8"
      unitRef="U_USD">9824000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_cf213a70-35ae-48c9-9339-37927b488110"
      decimals="-3"
      id="F_61cab7be-f2c5-4ff8-b70f-d60855b8e835"
      unitRef="U_USD">387391000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_5d513fe3-41de-49c7-8231-3b67764cba30"
      decimals="-3"
      id="F_39d36e08-56d1-426c-8a4a-f37ebf28a716"
      unitRef="U_USD">21179000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_659d9bd3-6f8d-448a-9462-197a2c4b64c7"
      decimals="-3"
      id="F_1bb5e682-2954-4cb5-9a63-b1235a706e00"
      unitRef="U_USD">8668000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      id="F_85b15263-cedb-4ae8-82a6-922b80944b0c">&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;1.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;            Basis of Presentation:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;On July 1, 2022, effective after the close of the market, the Company changed its corporate name from "Mednax, Inc." to &#x201c;Pediatrix Medical Group, Inc." signifying the Company's return to its core focus in caring for women, babies and children.  The Company&#x2019;s common stock continues to trade on the New York Stock Exchange under the ticker symbol &#x201c;MD.&#x201d;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;The accompanying unaudited Consolidated Financial Statements of the Company and the notes thereto presented in this Form 10-Q have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission ("SEC") applicable to interim financial statements, and do not include all disclosures required by accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;) for complete financial statements. In the opinion of management, these financial statements include all adjustments, consisting only of normal recurring adjustments, necessary for a fair statement of the results of interim periods. The financial statements include all the accounts of Pediatrix Medical Group, Inc. and its consolidated subsidiaries (collectively, &#x201c;PMG&#x201d;) together with the accounts of PMG&#x2019;s affiliated business corporations or professional associations, professional corporations, limited liability companies and partnerships (the &#x201c;affiliated professional contractors&#x201d;). Certain subsidiaries of PMG have contractual management arrangements with its affiliated professional contractors, which are separate legal entities that provide physician services in certain states. The Company ceased providing services in Puerto Rico effective December 31, 2022.  The terms &#x201c;Pediatrix&#x201d; and the &#x201c;Company&#x201d; refer collectively to Pediatrix Medical Group Inc., its subsidiaries and the affiliated professional contractors.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Compan&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;y is a party to a joint venture in which it owns a &lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;37.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;% economic interest.  The Company accounts for this joint venture under the equity method of accounting because the Company exercises significant influence over, but does not control, this entity.  The Company was also a party to another joint venture in which it owned a &lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;51&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;% economic interest and for which it was deemed the primary beneficiary. This joint venture was dissolved in February 2022.  The operating results related to this joint venture prior to the dissolution and impacts from such dissolution were not material.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;The consolidated results of operations for the interim periods presented are not necessarily indicative of the results to be experienced for the entire fiscal year. In addition, the accompanying unaudited Consolidated Financial Statements and the notes thereto should be read in conjunction with the Consolidated Financial Statements and the notes thereto included in the Company&#x2019;s most recent Annual Report on Form 10-K (the &#x201c;Form 10-K&#x201d;).&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="C_7ae55b15-375d-4829-8fee-0964b045a7cf"
      decimals="3"
      id="F_9182de45-7c4e-421c-8d20-bbbe3b134cd1"
      unitRef="U_pure">0.375</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="C_99787654-98fb-4075-b2d1-551ddbc6deed"
      decimals="2"
      id="F_8d64eca6-569c-4fa2-bc5c-f5e63775a2cf"
      unitRef="U_pure">0.51</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      id="F_cb286af8-9507-4f56-8c4c-147459d064a1">&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;2.            Cash Equivalents and Investments:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of September 30, 2023 and December 31, 2022, the Company's cash equivalents consisted entirely of money market funds totaling $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;1.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;1.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:9pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Investments held are all classified as current and at &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;September 30, 2023 and December 31, 2022 are summarized as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:74.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:56.52%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.42%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:18.32%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.42%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:18.32%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;"&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;September 30, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;"&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Corporate securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;58,830&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;61,385&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;"&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Municipal debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;13,419&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;14,377&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;"&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;21,888&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;10,205&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;"&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Certificates of deposit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;3,906&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;3,710&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;"&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Federal home loan securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;5,498&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;3,562&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;"&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;103,541&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;93,239&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="C_d1b666e6-0f27-4c23-9240-3207e18d4a31"
      decimals="-5"
      id="F_d64de107-ae35-4336-af98-d93907056dd3"
      unitRef="U_USD">1200000</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="C_ece3d6f0-dcae-48a9-bc24-698ee8c17506"
      decimals="-5"
      id="F_8b3ec187-d9f8-4ce8-b827-3f6c75d25597"
      unitRef="U_USD">1400000</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      id="F_d993e294-a7d5-4c97-b940-8ac0f3460f7d">&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Investments held are all classified as current and at &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;September 30, 2023 and December 31, 2022 are summarized as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:74.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:56.52%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.42%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:18.32%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.42%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:18.32%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;"&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;September 30, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;"&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Corporate securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;58,830&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;61,385&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;"&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Municipal debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;13,419&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;14,377&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;"&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;21,888&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;10,205&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;"&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Certificates of deposit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;3,906&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;3,710&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;"&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Federal home loan securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;5,498&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;3,562&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;"&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;103,541&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;93,239&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_ecfb99fe-0958-4180-b890-77afb1efe059"
      decimals="-3"
      id="F_f6d1e09d-7e6e-4668-a3ce-1f1a22542ba8"
      unitRef="U_USD">58830000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_f2e4e009-3726-45e0-a90a-5d336cda6f04"
      decimals="-3"
      id="F_e142e9cf-6b63-4eb0-8ac4-37f8588762d9"
      unitRef="U_USD">61385000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_7ad99fb3-5525-4459-a4cb-b1188d7c5224"
      decimals="-3"
      id="F_d643ec94-9b5b-43c2-ae66-621517ce96b1"
      unitRef="U_USD">13419000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_36d93c5d-b688-4948-8aa6-b10b1986e10f"
      decimals="-3"
      id="F_469e0776-9511-4f29-a14b-1c923845152c"
      unitRef="U_USD">14377000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_b98e3dec-68cf-411f-84d8-48f4345c2f5e"
      decimals="-3"
      id="F_8bb6ddd3-27e2-4f57-9a9f-719d32035d82"
      unitRef="U_USD">21888000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_64e6ce54-7a3c-4a04-9100-a67300b48c30"
      decimals="-3"
      id="F_aca2620c-9fc8-4e89-8ca6-3cfd50657c7f"
      unitRef="U_USD">10205000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_012cf148-5766-4e38-bab9-71a218133486"
      decimals="-3"
      id="F_2030c7da-1a30-4855-b977-37b75d541122"
      unitRef="U_USD">3906000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_c8155ad1-ff2e-4bfe-b9f9-a6805aed62f4"
      decimals="-3"
      id="F_31f17d3d-ea03-44c8-b49a-55f8488b496c"
      unitRef="U_USD">3710000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_b42eab6a-90cf-43fc-9fc6-2ad25a6ef134"
      decimals="-3"
      id="F_4d387c5e-f673-4d1a-b97d-cda7efbc0de9"
      unitRef="U_USD">5498000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_ee5ce32e-37b5-4efc-a6e1-d6be8df2025a"
      decimals="-3"
      id="F_d6f13c45-e6ee-4816-8e58-3f95aceea311"
      unitRef="U_USD">3562000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_5d513fe3-41de-49c7-8231-3b67764cba30"
      decimals="-3"
      id="F_8700d041-1a46-4820-a5d5-12738be096b8"
      unitRef="U_USD">103541000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_ad3c19c0-ada4-44fc-bdd3-c29b5398a40a"
      decimals="-3"
      id="F_27e79806-f0c0-4df2-9c61-38a19974207d"
      unitRef="U_USD">93239000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      id="F_d9933e2c-0522-40b2-b28c-016aafe487f3">&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;3.            Fair Value Measurements:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;The accounting guidance establishes a fair value hierarchy that prioritizes valuation inputs into three levels based on the extent to which inputs used in measuring fair value are observable in the market. Each fair value measurement is reported in one of three levels:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:0;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 1 &#x2013; inputs are based upon unadjusted quoted prices for identical instruments traded in active markets.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:0;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 2 &#x2013; inputs are based upon quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:0;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 3 &#x2013; inputs are generally unobservable and typically reflect management&#x2019;s estimates of assumptions that market participants would use in pricing the asset or liability. The fair values are therefore determined using model-based techniques that include option pricing models, discounted cash flow models, and similar techniques.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:9pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table presents information about the Company&#x2019;s financial instruments that are accounted for at fair value on a recurring basis at &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;September 30, 2023 and December 31, 2022 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:95.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:47.464%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.062%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.668%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.062%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.818999999999999%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.105%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.818999999999999%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;"&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;"&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Fair Value&lt;br/&gt;Category&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;September 30, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;"&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;"&gt;
        &lt;td style="background-color:#ffffff;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;1,201&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;1,415&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;"&gt;
        &lt;td style="background-color:#cff0fc;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Short-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;103,541&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;93,239&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;"&gt;
        &lt;td style="background-color:#ffffff;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Mutual Funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;15,851&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;14,544&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:9pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table presents information about the Company&#x2019;s financial instruments that are not carried at fair value at &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;September 30, 2023 and December 31, 2022 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.72%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.08%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.24%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.08%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.84%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.32%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.72%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;"&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;September 30, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;"&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;"&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;"&gt;
        &lt;td style="background-color:#ffffff;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;2030 Notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;400,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;352,680&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;400,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;344,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;The carrying amounts of cash equivalents, accounts receivable and accounts payable and accrued expenses approximate fair value due to the short maturities of the respective instruments. The carrying value of the line of credit approximates fair value.  If the Company&#x2019;s line of credit was measured at fair value, it would be categorized as Level 2 in the fair value hierarchy.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      id="F_9ed74e82-7c54-4a75-9819-f3c854ceab6a">&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table presents information about the Company&#x2019;s financial instruments that are accounted for at fair value on a recurring basis at &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;September 30, 2023 and December 31, 2022 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:95.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:47.464%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.062%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.668%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.062%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.818999999999999%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.105%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.818999999999999%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;"&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;"&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Fair Value&lt;br/&gt;Category&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;September 30, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;"&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;"&gt;
        &lt;td style="background-color:#ffffff;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;1,201&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;1,415&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;"&gt;
        &lt;td style="background-color:#cff0fc;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Short-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;103,541&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;93,239&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;"&gt;
        &lt;td style="background-color:#ffffff;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Mutual Funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;15,851&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;14,544&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <md:MoneyMarketFundsFairValueDisclosure
      contextRef="C_3f1eae59-7db7-4f63-b33e-689ca6ac6166"
      decimals="-3"
      id="F_80b7c1ea-eb40-4a5b-ab85-8bd359f2a1f6"
      unitRef="U_USD">1201000</md:MoneyMarketFundsFairValueDisclosure>
    <md:MoneyMarketFundsFairValueDisclosure
      contextRef="C_af3a863a-e1d2-476d-ab71-08e497384468"
      decimals="-3"
      id="F_5baeb897-7266-4d0c-b6d0-744582525290"
      unitRef="U_USD">1415000</md:MoneyMarketFundsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_f56f4f7a-19b8-4635-8355-ce0222c24e4b"
      decimals="-3"
      id="F_327c0ec7-105c-4015-a8a8-75a6fb9bfd2a"
      unitRef="U_USD">103541000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_2ed09d19-c783-4eb4-860c-7e590254f539"
      decimals="-3"
      id="F_a4527b7a-1e53-4cc8-8bca-54768285f6c0"
      unitRef="U_USD">93239000</us-gaap:InvestmentsFairValueDisclosure>
    <md:MutualFundsFairValueDisclosure
      contextRef="C_3f1eae59-7db7-4f63-b33e-689ca6ac6166"
      decimals="-3"
      id="F_f819e413-e59f-455f-ac61-91d0da3ff34b"
      unitRef="U_USD">15851000</md:MutualFundsFairValueDisclosure>
    <md:MutualFundsFairValueDisclosure
      contextRef="C_af3a863a-e1d2-476d-ab71-08e497384468"
      decimals="-3"
      id="F_348c3779-c95c-4203-8ae7-d641b6ec2cd5"
      unitRef="U_USD">14544000</md:MutualFundsFairValueDisclosure>
    <md:FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      id="F_51d10d86-ef0b-4149-bf26-5b01424c15ba">&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table presents information about the Company&#x2019;s financial instruments that are not carried at fair value at &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;September 30, 2023 and December 31, 2022 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.72%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.08%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.24%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.08%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.84%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.32%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.72%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;"&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;September 30, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;"&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;"&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;"&gt;
        &lt;td style="background-color:#ffffff;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;2030 Notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;400,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;352,680&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;400,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;344,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</md:FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock>
    <us-gaap:NotesPayable
      contextRef="C_06c01cd0-0e05-46ab-a1e5-d6467d9be312"
      decimals="-3"
      id="F_0a2c5b3d-3e4f-4868-ba14-74a0c9053641"
      unitRef="U_USD">400000000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="C_06c01cd0-0e05-46ab-a1e5-d6467d9be312"
      decimals="-3"
      id="F_a83d196b-674a-46fd-868a-8663a39ef6c9"
      unitRef="U_USD">352680000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="C_0a32aa8a-cbb8-411d-957d-680d318c2384"
      decimals="-3"
      id="F_5ec06143-d379-43c5-9412-489a2d8f31d0"
      unitRef="U_USD">400000000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="C_0a32aa8a-cbb8-411d-957d-680d318c2384"
      decimals="-3"
      id="F_45cc327e-b0d1-4591-8629-1c348399e49c"
      unitRef="U_USD">344000000</us-gaap:NotesPayableFairValueDisclosure>
    <md:AccountsReceivableAndNetRevenueDisclosureTextBlock
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      id="F_6ee7e28a-0388-4873-8097-fbd1e664274c">&lt;p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;4. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Arial;min-width:fit-content;"&gt;            &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accounts Receivable and Net Revenue:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:9pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accounts receivable, net consists of the following (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:96.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:64.696%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.042%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.61%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.042%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.61%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;"&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;September 30, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;"&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Gross accounts receivable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;1,448,620&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;1,548,492&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;"&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Allowance for contractual adjustments and uncollectibles&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;1,171,268&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;1,251,705&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;"&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;277,352&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;296,787&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Patient service revenue is recognized at the time services are provided by the Company&#x2019;s affiliated physicians. The Company&#x2019;s performance obligations related to the delivery of services to patients are satisfied at the time of service. Accordingly, there are no performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period with respect to patient service revenue. Almost all of the Company&#x2019;s patient service revenue is reimbursed by government-sponsored healthcare programs (&#x201c;GHC Programs&#x201d;) and third-party insurance payors. Payments for services rendered to the Company&#x2019;s patients are generally less than billed charges. The Company monitors its revenue and receivables from these sources and records an estimated contractual allowance to properly account for the anticipated differences between billed and reimbursed amounts.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accordingly, patient service revenue is presented net of an estimated provision for contractual adjustments and uncollectibles. The Company estimates allowances for contractual adjustments and uncollectibles on accounts receivable based upon historical experience and other factors, including days sales outstanding (&#x201c;DSO&#x201d;) for accounts receivable, evaluation of expected adjustments and delinquency rates, past adjustments and collection experience in relation to amounts billed, an aging of accounts receivable, current contract and reimbursement terms, changes in payor mix and other relevant information. Contractual adjustments result from the difference between the physician rates for services performed and the reimbursements by GHC Programs and third-party insurance payors for such services.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Collection of patient service revenue the Company expects to receive is normally a function of providing complete and correct billing information to the GHC Programs and third-party insurance payors within the various filing deadlines and typically occurs within 30 to 60 days of billing.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Some of the Company&#x2019;s hospital agreements require hospitals to pay the Company administrative fees. Some agreements provide for fees if the hospital does not generate sufficient patient volume in order to guarantee that the Company receives a specified minimum revenue level. The Company also receives fees from hospitals for administrative services performed by its affiliated physicians providing medical director or other services at the hospital.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:9pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table summarizes the Company&#x2019;s net revenue by category (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:30.731%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.147%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.426%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.147%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.552999999999999%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.147%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.84%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.68%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.324%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;"&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;"&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;"&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Net patient service revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;437,321&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;421,085&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;1,290,888&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;1,245,627&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;"&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Hospital contract administrative fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;68,712&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;67,418&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;204,286&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;196,425&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;"&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Other revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;579&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;1,412&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;3,023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;16,125&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;"&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;506,612&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;489,915&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;1,498,197&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;1,458,177&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:9pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;text-indent:6.983%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;The approximate percentage of net patient service revenue by type of payor was as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:91.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:36.233%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.597%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.82%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.798%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.078%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.177999999999999%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;"&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;"&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;"&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Contracted managed care&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;67&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;65&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;67&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;67&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;"&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Government&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;28&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;26&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;"&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Other third-parties&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;"&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Private-pay patients&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;"&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</md:AccountsReceivableAndNetRevenueDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      id="F_ecbd98fa-61dd-4859-a0ca-9c1d04f274b4">&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accounts receivable, net consists of the following (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:96.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:64.696%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.042%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.61%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.042%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.61%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;"&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;September 30, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;"&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Gross accounts receivable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;1,448,620&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;1,548,492&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;"&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Allowance for contractual adjustments and uncollectibles&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;1,171,268&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;1,251,705&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;"&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;277,352&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;296,787&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
    <us-gaap:AccountsReceivableGrossCurrent
      contextRef="C_5d513fe3-41de-49c7-8231-3b67764cba30"
      decimals="-3"
      id="F_ef95e3c6-0055-43bc-aa71-75df3a1e96b9"
      unitRef="U_USD">1448620000</us-gaap:AccountsReceivableGrossCurrent>
    <us-gaap:AccountsReceivableGrossCurrent
      contextRef="C_ad3c19c0-ada4-44fc-bdd3-c29b5398a40a"
      decimals="-3"
      id="F_cb72d82d-b720-4d6f-9fbd-02fac7b7b0a3"
      unitRef="U_USD">1548492000</us-gaap:AccountsReceivableGrossCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="C_5d513fe3-41de-49c7-8231-3b67764cba30"
      decimals="-3"
      id="F_48fb7516-0775-4000-8b21-c83e4c098247"
      unitRef="U_USD">1171268000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="C_ad3c19c0-ada4-44fc-bdd3-c29b5398a40a"
      decimals="-3"
      id="F_6ae96a95-0c7b-4ffd-a72f-90e6d81bd572"
      unitRef="U_USD">1251705000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_5d513fe3-41de-49c7-8231-3b67764cba30"
      decimals="-3"
      id="F_c528d194-b55a-4f76-bf26-1f5fb20232db"
      unitRef="U_USD">277352000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_ad3c19c0-ada4-44fc-bdd3-c29b5398a40a"
      decimals="-3"
      id="F_514aa901-c4a0-4a52-ba6f-8a9a83af9537"
      unitRef="U_USD">296787000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      id="F_8baf98d9-c6d5-449b-970b-9ff3b42f90a7">&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table summarizes the Company&#x2019;s net revenue by category (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:30.731%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.147%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.426%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.147%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.552999999999999%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.147%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.84%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.68%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.324%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;"&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;"&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;"&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Net patient service revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;437,321&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;421,085&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;1,290,888&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;1,245,627&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;"&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Hospital contract administrative fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;68,712&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;67,418&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;204,286&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;196,425&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;"&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Other revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;579&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;1,412&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;3,023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;16,125&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;"&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;506,612&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;489,915&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;1,498,197&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;1,458,177&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_ee0dda75-7533-43f8-ba6d-8b3ddadca454"
      decimals="-3"
      id="F_38bd285e-ec0c-4bc2-9e36-ccbdc1c1dbba"
      unitRef="U_USD">437321000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_ec45eaa6-d9c5-4fd0-84cf-6b2be759e02b"
      decimals="-3"
      id="F_5b36f8d1-d29b-4924-b8f3-ef52a68dbf99"
      unitRef="U_USD">421085000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_56cb679d-6a88-4a31-abf3-f1c779c4bcb9"
      decimals="-3"
      id="F_168d3e20-67ed-4a38-835e-3ea454b2e74a"
      unitRef="U_USD">1290888000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_f6042715-3400-472b-a63f-651373917338"
      decimals="-3"
      id="F_27bbcaa5-d4ab-4d95-887e-91158c61d748"
      unitRef="U_USD">1245627000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_3f7aa872-26d0-45a9-b1bb-119611e8d6c8"
      decimals="-3"
      id="F_3a3923a6-6b1c-4790-a07a-bc03809e4110"
      unitRef="U_USD">68712000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_07cad879-2c61-450d-9518-d6bbda76d09e"
      decimals="-3"
      id="F_fbe4de99-d056-42e4-93fb-9211340573ab"
      unitRef="U_USD">67418000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_13a9d66b-1b0e-497a-b873-fe7ac09c44cf"
      decimals="-3"
      id="F_9549cf7e-a640-4974-87c8-9943c4dcb864"
      unitRef="U_USD">204286000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_c7f29732-6f5b-49e4-a848-639b94127316"
      decimals="-3"
      id="F_e4db46d9-8733-4cba-9e3d-d3f72eb78d2c"
      unitRef="U_USD">196425000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_9d124535-a548-449d-8d4b-80ec4d95973a"
      decimals="-3"
      id="F_ba942851-31f0-45ad-bd3d-2cd0863da2bb"
      unitRef="U_USD">579000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_97d10031-02ee-416c-bb86-cd6e6928957a"
      decimals="-3"
      id="F_9a45574a-f71b-4b9e-a3a2-09bc6f335cd5"
      unitRef="U_USD">1412000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_7b75f74d-09a8-4e26-8d61-3a48b9fa176e"
      decimals="-3"
      id="F_507601c0-d789-42ff-a1b4-62928afd4b40"
      unitRef="U_USD">3023000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_dba1d7c4-12e0-4e88-888d-efc09f476c71"
      decimals="-3"
      id="F_696cc059-84e3-4301-8a4c-3367988748d7"
      unitRef="U_USD">16125000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_e5943398-0732-4d17-9fe7-25777d223b65"
      decimals="-3"
      id="F_34be22ff-66f0-4553-9b14-fd6bf0193b39"
      unitRef="U_USD">506612000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_350c5db7-f64b-4e63-97fa-733cc8e8f783"
      decimals="-3"
      id="F_a8864712-8ffe-447f-94c7-4218452b12dc"
      unitRef="U_USD">489915000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      decimals="-3"
      id="F_2e76be2b-622b-4c59-b4e0-a080aefd8201"
      unitRef="U_USD">1498197000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72"
      decimals="-3"
      id="F_1bc093e1-281f-4414-9d75-b1f3680bd879"
      unitRef="U_USD">1458177000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      id="F_374b8d02-68d0-4bc7-80ef-565379d13594">&lt;p style="margin-left:4.533%;text-indent:6.983%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;The approximate percentage of net patient service revenue by type of payor was as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:91.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:36.233%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.597%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.82%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.798%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.078%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.177999999999999%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;"&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;"&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;"&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Contracted managed care&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;67&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;65&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;67&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;67&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;"&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Government&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;28&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;26&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;"&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Other third-parties&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;"&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Private-pay patients&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;"&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="C_1a90cf11-7660-475d-b876-c49b675c3a0d"
      decimals="2"
      id="F_897fe119-c40a-4380-9ffc-487b552ec1a0"
      unitRef="U_pure">0.67</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="C_33f86df0-142f-4408-9f5e-9de3e9f21458"
      decimals="2"
      id="F_2e2eae32-e31e-4634-8cdb-51887825659c"
      unitRef="U_pure">0.65</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="C_530a9bb3-d0af-4d65-93b6-103b6c414d75"
      decimals="2"
      id="F_a4315de3-e6e5-4a20-8901-3222a9fc578b"
      unitRef="U_pure">0.67</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="C_6ea9b9a0-3cfd-421c-9583-235675ef66b6"
      decimals="2"
      id="F_4b89f645-8956-4410-9b45-eac3815abfc5"
      unitRef="U_pure">0.67</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="C_134848fe-680a-4e25-830f-371c8b8fb100"
      decimals="2"
      id="F_0a4591aa-45af-41ac-b628-bc042a80706b"
      unitRef="U_pure">0.25</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="C_340f9a3e-b672-4edc-82ab-7e12ef61b6da"
      decimals="2"
      id="F_55db95f4-b93e-4f22-9157-1dbc7e1d95b0"
      unitRef="U_pure">0.28</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="C_4a7eedc9-2d63-42bd-9695-8d9ce87c5067"
      decimals="2"
      id="F_343c6340-6e7f-477c-920f-b661e7caa767"
      unitRef="U_pure">0.25</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="C_6494afcc-dadf-426c-b613-8f9a7abfe318"
      decimals="2"
      id="F_e42d64e5-2d62-49b0-a7d6-2053ef325b4d"
      unitRef="U_pure">0.26</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="C_45911ccf-f5d4-4c4e-8dd0-c5ea09a1db36"
      decimals="2"
      id="F_b1201bdd-6579-40c7-a573-2807019ff47a"
      unitRef="U_pure">0.05</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="C_477d8b88-2dd5-4c27-a308-f22d4cb31970"
      decimals="2"
      id="F_3454cd16-dabd-4029-bba3-b01528179cc5"
      unitRef="U_pure">0.05</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="C_86ceec74-75ab-4b30-bf4d-aa99084da5fc"
      decimals="2"
      id="F_d6052b92-7988-4e54-9f5f-d65a76f288af"
      unitRef="U_pure">0.06</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="C_61935c85-fd8d-48a0-b0e8-e2ace38d0aca"
      decimals="2"
      id="F_1c57df55-3821-48a0-abdc-d44df2f5c9f1"
      unitRef="U_pure">0.05</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="C_f61ab540-a2d0-4d45-8e9f-d043538b0a26"
      decimals="2"
      id="F_1ae46cc2-e8c5-4e1a-8347-ad0aa2527449"
      unitRef="U_pure">0.03</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="C_a53e34bc-3154-419c-8471-2c496997bd8c"
      decimals="2"
      id="F_9d0d640b-91db-4863-b434-d968c9779c24"
      unitRef="U_pure">0.02</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="C_99c7da7a-966d-481a-9f87-07899a403107"
      decimals="2"
      id="F_6d3d7e9d-9852-4eab-b9f7-8ef7ae38fa1b"
      unitRef="U_pure">0.02</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="C_8fa77ca8-719f-4df1-bf5f-88fe5ee7eebb"
      decimals="2"
      id="F_fd24f76b-e812-42af-8de3-938814012b3f"
      unitRef="U_pure">0.02</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="C_e5943398-0732-4d17-9fe7-25777d223b65"
      decimals="INF"
      id="F_6cc28bf6-0331-4cc4-bdaf-7243baaf4314"
      unitRef="U_pure">1</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="C_350c5db7-f64b-4e63-97fa-733cc8e8f783"
      decimals="INF"
      id="F_aecc3b0d-1630-4608-bc63-5922e5c096ef"
      unitRef="U_pure">1</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      decimals="INF"
      id="F_6df9bb3b-c4f9-43a7-9894-b07e5a36713c"
      unitRef="U_pure">1</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72"
      decimals="INF"
      id="F_c53e3bf1-5f62-4311-8ea7-ef72d5128943"
      unitRef="U_pure">1</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      id="F_8485ca08-a4a0-4ece-940a-a6c2a355c67f">&lt;p style="text-indent:0;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;5.            Accounts Payable and Accrued Expenses:	&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:9pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accounts payable and accrued expenses consist of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:54.314%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.253%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:21.479%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.253%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:17.7%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;"&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;September 30, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;"&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accounts payable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;31,696&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;31,857&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;"&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accrued salaries and incentive compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;150,014&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;197,831&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;"&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accrued payroll taxes and benefits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;35,366&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;34,983&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;"&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accrued professional liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;30,169&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;32,232&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;"&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accrued interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;3,204&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;8,921&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;"&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Other accrued expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;52,134&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;68,401&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;"&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;302,583&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;374,225&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;The net decrease in accrued salaries and incentive compensation of $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;47.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, from December 31, 2022 to September 30, 2023, is primarily due to the payment of performance-based incentive compensation, principally to the Company&#x2019;s affiliated physicians, partially offset by performance-based incentive compensation accrued during the nine months ended September 30, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;. A majority of the Company&#x2019;s payments for performance-based incentive compensation is paid annually during the first quarter.&lt;/span&gt;&lt;/p&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      id="F_46d81c01-e39a-41e1-b607-507dcdf4784b">&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accounts payable and accrued expenses consist of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:54.314%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.253%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:21.479%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.253%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:17.7%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;"&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;September 30, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;"&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accounts payable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;31,696&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;31,857&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;"&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accrued salaries and incentive compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;150,014&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;197,831&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;"&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accrued payroll taxes and benefits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;35,366&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;34,983&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;"&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accrued professional liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;30,169&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;32,232&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;"&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accrued interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;3,204&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;8,921&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;"&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Other accrued expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;52,134&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;68,401&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;"&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;302,583&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;374,225&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_5d513fe3-41de-49c7-8231-3b67764cba30"
      decimals="-3"
      id="F_f49b9748-e887-4472-b408-4ff787baa2a7"
      unitRef="U_USD">31696000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_ad3c19c0-ada4-44fc-bdd3-c29b5398a40a"
      decimals="-3"
      id="F_6dd383ce-3695-4d4d-96bb-679f5efb45b2"
      unitRef="U_USD">31857000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedSalariesCurrent
      contextRef="C_5d513fe3-41de-49c7-8231-3b67764cba30"
      decimals="-3"
      id="F_504fa1a4-757a-4c34-9a03-c63be7082262"
      unitRef="U_USD">150014000</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedSalariesCurrent
      contextRef="C_ad3c19c0-ada4-44fc-bdd3-c29b5398a40a"
      decimals="-3"
      id="F_b232405e-7779-46c6-8f6a-20c7adad3f17"
      unitRef="U_USD">197831000</us-gaap:AccruedSalariesCurrent>
    <md:AccruedPayrollTaxesAndBenefitsCurrent
      contextRef="C_5d513fe3-41de-49c7-8231-3b67764cba30"
      decimals="-3"
      id="F_10db8282-116d-4b43-98da-bb98136dffec"
      unitRef="U_USD">35366000</md:AccruedPayrollTaxesAndBenefitsCurrent>
    <md:AccruedPayrollTaxesAndBenefitsCurrent
      contextRef="C_ad3c19c0-ada4-44fc-bdd3-c29b5398a40a"
      decimals="-3"
      id="F_91dd8815-5544-4769-acdb-60c68bd0fc06"
      unitRef="U_USD">34983000</md:AccruedPayrollTaxesAndBenefitsCurrent>
    <us-gaap:MalpracticeLossContingencyAccrualUndiscountedCurrent
      contextRef="C_5d513fe3-41de-49c7-8231-3b67764cba30"
      decimals="-3"
      id="F_2d5440a1-28f2-40b0-809f-afa2b008f1d0"
      unitRef="U_USD">30169000</us-gaap:MalpracticeLossContingencyAccrualUndiscountedCurrent>
    <us-gaap:MalpracticeLossContingencyAccrualUndiscountedCurrent
      contextRef="C_ad3c19c0-ada4-44fc-bdd3-c29b5398a40a"
      decimals="-3"
      id="F_6b87c6e8-48bb-412c-82f7-764dbb33e6a2"
      unitRef="U_USD">32232000</us-gaap:MalpracticeLossContingencyAccrualUndiscountedCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="C_5d513fe3-41de-49c7-8231-3b67764cba30"
      decimals="-3"
      id="F_e2f3a222-82ff-4ecd-92ef-453ff6682dd3"
      unitRef="U_USD">3204000</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="C_ad3c19c0-ada4-44fc-bdd3-c29b5398a40a"
      decimals="-3"
      id="F_79b9b388-c7b7-4ff5-94e7-c51a79c1eca0"
      unitRef="U_USD">8921000</us-gaap:InterestPayableCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_5d513fe3-41de-49c7-8231-3b67764cba30"
      decimals="-3"
      id="F_a1ec613f-df46-4bbf-99d5-5968fd0bb6ca"
      unitRef="U_USD">52134000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_ad3c19c0-ada4-44fc-bdd3-c29b5398a40a"
      decimals="-3"
      id="F_30a2541d-ddfd-4a49-b5d9-000776d65ddf"
      unitRef="U_USD">68401000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="C_5d513fe3-41de-49c7-8231-3b67764cba30"
      decimals="-3"
      id="F_d607ce6d-09ea-494a-8fd0-674eedcbf56a"
      unitRef="U_USD">302583000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="C_ad3c19c0-ada4-44fc-bdd3-c29b5398a40a"
      decimals="-3"
      id="F_273c0ba0-a554-44fa-b9ed-cad6d6bf4765"
      unitRef="U_USD">374225000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <md:IncreaseDecreaseInAccruedSalariesAndBonuses
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      decimals="-5"
      id="F_556f52b4-69d5-4ed7-85d6-9a0778ea096e"
      unitRef="U_USD">47800000</md:IncreaseDecreaseInAccruedSalariesAndBonuses>
    <md:LineOfCreditAndLongTermDebtTextBlock
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      id="F_af8eef81-8cb0-4865-8bcc-27c84be43945">&lt;p style="text-indent:0;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;6.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Arial;min-width:fit-content;"&gt;          &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Line of Credit and Long-Term Debt:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;On February 11, 2022, the Company issued $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;400.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of &lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;5.375&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;% unsecured senior notes due 2030 (the &#x201c;2030 Notes&#x201d;).  The Company used the net proceeds from the issuance of the &lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;2030&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; Notes, together with $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;100.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; million drawn under the Revolving Credit Line (as defined below), $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;250.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of Term A Loan (as defined below) and approximately $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;308.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of cash on hand, to redeem (the &#x201c;Redemption&#x201d;) the &lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;6.25&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;% senior unsecured notes due 2027, which had an outstanding principal balance of $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; billion, and to pay costs, fees and expenses associated with the Redemption and the Credit Agreement Amendment (as defined below).&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Interest on the 2030 Notes accrues at the rate of &lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;5.375&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;% per annum, or $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;21.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, and is &lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;payable semi-annually in arrears on February 15 and August 15, beginning on August 15, 2022&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The Company's obligations under the 2030 &lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Notes are guaranteed on an unsecured senior basis by the same subsidiaries and affiliated professional contractors that guarantee the Amended Credit Agreement (as defined below). The indenture under which the 2030 Notes are issued, among other things, limits the Company's ability to (1) incur liens and (2) enter into sale and lease-back transactions, and also limits the Company's ability to merge or dispose of all or substantially all of its assets, in all cases, subject to a number of customary exceptions&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;. Although the Company is not required to make mandatory redemption or sinking fund payments with respect to the 2030 Notes, upon the occurrence of a change in control, the Company may be required to repurchase the 2030 Notes at a purchase price equal to &lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;101&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the aggregate principal amount of the 2030 Notes repurchased plus accrued and unpaid interest.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Also in connection with the Redemption, the Company amended its credit agreement (the &#x201c;Credit Agreement&#x201d;, and such amendment, the "Credit Agreement Amendment"), concurrently with the issuance of the 2030 Notes. The Credit Agreement Amendment, among other things, (i) refinanced the prior unsecured revolving credit facility with a $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;450&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; million unsecured revolving credit facility, including a $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;37.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; million sub-facility for the issuance of letters of credit (the &#x201c;Revolving Credit Line&#x201d;), and a $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;250&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;term &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;A loan facility (&#x201c;Term A Loan&#x201d;) and (ii) removed JPMorgan Chase Bank, N.A., as the administrative agent under the Credit Agreement and appointed Bank of America, N.A. as the administrative agent for the lenders.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Credit Agreement, as amended by the Credit Agreement Amendment (the &#x201c;Amended Credit Agreement&#x201d;) matures on February 11, 2027 and is guaranteed on an unsecured basis by substantially all of the Company's subsidiaries and affiliated professional contractors. At the Company's option, borrowings under the Amended Credit Agreement bear interest at &lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;(i) the Alternate Base Rate (defined as the highest of (a) the prime rate as announced by Bank of America, N.A., (b) the Federal Funds Rate plus 0.50% and (c) Term Secured Overnight Financing Rate ("SOFR") for an interest period of one month plus 1.00% with a 1.00% floor) plus an applicable margin rate of 0.50% for the first two fiscal quarters after the date of the Credit Agreement Amendment, and thereafter at an applicable margin rate ranging from 0.125% to 0.750% based on the Company's consolidated net leverage ratio or (ii) Term SOFR rate (calculated as the Secured Overnight Financing Rate published on the applicable Reuters screen page plus a spread adjustment of 0.10%, 0.15% or 0.25% depending on if the Company selects a one-month, three-month or six-month interest period, respectively, for the applicable loan with a 0% floor), plus an applicable margin rate of 1.50% for the first two full fiscal quarters after the date of the Credit Agreement Amendment, and thereafter at an applicable margin rate ranging from 1.125% to 1.750% based on the Company's consolidated net leverage ratio. The Amended Credit Agreement also provides for other customary fees and charges, including an unused commitment fee with respect to the Revolving Credit Line ranging from 0.150% to 0.200% of the unused lending commitments under the Revolving Credit Line&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;, based on the Company's consolidated net leverage ratio.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Amended Credit Agreement contains customary covenants and restrictions, including covenants that require the Company to maintain a minimum interest coverage ratio, a maximum consolidated net leverage ratio and to comply with laws, and restrictions on the ability to pay dividends, incur indebtedness or liens and make certain other distributions subject to baskets and exceptions, in each case, as specified therein. Failure to comply with these covenants would constitute an event of default under the Amended Credit Agreement, notwithstanding the ability of the Company to meet its debt service obligations. The Amended Credit Agreement includes various customary remedies for the lenders following an event of default, including the acceleration of repayment of outstanding amounts under the Amended Credit Agreement. In addition, the Company may increase the principal amount of the Revolving Credit Line or incur additional term loans under the Amended Credit Agreement in an aggregate principal amount such that on a pro forma basis after giving effect to such increase or additional term loans, the Company would be in compliance with the financial covenants, subject to the satisfaction of specified conditions and additional caps in the event that the Amended Credit Agreement is secured.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;At September 30, 2023, the Company had an outstanding principal balance on the Amended Credit Agreement of $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;231.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, comprised solely of the Term A Loan. The Company had $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;450.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; million available on its Amended Credit Agreement at &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;September 30, 2023.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;At September 30, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company had an outstanding principal balance of $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;400.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; million on the 2030 Notes.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</md:LineOfCreditAndLongTermDebtTextBlock>
    <us-gaap:SeniorNotes
      contextRef="C_2f1c7dd7-f01c-4015-a37d-1caeb69540b9"
      decimals="-5"
      id="F_9d23fbb1-ee72-4c5e-b372-731d896ebae3"
      unitRef="U_USD">400000000</us-gaap:SeniorNotes>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="C_2f1c7dd7-f01c-4015-a37d-1caeb69540b9"
      decimals="5"
      id="F_8061c29d-724c-44e2-ae8b-a80e793dd8db"
      unitRef="U_pure">0.05375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <md:DebtInstrumentMaturityYear
      contextRef="C_1c0cfd23-24b4-45dc-8a0f-30d68714c292"
      id="F_53ffe27f-4e86-465d-92e9-b3e5993d9687">2030</md:DebtInstrumentMaturityYear>
    <us-gaap:ProceedsFromIssuanceOfUnsecuredDebt
      contextRef="C_f2431026-3a3b-40cd-9fb3-55962d2dfba5"
      decimals="-5"
      id="F_acbeac04-9b28-4c56-879d-009b7351018f"
      unitRef="U_USD">100000000</us-gaap:ProceedsFromIssuanceOfUnsecuredDebt>
    <us-gaap:UnsecuredLongTermDebt
      contextRef="C_48f6c028-da90-4698-9d57-8fadb9aedae6"
      decimals="-5"
      id="F_fa98cf72-5151-466f-b90a-87f281203dbb"
      unitRef="U_USD">250000000</us-gaap:UnsecuredLongTermDebt>
    <us-gaap:Cash
      contextRef="C_48f6c028-da90-4698-9d57-8fadb9aedae6"
      decimals="-5"
      id="F_5c481440-9fc9-4c83-aa3f-d9cff586bd0c"
      unitRef="U_USD">308000000</us-gaap:Cash>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="C_fdee2685-4fe9-4dac-b896-4bbc5d69816d"
      decimals="4"
      id="F_49550e3e-3af5-4c54-bcb2-442b7080974f"
      unitRef="U_pure">0.0625</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="C_4ec257e6-7ad0-419f-b83a-531d36bb3987"
      decimals="-8"
      id="F_ec07acbd-d30d-4227-a376-0570df7c3d9d"
      unitRef="U_USD">1000000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="C_5d513fe3-41de-49c7-8231-3b67764cba30"
      decimals="5"
      id="F_b430f25c-87bd-4fa1-881e-b57ba3d12ba1"
      unitRef="U_pure">0.05375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentPeriodicPaymentInterest
      contextRef="C_ebc061e7-b2d9-4c21-8b03-fda66e7ff5fd"
      decimals="-5"
      id="F_8aaee20e-8b5c-472f-88ef-ad1f566114d7"
      unitRef="U_USD">21500000</us-gaap:DebtInstrumentPeriodicPaymentInterest>
    <us-gaap:DebtInstrumentFrequencyOfPeriodicPayment
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      id="F_a6b3266f-b030-4629-a4ae-2c6841843195">payable semi-annually in arrears on February 15 and August 15, beginning on August 15, 2022</us-gaap:DebtInstrumentFrequencyOfPeriodicPayment>
    <us-gaap:DebtInstrumentDescription
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      id="F_9dcd5aca-95aa-473b-be9f-d53f9fb5f327">Notes are guaranteed on an unsecured senior basis by the same subsidiaries and affiliated professional contractors that guarantee the Amended Credit Agreement (as defined below). The indenture under which the 2030 Notes are issued, among other things, limits the Company's ability to (1) incur liens and (2) enter into sale and lease-back transactions, and also limits the Company's ability to merge or dispose of all or substantially all of its assets, in all cases, subject to a number of customary exceptions</us-gaap:DebtInstrumentDescription>
    <md:PurchasePrice
      contextRef="C_5d513fe3-41de-49c7-8231-3b67764cba30"
      decimals="2"
      id="F_60ee85ec-06ca-4c33-b2de-4ede79a7c497"
      unitRef="U_pure">1.01</md:PurchasePrice>
    <us-gaap:UnsecuredDebt
      contextRef="C_894b93ff-c06d-4c0f-a734-2f6884d5b7f7"
      decimals="-6"
      id="F_66217e07-bc79-4161-ab4b-28fdb0f7aa10"
      unitRef="U_USD">450000000</us-gaap:UnsecuredDebt>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="C_f4b8c51a-4dae-4dd3-9d9f-ef95a7c7a1b4"
      decimals="-5"
      id="F_77b91daa-16ff-4a9e-a0fc-20f30d856490"
      unitRef="U_USD">37500000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:UnsecuredLongTermDebt
      contextRef="C_e97fbd72-ea7b-4883-b296-14825e3e504f"
      decimals="-6"
      id="F_b1d62f75-5ba0-49c3-8711-cd61fc3973e8"
      unitRef="U_USD">250000000</us-gaap:UnsecuredLongTermDebt>
    <us-gaap:DescriptionOfInterestRateRiskExposure
      contextRef="C_24d8347f-a523-4cf1-8d04-a1595106e838"
      id="F_012bd1e1-13bd-42e3-a9ae-393af576cac6">(i) the Alternate Base Rate (defined as the highest of (a) the prime rate as announced by Bank of America, N.A., (b) the Federal Funds Rate plus 0.50% and (c) Term Secured Overnight Financing Rate ("SOFR") for an interest period of one month plus 1.00% with a 1.00% floor) plus an applicable margin rate of 0.50% for the first two fiscal quarters after the date of the Credit Agreement Amendment, and thereafter at an applicable margin rate ranging from 0.125% to 0.750% based on the Company's consolidated net leverage ratio or (ii) Term SOFR rate (calculated as the Secured Overnight Financing Rate published on the applicable Reuters screen page plus a spread adjustment of 0.10%, 0.15% or 0.25% depending on if the Company selects a one-month, three-month or six-month interest period, respectively, for the applicable loan with a 0% floor), plus an applicable margin rate of 1.50% for the first two full fiscal quarters after the date of the Credit Agreement Amendment, and thereafter at an applicable margin rate ranging from 1.125% to 1.750% based on the Company's consolidated net leverage ratio. The Amended Credit Agreement also provides for other customary fees and charges, including an unused commitment fee with respect to the Revolving Credit Line ranging from 0.150% to 0.200% of the unused lending commitments under the Revolving Credit Line</us-gaap:DescriptionOfInterestRateRiskExposure>
    <us-gaap:LongTermDebt
      contextRef="C_0b560b9e-bc42-4716-8570-2af20d2cca64"
      decimals="-5"
      id="F_3974d7a3-f4ec-4976-9fc3-acee00758dcd"
      unitRef="U_USD">231300000</us-gaap:LongTermDebt>
    <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity
      contextRef="C_0b560b9e-bc42-4716-8570-2af20d2cca64"
      decimals="-5"
      id="F_2d2dc8ab-7844-4a58-bb20-3f38963c8020"
      unitRef="U_USD">450000000</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
    <us-gaap:LongTermDebt
      contextRef="C_ec1dd730-3062-4268-8e06-714c3ed2af24"
      decimals="-5"
      id="F_723ba245-1356-486e-b98b-68c14e1825e9"
      unitRef="U_USD">400000000</us-gaap:LongTermDebt>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      id="F_2addddaa-c963-4954-a21d-d00d348de6c6">&lt;p style="text-indent:0;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;7.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Arial;min-width:fit-content;"&gt;            &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Common and Common Equivalent Shares:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Basic net income per common share is calculated by dividing net income by the weighted average number of common shares outstanding during the period. Diluted net income per common share is calculated by dividing net income by the weighted average number of common and potential common shares outstanding during the period. Potential common shares consist of outstanding restricted stock and stock options and is calculated using the treasury stock method.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:9pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;The calculation of shares used in the basic and diluted net income per common share calculation for the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;three and nine months ended September 30, 2023 and 2022 is as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.07%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.498%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.88%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.178%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.978%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.398%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;"&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;"&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;"&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Weighted average number of common shares outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;82,543&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;82,126&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;82,127&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;84,122&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;"&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Weighted average number of dilutive common share&lt;br/&gt;&#160;&#160;&#160;equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;407&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;650&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;365&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;699&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;"&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Weighted average number of common and common&lt;br/&gt;&#160;&#160;&#160;equivalent shares outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;82,950&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;82,776&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;82,492&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;84,821&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;"&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Antidilutive securities (restricted stock and stock options) not included in the diluted net income per common share calculation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;888&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;1,201&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;273&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:5.36pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      id="F_f21cf8ae-4855-417a-9b91-23c9ff6c689f">&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;The calculation of shares used in the basic and diluted net income per common share calculation for the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;three and nine months ended September 30, 2023 and 2022 is as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.07%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.498%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.88%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.178%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.978%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.398%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;"&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;"&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;"&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Weighted average number of common shares outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;82,543&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;82,126&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;82,127&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;84,122&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;"&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Weighted average number of dilutive common share&lt;br/&gt;&#160;&#160;&#160;equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;407&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;650&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;365&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;699&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;"&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Weighted average number of common and common&lt;br/&gt;&#160;&#160;&#160;equivalent shares outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;82,950&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;82,776&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;82,492&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;84,821&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;"&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Antidilutive securities (restricted stock and stock options) not included in the diluted net income per common share calculation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;888&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;1,201&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;273&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_e5943398-0732-4d17-9fe7-25777d223b65"
      decimals="-3"
      id="F_67c1160e-c408-4dc0-850b-663f5f75af84"
      unitRef="U_shares">82543000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_350c5db7-f64b-4e63-97fa-733cc8e8f783"
      decimals="-3"
      id="F_bc293ef6-848f-46aa-b6ed-e375d468e477"
      unitRef="U_shares">82126000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      decimals="-3"
      id="F_c0a0e541-1ff4-454a-8ce1-ea90c445b9b6"
      unitRef="U_shares">82127000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72"
      decimals="-3"
      id="F_dc452491-2f95-4ba8-a19e-b26f5c5ae2b1"
      unitRef="U_shares">84122000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="C_e5943398-0732-4d17-9fe7-25777d223b65"
      decimals="-3"
      id="F_6cd3fada-f28e-4b41-9588-4b263e5d926e"
      unitRef="U_shares">407000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="C_350c5db7-f64b-4e63-97fa-733cc8e8f783"
      decimals="-3"
      id="F_8ab90170-ca1a-4ebe-af9f-96b991349964"
      unitRef="U_shares">650000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      decimals="-3"
      id="F_cd61e4ec-7575-45d7-98b3-9215a4dff5c6"
      unitRef="U_shares">365000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72"
      decimals="-3"
      id="F_475c21e4-b0f2-41c2-98cc-cdc6210ea3b0"
      unitRef="U_shares">699000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_e5943398-0732-4d17-9fe7-25777d223b65"
      decimals="-3"
      id="F_006cbebe-6cfc-48de-bec7-f486c6d861e7"
      unitRef="U_shares">82950000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_350c5db7-f64b-4e63-97fa-733cc8e8f783"
      decimals="-3"
      id="F_23b5e724-0a6a-4712-9fbb-caf6e589b5cf"
      unitRef="U_shares">82776000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      decimals="-3"
      id="F_57d616fe-affa-4468-835c-5edae52c0070"
      unitRef="U_shares">82492000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72"
      decimals="-3"
      id="F_82742aab-2891-483b-b886-9cb471337597"
      unitRef="U_shares">84821000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_e5943398-0732-4d17-9fe7-25777d223b65"
      decimals="INF"
      id="F_433b9cb3-f0a2-4805-a157-56837c84bf56"
      unitRef="U_shares">888000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_350c5db7-f64b-4e63-97fa-733cc8e8f783"
      decimals="INF"
      id="F_8277df68-1012-49ae-a68d-d2db0388c4dc"
      unitRef="U_shares">1000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      decimals="INF"
      id="F_217a14e3-26c5-4f18-b24b-ba2be32643c3"
      unitRef="U_shares">1201000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72"
      decimals="INF"
      id="F_ef4e34e1-41a4-4256-af09-1798d37225a2"
      unitRef="U_shares">273000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      id="F_ec64bf19-3694-4ee7-a70f-60219a187d47">&lt;p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;8.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Arial;min-width:fit-content;"&gt;            &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Stock Incentive Plans and Stock Purchase Plans:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s Amended and Restated 2008 Incentive Compensation Plan (the &#x201c;Amended and Restated 2008 Incentive Plan&#x201d;) provides for grants of stock options, stock appreciation rights, restricted stock, deferred stock, and other stock-related awards and performance awards that may be settled in cash, stock or other property.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Under the Amended and Restated 2008 Incentive Plan, options to purchase shares of common stock may be granted at a price not less than the fair market value of the shares on the date of grant. The options must be exercised within &lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;10 years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; from the date of grant and generally become exercisable on a pro rata basis over a &lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;three-year&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; period from the date of grant. The Company issues new shares of its common stock upon exercise of its stock options. Restricted stock awards generally vest over periods of &lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;three years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; upon the fulfillment of specified service-based conditions and in certain instances performance-based conditions. Deferred stock awards generally vest upon the satisfaction of specified performance-based conditions and service-based conditions. The Company recognizes compensation expense related to its restricted stock and deferred stock awards ratably over the corresponding vesting periods. During the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;nine months ended September 30, 2023, the Company granted &lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; million shares of restricted stock to its employees and non-employee directors under the Amended and Restated 2008 Incentive Plan. At &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;September 30, 2023, the Company had &lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;8.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; million shares available for future grants and awards under the Amended and Restated 2008 Incentive Plan.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;   &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Under the Company&#x2019;s Amended and Restated 1996 Non-Qualified Employee Stock Purchase Plan, as amended (the &#x201c;ESPP&#x201d;), employees are permitted to purchase the Company's common stock at &lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;85&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of market value on January 1st, April 1st, July 1st and October 1st of each year. Under the Company&#x2019;s 2015 Non-Qualified Stock Purchase Plan (the &#x201c;SPP&#x201d;), certain eligible non-employee service providers are permitted to purchase the Company&#x2019;s common stock at &lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;90&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of market value on January 1st, April 1st, July 1st and October 1st of each year.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company recognizes stock-based compensation expense for the discount received by participating employees and non-employee service providers. During the nine months ended September 30, 2023, approximately &lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; million shares were issued under the ESPP. At &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;September 30, 2023, the Company had approximately &lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;2.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; million shares reserved for issuance under the ESPP. At &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;September 30, 2023, the Company had approximately &lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;61,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares in the aggregate reserved for issuance under the SPP.  &lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares have been issued under the SPP since 2020.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;During the three and nine months ended September 30, 2023 and 2022, the Company recognized stock-based compensation expense of $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;3.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;9.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;4.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;12.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_86f7c920-c7dd-49eb-b9e5-c81407859e32"
      id="F_2e72ff87-2ad2-4039-b30d-4ba7497bd2e7">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_830bbec2-bf82-42ba-aab7-1b87e55627e6"
      id="F_f95d5c0d-7ab2-4db1-9fd6-075c46d6019c">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_19a977fa-7760-40e4-8833-ab4c31af2173"
      id="F_4bedc097-e7c4-43e2-989c-051ba75df91c">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_0c7585a4-747b-415b-a754-892864d85f80"
      decimals="-5"
      id="F_edc46cc0-7182-452b-ad1f-5af51d5a6244"
      unitRef="U_shares">800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_9340fe71-cf84-4fe9-b488-79ab1cff7146"
      decimals="-5"
      id="F_6c6b18fc-35a2-4b11-83ae-78eab08ae793"
      unitRef="U_shares">8100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="C_a04c17b2-e635-4a34-a0cc-839bf6802112"
      decimals="2"
      id="F_e03143e7-ce7b-464d-9f3a-cc17574f903b"
      unitRef="U_pure">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="C_0be151b0-34b3-4da7-b3ba-2f77da9f751e"
      decimals="2"
      id="F_2ea1923f-5c38-4a7e-acda-3baa2a11a80c"
      unitRef="U_pure">0.90</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_a04c17b2-e635-4a34-a0cc-839bf6802112"
      decimals="-5"
      id="F_82dcd0ed-010c-42b6-8f83-54b7b71e471d"
      unitRef="U_shares">300000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_03cd8a32-d1bc-4934-bd34-28363e85b18a"
      decimals="-5"
      id="F_ebc44efa-a76e-455f-b81d-c695d2b39df6"
      unitRef="U_shares">2200000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_eb46e330-b646-43c3-95f2-112f68583c49"
      decimals="0"
      id="F_218bca35-7cb6-4781-92c7-dad2a70ca641"
      unitRef="U_shares">61000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_c2300a5a-f622-49a9-b54c-dcabb14d6824"
      decimals="-6"
      id="F_118079d5-8260-4326-a772-fb2e3857b439"
      unitRef="U_shares">0</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_e5943398-0732-4d17-9fe7-25777d223b65"
      decimals="-5"
      id="F_bb810f6f-f5ac-4822-892a-0a5140bb546d"
      unitRef="U_USD">3200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      decimals="-5"
      id="F_dfd3dba1-60ad-43ab-8451-11d8ad040d02"
      unitRef="U_USD">9300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_350c5db7-f64b-4e63-97fa-733cc8e8f783"
      decimals="-5"
      id="F_da26af57-bfeb-4802-afd2-faa587c256ff"
      unitRef="U_USD">4100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_18f7fb6a-b81e-443d-bed1-35bc9b77ac72"
      decimals="-5"
      id="F_69105bec-ac33-43a3-8837-aea9ced50872"
      unitRef="U_USD">12900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <md:CommonStockRepurchasesTextBlock
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      id="F_32a48e64-a6f1-42ab-9608-49bc6ab17459">&lt;p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;9.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Arial;min-width:fit-content;"&gt;            &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Common Stock Repurchase Programs:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;In July 2013, the Company&#x2019;s Board of Directors authorized the repurchase of shares of the Company&#x2019;s common stock up to an amount sufficient to offset the dilutive impact from the issuance of shares under the Company&#x2019;s equity compensation programs. The share repurchase program allows the Company to make open market purchases from time-to-time based on general economic and market conditions and trading restrictions. The repurchase program also allows for the repurchase of shares of the Company&#x2019;s common stock to offset the dilutive impact from the issuance of shares, if any, related to the Company&#x2019;s acquisition program. &lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares were purchased under this program during the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;nine months ended September 30, 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;In August 2018, the Company announced that its Board of Directors had authorized the repurchase of up to $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;500.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of the Company&#x2019;s common stock in addition to its existing share repurchase program, of which $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;5.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; million remained available for repurchase as of December 31, 2022. Under this share repurchase program, during the nine months ended September 30, 2023, the Company purchased a nominal number of shares of its common stock for $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;0.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; million representing shares withheld to satisfy minimum statutory withholding obligations in connection with the vesting of restricted stock, resulting in $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;4.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; million remaining available for repurchase under this authorization as of September 30, 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company intends to utilize various methods to effect any future share repurchases, including, among others, open market purchases and accelerated share repurchase programs. The amount and timing of repurchases will depend upon several factors, including general economic and market conditions and trading restrictions.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</md:CommonStockRepurchasesTextBlock>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      decimals="INF"
      id="F_d000cdf2-2ff7-4c01-9d62-6a2028e8f046"
      unitRef="U_shares">0</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="C_4c2decbf-697c-4da3-a4c5-727a578f77dc"
      decimals="-5"
      id="F_94aa2aee-d90d-4a03-80a0-17075755876f"
      unitRef="U_USD">500000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
      contextRef="C_4c2decbf-697c-4da3-a4c5-727a578f77dc"
      decimals="-5"
      id="F_5799655f-0fb2-45cd-8f27-0455393e448d"
      unitRef="U_USD">5500000</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="C_965dd392-85a0-4cd0-8ea9-4961c1f6dc80"
      decimals="-5"
      id="F_0885e3f9-7c14-4389-b748-0bfbd6041fa6"
      unitRef="U_USD">900000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
      contextRef="C_22bf64d7-53dd-4c56-b931-fbaef641de7e"
      decimals="-5"
      id="F_be3956c1-3129-4907-a014-c8d7c9143253"
      unitRef="U_shares">4600000</us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased>
    <md:CoronavirusPandemicCOVIDNineteenDisclosureTextBlock
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      id="F_2a25024b-607e-484b-a36e-c25a0321ce89">&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;10.            Coronavirus Pandemic (&#x201c;COVID-19&#x201d;):&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;COVID-19 has had an impact on the demand for medical services provided by the Company's affiliated clinicians. &lt;/span&gt;&lt;span style="color:#222222;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Beginning in mid-March 2020 and throughout the second quarter of 2020, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;the Company's operating results were significantly impacted by COVID-19, but volumes began to normalize in mid-2020 and substantially recovered throughout 2020 with no material impacts from COVID-19 or its variants since that time. However, due to the continued uncertainties surrounding the timeline of and impacts from COVID-19 and with multiple variant strains still circulating, the Company is unable to predict the ultimate impact of COVID-19 on its business, financial condition, results of operations, cash flows and the trading price of its securities at this time.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;span style="color:#222222;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;CARES Act&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;In March 2020, the Coronavirus Aid, Relief, and Economic Security Act ("CARES Act") was signed into law. The CARES Act is a relief package intended to assist many aspects of the American economy, including providing financial aid to the healthcare industry to reimburse healthcare providers for lost revenue and expenses attributable to COVID-19. The Department of Health and Human Services is administering this program and began disbursing funds in April 2020, of which the Company&#x2019;s affiliated physician practices within continuing operations recognized an aggregate of $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;11.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; million during the three and nine months ended September 30, 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</md:CoronavirusPandemicCOVIDNineteenDisclosureTextBlock>
    <md:ProceedsFromContributionInAidOfReimbursementOfLostRevenue
      contextRef="C_6a82b64e-6fb9-48f9-99fe-5081ff6fca6c"
      decimals="-5"
      id="F_a4a0a148-9225-4404-b241-39fbacc7dc2e"
      unitRef="U_USD">300000</md:ProceedsFromContributionInAidOfReimbursementOfLostRevenue>
    <md:ProceedsFromContributionInAidOfReimbursementOfLostRevenue
      contextRef="C_43c976d5-88bb-433a-adbb-5b5571f16c99"
      decimals="-5"
      id="F_8bc5bc6e-d23d-4533-9aed-e17ccf7afb0d"
      unitRef="U_USD">11400000</md:ProceedsFromContributionInAidOfReimbursementOfLostRevenue>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      id="F_f1d670d8-f539-4c51-93f9-ad01a2ac5384">&lt;p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;11.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Arial;min-width:fit-content;"&gt;            &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Commitments and Contingencies:	&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company expects that audits, inquiries and investigations from government authorities and agencies will occur in the ordinary course of business. Such audits, inquiries and investigations and their ultimate resolutions, individually or in the aggregate, could have a material adverse effect on the Company's business, financial condition, results of operations, cash flows and the trading price of its securities. The Company has not included an accrual for these matters as of September 30, 2023 in its Consolidated Financial Statements, as the variables affecting any potential eventual liability depend on the currently unknown facts and circumstances that arise out of, and are specific to, any particular future audit, inquiry and investigation and cannot be reasonably estimated at this time.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;In the ordinary course of business, the Company becomes involved in pending and threatened legal actions and proceedings, most of which involve claims of medical malpractice related to medical services provided by the Company's affiliated physicians. The Company's contracts with hospitals generally require the Company to indemnify them and their affiliates for losses resulting from the negligence of the Company's affiliated physicians. The Company may also become subject to other lawsuits which could involve large claims and significant costs. The Company believes, based upon a review of pending actions and proceedings, that the outcome of such legal actions and proceedings will not have a material adverse effect on its business, financial condition, results of operations, cash flows and the trading price of its securities. The outcome of such actions and proceedings, however, cannot be predicted with certainty and an unfavorable resolution of one or more of them could have a material adverse effect on the Company's business, financial condition, results of operations, cash flows and the trading price of its securities.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;Although the Company currently maintains liability insurance coverage intended to cover professional liability and certain other claims, the Company cannot assure that its insurance coverage will be adequate to cover liabilities arising out of claims asserted against it in the future where the outcomes of such claims are unfavorable. With respect to professional liability risk, the Company generally self-insures a portion of this risk through its wholly owned captive insurance subsidiary. Liabilities in excess of the Company's insurance coverage, including coverage for professional liability and certain other claims, could have a material adverse effect on the Company's business, financial condition, results of operations, cash flows and the trading price of its securities.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      id="F_db7bad9e-2b2d-4060-91f4-b43e068d75a2">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      id="F_f86f2217-3287-481e-a206-a4830f08c620">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      id="F_25ee6790-1cb0-4b0b-a508-44ed22c0bc21">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag
      contextRef="C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a"
      id="F_2f7b80dc-eedb-4fc8-bc3a-ad4f2dbaad21">false</ecd:NonRule10b51ArrTrmntdFlag>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#F_e8442405-4700-449c-a708-92b165088fb6"
          xlink:label="F_e8442405-4700-449c-a708-92b165088fb6"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_30c66a9a-0756-4d02-9e4a-1f60b3066ad9"
          xlink:label="F_30c66a9a-0756-4d02-9e4a-1f60b3066ad9"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_db831608-272d-4dea-9813-f388fa6a3dd7"
          xlink:label="F_db831608-272d-4dea-9813-f388fa6a3dd7"
          xlink:type="locator"/>
        <link:footnote id="FNT_6b743967-0814-4084-a3b5-92c63ce424bd" xlink:label="FNT_6b743967-0814-4084-a3b5-92c63ce424bd" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">Net loss component is presented within retained deficit on the consolidated balance sheet as the balance is immaterial.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_e8442405-4700-449c-a708-92b165088fb6"
          xlink:to="FNT_6b743967-0814-4084-a3b5-92c63ce424bd"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_30c66a9a-0756-4d02-9e4a-1f60b3066ad9"
          xlink:to="FNT_6b743967-0814-4084-a3b5-92c63ce424bd"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_db831608-272d-4dea-9813-f388fa6a3dd7"
          xlink:to="FNT_6b743967-0814-4084-a3b5-92c63ce424bd"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>53
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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MYI.Z_TON @I:?ZDJ=/<_N=_9>@N2-MJH<M<8%)1YU?\5#[N.V&M _9D&;->
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M \H&X/Q"2O/2L==F\Y:4_ -02P,$%     @ %3AB5VV]OV[5!P  JR4  !@
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M2.!$C [THU?2;[;;<D^?RS43B%M)"H4CLGEBBA,C&A J#HQJ2VU40C&)C5
M* _'"1R(^!"(V!F([]2,B[QLZ>=+)5H*O1IH0>AD'UMC"2+?"PWV$"J.#5ZI
MC<*1[T<F?0 6>]3W8/[)@7_BY)\R55R+(N^4L ["A@M9_-W>@)@G]BP0;&3M
MW ;%26!$)[5!),*>D4$9@ H#;X0U]@8IZ3EY_R+RJN[V+HIHGP"JS4C1+&0C
M=/8+5K9*TY4'_5..AV=4^AR ))%9 >?]9  DBF@X$H@C38W=@>!2L7]=S?>N
MCH?@A^%Q#O:4 9Q/ K.B4P"':930.#2Y0T"" S*R'F,RT"=.^KT>7 F^V0=!
M[3) \L0FY9'(%"(0+**Q->$V#.,X-BLI@W T#(.Q AAT,':*.D5\I[*]E<!#
MZR_::(#L*5"MU.1N@T)L,0<\>8DUXP"*CF;[H#6Q6VQ^J"335;Y/<Y"J;SWZ
M"GLT,E=Z")<$V&QS$$PME(EO,@9P)(E\.L)YT)S8*:1F/_!:[9$KQ')1?E;$
M=9DW1;UNYU[MG9?L48)Q",[WMK.0]#PD R!70>3AL=D>-!YVB[SLKZ:0G_5^
M7G&O%.WVK*!127YTD)"O5D6I%D X%VS]I38?9A0 S6<*N10 X<!:Y"'4L:HZ
M#<2@]K!;[G5-ON+5U2L;O:VUKA+?[O, + ;:/  C,256'D#N*#Z2V*?T!XV'
MW2+ON,FKN5?T&QV!H=\KX:^T .O['Y+YRTA<;!%&/<7$C L B^,@,>-BPQ+/
M3ZPE )"1-/#'JF-0?M@M_3X<R**MX+NB'E%\V)9@.AFL*@!@V/,"JQ  '+%W
M]!GH3VW61W8^9)!^Q"W]SF8#% 1BJR^"J3E7<P@6QYY9$0 L5!K!U+X C,9!
M.%(/9-!\Q*WY]H>BI5H9WG2!6!9U'PO5$H=0O$45:Q<)E25@6&QA9C8) ((3
ML_;3\XXR '*E]G]C^3!(0.*6@/H :ESX$%N @1-OPZ@76:T0@($3#W@+PVB,
MZB#ZB%OT::IZTE$NI2@>&YD_EJH#<+TTZ.D7O"QU+12]3 (#8BLS:\K/0M+S
MD R C&7^H/_(^</&OLF;(;AG2Z4"1/&"/JI/"[5>?B=XLWVK?T)X!P;"%FQ@
M9M@P,#-L&)@9@#>5&2.+ 1E$(G&+Q)]:_;\X^>VD[P]=O,YV EO$69$ =!X.
MK#-: $:P*90@7X&/1_:#9)",Q"T9.Z5T&H>+)4QHG2KKA#'5 P1+%- ,DPT+
M?<\ZR09@%)-@1%*205*2R'F4_5\K"3SP)D[Y^F]/O"_J+;VHM^Q2WDYG;5#"
MQ*V$[_*Z6( ST-E%Q_WX'3$/-$$4-7?X(,K:ZH H?ZS##ZJ6G#G0+,I&@K^[
MWO66YSA"*)LCA#*/]3(0-;:CIX."I9ZS]GYK7RG0>]>=$FI/3/>KC=KA=[]G
M@Q5&G9KX7_^2>4EOZ46]99?R=CHW@[:F;FT]6F'4EJ\Q"7SS# V$83-+TQ&8
MF8 0S,=D1$C203-3MV9V5!FUM6M,$O,'L#D(BR*+)P3SS34S@V"^"HC!<WKT
M\LF&B:?VK9]:E4]3R>X=@L/=PYM%[]OW:8S[=_AZCH'[*;[.NO>&!O?=:TP?
M<_%45#4JV4H]2O4*-5;1O1G474B^;5]]>>12\DW[<<WR)1,:H+Y?<2[W%_H!
MA_>S9O\ 4$L#!!0    ( !4X8E<?VNWKVP(  $$(   8    >&PO=V]R:W-H
M965T<R]S:&5E=#4N>&ULK59M;]HP$/XKIZR:BD2;$"CK.HC$V[1*JX9*NWV8
M]L$D!['FV)GM0/?O9SLAHVU U=8OQ#[?\]R+SW<,MD+^5"FBAH>,<37T4JWS
M*]]7<8H94><B1VY.5D)F1)NM7/LJET@2!\J8'P9!W\\(Y5XT<+*YC :BT(QR
MG$M01981^7N,3&R'7L?;"6[I.M56X$>#G*QQ@?H^GTNS\VN6A&;(%14<)*Z&
MWJAS->M9?:?PE>)6[:W!1K(4XJ?=7"=#+[ .(<-86P9B/AN<(&.6R+CQJ^+T
M:I,6N+_>L7]TL9M8ED3A1+!O--'IT+OT(,$5*9B^%=M/6,5S8?EBP93[A6VE
M&W@0%TJ+K (;#S+*RR]YJ/*P!S \S8"P H1/ ;T#@&X%Z+[40J\"]%YJX:("
MN-#],G:7N"G1)!I(L05IM0V;7;CL.[3)%^6V3A9:FE-J<#J:"*X$HPG1F,!"
MFX\I JU K.":QR)#(#R!B<A,%::V/#:X.SB]YZ1(J &VX'1.I,&EJ&E,6 O.
MX'XQA=.3%IP Y7"7BD(9(C7PM7':FO;CRL%QZ6!XP,$NW A#K&#&$TP:\-/C
M^/='\+Y)5IVQ<)>Q<7B4<('Y.72#-H1!V&WP9_)R>-@4SO]9G_VS]4?)Z-;E
MTW5\W0-\52G4A0/?1TNEI7G^/YJNNB3K-9/9EGBE<A+CT#/5IE!NT(O>ONGT
M@P]->7Y-LNEKDLU>B>S1C?3J&^D=8X^^F$<H#SS8ST*I5AM&&T(963(\,W/F
M;$&8N4","TDU1=6&._+0AKF0KI&/M)9T66BK#EI ^<Z;[K9TJ^_<LM-I$P4#
M?[-_8<\U+H++QSK3YSJ=X G/K$'GLM.OE<JT^7L],4.Y=L-(02P*KLOZKJ7U
MO!NY-O]$/NY<33H-\JF9C^4X^TM?#M<;(M>4*V"X,J:"\W>F9<MR8)4;+7+7
MD9="F_[NEJF9\2BM@CE?":%W&VN@_M<0_0%02P,$%     @ %3AB5YJ_!"C5
M#P  _YH  !@   !X;"]W;W)K<VAE971S+W-H965T-BYX;6S-76UOVS@2_BM"
M;G%H@:811;WVD@#;..3U<'M7M-N[#XO]H-A*+-2VO+;<=._7'Z6ZIDF.QZ([
M08L%MK%-/D/QX=L\'%*7C\WJXWI:56WP>3Y;K*_.IFV[?'5QL1Y/JWFY?MDL
MJX7ZY;Y9S<M6?5P]7*R7JZJ<])GFLXLH#-.+>5DOSJXO^^_>KJXOFTT[JQ?5
MVU6PWLSGY>K/U]6L>;PZ8V=?OWA7/TS;[HN+Z\ME^5"]K]H/R[<K]>EBAS*I
MY]5B73>+8%7=7YW]S%[)(NXR]"G^4U>/Z[V_@^Y1[IKF8_?AS>3J+.Q*5,VJ
M<=M!E.J?3]5--9MU2*H<?VQ!SW8VNXS[?W]%%_W#JX>Y*]?533/[;SUIIU=G
M^5DPJ>[+S:Q]USS^O=H^4-+AC9O9NO]_\+A-&YX%X\VZ;>;;S*H$\WKQY=_R
M\[8B]C(P?B!#M,T0#<W MQFXE2&*#F2(MQEB*P-/#V1(MAD2*T-\*$.ZS9#:
M13J4(=MFR'JROM1N3\VH;,OKRU7S&*RZU JM^Z/GM\^M&*D775-\WZ[4K[7*
MUU[?-(MU,ZLG95M-@O>M^D>ULW8=-/?![1^;NOTS>/9A46XFM?K]>7 >?'@_
M"I[]]#SX*:@7P:_39K,N%Y/UY46KRM(A7HRW=F^^V(T.V/VU:<L9D&V$9[MI
MYG/5@-^WS?AC\-LOU?RN6OT.P-SB,#]/U .IGE#.@K=E/3E7SW)3+FM5) Q4
M' $=CS?SS:ROR7^WTVH5J-*J\6':==Q/5?#/9KW&X"4._ZYJU<BBL$?5?3VN
MVP-0%ZH![%I!M&L%48\='\!^7<[*Q;@*RE:ACU\&G+T(HC!B$*]?D-(>J1OH
M/EWG19H6T>7%IWT>@61I;*:Y==.P,"[2(C73"2 =9YF92+J)SEF2L#S9I3.J
MAN^JA@^IFA?!^VFYJM:#J@A%[":75^ME.:ZNSE3K6%>K3]79]5__PM+P;U"'
M^ *6F!49\3 ,K=JDM"HHP201F,%?O.,O1OG[EYK.WRS&S;P*GG4]\#E$6.S4
M\7G$6)Y;;1JUY%DIMY1@@A),'JT-@XAD1T2"$C&JUVJFV?0+$#6[J&DC6"AN
M9MVH6+;MJK[;M.7=K K:)E@TBK%%NVIF"N5!335MI<K= H5]C1O]C4$C[4T"
M/&'(+;919%^V78O,ZK^"TIZ$GI!QF,%TQV"*5N:'A5KLSNK_J3EHVLPF'3,/
M:DH*GG4</@\4K_7BDZ*I7T&\Z-E51+?E9XB"%"A@FMH]#BV0+P>48&)0^261
M28.N;$=7AM*U72NM^[62ZGP;Q=MF,5'KDFJ^G#5_5M7VMV;9=<H7]M?+S6H\
M5:O\8*EFP+Z_ M]#U&9N6V>9-?>/T++[,CO$HJ"T*(G #&+S';'Y]R?V1;#N
M%SP0P6CQ?-<WN<-=$KJ+&TJ3@A),$H$9+:'8M80";0EO%/G]PEV-L]T$N:K'
MG??1TPD1AZ+Y$E>X*WR+M,(=(ZTD@K)$D@C,H(*%VI,.3R8#ZTTXK"\K6[3]
M2L_2U.U0I%8%*9JD0C.)W)-$&$JD:%;W5=UN.G?/ETL4V9M+YG:@!*"2TJ@@
M19-4:":56M=@N+#1"T7GG58Y"90/N*P6Z[+W0*K/W=\5R&'DU'H<\\1:O^"&
M?1<P@VP*4IN2"LVD1NLJ#!=6WE5?UQL]-;L5#4B)*X*<,Y:F-B>4JL7M,*."
MU*BD0C-)T6()P]620Z2@8QZE^#!B@/H +0A)K0I2-$F%9I*HA1:&BQY[:NXO
MY6HG548@>:Y0D&=9F#E=*W%7>UED<P*I'$G,8F;W&4">8#RQDDDP698F>0H+
M&4PK&0R7,@!5]WA54>H'(^8*"'G&\AAHZ:2Z!2F:I$(S:=0*!\,E#I]]"^:*
M!.#&Q38=OG,!@,%;%U!"=^\"2(5N7C M%3!<*SAE^P*']&[HKH-_8 .#U*X@
M19-4:":-VL]GN*,_:!>#N?XV3U-W**?TN6])T00IFJ1",_=4M2 0X8+ WNCT
MOEJJ/A<>GEPBUVW/U3R76B/%:)O.&)VXW9$ L"(/TZ2P]U7==.<QL_NEA)(Q
MIJ;_"!Z=(NUI1[BG#8Q.QVN*U,6.7!=;U6<("":D=@4IFJ1",VG<BQX8'#YP
M=!45N9XNN.",@  "9\$)@,$+3B AM. $DR$+SDA[NY%W&,'QJB*-(XB 0 )X
MP4EJ5Y"B22HTDT;M'T<$T021Z\)&&>-."R<-)R!%$Z1H\FB%F&QH1S?"'5W2
M#>D(<C8C;N];XD7R9HT230Q[!$EEU&1-^]X1[GM_MWWIR'6Y66J[=J-M*B/:
MS!X@02!NSSFDGC85FDF:]K2C'R"8 %,9\?)Y3X: &! !,R&E44&*)JG0S :A
MA84(%Q9\MYYQ.&_^\N.=U-4=SIUE(:E&0(5F,J(U@NCT8 "T9Y%&!42N")%!
M:TQ2V8 435*AF?'&6C;@N&SP#=O/.+)WY#'@]P/;SZ1&!2F:I$(SJ=3Z!L?U
MC5.VG[FK2"0LMYT'W+#O,G2034%J4U*AF=1HS8+CFH7/]C,'9($TYH4=K<J!
M,PB<V]T%!DOMS7Z\_-ZU_12;_7SO$,5IF_WH8$9[C +8S>=1!HUGM <I:$]2
M/(7\P;7\P7'Y8T_H^\=F@>NTW'7Z\SB);;%ZM$UG"'VV?G<+@!5%FD9VC"^0
M[CQ*<JMO22@9BXLX"6%)@FM)@@_:>]_7^8[7%*4(,.+ CG[<"]I.0R<5'TC1
M)!6:2:/6*#BN40S2^;@K _ PBYQ9@?00 RF:($631RO$9$.+#QP7'TAU/@[N
MM3,[O@\ODC=KI$+"L$>05$9-UK1"P'^ 8PH@PZ[GSWC.;(*/2P@PD'UN"Z\&
M[S[T%"("UR("QT6$[Z[SX>7SG@R'J1&D1@4IFJ1",T_/:C4B?II3#3BL+X^Q
M*T4PET92FX(435*AF31J)2+^IC,-((.D@19;-/-\OLV?*T/8BBUIH205FDF*
MUB!B7(/X!J4/1_8F!] D<J!_41H5I&B2"LVD4@L<,2YPG*+TQ:XD$;/(]H]Q
MP]ZW#@RQ*4AM2BHTDYJ]"R!PT<)'Z8LA_8#%F1V&%[NBQ3ESAC,8S#E!@I??
MN[:)T,S:U@)(C L@IRA].*3W8 9%0; (6B^0"B"D:)(*S:11"R#QH ,2@R(R
M8^ H Q2[&KN1%6[L*@ &QJX"Z:#852@9%KL::U$B'G3VP"MV%8?T;NA $ ,<
MNTIJ5Y"B22HTDT:M4L2##DC8!R-@^H"C# 5+N7V$)':EA3PJ;$Y<L"+G:>BL
M>($X!I[99T,EE"POPO3 G2^Q5@1B7!$X<H($KBA2)SYVG7A5G7$&M'-2/YX4
M35*AF9<O:3\^P?WX08IV KC9<13:F\^X*=\E*2F:($631RO$9$.[XPGNCI,J
MVHGK-J>A'=:(%\B;,]+#$$,>0%*9-!G3OGJ"^^K?3<U.H#,.A;U=@9?>F]XA
M-@6I34F%9O*K'?@$=^"_N_"-E\]WSDR@:R/="9/4J"!%DU1H9H/0LD&"RP:^
M :XXG#=_KL!@+R 30%ZPO2320DDJ-).1O0LD<6GAU*T('-:;&>C&!$!<(+4J
M2-$D%9I)I!87$EQ<.&$S D?TYM!5(L[MLX6)JQQ$=N\BC9Z@0C-)T7I&@NL9
MW[ 9@2-[DP-$-T20?$=J5I"B22HTDTRM:B2XJG'*=D3B*@@\# M[H4D9[7 [
MR*8@M2FIT$QJM)Z2X'J*SW9$ MR@F&7.VI_T0H=!-@6I34F%9EYKK+61%-=&
M3MFSP"%]Q[P4NHFA<(<\4JN"%$U2H9DD:DDE'727A'VRGH/DN8)#$1999L>(
MI6[00FZ?X[Z%P/*TB.SSH$"Z<\ZX?0<!E"R+\R2#-:=4*QCIH%L:#EU! %<4
M:9A!"MS]P%,.!&21VA6D:)(*S:11"Q7IH)LD!NGP*: "0!L6VW3XA@4 !FY8
M .F@#0LH&;)AD6K'/<4=]U,V+'!([W;N>N8'-BQ([0I2-$F%9M*HO?T4]_8'
M;5BD[K6$*<\S>]&*F_)=(9&B"5(T285FDK;WA@C<LS]I)>4ZVG8,%&[5FS_:
M%T&0B@!4:"9_6@1(!U^HN!_, *\-W(L2BS0K[,-6(R!=SIW)Q77ZBR+)X\R>
M7 !Q@"?.A8I0LBAA>7Q@<M&.=>I]G^+QBB*]^B %@A!X$4'. NE]BJ1HD@K-
MI%$[X>F@H(9A:V#7(8:=!>"%"*ZS ("!S@+@A4/. N2L'W86,NT29X/N+O1R
M%G!(WW:> 3<BPLX"J5U!BB:IT$P:M5.<X4[QH$54YGJ<4:[^L]HW;LIW$B9%
M$Z1H\FB%F&QH#SS#/7#2J(\,B-E72U^;--*X %(T,>@)))5-DS/M;F<_0%P
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MVRROSE0GNVO:MIGW?TZK4CD^70+U^WW3M%\_= 8>F]7'_I&N_P]02P,$%
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M$+3HW8H))YDZV)\)%VV"&D:BW454&HC[2T+X=B(=5 VT_P]02P,$%     @
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MX&YN7J=L.U\[T:)RW68OM.E=;EB8GP5(&V">9T+HX\1NT/]^DC=02P,$%
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MSTS 30,</B/ZP88PN&A:4L@XX$U52YT11)A"R,E 0#"GBEWC#JK:ME+&I*!
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MKU[RKPRVT;:L#L;H@X#R*9W3#WMBBZ?6LWX"$M+ QHM7$)F\EX+TDJM<( $
M.Q#JI(A]18=IZ*E^*&M#,V1(!ZM$4,;]2.#$0C1-YE #WI$G &/,M)E#X;D*
MO<9/TP4!\$F#2\Z08XQ[]B#P'0#2_FR$B5&C#WS?(\1<O&/.H#_-,/)/U &
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MAN.X6O,*>/$/]0D=% 1D2W<MJ"E<U]NJA5,""=/09TD&9V[&XM!/@QC.!B?
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M    >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;(U576^;,!1]SZ^X8M/42:B
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MF-$+B-HIT/^54G:W<0Z:-W7Z#U!+ P04    "  5.&)7XYCM8&T"   '!P
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M+Y;VI4+E#.S]0DKSI+CMV;Y]V1]02P,$%     @ %3AB5TV;70]% @  ) 8
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MP[''82!949T<K)B4+*LNMT"4CG6 FM\P)I\'^C"B.7R:_0902P,$%     @
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MXGPL\&S"Z XQ92UIZJ+(?N$M\Y40U2B/@LFWB?03L]LPI!LB.'J $)(M7J:
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MU>3N4)A6[I6C\0"WO].:CH&_2.-_(_\#4$L#!!0    ( !4X8E<^8,1\'@,
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MYOQHUGM^H<;M6&@NUUW<'OGC]D_/U69WM&8CL!3>,AD_V,&$^X<VY$>V5*6
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MIW&VN"4X(*D,$/O7E/+CBFR@G*,T_Q=02P,$%     @ %3AB5Z"2/MA0 @
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MZY^WOR\?F[V'<,?9P2^-U2]02P,$%     @ %3AB5XB,J3>E 0  +QD  !,
M  !;0V]N=&5N=%]4>7!E<UTN>&ULS9G-;H,P$(1?!7&-@F,[37^4Y-+VVN;0
M%W!A"2B +=M)D[>O(3]2JQ0U2J7.!0N\.S-XI>\ T[>=(1=MZZIQL[CPWCPP
MYM*":N42;:@).[FVM?+AUBZ94>E*+8F)T6C"4MUX:OS0MQKQ?/I$N5I7/GK>
MAL>NU,TLME2Y.'K<%[9>LU@94Y6I\F&?;9KLF\OPX)"$SJ[&%:5Q@U 0L[,.
M[<[/!H>^UPU96V84+93U+ZH.56Q;,>=W%;FD7^),1IWG94J93M=U:$F<L:0R
M5Q#YNDKVHH-^9Q].F/97?K5_)]-G&"H75AL7)F;I<KOC2-KNH0E"9'W9_XHG
MQR!]]?M1.^V,LE]ZA^/]T';5S<.Q;KG^C+_.^*1_80X!DD."Y!B#Y+@!R3$!
MR7$+DN,.),<]2 X^0@F"0E2.@E2.PE2. E6.0E6.@E6.PE6. E:.0E:!0E:!
M0E:!0E:!0E:!0E:!0E:!0E:!0E:!0E:!0E:)0E:)0E:)0E:)0E:)0E:)0E:)
M0E:)0E:)0E:)0M8Q"EG'_TG6=ZU7?_T)OUV36I7-T9]U_TGFGU!+ 0(4 Q0
M   ( !4X8E<'04UB@0   +$    0              "  0    !D;V-0<F]P
M<R]A<' N>&UL4$L! A0#%     @ %3AB5\O*$LOM    *P(  !$
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M970R+GAM;%!+ 0(4 Q0    ( !4X8E?2@$'LU0(  #$)   8
M  " @1L5  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    "  5
M.&)7;;V_;M4'  "K)0  &               @($F&   >&PO=V]R:W-H965T
M<R]S:&5E=#0N>&UL4$L! A0#%     @ %3AB5Q_:[>O; @  00@  !@
M         ("!,2   'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0
M   ( !4X8E>:OP0HU0\  /^:   8              " @4(C  !X;"]W;W)K
M<VAE971S+W-H965T-BYX;6Q02P$"% ,4    "  5.&)7-Q??BA,(  #I(P
M&               @(%-,P  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L!
M A0#%     @ %3AB5ZZS.CKK @  3 L  !@              ("!ECL  'AL
M+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( !4X8E>]%G660P(
M (H&   8              " @;<^  !X;"]W;W)K<VAE971S+W-H965T.2YX
M;6Q02P$"% ,4    "  5.&)7U_Z"M+ &   V$   &0              @($P
M00  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( !4X8E<%
M^"X^/0,  "X'   9              " @1=(  !X;"]W;W)K<VAE971S+W-H
M965T,3$N>&UL4$L! A0#%     @ %3AB5]Q*CQ99!0  =@T  !D
M     ("!BTL  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4
M"  5.&)7!BMIB44'   0$@  &0              @($;40  >&PO=V]R:W-H
M965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( !4X8E>PZ!U5G ,  &P(   9
M              " @9=8  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L!
M A0#%     @ %3AB5Q/\%?(9"@  .QP  !D              ("!:EP  'AL
M+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    "  5.&)7+;="_7 #
M   9"0  &0              @(&Z9@  >&PO=V]R:W-H965T<R]S:&5E=#$V
M+GAM;%!+ 0(4 Q0    ( !4X8E>&0!S0Q@4  (X0   9              "
M@6%J  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @ %3AB
M5X'S6<N$!   T0L  !D              ("!7G   'AL+W=O<FMS:&5E=',O
M<VAE970Q."YX;6Q02P$"% ,4    "  5.&)7N(7AQ? $  ">"@  &0
M        @($9=0  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0
M   ( !4X8E?KRS8QR 4  )D/   9              " @4!Z  !X;"]W;W)K
M<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ %3AB5P4M= GS @  608
M !D              ("!/X   'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q0
M2P$"% ,4    "  5.&)7H-9>MF4#  !P"   &0              @(%I@P
M>&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( !4X8E?^\P=P
M#@0  )X)   9              " @06'  !X;"]W;W)K<VAE971S+W-H965T
M,C,N>&UL4$L! A0#%     @ %3AB5PK0>I3H @  :P8  !D
M ("!2HL  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    "  5
M.&)7X!Q\ZBP#  !?!P  &0              @(%IC@  >&PO=V]R:W-H965T
M<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( !4X8E?CF.U@;0(   <'   9
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M970S,"YX;6Q02P$"% ,4    "  5.&)7(F-9?:8"  "N!@  &0
M    @(&?H   >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    (
M !4X8E>:X:76\ ,  %P4   9              " @7RC  !X;"]W;W)K<VAE
M971S+W-H965T,S(N>&UL4$L! A0#%     @ %3AB5U_UK"TL!   EQD  !D
M             ("!HZ<  'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"
M% ,4    "  5.&)7JGP(X X"  !#!   &0              @($&K   >&PO
M=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( !4X8E<^8,1\'@,
M %\)   9              " @4NN  !X;"]W;W)K<VAE971S+W-H965T,S4N
M>&UL4$L! A0#%     @ %3AB5T02^/@; @  .P0  !D              ("!
MH+$  'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4    "  5.&)7
MD0 _]=8*  "N1P  &0              @('RLP  >&PO=V]R:W-H965T<R]S
M:&5E=#,W+GAM;%!+ 0(4 Q0    ( !4X8E=#&036D ,  .H+   9
M      " @?^^  !X;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%
M  @ %3AB5T5=P^#7!@  MS@  !D              ("!QL(  'AL+W=O<FMS
M:&5E=',O<VAE970S.2YX;6Q02P$"% ,4    "  5.&)7*?"#;\0$  "O)
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M+G)E;'-02P$"% ,4    "  5.&)79,>C/-T#   6'   #P
M@ &<U0  >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ %3AB5RE=B*"3 0
MXA@  !H              ( !IMD  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR
M96QS4$L! A0#%     @ %3AB5XB,J3>E 0  +QD  !,              ( !
M<=L  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     #$ ,0!.#0  1]T

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>148</ContextCount>
  <ElementCount>211</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>37</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="md-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20230930/taxonomy/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="md-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Consolidated Balance Sheets (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20230930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited</Role>
      <ShortName>Consolidated Balance Sheets (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="md-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100020 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20230930/taxonomy/role/ConsolidatedBalanceSheetsUnauditedParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="md-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100030 - Statement - Consolidated Statements of Income and Comprehensive Income (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited</Role>
      <ShortName>Consolidated Statements of Income and Comprehensive Income (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="md-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100040 - Statement - Consolidated Statements of Income and Comprehensive Income (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnauditedParenthetical</Role>
      <ShortName>Consolidated Statements of Income and Comprehensive Income (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="md-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100050 - Statement - Consolidated Statements of Equity (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfEquityUnaudited</Role>
      <ShortName>Consolidated Statements of Equity (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="md-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100060 - Statement - Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited</Role>
      <ShortName>Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="md-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="md-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="md-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995455 - Disclosure - Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20230930/taxonomy/role/DisclosureBasisOfPresentation</Role>
      <ShortName>Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="md-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995465 - Disclosure - Cash Equivalents and Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20230930/taxonomy/role/CashEquivalentsAndInvestments</Role>
      <ShortName>Cash Equivalents and Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="md-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995475 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20230930/taxonomy/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="md-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995485 - Disclosure - Accounts Receivable and Net Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20230930/taxonomy/role/AccountsReceivableAndNetRevenue</Role>
      <ShortName>Accounts Receivable and Net Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="md-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995505 - Disclosure - Accounts Payable and Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20230930/taxonomy/role/AccountsPayableAndAccruedExpenses</Role>
      <ShortName>Accounts Payable and Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="md-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995515 - Disclosure - Line of Credit and Long Term Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20230930/taxonomy/role/DisclosureLineOfCreditAndLongTermDebt</Role>
      <ShortName>Line of Credit and Long Term Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="md-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995525 - Disclosure - Common and Common Equivalent Shares</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20230930/taxonomy/role/CommonAndCommonEquivalentShares</Role>
      <ShortName>Common and Common Equivalent Shares</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="md-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995535 - Disclosure - Stock Incentive Plans and Stock Purchase Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20230930/taxonomy/role/StockIncentivePlansAndStockPurchasePlans</Role>
      <ShortName>Stock Incentive Plans and Stock Purchase Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="md-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995545 - Disclosure - Common Stock Repurchase Programs</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20230930/taxonomy/role/CommonStockRepurchasePrograms</Role>
      <ShortName>Common Stock Repurchase Programs</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="md-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995555 - Disclosure - Coronavirus Pandemic (COVID-19)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20230930/taxonomy/role/DisclosureCoronavirusPandemicCovid191</Role>
      <ShortName>Coronavirus Pandemic (COVID-19)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="md-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995565 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20230930/taxonomy/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="md-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995585 - Disclosure - Cash Equivalents and Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20230930/taxonomy/role/CashEquivalentsAndInvestmentsTables</Role>
      <ShortName>Cash Equivalents and Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.mednax.com/20230930/taxonomy/role/CashEquivalentsAndInvestments</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="md-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995595 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20230930/taxonomy/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.mednax.com/20230930/taxonomy/role/FairValueMeasurements</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="md-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995605 - Disclosure - Accounts Receivable and Net Revenue (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20230930/taxonomy/role/AccountsReceivableAndNetRevenueTables</Role>
      <ShortName>Accounts Receivable and Net Revenue (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.mednax.com/20230930/taxonomy/role/AccountsReceivableAndNetRevenue</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="md-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995615 - Disclosure - Accounts Payable and Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20230930/taxonomy/role/AccountsPayableAndAccruedExpensesTables</Role>
      <ShortName>Accounts Payable and Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.mednax.com/20230930/taxonomy/role/AccountsPayableAndAccruedExpenses</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="md-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995625 - Disclosure - Common and Common Equivalent Shares (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20230930/taxonomy/role/CommonAndCommonEquivalentSharesTables</Role>
      <ShortName>Common and Common Equivalent Shares (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.mednax.com/20230930/taxonomy/role/CommonAndCommonEquivalentShares</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="md-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995635 - Disclosure - Basis of Presentation - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20230930/taxonomy/role/DisclosureBasisOfPresentationAdditionalInformationDetail</Role>
      <ShortName>Basis of Presentation - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="md-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995645 - Disclosure - Cash Equivalents and Investments - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20230930/taxonomy/role/CashEquivalentsAndInvestmentsAdditionalInformationDetail</Role>
      <ShortName>Cash Equivalents and Investments - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="md-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>995655 - Disclosure - Cash Equivalents and Investments - Schedule of Investments (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20230930/taxonomy/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail</Role>
      <ShortName>Cash Equivalents and Investments - Schedule of Investments (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="md-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>995665 - Disclosure - Fair Value Measurements - Schedule of fair value on a recurring basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20230930/taxonomy/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of fair value on a recurring basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="md-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>995675 - Disclosure - Fair Value Measurements - Schedule of financial instruments that are not carried at fair value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20230930/taxonomy/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of financial instruments that are not carried at fair value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="md-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>995695 - Disclosure - Accounts Receivable and Net Revenue - Schedule of Accounts Receivable, Net (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20230930/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail</Role>
      <ShortName>Accounts Receivable and Net Revenue - Schedule of Accounts Receivable, Net (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="md-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>995705 - Disclosure - Accounts Receivable and Net Revenue - Schedule of Net Revenue (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20230930/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail</Role>
      <ShortName>Accounts Receivable and Net Revenue - Schedule of Net Revenue (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="md-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>995715 - Disclosure - Accounts Receivable and Net Revenue - Schedule of Net Patient Service Revenue by Type of Payor (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20230930/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail</Role>
      <ShortName>Accounts Receivable and Net Revenue - Schedule of Net Patient Service Revenue by Type of Payor (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="md-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>995725 - Disclosure - Business Combinations and Discontinued Operations -  Additional information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20230930/taxonomy/role/BusinessCombinationsAndDiscontinuedOperationsAdditionalInformationDetail</Role>
      <ShortName>Business Combinations and Discontinued Operations -  Additional information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="md-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>995735 - Disclosure - Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20230930/taxonomy/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail</Role>
      <ShortName>Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="md-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>995745 - Disclosure - Accounts Payable and Accrued Expenses - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20230930/taxonomy/role/AccountsPayableAndAccruedExpensesAdditionalInformationDetail</Role>
      <ShortName>Accounts Payable and Accrued Expenses - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="md-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>995755 - Disclosure - Line of Credit and Long Term Debt (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20230930/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails</Role>
      <ShortName>Line of Credit and Long Term Debt (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.mednax.com/20230930/taxonomy/role/DisclosureLineOfCreditAndLongTermDebt</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="md-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>995765 - Disclosure - Common and Common Equivalent Shares - Schedule of Calculation of Shares Used in Basic and Diluted Net Income Per Share (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20230930/taxonomy/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail</Role>
      <ShortName>Common and Common Equivalent Shares - Schedule of Calculation of Shares Used in Basic and Diluted Net Income Per Share (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="md-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>995785 - Disclosure - Stock Incentive Plans and Stock Purchase Plans - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20230930/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail</Role>
      <ShortName>Stock Incentive Plans and Stock Purchase Plans - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="md-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>995795 - Disclosure - Common Stock Repurchase Programs - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20230930/taxonomy/role/CommonStockRepurchaseProgramsAdditionalInformationDetail</Role>
      <ShortName>Common Stock Repurchase Programs - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="md-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>995805 - Disclosure - Coronavirus Pandemic (COVID-19) - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20230930/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail</Role>
      <ShortName>Coronavirus Pandemic (COVID-19) - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.mednax.com/20230930/taxonomy/role/DisclosureCoronavirusPandemicCovid191</ParentRole>
      <Position>41</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="md-20230930.htm">md-20230930.htm</File>
    <File>md-20230930.xsd</File>
    <File>md-20230930_cal.xml</File>
    <File>md-20230930_def.xml</File>
    <File>md-20230930_lab.xml</File>
    <File>md-20230930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img259349275_0.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="523">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>58
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "md-20230930.htm": {
   "nsprefix": "md",
   "nsuri": "http://www.mednax.com/20230930",
   "dts": {
    "inline": {
     "local": [
      "md-20230930.htm"
     ]
    },
    "schema": {
     "local": [
      "md-20230930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-sub-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "md-20230930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "md-20230930_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "md-20230930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "md-20230930_pre.xml"
     ]
    }
   },
   "keyStandard": 192,
   "keyCustom": 19,
   "axisStandard": 14,
   "axisCustom": 1,
   "memberStandard": 22,
   "memberCustom": 15,
   "hidden": {
    "total": 6,
    "http://xbrl.sec.gov/dei/2023": 4,
    "http://fasb.org/us-gaap/2023": 2
   },
   "contextCount": 148,
   "entityCount": 1,
   "segmentCount": 37,
   "elementCount": 490,
   "unitCount": 4,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 523,
    "http://xbrl.sec.gov/ecd/2023": 4,
    "http://xbrl.sec.gov/dei/2023": 29
   },
   "report": {
    "R1": {
     "role": "http://www.mednax.com/20230930/taxonomy/role/CoverPage",
     "longName": "100000 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.mednax.com/20230930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited",
     "longName": "100010 - Statement - Consolidated Balance Sheets (Unaudited)",
     "shortName": "Consolidated Balance Sheets (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "C_5d513fe3-41de-49c7-8231-3b67764cba30",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5d513fe3-41de-49c7-8231-3b67764cba30",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.mednax.com/20230930/taxonomy/role/ConsolidatedBalanceSheetsUnauditedParenthetical",
     "longName": "100020 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Unaudited) (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "C_5d513fe3-41de-49c7-8231-3b67764cba30",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "U_USDollarShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5d513fe3-41de-49c7-8231-3b67764cba30",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "U_USDollarShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited",
     "longName": "100030 - Statement - Consolidated Statements of Income and Comprehensive Income (Unaudited)",
     "shortName": "Consolidated Statements of Income and Comprehensive Income (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "C_e5943398-0732-4d17-9fe7-25777d223b65",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e5943398-0732-4d17-9fe7-25777d223b65",
      "name": "md:PracticeSalariesAndBenefits",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20230930.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnauditedParenthetical",
     "longName": "100040 - Statement - Consolidated Statements of Income and Comprehensive Income (Unaudited) (Parenthetical)",
     "shortName": "Consolidated Statements of Income and Comprehensive Income (Unaudited) (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "C_e5943398-0732-4d17-9fe7-25777d223b65",
      "name": "us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e5943398-0732-4d17-9fe7-25777d223b65",
      "name": "us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfEquityUnaudited",
     "longName": "100050 - Statement - Consolidated Statements of Equity (Unaudited)",
     "shortName": "Consolidated Statements of Equity (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "C_cf213a70-35ae-48c9-9339-37927b488110",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_bbb0586b-efa6-4d4e-b6e9-1b625c1dbc91",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20230930.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited",
     "longName": "100060 - Statement - Consolidated Statements of Cash Flows (Unaudited)",
     "shortName": "Consolidated Statements of Cash Flows (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a",
      "name": "us-gaap:AmortizationOfFinancingCostsAndDiscounts",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20230930.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "C_e5943398-0732-4d17-9fe7-25777d223b65",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20230930.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R9": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.mednax.com/20230930/taxonomy/role/DisclosureBasisOfPresentation",
     "longName": "995455 - Disclosure - Basis of Presentation",
     "shortName": "Basis of Presentation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.mednax.com/20230930/taxonomy/role/CashEquivalentsAndInvestments",
     "longName": "995465 - Disclosure - Cash Equivalents and Investments",
     "shortName": "Cash Equivalents and Investments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.mednax.com/20230930/taxonomy/role/FairValueMeasurements",
     "longName": "995475 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.mednax.com/20230930/taxonomy/role/AccountsReceivableAndNetRevenue",
     "longName": "995485 - Disclosure - Accounts Receivable and Net Revenue",
     "shortName": "Accounts Receivable and Net Revenue",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a",
      "name": "md:AccountsReceivableAndNetRevenueDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a",
      "name": "md:AccountsReceivableAndNetRevenueDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.mednax.com/20230930/taxonomy/role/AccountsPayableAndAccruedExpenses",
     "longName": "995505 - Disclosure - Accounts Payable and Accrued Expenses",
     "shortName": "Accounts Payable and Accrued Expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.mednax.com/20230930/taxonomy/role/DisclosureLineOfCreditAndLongTermDebt",
     "longName": "995515 - Disclosure - Line of Credit and Long Term Debt",
     "shortName": "Line of Credit and Long Term Debt",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a",
      "name": "md:LineOfCreditAndLongTermDebtTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a",
      "name": "md:LineOfCreditAndLongTermDebtTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.mednax.com/20230930/taxonomy/role/CommonAndCommonEquivalentShares",
     "longName": "995525 - Disclosure - Common and Common Equivalent Shares",
     "shortName": "Common and Common Equivalent Shares",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.mednax.com/20230930/taxonomy/role/StockIncentivePlansAndStockPurchasePlans",
     "longName": "995535 - Disclosure - Stock Incentive Plans and Stock Purchase Plans",
     "shortName": "Stock Incentive Plans and Stock Purchase Plans",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.mednax.com/20230930/taxonomy/role/CommonStockRepurchasePrograms",
     "longName": "995545 - Disclosure - Common Stock Repurchase Programs",
     "shortName": "Common Stock Repurchase Programs",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a",
      "name": "md:CommonStockRepurchasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a",
      "name": "md:CommonStockRepurchasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.mednax.com/20230930/taxonomy/role/DisclosureCoronavirusPandemicCovid191",
     "longName": "995555 - Disclosure - Coronavirus Pandemic (COVID-19)",
     "shortName": "Coronavirus Pandemic (COVID-19)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a",
      "name": "md:CoronavirusPandemicCOVIDNineteenDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a",
      "name": "md:CoronavirusPandemicCOVIDNineteenDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.mednax.com/20230930/taxonomy/role/CommitmentsAndContingencies",
     "longName": "995565 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.mednax.com/20230930/taxonomy/role/CashEquivalentsAndInvestmentsTables",
     "longName": "995585 - Disclosure - Cash Equivalents and Investments (Tables)",
     "shortName": "Cash Equivalents and Investments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "21",
     "firstAnchor": {
      "contextRef": "C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.mednax.com/20230930/taxonomy/role/FairValueMeasurementsTables",
     "longName": "995595 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "22",
     "firstAnchor": {
      "contextRef": "C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.mednax.com/20230930/taxonomy/role/AccountsReceivableAndNetRevenueTables",
     "longName": "995605 - Disclosure - Accounts Receivable and Net Revenue (Tables)",
     "shortName": "Accounts Receivable and Net Revenue (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "md:AccountsReceivableAndNetRevenueDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "md:AccountsReceivableAndNetRevenueDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.mednax.com/20230930/taxonomy/role/AccountsPayableAndAccruedExpensesTables",
     "longName": "995615 - Disclosure - Accounts Payable and Accrued Expenses (Tables)",
     "shortName": "Accounts Payable and Accrued Expenses (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.mednax.com/20230930/taxonomy/role/CommonAndCommonEquivalentSharesTables",
     "longName": "995625 - Disclosure - Common and Common Equivalent Shares (Tables)",
     "shortName": "Common and Common Equivalent Shares (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a",
      "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a",
      "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.mednax.com/20230930/taxonomy/role/DisclosureBasisOfPresentationAdditionalInformationDetail",
     "longName": "995635 - Disclosure - Basis of Presentation - Additional Information (Detail)",
     "shortName": "Basis of Presentation - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "26",
     "firstAnchor": {
      "contextRef": "C_7ae55b15-375d-4829-8fee-0964b045a7cf",
      "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7ae55b15-375d-4829-8fee-0964b045a7cf",
      "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.mednax.com/20230930/taxonomy/role/CashEquivalentsAndInvestmentsAdditionalInformationDetail",
     "longName": "995645 - Disclosure - Cash Equivalents and Investments - Additional Information (Detail)",
     "shortName": "Cash Equivalents and Investments - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "27",
     "firstAnchor": {
      "contextRef": "C_d1b666e6-0f27-4c23-9240-3207e18d4a31",
      "name": "us-gaap:MoneyMarketFundsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_d1b666e6-0f27-4c23-9240-3207e18d4a31",
      "name": "us-gaap:MoneyMarketFundsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.mednax.com/20230930/taxonomy/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail",
     "longName": "995655 - Disclosure - Cash Equivalents and Investments - Schedule of Investments (Detail)",
     "shortName": "Cash Equivalents and Investments - Schedule of Investments (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "C_5d513fe3-41de-49c7-8231-3b67764cba30",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5d513fe3-41de-49c7-8231-3b67764cba30",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.mednax.com/20230930/taxonomy/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails",
     "longName": "995665 - Disclosure - Fair Value Measurements - Schedule of fair value on a recurring basis (Details)",
     "shortName": "Fair Value Measurements - Schedule of fair value on a recurring basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "C_3f1eae59-7db7-4f63-b33e-689ca6ac6166",
      "name": "md:MoneyMarketFundsFairValueDisclosure",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3f1eae59-7db7-4f63-b33e-689ca6ac6166",
      "name": "md:MoneyMarketFundsFairValueDisclosure",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.mednax.com/20230930/taxonomy/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails",
     "longName": "995675 - Disclosure - Fair Value Measurements - Schedule of financial instruments that are not carried at fair value (Details)",
     "shortName": "Fair Value Measurements - Schedule of financial instruments that are not carried at fair value (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "C_06c01cd0-0e05-46ab-a1e5-d6467d9be312",
      "name": "us-gaap:NotesPayable",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "md:FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_06c01cd0-0e05-46ab-a1e5-d6467d9be312",
      "name": "us-gaap:NotesPayable",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "md:FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.mednax.com/20230930/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail",
     "longName": "995695 - Disclosure - Accounts Receivable and Net Revenue - Schedule of Accounts Receivable, Net (Detail)",
     "shortName": "Accounts Receivable and Net Revenue - Schedule of Accounts Receivable, Net (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "C_5d513fe3-41de-49c7-8231-3b67764cba30",
      "name": "us-gaap:AccountsReceivableGrossCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "div",
       "md:AccountsReceivableAndNetRevenueDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5d513fe3-41de-49c7-8231-3b67764cba30",
      "name": "us-gaap:AccountsReceivableGrossCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "div",
       "md:AccountsReceivableAndNetRevenueDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.mednax.com/20230930/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail",
     "longName": "995705 - Disclosure - Accounts Receivable and Net Revenue - Schedule of Net Revenue (Detail)",
     "shortName": "Accounts Receivable and Net Revenue - Schedule of Net Revenue (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "C_e5943398-0732-4d17-9fe7-25777d223b65",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ee0dda75-7533-43f8-ba6d-8b3ddadca454",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "div",
       "md:AccountsReceivableAndNetRevenueDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20230930.htm",
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.mednax.com/20230930/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail",
     "longName": "995715 - Disclosure - Accounts Receivable and Net Revenue - Schedule of Net Patient Service Revenue by Type of Payor (Detail)",
     "shortName": "Accounts Receivable and Net Revenue - Schedule of Net Patient Service Revenue by Type of Payor (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "C_e5943398-0732-4d17-9fe7-25777d223b65",
      "name": "md:PercentageOfNetPatientServiceRevenueByTypeOfPayor",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "div",
       "md:AccountsReceivableAndNetRevenueDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e5943398-0732-4d17-9fe7-25777d223b65",
      "name": "md:PercentageOfNetPatientServiceRevenueByTypeOfPayor",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "div",
       "md:AccountsReceivableAndNetRevenueDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.mednax.com/20230930/taxonomy/role/BusinessCombinationsAndDiscontinuedOperationsAdditionalInformationDetail",
     "longName": "995725 - Disclosure - Business Combinations and Discontinued Operations -  Additional information (Detail)",
     "shortName": "Business Combinations and Discontinued Operations -  Additional information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "C_5d513fe3-41de-49c7-8231-3b67764cba30",
      "name": "us-gaap:OtherAssetsNoncurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20230930.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R35": {
     "role": "http://www.mednax.com/20230930/taxonomy/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail",
     "longName": "995735 - Disclosure - Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Detail)",
     "shortName": "Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "C_5d513fe3-41de-49c7-8231-3b67764cba30",
      "name": "us-gaap:AccountsPayableCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5d513fe3-41de-49c7-8231-3b67764cba30",
      "name": "us-gaap:AccountsPayableCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.mednax.com/20230930/taxonomy/role/AccountsPayableAndAccruedExpensesAdditionalInformationDetail",
     "longName": "995745 - Disclosure - Accounts Payable and Accrued Expenses - Additional Information (Detail)",
     "shortName": "Accounts Payable and Accrued Expenses - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a",
      "name": "md:IncreaseDecreaseInAccruedSalariesAndBonuses",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a",
      "name": "md:IncreaseDecreaseInAccruedSalariesAndBonuses",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.mednax.com/20230930/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails",
     "longName": "995755 - Disclosure - Line of Credit and Long Term Debt (Additional Information) (Details)",
     "shortName": "Line of Credit and Long Term Debt (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "C_5d513fe3-41de-49c7-8231-3b67764cba30",
      "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "5",
      "ancestors": [
       "span",
       "p",
       "md:LineOfCreditAndLongTermDebtTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5d513fe3-41de-49c7-8231-3b67764cba30",
      "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "5",
      "ancestors": [
       "span",
       "p",
       "md:LineOfCreditAndLongTermDebtTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.mednax.com/20230930/taxonomy/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail",
     "longName": "995765 - Disclosure - Common and Common Equivalent Shares - Schedule of Calculation of Shares Used in Basic and Diluted Net Income Per Share (Detail)",
     "shortName": "Common and Common Equivalent Shares - Schedule of Calculation of Shares Used in Basic and Diluted Net Income Per Share (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "C_e5943398-0732-4d17-9fe7-25777d223b65",
      "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e5943398-0732-4d17-9fe7-25777d223b65",
      "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20230930.htm",
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.mednax.com/20230930/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail",
     "longName": "995785 - Disclosure - Stock Incentive Plans and Stock Purchase Plans - Additional Information (Detail)",
     "shortName": "Stock Incentive Plans and Stock Purchase Plans - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "C_e5943398-0732-4d17-9fe7-25777d223b65",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e5943398-0732-4d17-9fe7-25777d223b65",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.mednax.com/20230930/taxonomy/role/CommonStockRepurchaseProgramsAdditionalInformationDetail",
     "longName": "995795 - Disclosure - Common Stock Repurchase Programs - Additional Information (Detail)",
     "shortName": "Common Stock Repurchase Programs - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "C_6e1b2a31-52e8-4f72-bf5e-e1d5bcb3dc5a",
      "name": "us-gaap:StockRepurchasedDuringPeriodShares",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "md:CommonStockRepurchasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4c2decbf-697c-4da3-a4c5-727a578f77dc",
      "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "md:CommonStockRepurchasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20230930.htm",
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.mednax.com/20230930/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail",
     "longName": "995805 - Disclosure - Coronavirus Pandemic (COVID-19) - Additional Information (Detail)",
     "shortName": "Coronavirus Pandemic (COVID-19) - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "C_6a82b64e-6fb9-48f9-99fe-5081ff6fca6c",
      "name": "md:ProceedsFromContributionInAidOfReimbursementOfLostRevenue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "md:CoronavirusPandemicCOVIDNineteenDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6a82b64e-6fb9-48f9-99fe-5081ff6fca6c",
      "name": "md:ProceedsFromContributionInAidOfReimbursementOfLostRevenue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "md:CoronavirusPandemicCOVIDNineteenDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20230930.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "md_MoneyMarketFundsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mednax.com/20230930",
     "localname": "MoneyMarketFundsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of money market funds.",
        "label": "Money Market Funds Fair Value Disclosure",
        "terseLabel": "Money market funds"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.mednax.com/20230930/taxonomy/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other accrued expenses",
        "label": "Other Accrued Liabilities, Current",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "md_IncrementalSharesInContinuingOperation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.mednax.com/20230930",
     "localname": "IncrementalSharesInContinuingOperation",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/DisclosureCommonAndCommonEquivalentSharesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incremental Shares In Continuing operation",
        "documentation": "Incremental Shares In Continuing operation"
       }
      }
     },
     "auth_ref": []
    },
    "md_AccountsReceivableAndNetRevenueDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.mednax.com/20230930",
     "localname": "AccountsReceivableAndNetRevenueDisclosureTextBlock",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/AccountsReceivableAndNetRevenue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Receivable and Net Revenue",
        "label": "Accounts Receivable And Net Revenue Disclosure [Text Block]",
        "documentation": "Accounts receivable and net revenue disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentPeriodicPaymentInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentPeriodicPaymentInterest",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Periodic Payment, Interest",
        "terseLabel": "Interest accrued periodically",
        "documentation": "Amount of the required periodic payments applied to interest."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_LongTermDebtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMember",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Long-Term Debt",
        "label": "Long-Term Debt [Member]",
        "terseLabel": "Term A loan",
        "documentation": "Debt arrangement having an initial term longer than one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "md_HospitalsContractsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20230930",
     "localname": "HospitalsContractsMember",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hospital contract administrative fees [Member]",
        "label": "Hospitals Contracts [Member]",
        "documentation": "Hospitals Contracts [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "md_FairValueDisclosuresTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.mednax.com/20230930",
     "localname": "FairValueDisclosuresTable",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Table]",
        "documentation": "Fair value disclosures."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CorporateJointVentureMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CorporateJointVentureMember",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/DisclosureBasisOfPresentationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Corporate Joint Venture [Member]",
        "documentation": "Corporation owned and operated by a small group of ventures to accomplish a mutually beneficial venture or project."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromSaleOfOtherProductiveAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleOfOtherProductiveAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Proceeds from Sale of Other Productive Assets",
        "documentation": "Amount of cash inflow from the sale of tangible or intangible assets used to produce goods or deliver services, classified as other."
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "md_FivePointThreeSevenFivePercentUnsecuredSeniorNotesDueTwoThousandThirtyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20230930",
     "localname": "FivePointThreeSevenFivePercentUnsecuredSeniorNotesDueTwoThousandThirtyMember",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Five point three seven five percent unsecured senior notes due two thousand thirty member.",
        "label": "Five Point Three Seven Five Percent Unsecured Senior Notes Due Two Thousand Thirty Member",
        "terseLabel": "5.375% Unsecured Senior Notes Due 2030 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.mednax.com/20230930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Short-term investments",
        "label": "Debt Securities, Available-for-Sale, Current",
        "totalLabel": "Debt Securities, Available-for-sale, Current, Total",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current."
       }
      }
     },
     "auth_ref": [
      "r262",
      "r308"
     ]
    },
    "us-gaap_DebtInstrumentFrequencyOfPeriodicPayment": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentFrequencyOfPeriodicPayment",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Debt Instrument, Frequency of Periodic Payment",
        "label": "Debt Instrument, Frequency of Periodic Payment",
        "terseLabel": "Debt instrument maturity date description",
        "documentation": "Description of the frequency of periodic payments (monthly, quarterly, annual)."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r82"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Axis]",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859"
     ]
    },
    "md_TwoZeroThreeZeroMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20230930",
     "localname": "TwoZeroThreeZeroMember",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Zero Three Zero [Member]",
        "label": "Two Zero Three Zero [Member]",
        "terseLabel": "2030 Notes [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r340",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r464",
      "r465",
      "r466",
      "r667",
      "r668",
      "r673",
      "r674",
      "r675"
     ]
    },
    "us-gaap_DebtInstrumentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentDescription",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Description",
        "label": "Debt Instrument, Description",
        "documentation": "Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r53",
      "r81",
      "r91",
      "r135",
      "r137"
     ]
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.mednax.com/20230930",
     "localname": "FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Financial Instruments Measured At Carrying Amount",
        "label": "Financial Instruments Measured At Carrying Amount Table Text Block",
        "documentation": "Tabular disclosure of financial instruments measured at carrying amount."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.mednax.com/20230930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and cash equivalents at beginning of period",
        "terseLabel": "Cash and cash equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r177",
      "r654"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award vesting period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r679"
     ]
    },
    "md_NorthAmericanPartnersInAnesthesiaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20230930",
     "localname": "NorthAmericanPartnersInAnesthesiaMember",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/BusinessCombinationsAndDiscontinuedOperationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "North American Partners In Anesthesia [Member]",
        "documentation": "North American Partners In Anesthesia [member]."
       }
      }
     },
     "auth_ref": []
    },
    "md_CashEquivalentsAndInvestmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.mednax.com/20230930",
     "localname": "CashEquivalentsAndInvestmentsTable",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/CashEquivalentsAndInvestmentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Equivalents and Investments [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "md_NumberOfMultiLocationPediatricUrgentCarePracticeAcquired": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.mednax.com/20230930",
     "localname": "NumberOfMultiLocationPediatricUrgentCarePracticeAcquired",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/BusinessCombinationsAndDiscontinuedOperationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of other multi location pediatric urgent care practice acquired",
        "label": "Number Of Multi Location Pediatric Urgent Care Practice Acquired",
        "documentation": "Number of multi location pediatric urgent care practice acquired."
       }
      }
     },
     "auth_ref": []
    },
    "md_ContributionsInAidOfReimbursementOfLostRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mednax.com/20230930",
     "localname": "ContributionsInAidOfReimbursementOfLostRevenue",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reimbursement of Lost Revenue",
        "label": "Contributions In Aid Of Reimbursement of Lost Revenue",
        "documentation": "Contributions In Aid Of Reimbursement of Lost Revenue."
       }
      }
     },
     "auth_ref": []
    },
    "md_NumberOfPediatricGastroenterologyPracticeAcquired": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.mednax.com/20230930",
     "localname": "NumberOfPediatricGastroenterologyPracticeAcquired",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/BusinessCombinationsAndDiscontinuedOperationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Pediatric Gastroenterology Practice Acquired",
        "label": "Number of Pediatric Gastroenterology Practice Acquired",
        "documentation": "Number of Pediatric Gastroenterology Practice Acquired"
       }
      }
     },
     "auth_ref": []
    },
    "md_BusinessCombinationAndDiscontinuedOperationsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.mednax.com/20230930",
     "localname": "BusinessCombinationAndDiscontinuedOperationsTextBlock",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/BusinessCombinationsAndDiscontinuedOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Business Combination and Discontinued Operations",
        "label": "Business Combination And Discontinued Operations [Text Block]",
        "documentation": "Business combination and discontinued operations [Text Block]."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve",
     "crdr": "debit",
     "calculation": {
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term professional liabilities",
        "label": "Increase (Decrease) in Liability for Claims and Claims Adjustment Expense Reserve",
        "documentation": "Amount of increase (decrease) in liability to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "md_RepaymentsOfLongTermCapitalLeaseObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mednax.com/20230930",
     "localname": "RepaymentsOfLongTermCapitalLeaseObligation",
     "crdr": "credit",
     "calculation": {
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payment on finance lease obligation",
        "documentation": "Repayments Of Long Term Capital Lease Obligation",
        "label": "Repayments Of Long Term Capital Lease Obligation"
       }
      }
     },
     "auth_ref": []
    },
    "md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20230930",
     "localname": "NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "1996 Non-Qualified Employee Stock Purchase Plan [Member]",
        "label": "Nineteen Ninety Six Non Qualified Employee Stock Purchase Plan [Member]",
        "documentation": "1996 non-qualified employee stock purchase plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r206",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r456",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r794"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail",
      "http://www.mednax.com/20230930/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://www.mednax.com/20230930/taxonomy/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r91",
      "r92",
      "r135",
      "r137",
      "r206",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r456",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r794"
     ]
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "EquityMethodInvesteeNameDomain",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/DisclosureBasisOfPresentationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r296",
      "r297",
      "r298"
     ]
    },
    "md_FivePointTwoFivePercentageSeniorNotesDueTwoThousandTwentyThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20230930",
     "localname": "FivePointTwoFivePercentageSeniorNotesDueTwoThousandTwentyThreeMember",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Five Point Two Five Percentage Senior Notes Due Two Thousand Twenty Three [Member]",
        "label": "Five Point Two Five Percentage Senior Notes Due Two Thousand Twenty Three [Member]",
        "documentation": "Five Point Two Five Percentage Senior Notes Due Two Thousand Twenty Three [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/AccountsReceivableAndNetRevenueTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Net Revenue",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r831"
     ]
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income from operations",
        "totalLabel": "Income from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r240",
      "r248",
      "r252",
      "r254",
      "r661"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/ConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, issued",
        "label": "Preferred Stock, Shares Issued",
        "totalLabel": "Preferred Stock, Shares Issued, Total",
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r351"
     ]
    },
    "md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20230930",
     "localname": "TwoThousandFifteenNonQualifiedStockPurchasePlanMember",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2015 Non-Qualified Stock Purchase Plan [Member]",
        "label": "Two Thousand Fifteen Non Qualified Stock Purchase Plan [Member]",
        "documentation": "Two Thousand Fifteen Non Qualified Stock Purchase Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_HealthCareOrganizationRevenueAndExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "HealthCareOrganizationRevenueAndExpenseAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Health Care Organization Revenue and Expense [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of common stock",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r53",
      "r54",
      "r74",
      "r75",
      "r77",
      "r80",
      "r122",
      "r123",
      "r206",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r456",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r794"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Domain]",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859"
     ]
    },
    "md_TwoThousandTwentyThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20230930",
     "localname": "TwoThousandTwentyThreeMember",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2023 Notes [Member]",
        "label": "Two Thousand Twenty Three [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "md_SixPointTwentyFivePercentageSeniorUnsecuredNotesDue2027Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20230930",
     "localname": "SixPointTwentyFivePercentageSeniorUnsecuredNotesDue2027Member",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "6.25% senior unsecured notes due 2027",
        "label": "Six Point Twenty Five Percentage senior unsecured notes due 2027 [Member]",
        "documentation": "Six Point Twenty Five Percentage senior unsecured notes due 2027 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401"
     ]
    },
    "us-gaap_DisaggregationOfRevenueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisaggregationOfRevenueAbstract",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue [Abstract]",
        "label": "Disaggregation of Revenue [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/AccountsPayableAndAccruedExpensesAdditionalInformationDetail",
      "http://www.mednax.com/20230930/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r181",
      "r182",
      "r183",
      "r205",
      "r224",
      "r228",
      "r230",
      "r232",
      "r238",
      "r239",
      "r299",
      "r323",
      "r325",
      "r326",
      "r327",
      "r330",
      "r331",
      "r351",
      "r352",
      "r353",
      "r354",
      "r356",
      "r447",
      "r548",
      "r549",
      "r550",
      "r551",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r567",
      "r583",
      "r605",
      "r623",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r773",
      "r793",
      "r801"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/ConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares authorized",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r583"
     ]
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited",
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Loss on early extinguishment of debt",
        "terseLabel": "Loss on early extinguishment of debt",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "totalLabel": "Gain (Loss) on Extinguishment of Debt, Total",
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r50",
      "r51"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/CommonStockRepurchaseProgramsAdditionalInformationDetail",
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock [Member]",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r686",
      "r687",
      "r688",
      "r690",
      "r691",
      "r692",
      "r693",
      "r797",
      "r798",
      "r860",
      "r879",
      "r881"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails",
      "http://www.mednax.com/20230930/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, interest rate, effective percentage",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r75",
      "r350",
      "r456"
     ]
    },
    "md_PurchasePrice": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.mednax.com/20230930",
     "localname": "PurchasePrice",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price",
        "label": "Purchase price",
        "terseLabel": "Purchase price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.mednax.com/20230930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total shareholders' equity",
        "label": "Equity, Attributable to Parent",
        "periodStartLabel": "Stockholders' Equity Attributable to Parent, Beginning Balance",
        "periodEndLabel": "Stockholders' Equity Attributable to Parent, Ending Balance",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r97",
      "r98",
      "r119",
      "r585",
      "r602",
      "r624",
      "r625",
      "r683",
      "r696",
      "r795",
      "r819",
      "r862",
      "r881"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Debt instrument interest rate",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r333"
     ]
    },
    "md_ExtraordinaryItemsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20230930",
     "localname": "ExtraordinaryItemsDomain",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extraordinary Items [Domain]",
        "documentation": "Extraordinary Items [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative expenses",
        "label": "General and Administrative Expense",
        "totalLabel": "General and Administrative Expense, Total",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r607"
     ]
    },
    "us-gaap_CashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashEquivalentsMember",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/CashEquivalentsAndInvestmentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Equivalents [Member]",
        "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r177"
     ]
    },
    "md_PercentageOfRefundOfIncomeTaxAtThePriorPeriodCorporateTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.mednax.com/20230930",
     "localname": "PercentageOfRefundOfIncomeTaxAtThePriorPeriodCorporateTaxRate",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Percentage of refund of income tax at the prior period corporate tax rate",
        "label": "Percentage Of Refund Of Income Tax At The Prior Period Corporate Tax Rate",
        "documentation": "Percentage of refund of income tax at the prior period corporate tax rate."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentMaturityDateDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentMaturityDateDescription",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Maturity Date, Description",
        "terseLabel": "Debt instrument maturity date description",
        "documentation": "Description of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAxis",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/CashEquivalentsAndInvestmentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Axis]",
        "documentation": "Information by type of cash and cash equivalent balance."
       }
      }
     },
     "auth_ref": [
      "r177"
     ]
    },
    "md_TwoThousandTwentyTaxYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20230930",
     "localname": "TwoThousandTwentyTaxYearMember",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2020 Tax Year [Member]",
        "label": "Two Thousand Twenty Tax Year [Member]",
        "documentation": "Two thousand twenty tax year."
       }
      }
     },
     "auth_ref": []
    },
    "md_OperatingAndFinanceLeaseRightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mednax.com/20230930",
     "localname": "OperatingAndFinanceLeaseRightOfUseAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.mednax.com/20230930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating and finance lease right-of-use assets",
        "label": "Operating And Finance Lease Right Of Use Assets",
        "documentation": "Operating and finance lease right-of-use assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r402",
      "r409"
     ]
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentMaturityDate",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Maturity Date",
        "terseLabel": "Debt Instrument Maturity Date",
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r666",
      "r861"
     ]
    },
    "md_NumberOfPediatricOrThopedicPracticesAcquired": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.mednax.com/20230930",
     "localname": "NumberOfPediatricOrThopedicPracticesAcquired",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/BusinessCombinationsAndDiscontinuedOperationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of other pediatric orthopedic practice acquired",
        "label": "Number Of Pediatric Or thopedic Practices Acquired",
        "documentation": "Number of pediatric or thopedic practices acquired."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/ConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, par value",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r351"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.mednax.com/20230930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r79",
      "r516",
      "r582"
     ]
    },
    "md_CovidNinenteenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20230930",
     "localname": "CovidNinenteenMember",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "COVID-19 [Member]",
        "label": "Covid Ninenteen [Member]",
        "documentation": "Covid Ninenteen [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r758"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r758"
     ]
    },
    "md_CashEquivalentsAndInvestmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.mednax.com/20230930",
     "localname": "CashEquivalentsAndInvestmentsLineItems",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/CashEquivalentsAndInvestmentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Equivalents And Investments [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "totalLabel": "Share-based Payment Arrangement, Noncash Expense, Total",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "md_DeferredTaxAssetsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20230930",
     "localname": "DeferredTaxAssetsDomain",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/BusinessCombinationsAndDiscontinuedOperationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromLinesOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromLinesOfCredit",
     "crdr": "debit",
     "calculation": {
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails",
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Proceeds from Lines of Credit, Total",
        "verboseLabel": "Borrowings on credit agreement",
        "label": "Proceeds from Lines of Credit",
        "terseLabel": "Borrowings on revolving credit line",
        "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r794"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail",
      "http://www.mednax.com/20230930/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://www.mednax.com/20230930/taxonomy/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r206",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r456",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r794"
     ]
    },
    "us-gaap_Cash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Cash",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash, Beginning Balance",
        "periodEndLabel": "Cash, Ending Balance",
        "label": "Cash",
        "terseLabel": "Cash on hand",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r517",
      "r566",
      "r591",
      "r683",
      "r696",
      "r785"
     ]
    },
    "us-gaap_UnsecuredDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnsecuredDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Unsecured Debt, Total",
        "label": "Unsecured Debt",
        "terseLabel": "Unsecured note issued",
        "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of uncollateralized debt obligations (with maturities initially due after one year or beyond the operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r137",
      "r875"
     ]
    },
    "us-gaap_RepaymentsOfSeniorDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfSeniorDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Redemption of senior notes, including call premium",
        "label": "Repayments of Senior Debt",
        "totalLabel": "Repayments of Senior Debt, Total",
        "documentation": "The cash outflow for a long-term debt where the holder has highest claim on the entity's asset in case of bankruptcy or liquidation during the period."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.mednax.com/20230930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and shareholders' equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r138",
      "r522",
      "r683",
      "r795",
      "r819",
      "r862"
     ]
    },
    "us-gaap_AccruedSalariesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedSalariesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.mednax.com/20230930/taxonomy/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued salaries and incentive compensation",
        "label": "Accrued Salaries, Current",
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r657"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "calculation": {
      "http://www.mednax.com/20230930/taxonomy/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail",
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Weighted average number of common and common equivalent shares outstanding",
        "terseLabel": "Diluted",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r223",
      "r232"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASSETS",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.mednax.com/20230930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retained deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total",
        "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance",
        "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r124",
      "r521",
      "r544",
      "r546",
      "r552",
      "r584",
      "r683"
     ]
    },
    "us-gaap_UnsecuredLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnsecuredLongTermDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unsecured Long-Term Debt, Noncurrent",
        "terseLabel": "Proceeds from issuance of unsecured debt",
        "documentation": "Carrying value as of the balance sheet date of uncollateralized debt obligation (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "calculation": {
      "http://www.mednax.com/20230930/taxonomy/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail",
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted average number of common shares outstanding",
        "terseLabel": "Basic",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r222",
      "r232"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LIABILITIES AND EQUITY",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Proceeds from maturities or sales of investments",
        "label": "Proceeds from Sale, Maturity and Collection of Investments",
        "totalLabel": "Proceeds from Sale, Maturity and Collection of Investments, Total",
        "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_GeographicDistributionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeographicDistributionDomain",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographic Distribution [Domain]",
        "documentation": "Allocation of business activity identified as domestic or foreign. Excludes names of countries, states and provinces, and cities."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r510",
      "r511"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/AccountsPayableAndAccruedExpensesAdditionalInformationDetail",
      "http://www.mednax.com/20230930/taxonomy/role/BusinessCombinationsAndDiscontinuedOperationsAdditionalInformationDetail",
      "http://www.mednax.com/20230930/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail",
      "http://www.mednax.com/20230930/taxonomy/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails",
      "http://www.mednax.com/20230930/taxonomy/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails",
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r207",
      "r208",
      "r209",
      "r237",
      "r492",
      "r547",
      "r567",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r583",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r592",
      "r593",
      "r594",
      "r595",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r603",
      "r606",
      "r607",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r623",
      "r689"
     ]
    },
    "us-gaap_RepaymentsOfLinesOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfLinesOfCredit",
     "crdr": "credit",
     "calculation": {
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments on credit agreement",
        "label": "Repayments of Lines of Credit",
        "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r794"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/StockIncentivePlansAndStockPurchasePlans"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Incentive Plans and Stock Purchase Plans",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r370",
      "r375",
      "r403",
      "r404",
      "r405",
      "r679"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Debt Securities, Available-for-sale, Total",
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Available-for-sale Securities",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r266",
      "r308",
      "r507",
      "r803"
     ]
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "USTreasurySecuritiesMember",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. Treasury securities [Member]",
        "label": "US Treasury Securities [Member]",
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)."
       }
      }
     },
     "auth_ref": [
      "r658",
      "r673",
      "r675",
      "r874"
     ]
    },
    "us-gaap_HealthCareOrganizationRevenueSourcesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "HealthCareOrganizationRevenueSourcesAxis",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Health Care Organization, Revenue Sources [Axis]",
        "label": "Health Care Organization, Revenue Sources [Axis]",
        "documentation": "Information by major payor source of revenue for health care organizations."
       }
      }
     },
     "auth_ref": [
      "r831"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shareholders' equity:",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_HealthCareOrganizationRevenueSourcesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "HealthCareOrganizationRevenueSourcesDomain",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Health Care Organization, Revenue Sources [Domain]",
        "label": "Health Care Organization, Revenue Sources [Domain]",
        "documentation": "Major payor source of revenue for health care organizations."
       }
      }
     },
     "auth_ref": [
      "r831"
     ]
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/CommonStockRepurchaseProgramsAdditionalInformationDetail",
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Payments for repurchase of common stock",
        "terseLabel": "Amount withheld to satisfy minimum statutory tax withholding obligations",
        "negatedLabel": "Repurchases of common stock",
        "label": "Payments for Repurchase of Common Stock",
        "documentation": "The cash outflow to reacquire common stock during the period."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_LongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Long-term Debt, Total",
        "label": "Long-Term Debt",
        "terseLabel": "Long term debt",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r137",
      "r339",
      "r349",
      "r667",
      "r668",
      "r875"
     ]
    },
    "us-gaap_ThirdPartyPayorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ThirdPartyPayorMember",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Third-Parties [Member]",
        "label": "Third-Party Payor [Member]",
        "documentation": "Organization other than the patient (first party) or health care provider (second party) involved in the financing of personal health services."
       }
      }
     },
     "auth_ref": [
      "r831"
     ]
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_USStatesAndPoliticalSubdivisionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "USStatesAndPoliticalSubdivisionsMember",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Municipal Debt Securities [Member]",
        "label": "US States and Political Subdivisions Debt Securities [Member]",
        "documentation": "Bonds or similar securities issued by state, city, or local US governments or the agencies operated by state, city, or local governments. Debt securities issued by state governments may include bond issuances of US state authorities including, for example, but not limited to, housing authorities, dormitory authorities, and general obligations while debt securities issued by political subdivisions of US states would include, for example, debt issuances by county, borough, city, or municipal governments."
       }
      }
     },
     "auth_ref": [
      "r673",
      "r878"
     ]
    },
    "us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRevenueSourcesHealthCareOrganizationTable",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Revenue Sources, Health Care Organization [Table]",
        "label": "Schedule of Revenue Sources, Health Care Organization [Table]",
        "documentation": "Schedule of the major payor source of revenue for health care organizations."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SelfPayMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SelfPayMember",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Private-Pay Patients [Member]",
        "label": "Self-Pay [Member]",
        "documentation": "Patients who pay out of pocket for a health-related service in absence of insurance to cover the medical or surgical procedure performed."
       }
      }
     },
     "auth_ref": [
      "r831"
     ]
    },
    "us-gaap_GeographicDistributionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeographicDistributionAxis",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographic Distribution [Axis]",
        "documentation": "Information by geographic distribution of business activity identified as either domestic or foreign. Excludes names of countries, states and provinces, and cities."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r510",
      "r511",
      "r663"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProductAndServiceOtherMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProductAndServiceOtherMember",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other revenue [Member]",
        "label": "Product and Service, Other [Member]",
        "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other."
       }
      }
     },
     "auth_ref": [
      "r832"
     ]
    },
    "us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MalpracticeLossContingencyAccrualUndiscountedCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.mednax.com/20230930/taxonomy/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued professional liabilities",
        "label": "Malpractice Loss Contingency, Accrual, Undiscounted, Current",
        "documentation": "Amount of the current portion of the accrued liability on an undiscounted basis for malpractice claims (including general and professional liability)."
       }
      }
     },
     "auth_ref": [
      "r825"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/DisclosureBasisOfPresentationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party, Type [Domain]",
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r367",
      "r459",
      "r460",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r601",
      "r603",
      "r626"
     ]
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Available-for-sale [Line Items]",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail",
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net revenue",
        "label": "Revenue from Contract with Customer, Including Assessed Tax",
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise."
       }
      }
     },
     "auth_ref": [
      "r241",
      "r242",
      "r247",
      "r250",
      "r251",
      "r255",
      "r256",
      "r257",
      "r358",
      "r359",
      "r492"
     ]
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "auth_ref": [
      "r220",
      "r369",
      "r774",
      "r775",
      "r800"
     ]
    },
    "us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MalpracticeLossContingencyAccrualUndiscountedNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.mednax.com/20230930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term professional liabilities",
        "label": "Malpractice Loss Contingency, Accrual, Undiscounted, Noncurrent",
        "documentation": "Amount of the noncurrent portion of the accrued liability on an undiscounted basis for malpractice claims (including general and professional liability)."
       }
      }
     },
     "auth_ref": [
      "r825"
     ]
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]"
       }
      }
     },
     "auth_ref": [
      "r220",
      "r369",
      "r774",
      "r800"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/AccountsPayableAndAccruedExpensesAdditionalInformationDetail",
      "http://www.mednax.com/20230930/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r181",
      "r182",
      "r183",
      "r205",
      "r224",
      "r228",
      "r230",
      "r232",
      "r238",
      "r239",
      "r299",
      "r323",
      "r325",
      "r326",
      "r327",
      "r330",
      "r331",
      "r351",
      "r352",
      "r353",
      "r354",
      "r356",
      "r447",
      "r548",
      "r549",
      "r550",
      "r551",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r567",
      "r583",
      "r605",
      "r623",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r773",
      "r793",
      "r801"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r758"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "totalLabel": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r57",
      "r372"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/BusinessCombinationsAndDiscontinuedOperationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets",
        "totalLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Total",
        "terseLabel": "Business combination consideration identifiable as current and long term liabilities",
        "documentation": "Amount of assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r758"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting period of options, maximum years",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r680"
     ]
    },
    "us-gaap_InterestPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.mednax.com/20230930/taxonomy/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued interest",
        "label": "Interest Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_CertificatesOfDepositMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CertificatesOfDepositMember",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Certificates of Deposit [Member]",
        "label": "Certificates of Deposit [Member]",
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r690",
      "r691",
      "r692",
      "r693"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r698"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r733"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r739"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r747"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r738"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r761"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r741"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r738"
     ]
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/AccountsPayableAndAccruedExpenses"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Payable and Accrued Expenses",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r743"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r698"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r742"
     ]
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r746"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r744"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r739"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r745"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities Act File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r745"
     ]
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited",
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfEquityUnaudited",
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "verboseLabel": "Net income",
        "totalLabel": "Net income attributable to Pediatrix Medical Group, Inc.",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r115",
      "r143",
      "r174",
      "r192",
      "r194",
      "r198",
      "r205",
      "r210",
      "r212",
      "r213",
      "r214",
      "r215",
      "r218",
      "r219",
      "r229",
      "r240",
      "r248",
      "r252",
      "r254",
      "r299",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r438",
      "r447",
      "r529",
      "r604",
      "r621",
      "r622",
      "r661",
      "r694",
      "r828"
     ]
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of investments",
        "label": "Payments to Acquire Investments",
        "totalLabel": "Payments to Acquire Investments, Total",
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period."
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/DisclosureBasisOfPresentationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r296",
      "r297",
      "r298"
     ]
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r739"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other Comprehensive Income (Loss), Available-for-Sale Securities, Tax, Portion Attributable to Parent, Total",
        "label": "Other Comprehensive Income (Loss), Available-for-Sale Securities, Tax, Portion Attributable to Parent",
        "verboseLabel": "Other Comprehensive Income (Loss), Available-for-Sale Securities, Tax, Portion Attributable to Parent",
        "terseLabel": "Other Comprehensive Income (Loss), Available-for-Sale Securities, Tax, Portion Attributable to Parent",
        "documentation": "Amount, after reclassification adjustment, of tax expense (benefit) for gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r12",
      "r129"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.mednax.com/20230930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital, Common Stock",
        "periodStartLabel": "Additional Paid in Capital, Common Stock, Beginning Balance",
        "periodEndLabel": "Additional Paid in Capital, Common Stock, Ending Balance",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r702",
      "r713",
      "r723",
      "r748"
     ]
    },
    "md_IncreaseInDeferredTaxAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mednax.com/20230930",
     "localname": "IncreaseInDeferredTaxAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/BusinessCombinationsAndDiscontinuedOperationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase in deferred tax assets",
        "label": "Increase In Deferred Tax assets",
        "documentation": "Increase in deferred tax Assets."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r739"
     ]
    },
    "us-gaap_RestructuringCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringCharges",
     "crdr": "debit",
     "calculation": {
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Transformational and restructuring related expenses",
        "label": "Restructuring Charges",
        "totalLabel": "Restructuring Charges, Total",
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r315",
      "r316",
      "r823"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r698"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.mednax.com/20230930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock; $.01 par value; 1,000 shares authorized; none issued",
        "label": "Preferred Stock, Value, Issued",
        "totalLabel": "Preferred Stock, Value, Issued, Total",
        "periodStartLabel": "Preferred Stock, Value, Issued, Beginning Balance",
        "periodEndLabel": "Preferred Stock, Value, Issued, Ending Balance",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r518",
      "r683"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of market value of common stock at which employees are permitted to purchase",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent",
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityRemainingBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit Facility, Remaining Borrowing Capacity",
        "terseLabel": "Line of Credit facility, available balance",
        "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding)."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "crdr": "credit",
     "calculation": {
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Acquisition payments, net of cash acquired",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "totalLabel": "Payments to Acquire Businesses, Net of Cash Acquired, Total",
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_GovernmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GovernmentMember",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Government [Member]",
        "label": "Government [Member]",
        "documentation": "Organization that is the governing authority of a community."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, reserved for issuance",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "crdr": "credit",
     "calculation": {
      "http://www.mednax.com/20230930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred income tax liabilities",
        "label": "Deferred Income Tax Liabilities, Net",
        "totalLabel": "Deferred Income Tax Liabilities, Net, Total",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r410",
      "r411",
      "r514"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "(Loss) income from continuing operations",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Income from continuing operations",
        "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r205",
      "r210",
      "r240",
      "r248",
      "r252",
      "r254",
      "r299",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r438",
      "r447",
      "r525",
      "r661",
      "r828"
     ]
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "crdr": "debit",
     "calculation": {
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of premiums, discounts and issuance costs",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "totalLabel": "Amortization of Debt Issuance Costs and Discounts, Total",
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r347",
      "r455",
      "r669",
      "r670",
      "r792"
     ]
    },
    "us-gaap_DescriptionOfInterestRateRiskExposure": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DescriptionOfInterestRateRiskExposure",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of Interest Rate Risk Exposure",
        "terseLabel": "Interest Rate, description",
        "documentation": "Description of the sources of interest rate risk exposure faced by the entity."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r68",
      "r69",
      "r70",
      "r71",
      "r72"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r739"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent, Total",
        "label": "Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Other comprehensive (loss) income, net of tax",
        "documentation": "Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r12",
      "r129"
     ]
    },
    "us-gaap_LineOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCredit",
     "crdr": "credit",
     "calculation": {
      "http://www.mednax.com/20230930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited",
      "http://www.mednax.com/20230930/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Long-term Line of Credit, Total",
        "label": "Long-Term Line of Credit",
        "terseLabel": "Line of credit",
        "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r137",
      "r875"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r739"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.mednax.com/20230930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accumulated other comprehensive loss",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r34",
      "r100",
      "r185",
      "r520",
      "r545",
      "r546"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r747"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "(Loss) income from continuing operations before income taxes",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income from continuing operations before income taxes",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r102",
      "r141",
      "r240",
      "r248",
      "r252",
      "r254",
      "r511",
      "r525",
      "r661"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r702",
      "r713",
      "r723",
      "r748"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Type [Domain]",
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r49"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r703",
      "r714",
      "r724",
      "r749"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r734"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r747"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.mednax.com/20230930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred income tax assets",
        "label": "Deferred Income Tax Assets, Net",
        "totalLabel": "Deferred Income Tax Assets, Net, Total",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r410",
      "r411"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r700"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/BusinessCombinationsAndDiscontinuedOperationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Incremental loss on sale, net",
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent",
        "totalLabel": "Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent, Total",
        "documentation": "Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r84",
      "r85",
      "r86",
      "r87",
      "r88",
      "r90",
      "r129"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r747"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r704",
      "r715",
      "r725",
      "r750"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsFairValueDisclosureAbstract",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets:",
        "label": "Assets, Fair Value Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r712",
      "r720",
      "r730",
      "r747",
      "r755",
      "r759",
      "r767"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r712",
      "r720",
      "r730",
      "r747",
      "r755",
      "r759",
      "r767"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total comprehensive income (loss) attributable to Pediatrix Medical Group, Inc.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Total comprehensive income attributable to Pediatrix Medical Group, Inc.",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r193",
      "r195",
      "r200",
      "r508",
      "r531"
     ]
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20230930",
     "localname": "NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "1996 Non-Qualified Employee Stock Purchase Plan and 2015 Non-Qualified Stock Purchase Plan [Member]",
        "label": "Nineteen Ninety Six Non Qualified Employee Stock Purchase Plan And Two Thousand Fifteen Non Qualified Stock Purchase Plan [Member]",
        "documentation": "Nineteen Ninety Six Non Qualified Employee Stock Purchase Plan And Two Thousand Fifteen Non Qualified Stock Purchase Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "md_UnnamedCorporateJointVentureOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20230930",
     "localname": "UnnamedCorporateJointVentureOneMember",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/DisclosureBasisOfPresentationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unnamed Corporate Joint Venture One [Member]",
        "documentation": "Unnamed Corporate Joint Venture [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited",
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Depreciation and amortization",
        "terseLabel": "Depreciation and amortization",
        "label": "Depreciation, Depletion and Amortization",
        "totalLabel": "Depreciation, Depletion and Amortization, Total",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r244"
     ]
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.mednax.com/20230930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r175",
      "r189",
      "r205",
      "r299",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r423",
      "r427",
      "r447",
      "r683",
      "r828",
      "r829",
      "r865"
     ]
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r772"
     ]
    },
    "md_PracticeSalariesAndBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mednax.com/20230930",
     "localname": "PracticeSalariesAndBenefits",
     "crdr": "debit",
     "calculation": {
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Practice salaries and benefits",
        "label": "Practice Salaries and Benefits",
        "documentation": "Practice salaries and benefits."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.mednax.com/20230930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses",
        "label": "Prepaid Expense, Current",
        "totalLabel": "Prepaid Expense, Current, Total",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r187",
      "r312",
      "r313",
      "r656"
     ]
    },
    "us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "USGovernmentSponsoredEnterprisesDebtSecuritiesMember",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Federal Home Loan Securities [Member]",
        "label": "US Government-sponsored Enterprises Debt Securities [Member]",
        "documentation": "Debentures, bonds and other debt securities issued by US government sponsored entities (GSEs), for example, but not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB). Excludes debt issued by the Government National Mortgage Association (GNMA or Ginnie Mae)."
       }
      }
     },
     "auth_ref": [
      "r833",
      "r874"
     ]
    },
    "us-gaap_ExtinguishmentOfDebtAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ExtinguishmentOfDebtAxis",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extinguishment of Debt [Axis]",
        "documentation": "Information pertaining to the debt extinguished including the amount of gain (loss), the income tax effect on the gain (loss), and the amount of gain (loss), net or the related income tax, by debt instrument."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_TextBlockAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TextBlockAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Text Block [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllOtherCorporateBondsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllOtherCorporateBondsMember",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Corporate Bonds [Member]",
        "terseLabel": "Corporate securities",
        "documentation": "Investments in corporate fixed maturity debt securities classified as other."
       }
      }
     },
     "auth_ref": [
      "r883"
     ]
    },
    "us-gaap_NotesPayableFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NotesPayableFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Notes Payable Fair Value Disclosure",
        "label": "Notes Payable, Fair Value Disclosure",
        "documentation": "Fair value portion of notes payable."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "md_BusinessCombinationAndDiscontinuedOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.mednax.com/20230930",
     "localname": "BusinessCombinationAndDiscontinuedOperationsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination And Discontinued Operations [Abstract]",
        "documentation": "Business combination and discontinued operations [Abstract]."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "md_PaymentsToTermLoan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mednax.com/20230930",
     "localname": "PaymentsToTermLoan",
     "crdr": "credit",
     "calculation": {
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments on term loan",
        "label": "Payments to Term Loan",
        "documentation": "Cash outflow to term loan."
       }
      }
     },
     "auth_ref": []
    },
    "md_TwoThousandTwentySevenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20230930",
     "localname": "TwoThousandTwentySevenMember",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027 Notes [Member]",
        "label": "Two Thousand Twenty Seven [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mednax.com/20230930",
     "localname": "ProceedsFromContributionInAidOfReimbursementOfLostRevenue",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds From Contribution In Aid Of Reimbursement of Lost Revenue",
        "label": "Proceeds From Contribution In Aid Of Reimbursement of Lost Revenue",
        "documentation": "Proceeds From Contribution In Aid Of Reimbursement of Lost Revenue."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Common stock issued under employee stock option, employee stock purchase plan and stock purchase plan",
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r93",
      "r94",
      "r124"
     ]
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/BusinessCombinationsAndDiscontinuedOperationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition, Acquiree [Domain]",
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree."
       }
      }
     },
     "auth_ref": [
      "r420",
      "r676",
      "r677"
     ]
    },
    "md_BasisOfPresentationAndNewAccountingPronouncementsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.mednax.com/20230930",
     "localname": "BasisOfPresentationAndNewAccountingPronouncementsTable",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/DisclosureBasisOfPresentationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Presentation and New Accounting Pronouncements [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "md_LineOfCreditLongTermDebtAndFinanceLeaseObligationsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.mednax.com/20230930",
     "localname": "LineOfCreditLongTermDebtAndFinanceLeaseObligationsDisclosureTextBlock",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/DisclosureLineOfCreditAndLongTermDebt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of Credit and Long Term Debt",
        "label": "Line Of Credit Long Term Debt And Finance Lease Obligations Disclosure Text Block",
        "documentation": "Line of credit long term debt and finance lease obligations disclosure text block."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MoneyMarketFundsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MoneyMarketFundsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/CashEquivalentsAndInvestmentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash equivalents",
        "label": "Money Market Funds, at Carrying Value",
        "documentation": "Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Forfeitures",
        "terseLabel": "Forfeitures of restricted stock",
        "documentation": "Value of stock related to Restricted Stock Awards forfeited during the period."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r93",
      "r94",
      "r124"
     ]
    },
    "md_AnesthesiologyServicesMedicalGroupMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20230930",
     "localname": "AnesthesiologyServicesMedicalGroupMember",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/BusinessCombinationsAndDiscontinuedOperationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Anesthesiology Services Medical Group [Member]",
        "documentation": "Anesthesiology services medical group."
       }
      }
     },
     "auth_ref": []
    },
    "md_UnnamedCorporateJointVentureTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20230930",
     "localname": "UnnamedCorporateJointVentureTwoMember",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/DisclosureBasisOfPresentationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unnamed Corporate Joint Venture Two [Member]",
        "verboseLabel": "Unnamed Corporate Joint Venture Two [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "md_AmendedAndRestatedTwoThousandEightPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20230930",
     "localname": "AmendedAndRestatedTwoThousandEightPlanMember",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amended and Restated 2008 Plan [Member]",
        "label": "Amended and Restated Two Thousand Eight Plan [Member]",
        "documentation": "Amended and restated two thousand eight plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ExtinguishmentOfDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ExtinguishmentOfDebtTypeDomain",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extinguishment of Debt, Type [Domain]",
        "documentation": "Type of debt extinguished."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "md_LineOfCreditAndLongTermDebtTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.mednax.com/20230930",
     "localname": "LineOfCreditAndLongTermDebtTextBlock",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/DisclosureLineOfCreditAndLongTermDebt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line Of Credit And Long Term Debt [Text Block]",
        "label": "Line Of Credit And Long Term Debt [Text Block]",
        "terseLabel": "Line of Credit and Long Term Debt"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "md_RadiologyServicesMedicalGroupMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20230930",
     "localname": "RadiologyServicesMedicalGroupMember",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/BusinessCombinationsAndDiscontinuedOperationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Radiology Services Medical Group [Member]",
        "label": "Radiology Services Medical Group [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/BusinessCombinationsAndDiscontinuedOperationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fixed assets",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment",
        "totalLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment, Total",
        "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r61"
     ]
    },
    "md_DebtInstrumentMaturityYear": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://www.mednax.com/20230930",
     "localname": "DebtInstrumentMaturityYear",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, maturity year",
        "label": "Debt Instrument Maturity Year",
        "documentation": "Debt instrument maturity year."
       }
      }
     },
     "auth_ref": []
    },
    "md_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationNetOfTaxPerBasicAndDilutedShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.mednax.com/20230930",
     "localname": "IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationNetOfTaxPerBasicAndDilutedShareAbstract",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income from discontinued operations:",
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operation, Net of Tax, Per Basic and Diluted Share [Abstract]",
        "documentation": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operation, Net of Tax, Per Basic and Diluted Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/BusinessCombinationsAndDiscontinuedOperationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other intangible assets",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles",
        "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r61"
     ]
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "md_BasisOfPresentationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.mednax.com/20230930",
     "localname": "BasisOfPresentationLineItems",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/DisclosureBasisOfPresentationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis Of Presentation [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "md_GaapSeniorNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20230930",
     "localname": "GaapSeniorNotesMember",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "GAAP Senior Notes [Member]",
        "label": "GAAP Senior Notes [Member]",
        "documentation": "GAAP Senior Notes [Member]."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsReceivableGrossCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableGrossCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.mednax.com/20230930/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail": {
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross accounts receivable",
        "label": "Accounts Receivable, before Allowance for Credit Loss, Current",
        "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r184",
      "r258",
      "r259",
      "r655"
     ]
    },
    "md_PediatricSubspecialtyPracticeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20230930",
     "localname": "PediatricSubspecialtyPracticeMember",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/BusinessCombinationsAndDiscontinuedOperationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pediatric Subspecialty Practice [Member]",
        "label": "Pediatric Subspecialty Practice [Member]",
        "terseLabel": "Pediatric Subspecialty Practice [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NotesPayable",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Notes Payable",
        "label": "Notes Payable",
        "totalLabel": "Notes Payable, Total",
        "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r137",
      "r875"
     ]
    },
    "md_SixPointTwoFivePercentageSeniorNotesDueTwoThousandTwentySevenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20230930",
     "localname": "SixPointTwoFivePercentageSeniorNotesDueTwoThousandTwentySevenMember",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Six Point Two Five Percentage Senior Notes Due Two Thousand Twenty Seven [Member]",
        "label": "Six Point Two Five Percentage Senior Notes Due Two Thousand Twenty Seven [Member]",
        "terseLabel": "Six Point Two Five Percentage Senior Notes Due Two Thousand Twenty Seven [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/CashEquivalentsAndInvestmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of Investments",
        "label": "Debt Securities, Available-for-Sale [Table Text Block]",
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815"
     ]
    },
    "md_ContractedManagedCareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20230930",
     "localname": "ContractedManagedCareMember",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contracted Managed Care [Member]",
        "label": "Contracted Managed Care [Member]",
        "documentation": "Contracted Managed Care [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/CashEquivalentsAndInvestmentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Domain]",
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r177"
     ]
    },
    "md_PediatricGastroenterologyAndGynecologyPracticeAndMultiLocationPediatricUrgentCarePracticeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20230930",
     "localname": "PediatricGastroenterologyAndGynecologyPracticeAndMultiLocationPediatricUrgentCarePracticeMember",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/BusinessCombinationsAndDiscontinuedOperationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pediatric Gastroenterology And Gynecology practice And Multi Location Pediatric Urgent Care Practice [Member]",
        "documentation": "Pediatric Gastroenterology And Gynecology practice And Multi Location Pediatric Urgent Care Practice [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentTypeAxis",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Type [Axis]",
        "documentation": "Information by type of investments."
       }
      }
     },
     "auth_ref": [
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r627",
      "r629",
      "r631",
      "r634",
      "r635",
      "r636",
      "r637",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r688"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.mednax.com/20230930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r180",
      "r205",
      "r240",
      "r249",
      "r253",
      "r299",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r423",
      "r427",
      "r447",
      "r513",
      "r596",
      "r683",
      "r696",
      "r828",
      "r829",
      "r865"
     ]
    },
    "md_IncreaseDecreaseInAccruedSalariesAndBonuses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mednax.com/20230930",
     "localname": "IncreaseDecreaseInAccruedSalariesAndBonuses",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/AccountsPayableAndAccruedExpensesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net decrease in accrued salaries and bonuses",
        "label": "Increase (Decrease) in Accrued Salaries and Bonuses",
        "documentation": "Increase (decrease) in accrued salaries and bonuses."
       }
      }
     },
     "auth_ref": []
    },
    "md_PrimaryBeneficiaryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20230930",
     "localname": "PrimaryBeneficiaryMember",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/DisclosureBasisOfPresentationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary beneficiary [Member]",
        "label": "Primary beneficiary [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "md_FairValueDisclosuresLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.mednax.com/20230930",
     "localname": "FairValueDisclosuresLineItems",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Line Items]",
        "documentation": "Fair value disclosures."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Basic",
        "label": "Earnings Per Share, Basic",
        "totalLabel": "Earnings Per Share, Basic, Total",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r201",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r222",
      "r224",
      "r230",
      "r231",
      "r232",
      "r236",
      "r437",
      "r438",
      "r509",
      "r532",
      "r659"
     ]
    },
    "md_CreditAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20230930",
     "localname": "CreditAgreementMember",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Credit Agreement [Member]",
        "label": "Credit Agreement [Member]",
        "documentation": "Credit Agreement [Member]",
        "terseLabel": "Amended Credit Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "md_CommonStockTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.mednax.com/20230930",
     "localname": "CommonStockTable",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/CommonStockRepurchaseProgramsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock [Table]",
        "label": "Common Stock [Table]",
        "documentation": "Common Stock [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "md_CommonStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.mednax.com/20230930",
     "localname": "CommonStockLineItems",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/CommonStockRepurchaseProgramsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock [Line Items]",
        "label": "Common Stock [Line Items]",
        "documentation": "Common Stock [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "md_PracticeSuppliesAndOtherOperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mednax.com/20230930",
     "localname": "PracticeSuppliesAndOtherOperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Practice supplies and other operating expenses",
        "label": "Practice Supplies And Other Operating Expenses",
        "documentation": "The aggregate amount of supplies and other operating expenses directly attributable to the physician practices."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReceivablesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReceivablesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivables [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/CommonStockRepurchaseProgramsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock authorized for repurchase",
        "label": "Stock Repurchase Program, Authorized Amount",
        "documentation": "Amount of stock repurchase plan authorized."
       }
      }
     },
     "auth_ref": []
    },
    "md_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20230930",
     "localname": "SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2027 Notes",
        "terseLabel": "6.25% Senior Unsecured Notes Due 2027 [Member]",
        "label": "Six Point Two Five Percent Senior Unsecured Notes Due Two Thousand Twenty Seven [Member]",
        "documentation": "Six point two five percent senior unsecured notes due two thousand twenty seven."
       }
      }
     },
     "auth_ref": []
    },
    "md_DeferredTaxAssetsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.mednax.com/20230930",
     "localname": "DeferredTaxAssetsAxis",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/BusinessCombinationsAndDiscontinuedOperationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r709",
      "r720",
      "r730",
      "r747",
      "r755"
     ]
    },
    "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/CommonStockRepurchaseProgramsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company's Common stock repurchased",
        "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount",
        "documentation": "Amount remaining of a stock repurchase plan authorized."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeitures of restricted stock, shares",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Forfeited",
        "negatedLabel": "Forfeitures of restricted stock, shares",
        "documentation": "Number of shares related to Restricted Stock Award forfeited during the period."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r93",
      "r94",
      "r124"
     ]
    },
    "md_CommonStockRepurchasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.mednax.com/20230930",
     "localname": "CommonStockRepurchasesTextBlock",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/CommonStockRepurchasePrograms"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock Repurchase Programs",
        "label": "Common Stock Repurchases [Text Block]",
        "documentation": "Entire disclosure of common stock repurchases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]",
        "documentation": "Schedule itemizing specific types of trade accounts and notes receivable, and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r711",
      "r722",
      "r732",
      "r757"
     ]
    },
    "md_ScheduleOfFinancingReceivablesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.mednax.com/20230930",
     "localname": "ScheduleOfFinancingReceivablesLineItems",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Financing Receivables [Line Items]",
        "label": "Schedule Of Financing Receivables [Line Items]",
        "documentation": "Schedule of financing receivables."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfEquityUnaudited",
      "http://www.mednax.com/20230930/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate number Shares issued under Stock Purchase Plans",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "verboseLabel": "Common stock issued under employee stock option, employee stock purchase plan and stock purchase plan, shares",
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r93",
      "r94",
      "r124"
     ]
    },
    "md_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20230930",
     "localname": "RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Retained Deficit [Member]",
        "label": "Retained Earnings And Accumulated Other Comprehensive Income [Member]",
        "documentation": "Retained earnings and accumulated other comprehensive income [Member]."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_HealthCarePatientServiceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "HealthCarePatientServiceMember",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net patient service revenue [Member]",
        "label": "Health Care, Patient Service [Member]",
        "documentation": "Service provided to patient for maintenance, diagnosis and treatment of physical and mental health. Excludes service to resident in health care facility."
       }
      }
     },
     "auth_ref": [
      "r832"
     ]
    },
    "md_PercentageOfNetPatientServiceRevenueByTypeOfPayor": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.mednax.com/20230930",
     "localname": "PercentageOfNetPatientServiceRevenueByTypeOfPayor",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of net patient service revenue",
        "label": "Percentage Of Net Patient Service Revenue By Type Of Payor",
        "documentation": "Percentage of net patient service revenue by type payor."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/AccountsReceivableAndNetRevenueTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accounts Receivable, Net",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]",
        "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Diluted",
        "label": "Earnings Per Share, Diluted",
        "totalLabel": "Earnings Per Share, Diluted, Total",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r201",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r224",
      "r230",
      "r231",
      "r232",
      "r236",
      "r437",
      "r438",
      "r509",
      "r532",
      "r659"
     ]
    },
    "md_ExtraordinaryItemsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.mednax.com/20230930",
     "localname": "ExtraordinaryItemsAxis",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extraordinary Items [Axis]",
        "documentation": "Extraordinary Items [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized holding gain (loss) on investments, net of tax",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r190",
      "r191",
      "r294"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.mednax.com/20230930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "totalLabel": "Property, Plant and Equipment, Net, Total",
        "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance",
        "periodEndLabel": "Property, Plant and Equipment, Net, Ending Balance",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r512",
      "r523",
      "r683"
     ]
    },
    "us-gaap_AccountsNotesLoansAndFinancingReceivableGrossAllowanceAndNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsNotesLoansAndFinancingReceivableGrossAllowanceAndNetAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts, Notes, Loans and Financing Receivable, Gross, Allowance, and Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "md_RuralAreaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20230930",
     "localname": "RuralAreaMember",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rural Area [Member]",
        "label": "Rural Area [Member]",
        "documentation": "Rural Area [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r710",
      "r721",
      "r731",
      "r756"
     ]
    },
    "md_DissolutionOfAndNetIncomeLossAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mednax.com/20230930",
     "localname": "DissolutionOfAndNetIncomeLossAttributableToNoncontrollingInterest",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dissolution Of And Net Income (Loss) Attributable to Noncontrolling Interest",
        "label": "Dissolution Of And Net Income (Loss) Attributable to Noncontrolling Interest",
        "terseLabel": "Dissolution of and net loss attributable to noncontrolling interest"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.mednax.com/20230930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current assets",
        "label": "Other Assets, Current",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r188",
      "r683"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r760"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfUnsecuredDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfUnsecuredDebt",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Unsecured Debt",
        "terseLabel": "Proceeds from issuance of unsecured debt",
        "documentation": "The cash inflow from the issuance of long-term debt that is not secured by collateral. Excludes proceeds from tax exempt unsecured debt."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r758"
     ]
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentTypeCategorizationMember",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments [Domain]",
        "documentation": "Asset obtained to generate income or appreciate in value."
       }
      }
     },
     "auth_ref": [
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r627",
      "r629",
      "r631",
      "r634",
      "r635",
      "r636",
      "r637",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r688"
     ]
    },
    "md_ExtraordinaryItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.mednax.com/20230930",
     "localname": "ExtraordinaryItemsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Extraordinary Items [Abstract]",
        "documentation": "Extraordinary Items [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxPeriodAxis",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/BusinessCombinationsAndDiscontinuedOperationsAdditionalInformationDetail",
      "http://www.mednax.com/20230930/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Period [Axis]",
        "documentation": "Information about the period subject to enacted tax laws."
       }
      }
     },
     "auth_ref": []
    },
    "md_AccruedPayrollTaxesAndBenefitsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mednax.com/20230930",
     "localname": "AccruedPayrollTaxesAndBenefitsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.mednax.com/20230930/taxonomy/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued payroll taxes and benefits",
        "label": "Accrued Payroll Taxes And Benefits Current",
        "documentation": "Accrued payroll taxes and benefits current."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r709",
      "r720",
      "r730",
      "r755"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "md_CoronavirusPandemicCOVIDNineteenDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.mednax.com/20230930",
     "localname": "CoronavirusPandemicCOVIDNineteenDisclosureTextBlock",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/DisclosureCoronavirusPandemicCovid191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Coronavirus Pandemic COVID Nineteen Disclosure [Text Block]",
        "documentation": "Coronavirus Pandemic COVID Nineteen Disclosure [Text Block]",
        "terseLabel": "Coronavirus Pandemic (COVID-19)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesIssued",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance, Shares",
        "periodEndLabel": "Balance, Shares",
        "label": "Shares, Issued",
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "us-gaap_CreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CreditFacilityAxis",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail",
      "http://www.mednax.com/20230930/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Facility [Axis]",
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireBusinessesGross",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/BusinessCombinationsAndDiscontinuedOperationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Businesses, Gross",
        "terseLabel": "Business acquisition consideration paid in cash",
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r421"
     ]
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtAndCapitalLeaseObligationsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.mednax.com/20230930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current portion of debt and finance lease liabilities, net",
        "label": "Long-Term Debt and Lease Obligation, Current",
        "totalLabel": "Long-Term Debt and Lease Obligation, Current, Total",
        "documentation": "Amount of long-term debt and lease obligation, classified as current."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/CommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r317",
      "r318",
      "r650",
      "r824"
     ]
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevolvingCreditFacilityMember",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revolving Credit Facility [Member]",
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
     "crdr": "debit",
     "calculation": {
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net cash used in investing activities - continuing operations",
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations",
        "totalLabel": "Net cash used in investing activities - continuing operations",
        "documentation": "Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r790"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r762"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r765"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r766"
     ]
    },
    "us-gaap_CreditFacilityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CreditFacilityDomain",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail",
      "http://www.mednax.com/20230930/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Facility [Domain]",
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r763"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/BusinessCombinationsAndDiscontinuedOperationsAdditionalInformationDetail",
      "http://www.mednax.com/20230930/taxonomy/role/CashEquivalentsAndInvestmentsAdditionalInformationDetail",
      "http://www.mednax.com/20230930/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail",
      "http://www.mednax.com/20230930/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Range [Axis]",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r319",
      "r320",
      "r321",
      "r322",
      "r360",
      "r368",
      "r398",
      "r399",
      "r400",
      "r467",
      "r491",
      "r540",
      "r573",
      "r574",
      "r628",
      "r630",
      "r632",
      "r633",
      "r638",
      "r651",
      "r652",
      "r662",
      "r671",
      "r678",
      "r685",
      "r688",
      "r822",
      "r830",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r764"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r765"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum [Member]",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r319",
      "r320",
      "r321",
      "r322",
      "r368",
      "r491",
      "r540",
      "r573",
      "r574",
      "r628",
      "r630",
      "r632",
      "r633",
      "r638",
      "r651",
      "r652",
      "r662",
      "r671",
      "r678",
      "r685",
      "r830",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r735"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsPerBasicShare",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Basic",
        "label": "Income (Loss) from Continuing Operations, Per Basic Share",
        "totalLabel": "Income (Loss) from Continuing Operations, Per Outstanding Share, Total",
        "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r139",
      "r142",
      "r201",
      "r210",
      "r212",
      "r213",
      "r214",
      "r215",
      "r224",
      "r230",
      "r231",
      "r438",
      "r509",
      "r876"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/AccountsPayableAndAccruedExpensesAdditionalInformationDetail",
      "http://www.mednax.com/20230930/taxonomy/role/BusinessCombinationsAndDiscontinuedOperationsAdditionalInformationDetail",
      "http://www.mednax.com/20230930/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail",
      "http://www.mednax.com/20230930/taxonomy/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails",
      "http://www.mednax.com/20230930/taxonomy/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails",
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r207",
      "r208",
      "r209",
      "r237",
      "r492",
      "r547",
      "r567",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r583",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r592",
      "r593",
      "r594",
      "r595",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r603",
      "r606",
      "r607",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r623",
      "r689"
     ]
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/BusinessCombinationsAndDiscontinuedOperationsAdditionalInformationDetail",
      "http://www.mednax.com/20230930/taxonomy/role/CashEquivalentsAndInvestmentsAdditionalInformationDetail",
      "http://www.mednax.com/20230930/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail",
      "http://www.mednax.com/20230930/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Range [Domain]",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r319",
      "r320",
      "r321",
      "r322",
      "r360",
      "r368",
      "r398",
      "r399",
      "r400",
      "r467",
      "r491",
      "r540",
      "r573",
      "r574",
      "r628",
      "r630",
      "r632",
      "r633",
      "r638",
      "r651",
      "r652",
      "r662",
      "r671",
      "r678",
      "r685",
      "r688",
      "r822",
      "r830",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r340",
      "r361",
      "r366",
      "r441",
      "r465",
      "r667",
      "r668",
      "r673",
      "r674",
      "r675"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r340",
      "r361",
      "r366",
      "r441",
      "r464",
      "r673",
      "r674",
      "r675"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in assets and liabilities:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "verboseLabel": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r319",
      "r320",
      "r321",
      "r322",
      "r368",
      "r491",
      "r540",
      "r573",
      "r574",
      "r628",
      "r630",
      "r632",
      "r633",
      "r638",
      "r651",
      "r652",
      "r662",
      "r671",
      "r678",
      "r685",
      "r830",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r371",
      "r373",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r765"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsPerDilutedShare",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Diluted",
        "label": "Income (Loss) from Continuing Operations, Per Diluted Share",
        "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r201",
      "r210",
      "r212",
      "r213",
      "r214",
      "r215",
      "r224",
      "r230",
      "r231",
      "r232",
      "r438",
      "r509",
      "r876"
     ]
    },
    "us-gaap_DebtConversionDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtConversionDescription",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Conversion, Description",
        "terseLabel": "Debt Conversion Description",
        "documentation": "The name of the original debt issue that has been converted in a noncash (or part noncash) transaction during the accounting period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited",
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income (loss) from discontinued operations, net of tax",
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest, Total",
        "verboseLabel": "Loss (income) from discontinued operations",
        "negatedLabel": "Loss from discontinued operations",
        "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r84",
      "r85",
      "r86",
      "r87",
      "r90",
      "r174",
      "r419",
      "r526"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r371",
      "r373",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401"
     ]
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Diluted",
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share",
        "totalLabel": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share, Total",
        "documentation": "Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r228",
      "r230",
      "r231"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "calculation": {
      "http://www.mednax.com/20230930/taxonomy/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average number of dilutive common share equivalents",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements",
        "totalLabel": "Incremental Common Shares Attributable to Share-based Payment Arrangements, Total",
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method."
       }
      }
     },
     "auth_ref": [
      "r225",
      "r226",
      "r227",
      "r232",
      "r374"
     ]
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/AccountsReceivableAndNetRevenueTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Percentage of Net Revenue",
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r46",
      "r47",
      "r48",
      "r73",
      "r132"
     ]
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Basic",
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share",
        "totalLabel": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share, Total",
        "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r201",
      "r228",
      "r230",
      "r231",
      "r873",
      "r876"
     ]
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.mednax.com/20230930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r176",
      "r205",
      "r299",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r424",
      "r427",
      "r428",
      "r447",
      "r683",
      "r828",
      "r865",
      "r866"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r766"
     ]
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations",
     "crdr": "debit",
     "calculation": {
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net cash used in operating activities - discontinued operations",
        "label": "Cash Provided by (Used in) Operating Activities, Discontinued Operations",
        "verboseLabel": "Net cash provided by operating activities - discontinued operations",
        "totalLabel": "Cash Provided by (Used in) Operating Activities, Discontinued Operations, Total",
        "documentation": "Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r113"
     ]
    },
    "us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations",
     "crdr": "debit",
     "calculation": {
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net cash used in investing activities - discontinued operations",
        "label": "Cash Provided by (Used in) Investing Activities, Discontinued Operations",
        "verboseLabel": "Net cash provided by investing activities - discontinued operations",
        "documentation": "Amount of cash inflow (outflow) of investing activities of discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r113"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r802",
      "r863"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r766"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/ConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares issued",
        "label": "Common Stock, Shares, Issued",
        "totalLabel": "Common Stock, Shares, Issued, Total",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r766"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.mednax.com/20230930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock; $.01 par value; 200,000 shares authorized; 83,929 and 82,947 shares issued and outstanding, respectively",
        "label": "Common Stock, Value, Issued",
        "totalLabel": "Common Stock, Value, Issued, Total",
        "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance",
        "periodEndLabel": "Common Stock, Value, Issued, Ending Balance",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r519",
      "r683"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r766"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/ConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock, shares authorized",
        "terseLabel": "Common stock, aggregate shares authorized",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r583"
     ]
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtAndCapitalLeaseObligations",
     "crdr": "credit",
     "calculation": {
      "http://www.mednax.com/20230930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Long-Term Debt and Lease Obligation, Total",
        "label": "Long-Term Debt and Lease Obligation",
        "terseLabel": "Long-term debt and finance lease liabilities, net",
        "documentation": "Amount of long-term debt and lease obligation, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r515"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/ConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares outstanding",
        "label": "Common Stock, Shares, Outstanding",
        "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance",
        "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r94",
      "r583",
      "r602",
      "r881",
      "r882"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income to net cash from operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expense (Benefit)",
        "totalLabel": "Income Tax Expense (Benefit), Total",
        "negatedLabel": "Income tax benefit (provision)",
        "negatedTerseLabel": "Income tax provision",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r150",
      "r218",
      "r219",
      "r246",
      "r412",
      "r416",
      "r533"
     ]
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Fair Value Disclosure",
        "totalLabel": "Investments, Fair Value Disclosure, Total",
        "terseLabel": "Short-term investments",
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method."
       }
      }
     },
     "auth_ref": [
      "r440"
     ]
    },
    "us-gaap_RestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockMember",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Stock [Member]",
        "label": "Restricted Stock [Member]",
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts receivable",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r698"
     ]
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable and accrued expenses",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "totalLabel": "Increase (Decrease) in Accounts Payable and Accrued Liabilities, Total",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-in Capital [Member]",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r406",
      "r407",
      "r408",
      "r555",
      "r797",
      "r798",
      "r799",
      "r860",
      "r881"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r758"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred income taxes",
        "label": "Deferred Income Tax Expense (Benefit)",
        "totalLabel": "Deferred Income Tax Expense (Benefit), Total",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r127",
      "r149",
      "r417",
      "r418",
      "r796"
     ]
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r698"
     ]
    },
    "us-gaap_TaxPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxPeriodDomain",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/BusinessCombinationsAndDiscontinuedOperationsAdditionalInformationDetail",
      "http://www.mednax.com/20230930/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Period [Domain]",
        "documentation": "Identified tax period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentIncomeNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentIncomeNet",
     "crdr": "credit",
     "calculation": {
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Investment and other income (expense)",
        "label": "Investment Income, Net",
        "totalLabel": "Investment Income, Net, Total",
        "terseLabel": "Investment and other income",
        "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r109"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Axis]",
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r255",
      "r492",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r653",
      "r672",
      "r684",
      "r777",
      "r826",
      "r827",
      "r831",
      "r877"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r698"
     ]
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/FairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r439"
     ]
    },
    "us-gaap_StockRepurchasedDuringPeriodValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockRepurchasedDuringPeriodValue",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Repurchased common stock",
        "negatedLabel": "Repurchased common stock",
        "label": "Stock Repurchased During Period, Value",
        "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r93",
      "r94",
      "r124",
      "r555",
      "r623",
      "r647",
      "r695"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r698"
     ]
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Type [Axis]",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Domain]",
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r255",
      "r492",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r653",
      "r672",
      "r684",
      "r777",
      "r826",
      "r827",
      "r831",
      "r877"
     ]
    },
    "us-gaap_DisposalGroupClassificationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupClassificationDomain",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/BusinessCombinationsAndDiscontinuedOperationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group Classification [Domain]",
        "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasicOtherDisclosuresAbstract",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average common shares:",
        "label": "Earnings Per Share, Basic, Other Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupClassificationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupClassificationAxis",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/BusinessCombinationsAndDiscontinuedOperationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group Classification [Axis]",
        "documentation": "Information by disposal group classification."
       }
      }
     },
     "auth_ref": [
      "r173"
     ]
    },
    "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/DisclosureBasisOfPresentation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Basis of Presentation",
        "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r117",
      "r118",
      "r128"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net increase (decrease) in cash and cash equivalents",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r113"
     ]
    },
    "us-gaap_PaymentsOfFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsOfFinancingCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments of Financing Costs",
        "totalLabel": "Payments of Financing Costs, Total",
        "terseLabel": "Payments for financing costs",
        "negatedLabel": "Payments for financing costs",
        "documentation": "The cash outflow for loan and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationConsiderationTransferred1",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/BusinessCombinationsAndDiscontinuedOperationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Consideration Transferred",
        "totalLabel": "Business Combination, Consideration Transferred, Total",
        "terseLabel": "Business acquisition total consideration",
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r2",
      "r11"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "totalLabel": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r113",
      "r204"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/CommonStockRepurchaseProgramsAdditionalInformationDetail",
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components [Axis]",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r31",
      "r171",
      "r196",
      "r197",
      "r198",
      "r207",
      "r208",
      "r209",
      "r211",
      "r217",
      "r219",
      "r237",
      "r300",
      "r301",
      "r357",
      "r406",
      "r407",
      "r408",
      "r414",
      "r415",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r436",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r458",
      "r541",
      "r542",
      "r543",
      "r555",
      "r623"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Antidilutive securities (restricted stock and stock options) not included in the diluted net income per common share calculation",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r233"
     ]
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/CashEquivalentsAndInvestments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash Equivalents and Investments",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "documentation": "The entire disclosure for investments in certain debt and equity securities."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r145",
      "r146",
      "r164",
      "r261",
      "r263",
      "r445",
      "r446"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "verboseLabel": "Net income attributable to Pediatrix Medical Group, Inc.:"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/CommonStockRepurchaseProgramsAdditionalInformationDetail",
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component [Domain]",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r171",
      "r196",
      "r197",
      "r198",
      "r207",
      "r208",
      "r209",
      "r211",
      "r217",
      "r219",
      "r237",
      "r300",
      "r301",
      "r357",
      "r406",
      "r407",
      "r408",
      "r414",
      "r415",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r436",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r458",
      "r541",
      "r542",
      "r543",
      "r555",
      "r623"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other current assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "totalLabel": "Increase (Decrease) in Prepaid Expense and Other Assets, Total",
        "terseLabel": "Prepaid expenses and other current assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Loss [Member]",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r13",
      "r34",
      "r430",
      "r433",
      "r458",
      "r541",
      "r542",
      "r786",
      "r787",
      "r788",
      "r797",
      "r798",
      "r799"
     ]
    },
    "us-gaap_SeniorNotes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SeniorNotes",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Senior Notes, Total",
        "label": "Senior Notes",
        "terseLabel": "Senior notes",
        "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer). Senior note holders are paid off in full before any payments are made to junior note holders."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r875"
     ]
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockRepurchasedDuringPeriodShares",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/CommonStockRepurchaseProgramsAdditionalInformationDetail",
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repurchased common stock, shares",
        "label": "Stock Repurchased During Period, Shares",
        "terseLabel": "Stock repurchased during period, shares",
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r93",
      "r94",
      "r124",
      "r551",
      "r623",
      "r647"
     ]
    },
    "us-gaap_IncreaseDecreaseInIncomeTaxesReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInIncomeTaxesReceivable",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/BusinessCombinationsAndDiscontinuedOperationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Income taxes payable",
        "terseLabel": "Income taxes receivable",
        "label": "Increase (Decrease) in Income Taxes Receivable",
        "documentation": "The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/BusinessCombinationsAndDiscontinuedOperationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase decrease in valuation allowance deferred tax assets",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r413"
     ]
    },
    "us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/BusinessCombinationsAndDiscontinuedOperationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Liabilities Arising from Contingencies, Amount Recognized",
        "terseLabel": "Business combination consideration identifiable as current and long term liabilities",
        "documentation": "The amount, measured at acquisition-date fair value, of all liabilities assumed that arise from contingencies and were recognized by the entity."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfSeniorLongTermDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Senior Long-Term Debt",
        "terseLabel": "Proceeds from senior notes and term loan",
        "documentation": "The cash inflow from a borrowing with the highest claim on the assets of the entity in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle, if longer)."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/DisclosureBasisOfPresentationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity method ownership percentage in joint venture",
        "label": "Equity Method Investment, Ownership Percentage",
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting."
       }
      }
     },
     "auth_ref": [
      "r296"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income taxes payable",
        "label": "Increase (Decrease) in Income Taxes Payable",
        "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxAdjustmentsSettlementsAndUnusualProvisions",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/BusinessCombinationsAndDiscontinuedOperationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax adjustments, sttlements and unusual provisions",
        "label": "Tax Adjustments, Settlements, and Unusual Provisions",
        "documentation": "Amount of increase (decrease) to previously recorded tax expense. Includes, but is not limited to, significant settlements of income tax disputes, and unusual tax positions or infrequent actions taken by the entity, including tax assessment reversal, and IRS tax settlement."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r126"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.mednax.com/20230930/taxonomy/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "totalLabel": "Accounts Payable, Current, Total",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r683"
     ]
    },
    "us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Health Care Organization, Receivable and Revenue Disclosures [Line Items]",
        "label": "Health Care Organization, Receivable and Revenue Disclosures [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.mednax.com/20230930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.mednax.com/20230930/taxonomy/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail",
      "http://www.mednax.com/20230930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Accounts payable and accrued expenses, total",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "terseLabel": "Accounts payable and accrued expenses",
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale [Table]",
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/DisclosureBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New Accounting Pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r340",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r441",
      "r464",
      "r465",
      "r466",
      "r667",
      "r668",
      "r673",
      "r674",
      "r675"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r735"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r735"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r440",
      "r441",
      "r442",
      "r443",
      "r444"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r738"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Net income",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r192",
      "r194",
      "r202",
      "r205",
      "r210",
      "r218",
      "r219",
      "r240",
      "r248",
      "r252",
      "r254",
      "r299",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r422",
      "r425",
      "r426",
      "r438",
      "r447",
      "r511",
      "r527",
      "r554",
      "r604",
      "r621",
      "r622",
      "r661",
      "r681",
      "r682",
      "r695",
      "r788",
      "r828"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r737"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/CommonAndCommonEquivalentShares"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common and Common Equivalent Shares",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r221",
      "r233",
      "r234",
      "r235"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.mednax.com/20230930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current portion of operating lease liabilities",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r457"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.mednax.com/20230930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/BusinessCombinationsAndDiscontinuedOperationsAdditionalInformationDetail",
      "http://www.mednax.com/20230930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other non-current assets",
        "terseLabel": "Other assets",
        "label": "Other Assets, Noncurrent",
        "totalLabel": "Other Assets, Noncurrent, Total",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r179"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other long-term assets",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r791"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r736"
     ]
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total equity",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r65",
      "r66",
      "r171",
      "r172",
      "r197",
      "r207",
      "r208",
      "r209",
      "r211",
      "r217",
      "r300",
      "r301",
      "r357",
      "r406",
      "r407",
      "r408",
      "r414",
      "r415",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r436",
      "r448",
      "r449",
      "r453",
      "r458",
      "r542",
      "r543",
      "r553",
      "r585",
      "r602",
      "r624",
      "r625",
      "r649",
      "r695",
      "r795",
      "r819",
      "r862",
      "r881"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r736"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r737"
     ]
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedIncomeTaxesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.mednax.com/20230930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Income Taxes, Current",
        "terseLabel": "Income taxes payable",
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r136"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r440",
      "r441"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.mednax.com/20230930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term operating lease liabilities",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r457"
     ]
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromEquityMethodInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity in earnings of unconsolidated affiliate",
        "label": "Income (Loss) from Equity Method Investments",
        "totalLabel": "Income (Loss) from Equity Method Investments, Total",
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss)."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r103",
      "r140",
      "r245",
      "r295",
      "r524"
     ]
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "crdr": "debit",
     "calculation": {
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Net loss attributable to noncontrolling interest",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "totalLabel": "Net Income (Loss) Attributable to Noncontrolling Interest, Total",
        "terseLabel": "Net loss attributable to noncontrolling interest",
        "negatedLabel": "Net loss attributable to noncontrolling interest",
        "verboseLabel": "Dissolution of and net loss attributable to noncontrolling interest",
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r130",
      "r192",
      "r194",
      "r218",
      "r219",
      "r528",
      "r788"
     ]
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r738"
     ]
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/AccountsPayableAndAccruedExpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accounts Payable and Accrued Expenses",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses."
       }
      }
     },
     "auth_ref": []
    },
    "md_PercentageIncreaseDecreaseInSalaryAndWage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.mednax.com/20230930",
     "localname": "PercentageIncreaseDecreaseInSalaryAndWage",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Decrease In Salary | %",
        "label": "Percentage Increase Decrease In Salary And Wage",
        "documentation": "Percentage Increase Decrease In Salary And Wage."
       }
      }
     },
     "auth_ref": []
    },
    "md_MutualFundsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mednax.com/20230930",
     "localname": "MutualFundsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mutual funds fair value disclosure.",
        "label": "Mutual Funds Fair Value Disclosure",
        "terseLabel": "Mutual funds"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/CommonAndCommonEquivalentSharesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Calculation of Shares Used in Basic and Diluted Net Income Per Share",
        "label": "Schedule of Weighted Average Number of Shares [Table Text Block]",
        "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit)."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "md_IncomelossFromContinuingOperationsPerBasicAndDilutedShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.mednax.com/20230930",
     "localname": "IncomelossFromContinuingOperationsPerBasicAndDilutedShareAbstract",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "(Loss) income from continuing operations:",
        "label": "Income Loss from Continuing Operations Per Basic and Diluted Share [Abstract]",
        "documentation": "It represents Income (Loss) from continuing operations, per basic and diluted share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/BusinessCombinationsAndDiscontinuedOperationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r59",
      "r420",
      "r676",
      "r677"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total non-operating expenses",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r108"
     ]
    },
    "us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/BusinessCombinationsAndDiscontinuedOperationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill",
        "label": "Business Acquisition, Goodwill, Expected Tax Deductible Amount",
        "documentation": "The amount of goodwill arising from a business combination that is expected to be deductible for tax purposes."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r707",
      "r718",
      "r728",
      "r753"
     ]
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNoncashIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other",
        "terseLabel": "Other",
        "label": "Other Noncash Income (Expense)",
        "totalLabel": "Other Noncash Income (Expense), Total",
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other."
       }
      }
     },
     "auth_ref": [
      "r115"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r439",
      "r444"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r709",
      "r720",
      "r730",
      "r755"
     ]
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expense",
        "label": "Interest Expense",
        "totalLabel": "Interest Expense, Total",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r144",
      "r199",
      "r243",
      "r454",
      "r608",
      "r694",
      "r880"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r769"
     ]
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/DisclosureBasisOfPresentationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party, Type [Axis]",
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r367",
      "r459",
      "r460",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r601",
      "r603",
      "r626",
      "r864"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.mednax.com/20230930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.mednax.com/20230930/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail",
      "http://www.mednax.com/20230930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Accounts receivable, net",
        "terseLabel": "Accounts receivable, net",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r258",
      "r259"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail",
      "http://www.mednax.com/20230930/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r309",
      "r310",
      "r311",
      "r348",
      "r355",
      "r435",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r530",
      "r664",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r815",
      "r816",
      "r817",
      "r818"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
     "calculation": {
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by operating activities - continuing operations",
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations",
        "documentation": "Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r114",
      "r115"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r709",
      "r720",
      "r730",
      "r755"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r709",
      "r720",
      "r730",
      "r755"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r203"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from financing activities:",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail",
      "http://www.mednax.com/20230930/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r348",
      "r355",
      "r435",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r530",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r815",
      "r816",
      "r817",
      "r818"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensationGross",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of restricted stock",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, before Forfeiture",
        "documentation": "Value, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r203"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r770"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from investing activities:",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r114",
      "r115"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r701",
      "r771"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from operating activities:",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensationGross",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of restricted stock and conversion of restricted stock units to common stock, shares",
        "terseLabel": "Issuance of restricted stock, shares",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, before Forfeiture",
        "documentation": "Number, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r706",
      "r717",
      "r727",
      "r752"
     ]
    },
    "us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireOtherPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of property and equipment",
        "label": "Payments to Acquire Other Property, Plant, and Equipment",
        "documentation": "Amount of cash outflow from the acquisition of or improvements to long-lived, physical assets used to produce goods and services and not intended for resale, classified as other."
       }
      }
     },
     "auth_ref": [
      "r112"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.mednax.com/20230930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets, net",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Finite-Lived Intangible Assets, Net, Total",
        "periodStartLabel": "Finite-Lived Intangible Assets, Net, Beginning Balance",
        "periodEndLabel": "Finite-Lived Intangible Assets, Net, Ending Balance",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r493"
     ]
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "terseLabel": "Other",
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other."
       }
      }
     },
     "auth_ref": [
      "r776",
      "r789"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r697"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r701",
      "r771"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r705",
      "r716",
      "r726",
      "r751"
     ]
    },
    "us-gaap_Goodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Goodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.mednax.com/20230930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill",
        "label": "Goodwill",
        "totalLabel": "Goodwill, Total",
        "periodStartLabel": "Goodwill, Beginning Balance",
        "periodEndLabel": "Goodwill, Ending Balance",
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r178",
      "r314",
      "r506",
      "r665",
      "r683",
      "r820",
      "r821"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.mednax.com/20230930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other liabilities",
        "label": "Other Liabilities, Noncurrent",
        "totalLabel": "Other Liabilities, Noncurrent, Total",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/ConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r390"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r701",
      "r771"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other liabilities",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "totalLabel": "Increase (Decrease) in Other Operating Liabilities, Total",
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r758"
     ]
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.mednax.com/20230930/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail": {
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Allowance for contractual adjustments and uncollectibles",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r186",
      "r260",
      "r302"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r699"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r709",
      "r720",
      "r730",
      "r755"
     ]
    },
    "us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/CommonStockRepurchaseProgramsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Repurchase Program, Number of Shares Authorized to be Repurchased",
        "documentation": "The number of shares authorized to be repurchased by an entity's Board of Directors under a stock repurchase plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.mednax.com/20230930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r205",
      "r299",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r424",
      "r427",
      "r428",
      "r447",
      "r581",
      "r660",
      "r696",
      "r828",
      "r865",
      "r866"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r705",
      "r716",
      "r726",
      "r751"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r710",
      "r721",
      "r731",
      "r756"
     ]
    },
    "us-gaap_LiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAbstract",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities:",
        "label": "Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r708",
      "r719",
      "r729",
      "r754"
     ]
    },
    "srt_ExecutiveOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ExecutiveOfficerMember",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Officer [Member]",
        "label": "Executive Officer [Member]"
       }
      }
     },
     "auth_ref": [
      "r802"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.mednax.com/20230930/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares available for future grants and awards under Stock Incentive Plans",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "940",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "7",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-7"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "8",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-8"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "405",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481047/942-405-50-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c),(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19,20,22)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.24)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-16"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-21"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-2"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-4"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481244/470-50-50-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "37",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479303/805-10-55-37"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-15"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-16"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4I"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1B"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-5"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.16)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-3"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-3A"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-3B"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-4"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-1"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7(a),(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "250",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//250/tableOfContent"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//275/tableOfContent"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482620/740-10-25-10"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482620/740-10-25-8"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//810/tableOfContent"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 5.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479836/810-10-S99-5"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21"
  },
  "r133": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "940",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//940-320/tableOfContent"
  },
  "r134": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r135": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r136": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r137": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r138": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r139": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r140": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r141": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r142": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r143": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r144": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r145": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//942-320/tableOfContent"
  },
  "r146": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//946-320/tableOfContent"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "210",
   "Topic": "946",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-20"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(a)(2))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(4)",
   "Publisher": "SEC"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(5)",
   "Publisher": "SEC"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(1)(i)",
   "Publisher": "SEC"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(1)(ii)",
   "Publisher": "SEC"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Subsection": "Instruction 5",
   "Publisher": "SEC"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1403",
   "Paragraph": "(b)",
   "Publisher": "SEC"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1406",
   "Paragraph": "(a)",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1406",
   "Paragraph": "(a)",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1406",
   "Paragraph": "(a)",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1406",
   "Paragraph": "(a)",
   "Subparagraph": "(4)",
   "Publisher": "SEC"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1406",
   "Paragraph": "(a)",
   "Subparagraph": "(5)",
   "Publisher": "SEC"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1406",
   "Paragraph": "(c)",
   "Publisher": "SEC"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(210.5-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//260/tableOfContent"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-22"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-23"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-28A"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-4"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//320/tableOfContent"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-2"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-10"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481664/323-10-45-1"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-1"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480454/718-10-45-1"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-4"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482551/740-270-45-3"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6B"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6B"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-21"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5D",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5D",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-3"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-8"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479294/326-20-55-12"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii",
   "Section": "6"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3"
  },
  "r776": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r777": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4H",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H"
  },
  "r778": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r779": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r780": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r781": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r782": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r783": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r784": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r785": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r786": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r787": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r788": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r789": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r790": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r791": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r792": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r793": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r794": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r795": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r796": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r797": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r798": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r799": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r800": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r801": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55"
  },
  "r802": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13"
  },
  "r803": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-1"
  },
  "r804": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r805": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r806": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r807": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r808": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r809": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r810": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r811": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r812": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r813": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r814": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r815": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r816": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r817": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r818": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r819": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r820": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r821": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r822": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r823": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482047/420-10-45-3"
  },
  "r824": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r825": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1"
  },
  "r826": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r827": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r828": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r829": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r830": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r831": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r832": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r833": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r834": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r835": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r836": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r837": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r838": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r839": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r840": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r841": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r842": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r843": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r844": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r845": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r846": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r847": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r848": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r849": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r850": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r851": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r852": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r853": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r854": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r855": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r856": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r857": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r858": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r859": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r860": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r861": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r862": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r863": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r864": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r865": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r866": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r867": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r868": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r869": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r870": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r871": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r872": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r873": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r874": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2"
  },
  "r875": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r876": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r877": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r878": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480109/944-80-50-1"
  },
  "r879": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r880": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r881": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r882": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r883": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>59
<FILENAME>0000950170-23-057738-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-23-057738-xbrl.zip
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M-AWB@TP$W=)(:"]-N()GK8T!B@:,1X]BMIL61X+ZCXJW[:(_*J-FQ5-8V,?
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M:"J>_RRG G,R,84@-#B-/!' +Z#BZ<3^=W0CN"?BA'[%W_,B[,4/,HDO&(2
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M>6<HS,L!ZR\W+P<7L(B[-]B%@_UG,\B?;&=B:\86(_$K75M5]0H,ZNSFB67
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MQ(!F9&=49_1@?,18Q3C)A,\DP&3(Y,>4QM3*M,I,PZS #&*^QUS&/,:"RR+
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MNSLFM&9^5?%7W);</!:LQL<M.QW)O6S!UY"ZZ0X.TCK1X^?%^^GFBJLSL4O
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MV'WQ0'M?;_B^L.A-X0@!GM@$BH5<6%_?._>Y_\7+>X6UF37=@G2W$[8Q;6S
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M;+@]():K8J39)6^8Q CU>IQ%R^M<6R^U"FJ2JWCPPL3:'XADZ)?G3-,J?VE
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MM&,MC!AOZY72XI/ !TH2]XW4&Q:;$_9'IM?(!47P_<GU6F<+^9+8^AV_/)A
MI0MQ%U^"7E0V1+J.Z#5R=X_0,;Y 8Q?]NAC\;\YX ^/=YX0.;'?2E^#B_GK
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M-USU*C*$VRQ[^DGXI1[+T4"#]I:V0\W)V=$,1Z2^[$(-+S/S*M^7O-$BFX5
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MZL8>3_<"A]D>N2H-A.IU6J$N 0<HG8D5W"+S?F?S&AQ^&AZ[RO;L2P\'R2D
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MDH4!U;P!;9I2$8THLYV?WN@RF-US__-MQZ"]7O0S!Z7[X BQL)Q6'-OH7+2
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M)RX0RXHKY#&EV:X.%E0<7)(#](-.DGJ%O8#)%+4O=GB%]\1FXI7]GK0ZG>T
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ML]GAZ '.^<N*,V":<#2-6.,P_MYG).C%_^9-R?EC6DWUU4' 6DXW*+EK=P$
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M#P1*KVK79:8\$&(NHT!J K65BE(.=RU&"0PZ!7]&J2AS%NYQSPV%]%>@-L?
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MAV6$Z/?O+MD3:>X3RXV>'L,NXU)[]/&S$H6N.44<X5/;EB'U+">C^$5MM._
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MXGU%P@Z;+I.U>%@E"#&0D[IV/0TJ6^#E+3SJ99!$Y'C9&8V&2/#G*0(%32U
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MM?BPXWKJGDEG6U:Q%L\Q:FV*C-?'M,,]Y1<P#F4?ZQB7H!'B8\V*YMFKJ9=
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MM[?%?_:XK3G/_?L0Y4=2+@1HIO0(=?&[V#U;/C^)M=43>^OG$D1O@PH"=7$
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M\SBU?>1H6P+++?<]OV/'.:2DR8V!*-(,[?XD$J=/&VL?3"-208LA98 ?H0N
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M?4:09 Y!#SAR\Q[D>H>+O?C .,Z*8A0SXTYGRY:%$O$5UB4@[MHZWG>1:9Y
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M*7&X'5P)<DUY-(P/8#M<,CH5)UX":S7/<O\1T#]HODQJN/CSB@0A\FDIBGK
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M[N@[00 $4PETS1N.DD,6VA-Z ]H']'I@T_HIJ3@'!T<NF6V]@B/H7$NUP%'
M1L-+O']EP9@JTP)*2QW"@EW3]NPY_*Y-)#>M)Y@.51*IG+*+4!4E^];$Q+T^
MMC-3_+4;?;]?^<=B;PR;E_.=_,YX:2Z*>;P(?S[BKUTFL$[>4;=4M/#9(!D!
M@:=V]E_LU+$8>W8.,?ALYN*J4:QH-"S;4N1E*E(?JRNM9PM5C066$\M3?ZX+
MDO#5K\=+H$JR2CZZ+Y^03!\48AOI;;A?#NAV&P+-=#-6#7)WX!4NW/I945E1
M1R,'XHSYE6+VL!E8VI%!$_FTK]N]=:%[F]Q0@)8TKQMOZ+&V]E )JF_5'08U
M[5;F-VT#Y*M[O02GUFE?,>+9:]=>FZ?X6[V%/ DRW/&Z_X15B$US6[MQ>2(W
MBN_L^M0S*^VC:PE!O=X44]1<--!V;5#RSRO_8/6VNGBES6'T^2S^ZH;3W/.N
MLW&V[:";5HR_?Y[>'4K,,$'/*@6*WIID2I&120Y=/8024,E_7C$949DQJ/AQ
M\!ERK?1]0N$,>M$ L3@Y'&Y7;PU3"_O&\YEOY_V.YJ<M?-^LD=QDNNT&V6U=
MS-@LEDHIN #?^^%#>FHE^S&/W00W,0&EY9G-KJE!06^7/B-XCTE&]ZC2$_Q_
M7B&L>%WJAY82CKA;)EV+7-<-E@56.V31.M2WYEL]>:/'^/Z]N%-X)=E2],R+
M#Z;@Z_&A+<G?\26,Y%0[>E^$@/KS2C$T\R;N-YCZF3.>]9K5\KWUY;I85;RP
M07P<LV6T;!&9B2R&B-W1#] D7_A4ST?&1Z>J\@*/_1=Z&.8Y F+4;9ABS4F.
M7QR_X"K'EZ3VC9)17TAZ9Z6G\;]XK60GSL>&MP6!PZW(:IG$I^[WEQ.]S%Q<
M+!0<GD)'-AN;.QP<MWAU%%RD3HAX!V]+%G)A7X>N^V<MHT_)9R>/DADB0"$6
M1_#*VK3O W(.C0CJ>>ID%,7@PF[J:P^55V-?!^S#-OSF,OJ@DOGW4-!%--#K
MU!^#9Q BN:EUV1L&&7"I9M$U+JO.^*UFR!97E=ARO5(ZWJ=8!GVR*]M;_(.B
MP),3(E]!M?9CU:T=$ZMUAA-3'!/$\JJ&OA7TJET9F.0\"[A#O+OXA2#4WJ?N
MT@>%>D2B.+W8J0/JGG#E:UD[DI\"%\-7#%PK"IJ^GS9@EI*CA^41@0PE^4,M
M9@V?[S-&U%;*RUUV2\84LDM$(FP?2>6_=?X*%^Y!:XN-;; $CP;IV%NH9C"V
M4QH>&""ZZ!R,T5GFSAW:Y["%KK."MS3X=Q5II'0XRKW Q=RK%X^_\=Q2P+*A
M9"G+ROIZ9"98+OEP?;[S#9K_0A)D*V=Z2[>C!N^HR:?:\C3I>Y*7? 6^Q^;N
M+ _4XH%B@#^3MUI#)R+W<,=@9)N<"R@U5'$4\Q]G$Y'<@ D$1^Z,]NA:];)S
M/-#4(/<_0BYLWJ^?AHQJCGO& GR=6K-B7.3M ?P) OP@\#,L+N_-FS<QV4Q,
M 3<B^E\]Q9KP7?Y\]O^=J?SO@N=O4'__^\+XMZCS_EUA_'MT"_^F,/X]+U_^
MF\+X=[V5\6\)X]^W<O)OR-_ZO/3?#L:_^9G"OQ>,_S?>_Y]NQ/\Q_F^\__!W
M7.CGCY55Q7DE&1Z>MM=R<DKXHXY]DM"+'TI*_F#*#3:8I!( #-)]S\!)BW'"
M6%Q"2@H3(YF>M<1%8Y;&3(+])9U&X_)FZ:6B.RBS[=B.RE6C:E%_6*DE^$ZH
M&RP1+ 5Q035%"537E-])[(E_\W.H$F=0A/QK<[OI^+X7XA[3[K#VT&).E2J.
M(S>M]F8?%0 #AR\NVJCXOHRT1%- @UUSS$[&@+@AF#V%H.0';#PN#5+TV?85
M_T)0:"$4K[5DQU\=M5BL"R BP>.2&3K#53XAD9 *O38SE!:D#61HI7V#V/==
M&)4K@LCJ?B#X0O8YG8M@C.2D'YNI>&?WF5P-*P0!#A/NZP#QZK.7X8*4LE[U
MG<<O>:V7]M9=^E>N;Y%)PR:'9_[XM*];7[VX0D^:,MT56WHF@9P>?UZIL_3F
M.;8&2>8NJCK(?'V\\ZXBS=*^P\(BZ$9#X(I4^HE8^[)DUZH?>MMFYJ%JL&ZQ
M*'$COFD7S2T/8["?W!X >"GA (:62$Q!S:5=(#E@<K4L]=6D*GW"^G,R+.U@
MF;/Y-7]#W!Q3"+W/R!J+LD^RVB)^:9S#KKCB#6:E_DBR.2BVJKCF+FC KN&"
M[8)FLO50$((@Z7D08Y#?5Z=[NP&ZFWJCV>FP.,F(1"^W1Q:J>.,/QVX845WH
MEK[[+?_\E%WY;)G4A)I!TECO!N1JA[Y(E4?("> 4XG8BHA\]2S.95_;U<8[<
MTG'(E?V +GXEURY](RI#$[?P"CAY6]V#P<%9I[ OFL@==Z:40*RKN?6FN_OB
M6;=F8Y=X/SJ&EN+FHD&H[F!O4S*T%O'^]8Q )R#<PLDO$'N4Y.AR<ZN^2O1S
M07DX&(V9%QCGT*P:C\K24=$N^-]OW8R:B<L*@W?CI^Q3DC2UHVQ&[LR4-_9(
M(YQ8#&1'MWR;E,9FASISN^Q5(75=YF#(LM1&17E3_\[ZA/V(HX=ED7ZXTDO<
MAJZ>E^T-(D!^)-$Q<V=GN)7V*GG46BL6V*$X"+X3C9@F"&(MV89_K4F88V*\
MX;5T^NVX."H=K<X;NHB1<&.Z+0<L!3]1!W;J 7L#:[+T7FD\C::17,7J21(I
M/B=@;NZ9FRGUT3B)@TG]GH(>H3;3^N1[JI_*"='Q$4 1:NKT8LN-<])YWQI7
M7!ZYXLWH@$B7@RPVG,M8VP5^[>(VRRI[DUIM>V^P,+1+ A[=6OMC6%CSO,)V
MPLLJTNMAD-)^>0&#UCR->O:J*.SFV6O*Q,FOU*IU0HKC.-!^>!TQG-?8H3@6
M\G29/6CKH&Z@X59FN,*A"+[0(#C0%A3T<W=[L[!%.3/",<-#V6+N\<YCE5F!
M\GUSL*E0Z2>XN[GQS/M/Q'+!^/T+PK>6G<=O#?+_O"*P>L)"&*)-40L;1^EQ
M5D/J1C_._ X:_+RG8"1>S]'2:RY+V-#J-URS7.#C"[:9@R^V#6RZ5IT7.9ZQ
MVJB!%'K^"[IUW4M1E.,WVAQ2QGYQ3G"!_QI\O[3]Y8SC#%\JIP-N5]IW>-#I
ML=SEUK1+7OV:@3XZ2#]7J2)(VWQX9JDN*&LDML1AP]Z;4#DU[(4XK[JO;X$F
M<7KL)49J^X$2X6-V"C,=EH\?>].KXE67N<,@R #D.BIQR'',] ,"T]Q7( UW
MJZH6>&IGYZ A-4V;GC37'=Y/+QC-GW:DZ^A\B9U8%.X18LOL3(5R'\\NA,_<
M,*<- @$C8/UT3IP]>[5"CUQJ$(,*Q_;U#^?_O\TUY&^:Y]RRKWO%5O^9LTUV
M&F'+'QFU>7$MY;P_>L<Z-:I@FR36&4DO$V2>(('81(H)8_X?]KXKK(UL69>9
M<;8Q-@:#,<$F&$1.(H<9P&!$,B(G84PR06 0.7H &Y.CB ),$$* P"21! S9
MB PBB62"1,XYWYFSS]GA/IQOS_WV/N?EKN?5JZNK_OIK5:WJ;J1FXUE4.5&W
M*B]&'"6ZZ5(D4@^5CAWTI/.$O49='SK"SBRW"&GJ)+0(!;DFJ(K09MIZVR#P
M#DO>O7K*1"(_+&'9)%[-#_F"8$F+!=L#Q/H"Y/(:B],[LR2M\V7OM\R:N-25
M=P5^NU TD55G&GYHOAD<[[@BJ#=I9[-D#U'2 [S_GJ6DK(#@M'Z%#5#??:3N
MFM]"!W]^=XKL<CA9J\)\8PRN.:'J:P:LDGQ3J#<KEMNJ2=O0R^^R=-Z.RZCD
MX#$MH3ZL?X>3B/?E-"LMU]C2GKSC^R6]PS5L;B9:ZG==_- PQ7#P<-'\1]BW
M$^:"+I:J9E[;KY>>*-<GY5F_P=Y9$Z?@M=>BS'76N\I9HYQO _PKV)']<O*I
M3'TF/9>OWUW:DS3[Y7+0TPI\K^OSXTM?[GN;S^AT#H/3W_L:SV4^BE$D75&(
M .7Y]VAA"2.PZ@1-3.6DFWU)1F:.EX]Q7(O:6S_M#H%L <J37PMJ&_*$+J8+
M>)/J3E:E<$6/O[K$=PDRMK!1UD/#K.)21=@;^U-"GWC+EWVS@+YZUUM-S2V?
M@L,1&,L)(Y5]V:')5-QPPX6)L9S)UT4:3>!M.Q3V$3@$FV\D]GFTEK_Q&V#I
MA!>7Z@T$=-^7 E)KZI*30>VB1R ^54<;0A3-Y+\:>/>N=_6!5C/9[?Q:?9S4
M^@N. SAH9>-R'VE-+U:7GU:KA2W0;O(Q[UE*#NV..]1RJ5+/>$-5[,:TJY8S
MZ+(<+E2=D?LD_J'YN2VO IV@_0/[[INMFG<=,RD;XL(32?0-,+U51):RE=[!
M#6^=H(^TM5 $^8)/RH&V7;(AS%'-,8^@XY#95' 3'?/LY(H"@4]/GP*U 2G-
M$DJ_2X&"\"J[6LR1Q,3/^N+X7X '-HN3(GO%I.H]7=2CAP7%/%T\+B1YCLID
MP&[-4#>@*++%!=2P\:ID-/= ^]-E1[0TNGE#52H>D?S0A+&37))'EGNS:MX[
M6!Y2ENMP6Z[O;H[.-'&DU5^5+ZKJ^JU&:JF;;R0__ZZ0:ZD^/CYYKG<_&(4\
M=EFSF]B,+"M3K"V):ZKP-SS'LLN.^G?0/9^'K7(TV:%5X4^8=5;9$SNL.+C6
MYW%3BQ[QY XS2;/AJ!*[6W/*APB#=VD0=1Z.4*C:BM5Q3MDZZ<:,K$$2;I*
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MO7P45PN?@FB!JLHM91Y+1.:ZQ]8+-Y6?:C_\=WA0F2ULZQ*4E:S]=*YH)-4
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MFYX(#J07DCQ5 V96/8[O,O-[R;<W+(TJ\*[/(KMET<@>2 GY#D=56CJF^6N
M-;P$^502C=1W-8VM1FGI[C5L,6#<I3;UB $TJV_.)=(O)24'_SG31F89:0TF
M=YM_=0S<_J@N;>XIGXD+WCR0IRMVS?3R(RS)NX;6ZTCB(N*X]_]R@8#1]DC
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M\-*W)KG,J7TFV;=.T6K7<%#.0?EAWP^&+*B^H%!,P>+++C&QU_OJ,>_7Q18
MR<)394)1218&C]HTJ[3U/Y8 3=WWA4$9L97($ZV# F97F#F0/%.4!'/+>"IU
M>[BRNI,9GR11S2LF564,+N(8RKTV]9RZI]:\&U&?1'25-*O7<RH"2J>-6Q!U
M6Z_E1H]HICF)SI\+VX%<V6E<=?(^_#EB_>'?UAGU;Z9L"@J+J*W.*)XNW(V
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MB_\Z*3$W5KE,I$ME<$A)+'&PZ]3K&&D!2H/\GMH#).:J%E8@LLJ;T3;.7_Z
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MCH]NW W\<SU,L\"<JM"GM'T EXNN?M20U5MT#BS&8TXYJ*$R]* =(0;L,^M
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MYV5,K7,?KZ^OZW'F%V:*61R\OC[TKX<6]>$.\?R[NUP-"#O#F1DP-%;^<A
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M#SG^_A[.?J-@Z%&13V5[  9-W:Y "HD8[?/00S7SW\V?I:\$:W28G:7(TCO
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M@;B>1Y+[.E.D^,T0N@E&:T!\UG.H<]6*[EQT\8?17&%AMF?N58Z0FCSR2!_
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MB6@52H#*QXSZE!#'Q2^\N&+$')MY-.09W:>P1?(%+?#MA%:A3@CPN'1E@Y&
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M)P8:+U!&IU5!W%6#'?M[;!&<+4<%J!NQZ2(..L\O:?K9$*8!1Y]TA)/DN()
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M'!S1A3"#"4P4 *C;I3R$P&1WCQ6?%&D<'.CN9Y\_B4DJ=H;V3L(!_!Z/??3
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M=KY0.[KEZCS=S;6GS)2MO<725T4AT+GUY;D'>'3&J(Q\KUR$];J>2AW:><.
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M[Q<W3^8!4G(;]K9G(IK:]X3J0^<>8NHRB\6.$QT&BVI0Y8H8I6O-=P5><^O
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M_!>3:X+\!A.'*ST@,_L44V F;.PA0.7%<#X[A^A1OCJF_Y795.OPGTFW175
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MP:29FPC]A'O1'<?'7[\;E>_X_O!12E$N.:^CA"V/<$*061&^Y%%YA<^#O3K
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M'\NQPC0LK0K^?BS_+ZA82'3L0;LVR7?/'!?3,RSRF+L*)89K_#HT#@^/6WG
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M] Z83 J;&G(U!BB..!#U'9YN5;R*,,>MCB+'W+/!O[;PV%=VR+U,A/&77XZ
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MQQJ_K&GZ=KC!QY]="V4U!I.]NAH9-6VN;\,Z^TL>C4GFY(O36JW6#1A-^^M
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M[P*+2_DHG]"\85?/$T<WME]52_<>60_^Z&OO$.'\&%/;GTB6N\PDLR/R4N5
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MYJ?,%P =-)'E]B\1E3*'*LU$B!L%+S=O.#Z8W+JBJ 8ME"J.35; <QU2#9>
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M7ESC631<,-]MD!$K]-:RIQO'';ZC#7E(T-;:$RXI,FN[!)VN<U!B]H9-NJ<
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M*'_=>?^F-VH-PG%PE^&GNL'""NS^^ZO[X0L[/\TV=UOP4V8>Y#="V6J]'I3
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M4&9Y-P]0?+7WG"W+P\V"WVY-O6HPTPQ$ B4IPD5GHIKJ)!A^J,D'Z?LZ$G@
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M T3'283S3PYH1YF!+POM2^V[!Y*LZ*M,L*&V=<42._:RG[IMHU8R/#W'F1U
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M/?5O='/]%1;7$_XHME:!2R;5LP<%&G^-)B#G7B454#)+/PLD)3KVXD&=I1Q
MEX=C#(-J51->K0<7V>HZ6DM1V ]VYGW^/ZC.%[N+WV:E$J8U-WP)*Y(5J_DV
MVQ*CE(C\<90+E&'ZJ\[XP+T526([AJ90,X#RD3.,M7Y5,7EEU:Q,?'-N6N*2
M_]<6_4+"EF5X"]\>9N8-R?++D&OKJE-IEK@,4&R<[4]G&6;D2*7!)16:Q10E
M+&QI:U:U_K['W0?QMNN,)A["8E/^Z16,=F+;0ZN^O^,</>N3S,24(=<P%MY?
M]>#;+#R%1TWLEHS@,(-OLPP$XY 28Z(8CU]M3<[>C\L278@]A0V%78N)<EX
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MP!%*#9GGP29JC3R5FJX;/6-Z@8?9(G>, $1A741C&-._JGZX6X]EZBU9-)O
M+9F,Z=9W70)]?$],>F_HB5ORXDAX[+B24%5,J.EEHPHL9-7^T[\]M-;7_>3^
MJB%M_F</3:>K6S(V['MB;[F/CZW8CM?S!$:/#H^[W8V'%2SKFY.-K').7#R7
MSPITN5[UNX7RR;B4XOMEX_FR#8HK3M=5*FMT2@RQGW6_G2[P29.:A-Y&K6D=
M\9@@'L5ZT5G#,GYH-3<^]P38YG8A^J5E/2TMU]=!9)8.Y0=J0^>G4Z&ZARTY
MH6H[2%M+ UV'1UT0IN':C-QN[M10F1X/T]BH'B\UH+6X56?(XH>+7@NDO>PG
M#ZGZ?-LTM;G23U_U>=*,H&!H-F?&+$-)2<>_>&=>NM:HT3Z]V46 [-\<#C?X
M0_%(:)=;Y//D.9T'+=7P,X*Q0M>!Y#KP& UZ[33:1J"W=!83X_AQA/.L%]74
MM\5$*<+D _XVT8OVRV7A]"4*4LVTW+!"WOB$@BBUHS%<G@"J*H?;NP.X%71I
MA34KRGT_5KVEX3;QLDKDC9T*YI/C3AB2C8&O21R2BR#DZ@LS\Q];65;(C*2W
MT&QTT$:N+M&&&RT.>0J]PCLK\"0.R(S04Q%)N,V\TZZ]UT%_S4:A?- F(_^L
M]9=N;Y> 1;ZY:9AU.W7K!4Y"L@[03"Y'L0I M2]VL3.F^Q_14M*$SWB17ON3
MMVGA/XAI1@T@U%#YK5[6LW<TK20V5GU;\><&1Y9G#<S9".T3>6E[$XD+JP7M
M'7!"TOC#DS.O$A4,V)V)GRV^Q+UT"B16F[9E=* <CLR1=X&/:NP*-*?9&A,[
M.[?%R4-3K!GGC!W6TA'QJU*GM9(OWZY!Q4RF(Y+-/FXD0S?F%H[/?VGH<6ZH
MXJX*,4V #Q%(N$J)]>$H6?1%RDO>,E&JG%NR%\U]PEB?U'$\&N:?AC7NSEM9
M2DAWZK/MCO%:^J$73RS.<N5[4P;D6%4]X'ZA$VB4?&N?( :Q:NK0!83HJ>;A
MN=743#7\K1GZA:F!^>4_\HK"1FG"P(@U+Q D<H^83\*-A7U8Z"B]#_#$"Q?&
M</4L._/HO8(_Z?[S=#9O2[-3?R>52_NM'->0]]2=L)?4#E)"4 N)N/44<SYU
M_[=G5BNE]3C(9O>LU=EA6^%I;.2;E7&#60L0DJ7RW78A<*_ ?99JH,\C=^VQ
M3^& >)41C]HB&*I[2T8R1VG(2W()#Z7!\<F2WP;P]YG.3\)J;0L.I?B.-NV$
M0'T2-[":<O%M>&%<SW!ZR-#(;*)M6AZV'G12,SZ HDSP&''@KCG/[FJT[4X_
M47FMNR/$#RR4<JU(?%0_%2W$ \Y_2 +E0"9F/+_58)97?F0D"9*HPZQ)6MG=
M/D 4W#Z%?^1"M)69YXF'7B!Z*J'&ZKO!533$]?4/_WVDZPN>CY)B]?]&>4.%
M"D[TX#HG3[]2\!?1>,^R=6-HG77'?^=U"5F:JH'@SOYG_Q=7*9>1EEE.Y \T
MYUV60S3WNS,7N\QGY58DD?M&/H7"D0*N&;_]%1>_*'OO^T<(@VZNAK)"9TPT
M%+>4%+U$PH\.GL5'> 2?Y_3YNC='OY:9?^PE\/ND&8._M._KJQ57PP6U @2F
MX[QAH-G0[$9(;ZI:JL<A:V$L<T]K$\P[0?Q&-E@&U1G<Z6WN&[>[+E:4#>!2
M=#]>VWKLY!8V<%YRA,ST?=1<6Y7Z>]T0_L]_EQ@0/\11WYPQVM%5QIO';]N$
M@H8'.+)XL&=6\YE+H+[FIF#K*@@[U+6U:#KP$A*!/TUE3!ETLQ6LIJC%\GOC
M^$EU"4DL1>^#W4X &_L&,:D264#21J-/<76BQH".#:!DB6UW9*:@N3!7D1]R
M].;J;N[WGPZH%Y^Q#\48N#C'11@N$RDZ2@KG&"HYU<;&Q%ET15ED=IYTL'J'
M@=F<4FU:]U[NZ9:L%BU]&GOMD<[R5?Q)6K#)69*;K9_:PVX#_7<>5)K(;>XX
M_?UU'&][Z>,'W=5SOQ!7.KS2!8<(\KEFP\%88PN&66C;Z_B9>CO)64%O&PQ^
M\2 .1QMF.^'";J0:H?A+P? G<.273JA%TTA*/#O0+C.*7S!)6P--^C6OY+%R
M%#\P-C:5(4B?;R07HE?8UHY&@80DAG7NI?E =2QU[*TJ@A8,'F$EL8R<PSHT
MPU-I2$MME#:KQA7;IW\0&2S]EYWOP^BU7;);L@6Z"6-#9_./D\VMXXO''Y[/
M-:^X&^]+[8X^^OHP[]7;_ODG]$N473$U[3*G^U^#&L\4-:R:G^!W!1.OAYN@
M-LUW0^MRUEM(P"$R)I;-X MYF=BSGR;8C,=D<1PW'M5KK04^$B[]*-\IVZP[
M)=M@F_>;CPJ51O :$(-@/@%0&!"B-92'YQGE!T5\B8R9>#.$O!< 12Q&S'NS
M7F3S)-5-ELHZ%O]+^% ).BBA[R$9I[&Z2^X!2U"-B?7:8W,YTT=(+LWD]<[X
MW1LYE*)9;F8OONQW?KG^9&6+'*#Y).W&*9P*+B3,%>&Z;Y84I5V9.WB_3?.M
MWO=B@8\FD[ > 9BE(CX:84O)#?%QM.MXFZD 0&SK>UN5XPFU^P/K8<M1?QN+
M=^, X"\/\SB"?%%Z/%E>5;JB)"D3LP5J#C?^2-EHWG/)-GI\2\98)X#AIF+H
M0?@**=6??[X<B%8BV2K_?+9R29%RL,H:'"OFDWL=KW1@["UE71?L'R__EZ_K
M>@7VL\KMNYC=DHF<M5N%DWCRH9XAY* 0E,O5:0O[0_"?;:*MZ"HT+T 2PMV)
M3HF]'-Q[RK2G[O'[RIJ@6X#X44"7K,%TE K%6,-!U",J'ZQ!/N63=[XOPA.!
MW[X_%V1ELB&.3]G^;MV<X$;N?U_01U:W1;\(, AF*'XW&9FW]&"Q)J_":)@G
MS:S1MWFYN,?75F>J<XD5Z^>D%J7_!TSNFFOFL[C$\^UX&V*(=?EB#SZ=)BPH
M**Z!1,M#ZM6//IRN*Q-QM9;UJ M)ZS^Z&^A<1KMGIUF84>7X5'/<P V.#..U
M?!\(VVI0(XR*9^0#I1(FY2%1C#Z^R29;W_*RWB?;)*VN-01>/GOV..Q("(7K
MJZXJCSON>2S J-.7)6L2G![3G2H&2E@J%5*SAXWEZJ:>B(L_=8QBDCS.59Y[
M].M[D&BX;B1D)LZ(,UD93G'?H 0TR@6KQJQQ3R>DHTB-Q%/B!5Q>]%CQ!UWU
M>FVK79Q*UTZT*KQ\($+@IUD78PD38\ZG XMR"R:1"Z"^\/[54OHK%UW$M,'T
MMJ")3(/0H'BP&# _LSW-A\F/+ZO.C1^25@0"BT6T24PA2OH !,"8=M;C1D^O
ML'8@07IUN"&Q*T.C92)&@&WBM*R^W/ZWIV'",A$.9Y#C(S0?.Z>H,S2%$]>#
MH+IL:(EB[MRMZFE$@;&KZD"KU,"VPJ0#4-"/1. ^"7C"IE5P"FE;XI%_X;>F
M?!8R-@5Y1^C;E!_K>H,1Z#H=-#_=VLE4 )4AF"6Y6%;ZOSOU]\O^$$+R2Z]L
M'J8K$@JPJ<BMY0K#\G*^ROC1FEI)Q63FZS![+F[Y[]&-Y$>@H=Y@/.EI^,*J
MB(!;J,"14U=:SGP(M5-%38@8J8RV<1C_?HJ(AJ9%:2QB/L5K]Z,H>UE$>Y^0
M#D.RRMIX%Z8&,ZE*7C6%?VS;]J..2. *7(A'8&L",]++_XTL 7]_R_A_5B'^
M2#8_KQW]SJKA\?(I#S&'WR^DH59R_[HK7-6XN%+(!R%$T(FEXX_\6,1$>AK!
M/\J8US?6$"PDV.F9V"W3UR,@;&\7$?D>]T2$[](-:W@]^P6ZH+VGMUF,&)E?
M[HGBX56GB.J>]7/K:316EPD1(V819H;-2B/3VK!;&PT\Y'.0A38U2$?>[O.D
M)>-3@:@U!M3(DQBJ7M["2@>;FY+%6%,W%:^[=/J2'\V$,_H46S^@[UFI?[W2
MB/D3*FF1/+=B>%+9VXXIF('WZVU"XUI>8SB7>+O<VH'Y,.W$G5)+6\T7%06%
M@V4/1G#2#9:\VGQJP!.)8?5!2L:-'_'_=45&32'(4H;".MGD]XX*$W#<,&>7
M2 F;%FP*QJ^A64DD9''Y/["1(Z_9"E=Z"['Y>_YNQ@YSO0B.?W27A\EU@382
M)].E1A6^X1P/%"9Z[>[N% O9SYOU0?[N@?$$6?XUK*\I* [UG0*EF&^RTNFU
MU765BQ#JVG=+DENSJ#.G2\)*G5#^5))$4*M,?1(Y%/$L5-O @&<4!)I1?8MV
M:+/%]C@;)M%A"@=IQ"1R!:8F#!H*&TV]N"*A<QM#1E!<K01F'X()KUTM>R'L
M%58D8+-3,P5I3RR1VN1M:^ <5]U4$O;91ZG0,ZC&H,<I[,G^+U6'[\]ND5MG
M.*+^%;;99_O[J7Z6K>3VZ\6:;2^WKVPD4H):_G."V.SZ03K@J<Z:_"'UL9[*
M7V]\FF&Z'<5G-@NS$<C[L@2FA(3?2,1/6)Y5[JM[ZGS=54^.Q'(3K/5FD>EA
MO-#W:##$)TG,7J /\93CNENQ@"TN1/V63,F>\DI9AO* KXMR>.3FP.,'>92U
MW>5(5\I>.]MR:J7<U3WY_2I!3.G\\G7 XJ\W7#+/+[RSYH1OR4Z7SJCZLKX>
M79Z0%D+/>"\^^8,8V:ZN"Y0.'@0\Q7R\5M#Y:VL/^O+#ZL"ZU_7%]'[K98+?
M:R6N)S$W_B-LWX.4PL :_IFXLXCFZYKK+RZVQ_(WUZCO%O_+/V/[@N-4TH'^
MM2UGQG]1INJ"-<"?>/7B9H5-C[)+A>.6+(MP_^8YY2(TC@V'OU[<NR5S5$(S
M3UY3*C7#_1EB!X!*FG.>Z/&19S&7,2X'AUOWQVH"CHNN\KJY5BX6AQ3,#P.!
M5BD$I=1[(:LF)/GSHYP.$7[9>NT62/UKD"YZ+L"E.3&M-2&5F#&<VB!<YJBP
M-3FD5\J^,CDW/9J5*"OZ?@'W4-,A2?I-A2<'SAF9T- Z+-_5X])[)I386$+I
MBQYQXP6J1X\U2F\'&P.79-KEJ.<C)B.$"P3>9'SZ25TGK.A@<;@Y+>GY=[.^
MX P/OO.*W@"8_A6D]P^_S1OSB9LRW/>^09.%%Q_:;7<>MT4K'[YW5S?NN-9)
MW %^CP1M3 J:P.01%,-?B%X3)P.]?,*$01&A4$ATB#^?*'ZSQ"W/]14_@&!]
M+?# 1$8MO7 *^@[8)4@]D];1[N#MH;%I"H>4"$G90@[U]$Q&);(>Q=L++8Z=
M9K)R6"O5&8Z$'OX^G75#7G1#)S$PO\=]2S8CF366/)9NN(M,8\MV5"IB*V6;
M%=A4.?\--7!+=F_TENPQY3^NBYD9EU!2G@DP4#+Q!1MOE UL<PO$EWWWZE1M
MM4K"+0]O":;SOI5#);O$ %T8WEI(3M*'U32%7>O&EZ_]T"BRX8GY.>6+/@F[
MB"&G/^N-5>B_P;7\U@2\8BSN0]8X&Q;@,W;@'#/Z2?R;!A&+_'&)9*,53)U)
M2,Y0R.*=D-[-])2GF]L+#6;<(S74'T/AAA<"+QG6B>.2XPF6+@@( #'@8/N0
M[U4I@9>8E=+'WMCH RL-[N4"HR>6.)<XK_CRQM.\/Y\I\IP.EY9O.94O13;T
M?'!+3H.EN^'@ND*D9^A[:HF<G9&1,7BV,,KE7,97[9HTIQ)G$@%0M+VNIP1L
M?$A@7'BS=)QNB5ZRL@.U+F@6'+,%?FDE3MYCXF]9R$NHZ9\BQ/E9_^ZF%I)K
M15DP%UG%GDFRY%U1_=?U-Y]RN&&V.=QY:!9:],NFR0343%N5V(TM-L2F3:TH
M*VJ-3R38U/!KL6J>_5&F1F#A*4.BA^-?9WM)K;S<C9(+4]*^7Z%6=?CIIG/&
MG%GXGAJ(':*5D$C%^/=QX^!X;I9.%$,Z3<4<_U_J9[#OC=*/5-T]/AH1ZK,H
MG*GWLSVP51U)VU39/'.3_NPE=A3Y630I&88M@\7/!/%1] 40!1Z]]/GR8;8U
M]BJY3Z:^@(5/!KYB$"V\NR!4HU 8Q0P%$U1)U4M@Z7[@^:]97*OC$H<W,*O"
M/#VDC11?D;?0]F3%*#YD%$19=!]BI@H[Q%+XP(O<4<*J#L7ICHY:W?.R X>3
MA:E./HX'?,"7C FPJ4[44Z/0>_RRXA0T!E];R>/@B(= JL=.PS DQQ C@%P)
M)Y2-1#B6!_W6< YLK,)D3O9K=^O0<T_"97;]TC<=ADK=,@T3V_IL(W$\:VH"
MKA:TE3^H7/A$G)H@XS"%GR)+T"J<FKWTRXLGFMS]8CVAON$8RU]SJKN<'TLU
M-NG[ <1U-+S,1=2FQ5D%.\1[*GUD5AD);7)P;R3C2)'T,(YVG*^OH R06?_L
M\7;_JJ0QBBF9%E<IL=$"Q62]%P7K]*K6V.N\%($HX!\)8:[A$9N@23RJ<V"G
M83<S#E&]Z-/09;0K87!:H:W8)B5\!TQU4ZY^=4O6:,A=R5^9#;HHM9#>,ZCF
MD5[ZAH=68D68>;@6Y"2U9Z?39!H!!EBL'&^/2TT10[/DKSO\ZFV\/-\D6<U;
M7PY([S>N1*6V&1]" F%%2[;INK6/%#,@TSI:+6E6HX=L/G@@6WEO@UJN3E,R
M_QKTO8%QGN56QF,3>91 ^]7R_!^3N%EX"CJ4QO'P7!$+6V(3K==K"I=(]O*6
M\(ZPTQ 7KJ20G[-EF*&1WIJ\EUU9.-G'E?1AY#A4],IZW'$249WL/1=K,/4T
M,]]^WQ"<C+UL/PS0UX\BY#L]A@W-@G?%B)Z-/=4%B733$PGVQ'FU)>41YNA5
MQPP<_YF,PRZ?NN\.ENF2[NRS=AU>:*<.83'<$,DHFJ<<R\[<N:>:3+5F"8K@
MPC'$,JE0/-/I^-B:!U+^FB-1\HA=[,?9E'/E>?11GX_ V\6=YIF?.3(,9T*Z
MR,CG\@);$'B>0!U+;2=M5PE_CF-_[=P%XK?ETN1EX8;.F@R+6 YG^-RXI?2-
MN K+M/3YV:A72;6G@4J,![4D[1&-!L]$0 Y<(E^9V7H,[M?(EE+G\VI3F\/#
MMLQ">V5D@3^17[N@CIG*B8B#^LE^-%K@W?&L ?!VM>U,L<F-RM!AB;6#0UG-
M..GA8&EA+GA8F3U&"OQT0\<C'RS,KXDS:$Y.U_G\;F.:/S."=<)%-)Q/IH].
M%,&]QXSK82M!];XG1L]9:M5S<XA%C4UXM8>!7E)EF2.&S% Z@M@TDZ$N>S !
M8]_W.L.H0"^#BV>R^YUV05?'?<[,ATGU2?TW^>;*^<@'D-I$:=ER'(^T6F[X
M4B3GD'-X$I\D,7>K7?[OV7*^-_!$R^_" O$VD]88>Q,X9<>N,R9N]6T4%;^=
MZ,6:4*E@7D'=,>K#CO3F *Z"6\'++W@.$: B6!Y89+:8QP=]/R^;R)G]H.Q)
MWI"9>)^/%RIY<K2Y(0VG%L0%<?;)??"J&^)_EV9:QM?E<6SM?2$9T9K:^[$^
MK<+;#NUN44(.R0\[>%^L/]16I(YFBK.)EZ8576B#Q7\C9&N>%K3-.Q^IP^Q8
M:),1 O),5;D,_9J7W4/M;H4!J_H)RQ4S::9WM9$H'9=B@OYI7FV;7&&T;L0)
M37(\B.TKCJ'MI'H>6*+B GA-5DG9&MP3L-X<>QY*=QBAQ/'KLA!PQJ*DRX<H
M05X1^*>[B^X$SY./@]/#-&.FAF9KYJ%W$V+QJL^;?5$_G;NHP[?2&2S1"3KO
MB8\=2I! =?JA2_X9<J'!*%"E#Q6O3SE2J4LVIRFV/I/&A?< TK9M2!/O*1P\
M!5G4P7;3+)*2?6B3=/ZK\?9IX(O.A=I.TQ(3Z32U9<SGDV__\'?K@=R?Z^I[
MK]8&OHW=!'W@>QH9$_RG(MT/\9(E?M-9;3XV4VQ8YJ]T=.&TZ]'4/9(V.Q30
MM=9LB-AV?&SV@$GKM_^U?53F5#Q>=.2K6I+>OBL'^YS>Y1".)3E'XBNC+"@U
M+$\KNB:<:1F'X.!E%R-CA9\%NB3:K#52+FC :J@-I]F.^NE5<KLM(7.P;I?=
MP",]8MO<2,3G8@-R>(OFHSBX/5#V'?)A37N_EPO>K@XR=&%C;UQB=&FM'05K
MT;1LM7?+([:(6+&/+!,_@Z*DDI.-%?I*U>/@D\N,=W>">GSJ>_"')4*[0@YL
M>OA3@R2H'BGKXU$A-+IA<X10T <2%Q>G\T,B4=8H<'\_!J&+I7V@3*4;Q$$;
M9,G0QL60%P?DC)OX\!,:;;;;L%N*XT^T!W:[Q#LGY,T)0^+;B'-CTVU5HS&U
M!^)TR4MS!\MFVE<?!]-P,E->/\OG)C\F[\!-5^GUK"+L37?B><]@WU<18F=A
M Q+CD'4DTV[>Z)2E^J3_ZU'Z8T&[G<]C> 890*.RT(%>\M!GD-D=F5A$\2T9
MU-2G1V=RM*%H"/^RZY5B:I<P@TA^NF:+9E/C=[?&5T=&3[0[?T-HO][:>3Y<
M,@$'3,9/[AT<S@M9PV,K0>P'NM0=PY,[^U1G4GL!75?$(BQ"KN>X4;^Q4M=?
MQ'>$%/#[#J.3NYG-_+"^L"729AY?8D[7X!<D4);C-[K6"AT(K]G5*!F0;HTK
M>0A@IS4(J&#7=E,UU\@JFHB47K;QOSO[6\1ZZA/3,M\;O?&T8*1)=_C)4+;C
MT UV9N4Z_CEZUC:E^NT*:+&E[#V@B.>ZWK,LQ\[@Z/CCR>.E&;YDF0ZF(P&,
M_2-FKZMTF!RTNM XI(NQWD(&0Z%Z_C'E)57:;!;5>Z!G4;9G=!'V_):L6\$4
M(GENXZ:6@7#0V]4KR9N>9:@[".+A^8KO-CIFWGOM;)L*L\<4K3+J&P]%CT,"
MH[Y -E"Z+@F0#9?(=QQ1=G DU)%+ T:3)_08B+6#Z1" $/U%-?5O5I85W&EM
M**U5<HE]GX'E )T%2Y'0W'#FL+[S>TU:B^?YQH6NPG5NF_+=?I"N@O2Z20?J
MC5&S!04*U>2?8D3Q24-)W>/4I[^T0<59[+7LO.;6S#:>5 &%:/U0H%LR0 /(
MU5*HM)MA8:^4E\ +-I*&A"/T#C->\:,3>'CD"'8[V@%X)?L2@9&JGA)TL"'+
M.*25S>?;<.2G"@B>.STT_L\E&;Z6 ^6*L.]D9/>%HFUOI'W+KE8\RA;41LQT
MA!6=Q-A&Q\PC(/SJ)E?$?D46C]T3<OMGJ87IJ7@_^=JRQG(F!6R!YTJ%^(Y/
MW ^I:VSZA)=2W[@P:>[5W4)+Z>,@WJNP6"MU<[WD >5&[*),>T#?'&S#8:I4
MO< EPD>S3E[>-7\9RRJMEH=N$?)ZG6!%W+6;<W:$(?M4DJ%]AR:EA#Z"F?"C
MC\!V$[%W20R$.EVT/XV5TV[BR?.KCY)KMV2!]K=DP9%*>V?Q ;O/=+8TM[1P
M_\<ZP;/*C]=/_3=U9^B5PLRNQ*0;Q,)R>U)#Z6:-HO;,U/PZ[&7,K+#OH7OQ
M"$>!P[!_76[XT0I-<MI &UC'11'CN1)G4EWW*>]JG7CSKX)I<:"CJ=#;4?#"
MR+2 _F03-E^>/")P><($KS;IIOO%ECV*859'!P-RJHFL8V13V92ET,17K^;E
M[$J<7#=>T9W#QW#&(L]P?!:KWQ!>I2J95OKZS+O]C9BY%5C"AM0B-!)]].2-
MN TGF7#8_K5W@NGN(T9F_MG:QV/GJ\T=F)HAQE<-N>X#O.,CG2H&*30;8I1-
MJMW<?4\%1NSAT89>'\1  I>8DMU3WQ3B\+AF*LPF'(?T@+X_3:"CPJ+E39!M
M0K'!'I'V@D_U:\S&X7=E?4A'H"4YDC>U8E$'&D4A (OSUP>)?@9%."$3N0)#
M3C?>$OD]Z^4?:(#VR<@ +BDF=2,8[L%SX8/I,9!]:4%X/5/[FYJ.PQB%GE4Q
M$E_YE8UXNVJM&#FAI(/VDMG]U^WD*"&)*J&E9$SSP'DR?GTC2N&)O=YAH5Z2
M0L8C8*GL*-,LPV(<?(V'09T1R $9FQKF_NIUU^263#;SU]#X!X+26WJ(_>'\
MS'/->S^B%<?GH+5FT=?DLB?LL8.O%W>:+2DL /=&E)VTF:3>#=F*]%;Y4JVO
MJVRN[*P9IFFKV+=\^87T--X8FR?68W#=HVBX$6U@1=4E<2)H#^0Q6P2ZC],^
M/1[VHS)JZD_SI1GVM.3A U4!]EX [K^H2K6I'=5ZSJS/1.54F7WO6I!>*[-?
MIID?A?K,VX8H6&^/]GJ1K5692M=4QYEZM*9AP\G[(L5=KRMN65JK(X)._!=L
MS5*$&.C7H-2"W@\?>CL6L2!71#<!P:O,5PNLCM-$HAK#N BD"K8ZUS4#^T3>
M6I V9UP;\90S;FIZ72,!]7R]=A/0^$FE/G_II/1.-!A%*>I5([3IAL>3?&'O
M*HK.H-YY0DH*%.QX#8EC,<-^'3,6?'WGH8>F?B*A'_6L;M!3&J;L(4>ZM)98
M?TN2V,3%J+6[%0?&^O:/2"R9A< %["%3.!?>KP<^)O/(P+DT7 B+7%1_S/Y7
ME\'US/W=WL4\X+V$@D]*F3NO.H7QFWE"$Q.:D7$1?S8PBRFQL6;('H6=#:V8
MV+]3ZY&(.^D.+F5U:=!9?S;B4^3R]/6BAY>O.;0$'?.5@%Q/FR<IW%<  E3Y
M#&(!+!0314')]-P&N7UX9[Z\:>N19'K&>MF>,.ZRL1PAEZ(+/I&?:A$WQU=I
M X5JP5HM[M1)*QYJKN/I$!8LP\(X?ZP9M6%_?<.1.D_^EG(W_<?H,Y2!N+^U
MC+L;UV+DLWTJ@22+<\>['XT6O<:$8A>\M.7F]E!1U@E)GCO7)N^%\]NB *U:
MG19^\CZF*)Z+P*8)&QE_).+Q56FC7!HMW0L\"(T':Y:*!Z+C]O/[ 5[6/LDF
MW0,O<F5I/^TG\"N_QICKY7+F946Q22N$)ES.6E2[TR4/B)9D%59>-M KMF[#
M"!W.OOZP'*/Q'H<H 1US&OG63H XM\ Z7*0:6WGD*$'X=& \IYY@KU5(!&9.
MMVP.+0H#^/2,VH'7M)S[Z 18@E5"SD@<DB-A=3+I5<I07Z7W$*DV6YA7+[!%
MUS]0VR$!AHYS%-.6C+@EN]#VSG_;],E[54TD);^(>KF_OC#R],\O;WES#5:.
M-V#/.2P7J#)TRV9FO;1)ED^B0('/OSQ7RS>/7$J4&^A7,S],EC:<]*!MU_3B
M+M#WL0;YF#=N290O :7 /K1&W&-/(X<J^L$NS@.IC);530NY:=.O9$?&.D>B
MVZ:'=)P>>_)U(''<R=@$>,I/K-%C9&1W>9MXG-K38Y3>W;\E>T!LZ:Z/NPKI
MNV%MIL][27%R2R90.?"O9O<"@S^TV07HW+^_:6;PU_)K%QT@A01Q[=4>JG!]
MM]9!6Y7M9ARF [X+*HS2J]'6@?]>KO3S<P5/I5?)7 '^")W676%.-K>L+/GD
M-J_O45UM]2U7@S9-<N8=O,Q[P0V)GQS*GB@Q*_+Z.]<)[.?J2?1;7LW9SA>5
M!= 5HF#/5H@Z^UL_1(P;#XT#_!V9W3@>MWZZ:KZZ5>T_QL:B%)<EY^UR$DRJ
M^[)V-79.&%"\:SXSV?O)%*'W[2?V!\<I)VSH!VAFY>EPY:'$[%>FAH- 70^N
M5S=GAQ^71;(P&)W[!2BTN;9(B>S;Y7D)IC8K$MMHS#C;^!GHXN.-QC.76[+/
MA("6CJ.SRZ[F,W+<"?8$=W8&Z*/\^N_KXF_B_7,'I]!KT@$U>B%#]A"C_&"N
M8?;S9S%,H!GCFQR(C9+NVCP/#Q=M 4K4SR7.S"=<L\]VU02S&O1V^5 S(T-7
M^[S;*(U \%SH%**KYG#9(*\JC-N:4T7(W3&W-L(P1F>9C?Q97A_>\_3!!9M]
M*EK5CS([9<Y9R#J/H-RAO>I.^BX(RT:#BN,N[%K ND<0 /.2YJ:VXOZ @[#@
MP42&/8 /M^@2KM/KT+)D]>+WGQ!9O\= +WMM13MJ^!H.I8K+,16COR_U:[OP
M@3M;#[%4#7/%_E:!FVY)&31Z!0"W&"DBARIQ52+EJVVC!R?*R7ES9G#H6$\8
M-4Y[+2U(:P_/&/HAD^!RMIL;EA!M66>79(69\RHTTD\S>>I]448C*LDE?AJ<
M?TOF0[PEJ\=?#YT 7KQOT^:=B30$2OWYWSKBYP1S:M*2=D=6S9U;LB"XA;5I
ME[^*S2T9I7G$T&^AWK=DB9.V?\[7ZPG\SAU+&R'G^\(\4HE;<8EA;;I5^>G9
MS/GSN"LQ7$VEX1GX7#OMBHYU,R+WT2R/!IF=1R']^OZJ^LS]-WZV1IN8F/.Y
MX2R*[.W! 1G"$2+3EX)4(9/VN("_@$R,%3LU>1HU*6TV,WI.,P-5_%/$8MFH
M;YN6/OVI[RM&/MRDH9X2DPK(6:*F%*NMV!HMMJDW'0Y<%+\*Y1\Y!_1G#? 6
MGB:_<]U4AF/,03Y+O U<#P6Y'G+Q5@_9Z'#WB[,HI;WNKTPKC>JK'MGH<P5\
M'5NCJXC,.8!$H!'Y@T/TPV49$Y1*GF>:!/2 ,W: SV^<98;I'']ON5A RE$J
MY8?ULH>E#/7?)A2:JF(9XR/3TF"-J_))T_F[[YQ)@!7%TJ)8,TN#L7R D "A
MDL#L;AG29I"55\0:9L%9PW-OYWZ224M/;50^?HVN!EJ#"Q*V6R(FFD@N#&T,
M#$.3M=#:!VI IT\KMJI_/8U<W)?1[P>(^3[-7Z]$;%KZZQ.N)E:52OAO^&Q^
M5SP)$-D.,!R^LEDO?9>B:BF$W:^^V5N[OZ<H?3.;\>#Q?/*VK&5'BC>=:M=N
MS*G6+5F;]?ILTB;MA=8/&L)!&HD948)[>V_HKY)V7G6[9YKOC3(%&M,TLX.A
M/HP)A?J-=6E*D@I"MBG#1+$X4ZVQ$9N8?K\JX>:NTM=K\C,C18+5CL%1S4]V
M=]^U00)]GC]Q!Q&TF'#THWP]78$R61)>R8F'X\_/KEOTRP26GMDS?-O4%JI,
M>J;/^Q:SLJ!KIA<[\/AC0]CT5?Y4*MWR['E4B'7ZLI-_%S<HJG *1L1 OEFF
M]($HN_X%_S4IK^-#"Y!K5-/0I0C=-MT4.WCAHV*EY[J;2HHBE-#6HA*6]Q?Q
M$/@:Q,@+FC1>(<@>IY^+=Y-T*ZKRKET-,!VO*3QKUF0X5J::?: ^TN8P-R=$
MW/\X&?EP#XTQY^X30:)]Y5@:>\20J0_#=*.7 '3TX\3*$;6\]I*"(M0D98V5
MFE5(NN[-I\.Y>6-K8E53+U)Y+A@0N:F'L7A06@O65A-HF5+/&1O:O5F43)+
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M>\A973WW'3TVV*[R%?M0)Y]H03.-7(B%P9#;8,$BS*J_P<T?#G6KW8AP.U7
MYZ'+5D@.1_8&3:Y!)'=&'>=HT]\I%/Y2ZLWN\6 Q*'5U)CNG%14N6-"3LDM6
M"^92HDBHJ?OH7708">M)8=9J8WBO,?8>TFEAI_,,7!0+UI4 @:)-$WWRW?/
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MBC63W@5Y.UK%*XPJT_)!/1AA$=JAD>_<*.)4U"<@XZCPRXN"(N_4Q/H=34\
M%.J JF0.KJ(=PHVT%SI-D" ]V0DY*9/!X;9IQIO&OY@7B=^41RJ5XDR\5!KU
MQJ42>4*DM3G:(&]4:2MGR@8@"V1D%+^LI><DT%P,RXLT5GQ4S)WX$N2\(2%$
MUR<E$_/N"'DJKU9@/:WE43I]ZJ]1;2</ .=-<AN+NLM8H&<VQC$E^/ NH535
MU\XX&X.ZZ7Z+F@?+D8#F:JA3G)>SLS)#DW/QA5[6Q0='+LQTGK%9D!"<B_S
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M7!"*\<0XV.6;.B<5-31Y??QX@$T?,*\A1ZCM.=PUFVR;%ES=4T6CQU5R:3;
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MBKH)"MS9LN$6/^^Y011FF#Z?=//(:1S&Y[1IK^[D5P,7=3CWER),$R W@N]
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MKE.$8"!_K[MV*&24:R$L:)N\NR-E8 ALZ#N]$%'5$9_MCM)VI.&'[ ^FZ-\
M2O1'/  9>XY^XI"TTT#B3?D/>(CQ:Y&JB?8MCV3";N^#U7;-PN",8XXR$JH&
M,YR67+6[_!=R8^-[VC_DR1*_8_D7IT7UTPMY+GBL]+>]HU-4H8.D@(=XGC:.
M/@95DS.^2T#/E+5?U/O>(B_-#W^)0\17Z_&FIX_ 9H<JEP#)M'-%=&DE_Q\\
MA*1O5_Z0OS^\LAMZ&#"4;EA\+7\+OE<K\*?QJ12[^[;LWOLZ^I<C@USO^%X5
M7YU^-Y*CE;(@^C"*)G)ZB=[DK&4]%Q8!26M]W.:XP<0F]HT )N!(B0(\&0?8
M3I 6:>?)0EU]2<<FMQ5]O*T["<@/_+L#[ZU"8LH2X1W2R(8Y656ZIF&)5H\:
M;5JNW$CF-@_L42,I":J#_:\EBXF?WMK[1!1=M+XP%=O>E1BX!'@;_^:4L,4
M%NP9L.QB&WX)6)%IG-.7_\@RHIPB'U/,(T_<K0@(;3Q$=0H<,NOOGFHT1$]N
MU9_?_.H+6MXQ__?Y_$E5EA?S'1?R-D=:I[7#EX!O>Y2AQA=W LR8G2^4:@HN
M 9TMDQ><E%-(WOH)+VCKICR9O,=O"R(QF^WRI/^,WF#K86D;CD\_]ARO;YH]
M[5]$GD;S')VC9Y6W#J$7'[OD.%R/A#?VAV]4E9"_G8E[ZGR(*&%]U542*H12
MF=\:?2?ROLOD^SJ176[S!<<MA=>$\MRVSY^[>K^U6C/V+A:^R5Q+E7V9  )G
MZ;(7;QHY-*BPQQL;.;G(CEH+["_*=$RYM@O,/QS,&7?WN,V>4^)PX$,EY42F
MP?<> ""3\E6#1M.FGA%**!L.['G7JS2ZH\Q/^HOG$BRN;NL3+UKW_>1;',.6
M;P<I"1'2R2OVD9V]WTTT]B]67IB>R2>Z'4YNU?:$"DBC+N ]=8M.&VO(AS1C
M:C_^Z_19TEUSB&_JEGU1%>IUO<&;V^.@,<-RH2#%8:[)B;&)L*?.^?,UY%M2
MLM".2"(]/?(SO@=DH-/II8)VL"W@V";WCH2[?]=U]J=IK6C0518M?A+0E;(U
ME]SL0\0^6-]86IVK85;JO9)U-9?Q",_2>#VJ+;*U2,TRS+Z#8VJQI63(9'5/
MGXVNX5%I["A+'\AA5)B_OD@@D\>G;G.!,[]4]=I9GAZ<6W0FW[#9ZSQN+[1O
M4FI,<\"P<)Y4SF]V?1ZMHG*:R4M\\H07\$^H,(N.U5ZRT2QLL\%"WVN[E'3O
M5N1:X#+9,574IS=::A> '!M"VE9*"B22*$$ JZ[AIS;/,"069PK\A>98B7^0
M7[AHG2^LJK+A5K3U]@Q6*%'__,>\C6C_OCR%NQ'5]H?C.A$DE=Y#?=8R Z?6
M;3;G;R:SE?L+]"&!N^P2ZZ5)&E ;;(F^WY[+2<+$ *[6KJVJ<P5[(I$!F:,R
M%4% 23%O:X>*S6"=G>$Z9WETY=JFM_NS1,[4J@0$$Q[<9XQ]^Z\WC&V 1)6H
M1N,%CZ/I<\,\GKB=%##(^6342FERZ4<-3,2 3RB);=O(R; MPJ6F5)15RM0#
M;6>[6D=L531V)3=9'%,/X:83U7?@6.-ZV5DLX_$4TV(LL>$*BSJ(E(:NX1EX
M7D-MI2IAFCFG7/7Z$']%KB/MW/GFD)5=V;:E^WX^,(2I\<(H141^^%G86,L!
M<<PUAS2N&NX5_KVLY"NQ1F]]6Z+"6.M4)TO0@Q:'.Q##;A0^QO1G/6RX%]8@
M^'=99X4P%0Y"6%IE9;$'#+RVI [G[M!.21L&JE0 Q8?&'=(U\N%UNI4XO>MY
MS][?M/ZZ$5'/W #+A<HD>R]S8&USKK3!KA7S(?CZC;82W1Q*P8-]0&%FQCW)
M[P-5HE-^21J!4SWQH$&.03*8:P*3 RI(7_4G7\'^(KW)DD>2T<*QK^?ZI$XP
M%W^5.HB'&17>7!<<[A.55>/=_[68T<V_H,]3VR+%26]6QS."GAGTT+OO9"0H
MV>BX\%M7[5*+6;V<5LQ1#;%WD1J>7\YW44(X',L2\I_T@\ M2IH558Y%!O:Q
MLXVWSGFU'+SMGI0-T%]/2_]N.F@#HAYHO,E)LZAV+K(8L4CJMS)G6$T!D$WZ
M*I^!+N(J%T.(R(<%>\0I.>.G<<(NPK+]5FL1:SZ:NJPO<$H59#DKLU+]WN[8
MKO9>KG:@H)!/BMUV6U++\DNH!KGO%*.;M@\;7('?@#]XK&]>;1N!Z0\;:ZN=
M^JATH3= +0K/%BQ,Z PL(K>KR.MO)M7U%).;D EC."NSGY<)7:.R7GW4Z;3A
MTWUNE&P\>JX^=+P11T@V5*]>5+"^VYTCR"R[,<AU"IZ4S=(]Z"G&#BZTPF]?
M @S,PP[__,52(V<(M4SX-5^+-3TI_VG."0F+<XXVRE<A9"=L 9MK6W476LK.
M0X>'D/O+C78NY]LP D;7!EA_72J,YM%T(VW"7O;KG/Y??YU<_WQU@:N:M<]7
M?R-,ZB5%D5>8=I>CQIKX^]F>A<<P>#FBK6_@I(@/FW66E>&2L$;KVS> %!53
MDHQ/$,!(A]G4"\JH\232$O&+!UX*S$EZ=)Z>D PQ9-+0S6=7/!35 3?56=1\
M,_G-5L\;53^'JT:6M)RK1,E@<Q.4I2D:W\T>F+1 BX#W3#CHVOQ4%ZC3>^SH
M%R=&">[[M!1+XKITA*%"[KZ+KJ'KA43<%EU-1=MZHZV>WHZ_E$Z6.G3LH[B]
MJ[#?[]=/L!:X!#Q2U_*'&97M(*T$A)'UCUWD!P^@X=K<XI"STNZZ1_"M/=$1
MQQNE?\4F U@^?20YF4/AW?G[?1]T?N-!+YXSJN&1MI*T31914MU]V$:,Y+MG
M3&< 27M7^=W&Q8!EGMH ,K%,HA=LS^O+15'I&20&++6\B(/MK-=[Y-II3G3K
M_.\HP.%,!5J 37(WI35KL'*>E$3$__QZ/+34-M-I?;4Q,P;5;E_!&RJOLRE3
M?K\U-ZC,RQ9,3<QJ%6UW0NPIIT#DXR6-\+T\W!5QX6Z\J^U2^^DO&YVL55G4
M].R"WQ)TEH-8%!</>>'R@J[7G1!@M\TL]KR);E&EV%6#$_Q7;PC,5X-ZL9'1
M G]_Y_3S6%S0B?RCOK' \I8\[D@]+V:5MPFZ,=9>OD./;)>?M6>7OE*-X^QP
MH,#%/ATQPV65JMADL^<I?_7]06#L).R7RV6DB7)[B:RV,O<$LX\',]AL1< <
M*G N+BG)B&3>Y%<K7<DO%JBQ%RJ,3RBY73UA@[G]<QBQB@X#]H259J[6:S'8
ME\IBOP#++.N&SR\DUWPZ*ITR5 XWHF_4FRD3^M?IF3$9-0[OM4Y?U\[T^\F&
ML6E@\>2A6\,>Y#VO%T0?G_-)D:8_#."+*<\DCG#QH;T^7D:NYA)!M3JK:IYH
M)Z6 #L6O6]:L?.B=RL6^1ZE=*;>7P8G]<S8R^*HTXI8[A^NHJ.A ]N@1R<'E
MV_W<^EY6^;B"Z]O-2((;=LF.9J%Y"ARWYJ(W$+BG8^O5U+X5YW-=6Z8S^PS#
M XDQO87?1:8L4LI4O"[NM_[SOP/:9/7W^/7IF$A=8W J1A!SKW#MR[#G((2*
M..IE[^PRN<.U@#<6S<*=*U#6-Q<O.*1S#'1JEG4CFVBYAX(G#3T?9$@Q=Y2:
MVC3XM)DJC,?K(RP.)G1Q.35\>I%0A3AKN3Z'ZXYI>P\SD8B%R@/A*]S&&U'$
MG#"J>R:=QM5>F\.M(&UB8F$#ZY/%.CS:W!)R4-36%[1TIAD>=W*+!#'JV5J+
M1\FKZ<$"=]NSZ\*E>K!CA@ZX+R;W^N^-W>KJ:N?2L%7%7&20W46D9"\<UJ):
MLV-_NK&,7+#T_T<=%Z5\G]FIN/#$;B:%UT+T62#:Q"2ME._QN?4;HIR7@-=!
MDX</SJ/;H9> (9W#VU3U>%<H]CCO$G!BX)/'_X7'.?7O>-FU%R<[]'2H=(Y;
M79\'Q4'W[Z>KH\_ES&_^JF]3>J?@\5=^>UW.WNZCN'"/X..L;E_W^BA-R>EP
M3Y[GHZ8/_25\-<\6W?1GE7)M4EJ/:WKK]4TO^'3&L.*=]NFS0VG;;];4N49P
M,X"^8FV-OLVN^N[A]^<%<E(!''+NI.5U<B=X:.]QX9Y=FB]9?559XG-\/^;'
M'V_ZUI^L68S=&Y.T24%1H+@40)^@;B"P"89U78-X;ZZXNIC#8MSK^AWHP/"9
MX*"^]'%> KED?MDJU\6=B_HZ#<( L;RG_NQ*<7UHZ]Z1VT+Q"AG+</&1^>GI
MSE+%:E(](>M(N#EQG6+-1#+^V26 7XSU'C9)37-]IV/Y<_SF9AQ4;R!4_IN-
M%KWOQU6-ZE8.C&J4E/]D^3!WOZE;7CF)LNEXM!L4,YL -^K2R3S;5Q/6=%_F
M\"*O9W;8'*T^*!I\RGSX.<:U:X^C/=]N<I=_K2/?D%\QS)2S3W#T!9WVBNE3
MJ;OI?4G*(,56-<L$W,."1QD*J9(J?B)9-,  E3)0#UP=10"#>XNW!)YYHB#8
M-46_-Y:<#R\!BFRW*;[^^//Z3[_KM=S%WQ/W&><7](3.9=<'BWFB#:YO* I:
M&I+-,62!QL7W^V\E-):RXG%<YC6Q6B+S<9'7[(+F[ 9J-60+7:5T)<VRUO,0
M"&3]^L]Y>@D9W4))OEBM6' Q1TF'("JJH\056EW/Q<_+_1*Z9JM.PPBM6>DV
MX\+P,C7-'>3,C66F33S"A(S9EU=^:/KYKP( +5_UZ4AQ9O\9RHO[#L'Q'AS'
M%,EGLOX"KP.9UB_T+=.O^F]J%@*27NGQ;N[\]']V]O4TPCS=B>*6ZK3K0HCJ
M3D?:7#MT4GI1S&[GKPT:P>.6^OA*QE0N-*LQD<69Z<-^JGF>B_RRC[JOU*<R
M99FEX>X<KQVIJ::E]_S?\K*V1#_MQQ?+]< $BG=;A*7/.CT.R>J6V9X@+N"X
MTT)YJZCO@<'AGV^\LOQU]OKL3O2(!2!SN<@#-;KK\U9ED?9+:TV:[";/8@ /
M[.1K[7?XC18<7$/R?FX7TMZ;!ZGF.)3T.BF<?>)C7\[P]0H^\M_434;>4>CK
MBI^&$>-4"_,@V*FCNB*PD78ZIUCQ;9XWII&L3EL74MRSPX@ZC^U**VP#FB5,
M]HX_H2D=JTF3>%O+QUUL+_5$QF9#/0F^1+42J=0.XT&,RX>,CY-/0S(;V^J:
M%X]I2;&F7M1519R239Q/&HAB29< P[NNKUF%5^PL">4<<:H;(MC5WV_RTB*E
MI7]82E\N1"2_P$P$R<10TEI6J%8[\-$?J-A!U4(5ZZ,>.3B*^T00$:75X.76
M\@11U#%@I]$HD8H6N^X(A#4C!_4PZ"Z0Z&/@2JYD9K2L;>@S)9[0L)FNS=&B
MOD[9/HOB:GLV$2O]U(*P0LGRKG.5R7[\2WN1=+<$WG(XB4UZ<2FWJK_J3,+.
MJ+,]5B.P7/Q BC ^319NNQK>0M4 B]6+R]JWTB[$GE,HQFF$Q5OB!.YRP^G0
M*-$^"=GHC (.1G.N"HWM?Y,=!?^+["A8]O]%ZGW7 \+3$"71G@L+PFN%9+$J
MZ1JK9Z#U"6<^G&QDK=VGX;.5;6Q1?1[_,L)#LW;1*J4R9,)EG/TBCY8T*R"E
M]1XS96G4,?S5<)'>ON%BM9@ZOT?KHE,I_6Z(#<?PQ<,4''L/C\N#:R\QDB/3
MCXTZ+834[Q=6)A95Y>8$K24=Q/"Y4<;P+&X*G;\O5#\U] -YKW-U,Q#M#-Q5
MCMY/Z"8;'-%X'E]0>7IHU@210BR1Z$5PS2;#CFZ6.L]*GS_,LH\\5/-_>NQ8
M+OO_69?=\S\BINK\4Y9;'>I\"P>I3;=1'JEG'[MY>,P/?@XG![H8?R]1CAUU
MLZI_PBYK]@"M4\$G3'\>6O[*02]@4C5%OOS$YX!2+C_*,G[ )"+[+#_\]>S#
MS56,4QB:'ZDV@$0,*N5? FJ@O %6KL7C=_XKD=SN[T1R?E,NO7$)$A#3^FY&
MO3K0-":EK+AQ<K7'2%Z"WVFS@T4:NLZ#S"<YJ"$<2TIKDR%UG7=6$GVK33Y%
MY1](J%.I<9?)D?CX]0JY@VHWCQN/'_">C]J<5)I,_00=P'QLC%3[?S4[IK8<
M%ZZ%M"05),6?CTN:'QL].Z_KP<P[V#PM9.,H17ENYW^<9I#./)2JUE:/4U^9
M^TNZ36WZ;YG-$#J7[:3\WJ'X2P!-&<]AK7(/1_':B7R$"<W";T/F*+J@O00L
M.PG7M8I8#\OD/I\Z"T@F34\*^$5BGIUF7P)2>OTS!T:-Z:[0K*EI CZP?%XG
M>3:=UJ]K% P'ZAY*'4\A?_#[I5))>Z0=8Z%W,C9L$8*TF?H?'E\@H-E.G^K=
M?7T.T)_8EWN[MC*/F#04F3CCIB5'.1LRSM"J6JK-Z#__GXU"_9\XOS%R=$[K
M LCTM_CT]?-?@;5' 4*KV]63/JE4IAZJ9^NI?AW3HX/\SWBPR7]_P8V;"Q>'
M+4>MK;6U=<0*\QRT_LRA(0_,HM*!=6XW1W:8KI7!D-Z_V]IJ W0@HYH?S8Y'
M8G&I]U'%HKBB3A(JT ^U_U[;P6'FH^=@[AGU*H: #.0=+K?**.]/LCW4,A7]
M:0/2_GF"F0V6\%S3@07NM#-BG;8=A,+7:Y*(1G%;1!X?GO'0'M*>U9A1ETEP
M4(64?U5K"J1W_XVI":J0_!%$3Z]D!J5T/XBU@NLG5[-7*+N.7W>S77484I\R
M#&4(<O%SB7.H%\7U@F5O_EBQ7E%$+=KTJIVK</<P?)O8>E10[6;X#,M G5ME
M$FBS*QEB/5"9_4M/IQV$]^,)4B2$8PA0;Q,5"L6>-PW4ELT:_,$\$O447%6#
MT+YB< $TF%9_<ITU3:7C%#@83:$ZJH./W='Q%9DFY0Z@!42^QC#UC/T3.L)E
MOG7=7':;:;"Z8M.AKJ!VB0"W^SGY4E33B/((H<!D&F1?%\C?,R28WI$3<8[^
M92SOWOV20K&]( U-*\H[*ZU2#-E<FKV^U+>!FHLQJ#EHYXAU518.>:BP!*OZ
MN*X[AQ9?TMUD6[IO((UI4Q4Z$Y&)# YVN>F\6W3@S:8T.1+L;A9<\:0G-$!L
M<(IT'O^*&GX),!)*\!V-8E$/">O?96-E"_8C8>'&G2J68SU#C.!.[HY(>RFN
MB9W<'M-;>D&/:T1#]2>AV@/?"4@\9,Z YP2&465.PDJD9-8(H215CH!T^C1%
MZK_^]20$MN[R$J>/7Z393C&\&_+;_WK-2FQJR$IZTLA5J.VMY$U QM>@1 :3
M#YH;^309KVP@O/-<>&#).[].TLU:H?PM<^C+SFK'H<'R\VY)H'[2NBYW[H"&
MM]O3"J'['N@A_^,N!Q'9[+-PBR)^JH"IWY2.LI',4=O.5??=86;^G%O,O?8Q
M)Y>--'G[""?'-=ZXXR<ESH?6]9$6F-R,&N^,4RGTJM7K:&AL<^*]"8E^4X>[
M_%*(T?S:,E!_/.T#K=6N9+V%0>S%MZSM<.E@&G ZXTQ.%E<W)[=+T,Y<F .0
M?>?G7+*2$5NOL)IX$KBG%%(;.7C'F+/Q=F658C,63:_,3"^2;%  ,Y"AKY^>
M-EG[<*R_$$"\^^T2T-@8=PF@\/UR?E5C^S#@]&/6Q?EQV<F[ "_<V:V+DVT=
MRHYZMDO %_C-"V;*V>)8EF\VYQ?;EP!G>?^ST7-!^9IQ_VL!?AYY-Q>A,9>
M-JF/OZG'S9WA=LI?(A>7 (]+0"5+O;_]Q=?T*8?Z/WQS/-;6USC+OA>4F5C7
MQ.+:OZ<L,U<T"]5X-P((=<NNT=,O3!P*7=>BGW^ZIUXZUZ\N@JW\* 2FCH_A
MJCV&>FQI6B3&U\'B+7YEN-J!:6QT(GT*S,!4X(@$T3%/D30*D4.1H<;6KZY9
MB57EP?9E@MT<>L%-'.K9'$K3MQ5L6K0\M31L?0;4G-2$Q#]92#H#W!Q(L,7Z
M@ZJ9*6QM3=E)1FFYJF+. :SF,%E*=XK^>DANJ:2MX6%EOJTUSU+=<78L!H0(
M2CP&46]/\3SWWSY.][&SNTO.<[C=:4][7[,0*#E@<AM<D*<@.(7)%5^-L?:-
M&0K >?\Q-#?GJZ\7,)L_=U#5KQKHA#I I+!/+8N+5%"E21@./___0ME(F=XI
MB)_HI&V'D2=TCT7DLU2U;$+X0QSUIO0E]25+.> "M*E:GE_V1TSU.HMSEVA[
MR1#<"MG0 060U@F0V:X3HC\4;_\;*T*H@NIR8+" %RG9.-H'\$+AC7GCA8@4
MWW! )]&8^_PCZ(N]R;L* 2V(T'O]4/>ZQN#?V!EZ5RMQW-I0MPAFL9OE 4JU
M=2JB>8NF.S=D37?E(3O6,X<EF/!RC^ND HLPVG%!R+1$XM7'GN%C9Y+&01_+
M)%1LLA=[;+PT&/=.\8CAY%1B^+61O6QKB>:LU&GI<G<GZ,L7GK':-.S*O]K"
M"D]G5QFJ.(6?8&Q^YM$WW]((SZJHB'BO$[:39QLT;93,RU9-BT(GK0 7A)$5
MEO$H1BD?[LU!M("8(U8?',A[E]60_?=B#29'W7%.?H+#UM?/3M,Z"3CQ6AN;
MF!C#]L"CX\9&ANTZXSRJJL!R<N]7B91\CG6G^> )" +%1; R]ZY8^B2TR;<Z
M!K'E[8GGUHIX<@LZJ?1?%2GS4 ^;V;.H8U78$VYD09$G=Y>P6XXNJF3QW"H=
MX/C4&A1091X(4D]V5,.-.^"F>/?K1ZY^N 3$R-^_!!"GT?*AG\8/2[KE#_GM
M+@$+CI> .[[U'HPUYU>1OJ#QG9>GOPV2R#DG?V%$6MY]YG\@B;Y8[ XXBYR>
M_;0UCTS_YK(=:N1_ZQLZWXHR>#U 2T[=3&K[7O,.K]!'KN:LOG<2IO+:X>;4
M!:^'10:R!;5?*'7>9WOBA%_O5.5C1Y1CK)10]*F%Q)O"765IOVTP#0;3VUHJ
MY"Z"V^FD0LILY[#:J2I5(#5%]F2G:[$382O+?,$A^EU=8XV\&>I3P5(( K _
MR&8@S,U&+.L6Q]_%RW&XD]=+3$%+'&?^S)1]M9%^PV+%PTK7M3QJCA>*=U2A
MYJPM/EC?X?XCQ=;25XN??WCL !9+NBX!K92_451*T?X9UUAX^V)K]]++$WSG
MKJWBZ_7TA-'6QJ+SJ8S"EZZBVH[[3E>JDJN=;4T2,9[CY>XWKL1PMU-[.0I'
MRINIOL_ST5\I?' 7<B?4]%5;/UL5B78L?('Q5':I@E^DQT:;HW<OV4@5+R/C
MEJ>CE>(Y3]]*T]=\6TGU1Q_>DA$_+'D U1!M+ZT.3[:M,:9Y<F.>GUY"]>8,
MPA@:+/SX$@#_E%N\ *_Y_2^M0D\:'YR2%BX!IV&=VVWM_BM5R2=4V]MO+AA)
MV/T'-N7X.B8GTY9?:)K18#687ZZ&2[61?3=(+JTI.Z)W1)$08-XKIZF26ZAH
M67%!A"JFMW;(67&$M_,?!(Q9!<MT]J6YRX2D1K-*%PF=4HKATBR7$M[#T1!#
MJMCLW A$'*N0T(IYGI)6BL[,@-J[I+$DGR0_8 I1"\$^S_'1B,%G8,UZ25YY
M 0O-&$8?HCWXX9M%C6.\EJ?BWG9&OW]%#VE)/U98OWCMK2IB(4*<+R^[)2E4
MJN?.4+*V1DZ#3P%U M1L)&<X87['IV9;S*N^\VPJ32L&KV=HLB&8X0%*CO=J
M9\\'(]8D&U)FQF ;JRW&5!'S<OP<M^W:F(V(O8:+95U[EN#M9^5I- YY:DH1
MV@[]F(<OE.!/V+_[NL+F(S)G0^[J4S;MWM'^HY7[V=DC^M:="5#@(SC)H(5/
M QH]3_H%$1:;'1P8%"-X;MY/3'R2TV_RIA?]N9C\K.$W;:G!?%V*7S.>T/75
MQNBY8, N?D(IR8CT8)Q:OC2/#'Z(UM"/2S-+S8S,;?ZA D^>8)B6ZH\8TLL6
M[]_G<59 $P:=/3O1,2SM+J,KKEI%VK2WMF*X$\?Y; BWK652&D]:\=<USKMZ
ML,]_":!:'2A,\Q D:'9YN7JAEWEM+2M<;.#@JL 4EF0]T;-M>D!U_T)LR3!M
M%4&/>KLP,WD=HZ#^P-124FNO8S7T3R4%,[\[DFSD45/?\'.R9P?K)13+NC:9
MI;?!=./,(AL-.D:,]/M4^,>(FI#KQL)P)5,C,).^Z=2<Q.[41R7"X!FJ)C6;
M<4NH2NDDR6CB/48)OS[J!"[8646P5LRX]VR/9:8E+BD6.%HVOGP64?AT:F%-
MHB-NSTXA!;8"MGX)TU),^.\KXHJ64VAOS!?+U_/3U#9HW%E>:Z%XFA]%^>%I
M')%-/MC./46$Y14^Q[@M%88ZFW.P%T#;!5F_-6G'P@U>B@\CG]D*:Y5^.W=1
M%RUBV'E7V&]GQ6WG;?%LVP2SVF/H&)W!:\Q8M,Z?,X!ZV?USR$&V4J*V"_,V
M_948.V5_A9K*5-VW"8,&H\\8^/ZX.O*=!5"$(8M6.N_T0+1,&SF0R1 [:5VU
M+\R_6!-T_Y"/+79O6*M1U04IVS51:2UM.#ZPOLG_O>)CM%$XIG5&RV'CS2IC
M1MMRKE<<PH"C^>&$$O:DDN\<;W#$CMDY6D@XB$*R(E4U 6269YHZ&JU3C(;M
MB(]<0R=H\4R;GC3R *;.D>]? N4S$6,B5M!5_]R2G@5QK;2OO?9Q1,RD5K(I
M&0)%LZ71\WC:A\=+6;Z#'\_II,=LS_WTO(_&X\&?H9:A=0QO>OA8Q'%6;((+
MY6=5\T7JD[8::+?D%%?)UJU'$5'UEP#+[:UTC3W9=. KYA-)!]4B0T,KZB&Y
M_2Z@I.<3<+"G^;E_MU=VXE:)'[F?GX>E^*<ZWCSG(TLRK.6G?<_IKZ8&>K?E
M_XZ(WWIY%$1<^3J=4^2A]H0@=A!0!A=CNT*FKRC/3ZN9LND@!@7&44<+H'^I
MI+>Q#[OYUJ&6)3<=WY;H)0SK6LZH(\VB]_,YEE(>U*1N\'D9PA0T;KJ:3B7M
ME&N7DX#B2XR7@.82FB9' 72"S(%V+_,C;:&QU#U)T>SE=H5;W5#M57<FO\G,
M<'19]ONMQ/3V@>(VR6EQ)S;SCFYE5\X0>H<%_4'UJ6RV<PR;QR(*6W3\*>97
M6.NC=;V+'-$,8( 5[^H6D!%W[S_Q]/Z-9?:!8(2*"@,BBQT%9!,%*OG=^AP^
M9D6176*]S^O.%E YO^K1$P5^\Z?W0/0QRE]8M,4'=[?QSP/\C_DFCXR\G\D3
M&,$>'X>8V(1)5:&I55(AU]E-SB&9G47_$+1\IV$Y_7"47)\3!\RD?,T8"'-W
M($D5I7@O1$7F2*IV49A(7( Z;5L0]74%J0Q .(8P.Z^*TM9&_ED>C1[^IO1E
MGJF0F;#@4*[_1)Q)M63#!B.74SF4]G/30 B66$Y(".7<MGI6NO7.(5]-Z..F
M$7RS;HR%ZTEWT?Y8LI%F?LS[-9<.H;70%M<Y]2VLZ3ZPM3WC-E]L,"=0%C/D
M'!?Z3-)ILO=Q?SQFZ20-UE6<$91UEY$/H^((B\ -QOJ@M;@*([7!(,6/UT#L
MG_\5_?U?[5ZF/&%'N<YCZI<R!X7.1UAY'"=L;]'X]2B]!)ZM.QQ"_+N9S*Z3
MT]T#L%"4P8LH*_<OH/GN>M)7>7_L== ?36E%CSX>IFW):XZS6:#Z98%+M3\U
MB7Z"XA@R 3'9O(?=UK(4>K,N/%!57N<5.Q1?.U@P#XY_O1V1N6MZ(VU5$4VO
M6-DN,B9X7*2+7$YT\,T2S<XWFGC1D,V!UXH=G_W-!-[.]=ODQ$DV>,<YTTF0
MSA>8<BIQAZ?=Y@C&C>@WUD1Z5B?NQO.%V+SUFZ,@B%HS*,61(_\VR!]6SD&1
M(Y,C-6']U*LX?L]:Y:5$Q2S*YV5(ZN*UBV8C2C7J@P-=9U<49U0/E]CR[?B/
MW?PF5HP5A+B.=7-P/TZXO&!X%#B_:C'4TY_&+4K;7:G"0=\4#1N^:ZNJGQV
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M%.)(3?^H+04#Q-!\"51H),E?DKP4GU_4R,\8D;@TGQ#WR9YOV34ZPZ_ZKZ9
M,0*! ?$R3.5)B=15@"N1_,U+3!I/VB/,:]M<H .20+,5E79Y>^:@6#Y<1D!$
MPX24KU5! [80D^# )"-@+43_(]71Q:!4_L?\:4L41FZ9$&6ZR,NL[?-=\89"
M=87D5>V?XM-EJE7+;#TU'NRS.R@ZB'!%[W\^>9>1)[RQZS'&']6\D5MF]^L
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M7R8*;Y:(O&TMPCMN_MZOPPX[-M=)1Q8^UOFGOX&;^RGL4'BD(8\Z'=Z%44P
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MT)=X5C>+$76LY!LU,8KL444I864?"4YP:68Y*(D>?XV2> U6$H0(AALG6):
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MD!NXI<N5FEB&WFG=KQ>F*8Q1C;04$3EM VE0<KS#B(C0; _KZ+6^/%J;I)Y
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MNE7HW& WK.HD4Y:N.4'1?78D=P<=2:B_#7(QX';W?KN"D*SS[UU=FVK.]W<
M]=IT1.O;EKG6=B 79JZZHF?7---%(N^=?#3'_U+\*+>_AM>:.C;-W8-C2IM;
MX! *XS=Q)5Q&HY_H^(P<U@K.>^%^L*@=/.9K=M)7X+B'V[)P(H] RAY/:J1,
ME-Y56.SK:S)%%C43P$K.Z+X=2U7"1$>?V(N>XQ#;KG#P$5C2.'ZZ,P3^G5)F
M!RR;$//9XO#^0?UV=_:\L31172 ;\P0AT(V1$,Q,;0V++UM2YN9E(ZAR!4V<
MVQ@=Z1\A=!/\WS2=M:NL%P+T\DPE\X!M!434'?D]X Y-M,4^[J$4C!CU52EF
ME:<XK'!FF>$T.3E3J^.P 9I[Q!?@N\%S'K$1X5;$HU,P&E&14&)V\ZV$C/9[
M:R]*_A:V\BR[VPU:N'O@T]/GI?OUA@FW*+K^#(#QQR$Q7/CR=B$$(BV"N3;X
M.6DE_+CV:0.PT@W?0]3DW=AZL$A5MJ VL*B>!=9BD6=]ME996UM:$[R, ?<7
M@HERK^.#YMDK(4(1L @-5ZB(KQ/?]LZ:^LA.&F(@-\WF;NN/;V9PM"GP;_@2
M6_)_%D;M_QY .<S^[\(LAE(VA3BVG#  F)J=34%!0?'KNW>-+PFDR=94F>UW
MUV3_Z6&_Q=-;H1<[(1KK=&R;-NQ#NT%Q0U>NJK=RAS7)2#[?23YNLC!"]M?0
M9R.+N-$,-&^6]5NCD6S^/*T,#YYAQE36+!['>,':<@( !7G,SST0D7@7)3Z8
MIIUXE]>H_4;B4J22!:&,8J:LNL<1N9.G^/K/F@S*.1C46E&*G,N@)YVI^V24
M/T)+9F0;KX2J+GX($0B:ZYT_?9[_P@CBZ\.DI!4Y7V*Q$M66AX5_V*YC'EIN
MQDR,,]1WA13A_=0GZVI@?4E<0OF%8*-"GU2<41.-5R].O1,'KQ7O1'8087-I
M[EN1B3<=#]OPZM^3/TPNZ1#[JZJVUE\/!%G<'WC\,6^>GBU>5QS+EY'".RD;
M^LA$O<OKW"*50ZBW6&==;>=*;?!E*I_ATL"<!4V)3]?89O<8%'W#?TAH]2LC
MG:_)2J)YIZ=-M)GIY?(]A#2_R- FQ(QM_9,L16SUR:O.#;-#1OUU+UKW2MM9
MY<=3 $7/B;24/<6DSS26!J_^PQ3T=9+]9_IPC6"'<O2MHK$13$EO8VV7Y.AI
MAKG,C5^\8.H4@.0;X/LB?1\J:Y:?*60L,]:BA073.BME<%^(D!#P!Y/Q9N=P
MK2RS0JY. XO/PZ!6L;>J=%4WW[SK=J&($",RCE=B&H86JJVXA^!#<*OHN[U"
M<,O]3XZ?3_]9?1'ZFZ92!/RM-K7[RX"1E1XTW:8 35LR*BH:JW6KU__V;PL?
M@B;IH;4:50_="OS9T/4#>@H5I(4HMN*'_%B:E TD.&,PBFGW14U]$,MC*[,&
MHSR^ L%P(HAM;SQ\\DUL5QE3!%=:WK*H#I\-,"B=462]AN]4[$YK9?040WS;
M@RZRV[F-'[,ZB07[W=EQ6+;VHJP&<U=Y/^/["RD3-X*.50+M]%^%TOLED7]"
M2DS$9>\)":Y5U-66_/"Y*,-_^YS;TKPXV"G!AA9'6\L(QRZBD,Y><NY5;HMZ
M&(5%+O4?2:C/$)9M4 ,'?!/X/Q*;B;_G/XPG?T$AJR<>T\I57,XM0']ZQ*AF
M9^PO%2+26&5SS&)CO2@@=(C.R2GD?@[3B6=EY<<MR JOW*HGWKZ[ZG$0&0^5
M[ I)\1DTQ0^=:9U%1_;O_="I5)&1H>'"&X/&*;ZWFJ,4QO]TQU^67$T#WFSE
MF2_-M#6CF*[)F &1!C3W':(&;71P,MPZ[P8;<3-EY\RNUI7Q3M_].MAYLI*T
M&2BJ1'M<C#/]K4^ 2)Y7BQ-:1 GM>4\K9B[QKMMO6ZT"/S'S7%3Q]]C[C I7
M$5Q5'Y]R-P-9PZ=.;5-:+?<\+4L%6?Z13#[Y6[U3GORO@F=WV&_KV\IYZL-&
M=7J;Z8[Y T'ZX;^_CK2[+QE7(*9>4:CQ-.+)S#W9>MDEK^D9\P^KSNI'Z):5
MB0A-N\Z4/H$B 1]^_OLSE9 I)@/4Z^.X)"HZ"L^2%B9:R=CXKC*U),Y%+T4<
MN=G@?9DVC(2)B?C>_FLE*0/+O78F04]G6R5ZU_\<Z-.7VZ_U\-5M#*K6 /FK
M)C#09_8QY*_F#7;,NN7,PXJHAL=V4\E999:J.W!@V30EY07A&N;<H13;ID:W
M%0N4A=8NI@&1D'I6=%<YS),9L&/+*C;XG39 M:2/=\WLI9,N42[;C%^\GB7X
MU9>M'K_[EX*N<"JH3Q0*1>PC0G0B>2RV*2PE)!N5X*],,"[DR\\5A*[)^N<D
MKHQG7--KK&G$5]4K]!4=?! Q/6FYQS$]R=V[WW_IC/@N$=<Y#)!)T<T?-+/6
M-;MYJ<U0NG?F;2^T+[%"&G-YKPJ)%CYW!:IR*&2$C.?QADRM^0^NK9HUMCS?
M8R">5*ZJ89N+D0MGPS@F_TBCLUO<TI,U^@R6VPZRO]3DAWZ%7SZ2?&46>94\
ML2$OM%Z-"S'ILNY0VO'Q2]]ZM\L;4^PZ;+A<&,DJD/TV$GQ-IORYK3#E)&I5
M#W5;?56F\(?L!G$95RY@[NFLKNQ;S8M2U,5.Y76Q$>0Y<5K%5>J%;A>H0ACJ
MJO=&B 7CR4\C;HZ+$K.W6XZNQ)C.L8MC2D#5<*V2;#!K/E"$5]F"\^N[1@>;
M^3D0K5WJROCP8$.O4][TB,^&'E&BW!_4"XL_[$VR2%P>UZVMZ-Q>GX099T&H
M"3<7(A^:_^O\IQCICW]LL.@U6203HHN_X$"-$",AQOZE"%<GLW!U30:;$Q/3
M&\R0*8:65Y06HTZF#4^)?Q:B*XP<_. 62'(>IIGC*$:XTN/U:?V@9S0U2H*Y
MV,>U#\&,E[WQ U685;17HI%NOM8BH'<F$L=Q4@/11#:1>V9D_J/<3Z7\-_N?
M_YO]1_P&OU3-D\D/4*RM,W4PSY^9/_+X_E/0HH''<#'1WV.H+V^V8ZRT876Z
M844Y=M7#R]\A/5UR>)0J%?'#DV6VKLGXS4W,CDU,GC8@,-7B)0MSV^S\S/ST
M^Q8A4CQ/OW3:C'- X_>O5"JP#A,6[6,#P?S\3)Z>U:S,_,P BVAQR[V9[O 7
M*VK77YM^)_L_>OW"Z 0M?6>?KI^Q(W79I?2Z$!DYOCPN_VT8MK.U.* CY,+Y
M)4+_3E0[M(*Z4,'L+I@Q 0Y1ZP(2A"A:=%9)*1X +0^Q2E9(7%K"\U6Q(.T$
M$J]9Z\B>*FVWGE?:.'PK>U&JVP1#;N1"U&KCAVF%MU;25,Z13DD-P5I>I?NL
M/5V"$3W_UVH/]=9/3#322_)<.W'7MRRMJ).ODO?=W/"G1YY]95U)FJJD?$FV
MM.2YV:F/WVF6;\T]KQ=5;KH\L=;;[%GH7>NIOBNUK?/,O7)SO?9F'A.:4EMJ
M5=!GGUMXU*)ZO?5%OT^7ED4O>+L\[]F<V*MU<I<TW^1-U=AYU/O:N>**VK4V
M4JMNSCWG7926GEX_X?[-F3-GGMJZ<_?.K5.OG#GSY_B34Y-^SW^I>W3UT\#.
MR_^D3MUF/0SL2_Y0YG#2/M.3++&>R;-44/CVN]6_5DW-\CZLZ154ESUER?W6
M;;_.-<1US)O_?8_ZX]1YOENR_)97O3\YY6=8KL\OH>"".4'SM$\<+(B\=]GG
MFJ!>RF\5\<SM2H%'(S4>"5T-GONL<G/VF;WIW#I]RS.G/O4J67&V*NIJVO7\
M.'M/=0ZGV;=[-#^NL?81[2L2GBXNQ>_M]]Z\G2UQQHXKJ\7W3;58?C.HWF?'
M4LMUG?Z-OWQB+G?<*D\@)TG8_[\XY%/UHV]NW-Y;3.]5K_GD]N=->5)BI1MO
MS?6DF,^:FVZ9O]"5?A/?^#7)Z?3"'Q(G4VXN/><^)RH]+)_K6NG*\.97<S6/
M+:G?*E)1[+.O+7=:3&JXMU2XR:J@^5>N-+?L:TZU-[U^F'FO^KGT7U%/GBT[
MJLUYR9)]W<::PPGG"J?,#W;6/!G<LZU59X_UE2R5TM>W]LU=GEAYO/:NOM?D
M/XV38F/\>>?]6.UVS^)'M7W-MNEA9ZHN<AF=>WFK::GKSW2S[8OYYAV;ZW6>
MGUT^8?K%PRLG'SY4[QXG6S#MTG[S8X:G8Y?NT#XQG3\K5STA)CK ,\A7;V_K
MA4.)7;>F5LP*U%SQSM>+UW?.444OY6Z9T^\%S_BE!<R+K(XRLRSY?NNVII-Q
M+-=63Z]0K74[=FKY/O@-.D\UP\XSHY<UROS;E*7EU;+7Q26\ FI+%DQJM6>9
M5"IT\]CEE-5\0J4?" <W%L#__])03T04 /[_ET>T[Z^,:-_?! !02P,$%
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M U1["<J#X,+#???BN)UT[\<PKF/XWJO)+$Z?'\=+T/?N$UQVNA<_QL4BW#S
M',2-.N>PT-*AF"P@7. 1.>#AB$"@(SP)SAM2JO9N,4Q0Y%L(B('*A!>V&P-O
MS11V^68*VB/?::9G"9 AS#2%&*G4$%HG4"\/%MBY-J!RY[P(TF@B0ZF*OM5,
ML]E=LE2['[]BK"!3M2JF2500G(([#88Z!*$@14;%A*B,*J@ MIG<HC7VHX2!
M8$35$"_/A-;:18$,]A!689?#;F*1XU;$)"B.F)8Z7;^7, 28U/!%.WICV[ [
M?F:/VID=+71ZDN$(.!,8'(=3*$D.TS-*!M,3^+ABS'L==5*:%3 ]OW2]ZOM=
MKQF((6$G)'8&D-5SBK@B$J(4!99B$\6!>F_EZD61X'_G;GEGOXO];%^56,1K
M(H0-!"4([P'_$BC&)(.LU%C8&"1-JZ>."ZB,77Z&A[DZ?9V>QZ/)M%VL9@:,
MZ;\K@[A\E[*8EV<<)V-9YM\*O$0,'FEJ'5*1T)@D$/)0;"+Q;]&.9@?/;!=?
M=_MVW/YWOQ;V-@="QW%OGCZ].D__.OD8N_%BW$8!+E\KKA0!IQ*U$GE-PR##
M@T .YK%E%,B<6'A8M1KI \*XYAI\,'A?"].>"J093H@IXK73R1&,Z[2_BS*_
M=]JSX:9]LH)@AL%SV4C @5M@[50"TP%"&#6G6K)B<T&KDTU8#/Y(H/ ^"HZ4
M91!Q67 &!FP/:)%B&#NN/2O6$&^E1>_WWG713H^[T[V<$("X*Z[.2H?Q*EAE
MD9$R(*XA"C9)@W4K;0Q0(D9PL4;UXQYR+X[2&WNZ>/?XO3FX =TC,=:H/D96
M,B^[YP5XS1BRCGM&(!HD:N$A\UTUN?/)=B'7$5U5U]L(!M?ZV=DB[UJJ+?K(
M@DP8!6\A8-360"1/.9(FHYHG2F!9JMJ>V>E!+MR _V1<^VA'UQ-17WRX*GX1
M*V^#5@;8A02R(7! 1A"-@G0._*4,V,32U#+M9MMONDDX]K/7W5[L/K;^<_7%
MWR;3/@,XS64VN?YE :HH(#9B2@4>B$,&\USRI'.E7U+(^V!)8@3,392FMY4F
MB0,F?;WP+C*3\_"Y&BXQC8SS&"E&\FIA,C2M_#K^$M+R]&H\?:\<FI06!RD0
M8X$B[K1'E@+E$,I1&SW%6A5+X[]30[DF<3)>$-]8#%8E'92SW "%T X"8VUS
MW3!%,0:56'+,Q87GG']X2K*!7E[+I+RA&$$< P&,B0XY$P7RFG (8H2)K+BU
MO S4;^UX_PR=\Z]_V)/V\/CPEBEW7T)]I<KR]5'V1&M)JJ6USD=+D3(*6 !Q
M"MF8R_F\]Y1P%:)>520IB 440/<P0% *T:.$?5[4H1 ]&0XQL'!8)65M7'PJ
M? TI QN.,D2NF0%V  Z9:C# 7$6;J$="$ G^F7M!%UYHLC:483#4I!%;F<M_
MK 2%<"<,LEQI! S<"2R"$>7F8\NVFZ$T1(B()*O$,YD#6<+!LTF"'#%66R4,
ML:9J:)DV%#T7T5J)@O&Y\C%@!.XL(>FHBZ"@B,OS;%]/$5U/JK^QLS;FRN3^
MJK6D#]J80+VU*%('D9/-=:M.1$2(8=HX[DFJ]&&%U"F$XEQQE)BAV6=*9,%]
MHJ0HL=%)RD.QN?02N$8!%1O8,FH!X! 0$:"+A.2\NPJY@",PHCUENMCZN>?1
MS6ZH9'SW:?+_8C=Y=]#%F']8E;028TG+D# BG":(K;!&)N]V-B&R:!+$T4*7
MJHKO7QK.I:9G*R(Q_&''=C^&_+VU=) 0?46JC06 (P1Q'!1H$S0LN7!,**:E
M*BY95I*#7$Q6'6!),ZX@&!/@2H%"$J0#.%]+A!$$RZA9L89VT^Z9S\OW'R>C
MC^UX_^I%0^4XEUH]7D"24SDEDN(![FAU+FZ4,&T@0F26:V>2)4JNT!+U1=N
M^:<[XW#V<9_/7$L%>L!09A5&3/2E']X@PUCN!V"H<EQK0A:>A/DQIS?@8J^0
MWDEE@-E9#;,W=U6QN?=-(@!2QG/G77'YC6*CY^7,7Z,"P1@4AVG,JRPR1\]:
M(A]DE 9XAE#%;2HHU $MAPXF(1-/"NB@R<&69+D\7@CD(SR&>LHC+RZ#=8'^
MMNW^W8Z.XU].+W[\&]S1=O[@]'<@^J.K:KVX:'=\=#R;]E?0P:C(Y\'\T5<"
M]ZSC91?_ZSB._>E71G+ITNG;7#G< 5=:E8UN7!A"O$\HB<"!M/((["-@Y$6T
M0$A(<*S87,N/%PZ_.VB[\ :,\O2-/9T\ !U9POX*K95U7 5$N13 )[5'6N:J
M$AP(X1[+)'VI&BVYC<IB@L9 G)2 LP@GJL#^8"88RH%+4JPBT2$SJE*U55K=
M\(!ND<: 32 &>:4AEH^.@Q%ACU04!E/!DV#%T=H*J?<RZ>%"HN]IUUA4/#B@
MX0#2<)N\1\&&A#C-P80D#.ED+. 2B(44FP0K>*OFC_4#&BRPP*!* Y$$MR[D
M3K84&0-<T2@JI,N[<DEQD>$J4(D"6CW%*'QD-"*F7&:)R2,K(\D;8Z(."1XF
MBE7M=^SD_&R8>Z#VZ:2+X06\?G?4M=,XS2M\J[?'D^:<6@@*)4QRNR,BD&7
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MRIA(N5QEE4H7ABRGI"Y)'A02+'=W\T("LV0$)6<C?$!"5,7M<2O)8R[HD)M
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MKZCB27$6[U/%_S#(P^FF%K@BS]J8^+(E6)&G3LN*/ M%'AH"\0%3E*CWB.-
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MX#KNQ6!)*5T8(]:LN^N:[2FHV$A4K-4L:B?U08/.XQQ.'A)<;N[8>&[.A$,
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M\.NM9[^_4WAVN6R_8UCEN[Z/.NN1S&)0CHDZZZG-8D1-503IR+MN%F--=Q=
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M2D6!H^'*0*V(56M.5M:&%F<;9%(CC2C*1FE5R_AB+S@:4QFH,^,Y4C&T59R
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MQ@CK;CUMSVM*8_6:4PZKL<4[7Y+9@9$ZC,R?G-E!J6!<<)*4EK6XC2.^.#!
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MBV5[_:YGS9N\7'G0U#M2VKSF9OGN/K:&6]QH6>.7R[H&-S/6":H*_A'/GC2
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MYO;K>'[]C+-18 FBZ;'0],W-FH0%]C$X7=W&O X&.N-WLPP[M-T,J!HF30&
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M?W5M)_D)3D*6@1BE#39+N+JI<Y;390U?I2"'Y!?++*OA.*4W]WYP?]QX6^&
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MK3FP%N+-1W%=%M=H^FK-5BJZ+RD GLC@1YQ(4)1??IP]+1[,:!(S-!H#)W
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M#B@PRM$A$^7N0VFC'AU./;+MD*7H3@]9Q@A.>0-5AT4D\^.0A3P.';%5DG3
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MYST4<V^^KO)*7OP!EEWR-;<2J05[Q=L*73VU6$Z$'1W;NA&T&@9;;5K1$Y+
M654NMCE2GI]+L105+0ID?IGIKCD2G4+(QW@(2@OVAEJP:SGP]C6<0OHX?)HE
M 0\8,&9$4\PS31V29#PD=A0P/^0AZ(=;23>Q9Z>P=#288_B.FU)":1H1)XTC
M$02A&XEP)Y_^O)]/?][D4_F__PN0 [:PXE3G#%BUN:J$(,BMY\"L*TG76WA6
MH:@V&:R\KENXZ1)N.J!Z#IK[&K*W*_BQ ]KNBC7%?B[%R'JIB-*^A^-Q#5<H
MYE<+E,]ZE%/@IX(S.XF(B)A/?$]@I]2$$3MP *\#GB7.UBEP$II$,M<L"FU
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M%\1#)?6W2WQ#?$:G[VOE\,N5T.)'PTW=XTUWCTJ,X6)N_1T110<55'K83CK
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M%-CBW!];6.9;RVA<%(=E]"=;/E6L9@J7 K+20F7S9K! D5:D*&2DI#YC*^"
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MT8KST<4Q4<WGN+AH&7V'^;Z"6CE2AUR9D2JS?SG=F>M5NKXL9?G?>51V1^5
M&7T*+8#O7INP,6Y/+/#RKR]*U7*B>V2,+<>BTB%<^+%E;<ZMK,5@:.OK"^Z&
M1?]>8.$TCTCH*]*ZW5HQHH+^,!\[!^EJZ5$OMR)S::((B>P1LF0WO.%Q!6RT
MFR1<]W:V'">!7[Y @C'HER%L);4 :++NDRH!@A&K*;8QIABQ:Q%RK)BFA^J%
M_U0_$S4G<0F0.&D[@21U&$(9(G0IE>)C9<TE6KKD')3"5?9TX3A6P9*L-JY0
M-:5"EB*+Z#?2.Y8KDJ/,\FFCQ-AV C#LX$F@\3FR/L-=LU(>MS!\@CZ+2 5$
M<.E8EQ>_67\'3N3%UH?(LZVCR:OOKUSU"W[ULFSQ?.G EV5S9U6:A<)$N0B*
MK"5#MD*I?WU5EE>MA!O72OP-Z,GITQ*=:AV=,1/?6&37>+F6RF67E<M2E;2^
M_/:W8HH.[P%?I:56B^FL+D1K>JU%N1)]OH4;F4+%9 W\@6U]R1,LF5;4W&[:
M&$\;I*H;$14$+UBGI&.*4:"TQ/6L6-FK9=%,!5RE?C?-3@F0#>WBM5,[>Y/J
M]3,Z*H' (V,V/?BG5&>35'=.G:1BRQ3KBPU]J'<V-3Y=LR13E;BU;,) H]+M
MK>AM1K?O)N16M-]2 A?Y+AXG<A$%,BML%+XZ.Y&^:C6X2'R*IE38&'N5+4A;
MX?KDE=SW;Y2.X2G3'HE:6']*9HIS9P6<LZ/D)ZUA [8P%M6(VE)FP@>PAFA8
MMNR\$\)I,1 V8R[W< \P%).JZM)W3=E1'4QQZFG")52Q^\3JX$6MU'29@@).
MG-Q5.5)2$I753F&F2"0 X \3O:V$LOI*D&,K:'C3FW%Y*3H>O;H;Q1MH55#'
M(A*3("N/JH;)*/U*SQ/HWB$EJ?$<7'K4+0NND?81QJ $)]Q.@A[G^G"J1I8J
ML59BC*K_1Y7OQ0V##J5Y[*Z8SY7K6 G]O@C=95KKCL=UGS#//D7!055K92N#
M3+2C#182OZQ]Q_"Y]?P99.HDV53! Y;>6%#ODUQ63RA<L?)+KJ\736.J*R U
M!4X9Y/)36"< 5@7'S]$I 573BWPWH8)C,>=.=/0,'?(3J@+JFHM6&K2+V'3)
MA$(FGUFP2'6G;P>K> =<VJOT<A>[DN!KP >!?IBPHG_IA3"H<B L0.,_A7KF
MR@X'GG1M8UN7H !I1SH\L+16X*&7G.$!:PCHR,H1X5NL.Y8);R9K\,$Z@)V*
M_^2LQE%\#Y7BKDM&V>JN-N77[!PB6.OUX^#W1/(&/_=D4<QB-#\G I682Z):
M&*KJ79,)99)*[S%</R4OE(_Q':&.BI\L\54=)1=HA^L;E,^T0WFF^4+5:4RT
ML"A)+OH8*K9)-L'AF LJ*2G57%GV'A!$][0H_158TGO>/],*^?[1N15[','P
M>*AK]Q<Q,*TM)4^&FC^7@*M-BQF[Q0T"S\,^@&'.J<S;ZGFD"M@,5&+ 28(6
M/,Z>Y=P.ZG645M).--&!H%N:%@K4K@%4.^B24VK^RX(Q<Y2(@IQ*5+Q;M.#V
MUJNVBWWP>AF'UY8=7OU66"W)Q]"WK7]'B9CBC=<>GQ?FD7UU0W:PO_M/CJ2I
M%?!%[/XW![U]X0"=O?*.G1COV./0X^T]4PP[W-<IF\T$R I.KP-PXF+_1;P#
MUF*(<6,Q=K6+95/FI05+".;YG J'YM0>CL8!-"?>KU7_;[#ZX )5E3+JO\V=
M<-!XAO/LGV6F15>!R9C;2L9<WV3,K<.)C%NY\GQR>;B4URXP@C=CK!R3T J
MO''!^'@7I-@XSUY3G< W/)6#'75?J!=0O'47J7B="I#W00Q4.T_H9&GL9S@_
M+* X"ZREP1+J:_6^? B>\@N8T'1#F.VL_P(!]BKSUSSD//9WQ^XYIX\=Q'[T
M,GIV_^31RWCL[P-[Z)P\&A;]X[L>&=JG@^H\\$=2QY49LXC31=: (MBT=9K$
M>>1W)<N9T']OK@$[F=I?,\WC%\V,"!26#+T5DCJ98A5Z*_JU1XO,HI9<EN)J
M#11])P\Y;1/7K0FWIP]-0Z7"41JS:3SSG9P43]$;_-"S>0![?RCH5_A\%?0
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MQ[UQUQWU  V&PN_WO=[8ZSO;Q.UOR3S*'H3:_<G)^+3G>UTA_#',ZIUVQ][
M[;K^<-+WQZ[K/WZE-=3>;+%MP(],)*C[[2ERH^*@2QE*M'>3Q(VF8HYF2"
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M< 3W2/70TE\)OB)"42+30ZD1L!!D=KZW='O1^/V'AZ<',&I%!#GQV5ZKL_O
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MNWGS0XH1?^Z-4(*]BS?G;]YV^_WN>?]+_]W%#_V+\Q_/ON_WW_SC_/SB_+S
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M>5):4T(KDAIJR>4,V;DH<4*W?##JU4Y,G>@@J>E4U&Y;[AJ>9\XT!7^:SR>
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MWE*R*_*5U([I*T$!^"@5NJ A#K!T 848AJ$/G3B_H&+_08%R@FG('8Q/^:F
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M<W#TG+3/; /_[!*?4B?Y\6ON)+F#N8XI>)N4^@ON5Z2]Q$DUG'J*+MVPEU]
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MW+6TEL'/4V8S8=@^>13#-(KS#54GF ]M30L_8#R6A[236>XRV$+603MI:=*
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MZRAS<'PZB=&<_5&26 0!M8I?FU&RE/K_2EJ)T/4V6 '38->M/YV\/QFD,1!
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M$X9X$3-0*.-E51LK[F&!^(@!R6<ELM17N#])A\HSUTP3GM<DE=1VK-S]_5R
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M2F.V$P@F+<M>;3FMZ+&V,*8]O8;) Q29_\\QY0'(34J$N=E0R&'1AC)IG#"
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M\!>UKI4M=N+KFWN3>#4+CO[11PT59 BG8UVW[#%G5I_N).>IOQYRLJ'=R:+
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M816 L9>6D;,%O(P"+#DL*]6/<Q.642-/@XNFZN'5;R*HVZP4[OL<Q]!C=UX
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M&,73('")ES-I_1\9>J(9U<4*5LTI,%+#I"G(CL5,KU1WS5U1).&.XJX8 &O
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M DISH>SE-91$>'9I7.6P_FH6H^H_4HM"U:+PG$YM4<1]MRPM2E!>%(M@CWF
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MH@2IVN2"YS/QZ IZZ:5>O[!OR8=&$[W3GOU([W(^5"\K72T+RKKM\<L#SV_
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MP=QD8@[&4?OM+G@L,G$<Y9T.]_WV)YNVL&P]>URK(\4!I$.IF&MEG_K>O_D
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M7P_'\ARHP#T^8%$-:4_QL!EYHJL(CDM10LB./BX#WG>J:O-G;W-TD( D552
M1F(6/R0NX5/U6VF+>+XKFJ@::%C=Z>IM&PC'A_CT??;RSS+75412X8Z6&1<S
MLO'>@DVV(3OJQ3;WLZMET#>XW,GZ#/3MC'G!QATO2H 5,Y$!)39!5%]E@#V>
M_#@*X<>EJ$9W%[%@N1/_.X@* V.18C!2'NUT660=N)L1,0CYL_RO5754BYQ8
MT3B6E=QD8#:_>'O&K0BJZH4*.,E38(-5.2B'2]R<#".5<)86;D9 ^*\S-<]
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M-%AQ\<0@_*K%$X-%"5)5^*"?MEVN,C0;2>6.HU60WAX/<%S#M)IDW.;Q;)9
MW8!7<5V/%3MS'=._9S1<[A8K\2@%2ZDT][O$*H$U,Y(/)#W,?"@58'=ZW+)?
M!ILE1#7D-2ABI39>*O"X?10>?)HLXX!C4UN$%U-5HV[";98FM_2%L@_]ZDKD
MY:+P6D&B,\+)D@\3RPF +\D15KCJUC-Y&.E\!5SE5N2NL>P2G48&P:*MJ4O,
M.RK, MS&,H+-: MW7"; (*MGW>:JHE)Y.,!MY(5)'J4'HL ]7=+@!<4$7G1A
MSECTB@XU 4_9,W1<#3T3$1-PD^#P?-GR"9!B!C/"YS C^2Q$A4Y</9M1YB I
M7[T!\2@&&<J+=QS5H8=<62(F,")L!M(.,_>*=#\R#^7W^I-\25%7&?"%GA5/
M-"HI$V?$+%$119*KCQ-GH8I<W"0P6589+^DVILM I(O0+:,<M3#TYQO4E@2&
M05_IOAB!7UF>1OJT&"N?GZ^&+5;G")-_)7'.W/QDF=/%EZX<6I,[,*!#%CI=
MQ++*Z3$/4@5]HUHXU=IK--3\V?A3UPM,O?_PQ$-A^H;1O/_P[=-W*D/>0OS/
MD;*^A-0<0/F3E+X*SD94 !6FZ;14P#Z+-[826%I!FQ4K/@<A32D-^7]W#\';
MYRC\8^:Q8!50_VJS9=&.4AYEF6-[PBAS=!KD_H/K8,5):#UK/?KG(;S_\<=_
M1EOU63X(4?,38: D!PW% ?G:?WCW_C>5/J:F=H-+)KW"RG$@)TG$+ D&[\-H
MI.-:S[GW2G-ER0E7:/S7VK?&!WV%WT!=U9^BD.X^>?'?:'J=A7XR3R^\.-X%
MX?-1 >&5 #\$J*$%0,W)L"$/'Z=*!%G"Z<XP^D"1%B9W2^J\B*/'@ N>%]L/
M,4%%Y?/ $DYO!)R$<H#UA9?29\RGX8>JUYU8*B1F,T#BIRC9!O# )QPDSEL>
MB]=4 I^4-,E2TB2>OPE"#/J E7FA9$6I322G =EB98X2DM,[C?E7KOEQ^2@*
MD:9X38+&^1+XU#_?826"FU#L<<S.7\*N$&!J1]KU2\&@>".O6/0JT7 "-0SQ
M\G%^=\K,*K&)XC4-O*JA,!WZ6UGDX3N2#TB*$4?!Q*G@EZ ):;F,0>FX#;RG
M@/&)# EJ(@%EA!U0C)1#%<Q(.HX3RP*S%5^5 F\1!C/)IS;*^,@T@W[9%J@@
MXY>U&,@%$O 0<.8\B@LCPD30\WA(YGT88-K<'^MSG^:D]<VCYKNT/5]8H4<9
M[@<'X<+C[RI'EUD\L>!9&%<&. V2!-G*"#K@S4=_51UJANF7 6AQ)\I\;0M>
M*G8%>% QP@A7GMW/7+TM.K)K/QT.Q K.;;E^\O'.!BZG\/2<&IZKY;!6;G*X
MIUME,(DQ"'US3U&C0FDL1T HVLPW^/P<G/E224C"K.1?)2H?B:,QD#@?PZ)9
M?SR.Y<<55IV"&I%#(OR^'%2K]*TW%.-:W,=\\;5*YHLL35*/9^@/D&]6KLX>
M%;1/@R-68J94F7U&%J?&31V'8B]CHT)1#,]K@4G1@5/;L!3MMT^YLE]Q&3Q&
MY[1H?'1EKL8+J%;A3[N'TH@\4:V7Q2NY,S[NN8Z/.PQ>'%^;&PZ?QK&CF(IT
M-!CCIP 1/,P2J)VQ#R/8:F)MO>!EUYC7P:$"<YU:CVK];%-'&)%IULQOQPC?
M4: #,0KF4MICT5UPK*=#DN!I85.P8XYGOSQ%;JMI8TMD.9.E>$VV:;L;[X\9
M"$@T9CMX^*+XZ'0JM0=S<D30<P*UW@=7NAUHW5Y@N;!TS54AP$&P9D3YNIRF
M70_5( RPDYUYQ;%V@AR43.Y8%1VNI''9$,%L3,;078C@-+@,B^ TE3P% H,>
M03>$FU"&T$G0!>XI7.8ST*IF6' 5NF!=GC09/UC4"BF&UF,'BUPPO4R\!*.Q
MF_$T^LI43O)-BF:ZF)?438@AWM*X2V:(TD&>\B7SY9(E=J-0&\267,2U)+:L
M<A':IMABG\ENDFBA,-B41,NE!F,92]03(Y.3(HK66&GME5QV!>HP5.I^-5M_
M-@)LA!4&R]7@!(W<T;V58WB,V<UNB-'-=$G%?V]"7@P183F$K^G  AE&S$U.
MDK#<'VZKJ(DMIFI/**=*OE7T48H@@LEB#&MU3?)K,0KSVASBF9+%+OK7_ BC
M\&S,NA^#L:(N=(U>_H1+DM_9C&'('?#]OX'FS9_DC.52W]J<)JHZ,DZ1^I^\
MT'NF/E;Y[J_P%&2)I"O*A]M5VX;CA7T=;%2UZ-'9*;FM!(2[7LF71[\7;@G=
M<<$A(7J]^# :C][A(( (B,<9YT[EDV=4][\D.3:^Q._9XY7)ZQ9?1_&*!FEF
M4X/BZX&%J.'+8%Q*>K#$7;^ZN=(G:?Z*)X?83%#MSX'2&7CG60VC[<ZS&V/5
MGX&Z[U^G^2LBJ#8P-FH4P%"\%K[_@S@=*PH -.HB0;:?57L,J+U>TS7C A*O
M^@FH'WCPJS?RB7*U3K@<.$BB18P1I5<>*E ;%;E<294JP?2F7575Y'RO)C[?
M<HIW>=+6HSW-6+\]G&J-2+^68SWO<RG*',!J_FT_ ;PYL-5Z\J$JUP/"VE,0
MRFB:9?0<8GC3C8\!/ZN )VIP2X2LJ^'#"FA*&_P-)'#_8@##B)H/T2:$,:!J
M2D2?D\K15+,2$<_%O(B<6![T;-V>,IGEU"^#4=;4^@TSG:75]*]\:9?%K-"Y
MDP2^].J00%]<#UK*9<-U17,FX>;,42PU(-RF7#M:K*0_PF-W6'X%K^I^/L&<
M-&JB.7&BJ(^2-/@GBG62X9.#\ =ZOXH7U?U[O8*WM2.EAB*>&(N$>9#HLJ@C
M(G\L,OM'#?.VO1PZEIIMF"'+O+#*5Y7#U$-_2^'0UKD6D137WA)OAEV?U!D1
MDJ$HC5 S3@<V:O._GQK \>"\% ZA:HR ,:K"&4#QX(SO0:1JX5X[A"/!#-?C
MD-O2EQ_M1E^;<KC'*U$_QA*P [G7Q=,Q@K#S-<'-]U2U=6M6Z/-=T40:J>>O
M7NSGT$N@:8I<!I76(^OZ],*3+)4&V@A4'EZY61-/1"ZAEY)7T+#7A$I@IH2@
MJP3.VR9(4Y'?HE);?@G+J'L<I&]!GU(I[>-I9_9!X,1F6DH,SHTGOY?RJ^0$
M1ZB>4"3-] 4+*<HG$(WH**)]SLWY+O_QIP">!5CE'2_AT$,ZTOC*:0IL]OG/
MUD6EG)U/U,/U+)7TZ(5FI1'4*I6,9U+B&KA4+H__.+F&K9&S_E'0$%>Q\-7L
M@N5?:"WS@D6E; ,>:&H"^.R=MZFLA\L*BAS>[E14A1-]?LGK5<KI;5NQI]R/
M]PM?-\TX/:M9IM%\F$<;B":XH)5?EGL4A;PJ"3,29-8$+/O+7'I=-7*[_ETT
MJWF\+"T\O)^*6?AQ#[^RQ0\P^))NTS.QZV1W5 1%I<V\9#BBFV :9OZMHX8&
M?,U_<#'9>N2HU%,>/.;%:(0._?,HS$!=JW!Q0$]'[%51O"H5=J1=76>K6P_7
M[##&0V_S(JVPRKYTZAF9:6GO;N.A+299K.Y$WHDG:R]\IJ]R[3%0*XY"^'%)
MQ6G!SU#9@\<1<<1T*1L:5#,A'HHL4IVOMG:.MUY#8LI"A1X7Z2(F"YQI<_:C
MZ&[[PN>0M_ABI2"SS%A9E2W;O:/C;VV.C:P;.LZKA@[^/S^++&\1:_G>].6'
MI._Z1G[Q H8WRW44P^M'98T.V+2815/\RW@[=^SKF,7]]O5<8I.5;_6(O,>H
M7/961?R8%L3.2(Z7CS_ FN6WR)HQ+4%S:_>[H"+SP=.[]0)?@9%+TSX\PIP'
M$;/0\)6/H#0Y]L5F??3>J"8K=N/7V-4Q@Z8JMN^;)<N6Y@X%RWKH3:.NJXS!
M5;'R"!)3^7*:L3MW:;5^.U,'=U^OBL 9^EIA ),*L+^#0V90J,7Z(B&6!JF?
MHX8F[B:L0K:7'SW8U1%."GI%SSM8UH^[D"[Y/^YPOP>\,NVGC*7!;2308_+>
M7^)GZ(J)3*JID7?+H[F6GVD81#$'XS**O\6?'4\4;P%QQZEBO]5")1=KE,EO
M0H%>:N+F4!J.688[SWM^CJE0M!:K>WBYX%HO!P*8^.S4T3%SA7E1AI6JYXR*
M^FS<7BP#3DT\'M+?,:LZ6'6SF%)OY5H;B)^]4!;- 04GB5C@\W\8[%EJ\2]I
MLHR#K:I16MBWH/,RV//86QW0T6)B=5!>&W.QN@G] )[1S&-_"M(U!]A$T6P=
M;!\C@0LB_,CZTAS1W?6#D@<UY;*;C!XO18U+3[J_P(AST!KAD_&OO/]R&W0
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MF  C;%U!M'.:!OZN\P^/^J\_AR?]*/_Z]$?W'_D#UL%/_P%02P,$%     @
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MRRSM 7(*RZN\S,"KPCF.T]Z.%;O&+%+4/A(3SFYK@6ALJ 4IEG\;@F(*HD5
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M[)15H'8@N _@-A ]Q^."3BSJ13%EQSE+3\JW8]?.\\]A2K$:/W>>D[JI076
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M=+!;;423LU1ZVIV0(D^)>HQA D)NXK4> ^'\IP65NMBV)[HFK*G*:\?SN<W
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M. CB/7 %\S]OHWPZF%9821[F3UVIMQTGY87_/UGQP.X33-.PJ#@>^=^C+,E
M^(#B#18%>'GX+DR-,8S8L"6BMU'+*]VV746-CUQ"85SQYL$GL1!$)&G_&K==
MK_AU:H;YM@50Z36%G.C[./*$Q7K8;2U>'CTDUG9:[]7((F9%?@TWIN4>(L*0
M6"U)H1F.<@\+9F"KO&=8"S*Y-W=Q))NW+UROO"U^HT@[N.9X:IYR+&Z7$=IS
M<,Q=QE2.B95\JAJD.DG(N(5?Y2B[BY<D=%;%26'CNXN3PONA,LYSMXZWL@+5
MCXHZGE+<69F*PK+N,IJN0E2/$[N+&5]R-4Y"[A: US?PY7%ZQ_/V=7>:4K[
M"7 8USQHN%[ZN,HP,BB8FZU[3L80ES_& !N7@[BF>H',CZ?*2WI)+WV@=51\
M)'B _*=392%Y4E$?"(V1;71WFJF$I0+?/[SA:R"GJ0#SCV]@FLN$*C#]TQNF
M?21.%>A^Z;=HX.CQ-9A?57HT7(U#*0.JEI-5PN6JIU$-+LU,KQ(T5[T@4L>1
M,,6L1,?Y(^M@*D.0R5:"[?RY3@@V)\.M!,?HZ644-7GQP:THY(-_@K">+(J
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M^15\@\%]5!3M*"X_NINL)Q/=QN.1CE] U)#T#>_L20'#W8)\@\O=VKP*>_#
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M?$92=,M7 1NDJ?<[ALVI@4+/2;8#[CA:LQ%/&X]&XN<AB&AR-OGISK%'?^A
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M/;]>1N20(FS$Q\ ,C"5,0" TI&6_Y]A?,&J&YTF3,IVRS]@B:S7K_V(Z9E]
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MR3HR\\8RS#/JH0%^4^<QY@<!5Q,^L_YK8?I[]&4R'W_L[_FOH?D?4$L#!!0
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ME.6I,SF@]QP'$59%4YNS!(^,Q#D=\PA/&:83S#V<+NQ6#%*(P%INIF22\#O
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MJQ_WW!O^XZ?C7OF_ 9\ 4$L! A0#%     @ %3AB5[9M$7.0%@0 ?-4$ !(
M             ( !     &EM9S(U.3,T.3(W-5\P+FIP9U!+ 0(4 Q0    (
M !4X8E?]!S,_?H@! %8B'@ /              "  < 6! !M9"TR,#(S,#DS
M,"YH=&U02P$"% ,4    "  5.&)7%%V^$]</   6I@  #P
M@ %KGP4 ;60M,C R,S Y,S N>'-D4$L! A0#%     @ %3AB5WB<7D^H#@
MG\8  !,              ( !;Z\% &UD+3(P,C,P.3,P7V-A;"YX;6Q02P$"
M% ,4    "  5.&)70.T_BH,?   .]0$ $P              @ %(O@4 ;60M
M,C R,S Y,S!?9&5F+GAM;%!+ 0(4 Q0    ( !4X8E>S4ZZ[1W\  /JB!0 3
M              "  ?S=!0!M9"TR,#(S,#DS,%]L86(N>&UL4$L! A0#%
M  @ %3AB5[XJ*%'L-@  4<L# !,              ( !=%T& &UD+3(P,C,P
M.3,P7W!R92YX;6Q02P$"% ,4    "  5.&)7P$.41 0(  "-1@  #0
M        @ &1E 8 ;60M97@S,5\Q+FAT;5!+ 0(4 Q0    ( !4X8E>U=%.B
M#P@  'E&   -              "  <"<!@!M9"UE>#,Q7S(N:'1M4$L! A0#
M%     @ %3AB5[P6T/O^ P  (B    T              ( !^J0& &UD+65X
>,S)?,2YH=&U02P4&      H "@!O @  (ZD&

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
